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NOTE TO THE READER
The term ‘carcinogenic risk’ in the IARC Monographs series is taken to mean that an agent is 
capable of causing cancer. The Monographs evaluate cancer hazards, despite the historical presence 
of the word ‘risks’ in the title.
Inclusion of an agent in the Monographs does not imply that it is a carcinogen, only that the 
published data have been examined. Equally, the fact that an agent has not yet been evaluated in a 
Monograph does not mean that it is not carcinogenic. Similarly, identification of cancer sites with 
sufficient evidence or limited evidence in humans should not be viewed as precluding the possibility 
that an agent may cause cancer at other sites.
The evaluations of carcinogenic risk are made by international working groups of independent 
scientists and are qualitative in nature. No recommendation is given for regulation or legislation.
Anyone who is aware of published data that may alter the evaluation of the carcinogenic risk 
of an agent to humans is encouraged to make this information available to the Section of IARC 
Monographs, International Agency for Research on Cancer, 150 cours Albert Thomas, 69372 Lyon 
Cedex 08, France, in order that the agent may be considered for re-evaluation by a future Working 
Group.
Although every effort is made to prepare the Monographs as accurately as possible, mistakes may 
occur. Readers are requested to communicate any errors to the Section of IARC Monographs, so that 
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The Preamble to the IARC Monographs describes the objective and scope of the programme, 
the scientific principles and procedures used in developing a Monograph, the types of 
evidence considered and the scientific criteria that guide the evaluations. The Preamble 
should be consulted when reading a Monograph or list of evaluations.
A. GENERAL PRINCIPLES AND 
PROCEDURES
1. Background
Soon after IARC was established in 1965, it 
received frequent requests for advice on the car-
cinogenic risk of chemicals, including requests 
for lists of known and suspected human carcino-
gens. It was clear that it would not be a simple 
task to summarize adequately the complexity of 
the information that was available, and IARC 
began to consider means of obtaining interna-
tional expert opinion on this topic. In 1970, the 
IARC Advisory Committee on Environmental 
Carcinogenesis recommended ‘...that a com-
pendium on carcinogenic chemicals be pre-
pared by experts. The biological activity and 
evaluation of practical importance to public 
health should be referenced and documented.’ 
The IARC Governing Council adopted a resolu-
tion concerning the role of IARC in providing 
government authorities with expert, independ-
ent, scientific opinion on environmental carcino-
genesis. As one means to that end, the Governing 
Council recommended that IARC should prepare 
monographs on the evaluation of carcinogenic 
risk of chemicals to man, which became the ini-
tial title of the series.
In the succeeding years, the scope of the pro-
gramme broadened as Monographs were devel-
oped for groups of related chemicals, complex 
mixtures, occupational exposures, physical and 
biological agents and lifestyle factors. In 1988, 
the phrase ‘of chemicals’ was dropped from 
the title, which assumed its present form, IARC 
Monographs on the Evaluation of Carcinogenic 
Risks to Humans.
Through the Monographs programme, IARC 
seeks to identify the causes of human cancer. This 
is the first step in cancer prevention, which is 
needed as much today as when IARC was estab-
lished. The global burden of cancer is high and 
continues to increase: the annual number of new 
cases was estimated at 10.1 million in 2000 and 
is expected to reach 15 million by 2020 (Stewart 
& Kleihues, 2003). With current trends in demo-
graphics and exposure, the cancer burden has 
been shifting from high-resource countries to 
low- and medium-resource countries. As a result 
of Monographs evaluations, national health agen-
cies have been able, on scientific grounds, to take 
measures to reduce human exposure to carcino-
gens in the workplace and in the environment.
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The criteria established in 1971 to evaluate 
carcinogenic risks to humans were adopted by the 
Working Groups whose deliberations resulted in 
the first 16 volumes of the Monographs series. 
Those criteria were subsequently updated by fur-
ther ad hoc Advisory Groups (IARC, 1977, 1978, 
1979, 1982, 1983, 1987, 1988, 1991; Vainio et al., 
1992; IARC, 2005, 2006).
The Preamble is primarily a statement of sci-
entific principles, rather than a specification of 
working procedures. The procedures through 
which a Working Group implements these prin-
ciples are not specified in detail. They usually 
involve operations that have been established 
as being effective during previous Monograph 
meetings but remain, predominantly, the pre-
rogative of each individual Working Group.
2. Objective and scope
The objective of the programme is to pre-
pare, with the help of international Working 
Groups of experts, and to publish in the form of 
Monographs, critical reviews and evaluations of 
evidence on the carcinogenicity of a wide range 
of human exposures. The Monographs repre-
sent the first step in carcinogen risk assessment, 
which involves examination of all relevant infor-
mation to assess the strength of the available evi-
dence that an agent could alter the age-specific 
incidence of cancer in humans. The Monographs 
may also indicate where additional research 
efforts are needed, specifically when data imme-
diately relevant to an evaluation are not available.
In this Preamble, the term ‘agent’ refers to 
any entity or circumstance that is subject to 
evaluation in a Monograph. As the scope of the 
programme has broadened, categories of agents 
now include specific chemicals, groups of related 
chemicals, complex mixtures, occupational or 
environmental exposures, cultural or behav-
ioural practices, biological organisms and physi-
cal agents. This list of categories may expand as 
causation of, and susceptibility to, malignant 
disease become more fully understood.
A cancer ‘hazard’ is an agent that is capable 
of causing cancer under some circumstances, 
while a cancer ‘risk’ is an estimate of the carci-
nogenic effects expected from exposure to a can-
cer hazard. The Monographs are an exercise in 
evaluating cancer hazards, despite the historical 
presence of the word ‘risks’ in the title. The dis-
tinction between hazard and risk is important, 
and the Monographs identify cancer hazards 
even when risks are very low at current exposure 
levels, because new uses or unforeseen exposures 
could engender risks that are significantly higher.
In the Monographs, an agent is termed ‘car-
cinogenic’ if it is capable of increasing the inci-
dence of malignant neoplasms, reducing their 
latency, or increasing their severity or multiplic-
ity. The induction of benign neoplasms may in 
some circumstances (see Part B, Section 3a) con-
tribute to the judgement that the agent is carci-
nogenic. The terms ‘neoplasm’ and ‘tumour’ are 
used interchangeably.
The Preamble continues the previous usage 
of the phrase ‘strength of evidence’ as a matter 
of historical continuity, although it should be 
understood that Monographs evaluations con-
sider studies that support a finding of a cancer 
hazard as well as studies that do not.
Some epidemiological and experimental 
studies indicate that different agents may act at 
different stages in the carcinogenic process, and 
several different mechanisms may be involved. 
The aim of the Monographs has been, from their 
inception, to evaluate evidence of carcinogenic-
ity at any stage in the carcinogenesis process, 
independently of the underlying mechanisms. 
Information on mechanisms may, however, be 
used in making the overall evaluation (IARC, 
1991; Vainio et al., 1992; IARC, 2005, 2006; see 
also Part B, Sections 4 and 6). As mechanisms 
of carcinogenesis are elucidated, IARC convenes 
international scientific conferences to determine 
whether a broad-based consensus has emerged 
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on how specific mechanistic data can be used 
in an evaluation of human carcinogenicity. The 
results of such conferences are reported in IARC 
Scientific Publications, which, as long as they still 
reflect the current state of scientific knowledge, 
may guide subsequent Working Groups.
Although the Monographs have emphasized 
hazard identification, important issues may also 
involve dose–response assessment. In many 
cases, the same epidemiological and experimen-
tal studies used to evaluate a cancer hazard can 
also be used to estimate a dose–response relation-
ship. A Monograph may undertake to estimate 
dose–response relationships within the range 
of the available epidemiological data, or it may 
compare the dose–response information from 
experimental and epidemiological studies. In 
some cases, a subsequent publication may be pre-
pared by a separate Working Group with exper-
tise in quantitative dose–response assessment.
The Monographs are used by national and 
international authorities to make risk assess-
ments, formulate decisions concerning preventive 
measures, provide effective cancer control pro-
grammes and decide among alternative options 
for public health decisions. The evaluations of 
IARC Working Groups are scientific, qualita-
tive judgements on the evidence for or against 
carcinogenicity provided by the available data. 
These evaluations represent only one part of the 
body of information on which public health deci-
sions may be based. Public health options vary 
from one situation to another and from country 
to country and relate to many factors, including 
different socioeconomic and national priorities. 
Therefore, no recommendation is given with 
regard to regulation or legislation, which are 
the responsibility of individual governments or 
other international organizations.
3. Selection of agents for review
Agents are selected for review on the basis of 
two main criteria: (a) there is evidence of human 
exposure and (b) there is some evidence or sus-
picion of carcinogenicity. Mixed exposures may 
occur in occupational and environmental set-
tings and as a result of individual and cultural 
habits (such as tobacco smoking and dietary 
practices). Chemical analogues and compounds 
with biological or physical characteristics simi-
lar to those of suspected carcinogens may also 
be considered, even in the absence of data on a 
possible carcinogenic effect in humans or experi-
mental animals.
The scientific literature is surveyed for pub-
lished data relevant to an assessment of carci-
nogenicity. Ad hoc Advisory Groups convened 
by IARC in 1984, 1989, 1991, 1993, 1998 and 
2003 made recommendations as to which 
agents should be evaluated in the Monographs 
series. Recent recommendations are avail-
able on the Monographs programme web site 
(http://monographs.iarc.fr). IARC may schedule 
other agents for review as it becomes aware of 
new scientific information or as national health 
agencies identify an urgent public health need 
related to cancer.
As significant new data become available 
on an agent for which a Monograph exists, a re-
evaluation may be made at a subsequent meeting, 
and a new Monograph published. In some cases it 
may be appropriate to review only the data pub-
lished since a prior evaluation. This can be useful 
for updating a database, reviewing new data to 
resolve a previously open question or identifying 
new tumour sites associated with a carcinogenic 
agent. Major changes in an evaluation (e.g. a new 
classification in Group 1 or a determination that a 
mechanism does not operate in humans, see Part 
B, Section 6) are more appropriately addressed by 
a full review.
4. Data for the Monographs
Each Monograph reviews all pertinent epi-
demiological studies and cancer bioassays in 
experimental animals. Those judged inadequate 
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or irrelevant to the evaluation may be cited but 
not summarized. If a group of similar studies is 
not reviewed, the reasons are indicated.
Mechanistic and other relevant data are also 
reviewed. A Monograph does not necessarily 
cite all the mechanistic literature concerning 
the agent being evaluated (see Part B, Section 
4). Only those data considered by the Working 
Group to be relevant to making the evaluation 
are included.
With regard to epidemiological studies, can-
cer bioassays, and mechanistic and other relevant 
data, only reports that have been published or 
accepted for publication in the openly available 
scientific literature are reviewed. The same publi-
cation requirement applies to studies originating 
from IARC, including meta-analyses or pooled 
analyses commissioned by IARC in advance of a 
meeting (see Part B, Section 2c). Data from gov-
ernment agency reports that are publicly avail-
able are also considered. Exceptionally, doctoral 
theses and other material that are in their final 
form and publicly available may be reviewed.
Exposure data and other information on an 
agent under consideration are also reviewed. In 
the sections on chemical and physical proper-
ties, on analysis, on production and use and on 
occurrence, published and unpublished sources 
of information may be considered.
Inclusion of a study does not imply accept-
ance of the adequacy of the study design or of 
the analysis and interpretation of the results, and 
limitations are clearly outlined in square brack-
ets at the end of each study description (see Part 
B). The reasons for not giving further considera-
tion to an individual study also are indicated in 
the square brackets.
5. Meeting participants
Five categories of participant can be present 
at Monograph meetings.
(a) The Working Group
The Working Group is responsible for the crit-
ical reviews and evaluations that are developed 
during the meeting. The tasks of Working Group 
Members are: (i) to ascertain that all appropriate 
data have been collected; (ii) to select the data rel-
evant for the evaluation on the basis of scientific 
merit; (iii) to prepare accurate summaries of the 
data to enable the reader to follow the reasoning 
of the Working Group; (iv) to evaluate the results 
of epidemiological and experimental studies on 
cancer; (v) to evaluate data relevant to the under-
standing of mechanisms of carcinogenesis; and 
(vi) to make an overall evaluation of the carci-
nogenicity of the exposure to humans. Working 
Group Members generally have published sig-
nificant research related to the carcinogenicity of 
the agents being reviewed, and IARC uses litera-
ture searches to identify most experts. Working 
Group Members are selected on the basis of (a) 
knowledge and experience and (b) absence of real 
or apparent conflicts of interests. Consideration 
is also given to demographic diversity and bal-
ance of scientific findings and views.
(b) Invited Specialists
Invited Specialists are experts who also have 
critical knowledge and experience but have 
a real or apparent conflict of interests. These 
experts are invited when necessary to assist in 
the Working Group by contributing their unique 
knowledge and experience during subgroup and 
plenary discussions. They may also contribute 
text on non-influential issues in the section on 
exposure, such as a general description of data 
on production and use (see Part B, Section 1). 
Invited Specialists do not serve as meeting chair 
or subgroup chair, draft text that pertains to the 
description or interpretation of cancer data, or 
participate in the evaluations.
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(c) Representatives of national and 
international health agencies 
Representatives of national and interna-
tional health agencies often attend meetings 
because their agencies sponsor the programme 
or are interested in the subject of a meeting. 
Representatives do not serve as meeting chair or 
subgroup chair, draft any part of a Monograph, 
or participate in the evaluations.
(d) Observers with relevant scientific 
credentials 
Observers with relevant scientific credentials 
may be admitted to a meeting by IARC in limited 
numbers. Attention will be given to achieving a 
balance of Observers from constituencies with 
differing perspectives. They are invited to observe 
the meeting and should not attempt to influence 
it. Observers do not serve as meeting chair or 
subgroup chair, draft any part of a Monograph, 
or participate in the evaluations. At the meeting, 
the meeting chair and subgroup chairs may grant 
Observers an opportunity to speak, generally 
after they have observed a discussion. Observers 
agree to respect the Guidelines for Observers 
at IARC Monographs meetings (available at 
http://monographs.iarc.fr).
(e) The IARC Secretariat
The IARC Secretariat consists of scientists 
who are designated by IARC and who have rel-
evant expertise. They serve as rapporteurs and 
participate in all discussions. When requested by 
the meeting chair or subgroup chair, they may 
also draft text or prepare tables and analyses.
Before an invitation is extended, each poten-
tial participant, including the IARC Secretariat, 
completes the WHO Declaration of Interests to 
report financial interests, employment and con-
sulting, and individual and institutional research 
support related to the subject of the meeting. 
IARC assesses these interests to determine 
whether there is a conflict that warrants some 
limitation on participation. The declarations are 
updated and reviewed again at the opening of 
the meeting. Interests related to the subject of 
the meeting are disclosed to the meeting par-
ticipants and in the published volume (Cogliano 
et al., 2004).
The names and principal affiliations of par-
ticipants are available on the Monographs pro-
gramme web site (http://monographs.iarc.fr) 
approximately two months before each meeting. 
It is not acceptable for Observers or third parties 
to contact other participants before a meeting or 
to lobby them at any time. Meeting participants 
are asked to report all such contacts to IARC 
(Cogliano et al., 2005).
All participants are listed, with their princi-
pal affiliations, at the beginning of each volume. 
Each participant who is a Member of a Working 
Group serves as an individual scientist and not as 
a representative of any organization, government 
or industry.
6. Working procedures
A separate Working Group is responsible for 
developing each volume of Monographs. A vol-
ume contains one or more Monographs, which 
can cover either a single agent or several related 
agents. Approximately one year in advance of the 
meeting of a Working Group, the agents to be 
reviewed are announced on the Monographs pro-
gramme web site (http://monographs.iarc.fr) and 
participants are selected by IARC staff in consul-
tation with other experts. Subsequently, relevant 
biological and epidemiological data are collected 
by IARC from recognized sources of information 
on carcinogenesis, including data storage and 
retrieval systems such as PubMed. Meeting par-
ticipants who are asked to prepare preliminary 
working papers for specific sections are expected 
to supplement the IARC literature searches with 
their own searches.
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For most chemicals and some complex mix-
tures, the major collection of data and the prep-
aration of working papers for the sections on 
chemical and physical properties, on analysis, on 
production and use, and on occurrence are car-
ried out under a separate contract funded by the 
US National Cancer Institute. Industrial associ-
ations, labour unions and other knowledgeable 
organizations may be asked to provide input to 
the sections on production and use, although 
this involvement is not required as a general rule. 
Information on production and trade is obtained 
from governmental, trade and market research 
publications and, in some cases, by direct con-
tact with industries. Separate production data 
on some agents may not be available for a vari-
ety of reasons (e.g. not collected or made public 
in all producing countries, production is small). 
Information on uses may be obtained from pub-
lished sources but is often complemented by 
direct contact with manufacturers. Efforts are 
made to supplement this information with data 
from other national and international sources.
Six months before the meeting, the mate-
rial obtained is sent to meeting participants to 
prepare preliminary working papers. The work-
ing papers are compiled by IARC staff and sent, 
before the meeting, to Working Group Members 
and Invited Specialists for review.
The Working Group meets at IARC for seven 
to eight days to discuss and finalize the texts 
and to formulate the evaluations. The objectives 
of the meeting are peer review and consensus. 
During the first few days, four subgroups (cov-
ering exposure data, cancer in humans, cancer 
in experimental animals, and mechanistic and 
other relevant data) review the working papers, 
develop a joint subgroup draft and write sum-
maries. Care is taken to ensure that each study 
summary is written or reviewed by someone 
not associated with the study being considered. 
During the last few days, the Working Group 
meets in plenary session to review the subgroup 
drafts and develop the evaluations. As a result, 
the entire volume is the joint product of the 
Working Group, and there are no individually 
authored sections.
IARC Working Groups strive to achieve a 
consensus evaluation. Consensus reflects broad 
agreement among Working Group Members, but 
not necessarily unanimity. The chair may elect 
to poll Working Group Members to determine 
the diversity of scientific opinion on issues where 
consensus is not readily apparent.
After the meeting, the master copy is verified 
by consulting the original literature, edited and 
prepared for publication. The aim is to publish 
the volume within six months of the Working 
Group meeting. A summary of the outcome is 
available on the Monographs programme web 
site soon after the meeting.
B. SCIENTIFIC REVIEW AND 
EVALUATION
The available studies are summarized by the 
Working Group, with particular regard to the 
qualitative aspects discussed below. In general, 
numerical findings are indicated as they appear 
in the original report; units are converted when 
necessary for easier comparison. The Working 
Group may conduct additional analyses of the 
published data and use them in their assessment 
of the evidence; the results of such supplemen-
tary analyses are given in square brackets. When 
an important aspect of a study that directly 
impinges on its interpretation should be brought 
to the attention of the reader, a Working Group 
comment is given in square brackets.
The scope of the IARC Monographs pro-
gramme has expanded beyond chemicals to 
include complex mixtures, occupational expo-
sures, physical and biological agents, lifestyle 
factors and other potentially carcinogenic expo-
sures. Over time, the structure of a Monograph 




Studies of cancer in humans
Studies of cancer in experimental animals
Mechanistic and other relevant data
Summary
Evaluation and rationale
In addition, a section of General Remarks at 
the front of the volume discusses the reasons the 
agents were scheduled for evaluation and some 
key issues the Working Group encountered dur-
ing the meeting.
This part of the Preamble discusses the types 
of evidence considered and summarized in each 
section of a Monograph, followed by the scientific 
criteria that guide the evaluations.
1. Exposure data
Each Monograph includes general informa-
tion on the agent: this information may vary sub-
stantially between agents and must be adapted 
accordingly. Also included is information on 
production and use (when appropriate), meth-
ods of analysis and detection, occurrence, and 
sources and routes of human occupational and 
environmental exposures. Depending on the 
agent, regulations and guidelines for use may be 
presented.
(a) General information on the agent
For chemical agents, sections on chemical 
and physical data are included: the Chemical 
Abstracts Service Registry Number, the latest pri-
mary name and the IUPAC systematic name are 
recorded; other synonyms are given, but the list 
is not necessarily comprehensive. Information 
on chemical and physical properties that are rel-
evant to identification, occurrence and biologi-
cal activity is included. A description of technical 
products of chemicals includes trade names, rel-
evant specifications and available information 
on composition and impurities. Some of the 
trade names given may be those of mixtures in 
which the agent being evaluated is only one of 
the ingredients.
For biological agents, taxonomy, struc-
ture and biology are described, and the degree 
of variability is indicated. Mode of replication, 
life cycle, target cells, persistence, latency, host 
response and clinical disease other than cancer 
are also presented.
For physical agents that are forms of radia-
tion, energy and range of the radiation are 
included. For foreign bodies, fibres and respir-
able particles, size range and relative dimensions 
are indicated.
For agents such as mixtures, drugs or lifestyle 
factors, a description of the agent, including its 
composition, is given.
Whenever appropriate, other information, 
such as historical perspectives or the description 
of an industry or habit, may be included.
(b) Analysis and detection
An overview of methods of analysis and 
detection of the agent is presented, including 
their sensitivity, specificity and reproducibility. 
Methods widely used for regulatory purposes 
are emphasized. Methods for monitoring human 
exposure are also given. No critical evaluation 
or recommendation of any method is meant or 
implied.
(c) Production and use
The dates of first synthesis and of first com-
mercial production of a chemical, mixture or 
other agent are provided when available; for 
agents that do not occur naturally, this informa-
tion may allow a reasonable estimate to be made 
of the date before which no human exposure to 
the agent could have occurred. The dates of first 
reported occurrence of an exposure are also pro-
vided when available. In addition, methods of 
synthesis used in past and present commercial 
production and different methods of production, 
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which may give rise to different impurities, are 
described.
The countries where companies report pro-
duction of the agent, and the number of compa-
nies in each country, are identified. Available data 
on production, international trade and uses are 
obtained for representative regions. It should not, 
however, be inferred that those areas or nations 
are necessarily the sole or major sources or users 
of the agent. Some identified uses may not be 
current or major applications, and the coverage 
is not necessarily comprehensive. In the case of 
drugs, mention of their therapeutic uses does not 
necessarily represent current practice nor does it 
imply judgement as to their therapeutic efficacy.
(d) Occurrence and exposure
Information on the occurrence of an agent in 
the environment is obtained from data derived 
from the monitoring and surveillance of levels 
in occupational environments, air, water, soil, 
plants, foods and animal and human tissues. 
When available, data on the generation, per-
sistence and bioaccumulation of the agent are 
also included. Such data may be available from 
national databases.
Data that indicate the extent of past and pre-
sent human exposure, the sources of exposure, 
the people most likely to be exposed and the fac-
tors that contribute to the exposure are reported. 
Information is presented on the range of human 
exposure, including occupational and environ-
mental exposures. This includes relevant findings 
from both developed and developing countries. 
Some of these data are not distributed widely and 
may be available from government reports and 
other sources. In the case of mixtures, indus-
tries, occupations or processes, information is 
given about all agents known to be present. For 
processes, industries and occupations, a histori-
cal description is also given, noting variations in 
chemical composition, physical properties and 
levels of occupational exposure with date and 
place. For biological agents, the epidemiology of 
infection is described.
(e) Regulations and guidelines
Statements concerning regulations and 
guidelines (e.g. occupational exposure limits, 
maximal levels permitted in foods and water, 
pesticide registrations) are included, but they 
may not reflect the most recent situation, since 
such limits are continuously reviewed and modi-
fied. The absence of information on regulatory 
status for a country should not be taken to imply 
that that country does not have regulations with 
regard to the exposure. For biological agents, leg-
islation and control, including vaccination and 
therapy, are described.
2. Studies of cancer in humans
This section includes all pertinent epidemio-
logical studies (see Part A, Section 4). Studies of 
biomarkers are included when they are relevant 
to an evaluation of carcinogenicity to humans.
(a) Types of study considered
Several types of epidemiological study con-
tribute to the assessment of carcinogenicity in 
humans — cohort studies, case–control studies, 
correlation (or ecological) studies and interven-
tion studies. Rarely, results from randomized tri-
als may be available. Case reports and case series 
of cancer in humans may also be reviewed.
Cohort and case–control studies relate indi-
vidual exposures under study to the occurrence of 
cancer in individuals and provide an estimate of 
effect (such as relative risk) as the main measure 
of association. Intervention studies may provide 
strong evidence for making causal inferences, as 
exemplified by cessation of smoking and the sub-
sequent decrease in risk for lung cancer.
In correlation studies, the units of inves-
tigation are usually whole populations (e.g. in 
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particular geographical areas or at particular 
times), and cancer frequency is related to a sum-
mary measure of the exposure of the population 
to the agent under study. In correlation studies, 
individual exposure is not documented, which 
renders this kind of study more prone to con-
founding. In some circumstances, however, cor-
relation studies may be more informative than 
analytical study designs (see, for example, the 
Monograph on arsenic in drinking-water; IARC, 
2004).
In some instances, case reports and case series 
have provided important information about the 
carcinogenicity of an agent. These types of study 
generally arise from a suspicion, based on clinical 
experience, that the concurrence of two events — 
that is, a particular exposure and occurrence of 
a cancer — has happened rather more frequently 
than would be expected by chance. Case reports 
and case series usually lack complete ascertain-
ment of cases in any population, definition or 
enumeration of the population at risk and esti-
mation of the expected number of cases in the 
absence of exposure.
The uncertainties that surround the inter-
pretation of case reports, case series and corre-
lation studies make them inadequate, except in 
rare instances, to form the sole basis for inferring 
a causal relationship. When taken together with 
case–control and cohort studies, however, these 
types of study may add materially to the judge-
ment that a causal relationship exists.
Epidemiological studies of benign neo-
plasms, presumed preneoplastic lesions and 
other end-points thought to be relevant to cancer 
are also reviewed. They may, in some instances, 
strengthen inferences drawn from studies of 
cancer itself.
(b) Quality of studies considered
It is necessary to take into account the pos-
sible roles of bias, confounding and chance in 
the interpretation of epidemiological studies. 
Bias is the effect of factors in study design or 
execution that lead erroneously to a stronger or 
weaker association than in fact exists between an 
agent and disease. Confounding is a form of bias 
that occurs when the relationship with disease is 
made to appear stronger or weaker than it truly is 
as a result of an association between the apparent 
causal factor and another factor that is associated 
with either an increase or decrease in the inci-
dence of the disease. The role of chance is related 
to biological variability and the influence of sam-
ple size on the precision of estimates of effect.
In evaluating the extent to which these fac-
tors have been minimized in an individual study, 
consideration is given to several aspects of design 
and analysis as described in the report of the 
study. For example, when suspicion of carcino-
genicity arises largely from a single small study, 
careful consideration is given when interpreting 
subsequent studies that included these data in an 
enlarged population. Most of these considera-
tions apply equally to case–control, cohort and 
correlation studies. Lack of clarity of any of these 
aspects in the reporting of a study can decrease 
its credibility and the weight given to it in the 
final evaluation of the exposure.
First, the study population, disease (or dis-
eases) and exposure should have been well 
defined by the authors. Cases of disease in the 
study population should have been identified in 
a way that was independent of the exposure of 
interest, and exposure should have been assessed 
in a way that was not related to disease status.
Second, the authors should have taken into 
account — in the study design and analysis — 
other variables that can influence the risk of dis-
ease and may have been related to the exposure 
of interest. Potential confounding by such vari-
ables should have been dealt with either in the 
design of the study, such as by matching, or in 
the analysis, by statistical adjustment. In cohort 
studies, comparisons with local rates of disease 
may or may not be more appropriate than those 
with national rates. Internal comparisons of 
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frequency of disease among individuals at differ-
ent levels of exposure are also desirable in cohort 
studies, since they minimize the potential for 
confounding related to the difference in risk fac-
tors between an external reference group and the 
study population.
Third, the authors should have reported the 
basic data on which the conclusions are founded, 
even if sophisticated statistical analyses were 
employed. At the very least, they should have 
given the numbers of exposed and unexposed 
cases and controls in a case–control study and 
the numbers of cases observed and expected in 
a cohort study. Further tabulations by time since 
exposure began and other temporal factors are 
also important. In a cohort study, data on all 
cancer sites and all causes of death should have 
been given, to reveal the possibility of reporting 
bias. In a case–control study, the effects of inves-
tigated factors other than the exposure of interest 
should have been reported.
Finally, the statistical methods used to obtain 
estimates of relative risk, absolute rates of can-
cer, confidence intervals and significance tests, 
and to adjust for confounding should have been 
clearly stated by the authors. These methods have 
been reviewed for case–control studies (Breslow 
& Day, 1980) and for cohort studies (Breslow & 
Day, 1987).
(c) Meta-analyses and pooled analyses
Independent epidemiological studies of the 
same agent may lead to results that are difficult 
to interpret. Combined analyses of data from 
multiple studies are a means of resolving this 
ambiguity, and well conducted analyses can be 
considered. There are two types of combined 
analysis. The first involves combining summary 
statistics such as relative risks from individual 
studies (meta-analysis) and the second involves a 
pooled analysis of the raw data from the individ-
ual studies (pooled analysis) (Greenland, 1998).
The advantages of combined analyses are 
increased precision due to increased sample size 
and the opportunity to explore potential con-
founders, interactions and modifying effects 
that may explain heterogeneity among studies in 
more detail. A disadvantage of combined analy-
ses is the possible lack of compatibility of data 
from various studies due to differences in sub-
ject recruitment, procedures of data collection, 
methods of measurement and effects of unmeas-
ured co-variates that may differ among studies. 
Despite these limitations, well conducted com-
bined analyses may provide a firmer basis than 
individual studies for drawing conclusions about 
the potential carcinogenicity of agents.
IARC may commission a meta-analysis or 
pooled analysis that is pertinent to a particular 
Monograph (see Part A, Section 4). Additionally, 
as a means of gaining insight from the results of 
multiple individual studies, ad hoc calculations 
that combine data from different studies may 
be conducted by the Working Group during 
the course of a Monograph meeting. The results 
of such original calculations, which would be 
specified in the text by presentation in square 
brackets, might involve updates of previously 
conducted analyses that incorporate the results 
of more recent studies or de-novo analyses. 
Irrespective of the source of data for the meta-
analyses and pooled analyses, it is important that 
the same criteria for data quality be applied as 
those that would be applied to individual studies 
and to ensure also that sources of heterogeneity 
between studies be taken into account.
(d) Temporal effects
Detailed analyses of both relative and abso-
lute risks in relation to temporal variables, such 
as age at first exposure, time since first exposure, 
duration of exposure, cumulative exposure, peak 
exposure (when appropriate) and time since 
cessation of exposure, are reviewed and sum-
marized when available. Analyses of temporal 
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relationships may be useful in making causal 
inferences. In addition, such analyses may sug-
gest whether a carcinogen acts early or late in the 
process of carcinogenesis, although, at best, they 
allow only indirect inferences about mechanisms 
of carcinogenesis.
(e) Use of biomarkers in epidemiological 
studies
Biomarkers indicate molecular, cellular or 
other biological changes and are increasingly 
used in epidemiological studies for various pur-
poses (IARC, 1991; Vainio et al., 1992; Toniolo 
et al., 1997; Vineis et al., 1999; Buffler et al., 2004). 
These may include evidence of exposure, of early 
effects, of cellular, tissue or organism responses, 
of individual susceptibility or host responses, 
and inference of a mechanism (see Part B, Section 
4b). This is a rapidly evolving field that encom-
passes developments in genomics, epigenomics 
and other emerging technologies.
Molecular epidemiological data that identify 
associations between genetic polymorphisms 
and interindividual differences in susceptibility 
to the agent(s) being evaluated may contribute 
to the identification of carcinogenic hazards to 
humans. If the polymorphism has been demon-
strated experimentally to modify the functional 
activity of the gene product in a manner that is 
consistent with increased susceptibility, these 
data may be useful in making causal inferences. 
Similarly, molecular epidemiological studies that 
measure cell functions, enzymes or metabolites 
that are thought to be the basis of susceptibil-
ity may provide evidence that reinforces biologi-
cal plausibility. It should be noted, however, that 
when data on genetic susceptibility originate 
from multiple comparisons that arise from sub-
group analyses, this can generate false-positive 
results and inconsistencies across studies, and 
such data therefore require careful evaluation. 
If the known phenotype of a genetic polymor-
phism can explain the carcinogenic mechanism 
of the agent being evaluated, data on this pheno-
type may be useful in making causal inferences.
(f) Criteria for causality
After the quality of individual epidemiologi-
cal studies of cancer has been summarized and 
assessed, a judgement is made concerning the 
strength of evidence that the agent in question 
is carcinogenic to humans. In making its judge-
ment, the Working Group considers several crite-
ria for causality (Hill, 1965). A strong association 
(e.g. a large relative risk) is more likely to indicate 
causality than a weak association, although it is 
recognized that estimates of effect of small mag-
nitude do not imply lack of causality and may be 
important if the disease or exposure is common. 
Associations that are replicated in several studies 
of the same design or that use different epidemi-
ological approaches or under different circum-
stances of exposure are more likely to represent 
a causal relationship than isolated observations 
from single studies. If there are inconsistent 
results among investigations, possible reasons 
are sought (such as differences in exposure), and 
results of studies that are judged to be of high 
quality are given more weight than those of stud-
ies that are judged to be methodologically less 
sound.
If the risk increases with the exposure, this is 
considered to be a strong indication of causality, 
although the absence of a graded response is not 
necessarily evidence against a causal relation-
ship. The demonstration of a decline in risk after 
cessation of or reduction in exposure in indi-
viduals or in whole populations also supports a 
causal interpretation of the findings.
Several scenarios may increase confidence in 
a causal relationship. On the one hand, an agent 
may be specific in causing tumours at one site or 
of one morphological type. On the other, carci-
nogenicity may be evident through the causation 
of multiple tumour types. Temporality, precision 
of estimates of effect, biological plausibility and 
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coherence of the overall database are consid-
ered. Data on biomarkers may be employed in 
an assessment of the biological plausibility of epi-
demiological observations.
Although rarely available, results from rand-
omized trials that show different rates of cancer 
among exposed and unexposed individuals pro-
vide particularly strong evidence for causality.
When several epidemiological studies show 
little or no indication of an association between 
an exposure and cancer, a judgement may be made 
that, in the aggregate, they show evidence of lack 
of carcinogenicity. Such a judgement requires 
first that the studies meet, to a sufficient degree, 
the standards of design and analysis described 
above. Specifically, the possibility that bias, con-
founding or misclassification of exposure or out-
come could explain the observed results should 
be considered and excluded with reasonable cer-
tainty. In addition, all studies that are judged to 
be methodologically sound should (a) be con-
sistent with an estimate of effect of unity for any 
observed level of exposure, (b) when considered 
together, provide a pooled estimate of relative 
risk that is at or near to unity, and (c) have a nar-
row confidence interval, due to sufficient popula-
tion size. Moreover, no individual study nor the 
pooled results of all the studies should show any 
consistent tendency that the relative risk of can-
cer increases with increasing level of exposure. 
It is important to note that evidence of lack of 
carcinogenicity obtained from several epidemio-
logical studies can apply only to the type(s) of 
cancer studied, to the dose levels reported, and to 
the intervals between first exposure and disease 
onset observed in these studies. Experience with 
human cancer indicates that the period from first 
exposure to the development of clinical cancer is 
sometimes longer than 20 years; latent periods 
substantially shorter than 30 years cannot pro-
vide evidence for lack of carcinogenicity.
3. Studies of cancer in experimental 
animals
All known human carcinogens that have been 
studied adequately for carcinogenicity in experi-
mental animals have produced positive results 
in one or more animal species (Wilbourn et al., 
1986; Tomatis et al., 1989). For several agents 
(e.g. aflatoxins, diethylstilbestrol, solar radiation, 
vinyl chloride), carcinogenicity in experimen-
tal animals was established or highly suspected 
before epidemiological studies confirmed their 
carcinogenicity in humans (Vainio et al., 1995). 
Although this association cannot establish that 
all agents that cause cancer in experimental ani-
mals also cause cancer in humans, it is biologically 
plausible that agents for which there is sufficient 
evidence of carcinogenicity in experimental ani-
mals (see Part B, Section 6b) also present a car-
cinogenic hazard to humans. Accordingly, in 
the absence of additional scientific information, 
these agents are considered to pose a carcinogenic 
hazard to humans. Examples of additional scien-
tific information are data that demonstrate that 
a given agent causes cancer in animals through 
a species-specific mechanism that does not oper-
ate in humans or data that demonstrate that the 
mechanism in experimental animals also oper-
ates in humans (see Part B, Section 6).
Consideration is given to all available long-
term studies of cancer in experimental animals 
with the agent under review (see Part A, Section 
4). In all experimental settings, the nature and 
extent of impurities or contaminants present in 
the agent being evaluated are given when avail-
able. Animal species, strain (including genetic 
background where applicable), sex, numbers per 
group, age at start of treatment, route of expo-
sure, dose levels, duration of exposure, survival 
and information on tumours (incidence, latency, 
severity or multiplicity of neoplasms or prene-
oplastic lesions) are reported. Those studies in 
experimental animals that are judged to be irrel-
evant to the evaluation or judged to be inadequate 
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(e.g. too short a duration, too few animals, poor 
survival; see below) may be omitted. Guidelines 
for conducting long-term carcinogenicity exper-
iments have been published (e.g. OECD, 2002).
Other studies considered may include: exper-
iments in which the agent was administered in 
the presence of factors that modify carcinogenic 
effects (e.g. initiation–promotion studies, co-
carcinogenicity studies and studies in geneti-
cally modified animals); studies in which the 
end-point was not cancer but a defined precan-
cerous lesion; experiments on the carcinogenic-
ity of known metabolites and derivatives; and 
studies of cancer in non-laboratory animals (e.g. 
livestock and companion animals) exposed to 
the agent.
For studies of mixtures, consideration is 
given to the possibility that changes in the phys-
icochemical properties of the individual sub-
stances may occur during collection, storage, 
extraction, concentration and delivery. Another 
consideration is that chemical and toxicological 
interactions of components in a mixture may 
alter dose–response relationships. The relevance 
to human exposure of the test mixture adminis-
tered in the animal experiment is also assessed. 
This may involve consideration of the following 
aspects of the mixture tested: (i) physical and 
chemical characteristics, (ii) identified constitu-
ents that may indicate the presence of a class of 
substances and (iii) the results of genetic toxicity 
and related tests.
The relevance of results obtained with an 
agent that is analogous (e.g. similar in structure 
or of a similar virus genus) to that being evalu-
ated is also considered. Such results may provide 
biological and mechanistic information that is 
relevant to the understanding of the process of 
carcinogenesis in humans and may strengthen 
the biological plausibility that the agent being 
evaluated is carcinogenic to humans (see Part B, 
Section 2f).
(a) Qualitative aspects
An assessment of carcinogenicity involves 
several considerations of qualitative impor-
tance, including (i) the experimental conditions 
under which the test was performed, including 
route, schedule and duration of exposure, spe-
cies, strain (including genetic background where 
applicable), sex, age and duration of follow-up; 
(ii) the consistency of the results, for example, 
across species and target organ(s); (iii) the spec-
trum of neoplastic response, from preneoplastic 
lesions and benign tumours to malignant neo-
plasms; and (iv) the possible role of modifying 
factors.
Considerations of importance in the inter-
pretation and evaluation of a particular study 
include: (i) how clearly the agent was defined and, 
in the case of mixtures, how adequately the sam-
ple characterization was reported; (ii) whether 
the dose was monitored adequately, particu-
larly in inhalation experiments; (iii) whether the 
doses, duration of treatment and route of expo-
sure were appropriate; (iv) whether the survival 
of treated animals was similar to that of con-
trols; (v) whether there were adequate numbers 
of animals per group; (vi) whether both male and 
female animals were used; (vii) whether animals 
were allocated randomly to groups; (viii) whether 
the duration of observation was adequate; and 
(ix) whether the data were reported and analysed 
adequately.
When benign tumours (a) occur together 
with and originate from the same cell type as 
malignant tumours in an organ or tissue in a 
particular study and (b) appear to represent a 
stage in the progression to malignancy, they are 
usually combined in the assessment of tumour 
incidence (Huff et al., 1989). The occurrence of 
lesions presumed to be preneoplastic may in cer-
tain instances aid in assessing the biological plau-
sibility of any neoplastic response observed. If an 
agent induces only benign neoplasms that appear 
to be end-points that do not readily undergo 
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transition to malignancy, the agent should nev-
ertheless be suspected of being carcinogenic and 
requires further investigation.
(b) Quantitative aspects
The probability that tumours will occur may 
depend on the species, sex, strain, genetic back-
ground and age of the animal, and on the dose, 
route, timing and duration of the exposure. 
Evidence of an increased incidence of neoplasms 
with increasing levels of exposure strengthens 
the inference of a causal association between the 
exposure and the development of neoplasms.
The form of the dose–response relation-
ship can vary widely, depending on the par-
ticular agent under study and the target organ. 
Mechanisms such as induction of DNA dam-
age or inhibition of repair, altered cell division 
and cell death rates and changes in intercellular 
communication are important determinants of 
dose–response relationships for some carcino-
gens. Since many chemicals require metabolic 
activation before being converted to their reac-
tive intermediates, both metabolic and toxicoki-
netic aspects are important in determining the 
dose–response pattern. Saturation of steps such 
as absorption, activation, inactivation and elim-
ination may produce nonlinearity in the dose–
response relationship (Hoel et al., 1983; Gart 
et al., 1986), as could saturation of processes such 
as DNA repair. The dose–response relationship 
can also be affected by differences in survival 
among the treatment groups.
(c) Statistical analyses
Factors considered include the adequacy of 
the information given for each treatment group: 
(i) number of animals studied and number exam-
ined histologically, (ii) number of animals with a 
given tumour type and (iii) length of survival. 
The statistical methods used should be clearly 
stated and should be the generally accepted tech-
niques refined for this purpose (Peto et al., 1980; 
Gart et al., 1986; Portier & Bailer, 1989; Bieler & 
Williams, 1993). The choice of the most appro-
priate statistical method requires consideration 
of whether or not there are differences in sur-
vival among the treatment groups; for example, 
reduced survival because of non-tumour-related 
mortality can preclude the occurrence of 
tumours later in life. When detailed informa-
tion on survival is not available, comparisons 
of the proportions of tumour-bearing animals 
among the effective number of animals (alive at 
the time the first tumour was discovered) can 
be useful when significant differences in sur-
vival occur before tumours appear. The lethal-
ity of the tumour also requires consideration: for 
rapidly fatal tumours, the time of death provides 
an indication of the time of tumour onset and 
can be assessed using life-table methods; non-
fatal or incidental tumours that do not affect 
survival can be assessed using methods such as 
the Mantel-Haenzel test for changes in tumour 
prevalence. Because tumour lethality is often dif-
ficult to determine, methods such as the Poly-K 
test that do not require such information can 
also be used. When results are available on the 
number and size of tumours seen in experimen-
tal animals (e.g. papillomas on mouse skin, liver 
tumours observed through nuclear magnetic 
resonance tomography), other more complicated 
statistical procedures may be needed (Sherman 
et al., 1994; Dunson et al., 2003).
Formal statistical methods have been devel-
oped to incorporate historical control data into 
the analysis of data from a given experiment. 
These methods assign an appropriate weight to 
historical and concurrent controls on the basis 
of the extent of between-study and within-study 
variability: less weight is given to historical con-
trols when they show a high degree of variability, 
and greater weight when they show little varia-
bility. It is generally not appropriate to discount 
a tumour response that is significantly increased 
compared with concurrent controls by arguing 
that it falls within the range of historical controls, 
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particularly when historical controls show high 
between-study variability and are, thus, of little 
relevance to the current experiment. In analys-
ing results for uncommon tumours, however, the 
analysis may be improved by considering histori-
cal control data, particularly when between-study 
variability is low. Historical controls should be 
selected to resemble the concurrent controls as 
closely as possible with respect to species, gen-
der and strain, as well as other factors such as 
basal diet and general laboratory environment, 
which may affect tumour-response rates in con-
trol animals (Haseman et al., 1984; Fung et al., 
1996; Greim et al., 2003).
Although meta-analyses and combined anal-
yses are conducted less frequently for animal 
experiments than for epidemiological studies 
due to differences in animal strains, they can be 
useful aids in interpreting animal data when the 
experimental protocols are sufficiently similar.
4. Mechanistic and other relevant 
data
Mechanistic and other relevant data may pro-
vide evidence of carcinogenicity and also help in 
assessing the relevance and importance of find-
ings of cancer in animals and in humans. The 
nature of the mechanistic and other relevant data 
depends on the biological activity of the agent 
being considered. The Working Group considers 
representative studies to give a concise descrip-
tion of the relevant data and issues that they con-
sider to be important; thus, not every available 
study is cited. Relevant topics may include toxi-
cokinetics, mechanisms of carcinogenesis, sus-
ceptible individuals, populations and life-stages, 
other relevant data and other adverse effects. 
When data on biomarkers are informative about 
the mechanisms of carcinogenesis, they are 
included in this section.
These topics are not mutually exclusive; thus, 
the same studies may be discussed in more than 
one subsection. For example, a mutation in a 
gene that codes for an enzyme that metabolizes 
the agent under study could be discussed in the 
subsections on toxicokinetics, mechanisms and 
individual susceptibility if it also exists as an 
inherited polymorphism.
(a) Toxicokinetic data
Toxicokinetics refers to the absorption, dis-
tribution, metabolism and elimination of agents 
in humans, experimental animals and, where 
relevant, cellular systems. Examples of kinetic 
factors that may affect dose–response relation-
ships include uptake, deposition, biopersis-
tence and half-life in tissues, protein binding, 
metabolic activation and detoxification. Studies 
that indicate the metabolic fate of the agent in 
humans and in experimental animals are sum-
marized briefly, and comparisons of data from 
humans and animals are made when possible. 
Comparative information on the relationship 
between exposure and the dose that reaches the 
target site may be important for the extrapola-
tion of hazards between species and in clarifying 
the role of in-vitro findings.
(b) Data on mechanisms of carcinogenesis
To provide focus, the Working Group 
attempts to identify the possible mechanisms by 
which the agent may increase the risk of cancer. 
For each possible mechanism, a representative 
selection of key data from humans and experi-
mental systems is summarized. Attention is 
given to gaps in the data and to data that suggests 
that more than one mechanism may be operat-
ing. The relevance of the mechanism to humans 
is discussed, in particular, when mechanistic 
data are derived from experimental model sys-
tems. Changes in the affected organs, tissues or 
cells can be divided into three non-exclusive lev-
els as described below.
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(i) Changes in physiology
Physiological changes refer to exposure-
related modifications to the physiology and/or 
response of cells, tissues and organs. Examples 
of potentially adverse physiological changes 
include mitogenesis, compensatory cell division, 
escape from apoptosis and/or senescence, pres-
ence of inflammation, hyperplasia, metaplasia 
and/or preneoplasia, angiogenesis, alterations in 
cellular adhesion, changes in steroidal hormones 
and changes in immune surveillance.
(ii) Functional changes at the cellular level
Functional changes refer to exposure-related 
alterations in the signalling pathways used by 
cells to manage critical processes that are related 
to increased risk for cancer. Examples of func-
tional changes include modified activities of 
enzymes involved in the metabolism of xenobi-
otics, alterations in the expression of key genes 
that regulate DNA repair, alterations in cyclin-
dependent kinases that govern cell cycle progres-
sion, changes in the patterns of post-translational 
modifications of proteins, changes in regula-
tory factors that alter apoptotic rates, changes 
in the secretion of factors related to the stimula-
tion of DNA replication and transcription and 
changes in gap–junction-mediated intercellular 
communication.
(iii) Changes at the molecular level
Molecular changes refer to exposure-related 
changes in key cellular structures at the molec-
ular level, including, in particular, genotoxicity. 
Examples of molecular changes include forma-
tion of DNA adducts and DNA strand breaks, 
mutations in genes, chromosomal aberrations, 
aneuploidy and changes in DNA methylation 
patterns. Greater emphasis is given to irrevers-
ible effects.
The use of mechanistic data in the identifica-
tion of a carcinogenic hazard is specific to the 
mechanism being addressed and is not readily 
described for every possible level and mechanism 
discussed above.
Genotoxicity data are discussed here to illus-
trate the key issues involved in the evaluation of 
mechanistic data.
Tests for genetic and related effects are 
described in view of the relevance of gene muta-
tion and chromosomal aberration/aneuploidy 
to carcinogenesis (Vainio et al., 1992; McGregor 
et al., 1999). The adequacy of the reporting of 
sample characterization is considered and, when 
necessary, commented upon; with regard to 
complex mixtures, such comments are similar 
to those described for animal carcinogenicity 
tests. The available data are interpreted critically 
according to the end-points detected, which 
may include DNA damage, gene mutation, sister 
chromatid exchange, micronucleus formation, 
chromosomal aberrations and aneuploidy. The 
concentrations employed are given, and men-
tion is made of whether the use of an exogenous 
metabolic system in vitro affected the test result. 
These data are listed in tabular form by phyloge-
netic classification.
Positive results in tests using prokary-
otes, lower eukaryotes, insects, plants and cul-
tured mammalian cells suggest that genetic and 
related effects could occur in mammals. Results 
from such tests may also give information on 
the types of genetic effect produced and on the 
involvement of metabolic activation. Some end-
points described are clearly genetic in nature 
(e.g. gene mutations), while others are associated 
with genetic effects (e.g. unscheduled DNA syn-
thesis). In-vitro tests for tumour promotion, cell 
transformation and gap–junction intercellular 
communication may be sensitive to changes that 
are not necessarily the result of genetic altera-
tions but that may have specific relevance to the 
process of carcinogenesis. Critical appraisals 
of these tests have been published (Montesano 
et al., 1986; McGregor et al., 1999).
Genetic or other activity manifest in humans 
and experimental mammals is regarded to be of 
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greater relevance than that in other organisms. 
The demonstration that an agent can induce 
gene and chromosomal mutations in mammals 
in vivo indicates that it may have carcinogenic 
activity. Negative results in tests for mutagenicity 
in selected tissues from animals treated in vivo 
provide less weight, partly because they do not 
exclude the possibility of an effect in tissues other 
than those examined. Moreover, negative results 
in short-term tests with genetic end-points can-
not be considered to provide evidence that rules 
out the carcinogenicity of agents that act through 
other mechanisms (e.g. receptor-mediated 
effects, cellular toxicity with regenerative cell 
division, peroxisome proliferation) (Vainio et al., 
1992). Factors that may give misleading results 
in short-term tests have been discussed in detail 
elsewhere (Montesano et al., 1986; McGregor 
et al., 1999).
When there is evidence that an agent acts by 
a specific mechanism that does not involve gen-
otoxicity (e.g. hormonal dysregulation, immune 
suppression, and formation of calculi and other 
deposits that cause chronic irritation), that evi-
dence is presented and reviewed critically in the 
context of rigorous criteria for the operation of 
that mechanism in carcinogenesis (e.g. Capen 
et al., 1999).
For biological agents such as viruses, bacteria 
and parasites, other data relevant to carcinogenic-
ity may include descriptions of the pathology of 
infection, integration and expression of viruses, 
and genetic alterations seen in human tumours. 
Other observations that might comprise cellu-
lar and tissue responses to infection, immune 
response and the presence of tumour markers 
are also considered.
For physical agents that are forms of radia-
tion, other data relevant to carcinogenicity may 
include descriptions of damaging effects at the 
physiological, cellular and molecular level, as 
for chemical agents, and descriptions of how 
these effects occur. ‘Physical agents’ may also be 
considered to comprise foreign bodies, such as 
surgical implants of various kinds, and poorly 
soluble fibres, dusts and particles of various 
sizes, the pathogenic effects of which are a result 
of their physical presence in tissues or body 
cavities. Other relevant data for such materials 
may include characterization of cellular, tissue 
and physiological reactions to these materi-
als and descriptions of pathological conditions 
other than neoplasia with which they may be 
associated.
(c) Other data relevant to mechanisms
A description is provided of any structure–
activity relationships that may be relevant to an 
evaluation of the carcinogenicity of an agent, the 
toxicological implications of the physical and 
chemical properties, and any other data relevant 
to the evaluation that are not included elsewhere.
High-output data, such as those derived from 
gene expression microarrays, and high-through-
put data, such as those that result from testing 
hundreds of agents for a single end-point, pose a 
unique problem for the use of mechanistic data 
in the evaluation of a carcinogenic hazard. In 
the case of high-output data, there is the possi-
bility to overinterpret changes in individual end-
points (e.g. changes in expression in one gene) 
without considering the consistency of that find-
ing in the broader context of the other end-points 
(e.g. other genes with linked transcriptional con-
trol). High-output data can be used in assessing 
mechanisms, but all end-points measured in a 
single experiment need to be considered in the 
proper context. For high-throughput data, where 
the number of observations far exceeds the num-
ber of end-points measured, their utility for iden-
tifying common mechanisms across multiple 
agents is enhanced. These data can be used to 
identify mechanisms that not only seem plausi-
ble, but also have a consistent pattern of carci-
nogenic response across entire classes of related 
compounds.
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(d) Susceptibility data
Individuals, populations and life-stages may 
have greater or lesser susceptibility to an agent, 
based on toxicokinetics, mechanisms of carcino-
genesis and other factors. Examples of host and 
genetic factors that affect individual susceptibil-
ity include sex, genetic polymorphisms of genes 
involved in the metabolism of the agent under 
evaluation, differences in metabolic capacity due 
to life-stage or the presence of disease, differ-
ences in DNA repair capacity, competition for 
or alteration of metabolic capacity by medica-
tions or other chemical exposures, pre-existing 
hormonal imbalance that is exacerbated by a 
chemical exposure, a suppressed immune sys-
tem, periods of higher-than-usual tissue growth 
or regeneration and genetic polymorphisms that 
lead to differences in behaviour (e.g. addiction). 
Such data can substantially increase the strength 
of the evidence from epidemiological data and 
enhance the linkage of in-vivo and in-vitro labo-
ratory studies to humans.
(e) Data on other adverse effects
Data on acute, subchronic and chronic 
adverse effects relevant to the cancer evaluation 
are summarized. Adverse effects that confirm 
distribution and biological effects at the sites of 
tumour development, or alterations in physiol-
ogy that could lead to tumour development, are 
emphasized. Effects on reproduction, embryonic 
and fetal survival and development are summa-
rized briefly. The adequacy of epidemiological 
studies of reproductive outcome and genetic and 
related effects in humans is judged by the same 
criteria as those applied to epidemiological stud-
ies of cancer, but fewer details are given.
5. Summary
This section is a summary of data presented 
in the preceding sections. Summaries can be 
found on the Monographs programme web site 
(http://monographs.iarc.fr).
(a) Exposure data
Data are summarized, as appropriate, on the 
basis of elements such as production, use, occur-
rence and exposure levels in the workplace and 
environment and measurements in human tis-
sues and body fluids. Quantitative data and time 
trends are given to compare exposures in dif-
ferent occupations and environmental settings. 
Exposure to biological agents is described in 
terms of transmission, prevalence and persis-
tence of infection.
(b) Cancer in humans
Results of epidemiological studies pertinent 
to an assessment of human carcinogenicity are 
summarized. When relevant, case reports and 
correlation studies are also summarized. The tar-
get organ(s) or tissue(s) in which an increase in 
cancer was observed is identified. Dose–response 
and other quantitative data may be summarized 
when available.
(c) Cancer in experimental animals
Data relevant to an evaluation of carcino-
genicity in animals are summarized. For each 
animal species, study design and route of admin-
istration, it is stated whether an increased inci-
dence, reduced latency, or increased severity 
or multiplicity of neoplasms or preneoplastic 
lesions were observed, and the tumour sites are 
indicated. If the agent produced tumours after 
prenatal exposure or in single-dose experiments, 
this is also mentioned. Negative findings, inverse 
relationships, dose–response and other quantita-
tive data are also summarized.
(d) Mechanistic and other relevant data
Data relevant to the toxicokinetics (absorp-
tion, distribution, metabolism, elimination) and 
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the possible mechanism(s) of carcinogenesis (e.g. 
genetic toxicity, epigenetic effects) are summa-
rized. In addition, information on susceptible 
individuals, populations and life-stages is sum-
marized. This section also reports on other toxic 
effects, including reproductive and developmen-
tal effects, as well as additional relevant data that 
are considered to be important.
6. Evaluation and rationale
Evaluations of the strength of the evidence for 
carcinogenicity arising from human and experi-
mental animal data are made, using standard 
terms. The strength of the mechanistic evidence 
is also characterized.
It is recognized that the criteria for these 
evaluations, described below, cannot encompass 
all of the factors that may be relevant to an eval-
uation of carcinogenicity. In considering all of 
the relevant scientific data, the Working Group 
may assign the agent to a higher or lower cat-
egory than a strict interpretation of these criteria 
would indicate.
These categories refer only to the strength of 
the evidence that an exposure is carcinogenic 
and not to the extent of its carcinogenic activ-
ity (potency). A classification may change as new 
information becomes available.
An evaluation of the degree of evidence is lim-
ited to the materials tested, as defined physically, 
chemically or biologically. When the agents eval-
uated are considered by the Working Group to be 
sufficiently closely related, they may be grouped 
together for the purpose of a single evaluation of 
the degree of evidence.
(a) Carcinogenicity in humans
The evidence relevant to carcinogenicity from 
studies in humans is classified into one of the fol-
lowing categories:
Sufficient evidence of carcinogenicity: 
The Working Group considers that a causal 
relationship has been established between expo-
sure to the agent and human cancer. That is, a 
positive relationship has been observed between 
the exposure and cancer in studies in which 
chance, bias and confounding could be ruled 
out with reasonable confidence. A statement that 
there is sufficient evidence is followed by a sepa-
rate sentence that identifies the target organ(s) or 
tissue(s) where an increased risk of cancer was 
observed in humans. Identification of a specific 
target organ or tissue does not preclude the pos-
sibility that the agent may cause cancer at other 
sites.
Limited evidence of carcinogenicity: 
A positive association has been observed 
between exposure to the agent and cancer for 
which a causal interpretation is considered by 
the Working Group to be credible, but chance, 
bias or confounding could not be ruled out with 
reasonable confidence.
Inadequate evidence of carcinogenicity: The 
available studies are of insufficient quality, con-
sistency or statistical power to permit a conclu-
sion regarding the presence or absence of a causal 
association between exposure and cancer, or no 
data on cancer in humans are available.
Evidence suggesting lack of carcinogenicity: 
There are several adequate studies covering the 
full range of levels of exposure that humans are 
known to encounter, which are mutually consist-
ent in not showing a positive association between 
exposure to the agent and any studied cancer 
at any observed level of exposure. The results 
from these studies alone or combined should 
have narrow confidence intervals with an upper 
limit close to the null value (e.g. a relative risk 
of 1.0). Bias and confounding should be ruled 
out with reasonable confidence, and the studies 
should have an adequate length of follow-up. A 
conclusion of evidence suggesting lack of carcino-
genicity is inevitably limited to the cancer sites, 
conditions and levels of exposure, and length of 
observation covered by the available studies. In 
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addition, the possibility of a very small risk at the 
levels of exposure studied can never be excluded.
In some instances, the above categories may 
be used to classify the degree of evidence related 
to carcinogenicity in specific organs or tissues.
When the available epidemiological stud-
ies pertain to a mixture, process, occupation or 
industry, the Working Group seeks to identify 
the specific agent considered most likely to be 
responsible for any excess risk. The evaluation 
is focused as narrowly as the available data on 
exposure and other aspects permit.
(b) Carcinogenicity in experimental 
animals
Carcinogenicity in experimental animals can 
be evaluated using conventional bioassays, bioas-
says that employ genetically modified animals, 
and other in-vivo bioassays that focus on one or 
more of the critical stages of carcinogenesis. In 
the absence of data from conventional long-term 
bioassays or from assays with neoplasia as the 
end-point, consistently positive results in several 
models that address several stages in the multi-
stage process of carcinogenesis should be con-
sidered in evaluating the degree of evidence of 
carcinogenicity in experimental animals.
The evidence relevant to carcinogenicity in 
experimental animals is classified into one of the 
following categories:
Sufficient evidence of carcinogenicity: The 
Working Group considers that a causal relation-
ship has been established between the agent and 
an increased incidence of malignant neoplasms 
or of an appropriate combination of benign and 
malignant neoplasms in (a) two or more species 
of animals or (b) two or more independent stud-
ies in one species carried out at different times 
or in different laboratories or under different 
protocols. An increased incidence of tumours in 
both sexes of a single species in a well conducted 
study, ideally conducted under Good Laboratory 
Practices, can also provide sufficient evidence.
A single study in one species and sex might be 
considered to provide sufficient evidence of carci-
nogenicity when malignant neoplasms occur to 
an unusual degree with regard to incidence, site, 
type of tumour or age at onset, or when there are 
strong findings of tumours at multiple sites.
Limited evidence of carcinogenicity: 
The data suggest a carcinogenic effect but are 
limited for making a definitive evaluation 
because, e.g. (a) the evidence of carcinogenicity 
is restricted to a single experiment; (b) there are 
unresolved questions regarding the adequacy of 
the design, conduct or interpretation of the stud-
ies; (c) the agent increases the incidence only of 
benign neoplasms or lesions of uncertain neo-
plastic potential; or (d) the evidence of carcino-
genicity is restricted to studies that demonstrate 
only promoting activity in a narrow range of tis-
sues or organs.
Inadequate evidence of carcinogenicity: 
The studies cannot be interpreted as showing 
either the presence or absence of a carcinogenic 
effect because of major qualitative or quantitative 
limitations, or no data on cancer in experimental 
animals are available.
Evidence suggesting lack of carcinogenicity: 
Adequate studies involving at least two species 
are available which show that, within the limits 
of the tests used, the agent is not carcinogenic. 
A conclusion of evidence suggesting lack of car-
cinogenicity is inevitably limited to the species, 
tumour sites, age at exposure, and conditions 
and levels of exposure studied.
(c) Mechanistic and other relevant data
Mechanistic and other evidence judged to 
be relevant to an evaluation of carcinogenicity 
and of sufficient importance to affect the over-
all evaluation is highlighted. This may include 
data on preneoplastic lesions, tumour pathol-
ogy, genetic and related effects, structure–activ-
ity relationships, metabolism and toxicokinetics, 
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physicochemical parameters and analogous bio-
logical agents.
The strength of the evidence that any carcino-
genic effect observed is due to a particular mech-
anism is evaluated, using terms such as ‘weak’, 
‘moderate’ or ‘strong’. The Working Group then 
assesses whether that particular mechanism is 
likely to be operative in humans. The strongest 
indications that a particular mechanism oper-
ates in humans derive from data on humans 
or biological specimens obtained from exposed 
humans. The data may be considered to be espe-
cially relevant if they show that the agent in ques-
tion has caused changes in exposed humans that 
are on the causal pathway to carcinogenesis. 
Such data may, however, never become available, 
because it is at least conceivable that certain com-
pounds may be kept from human use solely on 
the basis of evidence of their toxicity and/or car-
cinogenicity in experimental systems.
The conclusion that a mechanism operates in 
experimental animals is strengthened by find-
ings of consistent results in different experimen-
tal systems, by the demonstration of biological 
plausibility and by coherence of the overall data-
base. Strong support can be obtained from stud-
ies that challenge the hypothesized mechanism 
experimentally, by demonstrating that the sup-
pression of key mechanistic processes leads to 
the suppression of tumour development. The 
Working Group considers whether multiple 
mechanisms might contribute to tumour devel-
opment, whether different mechanisms might 
operate in different dose ranges, whether sepa-
rate mechanisms might operate in humans and 
experimental animals and whether a unique 
mechanism might operate in a susceptible group. 
The possible contribution of alternative mecha-
nisms must be considered before concluding 
that tumours observed in experimental animals 
are not relevant to humans. An uneven level of 
experimental support for different mechanisms 
may reflect that disproportionate resources 
have been focused on investigating a favoured 
mechanism.
For complex exposures, including occupa-
tional and industrial exposures, the chemical 
composition and the potential contribution of 
carcinogens known to be present are considered 
by the Working Group in its overall evaluation 
of human carcinogenicity. The Working Group 
also determines the extent to which the materi-
als tested in experimental systems are related to 
those to which humans are exposed.
(d) Overall evaluation
Finally, the body of evidence is considered as 
a whole, to reach an overall evaluation of the car-
cinogenicity of the agent to humans.
An evaluation may be made for a group of 
agents that have been evaluated by the Working 
Group. In addition, when supporting data indi-
cate that other related agents, for which there is 
no direct evidence of their capacity to induce 
cancer in humans or in animals, may also be 
carcinogenic, a statement describing the ration-
ale for this conclusion is added to the evaluation 
narrative; an additional evaluation may be made 
for this broader group of agents if the strength of 
the evidence warrants it.
The agent is described according to the word-
ing of one of the following categories, and the 
designated group is given. The categorization of 
an agent is a matter of scientific judgement that 
reflects the strength of the evidence derived from 
studies in humans and in experimental animals 
and from mechanistic and other relevant data.
Group 1: The agent is carcinogenic to 
humans .
This category is used when there is suffi-
cient evidence of carcinogenicity in humans. 
Exceptionally, an agent may be placed in this 
category when evidence of carcinogenicity in 
humans is less than sufficient but there is suffi-
cient evidence of carcinogenicity in experimental 
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animals and strong evidence in exposed humans 
that the agent acts through a relevant mechanism 
of carcinogenicity.
Group 2 .
This category includes agents for which, at 
one extreme, the degree of evidence of carcino-
genicity in humans is almost sufficient, as well as 
those for which, at the other extreme, there are 
no human data but for which there is evidence of 
carcinogenicity in experimental animals. Agents 
are assigned to either Group 2A (probably car-
cinogenic to humans) or Group 2B (possibly 
carcinogenic to humans) on the basis of epide-
miological and experimental evidence of carci-
nogenicity and mechanistic and other relevant 
data. The terms probably carcinogenic and possi-
bly carcinogenic have no quantitative significance 
and are used simply as descriptors of different 
levels of evidence of human carcinogenicity, with 
probably carcinogenic signifying a higher level of 
evidence than possibly carcinogenic.
Group 2A: The agent is probably 
carcinogenic to humans .
This category is used when there is limited 
evidence of carcinogenicity in humans and suffi-
cient evidence of carcinogenicity in experimental 
animals. In some cases, an agent may be classi-
fied in this category when there is inadequate evi-
dence of carcinogenicity in humans and sufficient 
evidence of carcinogenicity in experimental ani-
mals and strong evidence that the carcinogenesis 
is mediated by a mechanism that also operates 
in humans. Exceptionally, an agent may be clas-
sified in this category solely on the basis of lim-
ited evidence of carcinogenicity in humans. An 
agent may be assigned to this category if it clearly 
belongs, based on mechanistic considerations, to 
a class of agents for which one or more members 
have been classified in Group 1 or Group 2A.
Group 2B: The agent is possibly carcinogenic 
to humans .
This category is used for agents for which 
there is limited evidence of carcinogenicity in 
humans and less than sufficient evidence of car-
cinogenicity in experimental animals. It may 
also be used when there is inadequate evidence 
of carcinogenicity in humans but there is suffi-
cient evidence of carcinogenicity in experimental 
animals. In some instances, an agent for which 
there is inadequate evidence of carcinogenicity in 
humans and less than sufficient evidence of car-
cinogenicity in experimental animals together 
with supporting evidence from mechanistic and 
other relevant data may be placed in this group. 
An agent may be classified in this category solely 
on the basis of strong evidence from mechanistic 
and other relevant data.
Group 3: The agent is not classifiable as to its 
carcinogenicity to humans .
This category is used most commonly for 
agents for which the evidence of carcinogenicity 
is inadequate in humans and inadequate or lim-
ited in experimental animals.
Exceptionally, agents for which the evidence 
of carcinogenicity is inadequate in humans but 
sufficient in experimental animals may be placed 
in this category when there is strong evidence 
that the mechanism of carcinogenicity in experi-
mental animals does not operate in humans.
Agents that do not fall into any other group 
are also placed in this category.
An evaluation in Group 3 is not a determi-
nation of non-carcinogenicity or overall safety. 
It often means that further research is needed, 
especially when exposures are widespread or 
the cancer data are consistent with differing 
interpretations.
Group 4: The agent is probably not 
carcinogenic to humans .
This category is used for agents for which 
there is evidence suggesting lack of carcinogenicity 
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in humans and in experimental animals. In 
some instances, agents for which there is inad-
equate evidence of carcinogenicity in humans 
but evidence suggesting lack of carcinogenicity in 
experimental animals, consistently and strongly 
supported by a broad range of mechanistic and 
other relevant data, may be classified in this 
group.
(e) Rationale
The reasoning that the Working Group used 
to reach its evaluation is presented and discussed. 
This section integrates the major findings from 
studies of cancer in humans, studies of cancer 
in experimental animals, and mechanistic and 
other relevant data. It includes concise state-
ments of the principal line(s) of argument that 
emerged, the conclusions of the Working Group 
on the strength of the evidence for each group of 
studies, citations to indicate which studies were 
pivotal to these conclusions, and an explanation 
of the reasoning of the Working Group in weigh-
ing data and making evaluations. When there 
are significant differences of scientific interpre-
tation among Working Group Members, a brief 
summary of the alternative interpretations is 
provided, together with their scientific rationale 
and an indication of the relative degree of sup-
port for each alternative.
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Part B of Volume 100 of the IARC Monographs on the Evaluation of Carcinogenic Risks to 
Humans considers 11 biological agents that were first classified in Volumes 1–99: seven 
viruses, three worms, and one bacterium.
Most of these agents were evaluated more than 15 years ago, and were classified by IARC 
as carcinogenic to humans (Group 1) with two exceptions: Kaposi sarcoma-associated 
herpesvirus (KSHV), and the worm Clonorchis sinensis, both previously classified as prob-
ably carcinogenic to humans (Group 2A). KSHV was last assessed ten years ago and, in view 
of the extensive scientific literature published since, needed to be re-evaluated. Clonorchis 
sinensis was also included because its biology and epidemiology of infection are very simi-
lar to those of Opisthorchis viverrini, another worm reviewed in this volume.
Volume 100 – General Information
About half of the agents classified in Group 1 were last reviewed more than 20 years ago, before 
mechanistic studies became prominent in evaluations of carcinogenicity. In addition, more recent 
epidemiological studies and animal cancer bioassays have demonstrated that many cancer hazards 
reported in earlier studies were later observed in other organs or through different exposure sce-
narios. Much can be learned by updating the assessments of agents that are known to cause cancer 
in humans. Accordingly, IARC has selected A Review of Human Carcinogens to be the topic for 
Volume 100. It is hoped that this volume, by compiling the knowledge accumulated through several 
decades of cancer research, will stimulate cancer prevention activities worldwide, and will be a valued 
resource for future research to identify other agents suspected of causing cancer in humans.
Volume 100 was developed by six separate Working Groups:
Pharmaceuticals
Biological agents
Arsenic, metals, fibres, and dusts
Radiation
Personal habits and indoor combustions
Chemical agents and related occupations
Because the scope of Volume 100 is so broad, its Monographs are focused on key information. 
Each Monograph presents a description of a carcinogenic agent and how people are exposed, critical 
35
IARC MONOGRAPHS – 100B
overviews of the epidemiological studies and animal cancer bioassays, and a concise review of the 
toxicokinetic properties of the agent, plausible mechanisms of carcinogenesis, and potentially sus-
ceptible populations, and life-stages. Details of the design and results of individual epidemiologi-
cal studies and animal cancer bioassays are summarized in tables. Short tables that highlight key 
results appear in the printed version of Volume 100, and more extensive tables that include all studies 
appear on the website of the IARC Monographs programme (http://monographs.iarc.fr). For a few 
well-established associations (for example, tobacco smoke and human lung cancer), it was impracti-
cal to include all studies, even in the website tables. In those instances, the rationale for inclusion or 
exclusion of sets of studies is given.
Each section of Volume 100 was reviewed by a subgroup of the Working Group with appropriate 
subject expertise; then all sections of each Monograph were discussed together in a plenary session 
of the full Working Group. As a result, the evaluation statements and other conclusions reflect the 
views of the Working Group as a whole.
Volume 100 compiles information on tumour sites and mechanisms of carcinogenesis. This infor-
mation will be used in two scientific publications that may be considered as annexes to this volume. 
One publication, Tumour Site Concordance between Humans and Experimental Animals, will ana-
lyse the correspondence of tumour sites among humans and different animal species. It will dis-
cuss the predictive value of different animal tumours for cancer in humans, and perhaps identify 
human tumour sites for which there are no good animal models. Another publication, Mechanisms 
Involved in Human Carcinogenesis, will describe mechanisms known to or likely to cause cancer in 
humans. Joint consideration of multiple agents that act through similar mechanisms should facilitate 
the development of a more comprehensive discussion of these mechanisms. Because susceptibility 
often has its basis in a mechanism, this could also facilitate a more confident and precise description 
of populations that may be susceptible to agents acting through each mechanism. This publication 
will also suggest biomarkers that could render future research more informative. In this way, IARC 
hopes that Volume 100 will serve to improve the design of future cancer studies.
Specific remarks about the review of biological agents in this volume
1. Historical aspects*
Current knowledge linking infection with some biological agents and carcinogenesis in humans 
is the result of a long and laborious but exciting succession of scientific discoveries, which started 
more than a century ago. These important historical steps have been thoroughly retraced by Dr 
Harald Zur Hausen in his recent book “Infections Causing Human Cancer” (2006) from which this 
paragraph has extracted some highlights.
At the end of the 19th century, the first suspicions arose that infectious agents (initially parasites, 
liver flukes and Schistosoma infections) could cause specific human cancers: in 1900 Askanazy reported 
a link between infection by a liver fluke and liver cancer in former East Prussia (Askanazy, 1900). Five 
years later, another report described a case of chronic infection with bilharzia (schistosomiasis) and 
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General remarks
bladder cancer (Goebel, 1905). It took more than 50 additional years before further evidence emerged 
of an involvement of infectious agents in human cancers.
In 1958, a British surgeon, Dennis Burkitt, described a specific childhood lymphoma in equatorial 
Africa occurring only in specific geographic regions: it was subsequently called Burkitt lymphoma. 
Because these regions coincided with areas of holoendemic malaria, Burkitt speculated that this 
tumour should have an infectious etiology, most likely vectored by an arthropod, possibly by a mos-
quito (Burkitt, 1962). In a small fraction of cultured Burkitt lymphoma cells Epstein and colleagues 
(1964) noticed herpesvirus-like particles: a new member of the Herpesvirus family was discovered 
and later named Epstein-Barr virus (EBV).
The development of immunofluorescence allowed the detection of highly elevated antibody 
titres against EBV viral antigens in patients with Burkitt lymphoma (Henle & Henle, 1966, Henle 
et al., 1969), and subsequently also in a second human cancer, nasopharyngeal carcinoma (Old et al., 
1966). EBV was also identified as the causative agent of infectious mononucleosis (Henle et al., 1968). 
Besides, the Henles’ laboratory first demonstrated that latent EBV infection was widespread in all 
human populations.
The first hints of an oncogenic potential of EBV originated from the establishment of lympho-
blastoid lines of cord-blood origin when co-cultivated with lethally X-irradiated Burkitt lymphoma 
cells in culture (Henle et al., 1967). This was further underlined by the discovery of persisting EBV 
DNA in “virus-negative” Burkitt lymphoma cells (zur Hausen & Schulte-Holthausen, 1970), as well 
as in primary biopsies from Burkitt lymphomas and nasopharyngeal cancer (zur Hausen et al., 1970; 
Wolf et al., 1973). The induction of lymphoproliferative disease after inoculation of EBV into cot-
tontop marmosets (Shope et al., 1973) or owl monkeys (Epstein et al., 1973) added to the evidence in 
this early phase.
In the 1970s, more infectious agents were considered as potential human carcinogens. Three inde-
pendent findings contributed to this development: the discovery of a role of hepatitis B virus (HBV) 
in liver cancer, the identification of a retrovirus in a rare form of human leukaemia, and the charac-
terization of novel types of papillomaviruses causing the second most frequent cancer in women, i.e. 
cancer of the cervix.
The frequent coincidence between infectious hepatitis and hepatocellular carcinoma (HCC) was 
noted early in Africa in the 1950s by British and French pathologists (reviewed in Szmuness, 1978). 
While investigating a potential role of human genetic polymorphisms in relation to inherited suscep-
tibility to disease, Blumberg et al. (1965) described a “new” antigen in the blood of an Australian abo-
rigine (the “Au“ antigen), which was shortly thereafter recognized to be the surface antigen of HBV, 
termed today HBsAg (Blumberg et al., 1967; Blumberg, 1997). In this case, basic research initially 
remote from studies on infectious agents led to the discovery of HBV, to diagnostic methods for viral 
detection efficiently used for donor blood testing, and finally to a vaccine. Several epidemiological 
studies followed this discovery and stressed a role of chronic infection with HBV in HCC develop-
ment. A key contribution was presented in 1981 by Beasley et al. with a prospective study in Taiwan 
(China) showing that HBV carriers had a more than 200-fold elevated risk for developing HCC than 
virus-negative individuals. Vaccination studies today underline the importance of this viral infection 
for hepatocellular carcinoma. Indeed, the world’s first universal HBV vaccination program launched 
in Taiwan (China) in July 1984 has resulted in a reduction of the original prevalence of HBV infection 
to approximately one-tenth, and a clear prevention for HCC by the vaccine was recently reported in 
childhood and early adulthood (Chang, 2011).
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The discovery of the first human retrovirus, human T-cell lymphotropic retrovirus (HTLV-1) 
and its association with human cancer originated from rather independent studies in Japan and 
in the USA. In 1977, a new type of leukaemia called adult-T-cell leukaemia/lymphoma (ATLL) was 
described by Takatsuki and colleagues in the coastal regions of southern and western Japan (Takatsuki 
et al., 1977; Uchiyama et al., 1977). The first isolation of HTLV-1 from a cutaneous T-cell lymphoma 
was reported in the USA (Poiesz et al., 1980). One year later, Japanese researchers identified the same 
virus from an ATLL cell line (Miyoshi et al., 1981), and could link this infection to this specific leu-
kaemia (Hinuma et al., 1981).
Shortly later, when the acquired immunodeficiency syndrome (AIDS) epidemic just started in the 
USA, the human immunodeficiency virus type 1 (HIV-1) was discovered as a new T-cell lympho-
tropic human retrovirus, first isolated from a patient with lymphadenopathy (Barré-Sinoussi et al., 
1983). The following year, the virus was firmly associated with AIDS (Gallo et al., 1984).
The initial link between human papillomavirus and cancer became clear as a result of research on 
a rare hereditary condition, epidermodysplasia verruciformis, described in 1922 by Lewandowsky and 
Lutz in Basel, and characterized by an extensive verrucosis. At sun-exposed sites of the body of these 
patients, some of the papillomatous lesions of the skin converted into squamous cell carcinomas. In 
Lutz (1946) and later Jablonska & Milewski (1957) proved the viral etiology of these warts in auto-
inoculation experiments. Then, in the late 1970s, novel types of papillomaviruses, most frequently 
HPV 5, were isolated within epidermodysplasia verruciformis lesions and biopsies of squamous cell 
carcinomas of those patients. (Orth et al., 1978, 1979).
Another track of papillomavirus research resulted in the identification of specific HPV types as 
causative agents for cancer of the cervix, other anogenital cancers, and a subset of oropharyngeal 
carcinomas. By the end of the 1960s and during the 1970s, serological studies suggested a role of her-
pes simplex virus type 2 (HSV 2) in cervical cancer (Rawls et al., 1968, Naib et al., 1969). However, 
a possible causal role of papillomavirus infections for cervical cancer was only postulated when sev-
eral anecdotal reports had shown malignant conversion of genital warts (condylomata acuminata). 
Attempts to characterize the viral DNA in genital warts started (zur Hausen et al., 1974, 1975, zur 
Hausen, 1976, 1977) leading initially to the discovery of the heterogeneity of the papillomavirus 
family (Gissmann & zur Hausen, 1976; Orth et al., 1977; Gissmann et al., 1977), which today com-
prises 120 fully sequenced genotypes (Bernard et al., 2010). The use of hybridization experiments, 
performed under conditions of reduced stringency with the DNA of the already isolated HPV types 
6 and 11 as probes permitted the subsequent cloning of HPV 16 (Dürst et al., 1983) and of HPV 18 
(Boshart et al., 1984), the two papillomavirus types most frequently found in cervical cancer.
The identification of three viral families with representative types clearly causing widespread 
human cancers gradually resulted in the acceptance of infectious agents as important human car-
cinogens. The subsequent identification of additional infections linked to other cancers further 
strengthened the role of infectious agents in human carcinogenesis. The hepatitis C virus (HCV) 
was identified in 1989 (Choo et al., 1989), and first reports on its relationship to a subset of HCC 
appeared in the same year (Bargiggia et al., 1989; Simonetti et al., 1989). There had been, however, 
some earlier reports, linking non-A, non-B hepatitis infections to liver cancer (Kiyosawa et al., 1982, 
Resnick et al., 1983 and others). Human herpesvirus type 8 (HHV-8) now called Kaposi sarcoma 
herpes virus (KSHV) was discovered in 1994 (Chang et al., 1994) as the most likely responsible agent 
for Kaposi’s sarcoma. In the early 1990s Helicobacter pylori, as a bacterial infection, was added to the 
list of potential human carcinogens (Forman et al., 1991; Nomura et al., 1991; Parsonnet et al., 1991; 
38
General remarks
and Wotherspoon et al., 1993), and several additional human papillomavirus genotypes were added 
to the list of oncogenic viruses.
Merkel cell polyomavirus (MCPyV), a novel member of the polyomavirus family has been recently 
identified (Feng et al., 2008). The available evidence seems to support an important role for this infec-
tion in the development of Merkel-cell carcinomas (Shuda et al., 2008).
Today, more than one hundred years after early attempts to link infections to human cancer, 
infections are recognized as a major factor in human carcinogenesis.
2. Global contribution of infections to human cancers
In 2002, it was estimated that 17.8% of cancers (1.9 million cases) were caused by viral (12.1%), 
bacterial (5.6%), and helminth (0.1%) infection (Parkin, 2006). Of these, the majority occur in devel-
oping countries (1.5 million cases), reflecting the higher prevalence of the major oncogenic infections 
in these areas. If the relevant infections could be controlled, it is conservatively estimated that there 
would be about 26% fewer cancers in developing countries, and approximately 8% fewer in developed 
countries. Since then, several new links between infectious agents and specific cancers have been 
established (Bouvard et al., 2009; this volume), further increasing the burden of infection-related 
cancers.
A better understanding of the role of infectious agents in the etiology of cancer is an essential 
element in public health policy, because such cancers are theoretically preventable by vaccination or 
early treatment of infection. Furthermore, cancer-causing infections often cause substantial morbid-
ity and mortality from non-malignant conditions (e.g. HBV). Therefore, an additional benefit of any 
public health plan to reduce the burden of cancers caused by infections would involve a reduction in 
the incidence of other diseases as well.
Temporal changes in the incidence of infection-associated cancers are difficult to predict. 
Although there is evidence that the prevalence of infection with, for example, Helicobacter pylori 
and HBV is declining as a result of efficient antibiotic treatments and vaccination respectively, other 
important oncogenic infections remain uncontrolled. For instance, it is unclear how changes in the 
prevalence of infection with HIV, or indeed how the roll-out of effective antiretroviral treatments 
for this virus, will impact on the associated cancer burden. Furthermore, vaccination against HPV 
is still too expensive for many developing countries.
3. Mechanistic considerations
3 .1 Specific tropism of the infectious agents leads to very specific cancers
The major distinctive feature of the biological agents as compared to other carcinogenic agents 
evaluated in the IARC monographs is that they are biological entities that have evolved to prefer-
entially target specific host species, specific organs or cell types within those species, and often – in 
the case of viruses – even cell types with a specific differentiation status. As a result, cancers asso-
ciated with viral infections are often very specific cancers, e.g. “adult T-cell leukaemia/lymphoma” 
associated with HTLV-1 and “extranodal NK/T-cell lymphoma (nasal type)” and “nasopharyngeal 
carcinoma,” both associated with EBV. Cell type-specific tropism also applies to bacteria such as 
Helicobacter pylori, associated with “non-cardia gastric carcinoma,” whereas worms such as liver 
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flukes or Schistosoma haematobium, associated with cholangiocarcinoma and urinary bladder can-
cer, respectively, only show organ-specific tropism.
3 .2 Mechanisms of carcinogenesis
From the overall data summarized in this volume, three major mechanisms of carcinogenesis 
have been recognized for biological agents that could be defined either as direct, indirect (acting via 
chronic inflammation), or indirect (acting via immune-suppression). To fully exploit their carcino-
genic potential, these agents have developed different strategies to evade the immune system. Finally, 
the data emphasize the potential role of cofactors, which are, however, largely understudied.
3 .2 .1 Direct carcinogens
Infectious agents can be direct carcinogens, and the ones known today are all viruses that fulfill 
the following criteria: 
The viral genome or part of it can usually be detected in each cancer cell. 
The virus can immortalize after the growth of target cells in vitro. 
It expresses several oncogenes that interact with cellular proteins and have multifunctional proper-
ties leading to disruption of the cell-cycle checkpoints, inhibition of apoptosis and cell immortaliza-
tion. 
Four viral agents have been described as direct carcinogens: several types of the human papil-
lomavirus family, the human T-cell lymphotropic virus type 1 (HTLV-1) and the two herpesviruses: 
Epstein-Barr virus (EBV) and Kaposi sarcoma- associated herpes virus (KSHV).
3 .2 .2 Indirect carcinogens that act via chronic inflammation
Infectious agents can be indirect carcinogens by causing chronic inflammation. Chronic infec-
tion followed by chronic inflammation will lead to the production of chemokines, cytokines, pros-
taglandins secreted by infected cells and/or inflammatory cells. This also leads to the production of 
reactive oxygen species – which have direct mutagenic effects – to the deregulation of the immune 
system, and to the promotion of angiogenesis, which is essential for tumour neovascularization and 
tumour survival.
Six infectious agents have been shown to be carcinogenic primarily by inducing chronic inflam-
mation. Those are the two hepatitis viruses, HBV and HCV, the bacterium Helicobacter pylori and, 
the three worms Schistosoma haematobium, Opistorchis viverrini, and Clonorchis sinensis.
3 .2 .3 Indirect carcinogens that act via immune-suppression
Infectious agents can act as indirect carcinogens by causing immune-suppression. This has been 
shown for HIV-1 infection which strongly increases the incidence of many different human cancers. 
Strikingly, the majority of cancers associated with HIV-1 infection have another known infectious 
etiology, and HIV-1 infection increases their incidence rate considerably. Among these cancers, those 
associated with the herpesviruses KSHV and EBV are the most strongly enhanced by immune sup-
pression. The same cancers are also increased by iatrogenic immune-suppression as shown by their 
increased incidence in transplant recipients, which lends additional support to the notion that HIV-1 
acts as a carcinogen mainly through immune-suppression. These considerations may suggest that 
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other cancers whose incidence is increased by immune suppression (e.g. non-melanoma skin cancer) 
may also have an infectious etiology.
3 .2 .4 Contribution of additional factors
It is estimated that about 5% of HTLV-1 carriers when infected before the age of 20 years will 
potentially develop adult-T-cell leukaemia/lymphoma (Cleghorn et al., 1995). Likewise, only a small 
proportion of carriers of the high-risk human papillomavirus type 16 in the cervix uteri will develop 
cervical cancer. The fact that infection with these carcinogenic viruses does not always lead to cancer 
is a common feature for all the infectious agents that were studied strongly suggests the involvement 
of cofactors in the carcinogenic process. Carcinogenesis would result from the interaction of multiple 
risk factors including those related to the infectious agent itself (e.g. variants or subtypes), host-related 
factors (e.g. gene polymorphisms and immune status) and environmental cofactors (e.g. chemicals, 
ionizing radiation, immunosuppressive drugs, or another infection that may lead to reactivation of 
latent oncogenic viruses such as EBV or KSHV). The contribution of several of these additional fac-
tors to the development of infection-associated cancers is likely to be substantial, but has not yet been 
elucidated in detail.
4. Other remarks
4 .1 The absence of a Section 3 “Cancer in Experimental Animals” in the Monographs on 
viruses
The Working Group decided not to include in this Volume a separate section on “Cancer in 
experimental animals” in the Monographs on viruses, but rather to include description of such stud-
ies under Section 4 “Other Relevant Data” for the following reasons:
• The use of animals as surrogate hosts for the study of a human tumour virus is often problem-
atic since species-specificity limits the feasibility of this approach for most of these viruses. 
HTLV-1 is one exception: this virus can infect several different animal species (rabbits, rats 
and monkeys) but does induce adult T-cell leukaemia/lymphoma in monkeys only. For some 
human tumour viruses (e.g. KSHV), the use of humanized SCID mice, in which the human 
target cell for the virus is placed into a mouse host context, can provide a platform for in-
vivo infection. However, apart from EBV, which causes lymphoproliferative diseases in New 
World monkeys and humanized SCID mice, the use of surrogate hosts has not proven very 
useful for assessing the carcinogenicity of human viruses in humans.
• Cancer models for human tumour viruses that make use of animal viruses are very scarce. In 
fact, although many viruses that infect non-human primate species are related to the human 
tumour viruses, the incidence of cancer is low in these species – as it is in humans – which 
makes cancer studies costly and difficult. Moreover, animal tumour virus models in non-
primate species often do not accurately reflect the mechanism of the disease caused by the 
cognate human tumour virus. For instance, woodchuck hepatitis virus induces HCC that is 
histopathologically very similar to that caused by HBV in humans, but it does so through a 
different mechanism.
• Transgenic mouse models provide powerful means for performing mechanistic studies to 
investigate the role of individual viral genes in cancer. Indeed, for many of the human tumour 
viruses described in this volume, transgenic mouse studies provide critical mechanistic 
41
IARC MONOGRAPHS – 100B
evidence. However, such transgenic mouse models do not represent models for understand-
ing the cancer etiology in the context of natural viral infections, and are therefore more 
appropriately discussed in Section 4.
4 .2 Difficulties in assessing causality for some cancers
The Working Group acknowledged the difficulties of assessing causality, on the basis of epide-
miological data, for certain rare cancer types in which presence of a specific infection was already 
been incorporated into the diagnostic criteria (e.g. HTLV-1 in relation to ATLL; KSHV and primary 
effusion lymphoma). In these instances, there was generally, but not always, convincing evidence for 
a causal relationship. Further epidemiological research on these cancers, often hampered by the rarity 
of the tumour, would require that currently accepted diagnostic criteria be reassessed.
4 .3 Classification of weakly carcinogenic human papillomavirus types
Previous IARC Monographs summarized the considerable evidence showing that virtually all 
cases of cervical cancer are caused by persistent infections with a restricted set of human papilloma-
viruses. However, the carcinogenic potential of HPV types is very heterogeneous. Most are not car-
cinogenic. Some HPV types, like HPV 16 and HPV 18, are clear and powerful carcinogens. It is the 
categorization of the most weakly carcinogenic HPV types that is most challenging. The distinctions 
are important for screening tests and vaccine development. Carcinogenic types are targeted in HPV-
screening assays to maximize sensitivity while others are excluded to preserve specificity. The types 
that are most carcinogenic are included in multivalent HPV vaccines to prevent the largest feasible 
fraction of cervical and other cancers. Thus, the Working Group made great efforts to consider the 
carcinogenic potential of each individual HPV type, with a strong emphasis on evolutionary relation-
ships and detection within cases of invasive cancers (Schiffman et al., 2009).
A summary of the findings of this volume appears in The Lancet Oncology (Bouvard et al., 2009).
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Dr. Baruch Blumberg received the Nobel Prize in Physiology or Medicine in 1976 for his 
discovery of the hepatitis B virus, one of the agents discussed in this Volume.
Dr. Blumberg died on 5 April 2011.
We wish to commemorate his achievements in the development of an HBV vaccine and 
the promotion of blood testing, which allowed millions of lives to be saved worldwide.
Photo © The Nobel Foundation

EPSTEIN-BARR VIRUS
The Epstein-Barr virus was considered by a previous IARC Working Group in 1997 (IARC, 
1997). Since that time, new data have become available, these have been incorporated in 
the Monograph, and taken into consideration in the present evaluation.
1. Exposure Data
1.1 Taxonomy, structure, and biology
1 .1 .1 Taxonomy
The Epstein-Barr virus (EBV), the first isolated 
human tumour virus, was identified in 1964 by 
Epstein’s group in a cell line derived from Burkitt 
lymphoma (Epstein et al., 1964). EBV is a human 
herpesvirus, classified within the gammaher-
pesviruses subfamily, and is the prototype of the 
Lymphocryptovirus genus. In keeping with the 
systematic nomenclature adopted for all human 
herpesviruses, the formal designation of EBV is 
human herpesvirus 4 (HHV-4).
Two major EBV types have been detected in 
humans: EBV-1 and EBV-2 (also known  as types 
A and B). EBV-1 and EBV-2 differ in the sequence 
of the genes that code for the EBV nuclear anti-
gens (EBNA-2, EBNA-3A/3, EBNA-3B/4, and 
EBNA-3C/6) (Sample et al., 1990). EBV-2 immor-
talizes B cells less efficiently than EBV-1 in vitro, 
and the viability of EBV-2-infected lymphoblas-
toid cell lines is less than that of EBV-1-infected 
lines (Rickinson et al., 1987). The differences in 
the immortalizing efficiency of the EBV subtypes 
may relate to a divergence in the EBNA-2 
sequences (Cohen et al., 1989).
In addition to type-specific polymorphism, 
significant DNA-sequence heterogeneity has 
been found when comparing selected regions of 
the EBV genome isolated in certain geographic 
areas or even from the same area. These poly-
morphisms define different viral strains within 
both types (Aitken et al., 1994).
1 .1 .2 Structure of the virion
Like other herpesviruses, EBV is a DNA virus 
with a toroid-shaped protein core that is wrapped 
with DNA, a nucleocapsid with 162 capsomers, a 
protein tegument between the nucleocapsid and 
the envelope, and an outer envelope with external 
virus-encoded glycoprotein spikes (Liebowitz & 
Kieff, 1993).
1 .1 .3 Structure of the viral genome
The EBV genome is a linear, double-stranded, 
~172-kb DNA molecule that encodes > 85 genes 
(Fig. 1.1).
 The nomenclature for EBV open-reading 
frames (ORFs) is based on the BamHI-restriction 
fragment in which they are found. For example, 
the BARF1 ORF is found in the BamHI A frag-
ment, and extends rightwards (Fig. 1.1).
The many EBV ORFs are divided into latent 
and lytic genes (further divided into immediate 
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Figure 1.1 The Epstein-Barr virus genome
 
a   Electron micrograph of the Epstein-Barr virus (EBV) virion
b   Diagram showing the location and transcription of the EBV latent genes on the double-stranded viral DNA episome
c   Location of open reading frames of the EBV latent proteins on the Bam H1 restriction-endonuclease map of the prototype B95.8 genome
Reprinted by permission from Macmillan Publishers Ltd: Young & Rickinson, Nature Reviews, 4:757, copyright (2004)
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Table 1 .1 Examples of identified EBV gene products and their open reading frames
Open reading frame Protein Main proposed function
Common name Alternative 
nomenclature
Latent genes
BKRF1 EBNA-1a Plasmid maintenance, DNA replication 
transcriptional regulation
BYRF1 EBNA-2a trans-activation
BERF1 EBNA-3Aa EBNA-3 Transcriptional regulation
BERF2 EBNA-3Ba EBNA-4 Unknown
BERF3/4 EBNA-3Ca EBNA-6 Transcriptional regulation
BWRF1 EBNA-LPa EBNA-5 trans-activation
BNLF1 LMP-1a B-cell survival, anti-apoptosis
BNRF1 LMP-2Aa/2B TP1/2 Maintenance of latency
BARF0 Not shown to be translated, unknown function
EBER1/2 Non-translated, regulation of innate immunity
Lytic genes
Immediate early genes
BZLF1 ZEBRA trans-activation, initiation of lytic cycle
BRLF1 trans-activation, initiation of lytic cycle





BORF2 Ribonucleotide reductase subunit





BKRF3 Uracil DNA glycosylase
Late genes
BLLF1 gp350/220 Major envelope glycoprotein
BXLF2 gp85 (gH) Virus–host envelope fusion
BKRF2 gp25 (gL) Virus–host envelope fusion
BZLF2 gp42 Virus–host envelope fusion, binds MHC class II




BHRF1ab Viral bcl-2 analogue
a Gene products involved in immortalization and/or other aspects of tumour cell phenotypes
b Expressed in latently infected cells as well
EBNA, EBV nuclear antigen; LP, leader protein; LMP, latent membrane protein; ZEBRA, Z EBV replication activation; gp, glycoprotein; MHC, 
major histocompatibility complex
Compiled from Liebowitz & Kieff (1993), Li et al. (1995), Nolan & Morgan (1995), Thompson & Kurzrock (2004)
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early genes, early genes, and late genes). Most of 
these genes are translated into proteins whose 
main proposed functions are listed in Table 1.1. 
Several lytic genes encode for human homologues 
(Table 1.2). In addition, some latent genes are non-
translated; this is the case for EBV-encoded RNA 
(EBER)-1 and -2 (Kieff, 1996; Kieff & Rickinson, 
2001). EBV also encodes at least 17 micro-RNAs, 
arranged in two clusters: ten are located in the 
introns of the viral BART gene, and three adja-
cent to BHRF1 (Cai et al., 2006).
 The viral genome also contains a series 
of 0.5-kb terminal direct repeats at either end 
and internal repeat sequences that serve to divide 
the genome into short and long unique sequence 
domains that have most of the coding capacity 
(Cheung & Kieff, 1982). These terminal repeats 
are good markers to determine if EBV-infected 
cells are from the same progenitor: when EBV 
infects a cell, the viral DNA circularizes and 
mainly persists as a circular episome with a 
characteristic number of terminal repeats that 
depends on the number of terminal repeats in 
the parental genome, with some variation intro-
duced during viral replication. If the infection is 
permissive for latent infection but not replica-
tion, future generations will have EBV episomes 
with the same number of terminal repeats (Raab-
Traub & Flynn, 1986).
1 .1 .4 Host range
Although herpesviruses are ubiquitous in 
nature, humans serve as the only natural host for 
EBV. Almost all higher primates have their own 
EBV-like virus. Antibodies to EBV have been 
detected in several primate species, probably 
due to the presence of cross-reactive antibodies 
against their own species-specific EBV homo-
logues (Kieff et al., 1979). Infection of newborn 
marmosets with EBV resulted in the establish-
ment of a long-term permissive infection, indi-
cating similarities in the responses of marmosets 
and humans to EBV (Cox et al., 1996).
1 .1 .5 Target cells
Like other gammaherpesviruses, EBV estab-
lishes latent infection in lymphocytes and can 
induce proliferation of the latently infected cells 
(Young & Rickinson, 2004). EBV infection of 
B cells is mediated through the interaction of 
the viral envelope glycoprotein gp350/220 with 
the cellular receptor for the C3d complement 
component CR2 (CD21) (Fingeroth et al., 1984, 
1988; Tanner et al., 1987). After binding of the 
viral particle to the surface of the host cell and 
endocytosis, the viral envelope fuses with the 
host-cell membrane by a mechanism involving 
three other viral glycoproteins: gp85, gp25, and 
gp42 (Li et al., 1995). It is worth noting that gp42 
can bind to major histocompatibility complex 
(MHC) class II, and EBV uses this as a cofactor 
in the infection of B lymphocytes (Li et al., 1997).
It has been shown nonetheless that EBV can 
also infect cells, albeit at low efficiency, via CD21-
independent mechanisms. Indeed, cells that do 
not express CD21 (as some epithelial cells) can 
be infected by the virus, and furthermore a virus 
deficient in gp350/220 was shown to be still infec-
tious (Imai et al., 1998; Janz et al., 2000).
Although EBV is considered to be a 
B-lymphotropic virus, it can also infect T 
lymphocytes or epithelial cells because it is 
found in some T-lymphoma cells and several 
important diseases of epithelial cells, including 
nasopharyngeal and gastric carcinomas, and 
oral hairy leukoplakia (Thompson & Kurzrock, 
2004). Other CD21-independent pathways may 
be responsible for EBV infection of cells other 
than B lymphocytes (Imai et al., 1998; Janz et al., 
2000).
Current evidence suggests that EBV infec-
tion in healthy chronic virus carriers is largely 
restricted to B cells, although in certain situ-
ations the virus can be detected in epithelial 
cells. The most likely role for epithelial cells is 
as a site for replication and amplification of EBV 
rather than as a site of persistent latent infection, 
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however, this remains controversial (Kieff, 1996) 
(see Section 1.1.6 and Fig. 1.2).
1 .1 .6 Viral life cycle
EBV, probably the most potent transforming 
human virus in culture, is nonetheless known 
to infect and persist for life in > 90% of human 
adults without causing disease.
Several reviews have described how EBV 
exploits the physiology of the normal B-cell 
differentiation, and uses different combinations 
of latent viral gene expression to progress from 
initial infection to long-term persistence within 
the memory B-cell pool of the immunocompe-
tent host (Thorley-Lawson & Gross, 2004; Young 
& Rickinson, 2004; Thorley-Lawson & Allday, 
2008).
Fig.  1.2 depicts the putative interactions 
between EBV and its host. EBV spreads via the 
saliva entering the epithelium of the Waldeyer 
tonsillar ring situated in the oropharynx where 
it probably initiates a lytic infection that leads to 
amplification of the virus. The virus then infects 
naïve B cells in the underlying lymphoid tissues, to 
become activated lymphoblasts using the growth 
transcription programme (latency III). Three of 
the growth-programme proteins (EBNA-3A, 
EBNA-3B, and EBNA-3C) negatively autoregu-
late the growth programme. This allows the cell 
to migrate into the follicle to initiate a germinal 
centre reaction, and to establish the default tran-
scription programme (latency II). The default 
programme provides rescue or survival signals 
that allow the cell to exit the germinal centre as 
memory B cell. Then, the latency transcription 
programme (latency 0) in which all viral protein 
expression is turned off begins in the resting 
memory B cells. These cells are maintained by 
normal memory B cell homeostasis. When they 
occasionally divide, they express the EBNA-
1-only programme (latency I). The memory B 
cells eventually return to the tonsil, where they 
occasionally undergo plasma-cell differentiation, 
which triggers viral replication. The resulting 
virus may be released into saliva for spreading 
to other hosts or may infect other B cells (Young 
& Rickinson, 2004; Thorley-Lawson & Allday, 
2008).
Primary EBV infection elicits a strong 
cellular immune response which brings the 
infection under control, and newly infected 
cells are thought to be efficiently removed by the 
latent-antigen-specific T-cell response. The virus 
can persist for life in the host only in the resting 
memory B cells in which no viral proteins are 
expressed, and is therefore shielded from the 
immune system (Thorley-Lawson & Gross, 2004; 
Young & Rickinson, 2004; Thorley-Lawson & 
Allday, 2008).
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Table 1 .2 Homology of EBV gene products with human proteins
Viral gene Human homologue Functional similarity established
BCRF1 Interleukin 10 Yes
BDLF2 Cyclin B1 No
BHRF1 BCL-2 Yes
BALF1 BCL-2 No
BARF1 C-FMS receptor Yes
ICAM-1 (CD54) No
Amino acid homology between viral and human product varies from ~20% to >80%.
Adapted from Thompson & Kurzrock (2004)
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Figure 1.2 Putative in vivo interactions between EBV and host cells
 
a   Primary infection
b   Persistent infection
Reprinted by permission from MacMillan Publishers Ltd: Young & Rickinson, Nature Reviews, 4:757, copyright (2004)
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1 .1 .7 Viral gene expression
(a) Viral gene expression in normal cells during 
the viral life cycle
Table 1.3 lists the different viral transcription 
programmes in normal B cells. The expression of 
EBV-encoded proteins differs depending on the 
type, differentiation, and activation status of the 
infected cell. The growth-stimulating programme 
is based on the expression of six nuclear and 
three membrane proteins. Six of these are essen-
tial for the activating and proliferation-driving 
effect of the virus. One virally encoded nuclear 
protein, EBNA-1 which is required for the main-
tenance of the viral episomes, is expressed to 
various degrees in these cells (Thorley-Lawson, 
2005). In all forms of latency, EBV expresses two 
classes of non-coding small RNA (EBER) 1 and 
2, which are highly structured RNAs of 167 and 
172 nucleotides, respectively. The expression of 
EBER-1 and -2 is restricted to the cell nucleus 
where they are present at approximately 107 
copies per cell (Sample & Sample, 2008). Also, 
EBV encodes at least 22 micro-RNAs which are 
expressed to various degrees in latency I, II, III 
(Cai et al., 2006; Grundhoff et al., 2006).
(b) Viral gene expression in EBV-associated 
malignancies
Specific latency EBV-transcription 
programmes have been demonstrated in many 
human tumours, including immunoblastic 
lymphoma in immunosuppressed patients, 
Burkitt lymphoma, Hodgkin disease, and naso-
pharyngeal carcinoma (Table 1.4). The origins of 
all of these tumours can be understood as arising 
from specific stages in the EBV life cycle, and 
appear to be associated with disturbances of the 
immune system as shown in Fig.  1.3 (Thorley-
Lawson, 2005).
 Latency I is generally associated with 
the EBV-related Burkitt lymphoma, latency 
II with Hodgkin disease, T-cell non-Hodgkin 
lymphoma, and nasopharyngeal and gastric 
carcinoma; latency III occurs mainly in 
immunocompromised individuals, in post-
transplant lymphoproliferative disorders, and 
HIV-associated lymphoproliferative disorders 
(Liebowitz & Kieff, 1993; Sbih-Lammali et al., 
1996; Niedobitek et al., 1997; Cesarman & Mesri, 
1999; Kis et al., 2006; Klein et al., 2007).
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Table 1 .3 The EBV transcription programmes in normal B cells
Transcription programme Gene products expressed Infected normal B-cell typea Function
Growth (latency III) EBNA-1, -2, -3A, -3B, -3C, 
-LP, LMP-1, LMP-2A and 
LMP-2B, EBERs
Naive Activate B cell
Default (latency II) EBNA-1, LMP-1 and LMP-
2A, EBERs
Germinal centre Differentiate activated B cell 
into memory
True latency (Latency 0) EBERs Peripheral memory Allow lifetime persistence
EBNA-1 only (latency I) EBNA-1, EBERs Dividing peripheral memory Allow virus in latency 
programme cell to divide
Lytic All lytic genes Plasma cell Replicate the virus in plasma 
cell
a Except where indicated, the cell types are primarily restricted to the lymphoid tissue of the Waldeyer ring.
Adapted from Thorley-Lawson (2005)
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1.2 Epidemiology of infection
1 .2 .1 Prevalence, geographic distribution
In the 1970s, IARC demonstrated that more 
than 90% of adults worldwide are infected with 
EBV, based on the detection of antibodies to 
EBV (especially antibodies to viral capsid (VCA) 
and complement-fixing soluble (CF/S) antigens) 
(de Thé et al., 1975). Many other epidemiological 
studies have shown since that EBV is highly 
prevalent throughout the world (IARC, 1997; 
Young, 2008), including in remote populations 
(Black et al., 1970; Tischendorf et al., 1970).
The age at primary infection varies substan-
tially worldwide, and exposure to EBV is likely 
to be due to socioeconomic factors (Evans, 1971) 
such as overcrowded living conditions with poor 
sanitation (de Thé et al., 1975). For example, 
while more than 80% of children in Uganda 
are estimated to be seropositive for EBV by age 
one (Kafuko et al., 1972), this estimate is only 
approximately 45% in the rural United States 
of America (Sumaya et al., 1975; Hsu & Glaser, 
2000).
Although primary EBV infection during 
early childhood is usually subclinical or has 
symptoms that are similar to other respiratory 
illnesses, a delay in acquiring a primary EBV 
infection at an older age in childhood or adoles-
cence, which usually occurs in more developed 
countries (Rickinson & Kieff, 1996), can manifest 
itself as infectious mononucleosis (occurring in 
approximately 25–75% of EBV-infected persons) 
(Evans, 1971; Sawyer et al., 1971; Niederman & 
Evans, 1997; Hsu & Glaser, 2000).
In a study in the Hong Kong Special 
Administrative Region (Chan et al., 2001), 
sequential measurements for markers of EBV 
infection from serum samples of a group of 
infants demonstrated a sudden seroconversion at 
the age of 8 months, which may imply a protec-
tive role for persistent maternal antibodies, and 
also partially explain why primary EBV infection 
in early childhood, unlike during adolescence, is 
usually asymptomatic (Chan et al., 2001).
Two major types of EBV – EBV-1 and EBV-2 
– have been identified and differ in geographic 
distribution. The role of specific EBV types in 
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Table 1 .4 EBV latency pattern and associated malignancies
Latency Type Viral products expressed Associated malignancies
Latency 1 EBNA-1 Burkitt lymphoma
EBERs Gastric carcinomab
BARF0
Latency II EBNA-1 Hodgkin disease
EBERs Nasopharyngeal carcinoma
LMP-1 Peripheral T/NK lymphoma
LMP-2A
BARF0
Latency III All EBNAsa AIDS-associated lymphomas




a EBNAs include EBNA-1, EBNA-2, EBNA-3A (EBNA-3), EBNA-3B (EBNA-4), EBNA-3C (EBNA-6), EBNA-LP (EBNA-5 or EBNA-4)
b Gastric carcinoma have been shown to express an intermediate Latency I/II pattern including expression of EBNA-1, EBERs, LMP-2A, BARF0 
and some lytic infection proteins such as BARF-1, BNRF-1 (Luo et al., 2005)
EBNA, EBV nuclear antigen; LMP, latent membrane protein; EBER, EBV-encoded RNA
Adapted from Thompson & Kurzrock (2004)
Epstein-Barr virus
57
Figure 1.3 Putative check points in the EBV life cycle that give rise to tumours
 
Events occurring normally in healthy carriers are denoted in thick arrows. EBV normally infects naive B cells in the Waldeyer ring, and can 
differentiate into memory cells and out of the cell cycle, and are not pathogenic. PTLD/HIV. If a cell other than the naive B cell in the Waldeyer 
ring is infected, it will express the growth programme and continue to proliferate because it cannot differentiate out of the cell cycle (thin dashed 
arrows) - a very rare event - highlighting how carefully controlled EBV infection is. Normally, these bystander B-cell blasts would be destroyed 
by CTLs, but if the CTL response is suppressed, then they grow into PTLD or AIDS-associated lymphomas. Note: a bystander-type cell could 
also arise if a latently infected germinal center or memory cell fortuitously switched on the growth programme. Hodgkin disease occurs from the 
default programme. Burkitt lymphoma evolves from a germinal-centre cell that is entering the memory compartment but is stuck proliferating. 
Consequently, the cell expresses EBNA-1 only. Nasopharyngeal carcinoma is assumed to occur from a latently infected epithelial cell blocked from 
terminal differentiation and viral replication.
Reprinted from the Journal of Allergy and Clinical Immunology, Volume 116, Thorley-Lawson DA, EBV the prototypical human tumor virus – just 
how bad is it?, 251–261, Copyright (2005), with permission from Elsevier.
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the etiology of different cancers is unknown. 
Immunocompromised patients more commonly 
harbour both subtypes of EBV (Borisch et al., 
1992; Thompson & Kurzrock, 2004). EBV-2 may 
be more common in Africa (Gratama & Ernberg, 
1995), and in homosexual men (van Baarle et al., 
2000; Higgins et al., 2007). It has been hypoth-
esized that the attenuated transforming ability 
of EBV-2 along with an immunosuppressive 
condition (HIV or malaria) may be necessary 
for EBV-2 to be capable of maintaining infection 
of B lymphocytes, and to cause transformation 
(Buisson et al., 1994; Thompson & Kurzrock, 
2004). However, other studies showing that 
HIV-infected haemophiliacs have lower rates of 
EBV-2 infection than HIV-infected homosexuals 
have challenged this hypothesis, and suggest that 
the acquisition of EBV-1 versus EBV-2 would 
rather be due to the opportunity for exposure 
(van Baarle et al., 2000; Thompson & Kurzrock, 
2004).
The fact that EBV is ubiquitous, and conse-
quently causes widespread and largely asymp-
tomatic infection, suggests that the specific 
geographic distribution of EBV-associated malig-
nancies, such as endemic Burkitt lymphoma and 
nasopharyngeal carcinoma, is probably not due 
to differences in EBV infection but rather due to 
the activation of viral replication by additional 
cofactors (Young, 2008).
1 .2 .2 Transmission and risk factors for 
infection
EBV infection usually occurs in individuals 
of a young age, with low socioeconomic status or 
development, from a larger than average family, 
and with poor hygienic standards. By their third 
decade of life, 80–100% of these individuals 
become carriers of the infection (IARC, 1997).
The oral route is the primary route of trans-
mission of the virus; however, transmission by 
transfusion has been documented. In developing 
countries, infection is acquired in the first few 
years of life. Crowding and/or the practice of 
pre-chewing food for infants may be contrib-
uting factors. In the developed world, infection is 
often delayed to adolescence, when transmission 
is more likely because of intimate oral exposure 
(Hjalgrim et al., 2007a). About 50% of primary 
EBV infections during young adulthood result in 
clinical infectious mononucleosis (CDC, 2006).
Infectious mononucleosis is usually acquired 
from a transfer of saliva, and in young adults, 
this is more likely to occur after the onset of 
sexual activity. However, only limited data are 
available to support this hypothesis (Macsween 
& Crawford, 2003). In a cohort study of sexually 
active young women, the development of detect-
able antibodies against EBV after primary infec-
tion increased with increasing number of sexual 
partners, and was greatest when a new sexual 
partner was encountered in the 2  years before 
seroconversion. In addition, transient EBV DNA 
loads were detected in cervical cytology samples 
in some of the women (Woodman et al., 2005). 
[The Working Group noted, however, that it is 
difficult to distinguish in this study whether 
transmission occurs through saliva or genital 
contact.]
1 .2 .3 Persistency, latency, and natural history 
of infection
Following primary infection via transmis-
sion of cell-free virus and/or of productively 
infected cells in saliva, EBV will enter into the 
circulating B-cell pool, and then remain in most 
cases undetected for life in a latent state (Young & 
Rickinson, 2004; Thorley Lawson, 2005). EBV can 
also infect the mucosal epithelial cells in which 
intermittent viral productive replication occurs 
(Frangou et al., 2005). The B-cell compartment, 
more precisely resting memory B cells, appears to 
be the true reservoir of the latent virus in healthy 
carriers. Resting memory B cells express a very 
restricted pattern of latent viral gene expression 
(see Table 1.3 and Miyashita et al., 1995); this is 
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how these infected cells can persist in the face of 
efficient cytotoxic T lymphocyte (CTL) surveil-
lance (Masucci & Ernberg, 1994). Nonetheless, 
cells that express the full repertoire of growth-
transformation-associated antigens are likely be 
generated sporadically in asymptomatic virus 
carriers, because memory CTLs that are reac-
tive against most EBNAs are maintained at high 
levels for life (see Fig. 1.2, and further details in 
Section 1.1, this Monograph; IARC, 1997).
Primary EBV infections occurring in adoles-
cence or early in adult life are manifested as infec-
tious mononucleosis, which is an acute form of 
primary infection occurring asymptomatically 
in early childhood.
EBV-associated malignancies are suspected 
to result from viral reactivation that is most 
likely due to interaction with additional cofac-
tors (Young, 2008).
1 .2 .4 Biological markers of the different 
status of EBV infection
(a) Antibody responses to EBV
The detection of antibodies to EBV in biolog-
ical fluids has been until recently the major 
means of diagnosis for EBV infection. Distinct 
patterns of antibody response have been identi-
fied during primary infection, latent infection of 
healthy carriers, viral reactivation, and in various 
EBV-associated diseases. Serological parameters 
include the detection of IgG, IgM, and occasion-
ally IgA, directed against EBNAs, early anti-
gens (EAs, divided into two components, EA-D 
(encoded by BMRF-1) and EA-R (a human BCL-2 
homologue encoded by BHRF-1)), and VCAs (for 
a review see IARC, 1997).
(i) Infectious mononucleosis
Most information available on primary anti-
body response has been provided by studies on 
infectious mononucleosis. Table  1.5 shows the 
variation over time of serological parameters both 
at and after the onset of infectious mononucleosis. 
At the onset of clinical symptoms of the disease, 
substantial titres of IgM antibodies to VCA are 
detected, with rising titres of IgG to EA, and to 
VCA. IgA antibodies to these antigens may also 
appear. Whereas anti-VCA IgM titres disappear 
over the next few months, anti-VCA IgG titres 
rise to a peak that may fall slightly, and anti-EA 
IgG titres become either undetectable or stabilize 
at very low levels. Neutralizing antibodies to the 
major envelop glycoprotein gp350 are detected 
during the acute phase of infectious mononu-
cleosis but only at very low titres, and increase to 
stable levels thereafter (IARC, 1997).
 The serology of infectious mononucleosis 
for the anti-EBNA response presents an interesting 
pattern. For the anti-EBNA response, during the 
acute phase of infectious mononucleosis, patients 
show an IgG response to EBNA-2 (and also prob-
ably to EBNA-3A, -3B, and -3C), whereas an IgG 
response to EBNA-1 is not usually detected until 
convalescence. The production of antibodies to 
EBNA-1 and EBNA-2 in the course of infectious 
mononucleosis follows an ordered progression. 
Anti-EBNA-2 is the first to be detected, reaches 
peak titres, and then declines to a lower persis-
tent level, and can remain undetected in about 
1/3 of the cases. Anti-EBNA-1 is detected long 
after anti-EBNA-2, and then persists indefinitely 
once it has reached its concentration plateau. 
Therefore, within the first year following infec-
tious mononucleosis, the ratio of anti-EBNA-1: 
anti-EBNA-2 is well below 1, but becomes well 
above 1 over time. The switch from dominant 
anti-EBNA-2 to dominant anti-EBNA-1 titres 
occurs in individual cases over a long span of 
time (Table 1.5; Henle et al., 1987; IARC, 1997).
(ii) Healthy EBV-carriers
IgG antibodies to VCA, to neutralizing anti-
gp350, and to EBNA-1 are consistently detected 
in the serum of healthy carriers. The titre of 
these antibodies is usually stable over time but 
can markedly differ among individuals (Henle & 
Henle, 1976). Antibodies to EA are only detected 
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in a proportion of healthy carriers. Although 
persisting for life, anti-EBNA-1 and anti-VCA 
do not appear to have much of a protective role 
(Moss et al., 1992).
Virus shed can be frequently detected from 
throat washes of asymptomatic carriers. The 
levels of shedding are thought to be quite stable 
over many months, although with different 
rate depending on the individuals. A direct 
relationship appears to exist between the level 
of virus shedding in the throat and the level of 
virus-infected B cells in the blood. However, no 
obvious relationship was shown between the 
levels of EBV virus shedding from the throat and 
either anti-VCA or anti-EA titres in the serum of 
healthy carriers (Yao et al., 1985).
(iii) EBV-associated malignant diseases
The major features of the humoral response 
to EBV in different EBV-associated malignancies 
have been reported (Khanna et al., 1995) but no 
specific pattern could be defined as useful prog-
nostic markers for these diseases.
Although anti-VCA IgA serology was 
proposed as an effective and sensitive prognostic 
and diagnostic marker for nasopharyngeal carci-
noma, more recent studies have shown high false 
positive rates for this antibody (Low et al., 2000). 
Furthermore, the follow-up of individuals with 
high titres of IgA to VCA demonstrated that a 
significant portion of those seroconverted back 
to normal, and did not develop nasopharyngeal 
carcinoma (Lo et al., 2004).
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Table 1 .5 Serological parameters at various times after the onset of infectious mononucleosis













% positive 100.0 73.1 0.0 0.0 0.0 0.0
Range of titres 80–640 10–80 <10 <10 <10 <10
Anti-EA
% positive 81.8 88.5 87.8 60.9 39.4 30.0
Range of titres 10–320 10–160 10–160 10–80 10–80 10–40
Anti-D
% positive 81.8 57.7 10.2 13.0 0.0 0.0
Range of titres 10–320 10–160 10–160 10–40 <10 <10
Anti-R
% positive –a 46.2 83.7 47.9 39.4 30.0
Range of titres – 10–160 10–160 10–80 10–80 10–40
Anti-EBNA-1
% positive 0.0 4.5 73.8 97.6 97.1 100.0
Geometric mean titre <2 <2 5.3 21.2 24.8 48.2
Anti-EBNA-2
% positive 0.0 93.2 87.9 60.2 71.4 71.1
Geometric mean titre <2 7.3 11.6 4.1 4.3 3.9
Ratio anti-EBNA-1/anti-EBNA-2
≤1.0 – 97.7 76.9 22.9 17.1 5.3
>1.0 – 2.3 23.1 77.1 82.9 94.7
a Anti-R can be measured only when exceeding anti-D in titre.
Adapted from Henle et al. (1987)
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(b) Detection of EBV in tissues and serum
(i) Healthy carriers
In healthy carriers, EBV is mostly present in a 
latent form as episomal DNA in resting memory 
B cells. The frequency of EBV-carrying cells in 
peripheral blood ranges from 1 in 2x105–107 
whole mononuclear cells or 1 in 2x104–106 B cells, 
and is quite stable in an individual over time. It 
was estimated that less than 1 in 40 EBV-infected 
cells can replicate the virus in the peripheral 
blood of healthy carriers (Miyashita et al., 1995; 
Decker et al., 1996). Therefore, only very highly 
sensitive polymerase chain reaction (PCR) assays 
can detect EBV DNA in peripheral blood cells.
(ii) EBV-associated malignancies
- EBV DNA in tumour tissues
The EBV genome can be detected in tumour 
cells by PCR or in-situ hybridization assays 
using the BamH1 internal fragment of the viral 
genome as a probe. However, a major technical 
breakthrough has been the use, especially by 
in-situ hybridization, of probes specific for the 
small nuclear EBV-encoded RNAs, EBER-1 and 
EBER-2, which are highly expressed in all forms 
of EBV infection (Wu et al., 1990). The high sensi-
tivity of this method allowed the determination 
of the incidence of EBV infection in the very 
scarce neoplastic Hodgkin and Reed-Sternberg 
cells (HRC) in biopsies from Hodgkin disease 
patient (IARC, 1997).
Detection of EBV genomic DNA by PCR 
using EBV genes (e.g. EBNA-1, EBNA-2, and 
LMP-1) as targets in tissue obtained from naso-
pharyngeal biopsy and fine-needle aspirate 
samples have also been shown as being reliable 
and accurate methods for the diagnosis of naso-
pharyngeal carcinoma (Yap et al., 2007). In addi-
tion, nasopharyngeal carcinoma patients have 
a very high load of EBV DNA as collected in 
non-invasive nasopharyngeal brushing. EBNA1 
and BARF1 mRNAs are detected at even higher 
levels in such samples, whereas no EBV mRNA is 
detected from nasopharyngeal brushing samples 
of healthy donors (Stevens et al., 2006).
- Cell-free EBV DNA in serum
Cell-free EBV DNA has been detected in 
the plasma and serum of patients with several 
EBV-associated malignant diseases: Hodgkin 
disease, post-transplant lymphoprolifera-
tive diseases, NK/T-cells lymphoma, Burkitt 
lymphoma, nasopharyngeal carcinoma, and 
EBER-positive gastric carcinoma; and, this detec-
tion correlated with the EBV status in tumours. 
In contrast, cell-free EBV DNA was not detected 
in any of the healthy control subjects (Lei et al., 
2000, 2002; Lo et al., 2001; Musacchio et al., 2006). 
Plasma EBV DNA, as measured by real-time 
quantitative PCR, has been proposed as a sensi-
tive and specific tumour marker for diagnosis, 
disease monitoring, and prediction of outcome 
for several of the EBV-associated diseases (Lo 
et al., 2001; Lei et al., 2002; Shao et al., 2004).
Low-level EBV DNA positivity in serum 
has been reported to occur relatively frequently 
after stem-cell transplantation, and may subside 
without specific treatment. However, high EBV 
DNA levels (i.e. > 50 000 copies/mL) are strong 
predictors for the development of post-trans-
plantation lymphoproliferative disease (Aalto 
et al., 2007).
The lack of detectable viral DNA in the serum 
of healthy carriers indicates that although most 
of these individuals are expected to be carrying 
EBV DNA in their lymphocytes, EBV DNA is not 
usually found in serum in the absence of active 
EBV disease. It is likely, however, that the viral 
DNA in serum is present in cases of EBV reac-
tivation as well as in cases of primary infection, 
and tests for viral DNA can not discriminate 
between the two cases unless they are used in 
conjunction with serology. EBV reactivation is 
particularly relevant in immunocompromised 
patients (Chan et al., 2001).
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2. Cancer in Humans
In the previous IARC Monograph, EBV infec-
tion was associated with several cancer types: 
Burkitt lymphoma, immunosuppression-related 
non-Hodgkin lymphoma, extranodal NK/T-
cell lymphoma (nasal type – Swerdlow et al., 
2008; previously known as angiocentric T-cell 
lymphoma – IARC, 1997); Hodgkin lymphoma, 
and nasopharyngeal carcinoma (IARC, 1997). 
The following text comprises updated relevant 
data from case–control and cohort studies for 
several cancer types in relation to infection with 
EBV.
2.1 Virus-associated B-cell lymphoma
2 .1 .1 Burkitt lymphoma
There are three subtypes of Burkitt lymphoma: 
endemic Burkitt lymphoma, sporadic Burkitt 
lymphoma, and immunodeficiency-associated 
Burkitt lymphoma. Endemic Burkitt lymphoma 
is defined as affecting children in equato-
rial Africa and New Guinea, sporadic Burkitt 
lymphoma affects children and young adults 
throughout the world, and immunodeficiency-
associated Burkitt lymphoma is primarily 
associated with HIV infection. The majority of 
endemic Burkitt lymphoma, sporadic Burkitt 
lymphoma, and immunodeficiency-associated 
Burkitt lymphoma form three distinct clinical 
entities. It has been reported that EBV is detected 
in the tumour tissue of almost 100% of the cases 
of endemic Burkitt lymphoma, this proportion is 
less in cases of sporadic and immunodeficiency-
associated Burkitt lymphoma (Carbone et al., 
2008).
With regard to endemic Burkitt lymphoma, 
two new studies (Carpenter et al., 2008; Mutalima 
et al., 2008) from Uganda and Malawi (with 325 
and 148 cases, respectively) add to the evidence 
from five case–control studies (including 431 
cases in total) (Henle et al., 1969, 1971b; Klein 
et al., 1970; Hirshaut et al., 1973; Nkrumah 
et al., 1976), and one cohort study (with 16 cases) 
(Geser et al., 1982) outlined in the previous 
IARC Monograph (IARC, 1997). Both studies 
(Carpenter et al., 2008; Mutalima et al., 2008) 
demonstrate there is a relationship between 
an increase in the titre of antibodies against 
EBV-VCA and an increase in risk for endemic 
Burkitt lymphoma (see Table  2.1 available at 
http://monographs.iarc.fr/ENG/Monographs/
vol100B/100B-01-Table2.1.pdf). There are no 
new data available relating to sporadic Burkitt 
lymphoma to add to the 90 cases in the four 
studies previously reported (Hirshaut et al., 1973; 
Ablashi et al., 1974; Gotleib-Stematsky et al., 
1976; Çavdar et al., 1994).
(a) Cofactors for endemic Burkitt lymphoma
A thorough review of potential cofactors 
for endemic Burkitt lymphoma (e.g. malaria, 
sickle-cell trait, Euphorbia tirucalli, and other 
medicinal plants) is outlined in the previous 
IARC Monograph (IARC, 1997), and, with the 
exception of malaria, no new data were avail-
able to the Working Group. Previously, the rela-
tionship between malaria and endemic Burkitt 
lymphoma was based mostly on ecological data 
– for example, geographic correlations between 
the prevalence of malaria and the reported 
incidence of endemic Burkitt lymphoma, and 
apparent declines in the incidence following 
widespread malaria eradication programmes. 
One intervention study (Geser et al., 1989) in 
the United Republic of Tanzania confirmed the 
relationship between malaria prevalence and the 
incidence of Burkitt lymphoma. More recently, 
two case–control studies have demonstrated an 
increasing risk of endemic Burkitt lymphoma in 
relation to an increase in the titre of antibodies 
against malaria, and also suggested that EBV and 
malaria act synergistically in the etiology of the 
disease (Carpenter et al., 2008; Mutalima et al., 
2008). In addition, the use of insecticides or bed 
nets in the home was associated with substantially 
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lower risks of endemic Burkitt lymphoma. There 
is evidence that malaria reduces T-cell-mediated 
immunosurveillance of EBV-infected cells, 
and is linked to an increased viral load of EBV 
(Moormann et al., 2005, 2007, 2009).
2 .1 .2 Hodgkin lymphoma 
EBV is more commonly associated with 
classic Hodgkin lymphoma, especially the 
mixed-cellular subtypes. The non-classical 
nodular lymphocyte-predominant Hodgkin 
lymphoma cases are very rarely associated with 
EBV (Khalidi et al., 1997). Developing countries 
have an increased incidence of EBV-positive 
cases, which may be attributed to the existence 
of underlying immunosuppression (Jarrett et al., 
1991; Murray & Young, 2005). A bimodal age 
distribution has been recognized for EBV-positive 
Hodgkin lymphoma patients; children (<  15 
years) and older-age groups tend to have much 
higher rates than young adults (Flavell & Murray, 
2000). In western populations, the EBV genome 
has been detected in the tumour tissue of 40–50% 
of Hodgkin lymphoma cases (Weiss, 2000). The 
subclassification of Hodgkin lymphoma cases as 
EBV-positive or EBV-negative provides the poten-
tial to identify etiological subgroups (Alexander 
et al., 2000). EBV has been identified as a cause of 
infectious mononucleosis, a potential risk factor 
for Hodgkin lymphoma, which results from 
hyperproliferation of EBV-containing B cells, 
and a reactive T-cell response (Henle et al., 1968).
Previously, epidemiological data on the asso-
ciation between Hodgkin lymphoma and EBV 
were derived from several sources:
• Investigations of the relationship between 
infectious mononucleosis and Hodgkin 
lymphoma from six case–control studies 
(odds ratios (ORs) ranging from 1.0–8.2) 
(Table 18, IARC, 1997; Henderson et al., 
1979; Gutensohn & Cole, 1981; Gutensohn, 
1982; Evans & Gutensohn, 1984; Bernard 
et al., 1987; Serraino et al., 1991) and 
six cohort studies (ORs ranging from 
2.0–5.0) (Table 22, IARC, 1997; Miller & 
Beebe, 1973; Connelly & Christine, 1974; 
Rosdahl et al., 1974; Carter et al., 1977; 
Muñoz et al., 1978; Kvåle et al., 1979). A 
2–4-fold increased risk for Hodgkin lym-
phoma within the first 3 years following 
infectious mononucleosis was also dem-
onstrated (Rosdahl et al., 1974; Muñoz 
et al., 1978)
• 41 case–control studies of Hodgkin lym-
phoma in which there was evidence of 
antibodies against EBV-VCA (22 studies; 
ORs, 0.8–79; Table 19, IARC, 1997), EA 
(11 studies; ORs, 1.2–infinity; Table 20, 
IARC, 1997), and EBNA (eight studies; 
five with equivocal results, and three with 
ORs ranging from 1.7–infinite; Table 21, 
IARC, 1997)
• Two large cohort studies, both report-
ing statistically significant excess risks 
associated with antibodies against EBV 
(Mueller et al., 1989; Lehtinen et al., 1993)
One further cohort study (Hjalgrim et al., 
2000) of patients with infectious mononucleosis 
(reporting 46 cases of Hodgkin lymphoma; 
OR, 2.6; 95%CI: 1.9–3.4), together with seven 
case–control studies (Gallagher et al., 1999; 
Alexander et al., 2000, 2003; Glaser et al., 2005; 
Berrington de González et al., 2006; Musacchio 
et al., 2006; Dinand et al., 2007; Hjalgrim et al., 
2007b) addressed the association between EBV 
and Hodgkin lymphoma (see Table 2.2 available 
at http://monographs.iarc.fr/ENG/Monographs/
vol100B/100B-01-Table2.2.pdf and Table 2.3 
available at http://monographs.iarc.fr/ENG/
Monographs/vol100B/100B-01-Table2.3.pdf). In 
two studies, one in the United Kingdom (Gallagher 
et al., 1999) and one in Brazil (Musacchio et al., 
2006), examining the association between EBV 
DNA (BamHI-W) in serum and risk for Hodgkin 
lymphoma, cases of both EBV-positive and 
EBV-negative Hodgkin lymphoma had a much 
higher proportion with detectable EBV DNA 
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in serum/plasma than that of healthy controls. 
In a case–control study involving 145 Hodgkin 
lymphoma cases and 25 follicular hyperplasia 
controls in India, EBV DNA was detected in the 
lymph nodes of 140 (96.6%) Hodgkin lymphoma 
cases and but not in controls (0%) (Dinand et al., 
2007). One case–control study from South Africa 
did not find a positive association between levels 
EBV antibody in serum and Hodgkin lymphoma 
(Berrington de González et al., 2006). In case–
control studies on the association between a 
history of infectious mononucleosis and risk for 
Hodgkin lymphoma, a significant association was 
observed in EBV-positive Hodgkin lymphoma 
cases, particulary in those with young age at 
onset in the United Kingdom (Alexander et al., 
2000, 2003), and Denmark and Sweden (Hjalgrim 
et al., 2007b). However, no significant association 
between a history of infectious mononucleosis 
and Hodgkin lymphoma was found in the USA 
(Glaser et al., 2005). A case–case analysis in a 
population-based case–control study compared 
95 EBV-positive and 303 EBV-negative Hodgkin 
lymphoma cases (Chang et al., 2004). EBV 
antibody titres were significantly higher in the 
EBV-positive cases, including anti-VCA IgG and 
IgA, EA and an EBNA-1:EBNA-2 ratio ≤ 1. With 
mutual adjustment, the odds ratios for elevated 
VCA IgG were 3.6 (95%CI: 1.4–8.7), and for low 
EBNA-1:EBNA-2 ratio, 3.2 (95%CI: 1.1–9.0).
2 .1 .3 Lymphomas in immunosuppressed 
individuals
(a) Post-transplant lymphoproliferative 
disorders
Since the original reports of post-trans-
plant lymphoproliferative disorders in 1969 
(McKhann, 1969; Penn et al., 1969), a higher inci-
dence of lymphoproliferative disorders in trans-
plant recipients of both a solid organ and bone 
marrow has been observed (Carbone et al., 2008). 
According to the WHO classification (Swerdlow 
et al., 2008), post-transplant lymphoproliferative 
disorders may be classified into: a) early lesions, 
generally represented by EBV-driven polyclonal 
lymphoproliferations; and, b) true monoclonal 
diseases, including polymorphic post-transplant 
lymphoproliferative disorders and monomorphic 
post-transplant lymphoproliferative disorders.
In addition to data presented previously 
(IARC, 1997), a case–control study of EBV DNA 
in plasma samples of four cases of post-transplant 
EBV-associated nasal NK/T-cell lymphoma, two 
cases of post-transplant lymphoproliferative 
disorders, and 35 healthy controls in the Hong 
Kong Special Administrative Region (Lei et al., 
2000) were considered – all six cases (100%) 
and no control (0%) had EBV DNA (BamHI-W) 
levels in plasma (see Table  2.4 available http://
monog r aphs . ia rc . f r/ ENG/Monog r aphs/
vol100B/100B-01-Table2.4.pdf).
(b) HIV-associated lymphoproliferative disorders
HIV-associated lymphoproliferative disor-
ders are a heterogeneous group of diseases 
that occur in the presence of HIV-associated 
immunosuppression. These aggressive disorders 
include both central nervous system and systemic 
lymphomas. Primary effusion lymphoma 
(reviewed in this volume, see Monograph on 
Kaposi Sarcoma Herpes Virus (KSHV)) also 
occurs and often involves EBV in addition to 
KSHV. The categories of HIV-associated non-
Hodgkin lymphoma (HIV-NHL) confirmed 
in the latest WHO Classification of Tumours 
(Raphael et al., 2001, 2008) are grouped as follows 
(Carbone et al., 2008):
• Lymphomas also occurring in immuno-
competent patients. Most of these HIV-
NHLs belong to three high-grade B-cell 
lymphomas: Burkitt lymphoma, diffuse 
large B-cell lymphoma with centroblastic 
features, and diffuse large B-cell lym-
phoma with immunoblastic features. 
According to the site of involvement, the 
present spectrum of HIV-NHL includes 
extranodal/nodal lymphomas, and 
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primary central nervous system lympho-
mas (Carbone et al., 2008);
• Unusual lymphomas occurring more 
specifically in HIV-positive patients – 
these lymphomas include two rare enti-
ties, namely, primary effusion lymphoma 
(Cesarman et al., 1995), and plasmablastic 
lymphoma of the oral cavity (Delecluse 
et al., 1997; Carbone et al., 1999);
• Lymphomas also occurring in other 
immunodeficient states (Carbone et al., 
2008).
One nested case–control study of non-
Hodgkin lymphoma among HIV-infected people 
identified an association between anti-VCA anti-
bodies and risk of disease, although no division 
by histological subtype of lymphoma was possible 
(Newton et al., 2006; see Table  2.5 available 
http://monographs.iarc.fr/ENG/Monographs/
vol100B/100B-01-Table2.5.pdf).
2 .1 .4 EBV-positive diffuse large B-cell 
lymphoma of the elderly
This is defined as an EBV-containing diffuse 
large B-cell lymphoma occurring in patients 
over 50 years of age without any prior lymphoma 
or other known immunodeficiency. These 
EBV-positive lymphomas account for 8–10% of 
diffuse large B-cell lymphomas in Asian coun-
tries, but there are little data from western coun-
tries (Oyama et al., 2007; Swerdlow et al., 2008).
2.2 Virus-associated T-cell and NK-cell 
lymphomas 
EBV is an established cause of extranodal 
NK/T-cell lymphoma (nasal type); previously 
called angiocentric T-cell lymphoma (IARC, 
1997; Chan et al., 2001b; Swerdlow et al., 2008). 
A higher incidence of extranodal NK/T-cell 
lymphoma (nasal type) has been described in 
central and south America, and in several east 
Asian countries (Suzuki et al., 2008). Several 
recent large case series confirm the presence of 
EBV in tumour cells in nearly 100% of cases 
(Barrionuevo et al., 2007; He et al., 2007). In a 
case–control study of anti-EBV VCA, EA, and 
EBNA in serum samples of 100 cases of peripheral 
NK/T-cell proliferative disease/lymphoma, and 
100 age- and sex-matched controls in Thailand 
(Mitarnun et al., 2002), elevated serum levels 
of anti-EBV VCA IgG and EA IgG were associ-
ated with an increased risk of the disease (see 
Table 2.4 on-line). In another case–control study 
of seven cases of peripheral NK/T-cell prolif-
erative disease, 38 cases of peripheral NK/T-cell 
lymphoma, and 45 age- and sex-matched healthy 
controls in Thailand (Suwiwat et al., 2007), 37 
(82.2%) cases and no control had detectable EBV 
DNA levels (BamHI-W) in their plasma .
Other T-cell lymphoproliferative disorders 
that have been reported to be associated with EBV 
include a subset of peripheral T-cell lymphomas 
(Dupuis et al., 2006a, b; Tan et al., 2006), enterop-
athy-type T-cell lymphomas (de Bruin et al., 1995; 
Quintanilla-Martínez et al., 1998; Isaacson et al., 
2001), γδ T-cell lymphomas (hepatosplenic and 
non-hepatosplenic) (Arnulf et al., 1998; Ohshima 
et al., 2000), T-cell lymphoproliferative disor-
ders after chronic EBV infection (Quintanilla-
Martinez et al., 2000), EBV-associated cutaneous 
T-cell lymphoproliferative disorders (especially 
in Asia) (Chan et al., 2001a; Kim et al., 2006), 
and aggressive NK-cell leukaemias/lymphomas 
(Chan et al., 2001b).
Angioimmunoblastic T-cell lymphoma is a 
distinct entity of peripheral T-cell lymphoma 
(Dupuis et al., 2006b). Angioimmunoblastic 
T-cell lymphomas are also nearly always asso-
ciated with EBV; however, the cellular origins 
remain unknown. The virus is present in B cells, 
rather than in the neoplastic T cells, suggesting 
an indirect role, hypothetically through anti-
genic stimulation (Knecht et al.,1990; Dupuis 
et al., 2006b; Dunleavy et al., 2007).
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2 .2 .1 Other non-Hodgkin lymphoma
Two cohort studies including a total of 115 
cases of non-Hodgkin lymphoma occurring 
in apparently immunocompetent individuals 
reported no excess risk in relation to anti-VCA 
antibody titres (Mueller et al., 1991; Lehtinen 
et al., 1993; IARC, 1997). Since then, four case–
control studies have investigated the serological 
evidence of infection with EBV: two reported no 
associations (Hardell et al., 2001a; Berrington 
de González et al., 2006), one reported a border-
line increased association (Hardell et al., 2001b), 
and the other showed a significant associa-
tion between abnormal reactive EBV antibody 
patterns and non-Hodgkin lymphoma (OR, 1.4; 
95%CI: 1.2–1.7; based on 1085 cases; de Sanjosé 
et al., 2007).
2.3 Cancers of the nasopharynx, 
stomach, and lymphoepithelium
2 .3 .1 Cancer of the nasopharynx
Cancer of the nasopharynx is rare in most 
populations around the world but common in 
South-East Asia (Ferlay et al., 2010). According to 
the WHO Classification of Tumours, cancers of 
the nasopharynx are classified into three types: 
keratinizing squamous cell carcinoma (Class 
I), non-keratinizing carcinoma (Class II), and 
basaloid squamous cell carcinoma (Class III) 
(Chan et al., 2005). Most cancers of the naso-
pharynx diagnosed in the high-risk areas belong 
to Class II. In the previous IARC Monograph, 
an increased risk of cancer of the nasopharynx 
was demonstrated in five case–control studies in 
which all 671 cases had evidence of infection with 
EBV (de Thé et al., 1978b; Lanier et al., 1980a; 
Pearson et al., 1983b; Chen et al., 1987; Zheng 
et al., 1994a), and one cohort study in which all 
seven cases had evidence of infection with EBV 
(Chan et al., 1991). Since then, two cohort (Chien 
et al., 2001; Ji et al., 2007) and eight case–control 
studies (Mutirangura et al., 1998; Lo et al., 1999; 
Chen et al., 2001; Lin et al., 2001, 2004; Fan et al., 
2004; Leung et al., 2004; Tiwawech et al., 2008) 
on the association between EBV and cancer of 
the nasopharynx have been reported.
The prospective cohort studies on the 
association between EBV biomarkers and the 
development of nasopharyngeal carcinoma are 
shown in Table  2.6 (available at http://mono-
graphs.iarc.fr/ENG/Monographs/vol100B/100B-
01-Table2.6.pdf) and include 22 and 131 cases 
(Chien et al., 2001; Ji et al., 2007, respectively). 
In one study (Chien et al., 2001), the relative 
risks of developing nasopharyngeal carcinoma 
were 22.0 (95%CI: 7.3–66.9) for anti-EBV VCA 
IgA-seropositivity, and 3.5 (95%CI: 1.4–8.7) for 
anti-EBV DNase-seropositivity. Compared with 
those who were seronegative for both anti-EBV 
markers as the referent group, the adjusted rela-
tive risk was 32.8 (95%CI: 7.3–147.2) for those 
who were seropositive for both anti-EBV markers 
(Chien et al., 2001). In the other study (Ji et al., 
2007), seropositivity of anti-EBV VCA IgA was 
associated with an increased risk of nasopharyn-
geal carcinoma during follow-up with a crude 
relative risk of [9.4; 95%CI: 6.8–13.5]. For seven 
case–control studies (see Table  2.7 available at 
http://monographs.iarc.fr/ENG/Monographs/
vol100B/100B-01-Table2.7.pdf), the odds ratios 
for nasopharyngeal carcinoma in relation to the 
evidence of infection with EBV ranged from 20.6 
to infinity (Mutirangura et al., 1998; Lo et al., 
1999; Lin et al., 2001, 2004; Chen et al., 2001; 
Fan et al., 2004; Leung et al., 2004). For only 
one study were the reported odds ratios below 3 
(Tiwawech et al., 2008).
Since the previous IARC Monograph, no new 




2 .3 .2 Lymphoepithelioma-like carcinomas
Rare carcinomas with a histological simi-
larity to nasopharyngeal carcinoma (in that both 
have lymphoid stroma) are called lymphoepithe-
lial-like carcinomas (Tsang & Chan, 2005). These 
can occur in multiple organ sites with epithelial 
lining, and have been reported most frequently 
in the salivary glands, and in the stomach. In 
the previous IARC Monograph (Table 30, IARC, 
1997), 19 case series reported on the associa-
tion of EBV with cancers of the stomach. These 
included a total of 102 lymphoepithelial cancers 
of which 90 had evidence of infection with EBV. 
In addition, five case series of lymphoepithelial 
cancers of the salivary gland indicated that 25/27 
reported cases had evidence of infection with 
EBV (Table  28, IARC, 1997). More recently, in 
a case–control study of lymphoepithelial cancer 
of the salivary gland, 16/16 cases had evidence 
of EBV DNA in tumour tissue compared to 0/12 
salivary gland tumours of other histology (Wang 
et al., 2004; see Table 2.8 available at http://mono-
graphs.iarc.fr/ENG/Monographs/vol100B/100B-
01-Table2.8.pdf). More recently, multiple case 
series including 209 cases of parotid gland 
lymphoepithelial carcinoma reported that EBV 
DNA was present in the tumour cells of 208 cases 
(Leung et al., 1995; Kim et al., 1999; Squillaci 
et al., 2000; Białas et al., 2002; Saku et al., 2003; 
Wu et al., 2004; Jen et al., 2005; Hsu et al., 2006; 
Saqui-Salces et al., 2006). Therefore, the evidence 
of an association between EBV infection and 
lymphoepithelioma-like carcinomas has become 
substantially stronger since the previous IARC 
Monograph (IARC, 1997).
2 .3 .3 Cancer of the stomach
In 19 case series of cancer of the stomach 
reported in 1997 (Table 30, IARC, 1997), 115/1322 
(9%) of cases had evidence of EBV DNA in tumour 
tissue. None of these studies provided information 
on possible infection with H. pylori. Since then, 
three case–control studies have been published 
in which two include a total of 69/174 cases with 
evidence of EBV DNA in tumour tissue (Shinkura 
et al., 2000; Lo et al., 2001; see Table 2.9 available 
at http://monographs.iarc.fr/ENG/Monographs/
vol100B/100B-01-Table2.9.pdf), while the other, a 
nested case–control study, considered only sero-
logical responses against EBV in relation to all 
cancers of the stomach (Koshiol et al., 2007; see 
Table 2.10 available at http://monographs.iarc.fr/
ENG/Monographs/vol100B/100B-01-Table2.10.
pdf). Recent findings indicate that people with 
EBV-positive tumours tend to have higher anti-
body titres against EBV (Shinkura et al., 2000) 
or higher EBV viral loads (Lo et al., 2001) than 
people with EBV-negative tumours or controls 
without cancer of the stomach. A recent review 
of over 30000 cancers of the stomach identified 
evidence of EBV DNA in 8% of the patients (Sousa 
et al., 2008). It is important to note that EBV DNA 
is present within tumour cells and not in the 
surrounding epithelium, and that virus mono-
clonality has been demonstrated in tumour cells 
only (Sousa et al., 2008). [The Working Group 
noted that the interaction of H.pylori and EBV 
in the etiology of cancer of the stomach needs 
further clarification.]
2.4 Other cancers 
Several other studies investigating the 
evidence of infection with EBV in relation to 
cancers of the oral cavity, breast, cervix, testis, 
prostate, and multiple myeloma and leukaemia 
show limited or no evidence of an association.
See Table 2.11 available online at http://mono-
graphs.iarc.fr/ENG/Monographs/vol100B/100B-
01-Table2.11.pdf), Table 2.12 available at 
http://monographs.iarc.fr/ENG/Monographs/
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3. Cancer in Experimental Animals
In this volume, the Working Group decided 
not to include a separate section on “Cancer in 
Experimental Animals” in the Monographs on 
viruses but rather to include description of such 
studies under Section 4 (below). The reasoning 
for this decision is explained in the General 
Remarks.
4. Other Relevant Data
The mechanistic evidence for EBV-associated 
oncogenesis was thoroughly reviewed in the 
previous IARC Monograph (IARC, 1997), and is 
based on the following:
• The ability of EBV to immortalize human 
B lymphocytes in vitro (Nilsson et al., 
1971)
• Other effects of EBV infection of human 
cells in vitro affecting their phenotype 
– migration and invasion (Pegtel et al., 
2005; Dawson et al., 2008)
• Convincing links of these phenotypic 
effects on cell proliferation, apoptosis, 
and cell migration to single EBV proteins 
or combinations thereof, primarily by the 
expression of or “knock down” of single 
proteins (Klein & Ernberg, 2007)
• Induction of EBV-positive lymphoprolif-
erative diseases or lymphomas by infec-
tion of animals (New World monkeys) 
with EBV, or transplantation of infected 
human B lymphocytes to immunosup-
pressed mice (SCID or nude; Mosier et al., 
1988; Young et al., 1989)
Although more circumstantial, in vivo 
evidence is also strong.
The EBV genome and the constant expression 
of viral proteins detected in a wide spectrum of 
human malignancies strongly support a role for 
EBV in carcinogenesis. EBV-associated tumours 
include diffuse large B-cell lymphomas that 
occur in immunocompromised persons, such as 
transplant recipients, certain congenitally immu-
nocompromised individuals, and HIV-infected 
persons. EBV is also involved in the pathogen-
esis of Burkitt lymphoma, Hodgkin lymphoma, 
some T/NK-cell lymphomas, cancer of the 
nasopharynx, and some cancers of the stomach 
(Ambinder & Cesarman, 2007; Table 4.1).
 In several of the high-risk groups for 
EBV-associated cancers, the EBV-genome load 
found in the peripheral blood lymphocytes or 
plasma precedes the development of malignancy 
(Lin et al., 2004).
Further convincing evidence comes from 
the successful prevention or regression of 
EBV-carrying lymphoid tumours in humans by 
the adoptive transfer of EBV-specific cytotoxic T 
cells (Heslop & Rooney, 1997; Gustafsson et al., 
2000; Bollard et al., 2007; Merlo et al., 2008).
4.1. Transforming capacity of EBV
In vitro, EBV has the unique ability to trans-
form resting B cells into permanent, latently 
infected lymphoblastoid cell lines, a system that 
has provided an invaluable, albeit incomplete, 
model of the lymphomagenic potential of the 
virus (Young & Rickinson, 2004). EBV can infect 
human B lymphocytes from any human donor 
as long as they express the CD21 consensus 
receptor for the attachment of EBV particles, 
and entry into the host cell (see Section 1.1). 
The B lymphocytes of several differentiation 
stages can be infected. The most efficient infec-
tion – and immortalization – has been seen in 
mature virgin B lymphocytes, which are IgM- 
and IgD-positive The virus establishes a ‘latent’ 
blastogenic “growth programme” (latency III) 
expressing nine latency-associated proteins and 
several non-translated genes, the two EBERs, 
micro-RNAs and BARF-transcripts. The infec-




Table 4 .1 EBV-associated tumours
Tumour type Approx % EBV positivity
Lymphoid tissues
Burkitt lymphoma
Endemic (Subequatorial Africa) >95a







Primary effusion lymphoma 70–90
Post-transplant lymphoproliferative disorders >90
Primary effusion lymphoma 70–90
Hodgkin lymphoma 20–90d
EBV-positive diffuse large B cell lymphoma of the elderly 100






Leiomyosarcoma in immunodeficient individuals 100
a The small fraction of EBV-negative cases in endemic regions may represent cases of sporadic Burkitt lymphoma.
b The proportion of positive cases varies widely with geographic distribution, ranging from 20% in some US and European studies to close to 
80% in India, Egypt, and Northeastern Brazil.
c EBV positivity in plasmablastic lymphoma of the oral cavity in AIDS patients is close to 100%.
d The proportion of positive cases varies widely with geographic distribution, age, histological type and immunocompetence status. It is more 
frequent in low-resource areas, in very young or older patients, in the mixed cellularity subtypes, and approaches 100% in patients with AIDS.
e Stomach, parotid and liver
Compiled by the Working Group mainly from two reviews (Ambinder & Cesarman, 2007; Cesarman & Chadburn, 2007)
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cells with a high efficiency, resulting in prolif-
eration with a 30–40-hour extended cell cycle 
(Einhorn & Ernberg, 1978).
In vivo, mucosal epithelial cells can also be 
infected (see Section 1.1). By contrast, the infec-
tion of epithelial cells in vitro does not activate 
the full growth-transforming programme of the 
virus, and rarely – if ever – achieves full lytic 
replication (Young & Rickinson, 2004).
4.2 Biochemical and biological 
properties of EBV gene products
This section provides an overview of the prop-
erties of the EBV-encoded latency-associated 
gene products, and their mechanism of action 
relevant to transformation and tumorigenesis.
4 .2 .1 The latent EBV nuclear gene products 
(EBNAs)
The main known functions of the six nuclear 
proteins, EBNA-1, -2, -3A, -3B, -3C and -LP are 
summarized in Table 4.2.
(a) EBNA-1
EBNA-1, encoded by the ORF BKRF1, is a 
protein of highly variable size (60–100  kDa) 
due to a glycine–alanine repetitive sequence 
(Hennessy et al., 1983). With the possible excep-
tion of latently infected resting B cells, EBNA-1 is 
expressed in most EBV-carrying cells, irrespec-
tive of the cell phenotype, level of differentiation 
or, in the case of lymphocytes, activation status 
(Section 1.1.7; Tables 1.3 and 1.4). EBV-positive B 
cells that only express EBNA-1 are poorly recog-
nized by CTLs. The glycine–alanine repeat of 
EBNA-1 inhibits its processing through the ubiq-
uitin–proteasome system and the subsequent 
MHC-class 1 association of the derived peptides, 
a prerequisite for recognition by CD8-positive 
CTLs (Levitskaya et al., 1995). This results in 
a dramatically extended half-life of EBNA-1 to 
more than 2 weeks, and may contribute to its 
likely presence in resting B cells without de novo 
synthesis.
EBNA-1 is a DNA-binding protein that can 
bind to three different specific palindromic 
target sites on the viral DNA, each of which 
occurs multiple times in the viral genome, and is 
involved in the control of episomal maintenance, 
DNA replication, and viral gene expression in 
latency. Twenty binding sites are located in the 
family of repeats (FR) element, four in the dyad 
symmetry (DS) element, both these elements 
being localized to the origin of replication (OriP), 
and finally, two EBNA-1-binding sites are situ-
ated downstream of the Q promoter (Ambinder 
et al., 1990; see also the map of the EBV genome 
depicted in Fig. 1.1). The dyad symmetry element 
controls S-phase-associated viral DNA replica-
tion. EBNA-1 regulates viral promoters via its 
multiple binding sites. The family of repeats 
element acts as an enhancer for the C promoter, 
directing transcription for all six EBNAs, and 
the Q-promoter elements are negative regulators 
of Q-promoter-driven EBNA-1 transcription 
through a negative autoregulatory feedback loop.
EBNA-1 acts as a transcriptional regulator 
of viral programmes, and maintains the viral 
genomes in the host cell. It is therefore neces-
sary for cell transformation. EBNA-1 might also 
directly contribute to the tumorigenic process 
as it is expressed in all tumour types (Sample 
& Sample, 2008). It has been shown to exert an 
anti-apoptotic effect. Blocking its function with 
dominant negative mutants induces apoptosis 
in Burkitt lymphoma cell lines (Kirchmaier & 
Sugden, 1997).
EBNA-1 induces the specific recombi-
nases RAG-1 and -2, which could contribute 
to genomic instability or even specific translo-
cations (Tsimbouri et al., 2002). EBNA-1 also 
induces genomic instability involving increases 
in the levels of reactive oxygen species (Gruhne 
et al., 2009).
Recently, it was shown that EBNA-1 can also 
physically bind to cellular promoters, but whether 
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or not this binding plays a role in regulating the 
transcription of these genes in vivo remains to be 
demonstrated (Dresang et al., 2009).
(b) EBNA-2
EBNA-2 is a phosphoprotein of about 82 kDa, 
and is among the earliest viral protein expressed 
in newly infected B cells. EBNA-2 is a potent 
transactivator of many cellular and viral genes 
but does not bind directly to DNA. It influences 
the responding promoters through its interac-
tion with CBF1/RBP-Jk, PU1, and other cellular 
proteins. The EBNA-2 protein complexes formed 
induce chromatin remodelling. Elements for 
EBNA-2 responsiveness have been found in the 
EBV-Cp, LMP-1, LPMP-2, and CD23 promoters 
(Klein & Ernberg, 2007).
EBNA-2 is essential for the transformation 
of B cells into immunoblasts, and for the deri-
vation of lymphoblastoid cell lines. EBNA-2-
defective viral substrains cannot immortalize B 
cells. EBNA-2 is the EBV-encoded oncoprotein 
that differs most extensively between EBV types 
1 and 2. EBV type 1 is a more efficient trans-
former of primary B lymphocytes than is type 2 
(Rickinson et al., 1987). Recruitment of EBNA-2 
to DNA is essential for the transforming activity 
of EBV, and CBF1/RBP-Jk is its most extensively 
studied partner. CBF1/RBP-Jk functions as a 
downstream target of the Notch cell-surface 
receptor. Notch genes encode cell-surface recep-
tors that regulate the developmental processes in 
a wide variety of organisms. The cleaved product 
of Notch is targeted to the nucleus where it binds 
to CBF1/RBP-Jk, and can activate transcription 
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Functions Interaction with cellular 
proteins
Expression in B 
cells
Evidence for 
role in B-cell 
immortalization
EBNA-1 - Viral episome 
maintenance 
- Viral DNA replication 
- Regulation of viral 
promoters
Karyopherins 2 α and β; 
TAP/p32; USP7 (HAUSP); 
RPA
Latency I, II, and 
III
Yes
EBNA-2 Activation of viral and 
cellular promoters
PU.1; hSNF5; Spi-B; CBF1/
RBP-J kappa; p300/CBP; 
DP103; p100; TFIIE; TFIIH; 




Repression of the CBF1/
RBP-J kappa dependent 
transcription
CBF1/RBP-J kappa; RBP-2N; 
CtBP; epsilon-subunit of 










Hsp27; Hsp70 (Hsp72); 
Hsc70 (Hsp73); HAX-
1; HA95; alpha & beta 
tubulins; prolyl-4-





Repression of the CBF1/
RBP-J kappa dependent 
transcription
CBF1/RBP-J kappa; RBP-2N; 
DP103; ProT- alpha; SMN; 
NM23-H1; pRB
Latency III Yes
Adapted from Klein & Ernberg (2007)
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(Strobl et al., 1997). EBNA-2 is regarded as 
a constitutively active homologue of Notch. 
However, Notch can only partially substitute for 
EBNA-2 in B-cell transformation experiments, 
probably owing to its inability to upregulate 
the transcription of LMP1 or c-myc. Thus, the 
functional homology is partial (Höfelmayr et al., 
2001).
EBNA-2 induces a variety of activation 
markers and other cellular proteins in B cells, 
including CD23, CD21, c-fgr, and c-myc. It is 
required for the expression of EBV-encoded 
LMP-1 and LMP-2A in immunoblastic cells 
(Wang et al., 1990a, b; Kaiser et al., 1999; Klein & 
Ernberg, 2007). The essential role of EBNA-2 in 
the immortalization of B cells is therefore due to 
its role in the transactivation of viral promoters 
(Cp, LMP-1 and -2) and of cellular genes associ-
ated with B-cell activation and growth, among 
them c-myc. C-myc activation in lymphocytes, 
in turn, induces protein synthesis (e.g. D-type 
cyclins and cyclin E) but also the downregula-
tion of the inhibitors p21 and p27. The induction 
of c-myc is regarded as a major link between 
EBV infection and cell-cycle control (Kaiser 
et al., 1999). EBNA-2 is required to maintain 
the EBV-driven proliferation of B cells. EBNA-2 
can be replaced by the constitutive expression of 
exogenous c-myc. The switch from the EBNA-2-
driven to the c-myc-driven state is accompanied 
by a phenotypic change of the lymphoblastoid 
cell line-like cell to a more Burkitt lymphoma-
like cell, resembling dividing germinal centre B 
cells (Polack et al., 1996).
(c) EBNA-LP
EBNA-LP (also known as EBNA-5) is a 
nuclear phosphoprotein. Together with EBNA-2, 
EBNA-LP is the earliest viral protein expressed 
in freshly infected B cells. Co-expression of 
EBNA-LP with EBNA-2 enhances EBNA-2-
mediated transcriptional activation (Klein & 
Ernberg, 2007). The two proteins can induce the 
entry of resting B cells into the G1-phase (Sinclair 
et al., 1994). EBNA-LP is tightly associated with 
the nuclear matrix, and often accumulates in 
the nuclear promyelocytic leukaemia bodies. 
EBNA-LP is also necessary for immortalization 
(Pokrovskaja et al., 2001). EBNA-LP was shown 
in vitro to exert an inhibitory effect on the p53–
Rb axis by targeting the p53 regulator p14 ARF. 
The latter can bind MDM2, suppress its ability to 
mediate in the degradation of p53, and thereby 
increase the expression level of p53. It was 
suggested that EBNA-LP participates in the elim-
ination of the p14 ARF–MDM2–p53 complexes 
and contributes to the downregulation of p14 
ARF and p53 protein levels in EBV-infected B 
cells (Kashuba et al., 2003).
(d) EBNA-3
The EBNA-3 family – EBNA-3A (ORF: 
BLRF3 + BERF1), EBNA-3B (or EBNA-4, ORF: 
BERF2a + BERF2b), and EBNA-3C (or EBNA-6, 
ORF: BERF3 + BERF4) – comprises three large 
nuclear phosphoproteins in sizes ranging from 
140–180  kDa. All three proteins are stable 
proteins that accumulate in intranuclear clumps, 
sparing the nucleolus (Klein & Ernberg, 2007).
All EBNA-3 proteins share a limited 
homology in a region near the N terminus, and 
this conserved domain mediates the binding to 
CBF1/RBP-Jk. This is how they all act as repres-
sors of EBNA-2-mediated transactivation of 
the CBF1/RBP-Jk-dependent Cp, LMP-2A, and 
LMP-1 promoters. EBNA-3C also physically 
associates with histone deacetylase HDAC1, and 
can repress transcription through the Notch 
signalling pathway (Radkov et al., 1999).
EBNA-3C (but not EBNA-3A or -3B) can also 
activate the transcription of both cellular and 
viral genes (e.g. CD21, CD23, and LMP-1). This 
activation is clearly distinct from the interaction 
of EBNA-3C with CBF1/RBP-Jk, and requires 
an intact Spi binding site as well as a fully func-
tional EBNA-2 protein (Zhao & Sample, 2000). 
EBNA-3C disrupts cell-cycle checkpoints at 
several levels. One is by recruiting the SCFskp2 
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ubiquitin ligase complex, which mediates the 
ubiquitination and degradation of pRB (Knight 
et al., 2005).
EBNA-3A and EBNA-3C, but not EBNA-
3B, are necessary for in vitro immortalization 
(Tomkinson et al., 1993).
4 .2 .2 The latent membrane proteins
EBV expresses three latent membrane 
proteins (LMPs) during latency II and III in 
immunoblasts as well as in derived tumours and 
cell lines: LMP-1, LMP-2A, and LMP-2B. All three 
proteins are also detected in epithelial tumours 
of the nasopharynx, and during the early stages 
of oral hairy leukoplakia (Webster-Cyriaque & 
Raab-Traub, 1998) (see Section 1.1; Table  1.4). 
LMP-2A transcripts can also be expressed in 
resting virus-carrying B lymphocytes in healthy 
individuals – the reservoir of persistently latent 
EBV (Chen et al., 1995).
LMP-2A together with LMP-1 are necessary 
for continued lymphoma cell survival via TRAF2 
regulation of NF-κB (Guasparri et al., 2008).
The three LMP proteins are highly multifunc-
tional and interact with several cellular signal-
ling pathways (Table 4.3). They are expressed at 
the cell surface membrane as well as in intracel-
lular membranes of the Golgi and endoplasmic 
reticulum (Hennessy et al., 1984; Lynch et al., 
2002).
(a) LMP-1
LMP-1 is a 356-amino-acid protein which 
consists in a short N-terminal cytoplasmic 
domain, six membrane-spanning domains, and 
a C-terminal cytoplasmic domain 200 amino-
acid long (Liebowitz et al., 1986).
LMP-1 is essential although not mandatory 
for the transformation of B lymphocytes into 
lymphoblastoid cell lines, and EBV mutants 
lacking LMP-1 fail to efficiently immortalize B 
cells (Dirmeier et al., 2003).
LMP-1 can induce lymphomas and epithelial 
tumours in transgenic mice, acting as tumour 
promoter after chemical initiation (Curran et al., 
2001).
LMP-1 as an integral membrane protein 
acts like a constitutively activated receptor. It 
almost completely mimics the CD40-mediated 
signalling, and is thus functionally homologous 
to the TNF-receptor (TNFR)-family of proteins 
in B lymphocytes and epithelial cells. Indeed, it 
constitutively activates major signalling systems 
such as NF-κB (canonical and non-canon-
ical), JNK-kinase, and JAK/STAT-pathways. 
Protection from apoptosis is one of its major 
downstream effects (Lam & Sugden, 2003a, b).
LMP-1 has been shown to interact with 
several proteins of the TNFR-signalling pathway 
through its C-terminal activation region (CTAR) 
1 and 2 (Table 4.3; Lam & Sugden, 2003b). These 
interactions result in the NF-κB-dependent 
upregulation of several genes. LMP-1 can block 
apoptosis due to the upregulation of several anti-
apoptotic proteins, including A20 and Bcl-2, 
and the block of p53-mediated apoptosis by the 
latter (Henderson et al., 1991; Hatzivassiliou & 
Mosialos, 2002). It may also alter the ratio of 
caspase-8, an initiator caspase, and its compet-
itor FLIP (FLICE inhibitor protein) (Tepper & 
Seldin, 1999).
LMP-1 also activates JNK-kinase (Eliopoulos 
et al., 1999; Kieser et al., 1999). It can also induce 
telomerase activity (Terrin et al., 2008).
Through its interference with several major 
signalling pathways in B cells and epithelial cells, 
LMP-1 mediates deregulation of several hundred 
cellular proteins. LMP-1 induces the expression 
of adhesion molecules such as ICAM-1 and LFA, 
and also MHC Class I and II (Hatzivassiliou & 
Mosialos, 2002).
Moreover, LMP-1 expressed in epithelial cell 
lines in vitro inhibits DNA repair and induces 
micronuclei formation, chromosomal aberra-
tions, and consequent genomic instability (Liu 
et al., 2004).
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(b) LMP-2A and LMP-2B
LMP-2A contains 12 trans-membrane 
domains, and two intracellular tails: a 27-amino-
acid C-terminal tail, important for protein aggre-
gation, and a 119-amino-acid N-terminal tail 
that confers the capacity of LMP-2A to activate 
signal cascade. LMP-2A has been reported to 
aggregate into ‘cap-like’ structures at the plasma 
membrane and specifically associate with lipid 
rafts, sites enriched for signalling molecules 
(Dykstra et al., 2001; Higuchi et al., 2001).
LMP-2A signalling mimics signalling 
through the B-cell receptor with which it 
shares structural and functional similari-
ties. The N-terminal tail of LMP-2A contains 
eight phosphotyrosine motifs that interact 
with SH2-domain-containing proteins such as 
the immunoglobulin-receptor (IgR)-induced 
kinases Lyn. In addition, LMP-2A also possesses 
an Immunoglobulin Transactivation Motif 
(ITAM) with complete homology to the corre-
sponding IgR-ITAM-motif of its gamma-chain 
that binds the Syk kinase in its activated phos-
phorylated state (Klein & Ernberg, 2007).
When expressed as a B-lineage-specific 
transgene in mice, it can both drive B-cell 
development, and promote the survival of 
mature B-cells in the absence of surface immu-
noglobulin expression (Merchant et al., 2000). 
EBV mutants with a deleted LMP-2A gene fail 
to allow germinal centre B cells to survive; it is 
thus essential for growth transformation of these 
B cells (Mancao & Hammerschmidt, 2007).
If LMP-2A mimics B-cell receptor signal-
ling, there is evidence however that expression 
of LMP-2A in B lymphocytes also attenuates 
normal activation through B-cell receptors. It was 
shown that LMP-2A blocks both B-cell receptor 
signalling and antigen-processing function in 
lymphoblastoid cell lines (Dykstra et al., 2001). 
It inhibits apoptosis pathways that are normally 
activated by B-cell receptor activation in Ramos 
and Akata cells, and prevents EBV reactivation 
in these cells. Thus, LMP-2A has an important 
role in maintaining viral latency.
LMP-2A has also been shown to activate 
PI3 kinase and the downstream phosphoryla-
tion of Akt in epithelial cells and B cells. This 
may modulate cell growth and apoptosis (Swart 
et al., 2000; Moody et al., 2005). It was shown 
to induce cell mobility and invasion in epithelial 
cells (Pegtel et al., 2005).
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Table 4 .3 Overview of the EBV latent membrane proteins: functions and interactions
Name Functions Major protein 
interactions
Expression in B cells Evidence for role in 
oncogenesis
LMP-1 Mimics CD 40 
Activation of NFkB, JNK 
kinase, JAK/STAT, MAP 
kinase, Akt 
Cell survival 
Induction of adhesion and 
immune regulatory membrane 
proteins




Latency II-III Yes 
- Anti-apoptotic 
- Survival of lymphoma cells 
- Transformation of primary 
rat embryo fibroblasts 
- Tumours in transgenic 
animals
LMP-2A Interacts with phosphotyrosine 
kinases including Src-family 
and PI3-kinase 
Blocks lytic cycle 
Block BCR activation
Src, Lyn, Lck 
ZAP-70, Syk, 
AIP4/Nedd4
Latency I-III Yes 
- Survival of B-cells and 
lymphoma cells 
- Cell migration and 
invasion
LMP-2B Modulates function of LMP-2A LMP-2A Latency III No
Adapted from Klein & Ernberg (2007)
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LMP-2A can also associate with Nedd4-
ubiquitin ligases via its PPPPY-motif located at its 
AA-terminus. It is conceivable that the binding 
of LMP-2A to the Nedd4 family of proteins can 
result in fast destruction of LMP-2A itself and 
LMP-2A-associated kinases, by guiding the 
complex to the ubiquitin–proteasome system 
(Winberg et al., 2000).
A major role of LMP-2A in relation to latent 
EBV infection may stem from its ability to inhibit 
the activation of lytic EBV replication in infected 
B cells by cell-surface-mediated signal transduc-
tion (Miller et al., 1994). This may prevent lytic 
replication in latently infected B cells as they 
circulate in the blood, bone marrow or lymphatic 
tissues, where they might encounter antigens or 
other ligands capable of engaging B-cell recep-
tors and activating the viral cycle.
LMP-2B is a splice variant of LMP-2A which 
lacks the N-terminal tail with its kinase-inter-
acting domains. It is thought to interact with 
LMP-2A, and thereby modulates its functions 
(Rovedo & Longnecker, 2007).
4 .2 .3 The non-coding RNAs
(a) The EBV-encoded RNAs (EBERs)
The EBERs are two non-coding, non-polyade-
nylated RNAs, EBER-1 (166 nucleotide long) and 
EBER-2 (172 nucleotides long), which are always 
expressed in very high abundance (105–106 copies/
cell) in latently EBV-infected cells irrespective of 
cell phenotype. Structural predictions suggest 
that they can form a compact structure with five 
major hairpin structures. They act as regulators 
of signalling and transcription factors, resulting 
in the production of interferons and cytokines 
(Samanta et al., 2008). The EBERs were shown to 
induce the anti-inflammatory cytokine IL10 as 
an autocrine growth factor in Burkitt lymphoma 
cells. This effect is produced via retinoic-acid-
inducible gene I (RIG-I, a sensor of innate 
immunity)-mediated activation of IRF-3. In cell 
lines derived from nasopharyngeal carcinoma, 
the EBERs induce insulin-like growth factor 1 
(IGF-1), which also acts as an autocrine growth 
factor. This is corroborated in vivo because naso-
pharyngeal carcinoma biopsies consistently 
express IGF-1 (Wu et al., 2007; Samanta et al., 
2008).
EBERs may also contribute to B-cell transfor-
mation; this was shown for EBER-2 RNA via its 
efficient induction of IL6 (Wu et al., 2007).
(b) The EBV micro-RNAs
Micro-RNAs are small non-coding RNAs, 
generally 20–24 nucleotides in length, that can 
transcriptionally downregulate the expression 
of mRNAs, bearing complementary sequences. 
EBV encodes at least 22 micro-RNAs which 
are expressed to various degrees in all forms of 
latency, and in tumour tissues (Pfeffer et al., 2004; 
Cai et al., 2006; Grundhoff et al., 2006). All EBV 
tumours that have been studied express at least 
some of the EBV-encoded micro-RNAs. They 
have been shown to target several interesting 
cellular genes, and thus they may very well turn 
out to play a central role in the tumorigenesis of 
EBV. Target genes identified so far include PUMA 
of the p53 pathway, and the chemokine CXCL11 
(Choy et al., 2008; Xia et al., 2008).
4.3 In vivo and in vitro evidence 
for a role of EBV in human 
malignancies
4 .3 .1 EBV-associated B-cell lymphomas
There are three histologically and clini-
cally distinct types of EBV-associated B-cell 
lymphomas that show different patterns of latent 
gene expression and seem, from the immuno-
globulin gene sequencing, to derive from cells 
at different position in the B-cell differentiation 
pathway (Fig. 1.3).
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(a) Lymphomas in immunosuppressed 
individuals
T-cell-immunocompromised patients — 
organ transplant recipients, congenitally immu-
nocompromised individual, particularly the 
X-linked lymphoproliferative syndrome (XLP) 
and AIDS patients — are at a high risk of devel-
oping B-cell lymphomas.
Most post-transplant lymphoproliferative 
diseases occur as polyclonal or monoclonal 
lesions within the first year of allografting, when 
immunosuppression is most severe. Almost all of 
these early onset tumours are EBV-positive, and 
express the full latency III programme, which 
identifies them as virus-transformed B cells that 
grow out in the absence of effective T-cell surveil-
lance. Some of the lymphomas that are seen in 
highly immunocompromised AIDS patients, 
particularly central nervous system lesions, 
show essentially the same phenotype. (Young & 
Rickinson, 2004). The EBV proteins expressed 
include the highly immunogenic members of the 
EBNA-3 triad (EBNA-3A, -3B, and -3C), which 
is why passive immunotherapy with in vitro-
expanded EBV-antigen-specific CD8-positive 
CTLs can bring about dramatic regression, even 
of widely disseminated tumours (Rooney et al., 
1995; Khanna et al., 2001).
(b) Burkitt lymphoma
EBV is associated with almost all of the 
paediatric Burkitt lymphomas in high ende-
micity areas, but only with a fraction of sporadic 
or AIDS-associated Burkitt lymphomas (Kelly & 
Rickinson, 2007).
In equatorial African endemic areas, high 
EBV VCA antibody titres are regularly detected 
in children as early as 4  years before tumour 
development, which indicates an early infection 
and a high viral load (Geser et al., 1982). In these 
countries, malaria is holoendemic and this infec-
tion appears to be a strong risk factor of Burkitt 
lymphoma (reviewed in Rochford et al., 2005).
EBV gene expression in Burkitt lymphoma 
is strictly latent and very constrained. Most cells 
express only EBNA-1 and the EBERs (latency I 
programme). The BARTs have also been detected 
in Burkitt lymphoma samples by PCR. In addi-
tion, some genes traditionally thought to be 
confined to expression during the lytic cycle can 
also be expressed in Burkitt lymphoma cells, by 
alternative splicing of transcripts driven from 
latent promoters. The expression of the bcl-2 
homologue BHRF-1 by this mechanism might be 
particularly significant (Kelly et al., 2006).
All Burkitt lymphomas, irrespective of form 
or EBV status, carry c-myc translocations to one 
of the immunoglobulin loci, the heavy chain 
locus on chromosome 14 or the light chain loci 
on chromosomes 2 or 22. Theses translocations 
are the hallmark of all Burkitt lymphomas. This 
may reflect the timing of the initiation of the 
lymphoma in relation to B-cell differentiation 
and at the time of the immunoglobulin gene rear-
rangement. As a result, the c-myc gene is in these 
cells under the control of a highly active immu-
noglobulin gene promoter leading to constitutive 
expression of c-myc (Klein, 1983).
Apart from the possible role of expanding 
the lifespan of the EBV-carrying B cells before 
lymphomagenesis, thus increasing the likelihood 
of secondary genetic events (such as the c-myc 
translocation), EBV can also play a direct role 
in lymphoma initiation. First, the expression of 
dominant-negative EBNA-1 mutants in Burkitt 
lymphoma cells in vitro induces apoptosis, 
which points to the requirement of EBNA-1 for 
the continued survival of EBV-positive Burkitt 
lymphoma cells (Kirchmaier & Sugden, 1997). 
In addition, genomic instability induced by 
EBNA-1 could be another possible mechanism 
(Tsimbouri et al., 2002; Gruhne et al., 2009).
It has also been proposed that EBV, by virtue 
of its anti-apoptotic BHRF1 gene, provides protec-
tion against apoptosis induced by deregulated 
c-myc expression (Kelly et al., 2006). Another 
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possibility is apoptotic protection by the EBERs 
(Takada, 2001).
(c) Hodgkin lymphoma
Hodgkin lymphoma is characterized by an 
expansion of Reed-Sternberg cells, which are now 
postulated to be of B-cell lineage. Several lines of 
evidence link EBV to Hodgkin lymphoma: 
• A 4-fold increase in risk in individu-
als with a past history of infectious 
mononucleosis; 
• Increased antibody titres to EBV viral 
capsid antigen; and,
• The detection of monoclonal EBV 
genomes in the HRCs.
Almost half of the Hodgkin lymphoma cases 
in Western countries carry EBV-positive HRCs 
that express the latency II pattern with EBNA-1, 
LMP-1, LMP-2A, LMP-2B, and the EBERs being 
expressed (reviewed in Thompson & Kurzrock, 
2004).
4 .3 .2 EBV-associated epithelial cancers
(a) Cancer of the nasopharynx
EBV is consistently detected in patients with 
cancer of the nasopharynx, with a stronger 
association with non-keratinizing carcinoma 
than with keratinizing carcinoma (Maeda et al., 
2009). Regardless of whether the patient with 
nasopharyngeal carcinoma lives in an area of 
endemic or sporadic incidence (see Section 1.2), 
all tumour cells contain EBV DNA as multiple 
clonal episomes as shown by terminal repeats 
analysis. The clonality of EBV DNA suggests 
that nasopharyngeal carcinoma occurs from the 
clonal expansion of a single EBV-infected cell, 
and that EBV infection is an early, possibly initi-
ating, event in the development of nasopharyn-
geal carcinoma (Raab-Traub & Flynn, 1986). This 
is further supported by studies showing that 
preneoplastic and preinvasive lesions of the naso-
pharynx are also infected by EBV, and express 
the same latency programme (Pathmanathan 
et al., 1995).
Nasopharyngeal carcinoma cells express an 
EBV-latency II pattern (see Section 1.1) including 
the expression of EBNA-1, LMP-1, LMP-2A, 
LMP-2B, the EBERS, and micro-RNAs.
Several genes relevant for the tumorigenic 
phenotype of the nasopharyngeal carcinoma 
cell are induced by LMP-1 (Thornburg & Raab-
Traub, 2007).
However, only about two-thirds of naso-
pharyngeal tumours express LMP-1 in vivo as 
measured by Western blot or in-situ staining. 
Clinical and follow-up data from 74 cases of 
nasopharyngeal carcinoma showed that LMP-1-
positive nasopharyngeal carcinoma grew faster 
and more expansively than LMP-1-negative 
tumours, in a short two-year follow-up (Hu et al., 
1995). In the LMP-1 non-expressing tumours, 
the promoter region of the LMP-1 gene is hyper-
methylated (Hu et al., 1991).
In a few early precancerous lesions in situ 
that could be studied, LMP-1 is always expressed 
(Pathmanathan et al., 1995). It might thus have 
an important role in the early process, but its 
functions can later be replaced by cellular genes.
LMP-2A induces migration and invasion of 
epithelial cells including nasopharyngeal-carci-
noma-derived cell lines, which could affect the in 
vivo phenotype of the tumour (Allen et al., 2005).
Both EBERs and some of the EBV micro-
RNAs are expressed in nasopharyngeal carci-
noma, but their respective role in tumorigenesis 
has not yet been addressed (Cosmopoulos et al., 
2009).
(b) Cancers of the stomach
EBV is detected in 5–10% of gastric carci-
nomas worldwide (see Section 1.2). It has been 
suggested that EBV-positive gastric carcinoma 
belongs to a separate clinico-histopatholog-
ical entity, distinguishable from most gastric 
carcinomas as this occurs at younger age, 
with a distinct histopathology (ranging from 
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adenocarcinoma with lymphoid infiltration to 
lymphoepithelioma-like), and with a more prox-
imal location (Fukayama et al., 2008). In these 
tumours, the EBV genome is present in (almost) 
all cells and is monoclonal, suggesting that the 
infection takes place at tumour precursor cell 
state. The latent pattern of EBV in gastric carci-
noma corresponds to an intermediate latency I /
II programme, with EBNA-1, EBERs, BARF-0, 
LMP-2A, and micro-RNAS. In addition, some 
lytic infection genes such as BARF-1 and BHRF-1 
have also been detected in these tumours. All 
tumour cells express the EBERs as shown by 
PCR and by in-situ hybridization, while expres-
sion of LMP-2A and the lytic genes is variable 
(Luo et al., 2005).
In gastric carcinoma cells in culture, EBV 
expresses a latency pattern that is similar to 
gastric carcinoma in vivo, including the viral 
micro-RNAs. In these cells, EBV uses LMP-2A 
to activate the NF-κB-surviving pathway which 
confers some resistance to apoptosis induced by 
serum deprivation (Hino et al., 2008). In parallel 
with the results in vitro, the NF-κB-surviving 
pathway has been shown to be highly activated in 
nearly all EBV-associated gastric carcinomas in 
the advanced stage, and the frequency is signifi-
cantly higher than that in EBV-negative gastric 
carcinomas (Luo et al., 2005). Various viral 
proteins (e.g. HTLV-1 Tax, HPV-16E6, HBx) are 
known to upregulate surviving protein expres-
sion in human neoplasms; this may be a common 
denominator in the mechanisms of human viral 
oncogenesis (Hino et al., 2008).
(c) Other carcinomas
Carcinomas showing morphological features 
that are similar to undifferentiated nasopharyn-
geal carcinomas or EBV-related gastric carci-
nomas, so-called lymphoepithelial carcinomas, 
can occur at other sites. Lymphoepithelial carci-
nomas of the salivary glands, of the lungs, and 
possibly of the thymus are frequently associated 
with EBV infection (IARC, 1997), but there is no 
mechanistic data demonstrating a specific role of 
EBV in these tumours.
4.4 Interaction between EBV and 
other agents; mechanisms 
involved in EBV reactivation
EBV coexists for a lifetime in a latent state 
in most human hosts without overt serious 
consequences. This strongly suggests that cofac-
tors able to reactivate EBV viral replication 
may potentially be required for EBV-associated 
carcinogenesis.
EBV can be reactivated from its latent state by 
several means, and its reactivation could poten-
tially lead to the development of EBV-related 
pathology.
(a) Foreign antigen
In healthy carriers, EBV remains silent 
and expresses only EBERs in infected resting 
memory B cells. Viral replication can only occur 
in dividing cells; this is the case when memory 
B cells divide for cell maintenance or when they 
differentiate into plasma cells following activa-
tion by the presence of a foreign antigen (Laichalk 
& Thorley-Lawson, 2005). This means that any 
additional infection may potentially reactivate 
EBV in these cells.
(b) Immunodeficiency
EBV infection is strictly kept under very 
tight control by cell-mediated immunity in 
immunocompetent individuals (see Fig.  1.2). 
Immunodeficiency (iatrogenic as in transplant 
recipients, congenital, or HIV-related) allows 
the spread of uncontrolled reactivated EBV from 
infected memory B cells, which can give rise to 





Infection with both EBV and Plasmodium 
falsiparum are recognized to be required for 
the genesis of endemic Burkitt lymphoma. 
Children living in areas endemic for malaria 
have an elevated EBV load, and have diminished 
EBV-specific T-cell immunosurveillance between 
the ages of 5–9 years, which coincides with the 
peak age incidence of the diseases (Moormann 
et al., 2005, 2007). In addition, acute malaria 
infection leads to increased levels of circulating 
EBV that are cleared following anti-malaria 
treatment (Rasti et al., 2005; Donati et al., 2006). 
A direct molecular mechanism of interaction 
has been demonstrated between P. falsiparum 
and EBV. CIDR1α, a cystein-rich domain of the 
P. falsiparum membrane protein 1 was shown to 
act as a polyclonal B-cell activator, and to induce 
the EBV lytic cycle (Chêne et al., 2007).
(d) Food
In the southern region of the People’s Republic 
of China, where nasopharyngeal carcinoma is a 
very common malignancy, the ingestion of salted 
fish especially during weaning has been shown 
to be an important risk factor for the condition 
(Yuan et al., 2000). Other preserved food prepa-
rations such as the spiced mixture “harissa” in 
Tunisia have also been identified as potential risk 
factors for nasopharyngeal carcinoma (Jeannel 
et al., 1990). Using Raji cells, an in vitro study 
demonstrated a strong EBV reactivation activity 
in aqueous extracts of some Cantonese salted fish 
from China, and harissa, and to a lesser extent 
qaddid (dry mutton preserved in olive oil) from 
Tunisia (Shao et al., 1988).
(e) Inflammation
TGFβ-1, a multifunctional cytokine, induces 
EBV reactivation in EBV-infected gastric carci-
noma cell lines in vitro as shown by the induc-
tion of EBV-early immediate BZLF-1 RNA, and 
its protein product ZEBRA (Fukuda et al., 2001). 
[The Working Group noted that TGFβ is highly 
expressed during inflammation suggesting that 
chronic inflammation may potentially reactivate 
latent EBV infection in vivo; this hypothesis still 
needs to be demonstrated.]
(f) Chemical agents and drugs
Stimuli that can activate the latency-to-lytic 
switch in cultured cell lines, include phorbol 
esters, which are protein kinase C agonists; 
sodium butyrate and trichostatin A, which are 
histone deacetylase inhibitors; 5-aza-2-deox-
ycytidine, which is a DNA methyltransferase 
inhibitor; and anti-immunoglobuline G, which 
activates the B-cell antigen receptor. While oper-
ating by different modes of action, these agents all 
lead to the expression of the EBV lytic activator 
genes BZLF-1 and BRLF-1, which encode ZEBRA 
and Rta (Countryman et al., 2009).
4.5 Transgenic models for EBV-
associated cancers
Transgenic mice models expressing EBNA-1 
and LMP-1 under various tissue-specific 
promoters are available. They show dysregulation 
of the haematopoetic and epithelial compart-
ments, depending on which tissue the transgene 
is directed to. Transplantable tumours occur 
with an elevated frequency in LMP-1-transgenic 
mice (Kulwichit et al., 1998; Curran et al., 2001; 
Shair et al., 2007). EBNA-1-transgenic mice have 
also been shown to develop tumours (Wilson 
et al., 1996).
A humanized mouse model in which the 
functional human immune system (including T, 
B, and natural killer lymphocytes) is reconsti-
tuted, can simulate key aspects of EBV infection. 
Inoculation of EBV in these mice causes B-cell 
lymphoproliferative disorder, with histopatho-
logical findings and latent EBV gene expression 
that are similar to that in immunocompromised 
patients (Yajima et al., 2008).
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4.6 Synthesis
Mechanistic data that strongly support an 
oncogenic role of EBV in human cancer can be 
summarized as follows:
• EBV immortalizes normal B cells in 
culture.
• One or several EBV gene products are 
expressed in all EBV-associated cancers.
• At the molecular level, these EBV-encoded 
gene products associated with latent viral 
infection induce cell proliferation, block 
apoptosis, induce genomic instability or 
modulate cell migration. These events 
occur before or during tumour initiation. 
Several of these gene products are also 
involved in mechanisms contributing 
to continued tumour maintenance, cell 
growth, and progression.
Mechanistic data strongly support an 
oncogenic role of EBV in diffuse large B-cell 
lymphomas in immunocompromised individ-
uals (post-transplant patients, XLP, AIDS). In 
these tumours, EBV adopts the growth-prolifer-
ative programme seen in EBV-infected human B 
cells, which is solely driven by the virus.
Mechanistic data strongly support an onco-
genic role of EBV in Burkitt lymphoma, where 
EBV promotes the survival of B cells that have 
undergone the pro-apototic myc-translocation.
Mechanistic data strongly support an onco-
genic role of EBV in Hodgkin lymphoma and 
nasopharyngeal carcinoma, where LMP-1 can 
act as a transforming viral protein.
There is positive mechanistic data for a role 
of the virus in EBV-positive gastric carcinoma.
Regarding the role of EBV in EBV-positive T/
NK-cell lymphomas, in vitro model systems still 
require optimization, and as a result, only weak 
mechanistic evidence is available to support a 
role of EBV in these types of cancer.
At the time of writing, no mechanistic studies 
have been published that directly investigate a 
role of EBV in lymphoepitheliomas of the sali-
vary gland.
5. Evaluation
There is sufficient evidence in humans for 
the carcinogenicity of EBV. EBV causes Burkitt 
lymphoma, immunosuppression-related non-
Hodgkin lymphoma, extranodal NK/T-cell 
lymphoma (nasal type), Hodgkin lymphoma, 
and cancer of the nasopharynx. Also, a positive 
association has been observed between exposure 
to EBV and lymphoepithelioma-like carcinoma.
In the case of gastric carcinoma, there is 
insufficient epidemiological evidence for the 
involvement of EBV. However, the fact that 
the EBV genome is present in the tumour cell 
in a monoclonal form, and that transforming 
EBV proteins are expressed in the tumour cell 
provides a mechanistic explanation of how EBV 
might cause a proportion of gastric cancer. 
EBV is carcinogenic to humans (Group 1).
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The hepatitis B virus was considered by a previous IARC Working Group in 1993 (IARC, 
1994). Since that time, new data have become available, these have been incorporated in 
the Monograph, and taken into consideration in the present evaluation.
1. Exposure Data
1.1 Taxonomy, structure, and biology
1 .1 .1 Taxonomy
The hepatitis B virus (HBV) is the proto-
type member of a family of hepatotropic DNA 
viruses, the Hepadnaviridae, that replicate by 
reverse transcription of an RNA pregenome. 
HBV infects humans, whereas other hepadnavi-
ruses infect mammals (orthohepadnaviruses) or 
birds (avihepadnaviruses) (Schaefer, 2007a).
HBV comprises eight genotypes (A to H) 
with distinct virological characteristics and 
geographic distributions (Kramvis et al., 2005; 
Schaefer, 2007a; see Section 1.2.3). Each genotype 
differs from the others by more than 8% of its 
nucleotide sequence. Genotypes may influence 
the disease caused, although further analysis of 
this association is required. The variability of 
the HBV genome may be further increased by 
recombination among genotypes, especially B/C 
and A/D.
HBV genotypes, with the exception of geno-
types E and G, are divisible into subgenotypes. 
Each subgenotype differs from the others by 
more than 4% of its nucleotide sequence. The 
number of subgenotypes per genotype described 
to date ranges from three to five (Kramvis et al., 
2005; Schaefer, 2007a).
1 .1 .2 Structure of the virion
HBV is an enveloped virus, measuring 
42–47 nm in diameter, with an icosahedral nucle-
ocapsid that encloses a partially double-stranded 
relaxed-circular (rc) DNA genome covalently 
bound to the viral polymerase. The envelope 
comprises a small amount of lipid of cellular 
origin and three hepatitis B surface proteins 
(HBs): large (LHB), medium, (MHB), and small 
(SHB), which form disulfide-linked homo- and 
heterodimers. The serum of infected individuals 
contains, in addition, two types of subviral parti-
cles: small spherical particles with a diameter of 
approximately 20 nm and filamentous particles 
also with a diameter of about 20 nm but of vari-
able length. These non-infectious subviral parti-
cles lacking genomic DNA greatly outnumber the 
infectious viral particles, and have a composition 
similar to that of the viral envelope (Kann, 2002).
The nucleocapsid is formed by multiple copies 
of core protein. Of the total 183–185 amino acids 
(depending upon genotype), the N-terminal 
149–151 amino acids are responsible for self-
assembly of the nucleocapsid. Although the 
steps in its assembly remain to be clarified, the 
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first step is the formation of homodimers linked 
by disulfide bridges. The nucleocapsid contains 
pores that allow the diffusion of nucleotides 
during the synthesis of the DNA genome. The 
C-terminal amino acids of the core protein play 
a role in the packaging of the pregenome–poly-
merase complex within the nucleocapsid (Bruss, 
2007).
1 .1 .3 Structure of the viral genome
HBV has a partially double-stranded but not 
covalently closed circular (ccc) DNA genome 
composed of between 3182–3248 nucleotides, 
depending on the genotype. The genome consists 
of a complete minus-DNA strand with a short-
terminal redundancy, and a shorter plus-DNA 
strand that leaves a single-stranded gap of vari-
able length in mature nucleocapsids and released 
viruses (Kann, 2002; Jilbert et al., 2002). Base-
pairing of plus- and minus-strands in the cohe-
sive overlap region of the genome maintains the 
circular configuration. The 5′end of the minus-
strand is covalently linked to the N-terminal 
portion of the viral polymerase. At its 5′end, the 
plus-strand is linked to a capped RNA oligo-
nucleotide that is derived from the 5′end of the 
RNA pregenome, and serves as the primer for 
plus-strand-DNA synthesis.
The genome consists of four partially overlap-
ping open reading frames (ORFs) (Kann, 2002) 
that express surface, precore/core, polymerase, 
and X proteins. Each ORF overlaps at least one 
other ORF, with the polymerase ORF overlap-
ping all of the others, and every nucleotide is part 
of at least one ORF. Translation of preS1, preS2, 
and S ORFs leads to the expression of the surface 
proteins, LHB, MHB, and SHB, respectively 
(Fig. 1.1).
 Four promoters (preC/C, preS1, S, and X) 
and two enhancers (Enh1 and Enh2) overlap the 
ORFs (Kann, 2002). The promoters initiate the 
transcription of messenger (m) RNAs of 3.5, 2.4, 
2.1 and 0.9 kb that allow, by the use of different 
start codons, the expression of seven proteins. 
All are of positive orientation, possess a 5′cap, 
are polyadenylated at their 3′ends, and serve as 
mRNAs for viral gene products. Enh1, which 
stimulates the transcription of all viral RNAs, is 
located between the S and X ORFs, and Enh2, 
a less potent enhancer, overlaps the preC/C 
promoter.
In addition to the enhancers, other regulatory 
elements have been identified: a glucocorticoid 
responsive element (GRE) is located between 
Enh1 and Enh2; a CCAAT element regulates the 
transcription of the upstream preS1 promoter, 
and activates the transcription of S mRNA; and 
a negative regulatory element (NRE) appears 
to inhibit only the precore/core mRNA (Kann, 
2002).
1 .1 .4 Host range
HBV primarily infects humans, although 
chimpanzees, Chacma baboons, and tree shrews 
are also susceptible to infection (Hu et al., 2000; 
Cao et al., 2003).
1 .1 .5 Target cells
HBV is primarily an hepatotropic virus, 
and hepatocytes are the only confirmed site of 
replication for all members of this virus family. 
Although the virus has been detected in other 
cells such as bile duct epithelial cells, peripheral 
blood mononuclear cells and cells in the pancreas 
and kidneys, the evidence for viral replication 
in these cells is controversial (Seeger & Mason, 
2000).
1 .1 .6 Function of the gene products
(a) Surface proteins
The HBV surface protein: small (SHB), 
medium (MHB) and large (LHB), together with 





Fig. 1.1 Transcriptional and translational map of HBV
 
The partially double-stranded, circular rc-DNA is indicated by thick black lines, with the polymerase (P) covalently linked to the 5′end of the (-)-
DNA, and the RNA primer (zigzag line) at the 5′end of (+)-DNA. The dashed part symbolizes the heterogeneous lengths of the (+)-strands. DR1 and 
DR2 are the direct repeats. The outer circle symbolizes the terminally redundant pgRNA with ε close to the 5′end, and the poly-A tail at the 3′end. 
The precore mRNA is nearly identical, except it starts slightly upstream. The relative positions of the open reading frames for core (C), P, preS/S, 
and X are shown inside. TP, Terminal protein domain of P; pgRNA, pregenomic RNA
From Beck J, Nassal M, Hepatitis B virus replication, World J Gastroenterology, 2007; 13(1):48-64
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SHB antigen which represents 85% of hepatitis 
B surface antigen (HBsAg), is highly immuno-
genic and provokes the host’s immune response 
to HBV. Excess surface protein circulating in 
subviral particles is thought to dilute the host’s 
immunological response to the virus.
LHB, in contrast to MHB, is essential for 
infection and viral morphogenesis. It represents 
10–30% of the HBsAg of virions and filaments. 
LHB plays a role in viral entry into hepatocytes, 
although SHB may also be needed in this process 
(Kann, 2002).
(b) Core protein and ‘e’ antigen
Core protein (C) is the major structural 
component of the nucleocapsid. The preC/C ORF 
is transcribed into a precore/core fusion protein. 
During entry into the endoplasmic reticulum, 
19 amino acids are cleaved from the N-terminal 
end of the precore protein by a signal peptidase. 
When transported into the Golgi compartment, 
additional amino acids are removed from the 
C-terminal end by intra-Golgi proteases to form 
HBe antigen. This antigen is secreted into the 
serum. The biological function of HBe remains 
unsolved (Kann, 2002).
(c) Polymerase protein
Polymerase (P) has four domains: a terminal 
domain, which serves as a protein primer for 
reverse transcription of pregenomic viral RNA; 
a spacer region without apparent function; the 
polymerase domain, which has reverse transcrip-
tion activity; and the RNase H domain, which 
is responsible for the degradation of the RNA 
template during reverse transcription (Kann, 
2002).
(d) X protein
The X protein (HBx) has been shown to be 
a promiscuous regulator of transcription that 
is essential for viral replication. Although not 
binding itself to DNA, it regulates transcription 
from HBV enhancers/promoters, and from the 
promoters of cellular genes, including oncogenes, 
cytokines, growth factors, and several genes 
involved in cell-cycle control and progression, 
DNA repair, apoptotic cell death, and cellular 
adhesion. HBx also forms complexes with several 
signal transduction proteins and regulators 
of cell growth and survival (Murakami, 1999; 
Feitelson et al., 2005; Benhenda et al., 2009). It is 
suspected to play a central role in HBV regula-
tion and pathogenesis (see Section 4).
1 .1 .7 Viral life cycle
During both acute and persistent infection, 
high levels of infectious HBV particles (virions) 
circulate in the bloodstream, together with an 
excess of empty particles.
Hepatocytes, the major targets of the virus, 
are separated from the bloodstream by endothe-
lial and Kupffer cells that line the sinusoids of the 
liver. Liver sinusoidal endothelial cells have long 
cytoplasmic components that contain fenestra-
tions with a diameter of 50–100 nm. Virions are 
thought to pass through these fenestrations from 
the sinusoids of the liver to the space of Disse, 
which is immediately adjacent to the surface of 
the hepatocytes. Infectious virions bind by means 
of the PreS1 domain of LHBs (and perhaps by 
the envelope lipid) to specific, as yet unidentified, 
receptors on the hepatocyte surface (Seeger & 
Mason, 2000; Jilbert et al., 2002; Beck & Nassal, 
2007; Kann et al., 2007).
HBV then proceeds following a characteristic 
replication strategy shared by all the members 
of the hepadnaviridae family (Fig. 1.2; Seeger & 
Mason, 2000; Jilbert et al., 2002; Beck & Nassal, 
2007; Kann et al., 2007). The nucleocapsid is 
released into the cytoplasm and translocated 
by microtubules to the microtubule-organizing 
centre (MTOC) near the nucleus. How the nucle-
ocapsid gets from the MTOC to the nucleus is 
not known at the time of writing. Access to the 
nucleus is gained through nuclear pores (Kann 
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et al., 2007), and may be mediated by polymerase 
or heat shock proteins. The exact stage and mech-
anism by which the viral genome is released from 
the nucleocapsid is not currently known. In the 
nucleus, rc-DNA is converted into cccDNA, the 
key template in HBV replication. The steps in 
achieving this conversion are uncertain, but they 
include completion of the positive DNA strand 
by polymerase; removal of the covalently linked 
polymerase, the 5′capped oligonucleotide primer 
(and the terminal redundancy), and ligation of 
the 5′ and 3′ends of the positive and negative 
DNA strands.
 Several genomic and subgenomic RNAs 
are transcribed by cellular RNA polymerase II 
using cccDNA as the transcriptional template. 
Of these, the polyadenylated pregenomic RNA, 
with a length corresponding to the entire 
genome length plus a terminal redundancy of 
120 nucleotides, is selectively packaged into 
nucleocapsids. It is then reverse-transcribed by 
the co-packaged polymerase into new rc-DNA 
genomes. Following encapsidation of the 
pregenomic RNA-polymerase complex, poly-
merase initiates negative-strand DNA synthesis 
by reverse transcription (Jilbert et al., 2002).
The synthesis of polymerase and core proteins 
is accomplished by two translation events (Jilbert 
et al., 2002). The mechanism that allows transla-
tion from the downstream polymerase protein 
start codon is not yet known, but may include a 
direct internal ribosomal entry-site-like binding 
of the ribosomal subunits at, or near to, the 
polymerase start codon, “leaky’ scanning of the 
ribosomes that allow passage to the downstream 
start codon, or the presence of a ‘minicistron’ 
upstream of the polymerase ORF that is trans-
lated (Jilbert et al., 2002).
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Fig. 1.2 Replication cycle of Hepanaviral genome
 
Enveloped virions infect the cell, releasing rc-DNA containing nucleocapsids into the cytoplasm. rc-DNA is transported to the nucleus, and 
repaired to form cccDNA (1). Transcription of cccDNA by RNA polymerase II (2) produces, among other transcripts (not shown), pgRNA. pgRNA 
is encapsidated, together with P protein, and reverse transcribed inside the nucleocapsid (3). (+)-DNA synthesis from the (-)-DNA template 
generates new rc-DNA. New cycles lead to intracellular cccDNA amplification; alternatively, the rc-DNA containing nucleocapsids are enveloped 
and released as virions. PM, plasma membrane; pgRNA, pregenomic RNA; cccDNA, covalently closed circular DNA; rc-DNA, relaxed-circular 
DNA; P, viral polymerase.
From Beck J, Nassal M, Hepatitis B virus replication, World J Gastroenterology, 2007; 13(1):48-64 
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1.2 Epidemiology of infection
HBV is one of the most common infectious 
viruses worldwide. It is estimated that more than 
two billion people are infected. Approximately 
360 million of these are chronically infected 
(Lee, 1997; Chen et al., 2007a; Dienstag, 2008). 
Approximately one million people die each year 
from HBV-related chronic liver disease, including 
liver cirrhosis and hepatocellular carcinoma 
(HCC) (Mahoney, 1999). HCC is one of the most 
common cancers in the world, and chronic HBV 
infection is responsible for 50–90% of HCC in 
high-risk areas (Chen et al., 1997).
1 .2 .1 Prevalence, geographic distribution
There is a wide variation of HBV infection 
in the world as shown in Fig. 1.3 (Custer et al., 
2004; CDC, 2012). Approximately 45% of the 
world population lives in areas where chronic 
HBV infection is highly endemic (> 8% of the 
population are HBsAg-positive); 43% live in 
areas where endemicity is intermediate (2–7% 
HBsAg-positive); and 12% live in areas where 
endemicity is low (< 2% HBsAg-positive). The 
prevalence of chronic HBV infection is lowest in 
North America, Northern and Western Europe, 
Australia and New Zealand; intermediate in 
Japan, the Middle East, Eastern and Southern 
Europe and parts of South America; and highest 
in sub-Saharan Africa, the Amazon Basin, the 
People’s Republic of China, the Republic of 
Korea, Taiwan (China), and several other coun-
tries in South-east Asia (Chen et al., 2000; Custer 
et al., 2004).
 The worldwide variation in the endemicity 
of HBV infection is influenced primarily by the 
predominant age at which infection occurs and 
the modes of transmission by which it occurs. 
In areas of high endemicity, the lifetime risk 
of HBV infection is more than 60%, and most 
infections are acquired from perinatal and 
child-to-child transmission, when the risk of 
developing chronic infection is greatest. In these 
areas, acute hepatitis B is uncommon because 
most perinatal and early childhood infections 
are asymptomatic. However, rates of liver cancer 
and cirrhosis in adults are very high. Chronic 
carriage is thought to result from vertical trans-
mission in China, Taiwan (China), and the 
Republic of Korea (Chen et al., 2000). Of note, 
HBV infection in newborns is less common in 
Africa. A lower prevalence of HBeAg positivity 
has been observed in mothers from sub-Saharan 
Africa compared with mothers in Asia. Child-to-
child horizontal transmission accounts for high 
hepatitis B infection in this region of Africa.
In areas where endemicity is intermediate, 
mixed patterns of transmission exist, including 
infant, early childhood, and adult transmission. 
In low endemicity areas, most HBV infections 
occur in adolescents and young adults with rela-
tively well defined high-risk groups, including 
injection drug users, homosexual males, health 
care workers, and patients who require regular 
blood transfusion or haemodialysis. In countries 
where adult horizontal transmission patterns are 
the principal transmission routes, the incidence 
of HBV infection is highest in adults (Custer 
et al., 2004).
HBV is a prototype member of the hepadna-
virus family. Currently, eight genotypes of HBV 
(A through H) have been identified on the basis 
of greater than 8% nucleotide divergence over the 
whole genome (Devesa et al., 2004). Genotype A is 
prevalent in Europe, Africa, and North America. 
Genotype B is prevalent in Taiwan (China), 
China, Thailand, South-east Asia, and genotype 
C is prevalent in China, Japan, the Republic 
of Korea, and South-east Asia. Genotype D is 
predominant in India, Mediterranean areas, and 
the Middle East region. Genotype E is limited 
to West Africa. Genotypes F and G are mostly 
found in Central and South America. Genotype 
H has been observed in Mexico and Central 
America (see Table 1.1). 
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 Compared with patients infected with the 
HBV genotype B, those infected with genotype 
C have a significantly lower rate of spontaneous 
HBeAg seroconversion (Furusyo et al., 2002; Kao 
et al., 2004), a higher histological activity index of 
necroinflammation or fibrosis score (Lindh et al., 
1999; Chan et al., 2002; Kobayashi et al., 2002; 
Lee et al., 2003a), and a higher risk of developing 
acute exacerbations (Chu et al., 2002; Kao et al., 
2004), reactivation of HBV (Chu & Liaw, 2005, 
2007), end-stage liver disease (Kao et al., 2000; 
Chan et al., 2003; Chu & Liaw, 2005), and HCC 
(Yu et al., 2005; Yang et al., 2008).
1 .2 .2 Transmission and risk factors for 
infection
HBV is highly contagious and is transmitted 
by percutaneous and permucosal exposure to 
infected blood and other body fluids (i.e. semen 
and vaginal fluid). The highest concentrations 
of the virus occur in blood and wound secre-
tions (WHO, 2001). Moderate concentrations of 
HBV are found in semen and vaginal fluid, and 
lower concentrations occur in saliva. HBV is not 
spread by air, food, or water. Common modes of 
transmission include mother-to-infant, child-
to-child, unsafe injection practices and blood 
transfusions, and sexual contact. HBV may be 
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Fig. 1.3 Prevalence of chronic infection with hepatitis B virus, 2006
 





















Table 1 .1 Global distribution of HBV genotypes
Region/Country Authors, Year Study subjects HBV genotypes
Asia/Taiwan, China Kao et al. (2000) 100 Asymptomatic carriers & 170 patients with 
histologically verified chronic liver disease and HCC
A:4%, B:53%, C:32%, D:5%, F:5%, unclassified:1%
Asia/Taiwan, China Liu et al. (2002) 122 Patients with chronic HBV A:< 1%, B:57%, C;39%, F:4%
Asia/Taiwan, China Lee et al. (2003a) 265 Patients with chronic HBV infection A:1%, B:60%, C:34%, D:2.5%, unclassified:2.5%
Asia/Taiwan, China Yu et al. (2005) 154 HCC cases and 316 matched controls Among control group: B:82%, C:15%
Asia/Taiwan, China Yang et al. (2008) 2762 HBsAg carriers B:64%, C:32%, B+C:4%
Asia/Japan Usuda et al. (1999) 514 HBsAg-positive blood donors A:5%, B:38%, C:55%, D:0.4%, F:0.6%
Asia/Japan Orito et al. (2001) 720 Patients with chronic HBV infection A:2%, B:12%, C:85%, D:0.4%, mixed type:1%
Asia/Japan Kobayashi et al. (2002) 1077 Patients with chronic hepatitis B A:2%, B:9%, C:88%, D:0.2%, F:0.2%, unclassified:0.6%
Asia/China Ding et al. (2001) 97 Asymptomatic HBV carriers, 46 chronic 
hepatitis, 37 liver cirrhosis and 44 HCC patients in 
Shanghai
A:1%, B:17%, C:81%
Asia/China Zeng et al. (2005) 1096 Chronic HBV carriers from nine provinces in 
China
B: 41%, C:53%, A and D: rare
Asia/China Zhu et al. (2008) 101 HBeAg(-) patients in Hong Kong Special 
Administrative Region, Shanghai, Beijing
B:36%, C:64%
Asia/Hong Kong Special 
Administrative Region
Yuen et al. (2004) 776 Asymptomatic HBsAg carriers B: 33%, C:63%, mixed type:4%
Asia/Republic of Korea Kim & Song (2003) 65 Patients with chronic HBV infection C:100%
Asia/Republic of Korea Song et al. (2005) 200 Patients with chronic HBV infection C:100%
Asia/Republic of Korea Kim et al. (2007) 209 Patients with chronic HBV infection (107 in 
Seoul and 102 in Jeju)
C2 (100%)
Asia/Thailand Sugauchi et al. (2002) 107 Hepatitis B carriers B:25%, C:72%, D:3%
Asia/Thailand Tangkijvanich et al. 
(2005)
93 Asymptomatic carriers, 103 chronic hepatitis 
patients, 60 cirrhosis patients, 76 HCC patients
B:21%, C:73%
Asia/Thailand Jutavijittum et al. (2006) 216 HBsAg-positive voluntary blood donors A:0.5%, B:7%, C:89%; B+C:2%
Asia/Thailand Suwannakarn et al. 
(2008)
147 Asymptomatic HBsAg and HBV DNA carriers A:1%, B:12%, C:87%
Asia/Philippines Sakamoto et al. (2006) 32 Chronic hepatitis patients, 37 cirrhosis patients, 
31 HCC patients
A:51%, B:22%, C:27%
Asia/Viet Nam Toan et al. (2006) 375 HBV-infected (289 symptomatic, 29 on 
haemodialysis, 86 asymptomatic)
A:18%, B:10%, C:25%, D:20%, E:4%, F:2%, G:5%
Asia/India Thakur et al. (2002) 130 Patients with chronic HBV infection A:46%, D:48%, A+D:6%
Asia/India Gandhe et al. (2003) 19 Asymptomatic carriers 
30 chronic hepatitis B patients 
8 acute hepatitis B patients 












Region/Country Authors, Year Study subjects HBV genotypes
Asia/India Vivekanandan et al. 
(2004)
122 Chronic hepatitis B patients and 67 blood 
donors
A:18%, C:12%, D:57% among chronic hepatitis B 
patients 
A:12%, C:0%, D:76% among blood donors
Asia/India Thippavazzula et al. 
(2006)
85 Chronic hepatitis B patients A:15%, B:2%, D:82%
Mediterranean/Turkey Yalcin et al. (2004) 32 Chronic hepatitis B patients 
and 12 HBsAg carriers
D:100%
Mediterranean/Turkey Bozdayi et al. (2004) 41 Chronic hepatitis B patients D:100%
Mediterranean/Turkey Sunbul & Leblebicioglu 
(2005)
88 Chronic hepatitis B patients D:89%
Africa/Nigeria Odemuyiwa et al. (2001) 20 New isolates of HBV E:100%
Africa/West Africa Mulders et al. (2004) 105 Strains from 12 locations in West Africa E:91%
Africa Kramvis & Kew (2007) Literature review A: predominantly in southern, eastern and central 
Africa 
D: predominantly in northern Africa 
E: predominantly in western Africa
America/USA Chu et al. (2003) 694 Chronic hepatitis B patients A:35%, B:22%, C:31%, D:10%, E:0.4%, F:0.6%, G: 1%
America/Central Arauz-Ruiz et al. (1997) 90 Strains from 5 different countries in Central 
America (Guatemala, El Salvador, Honduras, 
Nicaragua and Costa Rica)
A:14%, C:1%, D:6%, F:79%
America/Mexican Sánchez et al. (2007) 42 Chronic or acute hepatitis B patients A:5%, D:21%, H:74%
Europe Schaefer (2007b) Literature review A: prevalent in northern Europe 
D: prevalent in Mediterranean countries and eastern 
Europe
Australian Sugauchi et al. (2001) 5 Australian Aborigines C:40%, D:60%
Australian Alestig et al. (2001) 5 Australian Aborigines C:100%
World Lindh et al. (1997) 187 HBeAg-positive chronic carriers northern Europeans: A:60%, D:31% 
southern Europeans and Middle Easterners: D:96% 
Africans: A:53%, D:27%, E:20% 
East Asians: A:14%, B:43%, C:43%
World Westland et al. (2003) 694 Chronic hepatitis B patients in clinical trial 
centres
Asian/Oceanic centres: B:2%, C:46% 
North American centres: A:34%, C:40% 
Mediterranean centres: A: 14%, D:83% 
European centres: A:40%, D:35%
HBV, hepatitis B virus; HCC, hepatocellular carcinoma; HBeAg, hepatitis B ‘e’ antigen; HbsAg, hepatitis B surface antigen
Compiled by the Working Group
Table 1 .1 (continued)
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detected in serum 30–60 days following infec-
tion, and may persist for widely variable periods 
of time.
Perinatal transmission from HBsAg-positive 
mothers to their newborn infants (vertical) or 
transmission from one child to another (hori-
zontal) is a major source of HBV infections in 
many countries where chronic HBV infection is 
highly endemic (WHO, 2001). Perinatal transmis-
sion usually happens at the time of birth; in-utero 
transmission is relatively rare, accounting for less 
than 2% of perinatal infections in most studies. 
There is no evidence that HBV can be spread by 
breastfeeding (Beasley et al., 1975). The risk of 
perinatal transmission depends on the HBeAg 
serostatus of the mother. The risk of HBV infec-
tion approximately ranges from 70–90% for 
HBeAg-positive mothers to 5–20% for HBeAg-
negative mothers (Okada et al., 1976; Beasley 
et al., 1977). The spread of HBV from child to 
child usually happens in household settings but 
may also occur in child daycare centres and 
schools (WHO, 2001). The most probable path-
ways of child-to-child spread involve contact of 
skin sores, small breaks in the skin, or mucous 
membranes with blood or skin sore secretions 
(Margolis et al., 1997). HBV may also spread 
because of contact with saliva through bites or 
other breaks in the skin, and as a consequence 
of the premastication of food (MacQuarrie et al., 
1974; Scott et al., 1980; Beasley & Hwang, 1983; 
Williams et al., 1997). The virus may spread from 
inanimate objects such as shared towels or tooth-
brushes, because it can survive for at least 7 days 
outside the body, and can be found in high titres 
on objects, even in the absence of visible blood 
(Petersen et al., 1976; Bond et al., 1981; Martinson 
et al., 1998). Among Gambian children aged 6 
months to 5 years, a significant association was 
observed between HBV infection and the pres-
ence of bedbugs in each child’s bed (Vall Mayans 
et al., 1990). But controlling bedbugs by insecti-
cide spraying of the child’s dwelling did not have 
any effect on HBV infection (Vall Mayans et al., 
1994).
Unsafe injection practices such as the re-use 
of a syringe or needle from patient to patient 
without sterilization are a common source of 
transmission of HBV in many developing coun-
tries (Kane et al., 1999; Simonsen et al., 1999). 
In addition, unsatisfactory infection control 
practices, including the re-use of contaminated 
equipment for medical, cosmetic or dental proce-
dures, failure to use appropriate disinfection 
and sterilization practices for equipment and 
environmental surfaces, and improper use of 
multidose medication vials, can also result in the 
transmission of HBV. Blood transfusion is also a 
common source of HBV transmission in coun-
tries where the blood supply is not screened for 
HBsAg. In addition, the injection of illicit drugs 
using shared needles is a common mode of HBV 
transmission in many developed countries.
HBV is efficiently transmitted by sexual 
contact, which accounts for a high proportion of 
new infections among adolescents and adults in 
countries with low and intermediate endemicity 
of chronic HBV infection (Alter & Margolis, 
1990). Risk factors for sexual transmission 
include multiple sexual partners, prostitution, 
and lack of protection in sexual activity (e.g. 
the use of condoms). In countries where HBV 
infection is highly endemic, sexual transmission 
does not account for a high percentage of cases 
because most persons have been infected since 
childhood.
1 .2 .3 Persistence, latency, and natural history 
of infection
Persons infected with HBV have both short-
term and long-term outcomes. On becoming 
infected, a person can have either a symptomatic 
disease (i.e. acute hepatitis B), or an asymptomatic 
infection with no signs or symptoms of disease. 
In persons with acute hepatitis B, the incuba-
tion period after becoming infected is usually 
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3–4 months, with a range of 6 weeks to 6 months. 
Symptoms and signs of disease usually last for 
several weeks. About 1–2% of persons with acute 
hepatitis B die from fulminant hepatitis. Both 
symptomatically and asymptomatically infected 
persons may either recover from the infection 
and develop lifelong immunity, or develop a 
chronic infection that usually lasts throughout 
life. Persons affected with chronic infection 
often do not become sick from their infection for 
decades after becoming infected. However, about 
25% of those who become chronically infected 
during childhood and 15% of those who acquire 
chronic infection at older ages develop either 
HCC or cirrhosis.
The age at which a person becomes infected 
with HBV is the main factor determining the risk 
of developing chronic infection. Among children 
who are under 5 years of age when they become 
infected, fewer than 10% are symptomatic. 
However, 80–90% of those infected infants and 
30–50% of children infected between 1–4 years 
of age develop a chronic infection. In contrast, 
30–50% of adults are symptomatic when first 
infected but only 2–5% of adults develop a chronic 
infection. Most of the disease burden associated 
with HBV infection is in persons who develop 
the chronic condition.
Thus, the natural course of chronic HBV 
infection is highly variable at an individual level 
but also varies with age of infection. The classical 
description of the natural history of chronic HBV 
infection is shown in Fig. 1.4 (Chen et al., 2007a; 
Dienstag, 2008). Early life/perinatal infection is 
characterized by a period of ‘immune tolerance’ 
where the host co-exists with the virus without 
apparent injury to the host. This period of 
immune tolerance is characterized by detectable 
circulating HBsAg, HBeAg, the absence of anti-
HBe antibody, high levels of circulating HBV 
DNA and normal serum alanine aminotrans-
ferase (ALT). This immune tolerance may last for 
years generally without evidence of liver injury.
 Following the immune tolerance phase, 
infected patients progress through a phase of 
immune detection/clearance where the host 
immune system tries to clear infected hepato-
cytes resulting in hepatic inflammation, elevation 
of serum ALT, and reduction of the circulating 
HBV DNA level. The immune clearance phase 
is highly variable in duration and frequency 
but a prolonged phase or recurrent episodes of 
acute liver inflammation may result in repeated 
cycles of injury and regeneration, resulting in 
necroinflammation/fibrosis and an increased 
risk of progression to cirrhosis and HCC. In 
some cases, conversion to anti-HBe-seropositive 
status follows the immune clearance phase. The 
progression of chronic hepatitis B to a state of 
detectable liver injury represents the start of the 
disease state, which is characterized by the pres-
ence of HBsAg and HBeAg in serum (HBeAg-
positive chronic hepatitis B), moderate-to-high 
levels of circulating HBV DNA, elevation of 
serum ALT, and the absence of anti-HBe anti-
body. In some cases, where seroconversion to 
anti-HBe-seropositive status is associated with 
ongoing viral replication, there is detectable anti-
HBe antibody (HBeAg-negative chronic hepatitis 
B). In these HBeAg-negative–anti-HBe-positive 
hepatitis B cases, the HBV DNA level in serum 
is usually lower than in HBeAg-positive chronic 
hepatitis B (Chen et al., 2007a). 
Finally, a proportion of infected persons will 
be able to inactivate the infection and go into the 
‘non-replicative phase’ of chronic HBV infection 
or what is sometimes referred to as the ‘inac-
tive carrier state’. This phase is characterized by 
the continued presence of HBsAg in serum, the 
absence of HbeAg, and the presence of anti-HBe 
antibody, low levels of serum HBV DNA, and 
normal serum ALT. The patients in the inac-
tive carrier state do not usually progress to liver 
injury. This may in part be dependent on the 
events that occurred during the immune clear-
ance phase and the presence or absence of pre-
existing liver fibrosis. Most of adult infections 
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resolve spontaneously, and the few patients 
(approximately 5%) who do not clear the infec-
tion progress directly to the chronic infection 
phase, and do not experience an immune toler-
ance phase (Chen et al., 2007a).
A specific group of patients who are seron-
egative on HBsAg but seropositive on HBV DNA 
has been identified, and their infection defined 
as occult hepatitis B (Hu, 2002; Torbenson & 
Thomas, 2002; Chen, 2005). Although occult 
hepatitis B has long been documented (Hoofnagle 
et al., 1978), it was difficult to investigate it before 
the availability of HBV polymerase chain reac-
tion (PCR). The molecular and immunological 
mechanisms underlying occult hepatitis B 
still remain incompletely elucidated. Several 
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Fig. 1.4 Natural history of chronic hepatitis B virus infection
 
CHB: Chronic hepatitis B, HBsAg: hepatitis B surface antigen; HBeAg: hepatitis Be antigen; HBeAb: anti-HBe antigen; ALT: alanine 
aminotransferase; HBV DNA: hepatitis B viral DNA
Reprinted from Clinical Liver Disease, Chen CJ, Iloeje UH, Yang HI (2007), Long-term outcomes in hepatitis B: the REVEAL-HBV study, Vol. 
11:797–816, Copyright (2011), with permission from Elsevier.
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hypotheses have been proposed for the occur-
rence of occult HBV infection. They include the 
mutation of HBV surface, core and X genes, the 
integration of HBV DNA into host genomes, the 
HBV infection of peripheral blood mononuclear 
cells, the formation of the circulating immune 
complex containing HBV, the altered host’s 
immune response to HBV, and the superinfec-
tion and interference of HBV by other viruses. 
Persons with occult HBV infection may transmit 
HBV through transfusion, haemodialysis, and 
organ transplantation. Occult HBV infection 
may contribute to the acute exacerbation of 
co-existing chronic hepatitis B and even fulmi-
nant hepatitis, and to the development of HCC. 
It also affects disease progression and treat-
ment response of chronic hepatitis C (Hu, 2002; 
Torbenson & Thomas, 2002).
There is a wide variation in the prevalence of 
occult hepatitis B among various patient groups, 
blood and organ donors, and healthy controls. 
The prevalence of seropositivity of HBV DNA 
in HBsAg-seronegative subjects is in the range 
of 0–10% among those without liver disease, 
11–19% in patients affected with chronic hepa-
titis, and 12–61% in HCC patients (Bréchot et al., 
2001; Chen, 2005).
1 .2 .4 Vaccination and viral treatment
Both vaccine and antiviral treatments are 
available for the control of HBV infection. The 
HBV vaccination programme has reduced the 
perinatal and horizontal transmission of HBVs 
and the prevalence of HBsAg in many countries 
including Taiwan (China) (Tsen et al., 1991; Hsu 
et al., 1999; Ni et al., 2001, 2007; Lin et al., 2002, 
2003; Chien et al., 2006; Lu et al., 2006; Su et al., 
2007, 2008), Saudi Arabia (Al-Faleh et al., 1999; 
Madani, 2007), southern Italy (Da Villa et al., 
1998), and Senegal and The Gambia (Vildósola, 
2000). HBV vaccination has been shown to result 
in a dramatic decrease in the number of HBV 
infections among health care workers (Mahoney 
et al., 1997). It has been well documented that 
national HBV vaccination programmes have 
reduced the mortality in childhood fulminant 
hepatitis (Kao et al., 2001; Chien et al., 2006), and 
HCC incidence (Chang et al., 1997, 2000, 2005; 
Chien et al., 2006).
Alpha-interferon and nucleotide/nucleo-
side analogues have been used to treat patients 
affected by chronic hepatitis B. Randomized 
controlled trials have shown the efficacy of anti-
viral treatment to improve the histological grade 
and to reduce the risk of liver cirrhosis and HCC 
(Dienstag, 2008).
2. Cancer in Humans
This section reviews the epidemiological data 
published since the previous IARC Monograph 
(IARC, 1994). The current review only focuses 
on cohort and case–control studies with the 
exception of those descriptive studies which may 
reflect the effect of hepatitis B vaccination. Many 
of these studies have not focused primarily on 
hepatitis B, but on other factors that potentially 
interact with hepatitis B in causing HCC.
2.1 Hepatocellular carcinoma
The previous IARC Monographs concluded 
that chronic HBV infection was associated with 
an increased risk of HCC in humans. The conclu-
sion was based primarily on 15 cohort studies and 
several dozens of case–control studies conducted 
mostly in Asia and Africa, and some in Europe 
and North America. In most studies, chronic 
infection with HBV was determined by the pres-
ence of HBsAg positivity in serum. In all cohort 
studies reviewed, the relative risks ranged from 
5.3–148. The majority of the case–control studies 
examined also showed a strong association. The 
odds ratios varied between 5–30, although the 
quality of some case–control studies was variable. 
This association did not appear to be confounded 
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by the presence of aflatoxin, infection with HCV, 
cigarette smoking or alcohol drinking. The eval-
uation of an association between the risk of HCC 
and the presence of other serological markers for 
HBV infection, such as antibody to hepatitis B 
core antigen (anti-HBc), and antibody to hepa-
titis B surface antigen (anti-HBs), was incon-
clusive due to the variability in the methods of 
determination, and the reporting of results.
2 .1 .1 Cohort studies
Table 2.1 (available at http://monographs.
iarc.fr/ENG/Monographs/vol100B/100B-02-
Table2.1.pdf) summarizes 12 cohort studies, 
published since the last IARC Monograph, that 
evaluate the risk of HCC among individuals who 
were infected with HBV. Of these, the majority 
of studies (n = 7) were conducted in Asia (Chang 
et al., 1994; Lu et al., 1998; Evans et al., 2002; 
Yang et al., 2002; Wang et al., 2003a; Tanaka 
et al., 2004; Gwack et al., 2007), followed by two 
studies in Europe (Crook et al., 2003; Ribes et al., 
2006) and one study each from Africa (Evans 
et al., 1998), America (Nomura et al., 1996), and 
Australia (Amin et al., 2006). Just as the locations 
of the studies spread across the globe, the study 
populations and their size, length of follow-up, 
and study methodologies vary widely.
In these studies, the cohorts consisted of 
general populations of both genders (Chang 
et al., 1994; Nomura et al., 1996; Lu et al., 1998; 
Evans et al., 2002; Yang et al., 2002; Wang et al., 
2003a; Gwack et al., 2007), Army recruits (Evans 
et al., 1998), blood donors (Crook et al., 2003; 
Tanaka et al., 2004; Ribes et al., 2006), and 
newly infected people notified to the Australian 
State Health Department (Amin et al., 2006). 
The average length of follow-up was as short 
as 4  years (Amin et al., 2006), and as long as 
22 years (Crook et al., 2003). Most studies used 
an HBsAg-seronegative cohort as a comparison 
group; a few studies used the general population 
as a reference cohort (Amin et al., 2006; Crook 
et al., 2003). Some studies collected information 
on several other known and potential risk factors 
for HCC and entered them into a stratified or a 
multivariate analysis (Chang et al., 1994; Evans 
et al., 2002; Yang et al., 2002; Wang et al., 2003a; 
Gwack et al., 2007). In these studies, the risk 
of HCC was still significantly associated with 
chronic HBV infection with adjustment for the 
presence of anti-HCV, cigarette smoking, alcohol 
drinking, or serum glucose level.
In the cohort studies reviewed, the relative 
risks ranged from 9.6 (95%CI: 6.0–15.2) (Yang 
et al., 2002) to as high as 74 (95%CI: 45–121) 
(Tanaka et al., 2004). The relative risk was found 
to be even higher, as high as 161 (95%CI: 46–557), 
if an individual was co-infected with HCV 
(Tanaka et al., 2004).
A second group of cohort studies included the 
individuals who had pre-existing liver disease. 
As pointed out in the previous IARC Monograph 
(IARC, 1994), these studies are difficult to inter-
pret because the causes of liver disease other than 
HBV infection may also be associated with an 
increased risk for HCC, leading to an attenua-
tion of the estimated relative risk associated with 
HBV (Benvegnù et al., 1994, 2001, 2004; Zoli et al., 
1996; Tsai et al., 1997; Yu et al., 1997a; del Olmo 
et al., 1998; Chiaramonte et al., 1999; Di Marco 
et al., 1999; Yamanaka et al., 2001; Sangiovanni 
et al., 2004; Ikeda et al., 2005; Mahmood et al., 
2005).
2 .1 .2 Case–control studies
Many case–control studies have been 
published on the relationship between HCC 
and HBV infection since the previous IARC 
Monograph. The primary purpose of many of 
these studies was not to examine HBV infection, 
but to assess the effect of co-infection by HBV and 
HCV along with other potential risk factors for 





In most studies, tests for HBV markers were 
performed once and “carriers” were defined as 
those positive for serum HBsAg at that time. 
Crude relative risks, as measured by odds ratio 
and 95% confidence intervals, were calculated by 
the Working Group when they were not provided 
by the authors, and wherever the data reported 
in the original papers allowed it. Studies of clin-
ical series (typically, patients with liver disease) 
in which cases of HCC were a subgroup but in 
which there was no specifically defined control 
group were not included.
As with the cohort studies described above, 
most of the 31 case–control studies presented in 
Table 2.2 (on-line) were conducted in either Asia 
(n = 14) or Europe (n = 9), followed by seven in 
Africa, and one in the USA. The results from the 
case–control studies continue to demonstrate a 
significant association between HBV infection 
and the risk of HCC in humans. The adjusted 
odds ratios for HBsAg seropositivity ranged 
from 1.5–87.4. Eleven studies reported a more 
than 20-fold increased risk of HCC (Pyong et al., 
1994; Park et al., 1995; Shin et al., 1996; Sun et al., 
1996; Tsai et al., 1996a; Kew et al., 1997; Zhang 
et al., 1998; Chiesa et al., 2000; Kuper et al., 2000; 
Franceschi et al., 2006a; Kumar et al., 2007). The 
wide range in reported odds ratios from these 
studies is likely to be explained by the differ-
ences in the underlying prevalence of HBV in the 
communities studied, the numbers of cases and 
controls studied, the duration of infection, and 
the type of controls selected for a study.
Potential confounding by other risk factors 
for HCC, particularly infection with HCV, was 
addressed in many of these studies. HBV was 
found to be an independent risk factor for HCC 
in the presence of other known and potential risk 
factors such as HCV infection, alcohol drinking, 
cigarette smoking, and/or diabetes.
(a) Occult hepatitis B infection
All of the epidemiological studies described 
above and in the previous IARC Monograph 
consider HBsAg seropositivity as a measure of 
persistent infection with HBV. However, the 
development of highly sensitive methods for the 
detection of HBV DNA has made it clear that 
there are individuals who are viraemic or who 
have integrated HBV DNA in hepatic tissue, and 
are negative for HBsAg (Bréchot et al., 2001). 
Several studies have now reported on the pres-
ence of occult HBV associated with HCC from 
Asia as well as regions with a low prevalence of 
typical chronic hepatitis B infection.
Yu et al. (1997c) presented a re-analysis of 
a case–control study included in the previous 
IARC Monograph. This was a study of 111 cases of 
histologically confirmed HCC and 128 controls, 
all non-Asian, living in Los Angeles County in 
the USA. They found a 4.7-fold (95%CI: 2.2–9.4) 
increased risk of HCC among individuals with 
evidence of a previous HBV infection but who 
were negative for HBsAg and HBV DNA. In 
a study of 19 HCC cases conducted at Johns 
Hopkins Hospital in the USA, it was found that 
three had HBV DNA present in the liver tissue 
despite being negative for HBsAg in serum 
(Kannangai et al., 2004). Squadrito et al. (2006) 
followed a cohort of 134 patients in Italy who had 
chronic hepatitis but were negative for HBsAg. 
The analysis of liver biopsy tissue established the 
presence of HBV DNA in 53 of these subjects. 
During a median 84-month follow-up, nine 
new HCC cases were observed, of which eight 
occurred in the group with occult HBV infec-
tion (P = 0.002).
2 .1 .3 Intervention studies
Vaccination to prevent hepatitis B infec-
tion and antiviral treatment of persistent HBV 
have both been evaluated in relation to their 
effect on HCC incidence. A decrease in the rate 
of HCC after vaccination against or treatment 
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for hepatitis B infection would provide further 
evidence that HBV is a cause of HCC.
A nationwide hepatitis B vaccination 
programme was introduced in Taiwan, China in 
July 1984. The subsequent age-specific incidence 
of HCC has been studied through the Taiwan 
(China) National Cancer Registry. In the initial 
report, the incidence of HCC in children aged 
6–14  years declined from 0.70/100000 children 
during 1981–86 to 0.57 during 1986–90, and 
to 0.36 during 1990–94 (Chang et al., 1997). 
Subsequently, it was reported that the decline 
was primarily in boys born after 1984 whereas 
the decrease observed in girls was non-signifi-
cant (Chang et al., 2000). The main problems 
preventing the eradication of HCC among chil-
dren were vaccine failure, and a failure to receive 
hepatitis B immune globulin at birth (Chang 
et al., 2005). A randomized study of hepatitis B 
vaccination of children to prevent HCC has been 
in progress since the mid-80s in Qidong, China 
(Sun et al., 1991), and The Gambia (The Gambia 
Hepatitis Study Group, 1987; Viviani et al., 2008). 
The results are expected in 2015–20 for the 
Chinese study, and 2017 for the Gambian study.
The treatment of persistent HBV infection 
with antivirals has been shown to reduce viral 
load and disease progression. Liaw et al. (2004) 
conducted a randomized placebo-controlled 
trial of lamivudine alone for 30 months in Asian 
patients with chronic hepatitis B and advanced 
liver disease. They reported that HCC developed 
in 7.4% of 215 subjects in the placebo group, and 
3.9% of 436 in the lamivudine group (hazard 
ratio, 0.49; 95%CI: 0.25–0.99).
2 .1 .4 HBV/HCV co-infection
No single study has sufficient numbers of 
co-infected individuals without clinically evident 
liver disease to provide a reliable estimate of the 
risk associated with dual infection with HBV and 
HCV. Two meta-analyses of studies have been 
carried out to address this difficulty. Donato 
et al. (1998) searched the literature published 
between 1993–97 for appropriate studies using 
healthy carriers from cohort studies or healthy 
controls without chronic liver disease in case–
control studies. Studies were only included if 
they used HBsAg and anti-HCV or HCV RNA 
for serological markers for HBV and HCV infec-
tion, respectively. No cohort studies were suitable 
to be included in the meta-analysis. A total of 
32 case–control studies were included providing 
4560 cases and 6988 controls. The summary odds 
ratio for being HBsAg-positive but anti-HCV/
HCV RNA-negative was 20.4 (95%CI: 18.0–23.2), 
and for HBsAg-positive and anti-HCV/HCV 
RNA-positive, 135 (95%CI: 79.7–242). The odds 
ratio for HBsAg-negative and anti-HCV/HCV 
RNA-positive was 23.6 (20.0–28.1). Significant 
heterogeneity was found between studies that 
could not be explained by the generation of the 
HCV test, geographic area, or type of controls 
used. However, the results remained consistent 
in showing that the risk of concurrent infection 
with HBV and HCV for HCC was more than a 
sum of the risk from each, but less than a multi-
plicative product of the two.
In the second meta-analysis, Shi et al. (2005) 
restricted studies to those conducted in China. 
They searched for all studies between 1979–2004 
that used appropriate serological markers of 
chronic viral infections: HBsAg for HBV and 
anti-HCV or HCV RNA for HCV infection. 
They only included studies that compared HCC 
cases with a control group without chronic 
liver disease. A total of 32 case–control studies, 
including 3201 cases and 4005 controls, met 
the inclusion criteria. Again, there was marked 
heterogeneity between studies that could not be 
explained by geographic area or type of control. 
The summary odds ratio for those HBsAg-
positive and anti-HCV/HCV RNA-negative was 
15.6 (95%CI: 11.5–21.3), and for HBsAg-positive 
and anti-HCV/HCV RNA-positive, 35.7 (95%CI: 
26.2–48.5). Because the odds ratio for HCV 
infection alone was 8.1 (95%CI: 5.0–13.0), the 
result again indicates that the combined effect of 
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HBV and HCV infections in causing HCC lies 
between additive and multiplicative.
2 .1 .5 Hepatitis B viral factors
Viral factors have been shown to influence 
the risk of HCC in several cohort studies. In 
particular, HBe antigenaemia (as a surrogate for 
high viral load) and a high level of HBV DNA 
markedly increase the subsequent risk of HCC 
(Yu et al., 2005; Chen et al., 2006a, b; Iloeje et al., 
2007; Chan et al., 2008).
The viral genotype also appears to modify the 
risk of HCC. Some of this data is difficult to inter-
pret because the subjects of the study had chronic 
liver disease at recruitment, and because of the 
global variation in viral genotypes. However, 
Kew et al. (2005), in a case–control study of liver 
cancer, found evidence for an association with 
genotype A among the Bantu-speaking people 
of South Africa. A total of 111 individuals with 
HCC were compared to an equal number of age- 
and sex-matched asymptomatic chronic carriers 
of HBV without HCC who were recruited after 
screening from factories in the Gauteng region of 
the country. Both cases and controls tested posi-
tive for the presence of HBsAg. Among cases, 96 
(86.5%) were positive for genotype A compared to 
76 (68.5%) of controls, resulting in a relative risk 
of 4.5 (95%CI: 1.9–10.9). The majority of other 
remaining subjects were infected with genotype 
D (8.1% of cases and 23.4% of controls). There 
was no genotype F detected in these populations. 
Livingston et al. (2007), in a cohort study 
of Alaskan native people, examined the viral 
genotype in 47 patients with HCC and in 1129 
subjects without HCC. Genotype F was found in 
68% of cases and in 18% of non-HCC subjects. 
In addition, the median age at diagnosis of HCC 
was lower for patients with genotype F than 
patients with other genotypes (22.5 years versus 
60 years). In the non-HCC population, 58% had 
genotype D, 13% genotype A, 7% genotype C, 
and 4% genotype B. This illustrates the marked 
differences in genotype prevalence between two 
countries. 
Yang et al. (2008) studied the incidence of 
HCC by genotype in a community-based cohort 
in Taiwan, China, where the prevalent viral geno-
types are B and C. In a multivariable analysis 
controlling for age, sex, smoking, alcohol and 
viral load, the relative risk of HCC for genotype 
C was 1.8 (95%CI: 1.2–2.6) compared to geno-
type B.
Several studies have also identified an 
increased risk of HCC associated with mutation 
in the core promoter sequence of the virus (e.g. 
Kao et al., 2003; Chen et al., 2007b, c; Chou et al., 
2008; Yang et al., 2008).
2 .1 .6 Factors modifying the risk of HCC 
associated with hepatitis B
(a) Aflatoxin
Aflatoxin was last reviewed by IARC in 
Volume 82 (IARC, 2002). It was concluded 
that a role of aflatoxin in liver cancer etiology, 
especially among individuals who are carriers 
of HBsAg, is supported by the overall body of 
evidence. A key study that examined aflatoxin 
as a factor in modifying the risk of HCC associ-
ated with HBV was a nested case–control study 
conducted by Qian et al. (1994). The odds ratio 
associated with urinary aflatoxin biomarkers 
was 3.4 (95%CI: 1.1–10), and for HBsAg positivity 
alone 7.3 (95%CI: 2.2–24.4). However, when these 
two risk factors were positive, the odds ratio was 
59 (95%CI: 17–212), suggesting multiplicative 
effect modification. Nonetheless, the previous 
Working Group commented that “the interpre-
tation of studies was hampered by the difficul-
ties in properly assessing an individual’s lifetime 
exposure to aflatoxins and the difficulties in 
disentangling the effects of aflatoxins from those 
of hepatitis infections.” Since then, a handful of 
studies have been published.
Wu et al. (2007, 2008) reported results from 
two different nested case–control studies based 
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on the same community-based Cancer Screen 
Program cohort in Taiwan, China. In one, they 
examined urinary 15-F
2t
-isoprostane as an 
indicator of oxidative stress, and showed that it 
was correlated with urinary aflatoxin–albumin 
adduct levels. They found that higher levels of 
this marker increased the risk of HCC particu-
larly in HBsAg-positive subjects. In comparison 
to those with low urinary 15-F
2t
-isoprostane and 
without HBV infection, those with chronic HBV 
infection and 15-F
2t
-isoprostane above mean 
level had an odds ratio of 19.0 (95%CI: 6.7–54.2). 
In the second study, the association between 
exposure to polycyclic aromatic hydrocarbons 
(PAHs) and the risk of HCC was examined. The 
levels of PAH–albumin adducts were associated 
with HCC, and appeared to modify the effect of 
aflatoxin and HBV infection.
Kirk et al. (2005a, b) has explored the effects 
of high dietary exposure to aflatoxins on the risk 
of HCC in a case–control study in The Gambia, 
where HBV infection is highly endemic. In the 
first study, mutations of the TP53 gene at codon 
249 (a mutation associated with aflatoxin expo-
sure) were measured in the plasma of HCC 
patients and of healthy subjects. The risk of HCC 
was found to be elevated in those HBsAg-positive 
(OR, 10.0; 95%CI: 5.2–19.6), in those 249(ser)-
positive alone (OR, 13.2; 95%CI: 5.0–35.0), and 
when both markers were present (OR, 399; 
95%CI: 48.6–3270). In the second study, human 
DNA was analysed for genetic polymorphisms 
in aflatoxin-metabolizing – and hence activating 
(GSTM1, GSTT1, HYL1*2) – and DNA-repair 
(XRCC1) enzymes. Statistically significant asso-
ciations were found for the null GSTM1 genotype 
(OR, 2.45; 95%CI: 1.21–4.95), and also for the 
combined metabolizing enzyme genotypes. The 
HCC risk was most prominent among the indi-
viduals with the highest groundnut consumption 
(OR, 4.67; 95%CI: 1.45–15.1). These data suggest 
susceptibility to HCC can be altered by aflatoxin, 
but do not clearly demonstrate an interaction of 
aflatoxin with HBV in carcinogenesis.
(b) Alcohol
The association between alcohol consumption 
and the risk of HCC has been reviewed recently 
by IARC in Volume 96 (IARC, 2010). The assess-
ment was made difficult by the fact that signs and 
symptoms of cirrhosis often preceded the cancer, 
which may have led to a modification of alcohol 
intake. Thus, in general, any interaction between 
alcohol and HBV infection is best addressed in 
cohort studies.
Of the cohort studies reported in that volume, 
Chang et al. (1994) found no effect of alcohol 
consumption on risk of HCC; therefore it was 
dropped from the final multivariable model. In 
the cohort study of 11893 men, Yang et al. (2002) 
found that while alcohol consumption was asso-
ciated with HCC (RR, 1.5; 95%CI: 1.0–2.3), when 
individuals who were positive for HBsAg were 
stratified according to alcohol use status, the 
relative risk for HCC was 11.4 (95%CI: 5.0–26.3) 
for men who drank alcohol, and 9.7 (95%CI: 
5.6–16.9) for men who did not drink alcohol.
In Evans et al. (2002), a relative risk of 0.9 
(95%CI: 0.8–1.0) was found for alcohol consump-
tion of more than three drinks per week in 
men in a multivariable model with no interac-
tion with HBsAg-positivity. In women, alcohol 
consumption had a relative risk of 0.6 (95%CI: 
0.3–1.2) in the multivariable model, and again, 
no interaction with HBsAg positivity was 
shown. The studies of blood donors by Crook et 
al. (2003) and Tanaka et al. (2004) did not have 
information on alcohol consumption. A recent 
cohort study in the Republic of Korea specifically 
assessed the independent effect and an interac-
tion of alcohol intake and HBV infection on the 
risk of mortality from HCC (Jee et al., 2004). A 
total of 1283112 men and women free of cancer 
at baseline were assessed and followed up from 
1993–2002. During this time, 3807 deaths from 
HCC were observed. Heavy alcohol consump-
tion in men was associated with a relative risk 
for HCC of 1.5 (95%CI: 1.2–2.0), but there was 
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no interaction between alcohol drinking and 
HBsAg positivity.
It is worth noting that these cohort findings of 
no interaction from Asia are contrary to the find-
ings of many case–control studies. For example, 
Donato et al. (1997) found a positive interaction 
between self-reported history of heavy alcohol 
consumption and HBV infection. The relative 
risk for joint exposures (RR, 64.7; 95%CI: 20–210) 
was greater than the sum of the relative risks for 
HBsAg-positivity (RR, 9.1; 95%CI: 3.7–22.5), and 
for alcohol intake alone (RR, 4.2; 95%CI: 2.4–7.4).
(c) Smoking
The cohort studies that examined smoking as 
a cofactor found modest elevations of the rela-
tive risk for HCC, with no evidence of interaction 
with HBsAg-positivity. Chang et al. (1994) found 
a small but statistically not significant increased 
risk of development of HCC associated with 
cigarette smoking (RR, 1.22; 95%CI: 0.55–2.71). 
The cohort study of Yang et al. (2002) found that 
when HBV-infected men (HBsAg-positive and 
HBeAg-positive) were stratified by their smoking 
status, the relative risk for HCC was higher 
among smokers (RR, 76.9; 95%CI: 39.4–150.3) 
than non-smokers (RR, 67.0; 95%CI: 26.1–171.7). 
Although cigarette smoking was associated 
with an increased risk of HCC (RR, 1.5; 95%CI: 
1.0–2.2), no interaction with HBV infection was 
apparent. Evans et al. (2002) found that smoking 
in men was not associated with an increased risk 
of HCC, whereas in women, smoking showed a 
dose–response trend with increasing cigarette 
consumption: 1–5 cigarettes/day, relative risk 1.5 
(95%CI: 0.4–6.3); 6–10/day, 2.0 (95%CI: 0.6–6.5); 
> 10/day, 4.2 (95%CI: 1.3–13.8). Jee et al. (2004) 
also found that cigarette smoking was associated 
with an increased relative risk for HCC mortality. 
However the increase was in male smokers (RR, 
1.4; 95%CI: 1.3–1.6), but not in women (RR, 1.1; 
95%CI: 0.8–1.7). No interaction was found in 
either sex with HBsAg positivity.
(d) Metabolic factors
Two of the cohort studies have reported on 
the effects of obesity (body mass index [BMI] 
≥  30  kg/m2) and diabetes on the risk of HCC. 
Chen et al. (2008) found that obesity was associ-
ated with a 4-fold risk of HCC (RR, 4.13; 95%CI: 
1.38–12.4) in those who were anti-HCV-positive 
but the association was not significant in HBsAg-
positive subjects (RR, 1.36; 95%CI: 0.64–2.89).
Diabetes was associated with an increased 
risk in those positive for HBsAg (RR, 2.27; 
95%CI: 1.1–4.7) as well as those positive for anti-
HCV (RR, 3.25; 95%CI: 1.20–8.85). In compar-
ison to the referent group of individuals with no 
chronic HBV and HCV infections, no diabetes, 
and low BMI (< 30 kg/m2), for individuals with 
chronic HBV and HCV infections, diabetes, and 
obesity (BMI ≥ 30 kg/m2), the relative risk was as 
high as 264.7 (95%CI: 35.2–1993). Yu et al. (2008) 
reported that excess weight increased the risk 
for HCC among HBsAg-positive men in Taiwan, 
China. In comparison to men with a normal 
weight, overweight men (BMI, 25–<  30  kg/m2) 
had a relative risk for HCC of 1.48 (95%CI: 1.04–
2.12), and obese men (BMI ≥  30  kg/m2), 1.96 
(95%CI: 0.7–5.4).
(e) Human genetics
There have been several studies of human 
genetic polymorphisms and their effect on the 
risk of HCC among HBV carriers, e.g. Yu et al. 
(2003). However, there are, as yet, no consistent 
findings.
2.2 Cancers other than HCC
2 .2 .1 Cholangiocarcinoma
In the previous IARC Monograph (IARC, 
1994), two case–control studies were reported 
showing no association between HBV and 
cholangiocarcinoma. Since then, many studies 
have examined this issue further, and these 
are summarized in Table  2.3 (available at 
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http://monographs.iarc.fr/ENG/Monographs/
vol100B/100B-02-Table2.3.pdf).
In all case–control studies, the carrier status 
for HBV was determined by the presence of 
HBsAg in serum. The risk for cholangiocarci-
noma was increased in association with HBsAg 
seropositivity, with estimates of odds ratios 
ranging from 1.3–8.9. Potential confounding by 
HCV, liver fluke infection, gallstones, alcohol 
consumption and cirrhosis appear to have been 
excluded in studies in which those factors were 
evaluated. The odds ratios for three studies were 
statistically significant, whereas odds ratios for 
four studies were not.
2 .2 .2 Non-Hodgkin lymphoma
(a) Cohort studies
Five cohort studies were carried out in coun-
tries where the prevalence of HBV carrier status 
is low, and the transmission patterns differ from 
that of Asia and Africa. Three were conducted 
in Europe (Crook et al., 2003; Franceschi et al., 
2006b; Ribes et al., 2006), and one study each 
from the USA (Ulcickas Yood et al., 2007), and 
Australia (Amin et al., 2006). In all five cohorts, 
the HBV carrier status of individuals was deter-
mined by the presence of HBsAg in serum. In 
recognition of the possibility of confounding by 
HIV infection, three of five studies addressed 
the potential effect of co-infection by multi-
variate analysis or by excluding HIV-infected 
individuals from the study (Amin et al., 2006; 
Franceschi et al., 2006b; Ulcickas Yood et al., 
2007). The remaining two studies (Crook et al., 
2003; Ribes et al., 2006) could not evaluate the 
potential confounding effect of HIV infection 
because no HIV-infected individuals were found 
in the HBsAg-negative group, or this informa-
tion was not collected. These two studies of blood 
donors present higher standardized mortality 
ratios (SMRs) among HBsAg-seropositive indi-
viduals: 3.2 (95%CI: 1.2–6.9), and 3.5 (95%CI: 
1.7–6.2). The estimates of relative risks among 
the three studies that controlled for HIV infec-
tion was lower than the above two studies, and 
ranged from 0.62 (95%CI: 0.32–1.20) to 2.8 
(95%CI: 1.2–6.8).
See Table 2.4 available at http://
monog r aphs . ia rc . f r/ ENG/Monog r aphs/
vol100B/100B-02-Table2.4.pdf.
(b) Case–control studies
Of the nine case–control studies, of vari-
able quality, that reported on the relationship 
between HBV infection and risk of non-Hodgkin 
lymphoma, seven studies found a positive associa-
tion with the odds ratios for HBsAg-seropositivity 
among non-Hodgkin lymphoma cases varying 
from 1.8 (95%CI: 1.1–3.1) to 4.1 (95%CI: 1.2–14.4). 
Potential confounding by HCV and HIV was 
addressed by exclusion or adjustment during 
the analysis in those studies that evaluated these 
factors. A concern was raised that because HBV 
infection can be reactivated in 14–50% of patients 
undergoing chemotherapy for non-Hodgkin 
lymphoma (Coiffier, 2006), some of the positive 
association observed in case–control studies may 
be artefactual (Anderson et al., 2008). Only one 
study provided information sufficient to discern 
when the viral marker screening was performed 
(Kim et al., 2002). In this study, laboratory 
tests for HBsAg, anti-HCV, and anti-HIV were 
performed on admission or during the first visit 
to the outpatient clinic, before any treatment 
including cancer chemotheraphy was adminis-
tered. The HBsAg carrier status was specifically 
associated with B-cell non-Hodgkin lymphoma 
(OR, 4.6; 95%CI: 2.0–10.3), but not with T-cell 
non-Hodgkin lymphoma (OR, 1.0; 95%CI: 
0.2–4.5). The odds ratio was larger against non-
cancer controls than other cancer controls (4.6 
versus 2.4).
(c) Other
There is very limited information available to 
evaluate the relationship between HBV infection 
and the risk of extra-hepatic cancer other than 
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non-Hodgkin lymphoma. A few studies were 
specifically conducted for this purpose.
(i) Cancer of the pancreas
Hassan et al. (2008) hypothesized that due 
to the anatomical proximity of the liver to the 
pancreas, and because the two organs share 
common blood vessels and ducts, the pancreas 
may be another potential target organ for hepa-
titis viruses. The fact that HBsAg was detected 
in pure pancreatic juice and bile supports the 
hypothesis. They compared 476 histologically 
confirmed cases of pancreatic cancer to 879 age-, 
sex-, and race-matched healthy controls who were 
genetically unrelated companions of patients at 
the same cancer centre in Texas, USA. Serum 
samples were tested for HBsAg, anti-HBc, and 
anti-HBs. No cases and only one control were 
positive for HBsAg. However, past exposure to 
HBV (anti-HBc-positive) with evidence for HBV 
recovery or immunity (anti-HBs-positive) was 
significantly associated with an increased risk of 
pancreatic cancer (OR, 2.3; 95%CI: 1.2–4.3). Past 
exposure to HBV without evidence of recovery 
(anti-HBc-positive/anti-HBs-negative) was 
associated with a greater risk (OR, 4.0; 95%CI: 
1.4–11.1). These odds ratios were adjusted for age, 
sex, race, state of residency, educational level, 
smoking, diabetes, alcohol, and family history of 
cancer. 
Berrington de Gonzalez et al. (2008) reported 
on pancreatic cancer and the HBsAg status of 
631172 men and women who participated in the 
Korean Cancer Prevention Study (Jee et al., 2004). 
HBsAg status was not associated with pancre-
atic cancer risk (RR, 1.13; 95%CI: 0.84–1.52). 
The interpretation of the result was somewhat 
limited because the information on HBsAg was 
only available for 32% of the cohort.
(ii) Hodgkin disease 
One case–control study of Hodgkin disease 
was available for evaluation. Dal Maso et al. 
(2004) studied 62 histologically confirmed inci-
dent Hodgkin disease cases, and 504 control 
patients. The prevalence of HBsAg in the cases 
was 1.9% (one HBsAg-positive), and 0.9% in 
controls (four HBsAg-positive), resulting in an 
adjusted odds ratio of 1.8 (95%CI: 0.1–21.5). 
One cohort study of HBV infected individuals 
listed Hodgkin disease as one of the outcomes, 
with a standardized incidence ratio (SIR) of 0.8 
(95%CI: 0.3–2.1) (Amin et al., 2006).
3. Cancer in Experimental Animals
In this volume, the Working Group decided 
not to include a separate section on “Cancer in 
Experimental Animals” in the Monographs on 
viruses but rather to include description of such 
studies under Section 4 (below). The reasoning 
for this decision is explained in the General 
Remarks.
4. Other Relevant Data
4.1 Introduction
At a molecular level, the genesis of 
HBV-induced HCC is a complex, multifaceted, 
and multistep process with the essential compo-
nents being a series of genetic or epigenetic 
changes in the genes that govern cell prolifera-
tion and cell death. The precise roles of the virus 
and the molecular mechanisms involved in 
hepatocarcinogenesis, how they interact, and the 
sequence in which they occur in the pathogenesis 
of HCC remain elusive. However, the available 
evidence supports the notion that the develop-
ment of the tumour is the result of a combination 
of host responses to the presence of the virus and 
molecular mechanisms that are directly or indi-
rectly induced by the virus.
HBV is a non-cytopathic virus and the hepatic 
inflammation and injury that occur in acute and 
chronic hepatitis and cirrhosis are attributed to 
the immune responses of the host to the presence 
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of the virus, especially those of class-1-restricted 
cytotoxic T lymphocytes. A large proportion 
of HBV-induced HCCs occurs in association 
with cirrhosis or, less often, chronic hepatitis, 
suggesting that the underlying chronic necro-
inflammatory hepatic disease frequently provides 
a mitogenic and possibly also a mutagenic envi-
ronment in which virus-induced genetic changes 
can lead to hepatocarcinogenesis (Chisari, 2000; 
Arbuthnot & Kew, 2001). However, the propor-
tion of patients developing HCC following pre-
existing cirrhosis seems to vary in different parts 
of the world. In particular, in regions of high 
exposure to aflatoxin, the proportion of patients 
with pre-existing cirrhosis may be significantly 
lower than in regions in which aflatoxin is not a 
risk factor (Brechot et al., 2010).
A recent study compared the transcrip-
tome-genotype-phenotype of more than 50 
HCCs, and could identify specific patterns for 
HBV-associated HCCs (Boyault et al., 2007).
4.2 Chronic necro-inflammatory 
hepatic disease in 
hepatocarcinogenesis
HBV-induced chronic necro-inflammatory 
hepatic disease (cirrhosis and chronic hepatitis) 
is characterized by continuous or intermittent 
necrosis of hepatocytes, followed by regenera-
tive proliferation. Its central role in hepatocar-
cinogenesis is supported by the observation that 
the lifetime risk for developing HCC in chronic 
HBV carriers with cirrhosis is higher than that 
in carriers without cirrhosis (Arbuthnot & Kew, 
2001).
Hepatocytes are normally in a quiescent state 
with an extremely low turnover rate, but they 
react to the loss of liver cells with an extraor-
dinarily vigorous proliferative response. This 
response is tightly controlled and lasts only until 
the initial number of hepatocytes is restored; it 
does not normally lead to cancer (Fausto, 1997, 
1999; Overturf et al., 1997). Existing quiescent 
hepatocytes are responsible for this regenera-
tive cell proliferation, and only uncommonly do 
hepatic progenitor (oval) cells directly give rise to 
tumour cells, although it is possible that hepato-
cytes originating from these cells are at higher 
risk for oncogenesis than other hepatocytes 
(Fausto, 1997, 1999).
The proliferation of hepatocytes is regulated 
by several factors, including nuclear factor-κ-B 
(NF-ĸB), transforming growth factor-α (TGF-
α), insulin-like growth factor-2 (IGF-2), and 
hepatocyte growth factor (HGF) (Grisham, 
2001). Transcriptional activation of these factors 
by mediators, such as tumour necrosis factor-α 
(TNF-α), chemokines, and interleukins released 
during the inflammatory process regulates 
proliferation, and has an anti-apoptotic effect 
through the upregulation of the anti-apoptotic 
target gene BCL2 (Grisham, 2001).
With sustained proliferation, at some point 
and for reasons as yet poorly understood, the regu-
lation of proliferation may become unrestrained, 
which is an essential step in hepatocarcinogen-
esis, complicating chronic necro-inflammatory 
hepatic disease. Unrestrained hepatocyte prolif-
eration, in association with the accumulation 
over time of several genetic and epigenetic 
changes, results in the formation of hyperplastic 
nodules that may progress to dysplastic nodules, 
and finally to HCC (Fausto, 1999).
By increasing the hepatocyte turnover rate, 
chronic necro-inflammatory hepatic disease:
• enhances the risk of a cell acquiring criti-
cal mutations,
• leads to reactivation of telomerase, and
• may also provides an opportunity for 
other selective growth advantage of cells 
to become manifest.
Concurrently with these oncogenic mecha-
nisms, distortion of the lobular architecture of 
the liver by fibrosis, and nodular regeneration of 
hepatocytes in cirrhosis modify normal cell-to-
cell and cell-to-extracellular matrix interactions, 
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which may contribute to the loss of cell-growth 
control, senescence, and apoptosis (Davis & 
Kresina, 1996).
4 .2 .1 Virus-induced chronic necro-
inflammatory hepatic disease 
One way in which mutations can arise is by 
the generation of reactive oxygen species and/
or reactive nitrogen species that induce oxida-
tive/nitrosative stress and DNA damage (Trush 
& Kensler, 1991; Bartsch & Nair, 2006). Putative 
mechanisms of free-radical-induced hepatocyte 
damage and malignant transformation are the 
mutagenic properties of the free radicals and 
their effect on lipid peroxidation (Cheeseman, 
1993; Bartsch & Nair, 2006). In addition to DNA 
modifications caused directly by reactive oxygen 
species and reactive nitrogen species, DNA bases 
can be modified by lipid peroxidation products 
such as trans-4-hydroxy-2-nonenal (HNE), 
4-hydroperoxy-2-nonenal (HPNE), and malon-




dG), and etheno- and propano-DNA 
adducts (Bartsch & Nair, 2006).
Oxidative stress and upregulation of inducible 
nitric oxide synthase (iNOS) has been demon-
strated in chronic viral hepatitis (Loguercio 
& Federico, 2003). A massive increase (up to 
90-fold) in the 1,N6-ethenodeoxyadenosine 
(εdA) concentration in urine was detected in 
HBV-infected patients with chronic hepatitis 
and liver cirrhosis (Bartsch & Nair, 2006). εdA 
could arise from HBV-induced chronic inflam-
mation, overproducing reactive oxygen species, 
reactive nitrogen species, and DNA-reactive 
lipid-peroxidation-derived aldehydes such as 
HNE (see Fig. 4.1).
4 .2 .2 Reactivation of telomerase
During the progression of chronic hepatitis 
to cirrhosis, progressive shortening of telomeres 
occurs as a consequence of multiple cycles of cell 
injury, death, and regeneration, and results in the 
premature senescence of hepatocytes. Telomere-
shortening beyond a critical length causes a 
proliferative block, which becomes manifest as 
chromosomal instability, end-to-end fusion, and 
cell death. Hepatocarcinogenesis is character-
ized by the evolution of clones of hepatocytes 
with increased telomerase expression and an 
immortalized phenotype (Farazi et al., 2003).
4.3 Direct mechanisms of 
hepatocarcinogenesis
HBV may also play a direct role in HCC via 
two major mechanisms. The first mechanism 
is the integration and mutation of the viral 
genome into the host cellular DNA, which may 
result in the altered expression of important 
cellular genes. The second one is the expression 
of HBV proteins, which may have a direct effect 
on cellular functions and in the promotion of 
malignant transformation (Brechot et al., 2010).
4 .3 .1 Role of the integration of HBV DNA into 
the host genome
Although insertion of hepadnaviral DNA 
into host DNA is not a requirement for viral 
replication, HBV genome integrations have been 
reported in over 85–90% of HBV-related HCCs 
(Bonilla Guerrero & Roberts, 2005). Integration 
occurs as a result of a recombination event and 
takes place at one or, far more often, multiple 
sites (Matsubara & Tokino, 1990; Rogler & 
Chisari, 1992; Robinson, 1994). Integration is an 
early event and selective clonal amplification of 
hepatocytes with unique integration patterns is 
thought to occur during progression to malig-
nancy (Minami et al., 2005). The integrant may 
be a single linear sequence of the viral genome 
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Fig. 4.1 Illustration explaining how chronic infection and inflammatory processes can lead to 
deregulation of cellular homeostasis and carcinogenesis
 
ROS, reactive oxygen species; RNS, reactive nitrogen species; iNOS, inducible nitric oxide synthase; COX-2, cyclooxygenase-2; NADPH-Ox, 
NADPH oxidase; MPO, myeloperoxidase; LOX, lipoxygenase; HNE, trans-4-hydroxy-2-nonenal; HPNE, 4-hydroperoxy-2-nonenal; MDA, 
malondialhedyde; M
1
dG, malondialdehyde-deoxyguanine; 8-oxo-dG, 8-oxo-7,8-dihydro-2’-deoxyguanosine; 8-NO
2
-dG, 8-nitroguanine
With kind permission from Springer Science+Business Media: Langenbecks Arch Surg, Chronic inflammation and oxidative stress in the genesis 
and perpetuation of cancer: role of lipid peroxidation, DNA damage, and repair, 391, 2006, 499–510, Bartsch H, Nair J, Fig. 1.
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(almost always with nucleotides missing from 
one or both ends), but more often comprises rear-
ranged fragments of viral DNA. Complete and 
intact viral genomic DNA has been found only 
rarely in integrants. No two insertions are alike. 
Linear viral DNA is the preferential form used 
as an integration substrate (Yang & Summers, 
1999).
The exact mechanisms of hepadnaviral DNA 
integration into cellular DNA are not known, 
but the evidence available suggests that inte-
gration preferentially occurs at sites of double-
strand DNA breaks in the cellular DNA (Bill & 
Summers, 2004). The frequent cell divisions and 
DNA strand breaks that occur in chronic hepa-
titis and cirrhosis create opportunities for HBV 
DNA to be integrated into chromosomal DNA 
(Dandri et al., 2002). In addition, the existence of 
preferred topoisomerase-1 cleavage motifs in the 
vicinity of the DR1 and DR2 sites, may predis-
pose the insertion of HBV DNA into cellular 
DNA (Wang & Rogler, 1991).
There are several ways in which integrated 
hepadnaviral DNA may contribute to hepato-
carcinogenesis. The insertion of HBV DNA into 
cellular DNA in human HCC does not occur at 
specific sites; however, several reports have found 
integration events near cellular oncogenes or 
other genes involved in cellular growth (Paterlini-
Bréchot et al., 2003; Bonilla Guerrero & Roberts, 
2005; Minami et al., 2005). Among the cellular 
genes with HBV integration events are retinoic 
acid receptor β, cyclin A2, mevalonate kinase, 
mcm8, neurotropic tyrosin receptor kinase 2 
(NTRK2), IL1R-associated kinase 2 (IRAK2), 
p42 mitogen-activated protein kinase 1 (p42 
MAPK1), telomerase, and others (Dejean et al., 
1986; Wang et al., 1990; Paterlini-Bréchot et al., 
2003; Bonilla Guerrero & Roberts, 2005; Minami 
et al., 2005). These studies suggest that the pres-
ence of an integrated HBV genome could lead to 
the inappropriate activation of targeted cellular 
genes, and in these cases, provide a mechanism 
for HBV-mediated carcinogenesis.
In the case of woodchuck hepatitis virus 
(WHV), the integration of the viral genome in 
or near c-MYC or N-MYC proto-oncogenes in 
50% of infected animals considerably enhances 
the transcriptional activity of the corresponding 
cellular promoters (Fourel et al., 1990; Tennant 
et al., 2004). This observation provides strong 
evidence for a direct role of WHV in hepato-
carcinogenesis. However, given that no human 
cellular gene appears to be targeted with a similar 
frequency by HBV, it is currently unclear to what 
extent this mechanism applies to human liver 
cancer.
Integration of HBV DNA into cellular 
DNA may also induce structural changes in 
the flanking DNA sequences. These are highly 
varied, include small and large deletions, trans-
locations, duplications, or amplification of chro-
mosomal sequences (Matsubara & Tokino, 1990; 
Takada et al., 1990; Buendia, 2000; Laurent-Puig 
et al., 2001). Such changes occur more frequently 
in HBV-related HCC than in HCC attributable to 
other causes (Laurent-Puig et al., 2001).
4 .3 .2 Role of HBV proteins
Transcriptional activation by HBV proteins of 
cellular genes distant from the site of integration 
(transactivation) that influence cellular prolif-
eration and differentiation or apoptosis is a more 
frequent, and probably more important, mecha-
nism of inherent hepatocarcinogenesis (Buendia, 
2000). This effect is mediated through signal 
transduction pathways. Two HBV proteins, HBx 
and PreS/S (when 3′ truncated during or after 
integration), have been shown to have indirect 
transactivating capability, and have been impli-
cated in the development of HCC by this means 
(Murakami, 1999; Feitelson, 2006).
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(a) Hepatitis B virus x protein (HBx)
The smallest HBV protein (16.5 kDa), HBx, 
expressed both in the cytoplasm and the nucleus, 
is essential for viral replication (Murakami, 1999; 
Feitelson, 2006).
Because the gene is close to the preferred 
integration sites of HBV, it is the region of the 
genome most often included in integrants 
(Paterlini et al., 1995), and a selective accumula-
tion of HBx gene transcripts has been reported 
in HBV-related HCC. Antibodies against HBx 
have been demonstrated in the sera of chronic 
carriers, which confirms the expression of the 
viral protein (Pál et al., 2006).
Integrated HBx, even when truncated and 
mutated, may still retain some of its functions. 
Alternatively, mutation and/or truncation may 
activate specific functions of HBx (Schlüter et al., 
1994). Evidence that HBx is contributing to HCC 
comes in part from knockdown experiments in 
which reduction in the levels of HBx leads to 
growth suppression (Chan & Ng, 2006; Cheng 
et al., 2007). In addition, no HCC related to avian 
hepadnaviruses, which are devoid of the X ORF, 
have been reported (Murakami, 1999).
HBx does not contain any structural motifs 
that indicate a capacity to bind DNA directly, 
and functions through protein-to-protein inter-
action. HBx activates transcription from various 
HBV promoters, other viral promoters, and 
from the promoters of a large number of cellular 
genes including oncogenes, cytokines, growth 
factors, and several genes involved in cell-cycle 
control and progression, DNA repair, apoptotic 
cell death, cellular adhesion, and angiogenesis 
(Murakami, 1999; Feitelson, 2006; Table 4.1).
 A wide variety of cis-elements have been 
shown to be responsive to HBx which includes 
binding sites for AP-1, AP-2, NF-κB, SRF, c/EBP, 
Ets, ATF1, and CREB (Table 4.1).
Transcriptional regulation by HBx may 
occur through direct interaction with transcrip-
tion factors in the nucleus, like shown for ATF-2, 
CREB, Oct-1, p53, bZIP, and other components 
of the basal transcription machinery (Table 4.2).
 HBx transactivation may also occur by 
modulating cell-signalling pathways within the 
cytoplasm (Table  4.3). NF-κB-signalling that 
mediates cellular stress responses that control 
the expression of several acute-phase response 
proteins, cytokines, and adhesion molecules is 
among the pathways modulated by HBx though 
the activation of “Mitogen Activated Protein 
Kinase” (MAPK) pathways (Benhenda et al., 
2009).
 HBx has also been shown to inhibit the 
activity of some serine protease inhibitors and 
components of the proteasome complex, specifi-
cally PSMA7 (Zhang et al., 2000), and might 
thus modulate the turnover of certain cellular 
proteins involved in transcription or regulation 
of cell-cycle progression, or both.
Among the cellular proteins whose functions 
are known to be perturbed by HBx protein is the 
tumour-suppressor p53. The p53 protein main-
tains chromosomal integrity by arresting the cell 
cycle in G
1
, regulating the DNA damage control 
responses, and regulating the induction of apop-
tosis and/or senescence (Shimamura & Fisher, 
1996). In vitro HBx expression studies have shown 
that HBx protein binds to specific sequences in 
the C-terminal end of p53, preventing its entry 
into the nucleus, and abrogating its sequence-
specific DNA-binding and transcriptional 
activity (Elmore et al., 1997; Takada et al., 1997).
“Phosphatase and Tensin homology deleted 
on chromosome 10” (PTEN) is another impor-
tant tumour-suppressor which has been shown 
to be a transcriptional target of p53 (Stambolic 
et al., 2001). Inactivation of both p53 and PTEN 
proteins by HBx protein results in increased 
levels of hypoxia-induced factor-1α (HF1-α) 
and vascular endothelial growth factor (VEGF), 
both of which are important for the survival 
and neovascularization of early-stage tumours 
(Huang & Kontos, 2002).
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HBx protein may impair DNA-repair mech-
anisms by several means. Besides its potential 
inhibition of p53-dependent DNA repair, HBx 
can repress the transcription of two compo-
nents of the repair factor TFIIH – XPB and 
XPD (Jaitovich-Groisman et al., 2001). The 
protein also directly interferes with DNA repair 
by forming a complex with the DNA-repair 
protein, HBx-associated protein (XAP-1), which 
normally binds to damaged DNA in the first 
step of nucleotide excision repair (Becker et al., 
1998). Recent evidence shows that HBx binds the 
UV-damaged DNA binding protein 1 (DDB1), a 
protein involved in DNA repair and cell-cycle 
regulation. This interaction leads to interference 
with S-phase progression and induces lagging 
chromosomes during mitosis. Consequently, 
HBx may exert deleterious activities in dividing, 
but not quiescent, hepatoma cells (Martin-
Lluesma et al., 2008).
In addition to its inhibitory effects on 
p53-induced apoptosis, HBx protein inhibits 
caspase-3-dependent apoptosis (Gottlob et al., 
1998). Conversely, HBx may also sensitize cells 
to programmed cell death induced by TNF-α, 
an effect mediated by prolonged stimulation by 
N-MYC transcription and the stress-mediated 
MAPK pathway (Su & Schneider, 1997).
(b) Hepatitis B virus 3′ truncated PreS/S proteins
Like the HBx gene, the PreS/S gene is 
frequently included in HBV DNA integrants in 
patients with HCC. When 3′ truncated during 
or after integration, the gene has transactivating 
properties and might contribute to oncogenesis 
(Schlüter et al., 1994). The truncated medium 
surface protein is exclusively cytoplasmic in loca-
tion and has pleotropic effects on gene transcrip-
tion. Its transactivating effects are mediated by 
modulating protein kinase C (PKC) signal trans-
duction and interaction with several transcrip-
tion factors such as NF-ĸB and AP-1 (Lauer et al., 
1994; Hildt et al., 1996). Potentially oncogenic 
transcriptional effects include the stimulation 
of promoter sequences of c-MYC, c-FOS, and 
c-HA-RAS oncogenes, and the inflammation-
associated cytokine, IL-6 (Kekulé et al., 1990; 
Meyer et al., 1992; Lauer et al., 1994). Mutated 
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Table 4 .1 Some targets of transactivation by HBx
Gene product Binding factor involved







   TGFβ Egr1 (Ets family)







a reference Kim & Rho (2002)
nd, not determined
Adapted from Murakami (1999)
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PreS protein may induce endoplasmic reticulum 
stress (Wang et al., 2003b), which in turn stimu-
lates the expression of cyclooxygenase-2 through 
activation of NF-ĸB and P38-MAPK (Hung et al., 
2004). In transgenic mice that overproduce in 
hepatocytes the large envelope protein of HBV, 
this protein accumulated in the endoplasmic 
reticulum. This led to cytopathic effects that 
contributed to a progressive disease culminating 
in liver cancer (Chisari et al., 1989). The relevance 
of this animal model to HBV-associated HCC in 
human remains unclear.
4.4 Epigenetic mechanisms
Methylation of CpG islands of tumour-related 
genes is an early and frequent event in the multi-
step process of hepatocarcinogenesis, with an 
increasing number of tumour-suppressor genes 
being affected by epigenetic silencing (Lee et al., 
2003b; Oh et al., 2007). There is evidence that 
genome-wide methylation patterns may vary 
according to HCC etiology (Hernandez-Vargas 
et al., 2010). Deregulated expression of DNA 
methyltranferases by HBx may contribute to the 
epigenetic modulation of cellular genes involved 
in cell cycle (Kanai et al., 1997; Lee et al., 2003b; 
Oh et al., 2007; Park et al., 2007; Su et al., 2007a).
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RPB5 A common subunit of pol I, II & III
TFIIB Initiation factor
DNA repair
TFIIH Complex necessary for initiation and elongation
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XAP2 AhR ligand-binding subunit 




P55sen In family of EGF-like proteins
Adapted from Murakami (1999)
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4.5 Other major risk factors in 
hepatocarcinogenesis
4 .5 .1 HCV infection
Dual infection with HBV and HCV is 
common, and is associated with more severe 
chronic hepatic parenchymal disease and an 
increased frequency and a younger age of devel-
opment of HCC than occurs with either virus 
alone (Kaklamani et al., 1991; Kew, 2006). 
Understanding the nature of the synergistic 
interaction between the two viruses in hepato-
carcinogenesis will have to wait until a clearer 
understanding of the mechanisms involved in 
HCC induced by either virus alone is attained. 
Moreover, the replicative dominance of one virus 
over the other and the effect that this may have on 
the progression of liver disease and the develop-
ment of HCC remains a matter of debate (Zarski 
et al., 1998; Kew, 2006). Nevertheless, several 
possible mechanisms for the synergistic hepato-
carcinogenic interaction between the two viruses 
are suggested by currently available information, 
and the major players appear to be HBx protein, 
HCV core, and NS5a proteins.
In Africa and Asia, chronic infection with 
HBV that gives rise to HCC is predominantly 
acquired very early in life, whereas chronic HCV 
infection in industrialized countries is largely 
acquired much later in life. It is likely that HCV 
infection is superimposed on a long-standing 
HBV infection in the great majority of patients 
with dual infection in Asia and Africa; whereas 
in developed countries, it is probable that the two 
infections are obtained either at the same time 
or within a relatively short interval. These differ-
ences may influence the mechanisms involved 
in hepatocarcinogenesis in patients co-infected 
with HBV and HCV (Kew, 2006).
Dual infection with HBV and HCV results in 
a higher incidence of cirrhosis than with either 
virus alone (Tsai et al., 1996b), so the possible 
mechanisms implicated in malignant transfor-
mations complicating chronic necro-inflam-
matory hepatic disease are even more likely to 
be applicable with co-infection. Apart from the 
importance of hepatocyte necrosis and regenera-
tion in generating oxidative damage, the HCV 
core and NS5a proteins have been reported to 
directly generate reactive oxygen species (Gong 
et al., 2001; Okuda et al., 2002).
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Table 4 .3 Some reported interactions of the HBx viral protein with major cellular signal-
transduction pathways
Signalling pathways Reported HBx interactions
p53/PTEN - binds to and inactivates p53 
- blocks PTEN expression via binding p53
pRB - promotes hyperphosphorylation  
(inactivation) of pRB 
- promotes pRB expression
p21WAF1/CIP1 - suppresses p21 promoter via binding to wild type p53 or p55sen
MYC - stimulates the c-MYC promoter
RAS/RAF/MAPK - stimulates RAS/RAF/MAPK signalling
E-Cadherin - stimulates methylation of the E-cadherin promoter
IGFR1 - upregulates IGFR1 
- inactivates p53
TGFβ1 - upregulates TGFβ1 and TGFβ1 signalling resulting in loss of sensitivity 
of cells to TGFβ1.
JAK/STAT - activates JAK
Adapted from Feitelson (2006)
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HBx and HCV core proteins can additively 
repress transcription of the p21 gene (Han 
et al., 2002). Because the tumour-suppressor 
protein p21 is a universal inhibitor of cyclin-
CDK complexes and proliferating cell nuclear 
antigen (PCNA) and hence DNA replication by 
inducing cell-cycle arrest at the G1-S checkpoint, 
the combined repression of p21 by HBx and HCV 
core proteins may result in an additive growth 
stimulation of hepatocytes (Han et al., 2002).
A specific mutation, T1936C, has been 
reported in the proximal core region of HBV that 
may be involved in the accelerated progression 
to HCC in co-infected patients (De Mitri et al., 
2006).
The relevance of potential interactions 
between the two viruses in human HCC is 
supported by the recent report by Rodríguez-
Iñigo et al. (2005), who demonstrated by in-situ 
hybridization that HCV and HBV can coexist in 
the same hepatocyte in liver biopsy samples from 
patients with chronic HCV infection with occult 
HBV infection.
4 .5 .2 Aflatoxin B
1
Early evidence of hepatocarcinogenic syner-
gism between hepadnavirus infection and 





) was provided by experiments in trans-
genic HBV-mice and in woodchucks infected 
with WHV. This evidence was confirmed in 
ecological studies wherein the majority of which, 
the increased risk was multiplicative (reviewed in 
Kew, 2003; Gouas et al., 2009; Wild & Montesano, 
2009).
Several mechanisms have been suggested 
to explain the synergism. The first is that the 
cytochrome P450s that convert the AFB
1
 parent 
molecule to the highly reactive AFB
1
-8,9-exo-
epoxide may be induced by either chronic hepa-
titis caused by HBV infection or the presence 
of the virus itself (Kirby et al., 1994). A recent 
study shows that this epoxide forms preferential 
adducts in DNA at G bases located in sequence in 
a similar context to the one of codon 249 in TP53 
(Besaratinia et al., 2009).
Another way in which hepatocytes may be 
sensitized to the carcinogenic effects of AFB
1
 is 
by the decreased activity of the phase II detoxifi-
cation enzymes, glutathione-S-transferase (GST) 
and EPHX (McGlynn et al., 1995). In human 
liver, GST activity is lower in the presence of 
HBV DNA (Zhou et al., 1997). This suggests 
that the ability of hepatocytes to detoxify 
chemical carcinogens may be compromised in 
HBV-infected individuals.
The accelerated hepatocyte proliferation 
caused by HBV-induced chronic necro-inflam-
matory hepatic disease increases the likelihood 
of AFB
1
-induced mutations (including 249ser 
TP53 mutation) being formed, and the subse-
quent clonal expansion of hepatocytes containing 
these mutations (Kew, 2003). It also results in 
the generation of reactive oxygen and nitrogen 
intermediates, which also induce these muta-
tions (Kew, 2003). AFB
1
–DNA adducts, which 
are normally repaired by the nucleotide excision 
repair pathway, may persist because of the inter-
ference of HBx protein with this pathway (Jia 
et al., 1999).
4.6 Role of HBV in other cancers
4 .6 .1 B-cell lymphoma
At the time of writing, no mechanisms are 
known that might explain the noted limited 
association between HBV and B-cell lymphoma.
4 .6 .2 Cholangiocarcinoma
At the time of writing, no mechanisms are 
known that might explain the noted limited asso-




There is strong evidence to support an 
indirect role for HBV in hepatocarcinogenesis 
resulting from chronic necro-inflammatory 
hepatic disease (cirrhosis), as well as moderate 
evidence for a direct role largely associated with 
HBx.
5. Evaluation
There is sufficient evidence in humans for the 
carcinogenicity of chronic infection with HBV. 
Chronic infection with HBV causes hepatocel-
lular carcinoma. Also, positive associations 
have been observed between chronic infection 
with HBV and cholangiocarcinoma and non-
Hodgkin lymphoma.
Chronic infection with HBV is carcinogenic 
to humans (Group 1).
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The hepatitis C virus was considered by a previous IARC Working Group in 1993 (IARC, 
1994). Since that time, new data have become available, these have been incorporated in 
the Monograph, and taken into consideration in the present evaluation.
1. Exposure Data
1.1 Taxonomy, structure, and biology
1 .1 .1 Taxonomy
In the 1970s and 1980s, serological tests 
developed for hepatitis A and B viruses (HAV, 
HBV) indicated that most transfusion-associ-
ated hepatitis was not caused by either HAV or 
HBV, and were therefore named non-A, non-B 
hepatitis (NANBH). After detection of the first 
NANBH-specific clone, the entire viral genome 
of the now termed hepatitis C virus (HCV) was 
sequenced, and based on its structural and func-
tional organization, HCV was classified into the 
family of the Flaviviridae, where it forms its own 
genus ‘hepacivirus’ (Choo et al., 1989; Kuo et al., 
1989).
At least six major viral genotypes (1 to 6) 
have been identified (Simmonds et al., 2005). 
Viral genotypes have specific geographic distri-
bution. The determination of the viral genotype 
is important for transmission studies, and has 
major therapeutic implications. Patients infected 
with genotype 1 have a significantly lower rate of 
response to antiviral therapy compared to other 
genotypes (Manns et al., 2007).
Genotypes display differences in nucleotide 
sequences below 30–35%, and within a genotype 
genomes are allocated into different subtypes 
if their sequences differ by over 20–25%. 
Furthermore, viral isolate(s) present in an 
infected individual can mutate into quasi-species 
(Simmonds et al., 2005; Xu et al., 2008).
1 .1 .2 Structure of the virion
In line with other members of the Flaviviridae, 
HCV consists of an enveloped nucleocapsid that 
assembles intracellularly in close conjunction 
with membranes derived from the endoplasmic 
reticulum (Moradpour et al., 2007). Released 
HCV particles are about 40–70 nm in diameter, 
but the morphology of particles detected in the 
serum of patients may be heterogeneous due to 
the association with immunoglobulins or very 
low density lipoproteins (vLDL) (André et al., 
2005).
1 .1 .3 Structure of the viral genome
The HCV genome is a single-stranded, positive 
sense RNA of approximately 9.6 kb, and is repre-
sented in Fig. 1.1. It contains short non-coding 
regions (NCRs) at each end that encompass the 
coding sequence of a polyprotein. The 5′ NCR, 
a well conserved 341nt sequence element which 
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forms into a complex secondary structure, is 
needed for efficient RNA replication and drives 
cap-independent translation of a single large 
open reading frame (ORF) that encodes approxi-
mately 3000 residues (Moradpour et al., 2007). 
The HCV 3′ NCR consists of a short variable 
domain of about 40nt and a polyuridine/polypy-
rimidine tract, followed by a highly conserved 
domain of 98nt that is essential for RNA replica-
tion (Tanaka et al., 1995). The N-terminal region 
of the polyprotein encodes the structural proteins 
including the nucleocapsid protein (core) and 
two envelope glycoproteins (E1 and E2) that 
form the viral particle, followed by several non-
structural proteins, designated as NS2 to NS5B 
(Fig.  1.1). The C-terminal regions of the core 
and envelope proteins contain signal sequences, 
and are cleaved in the endoplasmic reticulum by 
host signal peptidase and signal peptide pepti-
dase (Yasui et al., 1998; McLauchlan et al., 2002; 
Okamoto et al., 2004). Alternative cleavage sites 
at the C-terminal of E2 yield the viroporin p7. 
The NS2/NS3 junction is cleaved in cis by metal-
loproteinase activity. The remaining cleavages 
are carried out by the NS3 serine protease, which 
requires NS4A as a cofactor. Besides partici-
pating in polyprotein processing, NS2 plays 
important roles in viral assembly (Moradpour 
et al., 2007; Jirasko et al., 2008). The non-struc-
tural genes NS3, NS4A, NS4B, NS5A and NS5B 
have diverse functions (see Section 4), and are 
all required for RNA replication (Lindenbach 
et al., 2007; Moradpour et al., 2007). NS5B, the 
viral replicase, lacks proofreading activity. This 
lack of proofreading in the context of a very 
high viral production rate, which has been esti-
mated to be as much as 1012 virions per day in 
infected patients, is thought to be responsible for 
the high genetic variability of HCV (Moradpour 
et al., 2007). Thus, HCV has been classified 
into six genotypes and several subtypes based 
on sequence similarities. In addition, the HCV 
genome is prone to acquiring mutations that 
lead to the presence of quasi-species in infected 
patients (Xu et al., 2008).
1 .1 .4 Host range
HCV is hepatotropic, and only man and 
higher primates such as chimpanzees have been, 
until recently, receptive to HCV infection and 
disease. Later, it was shown that the marmoset 
as well as tupaias, which are members of the 
tree shrew genus, are also susceptible to HCV 
infection (Shimizu et al., 1998; Sung et al., 2003; 
Pachiadakis et al., 2005).
1 .1 .5 Tissue target
While HCV RNA has been unequivocally 
detected in the hepatocytes of liver biopsies of 
chronically infected patients and chimpan-
zees, the HCV genome has also been suggested 
to replicate in cells of lymphoid origin and 
dendritic cells (Shimizu et al., 1998; Sung et al., 
2003; Pachiadakis et al., 2005), but this observa-
tion remains to be substantiated. Whether the 
tropism of HCV is limited to hepatocytes at the 
level of cell entry and/or replication via the asso-
ciation of HCV with lipoproteins and/or by other 
factors remains unclear. Expression patterns of 
all cell entry factors isolated to date are either 
ubiquitous or not unique to hepatocytes. This 
includes the lipoprotein receptors scavenger 
receptor B1 (SR-B1), and the low-density lipopro-
tein receptor (LDLr), which may mediate indirect 
uptake of HCV via HCV-associated lipoproteins 
(Moradpour et al., 2007). The replication of HCV 
seems mostly restricted to hepatocytes, and even 
though HCV replicons have been shown to 
amplify in cell lines of non-hepatic origin, the 
levels of replication reported are significantly 
lower than those observed in cell lines of hepatic 




1 .1 .6 Life cycle, replication, and regulation of 
gene expression
Virus-binding to the cell surface and cell 
entry may involve the LDLr, glycosaminoglycans, 
SR-B1, the tetraspanin CD81, and the tight junc-
tion factors Claudin-1 and Occludin (Evans et al., 
2007; Lindenbach et al., 2007; Moradpour et al., 
2007; Ploss et al., 2009;). The tight junction factors 
are thought to act at late stages of cell entry, and 
their involvement in HCV cell entry suggests that 
the state of polarization of hepatocytes is likely 
to be important for the cell entry process (Evans 
et al., 2007). Internalization occurs via clathrin-
coated vesicles, and their acidification induces 
the fusion machinery of the HCV glycoproteins. 
Little is known about the uncoating process and 
the initial events that allow the assembly of repli-
cation complexes, IRES-mediated replication, 
polyprotein processing, and virion assembly. 
RNA replication occurs in membrane-like webs 
that are formed at the endoplasmic reticulum. 
The assembly and secretion process is thought 
to occur in tight relation with the vLDL biosyn-
thesis machinery, which may explain the possible 
association of secreted HCV particles with vLDL 
(André et al., 2005; Nielsen et al., 2006; Miyanari 
et al., 2007).
1 .1 .7 Diagnosis of HCV infection
The diagnosis of HCV infection relies on 
laboratory tests which include: 1) anti-HCV anti-
body detection assays relying on third-gener-
ation enzyme-linked immunosorbent assays 
(ELISAs) whose sensitivity and specificity have 
been demonstrated; 2) viral genome detection 
assays mainly relying on real time Polymerase 
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Chain Reaction (PCR) technologies allowing the 
quantification of the viral genome; 3) genotyping 
assays to determine viral genotypes that allow 
the prediction of treatment outcome, and the 
determination of treatment duration (Zoulim, 
2006).
The detection of anti-HCV antibodies in 
plasma or serum is based on the use of third-
generation enzyme immunoassays (EIAs) that 
detect antibodies directed against various HCV 
epitopes. Recombinant antigens are used to 
capture circulating anti-HCV antibodies onto 
the wells of microtitre plates, microbeads, or 
specific holders adapted to closed automated 
devices. The specificity of third-generation EIAs 
for anti-HCV is greater than 99% and has been 
improved by the addition of viral epitopes that 
are recognized by antibodies present in the 
serum of infected patients (Colin et al., 2001). 
Their sensitivity is more difficult to determine, 
given the lack of a gold standard method, but it 
is excellent in HCV-infected immunocompetent 
patients. EIAs can be fully automated, and are 
well adapted to large volume testing. Immunoblot 
tests are nowadays clinically obsolete given the 
good performance of third-generation anti-HCV 
EIAs (Colin et al., 2001).
1.2 Epidemiology of infection
1 .2 .1 Prevalence and geographic distribution
The estimated prevalence of HCV infection 
worldwide is 2.2%. Region-specific estimates 
range from < 1.0% in northern Europe to > 3% 
in northern Africa (Fig. 1.2; Alter, 2007). High 
prevalences of HCV (≥ 10%) were found in some 
areas of Italy and Japan and, most notably, in 
Egypt (15–20%) following mass injection treat-
ment for schistosomiasis. More recently, high 
HCV prevalences have been reported in some 
Asian areas, notably in Pakistan (Ahmad, 2004), 
and the People’s Republic of China (Zhang et al., 
2005). Within Europe, the highest prevalence 
rate of HCV infection was reported in southern 
Italy where 7.5% of the general population and 
up to 23.2% of those aged 65 years old or older 
who were randomly selected were HCV-infected 
(Fusco et al., 2008). The lowest prevalence (0.01–
0.1%) was reported for the United Kingdom and 
Scandinavia.
1 .2 .2 Transmission and risk factors for 
infection
HCV can be transmitted by transfusion of 
blood and blood products, transplantation of 
solid organs from infected donors, injection drug 
abuse, unsafe therapeutic injections, and occupa-
tional exposure to blood (primarily contaminated 
needles) (Alter, 2007). Transfusion-associated 
HCV infection was an important source of 
infection before HCV testing of blood donors 
was introduced in the early 1990s. Since then, 
transfusion-associated HCV infection has been 
virtually eliminated in those countries where 
routine HCV-testing has been implemented 
(Safe Injection Global Network (SIGN), 2001). 
Iatrogenic HCV transmission through unsafe 
(therapeutic) injections has sustained substantial 
epidemics of the infection in Japan, Italy in the 
1940s and Egypt in the 1950s, and it is currently 
very frequent in low-resource countries (Ahmad, 
2004; Raza et al., 2007) where disposable needles 
tend to be re-used, and injections tend to be 
preferred to the oral route for the administration 
of common treatments. It has been estimated 
that approximately 2 million HCV infections are 
caused annually by contaminated health-care-
related injections. Injection drug use accounts 
for most of the newly acquired infections in 
developed countries. The incidence rate among 
new drug injectors has been observed to range 
from 9 to 30% per 100 person–years (Des Jarlais 
et al., 2003).
HCV is less efficiently transmitted by occupa-
tional, perinatal and high-risk sexual exposures 
compared to those involving large or repeated 
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The rate of transmission after an accidental 
needle-stick injury involving HCV-positive 
blood ranges from 0–10% (Hernandez et al., 
1992; Mitsui et al., 1992). The rate of perinatal 
HCV transmission is 4–7% and occurs only 
when HCV RNA is detectable in the maternal 
serum at delivery. There has been no difference 
in the rate of HCV transmission between vaginal 
delivery, caesarian section or breastfeeding. 
However, co-infection with HIV increases the 
rate of transmission 4–5-fold. The extent to 
which HCV is transmitted by sexual activity is 
very controversial (Alter, 2007). Although case–
control studies of acute hepatitis C have identi-
fied sex with an infected partner or with multiple 
partners as independent risk factors for acquiring 
the disease, in long-term monogamous relation-
ships with a partner with chronic HCV infection, 
there was little evidence for sexual transmission 
of HCV (Clarke & Kulasegaram, 2006).
Currently the data are too scant to determine 
whether cosmetic procedures (e.g. tattooing, 
body piercing) or intranasal illicit drug use 
significantly contribute to the overall HCV 
transmission (Alter, 2002; Hwang et al., 2006).
1 .2 .3 Persistence, latency, and natural history 
of infection
Persistence of HCV infection occurs in the 
majority of HCV-infected individuals. HCV 
infection is often asymptomatic. Indeed, acute 
HCV infection, whether symptomatic or not, 
resolves spontaneously only in 10–40% of cases 
(Poynard et al., 2003; Afdhal, 2004). Persistent 
HCV infection is characterized by the persistence 
of elevated aminotransferase levels and HCV 
RNA in serum. Serological distinction of chronic 
carriers is difficult. Chronically HCV-infected 
patients are in general asymptomatic, and some 
report nonspecific symptoms such as fatigue or 
abdominal discomfort. Approximately 15–27% 
of chronically infected patients are estimated 
to develop cirrhosis. The time to progression to 
severe liver disease is highly variable. Factors 
that accelerate clinical progression include being 
of masculin gender, older at the age of infection, 
alcohol intake, and co-infection with HIV and/
or HBV (Lauer & Walker, 2001; Perz et al., 2006; 
Alter, 2007).
1 .2 .4 Vaccination and viral treatment
To date, an active or passive vaccination 
against HCV is not yet available. The main factor 
that hampers the development of an efficient 
vaccine is the considerable genetic heterogeneity 
of this positively-stranded RNA virus. However, 
better understanding of the natural immunity 
to HCV and the proof of vaccine efficacy in the 
chimpanzee challenge model allows some opti-
mism about the development of an at least partly 
effective vaccine against this heterogeneous 
pathogen (Houghton & Abrignani, 2005).
In view of the fact that the natural course 
of chronic HCV infection is variable and that 
the currently established antiviral combination 
therapy with a pegylated interferon (PEG-IFN) 
and ribavirin (RBV) has numerous side-effects, 
the decision to treat or not to treat must be deter-
mined on an individual basis (Poynard et al., 
2003; Afdhal, 2004; Deutsch & Hadziyannis, 
2008). The main goal of antiviral therapy is a 
sustained virological response, defined as unde-
tectable HCV RNA in serum 24 weeks after the 
end of treatment, determined with the most 
sensitive PCR technique. Treatment, regimens, 
and responsiveness vary depending of the HCV 
genotypes.
In patients infected with genotype 1 or 4, 
HCV eradication rates range between 45–52%. In 
contrast, in patients infected with HCV genotype 
2 or 3, antiviral therapy results in HCV eradica-
tion in 75–90% of cases. Currently, several novel 
antiviral agents are being evaluated in indi-
vidual studies, e.g. NS3–4A protease inhibitors, 
RNA-dependent RNA polymerase inhibitors, 




2. Cancer in Humans
This section focuses on cohort and case–
control studies published since the last IARC 
Monograph (IARC, 1994). Only those studies 
that used second- or third-generation assays to 
determine HCV antibody status are examined. If 
a measure of relative risk (RR) was not provided 
by the authors, the Working Group calculated a 
crude relative risk and 95% confidence intervals 
(CI). Only those studies in which a relative risk 
could be specifically estimated were included. 
Studies that focused specifically on the effect 
of the interaction of HCV and another factor 
(e.g. HBV) on the occurrence of hepatocellular 
carcinoma (HCC) are addressed in the relevant 
subsection.
2.1 Hepatocellular carcinoma
In the previous IARC Monograph (IARC, 
1994), data on the relationship between infec-
tion with HCV, as indicated by the presence of 
antibodies to HCV (anti-HCV), were examined 
in three cohort studies and over 20 case–control 
studies. Seropositivity for HCV antibodies was 
measured by either first- or second-generation 
tests. An increased risk for HCC was apparent in 
all three cohort studies. Among the case–control 
studies, odds ratio (OR) estimates ranging from 
1.3–134 were observed in 17 studies in which 
first-generation tests were used, and were statis-
tically significant in 15 of the studies. In six case–
control studies that used second-generation 
assays, the estimated odds ratios ranged from 
1.1–52, and were significant in three studies. In 
the few case–control studies in which the anal-
ysis took into account possible confounding of 
the effects of HCV by other risk factors for HCC, 
such as smoking and alcohol consumption, the 
association with HCV was not materially altered.
2 .1 .1 Cohort studies
Table 2.1 (available at http://monographs.
iarc.fr/ENG/Monographs/vol100B/100B-03-
Table2.1.pdf) provides a detailed summary of 
the cohort studies that investigated the associa-
tion of HCV with the development of HCC, by 
geographic area. Cohort studies of patients with 
chronic liver disease/cirrhosis were excluded, 
due to the difficulties in interpreting the findings 
from such studies; this exclusion is analogous to 
that for case–control studies involving control 
groups comprising chronic liver disease patients.
Of the eight cohort studies considered, six 
were conducted in Asia and one each in the 
Americas and Australia. Of note, the cohort 
study conducted in Australia (Amin et al., 
2006) involved persons included in the New 
South Wales Notifiable Diseases Database. An 
association between HCV seropositivity and 
HCC was observed in each of the eight cohort 
studies, with relative risks ranging from 2.5–88. 
The effect estimate was statistically significant 
in all but one study (Yuan et al., 1995). Potential 
confounding by risk factors for HCC, particu-
larly infection with HBV, was not addressed in 
four of the studies (Yuan et al., 1995; Boschi-
Pinto et al., 2000; Mori et al., 2000; Guiltinan 
et al., 2008). The wide range in the relative risks 
reported most likely reflects variations across the 
study populations in the underlying prevalence 
of HCV, as well as in the duration of HCV infec-
tion. Only the study by Mori et al. (2000) exam-
ined the effect of anti-HCV titre and reported a 
stronger association for a high anti-HCV titre 
(RR, 40.4) than for a low antibody titre (RR, 3.4).
2 .1 .2 Case–control studies
Details of the 18 case–control studies 
summarized can be found in Table 2.2 (available 
at http://monographs.iarc.fr/ENG/Monographs/
vol100B/100B-03-Table2.2.pdf). A few studies 
were excluded based on the following criteria: less 
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than 20 HCC cases were included in the study; 
the control group was comprised of patients with 
chronic liver disease; or, information related to 
the comparability of case and control subjects 
with respect to age and sex was not provided.
Most of the case–control studies were 
performed either in Europe (n = 7) or Asia (n = 6). 
The results from all 18 studies, both hospital-
based and population-based, support a carcino-
genic role of HCV in the development of HCC. 
The adjusted odds ratios for anti-HCV seroposi-
tivity ranged from 2.8–170; eight studies reported 
a more than 20-fold increased risk of HCC (Park 
et al., 1995; Shin et al., 1996; Tanaka et al., 1996; 
Tsai et al., 1996; De Vita et al., 1998; Tagger 
et al., 1999; Kuper et al., 2000; Yuan et al., 2004). 
Potential confounding by risk factors for HCC, 
particularly infection with HBV, was addressed 
in half of these studies (see Table  2.2 on-line). 
As with the cohort studies, the wide range in 
the observed odds ratios across the case–control 
studies is likely to be related to the underlying 
prevalence of HCV, and duration of infection. In 
those case–control studies in which the presence 
of anti-HCV and HCV RNA was determined, the 
observed association was stronger for positivity 
to both markers than for anti-HCV alone (Kew 
et al., 1997; Tagger et al., 1999; Gelatti et al., 2005; 
Franceschi et al., 2006a).
2 .1 .3 Meta-analyses
Two meta-analyses have examined the inter-
active effect of HBV and HCV infections on the 
occurrence of HCC (see the Monograph on HBV 
in this volume) based on case–control studies 
(including case–control studies nested within 
cohorts). In both analyses, estimates of the 
overall association between HCV and HCC were 
also provided. Donato et al. (1998) calculated a 
summary odds ratio for 21 studies, published 
between 1992–97, using second-generation anti-
HCV or HCV RNA assays. The overall odds ratio 
for HCV was 8.2 (95%CI: 6.7–9.9). The estimate 
was higher for studies in areas where HBV infec-
tion is at low-to-intermediate endemicity and 
where HCV infection is predominant among 
HCC cases (Japan and Mediterranean countries; 
OR, 16.8; 95%CI: 11.9–24.1) than for studies in 
areas where HBV infection is highly endemic 
(subSaharan and southern Africa, Taiwan 
(China), China, Republic of Korea, Viet Nam; 
OR, 6.2; 95%CI: 4.9–7.8). The summary odds ratio 
was also slightly higher for studies with commu-
nity controls (OR, 9.0; 95%CI: 7.0–11.6) than for 
those with hospital controls (OR, 6.8; 95%CI: 
5.1–9.1). In a similar analysis of 32 case–control 
studies published in the Chinese literature, Shi et 
al. (2005) reported a summary odds ratio of 4.6 
(95%CI: 3.6–5.9) for anti-HCV/HCV RNA posi-
tivity and HCC. The calculated odds ratio was 
somewhat larger in higher HCC incidence areas 
(OR, 5.3; 95%CI: 3.8–7.4) than in lower incidence 
areas (OR, 3.8; 95%CI: 2.8–5.2). There was little 
difference in the estimates based on studies with 
community controls or with hospital controls 
(OR, 4.7; 95%CI: 3.6–6.1 and OR, 4.4; 95%CI: 
2.9–6.6, respectively).
2 .1 .4 HCV genotype
Table 2.3 (available at http://monographs.
iarc.fr/ENG/Monographs/vol100B/100B-03-
Table2.3.pdf) summarizes the results from four 
case–control studies and one community-based 
cohort study in which the effect of HCV geno-
type on HCC was examined. Two case–control 
studies in Japan reported significant increased 
odds ratios for HCV genotype 1b, compared to 
other genotypes, among persons infected with 
HCV (Tanaka et al., 1996, 1998a). A weaker crude 
association between Group 1 (1a, 1b) infection 
and HCC incidence was obtained from the nested 
case–control study of HCC conducted within the 
community-based Town C HCV Study (Suruki 
et al., 2006). The Brescia HCC study examined 
the HCV genotype in the HCV RNA-positive 
HCC cases and non-cancer patient controls 
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(Tagger et al., 1999), and reported a larger effect 
size for genotype 1b infection (OR, 34.2) than 
for genotype 2 infection (OR, 14.4), relative to 
anti-HCV seronegatives. A comparison of HCV 
genotypes 1b to 2 yielded an adjusted odds ratio 
of 2.9 (95%CI: 0.9–10) (Donato et al., 1997). In 
contrast, an additional hospital-based study in 
Italy observed increased risks (27-fold) of HCC 
for both genotype 1 and genotype 2 infections, 
compared to anti-HCV seronegatives (Franceschi 
et al., 2006a).
Seven cohort studies (Bruno et al., 1997, 
2007; Naoumov et al., 1997; Niederau et al., 1998; 
Tanaka et al., 1998b; Ikeda et al., 2002; Imazeki 
et al., 2003a; Obika et al., 2008) and two case–
control studies (Hatzakis et al., 1996; Silini et al., 
1996) have examined the association between 
HCV genotype and HCC among patients with 
HCV-related liver disease. However, uncertainty 
about HCV treatment in these patients as well as 
potential bias related to their identification and 
inclusion as study subjects make the interpreta-
tion of the findings from such studies difficult.
2 .1 .5 Cofactors modifying the risk of HCV-
associated HCC
A brief summary of the findings from studies 
that examined potential modifiers of the effect 
of HCV on the development of HCC is provided 
below and in Table 2.4 (available at http://mono-
graphs.iarc.fr/ENG/Monographs/vol100B/100B-
03-Table2.4.pdf). Those studies that evaluated 
the interaction of the factor with a combined 
HCV and/or HBV infection status were not 
considered.
(a) Heavy alcohol consumption
Alcohol consumption has been classified 
by IARC as a human carcinogen, with a role in 
the etiology of liver cancer (IARC, 1988, 2010). 
A positive interaction, on the additive scale, 
between HCV and habitual alcohol drinking was 
observed in a community-based cohort study 
in Japan (Mori et al., 2000); of note, only crude 
relative risks could be calculated for this study. 
Sun et al. (2003) also investigated the potential 
synergy of HCV infection with habitual alcohol 
drinking in their cohort study in Taiwan, China 
(Sun et al., 2003; Wang et al., 2003), and no inter-
action was observed in this low (20% prevalence) 
alcohol consumption population. The synergy 
index obtained suggested that the combined 
effect of HCV and habitual alcohol drinking was 
not more than the additive effect of either factor 
alone. A positive, more than additive, interaction 
between HCV and heavy alcohol consumption 
was reported in the hospital-based Brescia HCC 
case–control study in Italy (Donato et al., 2002). 
However, because alcohol-induced cirrhosis may 
alter alcohol consumption before the develop-
ment of HCC, the evaluation of alcohol in case–
control studies can be problematic.
(b) Smoking
IARC has also identified tobacco smoking as 
a liver carcinogen (IARC, 2004). In the cohort 
studies in Japan (Mori et al., 2000) and Taiwan, 
China (Sun et al., 2003), a more than additive 
effect of anti-HCV seropositivity and cigarette 
smoking on HCC incidence was suggested; as 
noted in the alcohol subsection above, no adjust-
ment for potential confounders was performed 
in the Japanese study.
(c) Diabetes mellitus
A meta-analysis of 26 studies (13 case–
control studies and 13 cohort studies) published 
through February 2005 indicated that diabetes 
mellitus appears to be an independent risk factor 
for HCC (El-Serag et al., 2006). However, no 
clear evidence with respect to a possible interac-
tion between diabetes and HCV infection on the 
risk of HCC was found based on a Surveillance, 
Epidemiology and End Results(SEER)-Medicare 
database case–control study of HCC in the 
United States of America (Davila et al., 2005), 
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and a community-based cohort study in Taiwan, 
China (Lai et al., 2006).
(d) Betel quid chewing
Two studies in Taiwan, China, examined 
the interaction between HCV and habitual 
betel quid chewing (Sun et al., 2003; Tsai et al., 
2001). The study by Sun et al. (2003) resulted in 
a synergy index of 4.2, suggestive of a greater 
than additive increased risk of HCC related to 
the combined effect of HCV infection and betel 
quid chewing than of either factor alone. The 
interaction appeared to be weaker in the study 
by Tsai et al. (2001), with a synergy index of 1.66; 
the reported odds ratios were not adjusted for 
potential confounders.
(e) Human T-lymphotropic virus type 1 infection
A more than additive effect of human 
T-lymphotropic virus type 1 (HTLV-1) co-infec-
tion on the association of HCV with liver cancer 
death was observed (RR, 21.9 for HCV-positive/
HTLV-1-positive) in the Miyazaki Cohort Study 
of an HTLV-1 endemic population in Japan 
(Boschi-Pinto et al., 2000).
(f) Radiation exposure
The Radiation Effects Research Foundation 
Life Span Study by Sharp et al. (2003) reported 
a greater than multiplicative interaction for the 
combined effect of HCV infection and radiation 
exposure in both the second (OR, 55.1) and third 
(OR, 28.7) tertiles.
(g) Schistosoma infection
A case–control study conducted at the 
National Cancer Institute in Egypt investigated 
the interaction between infection with HCV 
and infection with Schistosoma mansoni among 
the subjects negative for HBsAg (Hassan et al., 
2001); however, no meaningful interaction was 
observed.
(h) Helicobacter pylori infection
It has been hypothesized that Helicobacter 
species could play a role in the development 
of HCC (Pellicano et al., 2008). Several cross-
sectional studies have detected the presence 
of Helicobacter in HCV-infected HCC cases 
(Ponzetto et al., 2000; Pellicano et al., 2004; 
Rocha et al., 2005).
2 .1 .6 Co-infection HCV/HBV
See the Monograph on HBV in this volume.
2.2 Cancers other than hepatocellular 
carcinoma
2 .2 .1 Biliary tract/gallbladder
(a) Cohort studies
The cohort study in Australia (Amin et al., 
2006), included in Table 2.1 (on-line), also inves-
tigated the effect of monoinfection with HCV on 
the incidence of gallbladder cancer; however, no 
increased rate of the malignancy was observed 
(standardized incidence ratio [SIR], 0.5; 95%CI: 
0.1–2.0; based on 2 newly reported cases).
(b) Case–control studies
Table 2.5 (available at http://monographs.
iarc.fr/ENG/Monographs/vol100B/100B-03-
Table2.5.pdf) summarizes the seven case–control 
studies that have examined the association of 
HCV with cholangiocarcinoma and biliary tract 
cancers, five of which were performed in Asian 
countries (Republic of Korea, Japan, and China).
In the Republic of Korea, a hospital-based 
study of 203 HCC cases (summarized in Table 2.2 
on-line) also included 41 cases of cholangiocarci-
noma, without distinction of site, and observed 
a positive association (OR, 3.9; 95%CI:0.9–17.1) 
of anti-HCV seropositivity with that malignancy 
(Shin et al., 1996). Five case–control studies 
provided results with respect to the association 
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between anti-HCV seropositivity and intrahe-
patic cholangiocarcinoma. Statistically signifi-
cant odds ratios were observed in three of those 
studies (Donato et al., 2001; Yamamoto et al., 
2004; Shaib et al., 2007), with a more than 5-fold 
increased risk of intrahepatic cholangiocar-
cinoma related to HCV. The largest study (Lee 
et al., 2008), which included 622 cases in the 
Republic of Korea, did not find any association 
between anti-HCV positivity and intrahepatic 
cholangiocarcinoma (OR, 1.0; 95%CI: 0.5–1.9); 
of note, the reported odds ratio was not adjusted 
for any potential confounders. One study also 
included cases of extrahepatic cholangiocar-
cinoma (Shaib et al., 2007), but the association 
between anti-HCV and this subtype was weaker, 
and not statistically significant. Not presented 
in Table  2.5 (on-line) is a case–control study 
based on the SEER cancer registry and Medicare 
claims data, which determined HCV infection 
status and case status using ICD-9 diagnostic 
codes (Welzel et al., 2007). In that study as well, 
the effect was more pronounced for intrahepatic 
cholangiocarcinoma (adjusted OR, 4.4; 95%CI: 
1.4–14.0; n  =  535 cases) than for extrahepatic 
cholangiocarcinoma (adjusted OR, 1.5; 95%CI: 
0.2–11.0; n = 549 cases).
Hsing et al. (2008) conducted a case–control 
study of incident biliary tract cancers in Shanghai. 
An age-adjusted increased risk associated with 
anti-HCV seropositivity was not observed for 
cancer of either the gallbladder, the extrahepatic 
bile ducts, or the ampulla of Vater.
2 .2 .2 Lymphoid malignancies
(a) Cohort studies
Table 2.6 (available at: http://monographs.
iarc.fr/ENG/Monographs/vol100B/100B-03-
Table2.6.pdf) includes detailed descriptions of 
seven cohort studies that examined the effect of 
HCV infection on the occurrence of lymphoid 
malignancies, by the HIV status of the subjects. 
In the five studies of HIV-negative subjects, 
three found an approximately 2-fold excess risk 
of either non-Hodgkin lymphoma generally or 
B-cell non-Hodgkin lymphoma, specifically 
among individuals who were infected with HCV 
(Ohsawa et al., 1999; Duberg et al., 2005; Ulcickas 
Yood et al., 2007). Due to the small number of 
cases that occurred in all three cohorts, the asso-
ciation was statistically significant only in the 
Swedish study of B-cell non-Hodgkin lymphoma 
(Duberg et al., 2005). The Swedish study also 
observed a similar, but statistically non-signifi-
cant, effect of HCV infection on the development 
of the chronic lymphocytic leukaemia subtype as 
well as multiple myeloma. A nested case–control 
study within a cohort of parents and offspring in 
the USA did not detect HCV in any of the B-cell 
non-Hodgkin lymphoma, multiple myeloma, or 
Hodgkin disease cases or the matched controls 
(Rabkin et al., 2002). A cohort study in Australia 
also reported no association of HCV with non-
Hodgkin lymphoma, nor with subtypes such 
as follicular lymphoma, diffuse non-Hodgkin 
lymphoma, and T-cell non-Hodgkin lymphoma 
(Amin et al., 2006); in addition, an increased 
risk was not found for either multiple myeloma 
or Hodgkin disease. Not included in Table  2.6 
is a cohort study from the USA, which used 
the Department of Veterans Affairs admin-
istrative patient databases with HCV status, 
and the occurrence of lymphoid malignancies 
based on ICD-9 CM diagnostic codes (Giordano 
et al., 2007). The adjusted relative risks were 1.28 
(95%CI: 1.12–1.45) for non-Hodgkin lymphoma 
(n  =  1359 cases), 0.89 (95%CI: 0.68–1.15) for 
chronic lymphocytic leukaemia (n = 412 cases), 
0.95 (95%CI: 0.76–1.19) for multiple myeloma 
(n = 526 cases), and 0.97 (95%CI: 0.74–1.27) for 
Hodgkin disease (n = 360 cases).
For both cohort studies of HIV-positive 
subjects, a null association was observed between 
anti-HCV seropositivity and non-Hodgkin 
lymphoma (Waters et al., 2005; Franceschi et al., 
2006b).
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(b) Case–control studies
This section summarizes the case–control 
studies included in the meta-analyses by Matsuo 
et al. (2004) and Dal Maso & Franceschi (2006). 
Other case–control studies were considered if: at 
least 20 cases of lymphoma were investigated in 
the study; the control group was not comprised 
of patients with other haematological malignan-
cies and/or lymphoproliferative diseases; and, 
information related to the comparability of case 
and control subjects with respect to age and sex 
was provided.
Results related to a particular non-Hodgkin 
lymphoma subtype are included when data 
were provided for ≥  20 cases. In addition to 
B-cell non-Hodgkin lymphoma, the subtypes 
evaluated were T-cell non-Hodgkin lymphoma, 
diffuse large B-cell lymphoma (DLBCL), folli-
cular lymphoma, marginal zone lymphoma, and 
chronic lymphocytic leukaemia/small lympho-
cytic lymphoma (CLL/SLL).
A large number of case–control studies have 
examined the association between HCV infec-
tion and non-Hodgkin lymphoma. The detailed 
description of these studies and their findings, 
by geographic area, are provided in Table  2.7 
(available at http://monographs.iarc.fr/ENG/
Monographs/vol100B/100B-03-Table2.7.pdf). 
Most studies were conducted in Europe 
(n = 20), followed by the Americas (n = 8), and 
Asia (n  =  7); one study each was performed 
in Africa and Australia. B-cell non-Hodgkin 
lymphoma specifically and/or non-Hodgkin 
lymphoma generally was the primary malig-
nancy of interest in all 37 case–control studies. 
Approximately 80% of the studies reported at 
least a 2-fold increased risk of non-Hodgkin 
lymphoma or a B-cell non-Hodgkin lymphoma 
with HCV seropositivity. The association was 
evident in case–control studies conducted across 
all geographic areas (except for the study in 
Australia), and using different sources of control 
groups (i.e. hospital-based, population-based, 
or blood donors). Odds ratios greater than 5.0 
were observed in 13 studies: nine studies were 
from Europe (Ferri et al., 1994; Mazzaro et al., 
1996; Musto et al., 1996; De Rosa et al., 1997; De 
Vita et al., 1998; Paydas et al., 1999; Vallisa et al., 
1999; Zucca et al., 2000; Yenice et al., 2003), and 
four studies were from elsewhere (Zuckerman 
et al., 1997; Harakati et al., 2000; Kuniyoshi etal., 
2001; Chindamo et al., 2002). An additional 16 
case–control studies reported a 2–4-fold excess 
risk of either non-Hodgkin lymphoma or B-cell 
non-Hodgkin lymphoma associated with HCV 
infection; the effect was statistically significant 
in more than half (Silvestri et al., 1996; Mizorogi 
et al., 2000; Montella et al., 2001b; Imai et al., 
2002; Mele et al., 2003; Cowgill et al., 2004; 
Engels et al., 2004; Iwata et al., 2004; Talamini 
et al., 2004; Schöllkopf et al., 2008; Spinelli et al., 
2008). The remaining eight case–control studies 
with odds ratios less than 2 did not demon-
strate a statistically significant effect of HCV 
on the occurrence of non-Hodgkin lymphoma 
or B-cell non-Hodgkin lymphoma (Kaya et al., 
2002; Avilés et al., 2003; Morgensztern et al., 
2004; de Sanjosé et al., 2004; Sève et al., 2004; 
Vajdic et al., 2006; Sonmez et al., 2007; Park et al., 
2008). Not included in Table 2.7 is the SMAHRT 
(SEER-Medicare Assessment of Hepatopoietic 
Malignancy Risk Traits) study, a case–control 
study of haematopoietic malignancies based on 
the use of the SEER-Medicare data in the USA 
(Anderson et al., 2008). Cancer diagnosis as well 
as HCV status was obtained from the ICD codes 
included in the two databases. The adjusted 
odds ratio for the association of HCV with non-
Hodgkin lymphoma overall (n  =  33940 cases) 
was 1.35 (95%CI: 1.1–1.7).
The findings of two pooled analyses are also 
included in Table 2.7. One pooled study reported 
an overall odds ratio of 1.5 (95%CI: 0.95–2.2) for 
B-cell lymphoma, based on 1465 cases from five 
European countries (Nieters et al., 2006). The 
other pooled study found a similar association 
(OR, 1.8; 95%CI: 1.4–2.3) for all non-Hodgkin 
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lymphoma, using 4784 cases from seven studies 
involving centres in the USA, Canada, Australia, 
and Europe (de Sanjosé et al., 2008). The latter 
analysis included the results from five previously 
published studies (Engels et al., 2004; Morton 
et al., 2004; Talamini et al., 2004; Nieters et al., 
2006; Vajdic et al., 2006).
In two case–control studies of non-Hodgkin 
lymphoma, a slightly stronger association 
was found for low-grade B-cell non-Hodgkin 
lymphoma, in contrast to intermediate/high-
grade disease (Engels et al., 2004; Talamini et al., 
2004). Based on an a priori hypothesis that HCV 
would be related to non-Hodgkin lymphoma at 
the potential target organ of infection, an early 
study in Italy examined the effect of HCV on 
liver/salivary gland non-Hodgkin lymphoma, 
and reported a marked elevation in risk (OR, 
51.5) (De Vita et al., 1998).
With respect to other subtypes of non-
Hodgkin lymphoma, an effect of HCV infection 
has less consistently been observed. Moreover, 
when an association is suggested, the effect esti-
mate usually is highly unstable, due to the small 
number of cases involved. From the results of the 
studies included in Table 2.7 (on-line), an associa-
tion with HCV seems more evident for the DLBCL 
and CLL/SLL subtypes. For DLBCL, results were 
available from 14 case–control studies; 13 studies 
observed an association consistent with an effect 
of HCV seropositivity on DLBCL, which was 
significant for about half (Silvestri et al., 1996; 
Vallisa et al., 1999; Zucca et al., 2000; Chindamo 
et al., 2002; Mele et al., 2003; Talamini et al., 2004; 
Spinelli et al., 2008). Eight of the 12 studies that 
examined CLL/SLL reported an odds ratio of at 
least 2, with the association being statistically 
significant in three case–control studies (Musto 
et al., 1996; De Rosa et al., 1997; Paydas et al., 
1999). For the fewer number of studies (n = 10) 
that included separate odds ratios for follicular 
lymphoma and marginal zone lymphoma, 
slightly more than half reported an odds ratio 
greater than 2 for HCV seropositivity (Silvestri 
et al., 1996; Vallisa et al., 1999; Zucca et al., 2000; 
Mele et al., 2003; Engels et al., 2004; Spinelli et al., 
2008). In contrast, the findings from almost all 
studies did not support a notable effect of HCV on 
T-cell non-Hodgkin lymphoma. The SMAHRT 
study reported the following odds ratios for 
non-Hodgkin lymphoma subtypes: 1.5 (95%CI: 
1.05–2.2) for DLBCL (n  =  10144 cases); 2.2 
(95%CI: 1.2–3.95) for marginal zone lymphoma 
(n = 1908 cases); 1.9 (95%CI: 1.2–3.0) for follicular 
lymphoma (n = 4491 cases); 1.1 (95%CI: 0.70–1.7) 
for chronic lymphocytic lymphoma (n  =  10170 
cases); and 0.42 (95%CI: 0.10–1.7) for T-cell non-
Hodgkin lymphoma (n = 1870 cases) (Anderson 
et al., 2008). In a pooled analysis (de Sanjosé 
et al., 2008), a statistically significant association 
was found for DLBCL (OR, 2.2; 95%CI: 1.7–3.0) 
and marginal zone lymphoma (OR, 2.5; 95%CI: 
1.4–4.2). The other pooled study (Nieters et al., 
2006) also reported a significant association for 
DLBCL (OR, 2.2; 95%CI: 1.2–3.9), but no associa-
tion was reported for marginal zone lymphoma. 
The effect of HCV was weaker and not statisti-
cally significant for CLL/SLL and not apparent 
for follicular lymphoma or T-cell lymphoma in 
both pooled studies.
Of eight case–control studies that examined 
multiple myeloma (Table 2.7 on-line), four studies 
observed a statistically significant association 
between HCV seropositivity and the malignancy 
(Musto et al., 1996; De Rosa et al., 1997; Paydas 
et al., 1999; Montella et al., 2001a, b). The pooled 
analysis by the EPILYMPH group (Nieters et al., 
2006) did not report a notable association for 
multiple myeloma (OR, 1.4; 95%CI: 0.61–3.2).
More than ten of the case–control studies 
included in Table 2.7 (on-line) conducted sepa-
rate analyses of the effect of HCV on the occur-
rence of Hodgkin disease. An increased risk was 
observed in eight case–control studies, although 
it was significant only in one study (Paydas et al., 
1999). The US record-based study by Anderson 
et al. (2008) found an odds ratio of 1.2 (95%CI: 
0.38–3.7) based on 1155 Hodgkin disease cases. 
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In the pooled analysis by Nieters et al. (2006), 
no effect of HCV on Hodgkin disease was found 
(OR, 0.97; 95%CI: 0.27–3.5).
(c) Meta-analyses
Several meta-analyses of the relation-
ship between HCV and lymphoma have been 
published (Gisbert et al., 2003; Matsuo et al., 
2004; Negri et al., 2004; Dal Maso & Franceschi, 
2006). Matsuo et al. (2004) performed a meta-
analysis of 23 case–control studies (including 
nested case–control studies) published between 
January 1990 and August 2003. Studies were 
included if an odds ratio or a relative risk was 
calculated “by comparing the HCV-positive 
category to the negative category”, and non-
cancer controls and a second- or third-generation 
HCV antibody test were used. A summary odds 
ratio of 5.7 (95%CI: 4.1–8.0) for non-Hodgkin 
lymphoma was obtained; the association was 
somewhat stronger for B-cell non-Hodgkin 
lymphoma (OR, 5.0; 95%CI: 3.6–7.1) than for 
T-cell non-Hodgkin lymphoma (OR, 2.5; 95%CI: 
1.4–4.6). The variation was related to the use of 
blood donor controls (OR: 8.4 versus OR: 4.65 
for non-blood donor controls), and to the year 
of publication (i.e. lower OR for the more recent 
publications). [The Working Group noted that 
the relative risks obtained in this meta-analysis 
might be inflated by underadjustment, particu-
larly by age group.]
In their meta-analysis, Dal Maso & Franceschi 
(2006) examined 15 case–control studies and 
three cohort studies published up to July 2006. 
Studies were eligible for inclusion based on the 
following criteria: if the control group did not 
include patients with other lymphoproliferative 
diseases, if cases and controls were comparable 
with respect to age and sex or age and sex were 
taken into account in the analysis, if second- or 
third-generation anti-HCV assays were used, 
and if HIV-positive subjects were excluded. 
Only case–control studies with ≥ 100 cases were 
included in the overall analyses of non-Hodgkin 
lymphoma; findings regarding specific non-
Hodgkin lymphoma subtypes and other 
lymphoid malignancies were shown when there 
were ≥ 20 cases for that subtype. The sex- and age-
adjusted meta-relative risk for all non-Hodgkin 
lymphoma was 2.5 (95%CI: 2.1–3.0), and was 
similar for case–control (RR, 2.5; 95%CI: 2.1–3.1) 
and cohort (RR, 2.0; 95%CI: 1.8–2.2) studies. The 
effect of HCV on non-Hodgkin lymphoma was 
estimated to be higher in those studies with a 
higher HCV prevalence (≥  5%) among control 
subjects (RR, 3.0; 95%CI: 2.4–3.75) than those 
studies with a lower prevalence (RR, 1.9; 95%CI: 
1.8–2.05). The results were relatively consistent 
by geographic area (RR, 2.7 in southern Europe; 
RR, 2.6 in the USA; RR, 2.1 in the Republic of 
Korea/Japan; RR, 2.3 in other areas) and year 
of publication (RR, 2.9 before 2003; RR, 2.2 
during 2003 and after). However, the association 
appeared to be somewhat weaker in studies using 
population-based control subjects (RR, 1.9) than 
in those using hospital-based controls (RR, 
2.7). With respect to non-Hodgkin lymphoma 
subtypes, the relative risks obtained were: 2.65 
(95%CI: 1.9–3.7) for DLBCL; 2.7 (95%CI: 2.2–3.4) 
for follicular lymphoma; 3.4 (95%CI: 2.4–4.9) for 
marginal zone; 1.65 (95%CI: 1.35–2.0) for CLL/
SLL; and 1.5 (95%CI: 1.13–2.05) for T-cell non-
Hodgkin lymphoma. In addition, a summary 
relative risk was estimated for multiple myeloma 
(RR, 1.6; 95%CI: 0.69–3.6) as well as for Hodgkin 
disease (RR, 1.5; 95%CI: 1.0–2.1). Of note, the 
meta-analysis did not include the results from 
two recently conducted, large case–control 
studies of lymphoid malignancies: the nation-
wide study of the Danish and Swedish popula-
tions by Schöllkopf et al. (2008), and the pooled 
InterLymph study by de Sanjosé et al. (2008).
(d) Treatment of HCV infection in patients with 
lymphoma
In a striking finding, Hermine et al. (2002) 
reported remission in seven of nine patients with 
splenic lymphoma with villous lymphocytes who 
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were infected with HCV after they were treated 
with interferon α; two more patients without 
a substantial antiviral response experienced 
remission after the addition of ribavirin to inter-
feron α. None of six HCV-negative patients with 
splenic lymphoma with villous lymphocytes 
responded to interferon treatment. A system-
atic review by Gisbert et al. (2005) reported on 
the findings of 16 case reports and case series in 
which a total of 65 HCV-infected patients with 
lymphoproliferative disorders were treated with 
interferon α (with and without ribavirin). Of the 
65 patients in those studies, complete remission 
of the disorder was achieved in 75% (95%CI: 
64–84) of the cases. [The Working Group noted 
that one case series contributed almost a third of 
the patients analysed (n = 20); however, the refer-
ence was to an abstract, for which a full paper has 
not been published.]
2 .2 .3 Other cancers
(a) Leukaemias
In the large cohort study of US veterans who 
were infected with HCV, a diagnosis of HCV was 
not related to an increased rate of acute lympho-
cytic leukaemia (RR, 0.75), chronic myeloid 
leukaemia (RR, 0.84), or acute non-lymphocytic 
leukaemia (RR, 1.04) (Giordano et al., 2007).
Table 2.8 (available at http://monographs.
iarc.fr/ENG/Monographs/vol100B/100B-03-
Table2.8.pdf) summarizes the four case–control 
studies that investigated the effect of HCV infec-
tion on the development of leukaemia. No study 
reported statistically significant associations 
between anti-HCV seropositivity and acute 
myeloid leukaemia, acute lymphocytic leukaemia, 
or chronic myeloid leukaemia. However, Bianco 
et al. (2004) suggested that HCV infection might 
be associated with both acute myeloid leukaemia 
and chronic myeloid leukaemia in the Italian 
study. In Japan, Murashige et al. (2005) reported 
no association of anti-HCV seropositivity with 
the risk of myeloid malignancy.
(b) Cancer of the thyroid
The three cohort studies in Sweden (Duberg 
et al., 2005), Australia (Amin et al., 2006), and the 
USA (Giordano et al., 2007) examined the inci-
dence of thyroid cancers among people who were 
infected with HCV. A non-significant increased 
risk was found based on five thyroid cancer cases 
in the Swedish cohort (SIR, 1.55; 95%CI: 0.50–
3.6); whereas a significant decreased risk was 
reported based on nine cases in the Australian 
cohort (SIR, 0.3; 95%CI: 0.2–0.7), and 46 cases 
in the US cohort (HR, 0.72; 95%CI: 0.52–0.99). 
A case–control study of a group of cancers in 
Italy (Montella et al., 2001a) observed a signifi-
cant association between HCV infection and this 
malignancy (OR, 2.8; 95%CI: 1.2–6.3).
3. Cancer in Experimental Animals
In this Volume, the Working Group decided 
not to include a separate section on “Cancer in 
Experimental Animals” in the Monographs on 
viruses but rather to include description of such 
studies under Section 4 (below). The reasoning 
for this decision is explained in the General 
Remarks.
4. Other Relevant Data
The sharp increase of HCC cases over the 
last several decades in industrialized countries 
(western Europe, North America, and Japan) has 
been attributed to an expansion of chronic HCV 
infections, and is frequently linked with liver 
cirrhosis. Most cohort studies and clinical expe-
rience have shown that liver fibrosis resulting 
from long-lasting chronic inflammation is likely 
to be an important predisposing factor of HCC 
development. The same clinical observations also 
suggest that ongoing liver regeneration resulting 
from chronic immune mediated hepatocyte 
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death is a likely factor contributing to the devel-
opment of HCC (Liang & Heller, 2004). This 
aspect has been developed in the Monograph on 
HBV in this volume.
But the mechanisms underlying the progres-
sion of HCV infection to liver cancer, which 
often takes many decades, remain ill-defined. 
Transcriptomics and proteomics have helped to 
identify many genetic and epigenetic alterations 
associated with HCC clusters. However, the iden-
tified changes to gene expression patterns are 
very heterogeneous in tumour cells, raising the 
question as to whether yet unidentified, specific 
changes at early, preneoplastic stages trigger 
the transformation process, and what cell type 
could be at the origin of HCC (Sell & Leffert, 
2008). HCV has an exclusively cytoplasmic 
life cycle (Lindenbach et al., 2007; Moradpour 
et al., 2007), and therefore, HCV replication and 
potentially pro-oncogenic events are restricted 
to the cytoplasm. While HCV infection leads 
to chronic inflammation, steatosis, fibrosis and 
oxidative chromosomal DNA damage, several 
HCV proteins have been shown to have direct 
oncogenic effects, and to upregulate mitogenic 
processes (Koike, 2007; McGivern & Lemon, 
2009). The accumulation of DNA damage within 
a setting of restricted cell-cycle checkpoint 
controls is thought to compromise gene and 
chromosome stability, and to form the genomic 
basis for the malignant phenotype.
One of the major challenges with the study 
of the carcinogenic role of HCV is the difficulty 
to localize the HCV genome and viral proteins 
in both the liver of infected patients and liver 
tumours.
4.1 Biochemical properties of HCV 
proteins 
See Table 4.1.
4 .1 .1 The structural proteins
(a) Core protein
The core protein is the most conserved 
among the structural proteins. It is highly basic, 
rich in proline, and multimerizes. Interaction 
of the mature core with the 5′ and 3′ NCRs can, 
respectively, inhibit IRES function, and mediate 
genome dimerization (Shimoike et al., 1999; 
Cristofari et al., 2004). The core protein is targeted 
to the cytoplasmic surface of the endoplasmic 
reticulum and lipid droplets (Moradpour et al., 
1996; Barba et al., 1997). Its interaction with lipid 
droplets may be related to the increased inci-
dence of liver steatosis in patients with HCV, and 
in certain transgenic mice that overexpress HCV 
core (Moriya et al., 1997a; Barbaro et al., 1999). 
It has also been shown that core can localize to 
mitochondrial outer membranes (Schwer et al., 
2004).
(b) HCV glycoproteins
The HCV glycoproteins, E1 (30 kDa) and E2 
(70 kDa), are type I transmembrane glycopro-
teins that associate into non-covalently attached 
heterodimers, and mediate HCV cell entry and 
membrane fusion (Bartosch & Cosset, 2006; 
Lavillette et al., 2006; Lindenbach et al., 2007).
4 .1 .2 The non-structural proteins
(a) p7
p7 is a small 7 kDa hydrophobic protein 
predicted to span the membrane twice, with 
endoplasmic-reticulum-lumenal N- and 
C-terminals and a short, positively charged cyto-
plasmic loop. The localization of p7 is not yet 
clear, but overexpression of an epitope-tagged p7 
has been localized to the endoplasmic reticulum 
and mitochondria (Griffin et al., 2005). The p7 
protein is essential for virus assembly and release 
in vitro (Steinmann et al., 2007), and infectivity 




NS2 is a 23 kDa membrane-spanning protein 
with a C-terminal cysteine protease activity that 
cleaves the NS2/3 junction (Grakoui et al., 1993; 
Lorenz et al., 2006). NS2 is furthermore required 
for viral assembly. Its N-terminal domain may 
interact with the structural proteins and p7, 
whereas downstream sequences may interact 
with other NS proteins (Lindenbach et al., 2007; 
Jirasko et al., 2008).
(c) NS3
HCV NS3 is a 70 kDa multifunctional protein, 
containing an N-terminal serine protease 
domain and a C-terminal RNA helicase/NTPase 
domain that unwinds double-stranded nucleic 
acids (Lindenbach et al., 2007). Although the 
precise role of the NS3 helicase is not yet known, 
helicase activity has been shown to be essential 
for HCV RNA replication and viral infectivity 
(Lam & Frick, 2006).
(d) NS4A
NS4A is an 8 kDa protein with multiple func-
tions in the virus life cycle. It is a cofactor that 
assists in the correct folding of the serine protease, 
and facilitates recognition of RNA substrates by 
the NS3 protease/helicase (Pang et al., 2002). 
NS4A can physically interact with NS4B and 
NS5A and uncleaved NS4B-5A to promote NS5A 
hyperphosphorylation (Lindenbach et al., 2007; 
and references therein).
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Table 4 .1 HCV proteins, their role in the viral life cycle, and putative role in hepatocyte 
transformation
HCV proteins Role in viral life cycle Potential role in cellular transformation (examples)
Core protein Nucleocapsid assembly Insulin resistance/steatosis
Interference (direct or indirect) with p53, p73, pRb
Interference with host cell signalling (NF-κB, Wnt/β-
catenin pathway)
Interference with TGF-β signalling
Transcriptional activation of cellular genes
Apoptosis
E1/E2 glycoprotein Virus morphogenesis Interference with the interferon-inducible protein 
kinase (PKR) activity
Cell entry
p7 Virus assembly, export and infectivity
NS2 Polyprotein processing and Viral assembly Inhibition of apoptosis
NS3 N-terminal domain Serine protease activity Interference with hepatocyte innate response
NS3 C-terminal domain Helicase activity
HCV genome replication
NS4A Co-factor of NS4B and NS5A Induction of ER stress
NS4B Formation of membranous web structures
NS5A Part of the replication complex Inhibition of the interferon-inducible PKR
Oxydative stress
Activation of cell signalling pathways (STAT-3, NF-κB 
etc)
Accumulation of β-catenin by indirect mechanism
NS5B RNA-dependent RNA polymerase
ER, endoplasmic reticulum; PKR, double-stranded RNA-activated protein kinase
Compiled by the Working Group
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(e) NS4B
NS4B is a 27 kDa integral membrane protein 
containing four central transmembrane domains 
with yet unclear topology. Its expression is suffi-
cient to induce the formation of ‘membraneous 
web’ structures that contain the membrane-
bound replication complex (Egger et al., 2002; 
Gosert et al., 2003), and it encodes a GTPase 
activity that seems to be critical for RNA repli-
cation (Einav et al., 2004).
(f) NS5A
NS5A is a 58 kDa phosphoprotein with an 
important yet unclear role in RNA replication 
(Shimakami et al., 2004). It localizes to active 
replication complexes (Gosert et al., 2003; 
Moradpour et al., 2004), interacts with NS5B and 
inhibits its RNA polymerase activity (Shirota 
et al., 2002; Dimitrova et al., 2003).
(g) NS5B
NS5B is a 68 kDa endoplasmic-retic-
ulum-membrane-associated protein with 
RNA-dependent polymerase activity. Mutations 
that interfere with its membrane association 
destroy RNA replication. Intramolecular interac-
tions as well as oligomerization of NS5B stimulate 
RNA synthesis, and the NS3 helicase enhances 
primed RNA synthesis activity in contrast to 
NS4B and NS5A, which inhibit RNA synthesis 
(Lindenbach et al., 2007; and references therein). 
NS5B has been and remains a major target for the 
development of HCV-specific drugs; at the time 
of writing, drug research and development is 
focusing on cellular cofactors of NS5B, the cyclo-
philins. The function of NS5B has been shown to 
be upregulated by cyclophilin B, which in turn is 
regulated, and thus sensitive to the immunosup-
pressant ciclosporin A. Compounds belonging 
to this family are currently investigated for their 
antiviral efficacy (Watashi et al., 2005; Watashi & 
Shimotohno, 2007).
4.2 Biological properties of HCV 
proteins 
See Table 4.1.
[The Working Group noted that besides the 
complex interactions among themselves, the 
viral proteins interact with a significant number 
of host factors and signalling pathways that may 
contribute to the pathological consequences of 
HCV infection. These interactions interfere with 
innate immunity and thus contribute to persis-
tence of infection and inflammation; but they 
have also been described to modulate transcrip-
tion, translation and post-translational events, to 
alter cell signalling, apoptosis, membrane physi-
ology and trafficking. Furthermore, they can 
induce oxidative stress, genomic instability and 
possibly cellular transformation.
Many studies of the potential role of viral 
proteins in hepatocyte transformation have been 
performed in experimental models that are based 
on the overexpression of viral proteins after tran-
sient transfection of already transformed hepat-
ocytes (such as HepG2 or Huh7 cells). These 
studies show the interaction of viral proteins 
with cellular partners that may be involved 
in cellular transformation. However, because 
the expression of these viral proteins has been 
difficult to demonstrate in liver tumours, a link 
between these in vitro observations and their in 
vivo relevance in infected humans still needs to 
be established. Because of the lack of relevant 
models for mechanistic studies of HCV-induced 
HCC, the results of the major molecular studies 
have been described below to provide an over-
view of the current hypotheses.]
Of the HCV gene products core, NS3, NS4B 
and NS5A have all been shown to exhibit trans-
formation potential when transiently or stably 
expressed in tissue culture, or in the context of 
transgenic mice carrying the single viral proteins 
or an HCV polyprotein (Sakamuro et al., 1995; 
Ray et al., 1996; Gale et al., 1999; Park et al., 2000). 
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However, many of the data below need to be 
substantiated in the context of a viral infection.
4 .2 .1 The structural proteins
(a) Core protein
Core has been implied in changes of host cell 
signalling, transcriptional activation, apoptosis, 
lipid metabolism, and transformation. Among 
an impressive list of interactions with cellular 
factors, core has been shown to physically and 
functionally interact with p53 (Ray et al., 1997; 
Lu et al., 1999), and p73 (Alisi et al., 2003), and 
to decrease the expression of pRb (Cho et al., 
2001) tumour-suppressor proteins. For instance, 
it was shown that HCV core co-immunoprecip-
itates with p73 in HepG2 and SAOS-2 cells. This 
interaction results in the nuclear translocation 
of HCV core protein. In addition, the interac-
tion with HCV core protein prevents p73-α-, 
but not p73-β-dependent cell growth arrest in 
a p53-dependent manner. The results suggested 
that HCV core protein may directly influence 
the various p73 functions, thus playing a role in 
HCV pathogenesis (Alisi et al., 2003).
Core also modulates the expression of the 
cyclin-dependent kinase (CDK) inhibitor p21/
Waf in a p53-independent manner (Kwun & 
Jang, 2003). p21, a well known transcriptional 
target of p53, blocks activities of cyclin/CDK 
complexes involved in cell-cycle control and 
tumour formation.
Core induces activation of the Raf1/mitogen-
activated protein kinase (MAPK) pathway (Aoki 
et al., 2000; Hayashi et al., 2000), relieves cells 
from serum starvation and growth arrest, and 
favours cell proliferation.
Conflicting reports have shown both activa-
tion (Ray et al., 2002) and repression (Joo et al., 
2005) of the NF-κB pathways by HCV core.
HCV core has been shown to activate the 
Wnt/β-catenin pathway, which is implicated in 
cell proliferation, DNA synthesis, and cell-cycle 
progression (Fukutomi et al., 2005).
Furthermore, core variants isolated from 
liver tumours, but not those isolated from adja-
cent non-tumourous liver, have been shown 
to interact with Smad3 and inhibit the TGF-β 
pathway (Pavio et al., 2005). TGF-β-signalling 
not only controls cell proliferation, differentiation 
and apoptosis but also stimulates liver regenera-
tion and fibrogenesis through its actions on the 
extracellular matrix. TGF-β levels are frequently 
increased in chronic HCV patients and correlate 
with the degree of fibrosis (Nelson et al., 1997; 
Marcellin et al., 2002).
Finally, HCV core protein associates with 
cellular membranes (Barba et al., 1997; Moriya 
et al., 1997a) and lipid vesicles (Moriya et al., 
1997a), binds to apolipoprotein II, and reduces 
microsomal triglyceride transfer protein (MTP) 
activity (Perlemuter et al., 2002), leading to defects 
in the assembly and secretion of vLDL and stea-
tosis, which in turn induces oxidative stress. The 
in vivo relevance of this interaction is supported 
by the development of steatosis (Moriya et al., 
1997b; Perlemuter et al., 2002) and liver cancer 
(Moriya et al., 2001; Lerat et al., 2002) in trans-
genic mice expressing HCV core.
(b) E2
Overexpression of E2 inhibits eIF2α phos-
phorylation by the dsRNA-activated protein 
kinase (PKR) or the endoplasmic-reticulum-
stress signalling kinase PERK. E2 also physically 
interacts with PKR; the E2/PKR interaction may 
account for the intrinsic interferon’s resistance of 
HCV genotypes 1a and 1b (Taylor et al., 1999; 
Pavio et al., 2003).
4 .2 .2 The non-structural proteins
(a) NS4A, NS4B or NS4A-4B
Overexpression of NS4A, NS4B, or NS4A-4B 
has been reported to induce an endoplasmic- 
reticulum- stress-mediated unfolded protein 
response, reduce endoplasmic-reticulum-to-
Golgi traffic, inhibit protein synthesis, and to 
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cause cytopathic effects (Lindenbach et al., 2007; 
and references therein).
(b) NS2
NS2 interacts with the cellular proapoptotic 
molecule CIDE-B and inhibits CIDE-B-induced 
apoptosis (Erdtmann et al., 2003). NS2 has also 
been shown to downregulate the transcription 
of several cellular and viral promoters in gene-
reporter assays (Dumoulin et al., 2003).
(c) NS3-4A
NS3-4A serine protease has been reported to 
block the activation of the transcription factors 
IRF-3 and NF-κB, and to antagonize innate anti-
viral defenses by interfering with the cytosolic 
RNA helicases, RIG-1- and MDA5-, and TLR3-
mediated signal transduction (Lindenbach et al., 
2007).
(d) NS5A
NS5A has multiple functions. It has been 
shown to interact with the geranylgeranylated 
cellular protein FBL2 (Wang et al., 2005), an 
F-box-motif-containing protein that is likely 
to be involved in targeting cellular proteins of 
yet unknown identity for ubiquitylation and 
degradation.
Several studies suggest that NS5A is also 
involved in the resistance to interferon treatment 
(Lindenbach et al., 2007; and references therein), 
and one possible mechanism may be its ability 
to induce expression of the type I interferon 
antagonist IL-8 (Polyak et al., 2001). In addition, 
NS5A contains an ‘interferon sensitivity deter-
mining region’ (ISDR) that mediates inhibition 
of PKR, an activator of innate immunity; accu-
mulation of mutations in this region is thought 
to correlate with treatment efficacy (Enomoto 
et al., 1995, 1996).
Overexpression of NS5A has been reported to 
induce several effects in cells, including oxida-
tive stress; activation of signalling pathways, 
including STAT-3, PI3K, and NF-κB (Gong 
et al., 2001; He et al., 2002; Street et al., 2004); 
and degradation of pRB (Munakata et al., 2005).
Other reported NS5A interaction partners 
include apolipoprotein A1, the major protein 
found on High Density Lipoprotein (HDL); 
the tumour suppressor, p53; Grb-2, an adaptor 
protein involved in mitogen signalling; SRCAP, 
an adenosine triphosphatase (ATPase) that acti-
vates cellular transcription; karyopherin β3, a 
protein involved in nuclear trafficking; Cdk1/2, 
cyclin-dependent and Fyn, Hck, Lck, and Lyn, 
Src-family kinases (Lindenbach et al., 2007; and 
references therein).
More recently, it has been reported that NS5A-
expression in the context of HCV polyprotein 
results in the inhibition of the transcription factor 
Forkhead as well as in the phosphorylation and 
inactivation of the GSK-3, leading to the accu-
mulation of β-catenin and to the stimulation of 
β-catenin-dependent transcription (Street et al., 
2005).
[The Working Group noted that, so far, 
the biological functions of the HCV proteins 
have been investigated in vitro or in vivo using 
transgenic mice constitutively expressing HCV 
proteins alone, in combination, or the entire 
polyprotein. Whether the results generated by 
these experimental approaches reflect the patho-
logical consequences of an HCV infection in vivo 
remains to be addressed, and this issue will only 
be resolved with the establishment of immuno-
competent mouse models or other more physi-




4.3 Experimental evidence for a role 
of HCV in malignant conversion
4 .3 .1 Role of HCV chronic infection in HCC 
development
Successful clearance of chronic HCV infec-
tion has been shown to reduce the overall liver-
related mortality and the incidence of HCC 
providing further evidence for a causal role of 
HCV in this cancer (Kasahara et al., 1998; Serfaty 
et al., 1998; Imazeki et al., 2003b).
Although chronic HCV infection is one 
major risk factor for HCC, the mechanisms 
by which HCV induces HCC remain uncer-
tain (Levrero, 2006; McGivern & Lemon, 
2009). Chronic endoplasmic reticulum stress 
and inflammatory responses and the associ-
ated oxidative stress and altered intracellular 
redox state lead to the accumulation of genomic 
damage. These are likely to contribute to and 
predispose infected cells to hepatocarcinogen-
esis, possibly via changes in MAPK signalling, 
that regulates both cell metabolism and growth 
(Tardif et al., 2002; Waris et al., 2007). Markers 
of intracellular oxidative stress have indeed been 
reported to be increased in chronic HCV patients 
(Shimoda et al., 1994; Sumida et al., 2000) as well 
as in HCV core transgenic mice (Moriya et al., 
1998; Moriya et al., 2001). However, in addition, 
direct interactions of the various HCV proteins 
with host factors correlate with changes in 
cellular signalling cascades that are involved in 
the regulation of cell metabolism and division. 
The expression of some HCV proteins seem to be 
sufficient to induce hepatocarcinogenesis, at least 
in some specific transgenic mice lineages such as 
transgenic C57BL/6 mice (Lerat et al., 2002); liver 
tumour development was shown to be associated 
with HCV-induced liver steatosis (Lerat et al., 
2002; Moriya et al., 1998).
Overall, because of the lack of an experimental 
model that replicates the viral life cycle and 
natural history of the disease, the current view is 
that synergistic effects between the consequences 
of chronic inflammation and direct virus–host 
cell interactions are most likely. Such synergistic 
effects would also explain the long ‘multistep’ 
transformation process in human HCC, which 
is consistent with the long time lag with which 
cirrhosis and HCC manifest themselves upon 
chronic infection, and would explain the wide 
variety of genetic defects observed in individual 
HCCs (Thorgeirsson & Grisham, 2002; Levrero, 
2006; McGivern & Lemon, 2009).
Prospective and retrospective cohort studies 
of patients with chronic HCV infection have 
demonstrated a role for the long duration of 
the disease in HCC development, and the link 
between HCC development and liver cirrhosis. 
These studies showed the sequential occurrence 
of advanced liver fibrosis followed by the devel-
opment of HCC. The incidence of HCC devel-
opment was estimated to be between 3–5%/year 
in cirrhotic patients (Tsukuma et al., 1993; Tong 
et al., 1995; Fattovich et al., 1997).
4 .3 .2 Role of HCV-induced steatosis, insulin 
resistance, and oxidative stress in HCC 
development
Pro-carcinogenic cofactors in chronic HCV 
infection are steatosis, oxidative stress and 
insulin resistance, suggesting many parallels 
with non-alcoholic fatty liver disease (NAFLD). 
In NAFLD, chronic excess of nutrients causes 
endoplasmic reticulum stress, and leads to an 
increase of hepatic fat (steatosis) and insulin 
resistance; a complex interplay between these 
factors can lead to chronic liver inflammation, 
apoptosis and fibrogenesis, which are thought 
to form the prelude to liver cirrhosis and cancer 
(Hotamisligil, 2006).
An increased prevalence of steatosis and 
insulin resistance in HCV patients is well estab-
lished and has prognostic implications, as it is 
associated with faster progression of fibrosis and 
a poorer response to treatment. In HCV patients 
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infected with genotypes 1 and 2, steatosis 
presents in general with concomitant obesity or 
other features of the metabolic syndrome, but 
this association is weak in genotype 3 patients. 
Genotype 3 is thought to induce steatosis in a 
direct fashion, as steatosis in these patients corre-
lates with viral load, and reverses with response 
to treatment (Negro, 2006). HCV is thought 
to induce steatosis by impairing secretion and 
degradation, and increasing the neosynthesis 
of lipids. The HCV core protein, which localizes 
to the surface of lipid droplets and mediates the 
viral assembly in close conjunction with cellular 
fatty acid metabolism (Miyanari et al., 2007), and 
also some HCV non-structural proteins, have 
all been shown to interfere with vLDL secretion 
(Wetterau et al., 1997; Domitrovich et al., 2005). 
HCV infection has also been associated with an 
upregulation of the neosynthesis of lipids (Waris 
et al., 2007), inhibition of fatty acid oxidation 
(Dharancy et al., 2005), and increased release of 
fatty acids from fat cells (Negro, 2006). Overall, 
the effects of HCV proteins on lipid synthesis, 
secretion and oxidation seem to be most potent 
in the context of genotype 3, but also occur in the 
context of other genotypes.
The development of severe steatosis and HCC 
was shown in PPARalpha-homozygous mice with 
liver-specific transgenic expression of the core 
protein gene, while tumours were not observed 
in the other transgenic mouse genotypes. This 
result suggested that persistent activation of 
PPARalpha, a central regulator of triglyceride 
homeostasis, is essential for the pathogenesis 
of hepatic steatosis, and HCC induced by HCV 
infection (Tanaka et al., 2008).
Besides changes in the lipid metabolism, core 
and several of the non-structural HCV proteins 
induce systemic oxidative stress and related 
signalling by various mechanisms (Tardif et al., 
2005).
With respect to insulin resistance, all HCV 
genotypes have been shown to interfere with 
glucose homeostasis, often at early stages of 
infection (Negro, 2006), but the underlying 
mechanisms and the degree of insulin resistance 
seem to be again genotype-dependent. HCV has 
been shown to interfere with insulin signalling by 
proteasomal degradation of the insulin receptor 
substrates, (IRS)-1 and −2 (Aytug et al., 2003).
The feedback circle between steatosis, insulin 
resistance and oxidative stress is an important 
denominator for disease progression in NAFLD as 
well as viral hepatitis, and induces tissue damage 
and inflammation and consequently, activation 
of hepatic stellate cells (HSCs). Activated HSCs 
become responsive to both proliferative and 
fibrogenic cytokines, and undergo epithelial-to-
mesenchymal transdifferentiation (EMT) into 
contractile myofibroblast-like cells, that synthe-
size extracellular matrix (ECM) components, 
which accumulate over time to form fibrous 
scars, or ‘fibrosis’. Ultimately, nodules of regener-
ating hepatocytes become enclosed by scar tissue, 
which defines cirrhosis. Activation of HSCs is 
regulated by products and effectors of oxidative 
stress and growth factors, cytokines, adipokines, 
and chemokines. The cytokine TGF-β, a potent 
inhibitor of epithelial cell growth and tumour 
suppressor, can also exert pro-oncogenic func-
tions, and is a key regulator of EMT. Importantly, 
recent findings imply that TGF-β induces EMT 
not only in HSCs but possibly also in hepato-
cytes (Matsuzaki et al., 2007). TGF-β signalling 
is upregulated in fibrotic HCV patients, and 
stimulates ECM deposition and accumulation. 
Insulin resistance may link fibrosis and steatosis, 
as it stimulates HSCs to deposit ECM. Several 
signalling cascades are implicated and modu-
lated during fibrogenesis, including SMADs, 
PI3K-Akt and various MAPK pathways, such 
as p38 and JNK. While SMADS are indispen-
sable for the EMT process, TGF-β signalling 
via SMAD synergizes with other signalling 
pathways to mediate pro-oncogenic EMTs. JNK 
activation by the pro-inflammatory cytokine 
interleukin-1β can shift TGF-β signalling away 
from a tumour-suppressive to a pro-oncogenic 
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profile with augmented fibrogenesis, increased 
cell motility, and transactivation of cell cycle 
regulatory genes (Matsuzaki et al., 2007). 
Thus, in the context of chronic inflammation, 
the interplay between endoplasmic reticulum/
oxidative stress, steatosis and insulin resistance 
induces a pro-oncogenic microenvironment that 
drives fibrogenic processes and genomic insta-
bility; and even though HCV has been reported 
to display direct transforming capacities, the 
liver microenvironment is thought to determine 
significantly the transformation process because 
HCC develops in chronic HCV infection only 
over long periods of time.
So far, it has not been possible to correlate 
hepatocarcinogenesis with a consistent pattern 
of proto-oncogene activation, but several growth 
factor signalling axes are frequently found to be 
dysregulated, including insulin-growth factor 
(IGF), hepatocyte growth factor, Wnt, TGF-α/
EGF and TGF-β signalling (Breuhahn et al., 
2006; Levrero, 2006). The interplay between 
these various pathways and their respective roles 
and contributions to the development of HCC 
remain to be unravelled.
4 .3 .3 Role of HCV in lymphomas and other 
tumours
The mechanisms by which lymphoma is 
induced by HCV remains the subject of debate. 
Several clinical studies have shown that the HCV 
genome may be detected in peripheral lymphoid 
cells as well as dendritic cells (Bain et al., 2001). 
However, evidence of true viral genome replica-
tion in extrahepatic sites is still lacking.
Some early studies showed that HCV may 
infect cultured peripheral blood mononuclear 
cells in vitro (Shimizu et al., 1998), but these 
observations were not confirmed by other groups.
Few studies showed that the HCV genome 
sequence from extrahepatic isolates may 
cluster differently from liver isolates providing 
indirect evidence for viral replication in these 
cells (Roque-Afonso et al., 2005).
Clinical studies have shown that HCV eradi-
cation by pegylated interferon and ribavirin 
treatment may lead to the cure of cryoglobu-
linemia, a B-cell proliferation disorder, and to the 
regression of HCV-associated splenic lymphoma 
(Hermine et al., 2002).
Several non-exclusive hypotheses have been 
discussed regarding the transforming role of 
HCV in the context of lymphoma: 1) antigen-
driven proliferation induced by continuous 
activation of B cells (Suarez et al., 2006); 2) a 
direct role of HCV replication and expression in 
infected B cells.
Further molecular and cellular biology 
studies are warranted to decipher the mecha-
nisms of HCV-induced lymphomas.
Regarding the role of HCV in the development 
of cholangiocarcinoma, both clinical evidence 
and strong experimental data are lacking.
4.4 Interaction between HCV and 
environmental agents
Regarding interactions between HBV and 
HCV please refer to the Monograph on HBV in 
this volume.
4.5 Animal models for HCV-
associated cancers
Chimpanzees and tree shrews do not, or only 
partially, develop HCV-associated pathologies 
upon infection. And given the long delay with 
which HCC develops in chronic hepatitis, these 
models are unsuitable to study HCV-induced 
HCC in the first place. In the absence of animal 
models that develop HCC in the context of an 
HCV infection, various groups have described 
the use of mouse models. Mice expressing 
HCV replicons, polyproteins or the single HCV 
proteins alone or in combination, using various 
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liver specific promoters, have been described 
by many groups (Levrero, 2006; McGivern & 
Lemon, 2009).
To date, studies using transgenic animals 
expressing HCV cDNA suggest that HCV proteins 
are not directly cytopathic (Kawamura et al., 
1997; Pasquinelli et al., 1997; Wakita et al., 1998). 
Only three different HCV core transgenic lines 
have been shown to develop liver steatosis and 
HCC (Moriya et al., 1998, 2001), and one group 
has been able to demonstrate that upon HCV 
polyprotein expression, the rate of liver cancer in 
transgenic mice increases in the absence of intra-
hepatic inflammation, suggesting a metabolic or 
genetic host susceptibility for HCV-associated 
HCC (Lerat et al., 2002).
NS5A transgenic mice, despite the abundant 
interactions of NS5A with host-cell factors, do 
not have any significant phenotype (Majumder 
et al., 2002, 2003).
4.6 HCV, host immune system, and 
genetic susceptibility
While many studies have been reported 
regarding the role of the humoral and cellular 
responses in the control of HCV infection, as 
well as micro-array analysis of primary liver 
tumours showing differential expression of many 
cellular genes in the tumours, no relevant data 
are available at the time of writing concerning 
specific immune or genetic mechanism involved 
in HCV-induced HCC.
4.7 Synthesis
Although there is strong evidence that HCV 
is one of the leading causes of HCC, there is 
still much to understand regarding the mecha-
nism of HCV-induced transformation. While 
liver fibrosis resulting from long-lasting chronic 
inflammation and liver regeneration resulting 
from immune-mediated cell death are likely 
factors contributing to the development of HCC, 
the direct role of HCV proteins remains to be 
determined. Many in vitro studies have shown 
that HCV expression may interfere with cellular 
functions that are important for cell differentia-
tion and cell growth. However, most studies were 
performed in artificial study models which can 
only give clues for potential mechanisms that 
need to be confirmed in more relevant models. 
Furthermore, the difficulty to localize HCV 
proteins as well as infected cells in vivo in the liver 
of infected patients contribute to the complexity 
of our current understanding.
For all these reasons, at the time of writing, 
the current view is that there is moderate experi-
mental evidence for a direct oncogenic role of 
HCV. Further studies are warranted to clarify 
these issues.
5. Evaluation
There is sufficient evidence in humans for the 
carcinogenicity of chronic infection with HCV. 
Chronic infection with HCV causes hepatocel-
lular carcinoma and non-Hodgkin lymphoma. 
Also, a positive association has been observed 
between chronic infection with HCV and 
cholangiocarcinoma.
Chronic infection with HCV is carcinogenic 
to humans (Group 1).
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Kaposi sarcoma herpesvirus was considered by a previous IARC Working Group in 1997 
(IARC, 1997). Since that time, new data have become available, these have been incorpo-
rated into the Monograph, and taken into consideration in the present evaluation.
1. Exposure Data
1.1 Taxonomy, structure, and biology
1 .1 .1 Taxonomy
First detected by Chang et al. (1994) in Kaposi 
sarcomas associated with the acquired immune 
deficiency syndrome (AIDS) (see IARC, 1996) by 
representational difference analysis, this virus 
was termed Kaposi-sarcoma-associated herpes-
virus, KSHV. KSHV is also associated with 
primary effusion lymphoma and some cases of 
multicentric Castleman disease (see Section 2). 
In keeping with the systematic nomenclature 
adopted for all human herpesviruses, the formal 
designation human herpesvirus 8 (HHV-8) was 
proposed by the herpesvirus subcommittee of 
the International Committee on the Taxonomy 
of Viruses. In this Monograph, the term KSHV 
is used throughout. 
On the basis of phylogenetic analyses 
(Moore et al., 1996a; Russo et al., 1996), KSHV 
is a gamma-2 herpesvirus (rhadinovirus), and 
represents the first ‘human’ member of this 
group. There are many more gamma-2 herpes-
virus species in old and new world non-human 
primates.
1 .1 .2 Structure of the virion
KSHV has the typical morphological char-
acteristics of a herpesvirus (Fig. 1.1; Arvanitakis 
et al., 1996; Renne et al., 1996a; Orenstein et al., 
1997) with 100–150 nm particles surrounded by a 
lipid envelope, and an electron-dense central core 
(Renne et al., 1996b). Cryo-electron microscopy 
(Cryo-EM) and Cryo-EM tomography studies 
suggest that KSHV capsomers are hexamers 
and pentamers of the major capsid protein 
(encoded by the open reading frame [ORF] 25), 
with the small capsid protein (encoded by ORF 
65), binding around the tips of both hexons and 
pentons (Trus et al., 2001; Deng et al., 2008).
1 .1 .3 Structure of the viral genome
KSHV has a double-stranded DNA genome. 
The genomic structure of the virus (Russo et al., 
1996; Neipel et al., 1997a) is similar to that of other 
primate rhadinoviruses, e.g. Herpesvirus saimiri 
(Albrecht et al., 1992) or Rhesus Rhadinovirus 
(Searles et al., 1999; Alexander et al., 2000), with 
a single, contiguous 140.5-kb-long unique region 
containing all the identified viral genes (Russo 
et al., 1996; Neipel et al., 1997a; Fig.  1.2). This 
region is flanked on either side by a terminal-
repeat (TR) region composed of a variable 
number of repeats of 801-bp length with a high 
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Fig. 1.1 Electron microscopic view of KSHV capsids in a cross-section of a spleen Kaposi sarcoma
Cytoplasmic viral capsids obtain their lipid outer membrane by budding into cisternae; the electron dense central core represents viral DNA. 
Original magnification: x53 000.



















Fig. 1.2 Annotated long unique region and terminal repeats of the KSHV genome
The orientation of identified open reading frames in the long unique region is denoted by the direction of arrows, with Herpesvirus saimiri homologous with open reading frames as shaded 
areas and those not homologous as lighter areas. Seven blocks (numbered) of conserved herpesviral genes with non-conserved interblock regions (lettered) are shown under the kilobase 
marker. Features and putative coding regions not specifically designated are shown above the open reading frame map. Repeat regions (frnk, vnct, waka/jwka, zppa, moi, mdsk) are shown 
as light lines, and putative coding regions and other features are not designated as open reading frames are shown as solid lines.
From Russo et al. (1996), PNAS 93: 1486–1487, “Copyright (2010) National Academy of Sciences, USA.”
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G:C (84.5%) content. Due to the variable number 
of repeat subunits (some of the repeat subunits 
may be truncated), the overall length of the TR 
region varies, and with it, the overall size of the 
KSHV genome. The latter has been calculated to 
be approximately 165 kb on the basis of studies of 
the viral genome from productive primary effu-
sion lymphoma cells (Arvanitakis et al., 1996; 
Renne et al., 1996b), and mapping of the whole 
genome (Russo et al., 1996).
(a) Terminal-repeat region
The TR region is a conserved feature of 
herpesviruses, and is involved in the packaging 
of the viral DNA into new virions during the 
lytic cycle of replication. Depending on the viral 
strain, KSHV has approximately 20–30 TR units. 
A particular feature of the KSHV TR unit is that 
it contains two binding sites for the KSHV latent 
nuclear antigen (LANA) and the latent (episomal) 
origin of replication (Garber et al., 2001; Hu et al., 
2002). By binding to multiple TR subunits, LANA 
tethers circular viral episomes to mitotic chro-
mosomes during mitosis (Ballestas et al., 1999; 
Barbera et al., 2006). LANA is also required for 
the replication of viral episomes by recruiting a 
range of cellular factors involved in DNA replica-
tion (see Section 4.1). Currently, the TR region is 
not known to contain any protein-coding ORFs 
in contrast to, for example, EBV (Longnecker & 
Neipel, 2007).
(b) Long unique region
The KSHV 140.5-kb long unique region 
encodes approximately 90 predicted ORFs (Russo 
et al., 1996; Neipel et al., 1997a; Fig. 1.2). The ORFs 
were named according to the corresponding 
herpesvirus saimiri genes with which they share 
a significant level of sequence similarity. Unique 
genes that are not homologous with herpesvirus 
saimiri have a K prefix. The long unique region 
has blocks of genes conserved among all subfam-
ilies of herpesviruses (Chee et al., 1990), which 
include genes that encode herpesvirus structural 
proteins and replication enzymes. Between the 
conserved herpesvirus gene blocks lie blocks of 
genes that are either found in rhadinoviruses or 
are unique to KSHV (Russo et al., 1996). Several 
of these share significant sequence similarity 
with cellular genes, and were presumably carried 
away at some point during the evolution of these 
viruses.
The long unique region also contains genes 
for untranslated RNAs. Among these is the PAN/
nut-1 transcript, a nuclear untranslated RNA, 
whose function is not yet clear (Sun et al., 1996; 
Zhong & Ganem, 1997). In addition, KSHV 
encodes at least 12 microRNAs, which are gener-
ated from one transcript, and located down-
stream of the ORFK13/vFLIP (Cai et al., 2005; 
Samols et al., 2005).
The probable function of these genes in the 
virus life cycle and tumour formation is discussed 
in Section 4.1.
1 .1 .4 Host range and tropism
Humans are the natural hosts for KSHV. 
Epidemiological studies indicate that KSHV is 
more prevalent in subSaharan Africa, several 
countries of southern Europe, the North African 
Mediterranean coast, and several countries of 
South America compared to northern Europe, 
North America, and Asia (see Section 1.2).
In vivo, KSHV has been detected in endothe-
lial and spindle cells of Kaposi sarcoma lesions, 
in circulating endothelial cells, primary effusion 
lymphoma cells, B cells, macrophages, dendritic 
cells, oropharynx and prostatic glandular epithe-
lium and keratinocytes (Ambroziak et al., 1995; 
Boshoff et al., 1995; Cesarman et al., 1995a; 
Moore & Chang, 1995; Corbellino et al., 1996; 
Li et al., 1996; Sirianni et al., 1997; Staskus et al., 
1997; Stürzl et al., 1997; Reed et al., 1998; Pauk 
et al., 2000).
Of the cell types targeted by KSHV in vivo, 
primary endothelial cells of different differentia-
tion (vascular, lymphatic, endothelial precursor 
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cells), monocytes, dendritic cells, fibroblasts, 
epithelial cells and keratinocytes can be infected 
in vitro (Renne et al., 1998; Blackbourn et al., 
2000; Cerimele et al., 2000; Wang et al., 2004a; 
Rappocciolo et al., 2006). It was shown that B 
cells can only be infected in vitro at a specific 
differentiation stage (Rappocciolo et al., 2006, 
2008).
1 .1 .5 Viral life cycle
KSHV, like all herpesviruses, can estab-
lish lifelong latent infections in their human 
host. Latenly infected cells provide a perpetual 
reservoir from which progeny viruses can be 
amplified for dissemination within the host 
and transmission between hosts. The peripheral 
blood CD19-positive B cells have been identi-
fied as a long-term latency reservoir for KSHV; 
other cells such as endothelial cells may also be 
a site for KSHV latency, but they do not appear 
to provide a long-term latent reservoir for the 
virus. Nonetheless, infected dermal endothelium 
spindle cells may release progeny virus that can 
subsequently infect local keratinocytes and the 
eccrine epithelium in the tumour. Lytic reacti-
vation from latently KSHV-infected cells that 
results in the release of progeny virions is a critical 
pathogenic step in multiple human diseases. In 
immunocompetent KSHV carriers, the immune 
system plays an essential role in tempering lytic 
reactivation of the virus (see Lukac & Yuan, 2007 
for a detailed review).
1.2 Epidemiology of infection
In the previous IARC monograph (IARC, 
1997), preliminary epidemiological data were 
presented based largely on Polymerase Chain 
Reaction (PCR) and initial serological studies. 
Subsequently, substantial additional data have 
become available with the advent of new sero-
logical techniques and large-scale studies.
1 .2 .1 Prevalence, geographic distribution
(a) Laboratory methods in epidemiological 
studies of KSHV
Difficulties have arisen in developing reli-
able serological tests to assess KSHV infection, 
and the interpretation of some published KSHV 
prevalence data is therefore challenging. KSHV 
encodes multiple antigenic proteins that may be 
expressed in the latent or lytic phase of the virus 
life cycle (Chandran et al., 1998). The major anti-
genic proteins are the LANAs encoded by ORF 
73, and the lytically expressed K8.1 encoded by 
ORF 65. First-generation serological assays were 
developed based on the immunofluorescence of 
latently infected primary effusion lymphoma 
cells (Gao et al., 1996; Kedes et al., 1996; Simpson 
et al., 1996) or primary effusion lymphoma cells 
induced by treatment with tetradecanoyl phorbol 
ester acetate (TPA) to produce lytic antigens 
(Lennette et al., 1996). More recently, enzyme-
linked immunosorbent assays (ELISAs) have 
been developed using recombinant proteins or 
peptides.
Concordance between assays detecting 
antibodies to these antigens has improved but 
remains moderate. Infected subjects may have 
antibodies to only lytic or latent antigens, and 
may develop antibody responses to lytic anti-
gens years before they develop antibodies to 
LANA, and the reverse can also occur (Biggar 
et al., 2003, Minhas et al., 2008). In addition, 
antibody titres are very high in Kaposi sarcoma 
patients but very low in asymptomatic subjects 
(Biggar et al., 2003). [The Working Group 
concluded that if the serum samples of Kaposi 
sarcoma patients are used as “gold standard” 
positive controls then the sensitivity of an assay 
is likely to be overestimated. At the other end of 
the spectrum, antibody levels in asymptomatic 
subjects are so low that establishing a clear assay 
cut-off is difficult. For these reasons, current 
assays for KSHV antibody detection, while 
suitable for comparisons between populations, 
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are inadequate for diagnostic purposes in low-
risk populations. Comparisons between studies 
using different assays or even different cut-offs 
are often problematic.]
(b) Seroprevalence estimates and geographic 
distribution
Despite the difficulties discussed above in esti-
mating the precise prevalence of KSHV, preva-
lence is in general low (< 10%) in northern Europe, 
the USA and Asia, elevated in the Mediterranean 
region (10–30%), and high in subSaharan Africa 
(>  50%) (Enbom et al., 2002; Dukers & Rezza, 
2003). A study of 1000 blood donors in the USA 
tested by six independent laboratories reported 
estimates ranging from 0.5–5% (Pellett et al., 
2003). More recently, a study of approximately 
14000 adults recruited for the National Health 
and Nutrition Examination survey (NHANES) 
III, designed to be representative of the general 
population, estimated KSHV prevalence to be 
around 7% (Engels et al., 2007). In northern 
Europe, KSHV is reported to be 2–3% in adults 
(Simpson et al., 1996; Marcelin et al., 1998; 
Preiser et al., 2001). Prevalence in Asia is similar 
to that in the USA and northern Europe. A large 
international study recently reported a preva-
lence of 5% for the Republic of Korea, 8–10% for 
Thailand, and 11–15% for Viet Nam (de Sanjosé 
et al., 2009).
KSHV prevalence is higher in adults in 
Mediterranean countries such as Italy than in 
northern Europe or the USA (Gao et al., 1996; 
Whitby et al., 1998), with prevalence higher in 
Southern Italy and in the Po Valley (13–20%) 
than in most of Northern Italy (Calabrò et al., 
1998; Whitby et al., 1998; Cattani et al., 2003; 
Serraino et al., 2006). The prevalence in Spain 
is reported to be 3.65% (de Sanjosé et al., 2009), 
in Greece 7.6% (Zavitsanou et al., 2007), and 
in Israel 10% (Davidovici et al., 2001). In South 
America, a high prevalence of KSHV infection is 
reported in Amerindians but not in the general 
population (Biggar et al., 2000; Whitby et al., 
2004; Cunha et al., 2005).
The prevalence of KSHV in Uganda is 40–50% 
(Gao et al., 1996; Wawer et al., 2001; Hladik et al., 
2003; Newton et al., 2003a). Similar estimates are 
reported for Kenya (~43%) (Baeten et al., 2002; 
Lavreys et al., 2003), Zambia (40%) (Klaskala 
et al., 2005), and the United Republic of Tanzania 
(~ ≥50%) (Mbulaiteye et al., 2003a). KSHV prev-
alence appears to be higher in Malawi (54–67%), 
Botswana (76%), and The Demographic Republic 
of Congo (82%) (Engels et al., 2000; DeSantis 
et al., 2002; Whitby et al., 2004).
KSHV prevalence is somewhat lower in South 
Africa (30%) (Sitas et al., 1999; Dedicoat et al., 
2004; Malope et al., 2007), and in West African 
countries such as Burkino Faso (~12.5%) and 
Cameroon (~25%) (Volpi et al., 2004; Collenberg 
et al., 2006). The Gambia had a low incidence 
of Kaposi sarcoma before and during the AIDS 
epidemic but has a high KSHV prevalence (~75%) 
(Ariyoshi et al., 1998). The prevalence of KSHV 
in Nigeria is intermediate (~45%) (de Sanjosé 
et al., 2009).
1 .2 .2 Transmission and risk factors for 
infection
KSHV is primarily transmitted via saliva. In 
countries where KSHV is highly prevalent, infec-
tion occurs during childhood and increases with 
age (Whitby et al., 2000; Dedicoat et al., 2004; 
Malope et al., 2007). The peak age of acquisition 
is generally between 6–10 years (Whitby et al., 
2000; Mbulaiteye et al., 2004), and the risk of 
infection is increased if family members, espe-
cially mothers, are infected (Plancoulaine et al., 
2000; Dedicoat et al., 2004; Malope et al., 2007; 
Minhas et al., 2008). Other reported risk factors 
for infection in childhood include human immu-
nodeficiency virus (HIV) infection (Malope 
et al., 2007; Minhas et al., 2008), environmental 
factors such as source of water (Mbulaiteye et al., 
2005), and insect bites (Coluzzi et al., 2003). In 
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the USA, Europe and Australia, KSHV preva-
lence is elevated in homosexual men, especially 
those infected by HIV (Martin et al., 1998; Smith 
et al., 1999; Grulich et al., 2005). There is consid-
erable evidence that the risk of infection with 
KSHV is associated with the number of sexual 
partners of an individual, and other sexual risk 
factors (Martin et al., 1998; Smith et al., 1999; 
Grulich et al., 2005). It is likely that the trans-
mission of KSHV between homosexual men is 
also via saliva (Martin, 2003; Martró et al., 2007). 
KSHV is not generally associated with sexual 
risk factors in heterosexuals (Smith et al., 1999; 
Engels et al., 2007; Malope et al., 2008; de Sanjosé 
et al., 2009).
KSHV can be detected in peripheral blood 
suggesting that blood-borne transmission is 
possible. Some studies have suggested that 
injecting drug use was not associated with a risk of 
KSHV infection (Renwick et al., 2002; Bernstein 
et al., 2003), but others have shown an increased 
risk of KSHV infection in injecting drug users, 
especially with prolonged use (Cannon et al., 
2001; Atkinson et al., 2003). KSHV transmission 
via blood transfusion is also likely to be rare, but 
evidence of both risk and actual transmission has 
been reported (Mbulaiteye et al., 2003b; Dollard 
et al., 2005; Hladik et al., 2006). KSHV transmis-
sion by organ donation has also been reported 
(Parravicini et al., 1997, Concato et al., 2008).
2. Cancer in Humans
2.1 Kaposi sarcoma
At the time of the previous IARC Monograph 
(IARC, 1997), KSHV was classified as ‘probably 
carcinogenic to humans’ (Group 2A) on the basis 
‘that the evidence was compelling but as yet 
limited’. Since then, a large number of studies 
have assessed the association between KSHV 
and Kaposi sarcoma (see Table  2.1 available at 
http://monographs.iarc.fr/ENG/Monographs/
vol100B/100B-04-Table2.1.pdf, and Table 2.2 
available at http://monographs.iarc.fr/ENG/
Monographs/vol100B/100B-04-Table2.2.pdf).
To date, data on the association between 
KSHV and Kaposi sarcoma come from 22 cohort 
studies and 80 case–control studies – all show 
broadly consistent evidence of an association 
between KSHV infection and Kaposi sarcoma. 
In most studies, the relative risks for the asso-
ciation between KSHV infection and Kaposi 
sarcoma are typically greater than 10. Of the 
22 cohort studies, conducted in nine countries 
across three continents, 13 were among cohorts 
of HIV-infected people and included data on 
561 cases. The largest study included 189 cases 
(Newton et al., 2006). Nine cohorts of transplant 
recipients yielded a total of 48 cases (Parravicini 
et al., 1997; Regamey et al., 1998; Francès et al., 
1999, 2000; Rabkin et al., 1999; Cattani et al., 2001; 
Emond et al., 2002; Marcelin et al., 2004; García-
Astudillo & Leyva-Cobián, 2006). No data were 
available from cohort studies on “classical” or 
“endemic” Kaposi sarcoma; to date, all studies 
have included only immunosuppressed subjects. 
Two studies used PCR to identify evidence of 
KSHV in peripheral blood mononuclear cells 
(PBMC) (Whitby et al, 1995; Moore et al., 1996b), 
most studies used serology, and one study used 
both (Engels et al., 2003). One study demon-
strated a statistically significant increasing risk 
of Kaposi sarcoma with increasing titre of anti-
bodies against KSHV, before diagnosis, both for 
a lytic and a latent assay (Newton et al., 2006).
Of the 80 case–control studies, nearly half 
included data on cases not infected by HIV – i.e. 
“classical,” “endemic”, and transplant-associ-
ated Kaposi sarcoma. A variety of assays were 
used to detect evidence of infection, including 
PCR of tumour lesions, semen, prostate tissue, 
saliva, and bronchial alveolar lavage. Serological 
studies used assays against lytic or latent anti-
gens, or both. Two studies (Sitas et al., 1999; 
Newton et al., 2003b) had substantial numbers 
of Kaposi sarcoma cases among HIV-uninfected 
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individuals and together with one other study 
(Albrecht et al., 2004) were able to demonstrate 
increasing risks of Kaposi sarcoma associated 
with increasing titres of anti-KSHV antibodies 
(Brown et al., 2006a, b). In addition, among 
KSHV-seropositive people, the presence of 
KSHV DNA in PBMC was associated both with 
an increased risk of Kaposi sarcoma, and with 
an increased risk of disease progression (Laney 
et al., 2007). Broadly, results were consistent 
across all studies, demonstrating a clear associa-
tion between infection with KSHV and Kaposi 
sarcoma.
2.2 Primary effusion lymphoma 
Primary effusion lymphoma is a very rare 
subgroup of B-cell non-Hodgkin lymphomas 
presenting as pleural, peritoneal, and pericardial 
(body cavity) lymphomatous effusions. These 
comprise less than 2% of HIV-related lymphomas 
(Sullivan et al., 2008). There is already strong 
evidence that KSHV is a causal agent of primary 
effusion lymphoma (IARC, 1997). Because of the 
rarity of primary effusion lymphoma, much of the 
information comes from case reports, with a few 
studies that have examined biopsy tissues, aspi-
rates or cell lines. Primary effusion lymphomas 
were described in HIV-immunosuppressed indi-
viduals by Cesarman et al. (1995a) in associa-
tion with KSHV, and by Nador et al. (1996) as a 
distinct disease entity, and almost all occurred 
in association with HIV (Gaidano et al., 2000). 
Because of the identification of KSHV in all of 
the cases presenting as primary lymphomatous 
effusions in early studies, the presence of this 
virus has been incorporated as a diagnostic crite-
rion for primary effusion lymphoma. However, it 
has since been recognized that other lymphoma 
subtypes such as Burkitt or diffuse large B-cell 
lymphoma can also present in body cavities, and 
these lack the presence of KSHV. In addition, some 
KSHV-positive lymphomas occur as solid tumour 
masses with or without accompanying effusions. 
However, KSHV-associated lymphomas have a 
multitude of morphological and immunophe-
notypical features that are characteristic, and so, 
have been grouped as a single clinicopathological 
entity. Cases without an effusion are considered 
to be extracavitary variants of primary effusion 
lymphoma (Said & Cesarman, 2008).
See Table 2.3 available at http://monographs.
iarc.fr/ENG/Monographs/vol100B/100B-04-
Table2.3.pdf, and Table 2.4 available at http://
monog r aphs . ia rc . f r/ ENG/Monog r aphs/
vol100B/100B-04-Table2.4.pdf.
Some primary effusion lymphomas occur in 
association with post-transplant immunosup-
pression (Kapelushnik et al., 2001). Many case 
reports show primary effusion lymphoma to be in 
association with Kaposi sarcoma or multicentric 
Castleman disease, both known to be caused by 
KSHV. Ascoli et al. (2001), for example, also iden-
tified four patients with multicentric Castleman 
disease and primary effusion lymphoma, all of 
which had evidence of KSHV DNA in pleural 
effusions. In a prospective cohort study of 60 
HIV-positive patients, three developed primary 
effusion lymphoma in association with multicen-
tric Castleman disease and/or Kaposi sarcoma, 
the latter conditions appear to be risk factors for 
the development of this disease (Oksenhendler 
et al., 2002). Komanduri et al. (1996) and 
numerous case reports (e.g. Ascoli et al., 1999a, b) 
described HIV-positive cases of primary effusion 
lymphoma that had evidence of KSHV infection. 
Likewise, four patients with primary effusion 
lymphoma and five cell lines were all reported to 
be KSHV-positive (Judde et al., 2000). Boulanger 
et al. (2005) identified 15 HIV-positive patients 
with primary effusion lymphoma, all of which 
were KSHV-positive. Of interest, in this study, six 
primary effusion lymphoma patients had neither 
Kaposi sarcoma nor multicentric Castleman 
disease. Asou et al. (2000) found KSHV to be 
present in 21/21 patients with primary effusion 
lymphoma, compared with 0/139 patients with 
other AIDS- and non-AIDS-related lymphomas, 
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and mucosa-associated lymphoid tissue (MALT) 
lymphomas.
During 1996–2008, a total of 95 subjects 
were identified in the literature as case reports. 
The majority of these were KSHV-positive and 
HIV-positive. Nineteen subjects were KSHV-
negative and HIV-negative; these were unusual 
in that all but three were elderly, seven of these 
were characterized by having had some form of 
genetic abnormality, three had cirrhosis (two of 
those were due to infection with the hepatitis C 
virus), two had some other idiopathic immuno-
deficiency, and one had a renal transplant. These 
cases do not fulfill the diagnostic criteria for 
primary effusion lymphoma (Said & Cesarman, 
2008), and probably represent another form of 
non-Hodgkin lymphoma involving body cavi-
ties. Primary effusion lymphoma has also been 
reported in people with no obvious immune 
suppression or HIV infection. See Table 2.5 
available at http://monographs.iarc.fr/ENG/
Monographs/vol100B/100B-04-Table2.5.pdf.
2.3 Multicentric Castleman disease
Strictly speaking, multicentric Castleman 
disease is not a cancer, but a rare polyclonal 
lymphoproliferative disease that can progress 
to plasmablastic lymphoma (Dupin et al., 2000). 
In addition, Oksenhendler et al. (2002) found 
that 14/60 HIV-infected patients with multicen-
tric Castleman disease developed non-Hodgkin 
lymphoma, three of which were primary effu-
sion lymphoma. Several studies have associated 
multicentric Castleman disease with KSHV. 
Multicentric Castleman disease was recognized 
in 1956 (Castleman et al., 1956), but appears to 
have increased in incidence as a result of the 
HIV epidemic, although multicentric Castleman 
disease in association with KSHV has also 
been documented in HIV-negative patients 
(Hernández et al., 2005).
Table 2.6 (available at http://mono-
g r a p h s . i a r c . f r / E N G / M o n o g r a p h s /
vol100B/100B-04-Table2.6.pdf) shows case 
series that have detected KSHV in patients with 
multicentric Castleman disease (Soulier et al., 
1995; Barozzi et al., 1996; Corbellino et al., 1996; 
Gessain et al., 1996). Several hospital-based 
studies have shown an association between KSHV 
and multicentric Castleman disease, irrespec-
tive of the way in which KSHV is detected and 
of differences in tissue type (Table 2.7 available 
at http://monographs.iarc.fr/ENG/Monographs/
vol100B/100B-04-Table2.7.pdf; Soulier et al., 
1995; Parravicini et al., 1997; Bélec et al., 1999a; 
Asou et al., 2000). For example, Soulier et al. 
(1995) found KSHV to be present in all 14/14 
HIV-positive cases and 7/17 HIV-negative cases 
compared with 1/34 controls. Treatment of three 
multicentric Castleman disease patients with 
ganciclovir, an inhibitor of KSHV lytic replica-
tion, has been reported to ameliorate multicen-
tric Castleman disease (Casper et al., 2004), while 
treatment with cidofovir, an inhibitor of KSHV 
DNA polymerase, was not effective (Corbellino 
et al., 2001; Berezne et al., 2004).
2.4 Multiple myeloma
A small number of early studies suggested a 
possible association between KSHV and multiple 
myeloma (Rettig et al., 1997; Said et al., 1997), 
but this was not confirmed by subsequent large 
well designed serology and PCR-based studies 
(see Table  2.8 available at http://monographs.
iarc.fr/ENG/Monographs/vol100B/100B-04-
Table2.8.pdf). In addition, the geographic distri-
bution of multiple myeloma is different from 
that of Kaposi sarcoma and of KSHV, strongly 
implying different etiologies (Cottoni & Uccini, 
1997; Globocan, 2008; Hjalgrim et al., 1998). [The 
Working Group noted that a map of the global 
distribution of Kaposi sarcoma was not available 
from Globocan 2008 because it is only possible 
to derive estimates for subSaharan African 
countries.]
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Several studies containing a clinical series of 
patients with multiple myeloma and a compar-
ison group of other hospital patients without 
monoclonal gammopathy of undetermined 
significance (MGUS, thought to be a precursor 
of multiple myeloma) or blood donors, have not 
found an association between markers of KSHV 
and multiple myeloma (Mackenzie et al., 1997; 
Marcelin et al., 1997; Masood et al., 1997; Rettig 
et al., 1997; Whitby et al., 1997; Agbalika et al., 
1998; Santarelli et al., 1998; Bélec et al., 1999b, c; 
Azzi et al., 2001; Beksac et al., 2001; Patel et al., 
2001; Santón Roldán et al., 2002; Zhu et al., 2002; 
Hermouet et al., 2003; Tsai et al., 2005). Rettig 
et al. (1997) reported the presence of KSHV 
sequences using PCR in all 15 of the patients with 
multiple myeloma, in 2/8 cases with MGUS, and 
in 0/26 control patients. [The Working Group 
noted that the majority of studies are based on 
series of hospital patients which are compared 
to a series of hospital patients admitted with 
several unrelated conditions or to blood donors 
(or both), and therefore the comparison group 
may not have been adequate. Most studies were 
typically small in size and did not adjust for age.]
Some of these studies were also reviewed by 
Tarte et al. (1998, 1999), and many used several 
serological assays against KSHV LANAs. In two 
of these studies (Agbalika et al., 1998; Bélec et al., 
1999b), 0/25 cases of multiple myeloma was sero-
positive versus 0/25 in controls. Neither of these 
studies attempted to account for age (through 
matching or adjusting the data).
The biological significance of some of the 
clinical series, especially those using small PCR 
fragments has been questioned by Zong et al. 
(2007). Four studies (Schönrich et al., 1998; 
Sitas et al., 1999; Tedeschi et al. 2001, 2005) had 
age-matched controls or were based on a case–
control/comparison design (Sitas et al., 1999), or 
had a case–control study design nested within 
a cohort (Tedeschi et al., 2001, 2005) (see Table 
2.9 available at http://monographs.iarc.fr/ENG/
Monographs/vol100B/100B-04-Table2.9.pdf). 
Schönrich et al. (1998) found KSHV lytic anti-
bodies were present in 4/99 multiple myeloma 
patients versus 2/67 controls. Sitas et al. (1999) 
measured the age- and gender-adjusted KSHV 
immunofluorescence assay seropositivity in 108 
black South African incident cancer patients with 
newly diagnosed multiple myeloma compared 
with 3185 cancer patients and 85 blood donors. 
The age- and gender-adjusted KSHV sero-
prevalence in multiple myeloma patients versus 
controls was, respectively, 24% versus 32%.
Tedeschi et al. (2001) measured the seroprev-
alence of KSHV in 47 multiple myeloma cases 
and 224 age-matched controls from a cohort of 
20243 men and 18814 women recruited between 
1968–72, and followed until the end of 1991 
through the Finnish Cancer Registry. Odds ratios 
(age-adjusted) for KSHV and multiple myeloma 
were calculated using IFA lytic antibodies (OR, 
2.02; 95%CI: 0.94–4.33; latent OR, 10.0; 95%CI: 
0.91–110.3), and Western blot confirmation (any 
one of ORF 65, 73 and K8.1A; OR, 0.89; 95%CI: 
0.25–3.25); none of the associations was found 
to be statistically significant. In another nested 
case–control study, Tedeschi et al. (2005) identi-
fied 329 cases of multiple myeloma, and matched 
these to 1631 controls, matched for age and 
gender. The cases and controls arose from about 
1133000 individuals from several Nordic cohorts 
who had donated blood samples. Seropositivity 
was 12% in multiple myeloma subjects versus 
15% in control subjects. No association was found 
between multiple myeloma and KSHV lytic (OR, 
0.8; 95%CI: 0.5–1.1), or latent antibody levels 
(OR, 0.6; 95%CI: 0.1–2.7). [The Working Group 
noted that after stratifying by detection method 
(PCR, LANA or lytic antibodies), no significant 
differences in the percent KSHV positivity were 
observed between multiple myeloma cases and 
controls when the Working Group used χ2 tests 




Sitas et al. (1999) measured the seroprevalence 
of KSHV in 16 major cancer types, including 
Kaposi sarcoma and multiple myeloma. As 
expected, the seroprevalence of KSHV among 
people with Kaposi sarcoma was greater than 
80%; among people with all other cancers (oral 
cavity, oesophagus, lung, stomach, liver, colon/
rectum, breast, cervix, prostate, non-Hodgkin 
lymphoma, Hodgkin disease, leukaemia, 
myeloma, other minor types [where n < 50 in each 
cancer type]), the seroprevalence was similar to 
the general population (about 20–30%). Several 
studies have examined the presence of KSHV 
sequences in various other cancers but the results 
are inconclusive. These include mesenchymal 
tumours (1/76 cases KSHV-positive) (Kazakov 
et al., 2002), and other lymphomas (e.g. Lazzi 
et al., 1998, 2006; de Sanjosé et al., 2004). A case 
series was reported suggesting an association with 
large-cell immunoblastic lymphomas (Hansen 
et al., 2000), but this has not been confirmed. 
No associations were found between KSHV 
and cancer of the prostate in several cohort and 
case–control studies (Sitas et al., 1999; Huang 
et al., 2008), however, one case–control study did 
present a significant inverse association (Sutcliffe 
et al., 2007). KSHV has not been detected in sali-
vary gland tumours (Atula et al., 1998), despite 
the fact that KSHV is thought to be transmitted 
via saliva.
2.6 Kaposi sarcoma and cofactors
Infection with KSHV alone is not sufficient 
to cause Kaposi sarcoma. The most important 
cofactor predisposing a KSHV-infected person 
to Kaposi sarcoma is HIV co-infection or, to a 
lesser extent, other immunodeficient states such 
as iatrogenic immune suppression in organ 
transplant recipients (IARC, 1997). Nonetheless, 
the incidence of Kaposi sarcoma in specific 
geographic areas before the HIV epidemic 
points to a role of as-yet-unknown cofactors in 
the etiology of this cancer (Dedicoat & Newton, 
2003).
2 .6 .1 Suspected unknown cofactors
Before the HIV epidemic, Kaposi sarcoma 
had a much greater geographic variation in inci-
dence than most other malignancies. Classic 
(sporadic) Kaposi sarcoma occurred but was rare 
in countries around the Mediterranean, particu-
larly in Italy, Greece, and the Middle East, and 
was almost non-existent elsewhere in Europe 
and in the USA, except in immigrants from these 
countries (Grulich et al., 1992; IARC, 1997). In 
contrast, it represented up to 9% of all cancers in 
parts of subSaharan Africa, such as Uganda, in 
both men and women (Oettlé, 1962; D’Oliveira 
& Torres, 1972; Templeton, 1981; Hutt, 1983; 
Cook-Mozaffari et al., 1998; Dedicoat & Newton, 
2003). KSHV infection is prevalent in many 
African countries, including places where Kaposi 
sarcoma was almost unknown before HIV, and 
is as common in women as in men (Dedicoat & 
Newton, 2003). However, the incidence of clas-
sical Kaposi sarcoma varied markedly across 
the African continent, primarily affecting men 
(Cook-Mozaffari et al., 1998).
Several exposures have been suggested as 
possible cofactors for diseases that might explain 
the geographic variation in incidence before the 
HIV epidemic, both in Africa and elsewhere. 
These include malaria and other parasitic infec-
tions (Serraino et al., 2003; Lin et al., 2008); fine 
volcanic soils, which are posited to cause local-
ized immunosuppression in the lower limbs 
(Ziegler, 1993); and exposure to specific plants, or 
“onco-weeds” that might increase viral replica-
tion (Whitby et al., 2007). Although the existence 
of cofactors is not disputed, for none of these is 
the evidence sufficiently strong to conclude that 
there is a definite increase in risk.
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2 .6 .2 HIV infection as a strong cofactor
In parts of Africa where Kaposi sarcoma was 
relatively common even before the era of HIV, 
the HIV epidemic has led to an explosion in the 
incidence of the disease (Curado et al., 2007). In 
the mid-1990s, the incidence of Kaposi sarcoma 
increased about 20-fold in Uganda, Zimbabwe, 
and other subSaharan African countries, such 
that it is now the most common cancer in 
men, and the second most common in women 
(Wabinga et al., 1993, 2000; Bassett et al., 1995; 
Dedicoat & Newton, 2003). As a result of the 
HIV epidemic, the incidence of Kaposi sarcoma 
has also increased in countries where it was 
previously relatively rare, but where KSHV was 
prevalent. For example, during 1988–96, the 
incidence of Kaposi sarcoma increased at least 
3-fold in South Africa, and has continued to 
increase as the HIV epidemic grows. Data from 
Johannesburg, South Africa, show that incidence 
rates of Kaposi sarcoma have doubled in men, 
but have increased 7-fold in women, such that 
the gender ratio of 7:1 in males versus females 
in 1988 has now declined to only 2:1 (Sitas & 
Newton, 2001). [The Working Group noted that 
this is an artefact of Kaposi sarcoma incidence 
being higher in men.] Therefore, in the presence 
of HIV infection, the role of other etiological 
cofactors may be less relevant for the develop-
ment of Kaposi sarcoma than before the spread 
of HIV (Dedicoat & Newton, 2003).
2 .6 .3 Host genetic susceptibility
Host genetic variation has been investigated 
in the etiology of Kaposi sarcoma. In particular, 
emphasis has been placed on genes that may be 
relevant to the modulation of host immunity 
against KSHV (Brown et al., 2006a, c; Alkharsah 
et al., 2007), but data in this area remain sparse. 
More recent evidence suggests that variations in 
the viral genome itself may also be of relevance, 
but currently the findings are inconclusive 
(Mancuso et al., 2008).
3. Cancer in Experimental Animals
In this volume, the Working Group decided 
not to include a separate section on “Cancer in 
Experimental Animals” in the Monographs on 
viruses but rather to include description of such 
studies under Section 4 (below). The reasoning 
for this decision is explained in the General 
Remarks.
4. Other Relevant Data
4.1 Transforming capacity of KSHV
Transformation is a multistep process and 
KSHV infection has been shown to induce most 
steps along this progression: a) KSHV infec-
tion of primary human endothelial cells leads to 
morphological alteration and reduced growth-
factor dependence (Ciufo et al., 2001); b) KSHV 
infection of immortalized human endothelial 
cells leads to extended survival, loss of contact 
inhibition, growth-factor and anchorage inde-
pendence (Flore et al., 1998; Moses et al., 1999; 
Wang & Damania, 2008), and the outgrowth 
of fully tumorigenic clones (An et al., 2006); c) 
KSHV transforms murine endothelial progen-
itor cells (Mutlu et al., 2007).
KSHV infection cannot transform mature 
human B cells in culture (Kliche et al., 1998). 
However, this may be due to low infectivity and/
or the absence of susceptible cell populations 
under routine culture conditions, which do not 
support the growth of haematopoietic cells. Yet, 
KSHV is clearly required for continued survival 
of primary effusion lymphoma cells in culture 
(Guasparri et al., 2004; Godfrey et al., 2005)
Individual KSHV proteins exhibit trans-
forming capacity in experimental systems (see 




4.2 Biochemical and biological 
properties of KSHV proteins
Several latent or lytic viral proteins are 
involved in the carcinogenesis process of KSHV 
(see Table 4.1).
Five KSHV proteins (K1/VIP, vGPCR, 
vIRF-1, Kaposin A, LANA) have been reported to 
have transforming properties in classical trans-
formation assays, others (vCYC, LANA, KbZIP) 
have been shown to affect cell-cycle regulation 
or the survival of tumour cells in vivo or in vitro 
(vFLIP, vIL6, vIRF-3). Because only some of 
these proteins are expressed during latency and 
in the majority of tumour cells, not only ‘direct’ 
transformations (as in classical models of virus-
mediated cellular transformation) but also indi-
rect (paracrine) effects are thought to play a role 
in KSHV-mediated oncogenesis (Ganem, 2007).
4 .2 .1 Latent KSHV proteins
(a) LANA/ORF 73
LANA, encoded by ORF 73, is expressed 
during latency and represents the most consist-
ently detected viral protein in KSHV-associated 
tumour cells (Rainbow et al., 1997; Dupin et al., 
1999; Katano et al., 2000; Parravicini et al., 2000). 
LANA is necessary for replicating the episomal 
viral DNA; it binds to the latent origin of repli-
cation in the TR subunits of the viral genome, 
and works by recruiting a large variety of cellular 
interaction partners, among them components 
of the chromosomal replication machinery such 
as origin recognition complexes (ORCs), but 
also cellular proteins linked to transcriptional 
regulation or proliferation control (see Table 4.1; 
reviewed in Verma et al., 2007).
Of relevance to a possible direct role of LANA 
in oncogenesis are the observations that LANA: 
(i) inactivates p53-dependent transcriptional 
activation (Friborg et al., 1999); (ii) interacts 
with pRB and enhances oncogenic ras-mediated 
transformation of rodent fibroblasts (Radkov 
et al., 2000); (iii) absorbs GSK-3β and thereby 
reduces the phosphorylation of, thus stabilizing, 
β-catenin (Fujimuro et al., 2003); (iv) interacts 
with Brd2/RING3, a chromatin-binding protein 
and a lymphomagenic member of the BET 
protein family (Platt et al., 1999; Viejo-Borbolla 
et al., 2005); (v) causes B-cell hyperplasia and 
B-cell lymphoma when expressed in transgenic 
mice (Fakhari et al., 2006).
(b) vCYC/ORF 72
In-situ hybridization studies indicate that 
the KSHV CYC/ORF 72 gene is expressed in 
the majority of tumour cells in vivo (Davis 
et al., 1997), in keeping with its classification as 
a latent gene. v-CYC represents another candi-
date KSHV oncoprotein because of its homology 
to the human Cyclin-D/Prad oncoprotein. In 







with specific cyclin-dependent kinases (CDKs), 
and these complexes phosphorylate pRB family 
members (reviewed in Sherr, 1996). An onco-
genic cyclin-D homologue is also present in other 
gammaherpesviruses (reviewed in Neipel et al., 
1997). Ectopic expression of the murine herpes-
virus 68 (MHV 68) cyclin in T cells causes T-cell 
lymphomas in transgenic mice (van Dyk et al., 
1999).
The mechanism of transformation by KSHV 
vCYC is most likely novel and unique, because 
it phosphorylates pRb but, unexpectedly, also 
histone H1, p27KIP1, and Bcl-2 (Chang et al., 1996; 
Godden-Kent et al., 1997; Li et al., 1997; Ojala 
et al., 2000). Unlike human cyclin-D, vCYC/
CDK6-mediated phosphorylation of pRB is 
resistant to inhibition by the cyclin-dependent 
kinase-inhibitors (CDKIs) p16INK4, p21CIP1, and 
p27KIP1 (Swanton et al., 1997). Moreover, vCYC/
CDK6 induces the degradation of p27KIP1 (Ellis 


































K1/VIP a ORF K1 May increase/
decrease viral 
reactivation




Blocks intracellular transport 







Lee et al. (1998a, b, 
2000), Lagunoff et al. 
(1999, 2001), Prakash et 
al. (2002), Tomlinson & 
Damania (2004), Wang 
et al. (2004a, 2006)





ORF 4 Inhibits complement 
activation by virions 
or virus-infected 
cells
Cofactor for complement 
factor I;  
Accelerates the decay of C3 
convertases
Lytic Mullick et al. (2003), 
Spiller et al. (2003), 
Mark et al. (2004)
vIL6 Interleukin-6 
(IL6) homologue





Lytic Tumour cell 
survival in vivo 
and in vitro 
Angiogenesis 
Haematopoiesis
Moore et al. (1996a), 
Burger et al. (1998), 
Aoki et al. (1999), 
Aoki & Tosato (1999), 
Hoischen et al. (2000), 
Kovaleva et al. (2006)
K3/MIR-1/ 
ZMP-B
ORF K3 Downmodulates 
HLA, ICAM-1, B7.2
E3 ubiquitin ligase Lytic Immune evasion Coscoy & Ganem 
(2000), Ishido et al. 
(2000), Coscoy et al. 
(2001), Cadwell & 















Boshoff et al. (1997), 
Dairaghi et al. (1999), 
Endres et al. (1999), 
Nakano et al. (2003)
vCCL-3/ 
vMIP-III
Some homology to 
chemokines TARC 
and eotaxin
ORF K4.1 Viral chemokine CCR4, XCR1 agonist Lytic Angiogenic 
properties
Nicholas et al. (1997), 
Stine et al. (2000), 
Lüttichau et al. (2007)








E3 ubiquitin ligase Lytic Immune evasion Ishido et al. (2000), 














































Nicholas et al. (1997), 
Boshoff et al. (1997), 
Nakano et al. (2003)
K7/ vIAP Structurally 
related to a splice 
variant of survivin
ORF K7 Apoptosis inhibitor Binds to and inhibits 
several proteins involved in 
apoptosis (see Table 4.2) 




Feng et al. (2002, 2004, 
2008), Wang et al. 
(2002)




Sarid et al. (1997)




Lytic Polson et al. (2001), 
Hamza et al. (2004), 
Izumiya et al. (2007)
ORF 45 ORF 45 Virion protein 




of type 1 interferon
Binds to and inhibits 
phosphorylation of IRF-7
Lytic Viron infectivity 
Immune evasion
Zhu et al. (2002a, 2006), 
Zhu & Yuan (2003)
K-RTA ORF 50 Immediate-early 
transactivator 
Ubiquitin E3 ligase
Binds to and activates several 
lytic viral promoters directly 
or by interacting with RBPJk 
Promotes ubiquitination and 
degradation of IRF7 
Represses p53
Lytic Reactivation 






Sun et al. (1998), 
Gradoville et al. (2000), 
Gwack et al. (2001), 
Lukac et al. (2001), 
Liang & Ganem (2003 ), 
Yu et al. (2005)
K-bZIP ORF K8 Modulates cell 
cycle and lytic 
reactivation
EBV Zta homologue; 
Binds to lytic replication 
origin;  
Binds to, antagonizes, and 
recruits p53 to ND10/PML 
bodies; 
Inhibits G1/S transition; 
Co-regulator of K-RTA
Lytic Deregulation of 
cell cycle
Lin et al. (1999, 2003), 
Park et al. (2000), 
Katano et al. (2001), 
Izumiya et al. (2003a, b)


































ORF 57 Exports intronless 




Required for the 
formation of viral 
progeny
Binds to intronless viral 
mRNA; 
Recruits hTREX complex
Lytic Malik et al. (2004), 
Nishimura et al. (2004), 
Majerciak et al. (2007), 









activity and prevents p53-
dependent apoptosis





Gao et al. (1997), 
Burýsek et al. (1999), 
Lin et al. (2001), 
Nakamura et al. (2001), 











ORF K10.5 Modulates viral 
interferon responses
Modulates p53 function; 











Rivas et al. (2001), 
Cunningham et al. 
(2003), Lubyova et al. 
(2004, 2007), Wies et al. 
(2008, 2009)
vIRF-2 Interferon factor 
homologue
ORF K11 Inhibits interferon induction; 
Inhibits induction of CD95L
Lytic Immune evasion 
Anti-apoptotic 
activity
Burýsek & Pitha 
(2001),.Kirchhoff et al. 
(2002), Fuld et al. (2006)





Zhong et al. (1996), 
Muralidhar et al. 
(1998),.Sadler et al. 
(1999), Kliche et al. 
(2001), Tomkowicz et al. 
(2005)











Sadler et al. (1999), 
McCormick & Ganem 
(2005, 2006)


































involved in B-cell 
differentiation)
miRK-11 regulates similar 








Cai et.al.2005), Pfeffer et 
al.(2005), Samols et al. 
(2005, 2007), Grundhoff 
et al. (2006), Skalsky et 
al. (2007), Gottwein et 
al. (2007)














induced apoptosis, anoikis, 
superoxide-induced cell 
death; 
 Modulates MHC-I 
expression




Keller et al. (2000), 
Grundhoff & Ganem 
(2001), An et al. (2003), 
Field et al. (2003), Sun 
et al. (2003), Guasparri 
et al. (2004, 2006), 
Grossmann et al. (2006), 
Lagos et al. (2007), 
.Matta et al. (2007), Ye 
et al. (2008), Efklidou et 










Phosphorylates H1, pRB, 
BCL-2, p27KIP1 in tandem 
with CDK6
Latent Deregulation of 
cell cycle
Chang et al. (1996), 
Godden-Kent et al. 
(1997), Li et al. (1997), 
Swanton et al. (1997), 
Ellis et al. (1999), Mann 
et al. (1999), Ojala et 
al. (2000), Sarek et al. 
(2006), Koopal et al. 
(2007)
































LANA ORF 73 Replication and 
maintenance of 




Interacts with histones, p53, 
pRB, BET proteins, GSK-3β 
and others; 











properties in cells 
Tumorigenicity in 
mice
Rainbow et al. (1997), 
Ballestas et al. (1999), 
Friborg et al. (1999), 
Platt et al. (1999), 
Radkov et al. (2000), 
Ballestas & Kaye 
(2001), Hu et al. (2002), 
Fujimuro et al. (2003), 
Watanabe et al. (2003), 
Verma et al. (2004), Hu 
& Renne (2005), Viejo-
Borbolla et al. (2005), 
Fakhari et al. (2006), 
Ottinger et al. (2006)
vOX2 OX2 homologue ORF K14 Modulates 
inflammatory and 
T-cell responses
Activates or downregulates 
myeloid lineage cells in a 
CD200-like manner
Lytic Chung et al. (2002), 
Foster-Cuevas et al. 
(2004)
vGCR Homologue of 
G-protein-coupled 
receptor
ORF 74 Stimulates cellular 
proliferation
Activates Akt, MEK/Erk, 
JNK, p38;  
Induces angiogenic cytokines
Lytic Transforming 






Arvanitakis et al. 
(1997), Bais et al. (1998), 
Yang et al. (2000), Holst 
et al. (2001), Montaner 
et al. (2001, 2003), Guo 
et al. (2003), Mutlu et al. 
(2007), Nicholas (2007) 
(review)
K15 proteina ORF K15 Recruits endothelial 
cells to infected cells
Activates NF-κB, MEK/Erk;  
Induces inflammatory 
cytokines;  
Interacts with proteins 
involved in signal 
transduction (e.g. TRAFs 1, 
2, 3), with members of src 
family of PTK, and with an 










Glenn et al. (1999), Choi 
et al. (2000), Sharp et al. 
(2002), Brinkmann et al. 
(2003, 2007), Wang et 
al. (2007)
a protein unique to KSHV
Compiled by the Working Group
Table 4 .1 (continued)
Kaposi sarcoma herpesvirus
(c) vFLIP/ORF 71
vFLIP/ORF 71 is transcribed from the LANA 
promoter, and translated from an internal ribo-
some entry site located within the v-cyclin coding 
region (Grundhoff & Ganem, 2001; Low et al., 
2001). It is therefore thought to be expressed 
during latency and in all tumour cells. The 
vFLIP protein is an adhesion molecule, a homo-
logue of cellular FLICE (caspase-8)-inhibitory 
protein (FLIP) (Hu et al., 1997). It inhibits CD95/
FAS-induced apoptosis in vitro by blocking 
caspase-3, -8 and -9 (Djerbi et al., 1999).
vFLIP directly binds IKKγ and TRAF2; this 
leads to a constitutive activation of NF-κB signal-
ling (Field et al., 2003; Guasparri et al., 2006). 
In addition, vFLIP induces MHC-I expression 
through NF-κB in KSHV-infected lymphatic 
endothelial cells (Lagos et al., 2007), which 
underscores the physiological importance of 
the vFLIP–NF-κB interaction. Moreover, vFLIP 
transgenic mice develop lymphoma (Chugh 
et al., 2005). Eliminating either vFLIP or NF-κB 
activity from primary effusion lymphoma cells 
induces apoptosis (Keller et al., 2000; Guasparri 
et al., 2004), demonstrating that this pathway is 
essential for lymphomagenesis.
(d) Kaposin A/ORF K12
The many transcripts spanning the predicted 
K12 ORF (originally called T0.7) are translated 
in different reading frames, giving rise to the 
proteins kaposin A, B, C (Zhong et al., 1996; 
Sadler et al., 1999). In addition, a long tran-
script extending through ORF K12 represents 
the precursor RNA for the KSHV microRNAs 
(Cai et al., 2005; Pfeffer et al., 2005; Samols et al., 
2005). One of these microRNAs, miRK-10, is 
located within the kaposin A sequence. These 
transcripts are expressed in all Kaposi sarcoma 
spindle cells (Staskus et al., 1997; Stürzl et al., 
1997), and increase after activation of the lytic 
replication cycle.
Muralidhar et al. (1998) reported that trans-
fection of the kaposin A reading frame into Rat-3 
cells induced focus formation, and that these 
cell lines were tumorigenic in nude mice. There 
is some discussion as to whether this is due to 
the kaposin A protein or the miR-K10 located 
within its sequence. Kaposin A interacts directly 
with Cytohesin-1, a guanine nucleotide exchange 
factor for ARF GTPases, and a regulator of inte-
grin-mediated cell adhesion. It was shown that 
the transformed cellular phenotype induced by 
Kaposin A in tissue culture could be reversed by 
a functionally dead Cytohesin-1 mutant (Kliche 
et al., 2001).
(e) vIRF-3/LANA-2
vIRF-3, one of the viral homologues of 
interferon regulatory factors, is constitutively 
expressed in latently KSHV-infected cells, and 
its expression appears to be tissue specific. 
vIRF-3 is indeed detected in nearly all primary 
effusion lymphoma cells and KSHV-associated 
Castleman disease cells (both of B-lymphocyte 
origin), but is not expressed in Kaposi sarcoma 
tumours (endothelial origin) (Rivas et al., 2001).
vIRF-3 binds to and antagonizes p53, and 
affects the regulation of the interferon response 
(see Table 4.1).
Knockdown of vIRF-3 in primary effusion 
lymphoma cells has been shown to induce apop-
tosis, suggesting that vIRF-3 is required for the 
survival of KHSV-infected B cells (Wies et al., 
2008).
4 .2 .2 Lytic KSHV proteins
(a) K1/VIP (variable, ITAM-containing protein)
K1/VIP is a viral type I transmembrane 
protein, featuring two hypervariable domains 
in its extracellular region, and an immuno-
globulin transactivation motif (ITAM) in its 
C-terminal, cytoplasmic region (Lee et al., 
1998b). The K1 protein is expressed during the 
lytic (productive) replication cycle (Jenner et al., 
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2001; Paulose-Murphy et al., 2001; Nakamura 
et al., 2003). Wang et al. (2006) reported that, 
while expression of K1 is not a consistent feature 
of Kaposi sarcoma, some Kaposi sarcoma biop-
sies show a marked K1-expression both at the 
transcript and protein level. K1-expression was 
also documented by immunohistochemistry on 
a small subpopulation of mantle zone lympho-
cytes of KSHV-positive multicentric Castleman 
disease, and in primary effusion lymphoma cell 
lines (Lee et al., 2003).
Lee et al. (1998a) showed that transfec-
tion of a K1-expression vector into rodent 
fibroblasts induced focus formation, and that 
K1-transfectants induced lymphoma in the 
common marmoset. Prakash et al. (2002) 
reported the emergence of sarcomatoid tumours 
and plasmablastic lymphoma in transgenic mice 
expressing the K1 protein under the control of an 
SV40 promoter. These mice showed an increased 
expression of bFGF; in transgenic B cells, a 
constitutive activation of NF-κB and increased 
c-Lyn activity was noted. Wang et al. (2006) 
showed that retroviral transduction of primary 
endothelial cells extended their life span.
K1 activates several intracellular signal-
ling cascades leading to increased Ca-influx, 
increased phosphorylation of Syk, Vav, Cbl, 
and the p85 subunit of PI3K, increased NF-κB 
activity, and activation of NFAT and AP1 (Lee 
et al., 1998b; Lagunoff et al., 1999, 2001). The acti-
vation of PI3K leads to the activation of AKT by 
K1 (Tomlinson & Damania, 2004). K1 induces 
the expression of angiogenic cytokines, including 
vascular endothelial growth factor (VEGF), and 
may therefore play a paracrine role in the patho-
genesis of Kaposi sarcoma or primary effusion 
lymphoma (Wang et al., 2004a, 2006).
(b) vIRF-1/ORF K9
vIRF-1 belongs to a group of four viral 
homologues of interferon regulatory factors 
(Russo et al., 1996; Cunningham et al., 2003). 
Stable vIRF-1 transfectants in murine NIH 
3T3 cells show signs of transformation (loss 
of contact inhibition, growth in soft agar), and 
cause tumours in nude mice (Gao et al., 1997). 
The main function of vIRF-1 appears to be the 
inhibition of interferon-β-regulated genes such 
as p21CIP1 (Gao et al., 1997); it also inhibits the 
induction phase of the interferon response by 
binding to cellular IRFs (IRF-3, IRF-7), and to the 
transcriptional co-activators p300 and CBP, and 
inhibits the formation of functional IRF-3/CBP/
p300 complexes and the induction of interferon 
β transcription (Gao et al., 1997; Burýsek et al., 
1999; Seo et al., 2000; Lin et al., 2001). Unlike 
cellular IRFs, vIRF-1 does not bind directly to 
cellular DNA.
vIRF-1 is expressed during the lytic (produc-
tive) replication in tissue culture and is directly 
transactivated by K-RTA, the central regulator of 
the viral lytic programme (Gao et al., 1997; Chen 
et al., 2000).
(c) vGPCR /ORF 74
ORF 74 encodes a homologue of a G-protein-
coupled chemokine receptor, and is constitutively 
active (reviewed in Nicholas, 2007). It activates 
a broad range of signalling pathways, including 
MEK/Erk, JNK, p38, Akt, NFAT, CREB, NF-κB, 
AP-1, and HIF-1α; these are relevant to the 
promotion of cell proliferation, cell survival, and 
angiogenic responses via cytokine gene induction 
(reviewed in Nicholas, 2007; Hartmann, 2008). 
Although constitutive, the activity of vGPCR can 
be modulated both positively and negatively by 
several cellular chemokines (Groα, IL8, IP-10, 
SDF-1α), and one viral (vCCL-2) chemokine 
(reviewed in Hartmann, 2008).
Multiple lines of evidence point to a role of 
vGPCR in KSHV-induced neoplasia, in particular 
Kaposi sarcoma. Early studies showed the prolif-
eration-enhancing, constitutive signalling, and 
transforming properties of vGPCR (Arvanitakis 
et al., 1997; Bais et al., 1998). Subsequently, 
vGPCR was shown to cause Kaposi-sarcoma-
like tumours in transgenic mice (Yang et al., 
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2000). In this model, vGPCR was only expressed 
in a few scattered cells, consistent with a parac-
rine model involving secretion of angiogenic 
cytokines (Holst et al., 2001; Guo et al., 2003; 
Montaner et al., 2003).
In a xenograft model, vGPCR involving a 
KSHV-transfected murine endothelial cell line 
was found to be required for tumorigenicity 
(Mutlu et al., 2007). The relevance of these results 
to KSHV-associated tumours in humans remains 
to be determined.
4 .2 .3 Genomic instability
Evidence of genomic instability has been 
noted in primary effusion lymphoma cells 
(microsatellite instability, chromosomal imbal-
ances) (Gaidano et al., 1997; Nair et al., 2006), 
and late Kaposi sarcoma (Pyakurel et al., 2006). 
Experimentally, genomic instability has been 
noted in KSHV-infected primary endothelial 
cells (Pan et al., 2004), as well as in cell lines 
stably transfected with LANA (Si & Robertson, 
2006), and vCYC-transgenic mice (Verschuren 
et al., 2004). Abnormal chromosome segrega-
tion in KSHV-infected cells was shown to be 
the consequence of nucleophosmin (NPM1) 
phosphorylation by CDK6 in concert with vCYC 
(Cuomo et al., 2008).
4 .2 .4 DNA-damage response
Transduction of vCYC into primary endothe-
lial cells by a retroviral vector induces a DNA 
damage response, resulting in the increased 
phosphorylation of γH2AX (a variant form of 
histone H2A), which is an early response to DNA 
double-strand breaks. Increase of γH2AX phos-
phorylation was also shown in KSHV-infected 
primary endothelial cells, albeit only after 2 weeks 
of culture (in spite of vCYC being expressed early 
on) (Koopal et al., 2007). Other KSHV proteins 
might therefore interfere with the triggering of 
the DNA-damage response.
Shin et al. (2006) reported that vIRF-1 
prevents the DNA-damage response and γH2AX 
and p53 phosphorylation by binding to and 
inhibiting ATM kinase, thereby promoting p53 
turnover. As noted above, vIRF-1 and LANA 
interact with p53 and antagonize the transcrip-
tion of p53-dependent cellular genes, including 
p21CIP1 (Gao et al., 1997; Friborg et al., 1999). 
In KSHV-infected primary effusion lymphoma 
cells, vIRF-3 also binds to p53 and inhibits the 
activation of the p53 promoter (Rivas et al., 2001). 
In primary effusion lymphoma cells, LANA, p53 
and Hdm2 form a trimeric complex (Sarek et al., 
2007), and the restoration of the p53 function by 
treatment with an inhibitor of the p53-Hdm2 
interaction – Nutlin-3a – induces apoptosis in 
primary effusion lymphoma cells (Petre et al., 
2007; Sarek et al., 2007).
Most reports have concluded that the inhi-
bition of p53-activated cellular genes by LANA, 
vIRF-1, and vIRF-3 involves other mechanisms 
than the degradation or increased turnover of 
p53. However, one report showed that the recruit-
ment of the Cul5-Elongin BC E3 ligase complex 
by LANA resulted in the degradation of p53 (Cai 
et al., 2006).
4 .2 .5 Cell proliferation and differentiation
KSHV-infected primary endothelial cells 
undergo spindle cell formation, which express 
markers of the lymphatic endothelium. Gene 
expression array studies have shown that KSHV 
can alter the transcriptome profile of vascular 
endothelial cells towards a profile that is typical 
for lymphatic endothelial cells (Carroll et al., 
2004; Hong et al., 2004; Wang et al., 2004b). This 
involves the activation of Prox-1, a transcription 
factor determining lymphatic endothelial cell 
differentiation, followed by the increased expres-
sion of podoplanin and VEGFR-3 – markers for 
the lymphatic endothelial cell lineage (Carroll 
et al., 2004; Hong et al., 2004). The signalling 
pathways gp130 (the β-chain of the IL6 receptor 
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used by vIL6) as well as PI3K/Akt and JAK2/
STAT3 have been reported to be involved in the 
induction of Prox-1 in KSHV-infected endothe-
lial cells (Morris et al., 2008).
These data raise the possibility that KSHV 
infects blood or circulating endothelial cells, and 
drives them to differentiate into the lymphatic 
endothelium as they become spindle cells. This 
may be of major importance to Kaposi sarcoma 
tumour formation (Morris et al., 2008).
The adoption of a spindle morphology in 
KSHV-infected cells is thought to be due to vFLIP, 
a homologue of cellular FLIPs, and potent NF-κB 
inducer; vFLIP is expressed in latently infected 
endothelial cells, and NF-κB activation appears 
to be required for the formation of spindle cells 
(Grossmann et al., 2006; Sun et al., 2006). vFLIP 
is also required essentially for primary effusion 
lymphoma cell survival (see Section 4.2.1).
The viral IL6 homologue, vIL6, is expressed 
in vivo in a subpopulation of primary effusion 
lymphoma cells and in many KSHV-infected 
B cells in multicentric Castleman disease 
lymphoid follicles (Moore et al., 1996c; Katano 
et al., 2000; Parravicini et al., 2000). It induces 
proliferation, angiogenesis, and haematopoesis 
in IL6-dependent cell lineages (Burger et al., 
1998; Aoki et al., 1999; Hoischen et al., 2000), and 
serves as an essential autocrine factor in primary 
effusion lymphoma cell lines (Jones et al., 1999). It 
also induces VEGF, which has been implicated in 
the pathogenesis of primary effusion lymphoma 
and of Kaposi sarcoma (Aoki & Tosato, 1999). A 
single-chain antibody to vIL6, blocking its inter-
action with the IL6 receptor complex, was found 
to inhibit the proliferation of a primary effusion 
lymphoma cell line and to inhibit vIL6-induced 
STAT 3 phosphorylation in vIL6-transfected 
cells (Kovaleva et al., 2006). Therefore, vIL6 may 
contribute to primary effusion lymphoma cell 
proliferation and to the angiogenesis noted in 
patients with this lymphoma.
Also, the viral D-type cyclin homologue 
vCYC and LANA each contribute to cell prolif-
eration (see Section 4.2.1)
One of the viral latent transcripts in primary 
effusion lymophoma cells, miRNA-K12–11, has 
been found to target the same cellular micro-
RNAs as miRNA-155, a cellular microRNA regu-
lating the germinal centre reaction during B-cell 
maturation (Gottwein et al., 2007; Skalsky et al., 
2007; Thai et al., 2007). Both miRNA-K12-11 and 
miR-155 downregulate several pro-apoptotic 
cellular genes (see Table 4.2). miRNA-K12–11 may 
therefore be involved in blocking terminal B-cell 
differentiation that contributes to the plasmab-
lastic phenotype of primary effusion lymphoma 
cells or play a role in the protection of primary 
effusion lymphoma cells against apoptosis.
These findings highlight how KSHV can 
affect the differentiation of endothelial cells and 
of B cells.
vIRF3, an interferon regulation factor homo-
logue, is required for primary effusion lymphoma 
cell survival (Wies et al., 2008).
Ablation of the human cytokines IL-6, IL-10, 
and VEGF or of VEGFR inhibits the growth of 
primary effusion lymphoma and Kaposi sarcoma 
(Masood et al., 1997; Nakamura et al., 1997; Aoki 
& Tosato, 1999; Arora et al., 1999; Jones et al., 
1999; Sin et al., 2007). IFN-α inhibits KSHV 
reactivation and Kaposi sarcoma tumour growth 
(Krown et al., 1986; Chang et al., 2000).
4 .2 .6 Apoptosis
Several KSHV proteins have been shown to 
protect against apoptosis when transfected indi-
vidually. Among them are some of the proteins 
already discussed above, as well as a viral homo-
logue of cellular Bcl2. Table 4.2 shows a summary 




















Table 4 .2 Mode of action of kSHV proteins involved in the protection against apoptosis
KSHV protein Mode of action References
K1/VIP Activation of PI3K/Akt;  
Inhibition of FKHR-mediated apoptosis;  
Inhibition of Fas-induced apoptosis
Tomlinson & Damania (2004), Wang et al. (2004a), 
Uddin et al. (2005), 
vBcl-2 Inhibition of Bax-mediated apoptosis; 
Selective interaction with BH3-only proteins




VEGF-independent anti-apoptotic effect Liu et al. (2001)
K7/vIAP Inhibition of apoptosis by binding to Bcl-2 and caspase-3;  
Promotes p53 and IκB degradation by interacting with Ubiquilin/PLIC1;  
Binds to cellular CAML (calcium-modulating cyclophilin ligand);  
Increases cytosolic Ca2+ response to an apoptotic stimulus
Feng et al. (2002, 2004), Wang et al. (2002)
K-RTA Represses p53-dependent transcription and apoptosis through interaction 
with CBP
Gwack et al. (2001)
vIRF-1 Degradation of p53 by binding to p53 and ATM; 
Inhibits ATM-mediated phosphorylation of p53 on serine 15;  
Interacts with GRIM-19 and inhibits interferon or retinoic-acid-induced 
apoptosis;  
Inhibits induction of CD95L
Gao et al. (1997), Nakamura et al. (2001), Seo et 
al. (2001, 2002), Kirchhoff et al. (2002), Shin et al. 
(2006)
vIRF-2 Inhibits induction of CD95L;  
Binds to and inhibits the activation of the IFN-induced ds-RNA-activated 
kinase (PKR)
Burýsek & Pitha (2001), Kirchhoff et al. (2002)
vIRF-3/LANA-2 Inhibits apoptosis in PEL cells;  
Binds to p53 and inhibits p53-induced transcription and apoptosis;  
Inhibits apoptosis triggered by PKR
Rivas et al. (2001), Esteban et al. (2003), Wies et al. 
(2008)
miRNA K12–11 Downregulation of proapoptotic cellular genes, e.g. LDOC1, Bim, BCLAF1 
(Bcl2-associated transcription factor 1), BAZF (NF-κB regulator)
Gottwein et al. (2007), Skalsky et al. (2007)
LANA Inhibits p53-induced apoptosis; 
Counteracts pro-apoptotic effects of simultaneously expressed vCyc; 
Stabilizes and activates c-Myc
Friborg et al. (1999), Curreli et al. (2005), Bubman et 
al. (2007), Liu et al. (2007a), Petre et al. (2007), Sarek 
et al. (2007), Cuomo et al. (2008)
vFLIP Binds to FLICE complex;  
Inhibits CD95/Fas-induced apoptosis; 
Persistent activation of NF-κB
Thome et al. (1997), Chaudhary et al. (1999), Djerbi 
et al. (1999), Stürzl et al. (1999), Liu et al. (2002), 
An et al. (2003), Field et al. (2003), Sun et al. (2003), 
Guasparri et al. (2004), Godfrey et al. (2005)
vGCR Promotes endothelial cell survival by activating PI3K/Akt pathway Montaner et al. (2001)
K15 Interacts with HAX-1 (an anti-apoptotic regulatory protein Sharp et al. (2002)
FLICE, (FADD [Fas-associated death domain]-like IL-1β-converting enzyme); FLIPs, FLICE-inhibitory proteins
Compiled by the Working Group
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4.3 Evidence for a role of KSHV in 
malignant conversion
4 .3 .1 Kaposi sarcoma
(a) Requirement of KSHV expression for cell 
growth invasion
In vitro, KSHV alters the transcriptional 
programme in infected primary endothelial 
cells, leading to a redifferentiation of vascular 
endothelial cells into lymphatic endothelial cells; 
this results in the formation of spindle cells that 
are similar to spindle cells in Kaposi sarcoma 
(see Section 4.2.4). These infected cells, however, 
cannot be maintained in long-term culture as 
they show evidence of spontaneous lytic reacti-
vation (Ciufo et al., 2001; Lagunoff et al., 2002).
Owing to a lack of an easily tractable in 
vivo model, not many published studies have 
addressed the question of whether or not KSHV 
is required for cell growth and invasion in vivo. 
Mutlu et al. (2007) reported that transfection of 
a bacterial artificial chromosome vector carrying 
a KSHV genome into murine endothelial cells 
derived from bone marrow generated a cell that 
would induce a Kaposi-sarcoma-like tumour 
when transplanted into mice. Sublines that had 
lost the KSHV genome in the absence of drug 
selection lost their tumour-inducing potential, 
as did KSHV-genome carrying cells, in which 
the expression of vGPCR had been silenced by 
siRNA (Mutlu et al., 2007).
(b) Persistence of the KSHV genome
Similarly to the Epstein-Barr virus (EBV), 
KSHV is capable of replicating its latent episomal 
genome synchronously with the host cell cycle. 
However, latent genomes do not appear to persist 
efficiently in infected primary endothelial cells, 
nor in epithelial, endothelial or fibroblast cell 
lines (Foreman et al., 1997; Renne et al., 1998; 
Blackbourn et al., 2000; Grundhoff & Ganem, 
2004). In several cell lines, only a small subpopu-
lation of cells are able to retain the virus in a stable 
manner following acute infection (Grundhoff & 
Ganem, 2004; An et al., 2006).
(c) Chromosomal abnormalities, and 
alterations of specific proto-oncogenes
Most cases of Kaposi sarcoma are cytogeni-
cally normal. However, in some cases, the loss of 
Y-chromosomal sequences and the gain at 11q13 
with an amplification of two oncogenes FGF4 
and INT
2
, as detected by comparative genome 
hybridization, have been noted (Kiuru-Kuhlefelt 
et al., 2000; Pyakurel et al., 2006). In short-term 
cultures of Kaposi sarcoma cells, numerical 
chromosomal abnormalities have been noted 
(Delli Bovi et al., 1986; Scappaticci et al., 1986; 
Saikevych et al., 1988). Defined chromosomal 
abnormalities (loss of copies of chromosomes 
14 and 21; deletions in the short arm of chromo-
some 3 at 3p14) were also noted in two perma-
nent cell lines, KS-Y1 and KS-SLK, established 
from Kaposi sarcoma biopsies (Popescu et al., 
1996). Abnormalities at 3p14 were also noted 
in another permanent Kaposi sarcoma cell line, 
KS-IMM, in addition to further chromosomal 
changes (Casalone et al., 2001).
No p53 mutations have been reported for 
the majority of Kaposi sarcoma. Host cell 
tumour-suppressor mRNAs are dysregulated in 
KSHV-associated-tumours.
4 .3 .2 Primary effusion lymphoma 
(a) Requirement of KSHV expression for cell 
growth and invasion
In primary effusion lymphoma cell lines, 
siRNA- and shRNA-mediated knockdown of 
several latent genes, in particular vFLIP and 
vIRF-3, induces apoptotic death (Godfrey et al., 
2005; Guasparri et al., 2006; Wies et al., 2008). 
This suggests that these viral genes need to be 
continuously expressed to ensure the survival of 
primary effusion lymphoma cells.
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(b) Persistence of the KHSV genome
B-Lymphoma cell lines derived from primary 
effusion lymphoma, contrary to most KSHV-
infected cells, retain a stable latent viral genome 
in high copy numbers (50–100 copies/cell) 
(Cesarman et al., 1995a, b; Boshoff et al., 1998; 
Katano et al., 1999; Morand et al., 1999).
Knockdown of LANA in primary effusion 
lymphoma cell lines leads to a reduction in the 
viral genome copy numbers, this in keeping with 
the accepted role of LANA in episome replica-
tion (Godfrey et al., 2005)
(c) Chromosomal abnormalities
In primary effusion lymphoma cells, complete 
or partial trisomy 12, trisomy 7, and abnormali-
ties of bands Iq21–25 were noted frequently in 
addition to mutations in the 5′ untranslated 
region of the BCL-6 gene (Gaidano et al., 1999; 
Wilson et al., 2002). Additional chromosomal 
changes were noted in the studies by Wilson et 
al. (2002) and by Nair et al. (2006).
No p53 mutations have been reported for the 
majority of primary effusion lymphoma.
4 .3 .3 Multicentric Castleman disease
Multicentric Castleman disease is a poly-
clonal lymphoproliferative disease that can be 
a precursor to frank lymphoma. In addition 
to LANA, vIL6 is expressed in multicentric 
Castleman disease B cells (see Section 4.2.4). 
Because vIL6 is a potent stimulator of B-cell 
growth, it is likely that this protein plays an 
important role in the B-cell proliferation seen in 
multicentric Castleman disease.
4.4 Interaction between KSHV and 
environmental agents
Many agents have an impact on the biology 
of KSHV:
1. EBV is present in 70–90% of primary effu-
sion lymphomas. EBV-positive and EBV-
negative primary effusion lymphomas can be 
distinguished from each other on the basis 
of host gene transcription (Fan et al., 2005). 
However, no differences in clinical appear-
ance, tumorigenicity in mice or response to 
therapy have been observed between EBV-
positive and EBV-negative primary effusion 
lymphomas (Keller et al., 2000; Petre et al., 
2007).
2. Cytomegalovirus (CMV) can reactivate 
KSHV, and the suppression of CMV has been 
shown to suppress KSHV viral loads (Martin 
et al., 1999; Vieira et al., 2001). However, at 
the time of writing, no evidence for a direct 
role for CMV in Kaposi sarcoma or primary 
effusion lymphoma exists.
3. HIV type 1 can reactivate KSHV and enhance 
KSHV infectivity (Mercader et al., 2000; 
Merat et al., 2002; Aoki & Tosato, 2004; Zeng 
et al., 2007). These phenotypes are likely to 
be mediated by cell-derived cytokines. HIV 
tat protein can cause endothelial cell prolif-
eration in experimental models (Ensoli et al., 
1990, 1994). However, Kaposi sarcoma and 
primary effusion lymphoma develop in the 
absence of HIV (Cesarman et al., 1996). Even 
in HIV-infected patients, these two viruses 
have never been found in the same cells 
(Delli Bovi et al., 1986).
To explain the well known high incidence 
of endemic KSHV in certain parts of Africa, it 
has been postulated that environmental agents 
might affect KSHV reactivation. In fact, natural, 
chemical and environmental products can reac-
tivate KSHV from latency, most notably sodium 
butyrate and phorbol esters or plant extracts 
(Renne et al., 1996; Zhong et al., 1996; Miller 
et al., 1997; Zoeteweij et al., 1999; Whitby et al., 
2007).
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4.5 Animal models
Following injection to experimental animals, 
KSHV can infect non-human primates (Renne 
et al., 2004), NOD-SCID mice (Parsons et al., 
2006), and humanized SCID mice (Dittmer 
et al., 1999; Foreman et al., 2001; Wu et al., 2006). 
These infections do not result in the formation 
of tumours. Nevertheless, they confirm the 
viral tropism (B cells and endothelial cells), and 
drug susceptibility (ganciclovir) in vivo. KSHV 
homologous viruses exist in the bank vole-mouse 
(MHV-68), and virtually in all non-human 
primates (Ensser & Fleckenstein, 2007). The 
infection of macaques with rhesus rhadinovirus 
in the context of Simian immunodeficiency virus 
(SIV) induces B-cell lymphoma and endothelial-
cell hyperplasia (Mansfield et al., 1999; Wong 
et al., 1999).
Multiple tumourgraft models of Kaposi 
sarcoma and primary effusion lymphoma have 
been established (Boshoff et al., 1998; Staudt 
et al., 2004; Wu et al., 2005; An et al., 2006; Mutlu 
et al., 2007; Sin et al., 2007).
4.6 Transgenic mice models
An alternative approach to infection studies 
is to use transgenic mice where individual KSHV 
proteins are expressed in the hope of replicating 
selected aspects of KSHV pathogenesis. There 
are some limitations to single transgenic models. 
Whereas lymphoproliferative lesions and 
lymphomas in mice are easily classified on the 
basis of histology and marker–gene expression, 
this is not the case for endothelial cell tumours. 
They are referred to as Kaposi-sarcoma-like 
lesions, but can easily be mistaken for fibrosar-
comas (Table 4.3).
4 .6 .1 Transgenic mice for KSHV latent genes
(a) LANA/ORF 73
The KSHV latent promoter (LANAp) showed 
B-cell lineage specificity in transgenic mice 
(Jeong et al., 2002). KSHV LANA expression in 
transgenic mice resulted in 100% B-cell hyper-
plasias and lymphomas at about twice the rate 
of background in the C57/BL6 strain of mice 
(Fakhari et al., 2006).
(b) vCYC/ORF 72
Whereas vCYC single transgenic mice did 
not develop tumours, lymphomas developed 
rapidly in a p53-null background (Verschuren 
et al., 2002, 2004). [The Working Group noted 
that, presumably, loss of p53 counteracted the 
pro-apoptotic signals that are associated with 
forced vCYC expression.]
(c) vFLIP/ORF 71
The vFLIP transgenic mice exhibited an 
increased incidence of lymphoma (Chugh et al., 
2005).
4 .6 .2 Transgenic mice for KSHV lytic genes
(a) vGPCR/ORF 74 .
vGPCR transgenic mice activated the same 
signalling pathways as predicted from human 
culture studies, and exhibited Kaposi-sarcoma-
like lesions (Yang et al., 2000; Holst et al., 2001; 
Guo et al., 2003; Montaner et al., 2003; Jensen 
et al., 2005; Grisotto et al., 2006). Tumour forma-
tion required the chemokine binding as well as 
the constitutive signalling activities of vGPCR 
(Holst et al., 2001). vGPCR was required for 
lesion initiation, though it was not essential once 
a fully malignant tumour had formed (Grisotto 
et al., 2006).
(b) K1/VIP
K1 transgenic mice also exhibited Kaposi-
sarcoma-like lesions and lymphomas (Prakash 




The available mechanistic data strongly 
support an oncogenic role of KSHV in human 
cancer.
KSHV alters the growth properties of 
endothelial cells in culture, and induces Kaposi-
sarcoma-cell-like morphology (spindle cells).
One or several KSHV gene products are 
expressed in all KSHV-associated cancers in all 
KSHV-infected tumour cells.
At the molecular level, KSHV-encoded gene 
products associated with latent viral infection 
induce cell proliferation, block apoptosis, induce 
genomic instability or modulate cell migration 
and tumour progression.
Mechanistic data strongly support an onco-
genic role of KSHV in primary effusion lymphoma 
and in Kaposi sarcoma in immunocompromised 
(post-transplant patients, AIDS patients), as well 
as in immunocompetent individuals.
KSHV proteins like vIL6 induce B-cell prolif-
eration, and are expressed in KSHV-associated 
multicentric Castleman disease, strongly 
suggesting that infection with KSHV is causally 
associated with this lymphoproliferative disease.
5. Evaluation
There is sufficient evidence in humans for the 
carcinogenicity of KSHV. KSHV causes Kaposi 
sarcoma and primary effusion lymphoma. Also, 
a positive association has been observed between 
exposure to KSHV and multicentric Castleman 
disease.
For multiple myeloma, there is evidence 
suggesting lack of carcinogenicity.
KSHV is carcinogenic to humans (Group 1).
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Table 4 .3 Transgenics for modelling kSHV-associated cancers
Viral Gene Promoter Incidence Mean time to onset, 
days
Reference
Primary effusion lymphoma/multicentric Castleman disease
MHV68vCYC1 Lck 40% 240 van Dyk et al. (1999)
vCYC Eµ 17% 300 Verschuren et al. 
(2002)
vCYC/p53del Eµ 100% 80 Verschuren et al. 
(2004)
vFLIP H2Kb 11% 600 Chugh et al. (2005)
LANA LANAp 10% 300 Fakhari et al. (2006)
K1/VIP SV40 15% ≥ 420 Prakash et al. (2002, 
2005)
Kaposi sarcoma
vCYC VEGFR-3 80% ≥ 200 Sugaya et al. (2005)






100% ≥ 150 Grisotto et al. (2006), 
Jensen et al. (2005) 
vGPCR SV40 30% ≥ 360 Guo et al. (2003)
vGPCR hCD2 100% 90 Holst et al. (2001), 
Yang et al. (2000)
Modified from Damania & Dittmer (2008), and compiled by the Working Group
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Human immunodeficiency virus-1 was considered by a previous IARC Working Group in 
1996 (IARC, 1996). Since that time, new data have become available, these have been incor-
porated in the Monograph, and taken into consideration in the present evaluation.
1. Exposure Data
1.1 Taxonomy, structure, and biology
1 .1 .1 Taxonomy
The human immunodeficiency virus type 
1 (HIV-1) was first isolated in 1983 (Barré-
Sinoussi et al., 1983; Gallo et al., 1983), and 
firmly associated with the acquired immunode-
ficiency syndrome (AIDS) in 1984 (Gallo et al., 
1984; Montagnier et al., 1984). A second related 
virus, called HIV-2, was subsequently discov-
ered in West Africa (Clavel et al., 1986). HIV-1 
and HIV-2 belong to the family of Retroviridae 
and subfamily Orthoretrovirinae. Retroviruses 
are enveloped RNA viruses that replicate via 
a DNA intermediate. They rely on the enzyme 
reverse transcriptase to transcribe their genome 
from RNA into DNA, which can then be inte-
grated into the host’s genome with an integrase 
enzyme, becoming part of the cellular DNA, and 
replicating with it. HIV-1 and HIV-2 are the two 
known human retroviruses that belong to the 
genus Lentivirus (lentus, Latin for “slow”).
1 .1 .2 Structure of the virion
HIV-1 virions contain two copies of a single-
stranded RNA genome within a conical capsid 
surrounded by a plasma membrane of host-cell 
origin containing viral envelope proteins. The 
RNA genome is 9750 nucleotides long (Ratner 
et al., 1985; Wain-Hobson, 1989), and the virions 
measure approximately 120  nm in diameter. A 
detailed three-dimensional structure of HIV-1 
envelope-glycoprotein spikes, which are required 
for the infection of host cells, has recently been 
elucidated by cryoelectron microscopy tomog-
raphy (Zhu et al., 2006).
The HIV-1 RNA is tightly bound to the 
nucleocapsid proteins, p6 and p7, which protect 
it from digestion by nucleases. This viral core 
further contains reverse transcriptase, integrase, 
and protease. The entire complex is surrounded 
by an icosahedral capsid (p24). A myristoylated 
matrix protein (p17) surrounds the capsid. 
Also enclosed within the virion particle are the 
proteins Vif, Vpr, and Nef (Fig.  1.1). The enve-
lope is formed when the capsid buds from the 
host cell, taking some of the host-cell membrane 
with it. Embedded within the lipid bilayer are 
the viral envelope glycoproteins that form the 
HIV-1 spikes: the external surface glycoprotein 
(gp120), and the transmembrane glycoprotein 
(gp41) (Turner & Summers, 1999; Bukrinskaya, 
2004; Freed & Martin, 2007).
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1 .1 .3 Structure of the viral genome
The HIV-1 genome, flanked by a long terminal 
repeat, contains the following genes (Fig. 1.1):
• gag (group-specific antigen): encodes p24 
(viral capsid); p6 and p7 (nucleocapsid 
proteins); and p17 (matrix protein).
• b) pol: encodes the viral enzymes, which 
are reverse transcriptase (transcribes the 
viral RNA into double-stranded DNA), 
integrase (allows integration of the DNA 
produced by reverse transcriptase into 
the host genome), and protease (cleaves 
the proteins derived from gag and pol into 
functional proteins).
• c) env (envelope): encodes gp160, which 
is the precursor of the gp120 and gp41 
proteins present in the viral envelope of 
mature virions. This protein forms spikes 
that allow the virus to attach to and fuse 
with target cells.
• d) tat, rev, nef, vif, vpr, vpu: each of these 
genes encodes for a single protein with the 
same name. Their function is described in 
Section 4.
The structural biology of HIV-1 has been re-
viewed (Turner & Summers, 1999; Bukrinskaya, 
2004; Freed & Martin, 2007).
1 .1 .4 Host range
Humans are the natural hosts of both HIV-1 
and HIV-2. Related viruses, e.g. simian immu-
nodeficiency virus (SIV), naturally occur in 
African non-human primates. HIV-1 and HIV-2 
have been shown to originate in West-Central 
Africa, and crossed species (zoonosis) from a non-
human primate to humans. HIV-1 was found to 
be closely related to an SIV strain found in chim-
panzees (Pan troglodytes) (SIVcpz) in Cameroon 
(Gao et al., 1999). HIV-2 is more closely related 
to the SIV of sooty mangabeys (Cercocebus atys) 
(SIVsm) (Hirsch et al., 1989), a primate species 
indigenous to West Africa.
1 .1 .5 Target cells
HIV-1 enters cells through interaction with 
the CD4 receptor and a chemokine co-receptor 
(CXCR4 or CCR5). The virus infects CD4-positive 
T cells and macrophages expressing these recep-
tors (Broder & Collman, 1997). HIV-1 can also 
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infect dendritic cells (Knight et al., 1990), which 
are thought to mediate transmission (de Witte 
et al., 2008).
HIV-1 can be assigned to one of three classes 
based on its ability to use the two co-receptors. 
Class R5 comprises the viruses that use CCR5 
but not CXCR4; they were previously called non-
syncytia-inducing (NSI) or M-tropic viruses. 
The viruses that use CXCR4 are in class X4; they 
were previously called syncytia-inducing (SI) 
or T-tropic viruses. Viruses that can use either 
CCR5 or CXCR4 are referred to as R5X4 or dual 
viruses (Coakley et al., 2005). Primary lympho-
cytes and macrophages express both co-recep-
tors, so co-receptor use does not strictly define 
cell tropism (Goodenow & Collman, 2006). Thus, 
while X4 virus infects T-cell lines, and R5 virus 
infects macrophage cell lines, in primary cells, 
these definitions are not as clear. CD4-positive T 
cells in lymphoid tissues can express both CCR5 
and CXCR4, and are the main target for replica-
tion in vivo. CCR5 is expressed predominantly 
on the CD45R0+ memory subset of CD4-positive 
T lymphocytes, while CXCR4 is expressed on 
CD4-positive CD45R0- and on CD4-positive 
CD45RAlow naïve cells (Bleul et al., 1997).
Within single patients, mixed populations of 
the virus exist, with any combination of R5, X4 
or R5X4. Phenotypic assays and genotyping can 
be used to determine tropism, as the primary 
determinants of co-receptor tropism are located 
in the V3 region of the gp120 envelope protein. 
Most individuals have the R5 virus at the time 
of diagnosis, whereas the presence of the X4 and 
dual virus is associated with progression to AIDS 
(Goodenow & Collman, 2006).
HIV-1 can be present in a variety of tissues, 
which is to be expected given the distribution 
of T cells, macrophages, and dendritic cells 
throughout the body. HIV-1 has been detected 
in tissues from infected patients by means of 
immunohistochemistry, in-situ hybridization, 
and transmission electron microscopy. HIV-1 
has been shown to be associated with germinal 
centre follicular dendritic cells in lymph nodes, 
tonsils and adenoids, and mucosa-associated 
lymphoid tissue (MALT) as well as in T and B 
cells (Teruya-Feldstein et al., 1995; Griffin et al., 
1996; Pantaleo et al., 1998; Orenstein et al., 1999). 
HIV-1 frequently infects the brain, and the 
microglial cells are the main location for viral 
replication in the central nervous system (Shaw 
et al., 1985; Vazeux et al., 1987). In reproduc-
tive organs of infected men, HIV-1 is present 
in cells of lymphocytic/monocytic morphology 
in the seminiferous tubules and interstitium of 
the testis, in the epididymal epithelium, and in 
connective tissue of the epididymis and pros-
tate (Pudney & Anderson, 1991). In semen-cell 
subpopulations isolated by use of an immu-
noaffinity technique with magnetic beads, T 
cells were found to be most common cell type 
infected with HIV-1 (75% of samples), followed 
by macrophages (38%). Viral DNA was not 
detected in spermatozoa or in immature germ-
cell populations (Quayle et al., 1997).
1 .1 .6 Life cycle, replication, and regulation of 
gene expression
The HIV-1 virus first binds to target cells 
through semi-specific or nonspecific interac-
tions between the viral envelope and cell-surface 
glycans or adhesion factors. The gp120 enve-
lope glycoprotein then interacts with the CD4 
molecule on the surface of the target cells. This 
induces a conformational change in gp120, 
which facilitates its binding to a co-receptor 
molecule (CCR5 or CXCR4), and the formation 
of a complex with the transmembrane glyco-
protein gp41. Further conformational changes 
in the gp120–gp41 complex then lead to expo-
sure of the fusion-peptide region of gp41, and 
its insertion into the host-cell membrane, which 
results in fusion of the virus with the host cell. 
Reverse transcription starts immediately after 
entry. A complex containing protein and viral 
cDNA (pre-integration complex) is transported 
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to the host-cell nucleus where the viral inte-
grase enzyme catalyses the integration of viral 
cDNA into the hosts genomic DNA to form the 
provirus. The provirus may remain latent for 
years, producing few or no new copies of HIV-1, 
which has hampered the treatment of individuals 
infected with HIV-1, as antiretrovirals can only 
target replicating virus. When HIV-1 replicates, 
the provirus uses the cellular RNA polymerase II 
to create RNA copies of the HIV-1 genome, as well 
as viral mRNA that encodes the HIV-1 proteins. 
Transcription of the viral genome is driven by 
a promoter in the 5′ long terminal repeat of the 
integrated provirus. Tat increases the amount of 
viral RNA by increasing transcriptional initia-
tion and/or elongation, and Rev regulates the 
splicing and transport of viral RNA from the 
nucleus to the cytoplasm. The core and envelope 
proteins are first synthesized as precursor poly-
peptides, which are then cleaved by proteases. 
Genomic RNA is subsequently packaged into 
virions. As the virion matures, Gag–Gag and 
Gag–Pol protein complexes are cleaved by the 
viral protease into subunit proteins, resulting in 
the mature virion, which is directed to the cell 
surface by N-terminal myristoylation of Gag. 
The virion is then released from the plasma 
membrane where it acquires its envelope. This 
completes the HIV life cycle (see review by Freed 
& Martin, 2007).
1.2 Epidemiology of infection
1 .2 .1 Prevalence, geographic distribution
Based on national surveillance systems, the 
joint United Nations programme on HIV/AIDS 
(UNAIDS) updates every year the geographic 
distribution of HIV-1 worldwide. In 2007, the 
HIV-1 prevalence ranged from less than 0.5% in 
most developed countries to up to 30% in Central 
and Southern Africa (UNAIDS, 2007).
1 .2 .2 Transmission, and risk factors for 
infection
HIV-1 infection is transmitted through three 
main routes: sexual intercourse, blood contact, 
and from mother to infant. HIV-1 infectivity, 
i.e., the average probability of transmission to 
another person after that person is exposed to an 
infected host, is determined by the interplay of 
three main groups of factors: host-related factors, 
environmental factors, and agent factors. The 
probability of HIV-1 transmission is highest for 
blood transfusion (> 0.95), followed by mother-
to-child transmission (about 0.10), intermediate 
for needle-sharing (about 0.01), and lowest for 
woman-to-man sexual transmission (about 
0.001) (Royce et al., 1997).
(a) Sexual contact
It has been well documented, since the first 
years of the epidemic, that HIV-1 is transmitted 
through unprotected (i.e., without condom) 
vaginal or anal intercourse from man to woman 
and from woman to man, and through anal 
intercourse from man to man. Worldwide, the 
majority of new HIV-1 infections originate 
from sexual exposures to virus transmitted 
from semen, with the risk of transmission being 
related to several virological, biological, and 
behavioural factors (e.g., HIV-1 subtype, mode 
of sexual exposure, condom use, penile circum-
cision, mucosal inflammation, the co-existence 
of other sexually transmitted diseases, stage of 
HIV-1 infection, hormonal factors or host genetic 
background). Before the introduction of Highly 
Active Anti-Retroviral Therapy (HAART), the 
quantification of the risk of HIV-1 sexual trans-
mission related to these factors was reviewed 
by Royce et al. (1997). Most of the accumulated 
evidence was already described in the previous 
IARC Monograph (IARC, 1996).
Higher viral load and genital ulceration are 
among the main determinants of sexual HIV-1 
transmission, and this also applies during the 
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HAART era. In a Ugandan population, the 
probabilities of transmission per single coital 
act increased from 0.0001 at viral loads of less 
than 1700 copies/mL to 0.0023 at 38500 copies 
(P = 0.002), and were 0.0041 with genital ulcera-
tion versus 0.0011 without (P  =  0.02) (Gray 
et al., 2001). The impact of antiretroviral therapy 
on HIV-1 transmission has been extensively 
assessed. A 70% reduction in risky sexual behav-
iour (e.g., not using condoms with HIV-1-negative 
partners or of unknown HIV-1 status) and a 98% 
reduction in HIV-1 transmission rate (from 45.7 
to 0.9/1000 person–years) was reported from a 
prospective study conducted among 926 infected 
adults enrolled in an antiretroviral therapy 
programme in Uganda (Bunnell et al., 2006). A 
study on 393 monogamous heterosexual couples 
conducted in Spain noted a reduction of approxi-
mately 80% in the heterosexual transmission of 
HIV-1 when HAART became available (Castilla 
et al., 2005). HIV-1 prevalence declined from 
10.3% during the pre-HAART period (1991–95) 
to 1.9% in the late HAART period (1999–2003) 
(odds ratio[OR], 0.14, 95%CI: 0.03–0.66), a 
decrease that was not influenced by potential 
confounders like condom use, duration of part-
nership, CD4-positive lymphocyte count and 
AIDS-defining diseases (Castilla et al., 2005).
HIV-1 sexual transmission from men to men 
occurs through anal intercourse, with seminal 
plasma viral load and blood plasma viral load 
associated with an increased risk of transmission 
(Butler et al., 2008), though other uncommon 
routes of transmission have also been suggested 
– mainly via oral sex (Richters et al., 2003). A 
systematic review of the literature, however, 
concluded that current data are insufficient to 
precisely estimate the risk of orogenital transmis-
sion of HIV-1 due to the small number of studies 
– the probability estimate was about 0.02–0.45% 
per single orogenital act (Baggaley et al., 2008).
(b) Blood contact
HIV-1 transmission through blood-to-blood 
contact occurs through the transfusion of HIV-1-
infected blood iatrogenically, occupationally, 
or through needle-sharing by intravenous drug 
users (IARC, 1996).
Iatrogenic transmission of HIV-1 is now 
extremely rare in developed countries due to 
the recruitment of safe donors, deferral of high-
risk donors, and screening. The introduction 
of nucleic acid testing, and of a new method 
for computing the residual risk of transfusion-
transmitted infections, has allowed precise esti-
mates for the infectious window period (Soldan 
et al., 2005; O’Brien et al., 2007). Accordingly, 
the risk (per million transfusions) of an HIV-1-
infected donation entering the blood supply was 
estimated at 1.91 in Italy (Gonzalez et al., 2005), 
at 0.14 in the United Kingdom (Soldan et al., 
2005), and at 0.13 in Canada (O’Brien et al., 
2007). Conversely, in many parts of Africa and 
in other developing countries, blood screening 
and banking programmes have been difficult to 
implement and to sustain. In Kenya, the preva-
lence of HIV-1 among blood donors ranged from 
2–20%, with an estimated 2% of transfusions that 
transmitted HIV-1 infection to HIV-1-negative 
blood recipients (Moore et al., 2001). Reasons 
for such elevated transfusion-transmitted HIV-1 
infections include inconsistent refrigeration, 
data entry errors, equipment failure, and a lack 
of quality assurance programmes.
Occupational transmission of HIV-1 in the 
health care setting has also been documented. 
The Health Protection Agency has registered, as 
of March 2005 (worldwide), 106 cases of HIV-1 
infections certainly acquired through occupa-
tional exposures (of those, 57 occurred in the 
United States of America and 35 in Europe). 
Moreover, for another 238 cases, an occupational 
source of HIV-1 infection was considered highly 
probable (Health Protection Agency, 2005). The 
occupational transmission of HIV-1 occurs 
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through skin injury with needles or bistouries 
or from splash exposure to mucosal membranes. 
Estimates from studies conducted in health 
settings of the USA and Italy have indicated that 
HIV-1 transmission occurs in 0.3% of percuta-
neous exposures, and in 0.1% of muco-membra-
neous exposures (Jagger et al., 2003).
The sharing of injection equipment by intra-
venous drug users represents a major mode of 
HIV-1 transmission worldwide. Since the early 
1980s, a high prevalence of HIV-1 has been 
reported among this group from many parts of 
the world; and in many areas, HIV-1 prevalence 
among intravenous drug users was raised to 50% 
or more within the first years of the epidemic. Such 
outbreaks continue to occur, and rapid spread 
has been documented in the newly independent 
states of the former Soviet Union (Rhodes et al., 
2002). In England and Wales, HIV-1 prevalence 
declined from 5.9% in 1990 to 0.6% until 1999, 
and thereafter it increased to 1.4% in 2003 (Hope 
et al., 2005). The timely introduction of compre-
hensive harm reduction measures, particularly 
needle exchange programmes, has prevented 
the rapid spread of HIV-1 in several northern 
European countries and Australia. Furthermore, 
trends in the prevalence of HIV-1 have reversed 
in several areas, like Northern Italy and New 
York City, and have been partially attributed to 
behavioural change, improved access to treat-
ment, and needle exchange programmes (Hurley 
et al., 1997; Des Jarlais et al., 2000; Sabbatini et al., 
2001). In Asia, 30% of intravenous drug users 
were reported to be infected with HIV-1 in India 
and Thailand (Razak et al., 2003; Panda et al., 
2005). In Yunnan province, China, HIV-1 infec-
tion was documented in 59.9% of 314 intravenous 
drug users, and it was positively associated with 
frequency of injection (Yao et al., 2009).
(c) Mother-to-child transmission
Despite substantial reductions in mother-to-
child transmission of HIV-1 infection achieved 
in North America and Europe (Fiscus et al., 
1999; Townsend et al., 2008), paediatric HIV-1 
infection remains a major worldwide pandemic. 
It is estimated that about 1800 new HIV-1 infec-
tions are transmitted daily from mother to 
infants (UNICEF, http://www.unicef.org/media/
files/RegionalSummary.doc) during pregnancy, 
labour, delivery, and postpartum through 
breastfeeding. Several randomized clinical 
trials were conducted in developing countries 
(where the majority of pregnant women have no 
access to antiretroviral therapies to treat their 
own HIV-1 infection), to assess mother-to-child 
transmission rates through the use of antiretro-
viral regimens (reviewed by Kourtis et al., 2006). 
Although not completely defined yet, the timing 
and mechanisms of mother-to-child transmis-
sion are important to quantify transmission 
rates, and to implement prevention strategies. In 
the absence of any intervention, it is estimated 
that in-utero and intra-partum transmission of 
HIV-1 occurs in approximately 25% of infants 
born to HIV-1-positive women (Connor et al., 
1994). The administration of zidovudine from 14 
weeks of gestation through to delivery, and to the 
newborn for 6 weeks, decreased intra-partum and 
delivery HIV-1 transmission by 67%, from 25.5% 
to 8.3% (P < 0.01) in a randomized, double-blind, 
placebo-controlled efficacy trial (Connor et al., 
1994). Similarly, a study conducted in Thailand 
that used a shortened zidovudine regimen 
starting at 36 weeks of gestation prevented 50% 
of HIV-1 transmission (Shaffer et al., 1999). 
Adding a single maternal/infant nevirapine 
dose to zidovudine further reduced the in-utero 
and intra-partum transmission risk (Lallemant 
et al., 2004). Overall, the findings from in-utero 
and intra-partum transmission studies indicate 
that the risk of mother-to-child transmission 
increases steadily towards the late stages of preg-
nancy, with nearly 80% of new HIV-1 infection 
occurring from 36 weeks to delivery (Kourtis 
et al., 2006). Thus, the HIV-1 transmission risk 
is reduced by up to 70% by elective Caesarean 
delivery, as compared to vaginal delivery 
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(European Mode of Delivery Collaboration, 
1999). In developed countries, where the majority 
of pregnant HIV-1-infected women are treated 
with HAART, mother-to-child transmission 
rates are less than 10% (Cooper et al., 2002). In 
resource-limited settings, postnatal transmission 
via breastfeeding may be as high as 18% (Miotti 
et al., 1999; Fawzi et al., 2002). Several interven-
tion studies have demonstrated, in this context, 
the efficacy to extend antiretroviral prophylaxis 
to reduce HIV-1 transmission. Studies have indi-
cated that 8.9 transmissions per 100 child–years 
of breastfeeding occur, with cumulative prob-
abilities of transmission at 6 months being about 
5% lower than that at 18 months (the standard 
duration of breastfeeding in African countries) 
(Coutsoudis et al., 2004). The extension of antiret-
roviral prophylaxis of breastfed infants born to 
HIV-1-positive mothers with nevirapine or with 
nevirapine plus zidovudine for the first 14 weeks 
of life significantly reduces the rate of postnatal 
HIV-1 infection in 9-month-old infants from 
10.6% in controls to 6.4% (nevirapine) or to 5.2% 
(nevirapine plus zidovudine) (Kumwenda et al., 
2008).
2. Cancer in Humans
The studies included in this section were 
published since the previous IARC Monograph 
(IARC, 1996), a calendar period that coincided 
with the introduction of HAART in developed 
countries, and later in developing countries. 
The introduction of HAART has dramatically 
improved the survival of HIV-1-infected patients 
and has reduced the incidence of several diseases 
associated with HIV-1 infection, including some 
types of cancer. In the years following the intro-
duction of HAART (the post-HAART era), the 
spectrum of cancers associated with HIV-1 
infection has substantially changed. This section 
focuses on those cancers for which the data 
are most strongly suggestive of a true increase 
in risk. It should be noted that HIV-1 infec-
tion causes cancer indirectly through immune 
deficiency, and the increased expression of the 
effects of oncogenic infections. In this way, the 
patterns of cancer are generally similar to those 
in other immunodeficient populations, such as 
solid organ transplant recipients. In addition, 
it is possible that immune deficiency results in 
impaired immune surveillance and the emer-
gence of cancers that are usually controlled by 
the immune system, as originally hypothesized 
by Thomas and Macfarlane Burnet in the early 
1950s (Beral & Newton, 1998; Kinlen, 2004).
2.1 Kaposi sarcoma
Kaposi sarcoma herpesvirus (KSHV) is now 
recognized as a necessary condition for the 
development of Kaposi sarcoma, with HIV-1-
related immunosuppression increasing the risk 
of developing Kaposi sarcoma by several orders 
of magnitude (in the thousands). In addition 
to the studies referenced in the previous IARC 
Monograph (IARC, 1996), there have been a large 
number of cohort studies (in developed coun-
tries) and a few case–control studies (all from 
Africa) that confirmed the strong association 
between HIV-1 infection and Kaposi sarcoma. 
Kaposi sarcoma has become the most frequently 
reported cancer in many subSaharan African 
countries. However, the relative risks (RRs) 
reported from Africa, though still elevated, are 
substantially lower than those reported in devel-
oped countries. The reasons for this are unclear 
but may reflect differences in background risk 
and competing mortality.
Effective antiretroviral therapy in individuals 
with HIV-1-related immunosuppression usually 
results in a substantial and rapid reduction in 
the risk of Kaposi sarcoma. Nevertheless, Kaposi 
sarcoma incidence rates remain very substan-
tially raised above population rates (and are no 
longer declining), and Kaposi sarcoma remains 
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a considerable cause of morbidity and mortality 
in people infected with HIV-1. According to a 
calendar-period meta-analysis on 47936 HIV-1-
positive people in North America, Europe and 
Australia, the relative risk for Kaposi sarcoma 
in the early post-HAART era (1997–99) was 
0.32 (95%CI: 0.26–0.40) when compared to the 
pre-HAART era (International Collaboration 
on HIV-1 and Cancer, 2000). Similar declines 
by calendar period were reported in Italy from 
1986 through to 1998 (Franceschi et al., 2003), 
and in the USA (RR, 0.19; 95%CI: 0.12–0.30, 
1997–2002 versus 1989–96) (Bedimo et al., 
2004). When the follow-up of HIV-1-positive 
patients was continued through to the late post-
HAART period (2002), time trends incidence 
rates for Kaposi sarcoma were observed to level 
off in the last study years (Patel et al., 2008). In 
the USA, the risk for Kaposi sarcoma declined 
83.5% during 1990–95 and 1996–2002 (stand-
ardized incidence ratio [SIR], 22100 and 3640, 
respectively; P < 0.0001). The pattern presented 
a steady decline that began in the 1980s and 
continued through 1990–95, with a further fall 
in risk offsetting the 1996–2002 period from the 
1990–95 period (RR, 0.41; 95%CI: 0.28–0.60). 
Subsequently, during the HAART era itself, 
the risk for Kaposi sarcoma remained constant 
(Engels et al., 2006).
A similar temporal pattern was observed for 
Kaposi sarcoma in Australia (Grulich et al., 2001), 
and in Europe (Franceschi et al., 2003; Clifford 
et al., 2005). In Switzerland, the incidence of 
Kaposi sarcoma in the Swiss HIV-1 cohort study 
following the advent of HAART fell abruptly in 
1996–98 to reach a plateau. Individual data on 
HAART use showed that the risk for Kaposi 
sarcoma declined steeply in the first months 
after HAART initiation, and continued to be low 
for another 7–10 years (hazard ratio [HR], 0.06; 
95%CI: 0.02–0.17) (Franceschi et al., 2008).
In addition to making Kaposi sarcoma a rela-
tively rare event, HAART use has also dimin-
ished the variation in Kaposi sarcoma risk by 
host characteristics, including gender, age group, 
HIV-1-transmission category, and CD4-positive 
cell count. Increases in SIR with declining number 
of CD4-positive count were seen in most of the 
studies with relative risks estimates according to 
strata of CD4-positive cell counts. In the Swiss 
HIV-1 cohort study, the SIR for Kaposi sarcoma 
was 571 (95%CI: 449–716) among persons with 
CD4-positive counts of less than 100 cells/mm3, 
but 76.5 (95%CI: 52.3–108) among persons 
with CD4-positive counts of ≥  500 cells/mm3 
(Clifford et al., 2005). In the USA, the risk for 
Kaposi sarcoma increased by 36% for each fall 
of 100 CD4-positive cells/mm3 (95%CI: 29–43%) 
(Mbulaiteye et al., 2003). A longitudinal study of 
2002 HIV-1-infected persons in Italy with known 
date of seroconversion followed up to 2004 found 
a relative risk of 0.11 (95%CI: 0.06–0.19) for 
Kaposi sarcoma associated with a CD4-positive 
count ≥ 350 cells/mm3 at enrolment (vs < 200) 
(Serraino et al., 2005). Homosexual men were at 
higher risk than injecting drug users (RR, 6.67; 
95%CI: 3.58–12.42), and women were at lower 
risk of Kaposi sarcoma than men (RR, 0.23; 
95%CI: 0.06–0.83) (Serraino et al., 2005).
See Table 2.1 available at http://monographs.
iarc .f r/ENG/Monographs/vol100B/100B-
05-Table2.1.pdf, Table  2.2 available at http://
monog r aphs . ia rc . f r/ ENG/Monog r aphs/




Non-Hodgkin lymphoma has been part of 
the AIDS case definition since 1985 (CDC, 1985). 
A recently published meta-analysis that included 
population-based prospective studies comparing 
rates of non-Hodgkin lymphoma in people 
with HIV-1 or AIDS to the general population 
reported an SIR of 77 in HIV-1 patients, and of 8 
in solid organ transplant recipients (Grulich et al., 
2007a). In Africa, the relative increase in people 
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with HIV-1 appears much less, and was about 
6-fold in case–control studies in Uganda, and 
in a South African case–control study (Newton 
et al., 2001; Stein et al., 2008). Non-Hodgkin 
lymphoma also occurs at increased rates in 
people with primary immune deficiency (Beral 
& Newton, 1998; Mellemkjaer et al., 2002).
There is no evidence that HIV-1 causes non-
Hodgkin lymphoma through a direct effect. 
Rather, the profound depletion of CD4-positive 
T lymphocytes that is caused by HIV-1 allows 
the dysregulation of control of B cells, and 
the expression of the effects of lymphotrophic 
viruses (Engels, 2007). As in the general popu-
lation, more than 90% of cases of non-Hodgkin 
lymphoma due to AIDS are of the B-cell pheno-
type. There are three B-cell lymphoma subtypes 
that occur most commonly. First, primary brain 
lymphoma occurs at profound levels of immune 
deficiency, and occurs several thousand times 
more commonly in people with AIDS than in the 
general population (Coté et al., 1996). Second, 
large-cell immunoblastic lymphoma occurs 
in the severely immunodeficient, and occurs 
several hundred times more commonly than in 
the general population (Engels & Goedert, 2005). 
Third, Burkitt lymphoma can occur at any stage 
of immune deficiency and, again, occurs nearly 
a hundred times more frequently than in the 
general population (Engels et al., 2008; Stein 
et al., 2008a). A rare lymphoma subtype that 
occurs in people with HIV-1 is primary effusion 
lymphoma, which presents as either a pleural or 
peritoneal effusion. It is associated with infec-
tion with KSHV, is more likely to present in a 
person with Kaposi sarcoma (Mbulaiteye et al., 
2002), and has also been described in associa-
tion with the KSHV-related disease, multi-
centric Castleman disease (Ascoli et al., 2001). 
In addition to these B-cell subtypes, a record 
linkage study in the USA demonstrated a 15-fold 
increase in the incidence of T-cell non-Hodgkin 
lymphoma (Biggar et al., 2001). The pathological 
spectrum of T-cell non-Hodgkin lymphoma in 
HIV-1 is diverse, and tends to occur at very low 
CD4-positive counts (Arzoo et al., 2004).
Of the non-Hodgkin lymphoma subtypes 
that are associated with HIV-1, the incidence of 
two primary brain lymphoma and diffuse large 
B-cell lymphoma is correlated closely with the 
severity of immune deficiency. These two types 
of lymphoma are uncommon when CD4-positive 
counts are maintained at relatively normal levels. 
Similarly, in organ transplant recipients, the risk 
of non-Hodgkin lymphoma is proportional to 
the intensity of immune suppression (Grulich 
et al., 2007b). On the other hand, the third non-
Hodgkin lymphoma subtype associated with 
HIV-1, Burkitt lymphoma, can occur at any level 
of immune deficiency. All three B-cell lymphoma 
subtypes are associated with markers of immune 
activation, such as serum immunoglobulin 
(Martínez-Maza & Breen, 2002), soluble CD44 
(Breen et al., 2005), and IL10 (Breen et al., 2003).
There was initially considerable debate about 
whether or not non-Hodgkin lymphoma rates 
decreased after the introduction of HAART 
(Grulich, 1999, 2000; Matthews et al., 2000; 
Powles et al., 2000; Tirelli et al., 2000; Ives et al., 
2001; Vilchez et al., 2002), but by around the turn 
of the millennium, it became clear that rates of 
non-Hodgkin lymphoma due to AIDS were 
declining (International Collaboration on HIV 
and Cancer, 2000; Besson et al., 2001; Grulich 
et al., 2001; Franceschi et al., 2003; Clayton & 
Mughal, 2004; Kinlen, 2004; Stebbing et al., 
2004; Engels et al., 2006; Gingues & Gill, 2006; 
Chiappini et al., 2007; Long et al., 2008; Polesel 
et al., 2008). Further case–control (Bonnet 
et al., 2006a) and cohort studies (Carrieri et al., 
2003; Stebbing et al., 2004; Clifford et al., 2005; 
Kirk et al., 2007; Serraino et al., 2007; Polesel 
et al., 2008) have shown that individual receipt 
of HAART is associated with a reduced risk of 
non-Hodgkin lymphoma. It is remarkable that 
the risk of non-Hodgkin lymphoma appears to 
decrease markedly within months of starting 
HAART (Kirk et al., 2007; Polesel et al., 2008). 
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Of the subtypes of AIDS-related non-Hodgkin 
lymphoma, rates have declined most dramati-
cally for primary brain non-Hodgkin lymphoma 
(International Collaboration on HIV and Cancer, 
2000; Besson et al., 2001; Kirk et al., 2001; Inungu 
et al., 2002; Bower et al., 2006; Diamond et al., 
2006; Haldorsen et al., 2008). Rates of large-cell 
immunoblastic lymphoma have also declined 
substantially, though not as markedly. Rates of 
Burkitt lymphoma appear to have changed little 
in most studies (International Collaboration 
on HIV and Cancer, 2000; Engels et al., 2006; 
Babel et al., 2007; Barclay et al., 2007), although 
a decline in risk was reported in a large European 
cohort (Kirk et al., 2001). Despite these recent 
very large declines in non-Hodgkin lymphoma 
risk, in the most recent studies, rates of non-
Hodgkin lymphoma remain 10-fold or more 
greater than population rates (Engels et al., 2008; 
Patel et al., 2008). Before 1996, AIDS-related non-
Hodgkin lymphoma was almost universally fatal 
(Tirelli et al., 2000). Since the advent of HAART, 
the mean CD4-positive count at non-Hodgkin 
lymphoma presentation has increased substan-
tially, and the prognosis has improved remark-
ably (Evison et al., 1999; Besson et al., 2001; Little 
et al., 2001; Baiocchi et al., 2002; Gérard et al., 
2002; Vaccher et al., 2003; Robotin et al., 2004; 
Bower et al., 2005; Lascaux et al., 2005; Lim et al., 
2005; Mounier et al., 2006; Miralles et al., 2007). 
Treatment schedules and responsiveness are now 
similar to that in the HIV-1-negative population 
(Clayton & Mughal, 2004; Lim et al., 2005).
2 .2 .1 The Epstein-Barr virus in AIDS-related 
non-Hodgkin lymphoma
The Epstein-Barr virus (EBV) can be detected 
in AIDS-related non-Hodgkin lymphoma in 
virtually all cases of primary brain lymphoma 
(Hansen et al., 2000; Tirelli et al., 2000), around 
40% of the cases are large cell lymphoma, and 
around 30% of the cases are Burkitt lymphoma 
(Tirelli et al., 2000). In solid organ transplant 
recipients, the risk of non-Hodgkin lymphoma 
is much higher in EBV-seronegative organ 
transplant recipients who contract primary EBV 
infection from the donated organ (Shapiro et al., 
1999; Swinnen, 2000). In this population, high 
EBV plasma viral load predicts the development 
of non-Hodgkin lymphoma, and regression of 
lymphoma is associated with declining EBV in 
plasma. In addition, cytokine polymorphisms 
favouring a pro-inflammatory state increase the 
risk of lymphoma after transplantation (Babel 
et al., 2007). In people with HIV-1, EBV viral 
loads are increased from the early stages of HIV-1 
infection (Piriou et al., 2004). In one study, high 
plasma EBV viral load was found in people 
with EBV-positive but not EBV-negative AIDS 
lymphoma, and viral loads fell with successful 
therapy (Fan et al., 2005). In a French study, 
plasma EBV declined with chemotherapy for 
non-Hodgkin lymphoma (Bonnet et al., 2006b). 
EBV DNA is found in the cerebral spinal fluid in 
80–100% of cases of primary brain lymphoma in 
people with AIDS (De Luca et al., 1995; Brink et al., 
1998; Antinori et al., 1999; Bossolasco et al., 2002; 
Fan et al., 2005). There is interest in using anti-
EBV therapies in the treatment of primary brain 
lymphoma in HIV-1 (Aboulafia et al., 2006). In 
one small study, latent antigen EBNA-1-specific 
CD4 T cells were lost before the diagnosis of AIDS 
lymphoma, but not in those who progressed to 
other AIDS illnesses, suggesting an important 
role of immunity to EBNA-1 (Piriou et al., 2005). 
A Japanese study documented a decline in the 
proportion of non-Hodgkin lymphoma positive 
for EBV, from 88% in the pre-HAART era down 
to 58% in the HAART era (Hishima et al., 2006). 
This is consistent with the declining occurrence 
of opportunistic EBV-related non-Hodgkin 
lymphoma. Studies which have examined anti-
herpesvirus agents as potential preventive agents 
for non-Hodgkin lymphoma have produced 
conflicting results (Fong et al., 2000; Grulich 
et al., 2000, 2001), and high-dose aciclovir was 
not protective against death from non-Hodgkin 
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lymphoma in a meta-analysis of trials of high-
dose aciclovir in people with HIV-1 (Ioannidis 
et al., 1998). [The Working Group noted that the 
power was limited to show this effect, and it was 
difficult to disentangle the subtypes of lymphoma 
from the individual trials.]
Despite an association of hepatitis C virus 
(HCV) infection with non-Hodgkin lymphoma 
in the general population, a cohort study did not 
find an association of non-Hodgkin lymphoma 
with HCV infection in those with HIV-1 (Waters 
et al., 2005).
See Table 2.4 available at http://monographs.
iarc.fr/ENG/Monographs/vol100B/100B-05-
Table2.4.pdf, Table  2.5 available at http://
monog r aphs . ia rc . f r/ ENG/Monog r aphs/




In the general population of developed coun-
tries, Hodgkin lymphoma is one of the most 
common malignancies diagnosed in people 
under the age of 45 years with upward trends 
recorded since the late 1990s (Hjalgrim et al., 
2001). Four subtypes have been distinguished 
within classical Hodgkin lymphoma: nodular 
sclerosis, mixed cellularity, lymphocyte-rich, and 
lymphocyte-depleted. These subtypes cannot be 
distinguished by the immunophenotype of the 
tumour cells, but are different in terms of charac-
teristics such as the sites of involvement, clinical 
features, growth pattern, and frequency of EBV 
infections (Stein et al., 2008b).
The epidemiology of Hodgkin lymphoma 
is characterized by a bimodal incidence curve 
– with a first peak around the age of 30 years 
and the second peak around the age of 50 – 
that has been taken as suggestive of an infec-
tious etiology (World Cancer Report, 2008). A 
particularly important etiological role has been 
attributed to EBV, whose genome is found in 
higher percentages among Hodgkin lymphoma 
cases that are HIV-1-positive compared to 
those that are HIV-1-negative (Carbone et al., 
1999; Frisch et al., 2001; Rezk & Weiss, 2007). 
Epidemiological studies conducted during the 
first years of the HIV-1 epidemic lacked statistical 
power to assess a significantly increased risk of 
Hodgkin lymphoma among the HIV-1-infected 
population (Biggar et al., 1987). However, with 
the spread of the epidemic and longer survival of 
HIV-1-infected persons, the scientific evidence 
has accumulated showing that HIV-1-positive 
persons have, overall, a 10-fold higher risk of 
developing Hodgkin lymphoma than HIV-1-
negative persons of the same sex and age. Such 
evidence comes from the different types of epide-
miological studies conducted worldwide.
In the pre-HAART period, a cohort study of 
6704 homosexual men conducted in the USA was 
the first to demonstrate a statistically significant 
excess risk for Hodgkin lymphoma in HIV-1-
positive persons (RR, 5.0; 95%CI: 2.0–10.3) 
(Hessol et al., 1992). A nearly 10-fold higher risk 
(95%CI: 8–111) was documented thereafter, in 
Italy, in a cohort study on 1255 HIV-1-positive 
persons with a known date of seroconversion 
(Serraino et al., 1997), by a record linkage of 
national AIDS registry and population-based 
cancer registries (SIR, 8.9; 95%CI: 4.4–16.0) 
(Franceschi et al., 1998), and, in Australia, 
through a similar record linkage study (RR, 7.8; 
95%CI: 4.4–13.0) (Grulich et al., 2002). A meta-
analysis of seven reports of HIV-1-associated 
cancer risk, involving 444172 people with HIV-1/
AIDS in the USA, Australia, Scotland, Italy, 
Switzerland, and England (Grulich et al., 2007a) 
reported an overall relative risk of 11.0 (95%CI: 
8.4–14.4). Although to a lesser extent than in 
developed countries, significant excess risk for 
Hodgkin lymphoma in people with HIV-1 infec-
tion or AIDS were also noted in Uganda (RR, 
5.7; 95%CI: 1.2–17) (Mbulaiteye et al., 2006), and 
in South Africa (RR, 1.6; 95%CI: 1.0–2.7) (Stein 
et al., 2008a).
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The excess risk for Hodgkin lymphoma in 
HIV-1-infected persons was not consistently 
observed across Hodgkin lymphoma histo-
logical types. A comparative study based on a 
clinical series of 92 cases of Hodgkin lymphoma 
in HIV-1-positive persons, showed a 4-fold 
increased frequency of the mixed cellularity 
type, and a 12-fold increased frequency of the 
lymphocyte depletion type in HIV-1-positive 
cases compared with the general population 
(Serraino et al., 1993). Similarly, a meta-anal-
ysis of 17 studies on Hodgkin lymphoma in 
HIV-1-positive individuals showed statisti-
cally significant differences in the proportion 
of distribution of all types, with odds ratios of 
0.4 (95%CI: 0.3–0.6) for lymphocyte predomi-
nance, 0.3 (95%CI: 0.2–0.4) for nodular sclerosis, 
3.2 (95%CI: 2.6–3.8) for mixed cellularity, and 
6.3 (95%CI: 4.5–8.8) for the lymphocyte deple-
tion type (Rapezzi et al., 2001). In the USA, very 
elevated SIRs according to histological type were 
reported by a large record linkage study of AIDS 
and cancer registries investigating the associa-
tion between cancer and immunosuppression. 
With regard to Hodgkin lymphoma, only the 
mixed cellularity type (RR, 18.3; 95%CI: 15.9–
20.9) and the lymphocytic depletion type (RR, 
35.3; 95%CI: 24.7–48.8) were associated with a 
significantly increased risk (Frisch et al., 2001).
In contrast with non-Hodgkin lymphoma, 
whose incidence has declined with immune resto-
ration due to the use of HAART (International 
Collaboration on HIV and Cancer, 2000), time 
trends in relative risks for Hodgkin lymphoma 
have generally shown upward trends in recent 
years. [Although the Working Group notesd 
that SIRs have methodological limitations 
when used to compare changes among HIV-1-
positive persons.] Whereas a cohort study of 
8074 HIV-1-positive persons in Italy and France 
showed no significant variations in the risk of 
Hodgkin lymphoma between those treated (RR, 
9.4; 95%CI: 2.0–27.6) or not treated (RR, 11.1; 
95%CI: 6.2–18.3) with HAART (Serraino et al., 
2007), the elevation in risk following HAART 
were noted in most investigations. Hodgkin 
lymphoma risk was higher in the post-HAART 
period (RR, 31.7) than in the pre-HAART period 
(RR, 22.8) according to a cohort study of 77025 
HIV-1-positive persons in France (Herida et al., 
2003). As seen in France, the findings of a record 
linkage between the Swiss HIV-1 cohort and 
cancer registries pointed to a higher risk for 
Hodgkin lymphoma in HIV-1-positive persons 
treated with HAART (RR, 36.2), when compared 
to those who were never treated (RR, 11.4) 
(Clifford et al., 2005). Another record linkage 
study of 57350 HIV-1-infected persons recruited 
from 1991–2002 with cancer registries in the 
USA indicated that the incidence of Hodgkin 
lymphoma increased 3-fold in the study period 
(RR, 2.7; 95%CI: 1.0–7.1; 1996–2002 versus 
1991–95) (Engels et al., 2008). These results, and 
those from another investigation from the USA 
showing increasing incidence rates of Hodgkin 
lymphoma with a higher count of CD4-positive 
cells in HIV-1-positive persons treated with 
HAART (Biggar et al., 2006), might suggest that 
the excess risk for Hodgkin lymphoma is more 
pronounced in HIV-1-infected individuals with 
moderate immunosuppression, where the mixed 
cellularity type is more frequent. It has been 
hypothesized that this finding could be the result 
of the strong association of Hodgkin lymphoma 
with EBV infection (Frisch et al., 2001).
See Table 2.7 available at http://monographs.
iarc .f r/ENG/Monographs/vol100B/100B-
05-Table2.7.pdf, Table  2.8 available at http://
monog r aphs . ia rc . f r/ ENG/Monog r aphs/





2.4 Cervical and anogenital cancers
2 .4 .1 Cancer of the cervix
HIV-1-positive women constitute a growing 
part of the population groups affected by the 
epidemic in developed countries, but they are 
particularly numerous in low- and middle-
resource countries, where the infection with 
HIV-1 and the human papillomavirus (HPV) is 
common (Franceschi et al., 2006). Because both 
HIV-1 infection and HPV infection are sexually 
transmitted, the two infections often co-exist 
(Strickler et al., 2005; Clifford et al., 2006). HPV 
is a necessary condition for cervical cancer to 
occur, and as a result of HIV-1-induced immune 
impairment in HIV-1-infected women, there 
is an increased probability that HPV infection 
will become persistent (Strickler et al., 2005), 
and evolve into cancerous lesions of the cervix 
uteri (Frisch et al., 2000; Dal Maso et al., 2003a). 
Invasive cervical cancer was the last type of 
cancer included among the AIDS-defining 
diseases in 1993, but an association with HIV-1 
infection started to emerge in Europe and in the 
USA several years later (Franceschi et al., 1998; 
Serraino, 1999; Ahdieh et al., 2000; Frisch et al., 
2000). The magnitude of the excess was weaker 
than that found for the other AIDS-defining 
cancers (i.e., Kaposi sarcoma and non-Hodgkin 
lymphoma), with increases 5–10-fold in devel-
oped countries, depending on the study site and 
characteristics of the populations under study. 
The relative risk for invasive cervical cancer 
among women living with HIV-1 infection varies 
from country to country, depending on factors 
like premature death due to other causes or early 
detection of cancer that prevents the progres-
sion of pre-invasive lesions to the invasive stage 
(Franceschi & Jaffe, 2007).
A meta-analysis of seven reports of HIV-1-
associated cancer risk, involving 444172 people 
with HIV-1/AIDS in the USA, Australia, Scotland, 
Italy, Switzerland, and England (Grulich et al., 
2007a) reported an overall relative risk of 5.8 
(95%CI: 3.0–11.3), with risk estimates in indi-
vidual studies ranging from 1.0 (95%CI: 0.2–2.9) 
in the United Kingdom (Newnham et al., 2005) to 
21.9 (95%CI: 13.0–34.7) in Italy (Dal Maso et al., 
2003a). An even higher risk for cervical cancer 
was reported among HIV-1-infected women in 
Spain (SIR, 41.8; 95%CI: 19.9–77.1) (Galceran 
et al., 2007). In Italy and Spain, the particularly 
elevated cervical cancer risk could be attributed to 
the concomitant high prevalence of intravenous 
drug users among HIV-1 women (who are at a 
particularly elevated risk of cervical cancer), and 
to poorly organized screening strategies in this 
population. Conversely, elevated rates of cervical 
cancer in the general population and competing 
risks of deaths are likely to explain the observa-
tion that risks from studies conducted in Africa 
tended to be of lower magnitude than those 
from developed countries (Serraino, 1999). For 
instance, a comparison of cancer rates between 
1988–2002 in Uganda showed that the relative 
risk of invasive cervical cancer among women 
with HIV-1, when compared to women in the 
general population, was 2.4 (95%CI: 1.1–4.4) 
(Mbulaiteye et al., 2006).
Trends in SIRs of cervical cancer indicate that 
the introduction of HAART has not influenced 
the occurrence of this cancer among HIV-1-
infected women. This observation was docu-
mented in the first years after HAART became 
available by a pooled analysis of cancer incidence 
data from 23 prospective studies that included 
47936 HIV-1-seropositive individuals from North 
America, Europe, and Australia (International 
Collaboration on HIV and Cancer, 2000), as well 
as by several other single investigations. Among 
2331 HIV-1-infected women in Italy and France, 
the risk of cervical cancer was 15.7 (95%CI: 
9.1–25) in those treated with HAART, and 11.8 
(95%CI: 3.8–27.5) in those who were not (Serraino 
et al., 2007). Also, in Italy, no change was noted 
by a record linkage study of AIDS and cancer 
registries with risks varying from 51.0 (95%CI: 
227
IARC MONOGRAPHS – 100B
23.1–97.3) in the pre-HAART period from 
1985–96 to 41.5 (95%CI: 28.0–59.3) in the post-
HAART era from 1997–2002 (Dal Maso et al., 
2009). Similar findings were documented in the 
USA (Bedimo et al., 2004; Biggar et al., 2007; Patel 
et al., 2008). Cervical cancer incidence rates were 
higher in 1996–2002 (86.5/100000 person–years) 
than in 1990–95 (64.2/100000 person–years) 
(RR, 1.41; 95%CI: 0.81–2.46), but this was not 
statistically significant (Biggar et al., 2007). Data 
from two large prospective cohort studies in the 
USA, the Adult and Adolescent Spectrum of HIV 
Disease (ASD) Project and the HIV Outpatient 
Study (HOPS) had statistically significant SIRs 
of 11.8 in 1992–95, 13.3 in 1996–99, and 10.1 in 
2000–03) (Patel et al., 2008).
(a) Cancer of the cervix in immunosuppressed 
individuals
The incidence of cervical cancer also increased 
in transplant recipients [SIR, 2.50; 95%CI: 1.33–
4.27] (Vajdic et al., 2006). Pre-invasive cervical 
cancer lesions altered in HIV-positive women led 
to the decision that the cohort study estimates 
were not just due to confounding.
See Table  2.10 available at http://mono-
graphs.iarc.fr/ENG/Monographs/vol100B/100B-
05-Table2.10.pdf, Table  2.11 available at http://
monog r aphs . ia rc . f r/ ENG/Monog r aphs/
vol100B/100B-05-Table2.11.pdf, and Table  2.12 
available at http://monographs.iarc.fr/ENG/
Monographs/vol100B/100B-05-Table2.12.pdf.
2 .4 .2 Cancer of the anus
A recent meta-analysis of population-based 
cohort studies estimated that rates of anal 
cancer are raised almost 30 times in people 
with HIV-1/AIDS, and are raised about 5 times 
in transplant recipients (Grulich et al., 2007a). 
Anal cancer is closely related to anal infection 
with high-risk subtypes of HPV (IARC, 2007). 
Determining whether anal cancer is associated 
with HIV-1 infection is complicated by the fact 
that HIV-1-negative homosexual men are much 
more likely than others to develop anal HPV 
infection and anal cancer (Daling et al., 1987). 
Nevertheless, cohort data do suggest that the rate 
of anal cancer is higher in HIV-1-positive than 
in HIV-1-negative homosexual men (D’Souza 
et al., 2008). Anal cancer occurs at younger 
ages in HIV-1-positive cases than in the HIV-1-
negative cases (Chiao et al., 2008; D’Souza 
et al., 2008). Among HIV-1-positive persons, 
lower CD4-positive counts are associated with 
a higher probability of infection with multiple 
HPV types (Orlando et al., 2008). HPV infection 
of the anal canal is extraordinarily prevalent in 
both people with HIV-1, and in transplant recipi-
ents (Drobacheff et al., 2003; Patel et al., 2007; 
Orlando et al., 2008). Rates of HPV infection of 
over 50% have been described even in HIV-1-
positive women (Palefsky et al., 2001), in whom 
anal cancer is relatively uncommon.
Many studies have noted increases in the 
incidence of anal cancer during the HAART era 
(Bower et al., 2004; Diamond et al., 2005; Hessol 
et al., 2007; D’Souza et al., 2008; Patel et al., 
2008; Piketty et al., 2008); this may be related 
to increased screening for anal cancer and its 
precursors, to an increase in risky behaviour of 
patients feeling safer by taking HAART, and/or 
to increased longevity allowing enough time for 
the cancer to develop (Hessol et al., 2007; Piketty 
et al., 2008). [The Working Group noted that 
although initially the introduction of a screening 
programme (as is beginning to occur in some 
specialized centres) may lead to an increase in 
the reported prevalence of a cancer, in the longer 
term, the detection and treatment of pre-invasive 
disease should lead to a decline in the incidence 
of invasive malignancy in the screened popula-
tion.] In the USA, record linkage of HIV/AIDS 
and cancer registries showed that the AIDS- and 
HIV-1-cancer matched rates of anal cancer were 
approximately the same in the pre- and post-
HAART eras (Engels et al., 2006; Engels et al., 
2008). Several studies conluded that the use of 
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HAART does not appear to reduce anal cancer 
risk (Clifford et al., 2005; Hessol et al., 2007; 
D’Souza et al., 2008;).
See Table  2.13 available at http://mono-
graphs.iarc.fr/ENG/Monographs/vol100B/100B-
05-Table2.13.pdf, Table  2.14 available at http://
monog r aphs . ia rc . f r/ ENG/Monog r aphs/
vol100B/100B-05-Table2.14.pdf, and Table  2.15 
available at http://monographs.iarc.fr/ENG/
Monographs/vol100B/100B-05-Table2.15.pdf.
2 .4 .3 Cancers of the vulva, vagina, and penis
A recent meta-analysis reported that rates of 
cancers of the vulva and vagina (SIR, 6.45; 95%CI: 
4.07–10.2) and penis (SIR, 4.42; 95%CI: 2.77–7.07) 
are increased in persons with HIV-1 (Grulich 
et al., 2007a). [The Working Group noted that the 
increase in transplant recipients is of a similar 
magnitude, suggesting that confounding by 
sexual behaviour does not completely explain the 
increased risk in people with HIV-1.] However, 
fewer than 50 cases of these cancers have been 
described in cohort studies of people with HIV-1 
(See Table  2.16 available at http://monographs.
iarc.fr/ENG/Monographs/vol100B/100B-05-
Table2.16.pdf).
2.5 Cancer of the skin
There has been limited research on non-
melanoma skin cancer in people with HIV-1, 
and a recent meta-analysis estimated that the 
rate was increased 4-fold (Grulich et al., 2007a). 
In contrast, in solid organ transplant recipients, 
rates of non-melanoma skin cancer are raised 
around 30-fold (Grulich et al., 2007a). While the 
majority of cases of non-melanoma skin cancer 
in transplant recipients is squamous cell carci-
noma, this does not appear to be the case in 
people with HIV-1, in whom basal cell carcinoma 
predominates (Bedimo et al., 2004). However, it 
is not clear whether data on basal cell carcinoma 
and squamous cell carcinoma are comparable in 
terms of completeness and allowance for differ-
ences in age distribution. In the US AIDS cancer 
match (record linked AIDS and cancer registries), 
increased rates of the rare Merkel cell carcinoma 
have been described (based on six cases), and 
this is also a cancer which has been described as 
occurring at increased rates in transplant recipi-
ents (Engels et al., 2002).
See Table  2.17 available at http://mono-
graphs.iarc.fr/ENG/Monographs/vol100B/100B-
05-Table2.17.pdf, and Table 2.18 available at 
http://monographs.iarc.fr/ENG/Monographs/
vol100B/100B-05-Table2.18.pdf.
2.6 Cancer of the conjunctiva
An association of HIV-1 with conjunctival 
cancer was first suggested by clinical observa-
tions of an increased number of diagnoses of this 
cancer in Africa at the time of the onset of the 
HIV-1 epidemic (Kestelyn et al., 1990; Waddell 
et al., 1996). Moreover, data from the Ugandan 
cancer registry demonstrated a 6-fold increase in 
incidence in the late 1980s compared to the inci-
dence rates in 1970–88 (Ateenyi-Agaba, 1995). 
Data in Table  2.19 (available at http://mono-
graphs.iarc.fr/ENG/Monographs/vol100B/100B-
05-Table2.19.pdf) and Table 2.20 (available at 
http://monographs.iarc.fr/ENG/Monographs/
vol100B/100B-05-Table2.20.pdf) demonstrate a 
consistent marked increase in risk of conjunc-
tival cancer among HIV-1-infected people, with 
a relative risk of around 10. One study described 
a case of conjunctival cancer that completely 
regressed after HAART was instituted with the 
occurrence of immune reconstitution (Holkar 
et al., 2005). Several studies suggest that mucosal 
HPV types are not involved in the etiology of this 
tumour, but a role for cutaneous types remains 
uncertain (de Koning et al., 2008).
Previous observations that conjunctival 
carcinoma was more common in tropical 
regions led to a hypothesis that exposure to solar 
ultraviolet (UV) radiation would be important 
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(Guech-Ongey et al., 2008). The risk is increased 
in those with a past history of skin cancer, and 
in an ecological analysis, rates were strongly 
correlated with ambient UV exposure (Newton, 
1996). In the USA, rates of AIDS-associated 
conjunctival cancer are higher in regions with 
higher ambient UV radiation (Guech-Ongey 
et al., 2008). Squamous cell carcinoma lesions 
contain classic UV-radiation-induced p53 
mutations (Waddell & Newton, 2007). A direct 
role of HIV-1-associated immune deficiency is 
supported by the fact that the incidence is also 
increased in kidney transplant recipients (based 
on five cases) (Vajdic et al., 2007). In addition, a 
case report of spontaneous regression of biopsy-
proven cancer in an African woman commencing 
HAART, co-incident with an improvement in 
CD4 count, has been described (Holkar et al., 
2005). In the largest African series of 476 cases 
diagnosed in Uganda in 1995–2001, 64% of cases 
were HIV-1-positive, and the median CD4 count 
in these was 111 cells/mL (Waddell et al., 2006). 
[The Working Group noted that the median CD4 
count was based on a subset of 159 cases.]
2.7 Cancer of the lung
Cancer of the lung is one of the most 
common cancers that occurs in men and 
women of the general population in developed 
countries (World Cancer Report, 2008). Most 
(> 90%) of the lung cancer cases are registered 
in cigarette smokers, and the risk of developing 
the disease is strongly associated with duration 
and intensity of the habit. Higher prevalence 
of smokers among HIV-1-infected people, as 
compared to their referent general population, 
has been hypothesized, but not well documented 
(Parker et al., 1998; Bower et al., 2003). In the 
USA, among a national representative sample 
of persons receiving care for HIV-1 infection in 
the late 1990s, 73% had ever smoked and 51% 
were current smokers, which is a much higher 
proportion than the 20–30% of the general US 
population who currently smoke (Giordano & 
Kramer, 2005). However, there was no evidence 
of an excess risk for lung cancer in HIV-1-infected 
people until prolonged survival due to the use of 
HAART had enhanced the likelihood of these 
persons developing cancer types (including lung 
cancer) rarely noted in the pre-HAART era. The 
epidemiological evidence of a statistically signifi-
cant excess risk for lung cancer was consolidated 
in the post-HAART era, with relative risks in the 
range of 2–4 (Bower et al., 2003; Dal Maso et al., 
2003a; Chaturvedi et al., 2007; Patel et al., 2008). 
The magnitude of the excess risk was, in Italy, 
2.4 (95%CI: 1.5–3.7) during 1985–98 (Dal Maso 
et al., 2003a); in the USA, 4.5 (95%CI: 4.2–4.8) 
during 1992–95, and 2.8 (95%CI: 2.4–3.1) during 
2002–05 (Frisch et al., 2001); and in Switzerland, 
3.2 (95%CI: 1.7–5.4) during 1985–2003 (Clifford 
et al., 2005). A meta-analysis of seven reports of 
HIV-1-associated cancer risk, involving 444172 
people with HIV-1/AIDS in the USA, Australia, 
Scotland, Italy, Switzerland, and England 
reported an overall relative risk of 2.7 (95%CI: 
1.9–3.9) (Grulich et al., 2007a).
Studies that assessed the risk of lung cancer 
in HIV-1-infected people according to individual 
antiretroviral treatment failed to demonstrate 
an effect of HAART on lung cancer risk, thus 
indicating that lung cancer is not strongly asso-
ciated with severe immunosuppression (Clifford 
et al., 2005; Serraino et al., 2007). In the United 
Kingdom, incidence rates of lung cancer increased 
from 0.8 (95%CI: 0.2–3.2)/105 patient–years 
follow-up in the pre-HAART era to 6.7 (95%CI: 
3.1–13.9)/105 patient–years follow-up in the post-
HAART era (Bower et al., 2003), while in Italy, 
incidence rates were 10.7 (95%CI: 6.2–17.2)/104 
person–years and 14.1 (95%CI: 3.7–36.4)/104 
person–years, respectively (Dal Maso et al., 
2003b). An update of these data indicated that 
the SIR for lung cancer among Italian people with 
AIDS has nearly doubled from the pre- to the 
post-HAART period, from 2.1 (95%CI: 1.2–3.3) 
during 1985–96 to 4.1 (95%CI: 2.9–5.5) during 
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1997–2004 (Dal Maso et al., 2009). [The Working 
Group noted that several aspects regarding the 
role of HIV-1-induced immunosuppression in 
the etiology of lung cancer still need to be clari-
fied, because factors like duration and intensity 
of smoking have not been controlled for, and 
could deeply confound the association between 
HIV-1 infection and lung cancer.]
Several studies have attempted to control 
for confounding by smoking but residual 
confounding is possible in these studies (Engels 
et al., 2006; Kirk et al., 2007). In a population 
where smoking rates did not differ by HIV-1 
status, lung cancer was not related to HIV-1 
status (Stein et al., 2008a). In the USA, it has been 
estimated that nearly twice as many cases of lung 
cancer would be observed in HIV-1-infected 
persons than the general population, simply 
because of the higher prevalence of smoking 
in that population (Giordano & Kramer, 2005). 
Only one study regarding the risk of lung cancer 
among HIV-1-infected persons (Phelps et al., 
2001) has included a control group with a history 
of smoking similar to that of the study group. 
Nearly 90% of the persons included in the study 
had ever smoked, and no statistically significant 
increase in the risk of lung cancer was reported. 
Interestingly, one study found a higher SIR for 
lung cancer among injecting drug users not 
infected with HIV-1 than among HIV-1-infected 
persons, which is further evidence that the rela-
tionship of HIV-1 infection to lung cancer is 
confounded by an exposure, most likely smoking 
(Serraino et al., 2000). [The Working Group noted 
that, clearly, persons with HIV-1 infection are at 
increased risk for lung cancer, compared with 
persons without HIV-1 infection. Much of that 
risk is due to the high prevalence of smoking in 
the HIV-1-infected population. Studies of large 
cohorts that can adequately adjust for smoking 
are needed to determine if HIV-1 infection itself 
increases the risk of lung cancer; in addition, 
Kaposi sarcoma can appear in the lungs and be 
potentially misdiagnosed as lung cancer.]
See Table  2.21 available at http://mono-
graphs.iarc.fr/ENG/Monographs/vol100B/100B-
05-Table2.21.pdf, and Table  2.22 available at 
http://monographs.iarc.fr/ENG/Monographs/
vol100B/100B-05-Table2.22.pdf.
2.8 Cancer of the liver
HIV-1-positive persons, in particular injecting 
drug users, have a greatly increased prevalence 
of HBV and HCV infections compared to the 
general population, and hence are at a higher 
risk for liver cancer (i.e., hepatocellular carci-
noma [HCC]) (Thio et al., 2002; Hisada et al., 
2005; Kramer et al., 2005; McGinnis et al., 2006). 
Studies on HBV/HCV natural history have 
shown that HIV-1-related immune suppression 
worsens the risk of cirrhosis and of liver-related 
death (Di Martino et al., 2001; Graham et al., 
2001; Thio et al., 2002; Kramer et al., 2005), but a 
direct effect of HIV-1-related immunodeficiency 
on HCC risk has not yet been demonstrated 
(Frisch et al., 2001; Kramer et al., 2005; McGinnis 
et al., 2006). Following the widespread use of 
HAART, liver disease has become a progres-
sively more important cause of morbidity and 
mortality among HIV-1-infected persons (Louie 
et al., 2002; Weber et al., 2006). Findings from 
cohort investigations, record linkage of HIV-1/
AIDS registries with population-based cancer 
registries and case–control studies conducted 
across Europe, the USA and Australia have 
documented 2–20-fold excess risks for HCC. 
A 5.2-fold elevated risk (95%CI: 3.3–8.2) was 
reported in a meta-analysis of seven population-
based studies of people with HIV-1 (Grulich 
et al., 2007a). Excess risks were more pronounced 
among HIV-1-infected injecting drug users (SIR, 
50.5; 95%CI: 15.9–11; Clifford et al., 2005) (SIR, 
24.3; 95%CI: 2.3–89.3; Serraino et al., 2000); than 
among other HIV-1-transmission categories, 
and among HIV-1-infected persons with low 
CD4-positive cell counts (Clifford et al., 2008). 
There is evidence indicating that the advanced 
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immunosuppression associated with HIV-1 
disease progression does not influence the occur-
rence of HCC (Frisch et al., 2001), but the role of 
HAART still needs to be better defined. Relative 
risks for HCC were higher in the HAART era 
than in preceding years (Hessol et al., 2007), 
though studies based on individual data on 
HAART use either reported lack of association 
(Serraino et al., 2007) or a significantly reduced 
risk of HCC in people treated with HAART (RR, 
0.3; 95%CI: 0.1–0.9) (Hessol et al., 2007). Data 
from African studies do not report an increase 
in risk in association with HIV-1 for that cancer 
(Newton et al., 2001; Mbulaiteye et al., 2006; 
Stein et al., 2008a).
See Table  2.23 available at http://mono-
graphs.iarc.fr/ENG/Monographs/vol100B/100B-




2 .9 .1 Cancer of the lip
A meta-analysis that included only studies 
that linked HIV-1/AIDS and cancer registries 
found an SIR for cancer of the lip of 2.80 (95%CI: 
1.91–4.11), and in solid organ transplant recipi-
ents, the SIR was 30.0 (95%CI: 16.3–55.3) (Grulich 
et al., 2007a). In the US AIDS cancer match, there 
was an increased risk of lip cancer, and a trend 
towards increasing risk across the pre- and post-
AIDS periods, suggesting a link with advancing 
immune deficiency (Frisch et al., 2001).
2 .9 .2 Cancer of the head and neck
A meta-analysis that included only studies 
that linked HIV-1/AIDS and cancer registries 
found an SIR for oral cavity and pharyngeal 
cancer of 2.32 (95%CI: 1.65–3.25), and in solid 
organ transplant recipients, the SIR was 3.23 
(95%CI: 2.40–4.35) (Grulich et al., 2007a). In 
people with HIV-1, HPV is particularly frequent, 
and it is also possible that the increase in rates 
is due to confounding factors, in particular, 
increased rates of smoking (Frisch et al., 2001; 
Haigentz, 2005; Silverberg & Abrams, 2007).
2 .9 .3 Cancer in transplant patients
Data on cohort studies of transplant recipi-
ents are presented in Table  2.25 (available at 
http://monographs.iarc.fr/ENG/Monographs/
vol100B/100B-05-Table2.25.pdf). Transplant 
recipients share immune suppression with 
people with HIV-1, but are not at an increased 
risk of oncogenic sexually transmitted viruses. 
[The Working Group concluded that if cancer 
patterns are similar between these two popula-
tions, it is likely that immune deficiency is the 
main factor involved.]
3. Cancer in Experimental Animals
In this volume, the Working Group decided 
not to include a separate section on “Cancer in 
Experimental Animals” in the Monographs on 
viruses but rather to include description of such 
studies under Section 4 (below). The reasoning 
for this decision is explained in the General 
Remarks.
4. Other Relevant Data
The first indication of the AIDS pandemic 
came in October of 1981 from the observation that 
a specific type of cancer, namely Kaposi sarcoma, 
was occurring with increased frequency in 
young homosexual men (Friedman-Kien, 1981). 
This report was quickly followed by the recog-
nition that the same risk group was affected by 
increased opportunistic infections and immu-
nodeficiency (Gottlieb et al., 1981; Siegal et al., 
1981), and the discovery of an AIDS-associated 
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virus, HIV (see Section 1). While HIV-1-infection 
has never been shown to transform any cell type, 
it is now clear that infected individuals are at a 
greatly increased risk for cancer development. 
The prevailing opinion is that HIV-1 acts indi-
rectly, mainly through immunosuppression.
4.1 Biochemical and biological 
properties of relevant HIV-1 
proteins
The proteins encoded by HIV-1 are illustrated 
in Fig. 1.1 (see Section 1.1). Several HIV-1 proteins 
are conserved as is the case for all other retrovi-
ruses. These include the structural proteins and 
viral enzymes described in Section 1.1. Although 
none of the proteins encoded by HIV-1 has been 
unequivocally shown to be directly oncogenic, 
some are unique to lentiviruses, and are associ-
ated with immunodeficiency, thereby indirectly 
promoting cancer development. In addition, 
there is evidence that some of the HIV-1-encoded 
proteins may promote cancer by other indirect 
mechanisms that are not dependent on immuno-
deficiency. Some of the proteins that are unique 
to HIV-1 and related immunodeficiency lentivi-
ruses are discussed below.
4 .1 .1 Tat
This multifunctional protein is an impor-
tant regulator of viral transcription. Tat recruits 
cellular transcription factors to the HIV-1 
promoter. Tat interacts with the protein–kinase 
complexes Cdk9/cyclin T1 and Cdk2/cyclin 
E, with p300/CBP, p300/CBP-associated factor 
and hGCN5, and with protein phosphatases, 
and multiple other cellular proteins. Tat vastly 
increases the level of transcription of the HIV-1 
DNA by inducing a positive feedback loop 
(Gatignol, 2007). It can also affect the course 
of HIV-1-associated disease indirectly, as it is 
secreted by infected cells, and can enter uninfected 
cells (Gupta & Mitra, 2007). Extracellular Tat 
has many functions, which are thought to play a 
major role in enabling HIV-1 to escape immune 
surveillance, and to act as a viral toxin contrib-
uting to the pathology of AIDS. Extracellular 
Tat is able to regulate cytokine–gene expression 
(Marone et al., 2000), and immune cell hyperac-
tivation (Kwon et al., 2008). Arguments in favour 
of Tat being involved in oncogenesis include:
• Tat can induce apoptosis in neighbour-
ing uninfected cells when secreted from 
infected cells (Li et al., 1995; Westendorp 
et al., 1995; Alimonti et al., 2003). This is 
thought to be due to the ability of Tat to 
upregulate the expression of Fas ligand 
mRNA in macrophages and increase the 
susceptibility of bystander CD4-positive 
T cells to crosslinking-induced death. 
This may contribute to the massive deple-
tion of CD4-positive T cells by apoptosis, 
leading to the severe immunodeficiency 
seen in AIDS.
• Tat has been shown to stimulate the 
growth of Kaposi sarcoma cells (Vogel 
et al., 1988; Aoki & Tosato, 2007; see 
Section 4.3).
Nevertheless, it appears that although Tat 
may contribute to carcinogenesis, it is probably 
involved only as a cofactor. While early studies 
found an increased incidence of lymphomas in 
Tat-transgenic mice (Corallini et al., 1993), these 
do not faithfully replicate the pathology of AIDS-
related malignancies (Altavilla et al., 2004).
Other effects of extracellular Tat include 
repression of major histocompatibility complex 
class I transcription (Weissman et al., 1998), and 
upregulation of the expression of CXC-chemokine 
receptor 4 (CXCR4) on resting CD4-positive T 
cells (Secchiero et al., 1999).
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4 .1 .2 Rev
The HIV-1 Rev protein regulates post-tran-
scriptional processing of viral mRNAs. Rev 
primarily functions to export unspliced and 
partially spliced viral RNAs from the nucleus 
into the cytoplasm (Suhasini & Reddy, 2009). 
Currently there is no evidence to support a direct 
role of this protein in the development of cancer.
A specific feature of primate immunode-
ficiency viruses is the presence of accessory 
proteins (e.g., Nef, Vif, Vpr, Vpu), which play 
a role in helping the virus to evade the various 
forms of cell-mediated antiviral resistance, 
thereby ensuring viral persistence and transmis-
sion (Malim & Emerman, 2008).
4 .1 .3 Nef
Nef is a multifunctional regulatory protein 
that affects HIV-1 virulence (Kestler et al., 1991; 
Deacon et al., 1995). Carriers of HIV-1 strains 
with Nef deletions have been identified, and they 
are characterized as slow progressors or long-
term non-progressors. The mechanisms whereby 
Nef favours the development of AIDS remain 
unclear, but there are some interesting insights 
(Foster & Garcia, 2008). Nef downregulates 
CD4 (Garcia & Miller, 1991), thus preventing 
the interaction of budding virions on infected 
cells with CD4, which would interfere with the 
production of fully infectious virions. Nef also 
downregulates the expression of surface major 
histocompatibility complex class I by altering 
the endocytotic machinery (Blagoveshchenskaya 
et al., 2002), thereby protecting infected cells 
from destruction by cytotoxic T lymphocytes 
(Collins et al., 1998). Nef protects infected cells 
from apoptosis (Baur et al., 1994). In addition, 
Nef manipulates signalling via multiple intracel-
lular kinases, thereby enabling infected dendritic 
cells and macrophages to attract, and subse-
quently infect, permissive CD4-positive T cells 
(Pope et al., 1994; Swingler et al., 1999, 2003). 
Similarly to the HIV-1 Tat protein, infected cells 
release the Nef protein into the extracellular 
environment and affect neighbouring cells (Fujii 
et al., 1996). Through this mechanism, Nef has 
been shown to be responsible for some B-cell 
defects seen in HIV-1-infected individuals by 
suppressing CD40-dependent immunoglobulin 
class-switching in bystander B cells (Qiao et al., 
2006). Therefore, Nef affects B-cell differen-
tiation and antigen selection, and contributes to 
immune dysregulation. These findings suggest 
that Nef may play a role in lymphomagenesis, but 
this has not been demonstrated experimentally.
4 .1 .4 Vif
The accessory protein Vif is involved in the 
inhibition of cytoplasmic defenses. It is critical for 
in vivo replication of HIV-1, and for the produc-
tion of infectious virions in a cell-type specific 
manner (Malim & Emerman, 2008). There is no 
evidence that Vif plays a role in AIDS-related 
malignancies.
4 .1 .5 Vpr
Truncation of the open reading frame that 
encodes the Vpr protein results in a slower-repli-
cating virus (Wong-Staal et al., 1987). In vitro 
analysis has demonstrated various Vpr functions 
that may contribute to HIV-1 pathogenesis. Vpr 
has been found to induce cell-cycle arrest in G2, 
followed by apoptosis, thereby leading to viral 
cytopathic effects in T cells (Andersen et al., 
2008). There is no evidence that Vpr plays a role 
in AIDS-related malignancies.
4 .1 .6 Vpu
The Vpu protein reduces the surface expres-
sion of CD4 of the host cell, and modulates the 
subcellular compartmentalization of the host 
membrane protein tetherin to help promote 
viral dissemination and replication (Malim & 
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Emerman, 2008). There is no evidence that Vpu 
plays a role in AIDS-related malignancies.
4.2 HIV-1, host immune system, and 
carcinogenesis
4 .2 .1 Comparison of AIDS-related and 
transplantation-associated tumours
(a) Immunosuppression
Although individuals with AIDS and those 
with iatrogenic immunosuppression following 
organ transplantation have immunodeficiency 
in common, the immunological abnormali-
ties appear to differ significantly between these 
two conditions. A direct comparison is diffi-
cult because the immune dysregulation in both 
groups can be qualitatively and quantitatively 
heterogeneous. Among transplant recipients, 
immunodeficiency depends on multiple factors. 
The immunosuppressive regimen can be a major 
determinant of the immunological dysfunction, 
and these regimens vary according to the organ 
transplanted (for example, there is more tolerance 
for rejection in kidney than in heart/lung trans-
plants), age, and time (as therapeutic approaches 
have evolved). Cytotoxic CD8-positive T-cell 
responses, in particular to EBV, have been 
recognized as a common immunological defect 
in organ transplant recipients with lymphopro-
liferative diseases (Kyaw-Tanner et al., 1994). 
One study that focused on immune function 
in renal transplant patients found that the most 
common abnormality was B-cell lymphopenia 
(seen in 85% of the patients), followed by reduced 
production of reactive oxygen species in neutro-
phils (in 63%), NK-cell lymphopenia (in 50%), 
and abnormal lymphocyte mitogen response (in 
49%). A low CD4 count was only found in about a 
quarter of the patients (Hutchinson et al., 2003). 
A characteristic feature of AIDS is CD4 defi-
ciency, which is well documented to be central 
to disease progression, but in addition, there 
is B-lymphocyte hyperactivation with hyper-
gammaglobulinaemia, and increased release of 
soluble markers from activated cells (De Milito, 
2004). However, AIDS patients, in particular 
those with advanced disease, suffer from a severe 
loss of memory B cells, and an impaired long-
term serological memory (Titanji et al., 2006). In 
HIV-1-infected individuals, EBV-specific cyto-
toxic T cells have been found in normal numbers, 
but their functional capacity decreases as AIDS 
progresses until, finally, immunological collapse 
occurs (Kersten et al., 1997; van Baarle et al., 
2001). Thus, the immune dysfunction in AIDS 
patients and transplant recipients is heteroge-
neous, and although it is different between these 
two categories, there is also overlap in immuno-
logical defects in selected groups of individuals.
(b) Cancer types
An obvious similarity between post-trans-
plant and AIDS patients is the increased inci-
dence in B-cell lymphomas, which often have 
plasmacytoid differentiation, and are associ-
ated with EBV. However, there are significant 
differences in lymphoma subtypes (Raphael & 
Knowles, 1990; Swerdlow et al., 2008). Specific 
differences include more frequent high-grade 
lymphomas in the setting of HIV-1 infection, 
and a more frequent EBV association and poly-
morphic lesions in transplant recipients (see 
Table 4.1).
 The second important malignancy that is 
greatly increased in incidence in HIV-1-infected 
individuals and transplant recipients is Kaposi 
sarcoma. This is the most common cancer in 
patients with HIV-1, and an AIDS-defining 
condition. A recent study of renal transplant 
recipients reported a more than 20-fold increased 
incidence of Kaposi sarcoma compared with the 
general population (Kasiske et al., 2004). While 
Kaposi sarcoma tends to be more aggressive in 
patients with AIDS than in those with other 
immunodeficiencies, there are no differences in 
histological, immunophenotypic, virological or 
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molecular features of AIDS-associated and post-
transplant-related Kaposi sarcoma. Both types 
may regress (but they not always do) after recon-
stitution of the immune response.
4 .2 .2 Immune dysfunction and 
carcinogenesis
The importance of immunodeficiency is easy 
to understand in the context of virus-associated 
malignancies. The three most common cancers 
in HIV-1-infected individuals are Kaposi 
sarcoma (caused by KSHV), lymphomas (many 
EBV-positive), and cervical and anogenital carci-
nomas associated with HPV infection. These 
infectious etiologies explain the reasons as to why 
the associated cancers are greatly increased in 
individuals with immunodeficiencies. Infection 
by “oncogenic” viruses is much more common 
than the diseases caused by those viruses, and 
the incidence and severity of these cancers is 
greatly increased by immunodeficiency. Viruses 
have evolved to survive through three essential 
properties: they can go from host to host (trans-
mission), get in and out of the host cells (lytic 
replication), and remain in the host in live cells 
without being recognized by its immune system 
(latency).
Immune dysregulation per se may facilitate 
cancer development. A clear example of this 
phenomenon is the B-cell hyperactivation mani-
fested by lymphadenopathies seen in HIV-1-
infected patients. Lymph nodes from these 
patients are characterized by a florid follicular 
hyperplasia, where the germinal centres are 
greatly enlarged. The germinal centre reaction is 
where B cells undergo somatic hypermutation of 
immunoglobulin genes and class-switch recom-
bination. These are dangerous processes in that if 
uncorrected mistakes are made, oncogenic genetic 
alterations can occur. These mistakes can lead to 
translocations involving the cMyc oncogene and 
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Table 4 .1 Major categories of lymphoproliferations associated with acquired immunodeficiency
Lymphoma subtype and 
frequency
Approximate 










Burkitt and Burkitt-like 
lymphoma
30% 30–50% (Rare) c-Myc, p53, BCL-6
DLBCL-Centroblastic 25% 30% (Rare) BCL-6
DLBCL-Immunoblastica 22% > 80% (Common)
Primary effusion lymphomaa 2–4% 70–90% (None) KSHV infection
KSHV-positive extracavitary 
lymphomaa
2–4% > 80% (Unknown) KSHV infection
Polymorphic B-cell 
lymphoma (PTLD-like) a
Rare 40% (Unknown) Unknown
Plasmablastic lymphoma of 
oral cavitya
Rare 80% (Rare) Unknown




Plasmacytic hyperplasia 30% > 90% (Common) None




20% 60% (Variable) BCL-6, c-Myc, N-Ras, 
p53
a These lymphoma subtypes occur much more frequently or almost exclusively in HIV-1-infected individuals, and share frequent EBV-
positivity and plasmacytoid differentiation.
DLBCL, diffuse large B-cell lymphoma; PTLD, post-transplant lymphoproliferative disorder; CNS, central nervous system
Adapted from Cesarman & Chadburn (2007)
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mutations in the p53 tumour-suppressor gene, 
giving rise to Burkitt lymphomas.
4.3 HIV-1 and other infectious agents 
associated with human cancers
The HIV-1 genome is not present in cancer 
cells, which is in contrast to what is observed 
with infectious agents that are directly onco-
genic. Therefore, any interaction between virus 
and host is indirect. The interaction between 
HIV-1 and some of the other infectious agents 
reviewed in this volume is discussed below.
4 .3 .1 KSHV
(a) In vivo
KSHV and HIV-1 are not present in the same 
cells. In germinal centres of patients with HIV-1 
infection, HIV-1 is frequently in dendritic cells 
and T cells (Burton et al., 2002), whereas KSHV 
is present in mantle zone B cells (Dupin et al., 
1999; Amin et al., 2003). In Kaposi sarcoma 
lesions, HIV-1 is localized to tumour-associated 
macrophages, whereas KSHV is in the Kaposi 
sarcoma spindle cells (Gessain & Duprez, 2005).
(b) At the molecular level
The only HIV-1 protein for which there is 
experimental evidence for a potential role in 
Kaposi sarcoma is Tat. Biologically active Tat is 
released by HIV-1-infected cells (Chang et al., 
1997), and it can enter readily into neighbouring 
infected and uninfected cells (Gupta & Mitra, 
2007), a property that has also been found for 
other cationic peptides. Three endocytic path-
ways appear to account for this process: macro-
pinocytosis, clathrin-mediated endocytosis, 
and caveolae/lipid-raft-mediated endocytosis 
(Duchardt et al., 2007). This indicates that 
although HIV-1 does not directly infect tumour 
cells, it has the potential to produce Tat, which 
may then enter the tumour cells, although this 
phenomenon has not been demonstrated to 
occur in vivo. Nevertheless, the potential effects 
of Tat have prompted investigators to test a role 
for HIV-1, and specifically the Tat protein, in 
Kaposi sarcoma development (Aoki & Tosato, 
2007). Tat binds and activates the Flk-1/kinase 
insert domain receptor (Flk-1/KDR) (Albini 
et al., 1996; Morini et al., 2000). Transgenic mice 
expressing HIV-1 Tat were found to develop 
vascular lesions that resembled Kaposi sarcoma 
(Vogel et al., 1988). Several studies found that 
Tat has an effect on Kaposi sarcoma cell lines, 
increasing proliferation in vitro, and growth in 
mice (Ensoli et al., 1990; Barillari et al., 1999a, 
b; Morini et al., 2000). However, when cells 
are removed from Kaposi sarcoma lesions and 
expanded in vitro, they lose the KSHV genome, 
therefore the question remains whether the 
“Kaposi sarcoma” cells lacking KSHV used in 
most of these studies represent a valid model for 
Kaposi sarcoma.
More recently, investigators have addressed 
the role of HIV-1 directly on KSHV infection. 
Individuals with Kaposi sarcoma and HIV-1 
infection had a 4-fold higher KSHV viral load in 
serum than those with Kaposi sarcoma without 
HIV-1 (Chandra et al., 2003). HIV-1 can induce 
lytic replication of KSHV by upregulating the 
expression of the replication and transcription 
activator (Rta) protein, which is the main regu-
lator of the lytic switch in this virus (Varthakavi 
et al., 2002). The HIV-1 Tat protein was shown 
to enhance the entry of KSHV into endothelial 
cells, thereby promoting KSHV cellular trans-
mission (Aoki & Tosato, 2004). Conversely, 
KSHV can increase HIV-1 replication in T cells, 
monocytic cells, and endothelial cells (Mercader 
et al., 2001; Caselli et al., 2005). Thus, there is 
evidence that HIV-1 and KSHV may enhance 
each other’s replication, which could be a mecha-
nism whereby HIV-1 can act as a cofactor in the 
complex process of Kaposi sarcomagenesis.
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4 .3 .2 EBV
There is some experimental evidence for a direct 
role for HIV-1 in EBV-related lymphomagenesis 
apart from the epidemiological associations, but 
most of the increase in incidence is probably due 
to immune dysfunction. As mentioned above, 
HIV-1 is not found to be present in lymphoma 
cells, but the virus can infect primary human 
B cells, and activate the expression of endog-
enous EBV (Astrin & Laurence, 1992). It is also 
possible that HIV-1-encoded proteins like Tat 
affect the growth of EBV-immortalized B cells 
(Colombrino et al., 2004). Several studies where 
interactions between HIV-1 and EBV have been 
tested involve the forced expression of viral 
proteins or infection with both viruses of cells 
that are not naturally co-infected (Kenney et al., 
1988; Scala et al., 1993; Zhang et al., 1997).
4 .3 .3 HPV
The third most common malignancy in HIV-1-
positive individuals, and an AIDS-defining 
condition, is cervical carcinoma associated 
with HPV infection. Anogenital intraepithelial 
neoplasms and carcinomas are also increased 
in frequency, and so are skin cancers associated 
with HPV infection. Infection of HPV-infected 
cells with HIV-1, or addition of Tat, induces 
transcriptional activation of the integrated HPV 
(Vernon et al., 1993; Dolei et al., 1999), and 
proliferation of infected cells (Kim et al., 2008). 
However, a direct interaction between HIV-1 and 
HPV has not been demonstrated to occur in vivo.
4 .3 .4 HBV and HCV
HIV-1-infected individuals have a greatly 
increased incidence of infection with HBV and 
HCV, and are therefore at risk for HCC (Grulich 
et al., 2007a). Although interactions between 
HBV and HIV-1 in co-infection experiments in 
vitro have been demonstrated (Barak et al., 2001; 
Gómez-Gonzalo et al., 2001), these have not been 
shown to occur in vivo.
4.4 Animal models for HIV-1-
associated cancers
Because HIV-1, like the oncogenic herpes-
viruses EBV and KSHV, is species-specific, 
there are no ideal animal models for HIV-1-
associated cancers. Four main approaches have 
been explored: a) the analysis of malignancies 
occurring in animals infected with the corre-
sponding animal virus (i.e., SIV, simian EBV, 
etc); b) xenograft studies; c) the use of transgenic 
mice expressing selected viral oncogenes; and d) 
the use of chimeric mice infected with human 
viruses.
4 .4 .1 Lymphomas in animals infected with 
species-specific viruses
Lymphomas occurring in HIV-1-infected 
individuals have been compared with those 
in SIV-infected macaques (Baskin et al., 2001). 
Like in humans, most simian AIDS-associated 
lymphomas are of the B-cell type, and may 
be classified as either immunoblastic/large-
cell lymphoma or Burkitt-like lymphoma. 
Furthermore, these simian lymphomas tend to 
be morphologically indistinguishable from the 
same lymphomas occurring in humans. The 
systemic simian AIDS-associated lymphomas 
in rhesus monkeys frequently contain rhesus 
lymphocryptovirus (LCV), while simian AIDS-
associated lymphomas in cynomolgus monkeys 
contain herpesvirus Macaca fascicularis 1 
(HVMF-1), both of which are homologues of 
EBV (Li et al., 1994; Habis et al., 1999), thereby 
replicating virological AIDS-related lymphomas 
in humans. A rhesus monkey rhadinovirus 
that is closely related to KSHV has also been 
described (Desrosiers et al., 1997). Although 
lymphoid hyperplasias and sometimes extran-
odal lymphomas are seen in some of these 
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monkeys (Wong et al., 1999; Orzechowska et al., 
2008), neither primary effusion lymphoma or 
Kaposi sarcoma have been observed.
The similarities between simian and human 
AIDS-related lymphomas make these animal 
models very attractive for mechanistic studies, 
but they are limited by the fact that the incidence 
of lymphoma is relatively low. While this low inci-
dence is not dissimilar to that seen in humans, 
it makes experiments with the monkeys chal-
lenging and expensive. For this reason, mouse 
models have been developed. The murine gamma-
herpesvirus 68 (gamma-HV68) is a member of 
the gammaherpesvirus family related to EBV 
and KSHV, and has been very useful in studies 
aimed at understanding the mechanisms of viral 
persistence and replication in vivo, and the role 
of several viral proteins. Lymphoproliferative 
disease, including lymphoma, has been reported 
in association with gamma-HV68 infection in 
wild-type mice, but at a low incidence (9%), and 
after a prolonged incubation period (up to 3 years) 
(Sunil-Chandra et al., 1994). More recently, infec-
tion with gamma-HV68 of beta2-microglobulin-
deficient mice was found to induce an atypical 
lymphoid hyperplasia that is similar to post-
transplantation lymphoproliferative disease, and 
this model has been used to evaluate the function 
of some viral genes in pathogenesis (Tarakanova 
et al., 2005, 2008).
4 .4 .2 Xenograft studies
Transplanting human cancers into immu-
nodeficient mice is a common approach to 
evaluate the biology and possible treatment strat-
egies for malignancies. Such models of HIV-1-
related cancers include those for EBV-associated 
lymphomas (Nilsson et al., 1977; Mosier et al., 
1990; Mosier, 1991), primary effusion lymphoma 
(Picchio et al., 1997; Staudt et al., 2004; Keller et al., 
2006), and Kaposi sarcoma (Masood et al., 1997; 
Barillari et al., 1999b; Mutlu et al., 2007). Most 
Kaposi sarcoma models are imperfect, however, 
because the cells from Kaposi sarcoma lesions 
lose the KSHV genome. In an attempt to resolve 
this, murine and human haematopoietic precur-
sors were infected with a bacterial artificial chro-
mosome containing the entire KSHV genome 
(KSHV Bac36), and spindle cell sarcomas were 
obtained, which had some interesting features in 
common with Kaposi sarcoma (An et al., 2006; 
Mutlu et al., 2007).
4 .4 .3 Viral malignancies in chimeric mice
Several attempts have been made to develop 
a mouse model of herpesviral malignancy by 
infecting chimeric mice. One of the first such 
studies used BNX immunodeficient mice to 
graft human B cells, followed by injection of EBV 
particles, which led to the development of rapidly 
fatal, polyclonal lymphomas (Dosch et al., 1991). 
More recently, immunodeficient mice recon-
stituted with human haematopoietic stem cells 
followed by EBV infection have been used to 
evaluate immune responses to EBV (Melkus 
et al., 2006); some of these mice also developed 
B-cell lymphoproliferative disorders (Yajima 
et al., 2008). Immunodeficient mice transplanted 
with human fetal thymus and liver grafts have 
been shown to be susceptible to KSHV infection. 
There was no effect of HIV-1 on KSHV viral 
replication, or vice versa (Dittmer et al., 1999). 
In addition, human haematopoietic stem cells 
have been infected with KSHV before transfer 
into immunodeficient mice (Wu et al., 2006), 
but these KSHV-infected mice did not develop 
angioproliferative or lymphoproliferative 
diseases. This may be due to the fact that these 
systems do not fully replicate the complexity of 
Kaposi sarcoma and lymphoma development in 
humans, or that these diseases would develop in 
only very rare occasions in mice, as is the case 
with KSHV-infected people. In contrast, injec-
tion of KSHV in human skin engrafted on SCID 
mice was found to induce Kaposi-sarcoma-like 
lesions (Foreman et al., 2001).
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4.5 Synthesis
HIV-1 increases the cancer risk in humans 
indirectly, primarily by immunosuppression.
Many of the AIDS-defining malignancies 
have a different primary cause, e.g. EBV, HPV, 
and KSHV.
In addition to HIV-1-mediated immuno-
suppression, other aspects of the HIV-1 biology 
contribute to the increased cancer incidence 
in AIDS patients. Suggested mechanisms 
include HIV-1-mediated immune dysregula-
tion, in particular B-cell hyperactivation, and 
perhaps effects of the secreted HIV-1 Tat protein. 
However, unlike what is known about other 
cancer-associated viruses, there is no evidence 
that HIV-1-infection by itself leads to cell trans-
formation or immortalization.
5. Evaluation
There is sufficient evidence in humans for the 
carcinogenicity of infection with HIV-1. Infection 
with HIV-1 causes cancer of the cervix, anus, and 
conjunctiva, and Kaposi sarcoma, non-Hodgkin 
lymphoma, and Hodgkin lymphoma. Also, a 
positive association has been observed between 
infection with HIV-1 and cancer of the vulva and 
vagina, penis, and hepatocellular carcinoma, and 
non-melanoma skin cancer
Infection with HIV-1 is carcinogenic to 
humans (Group 1).
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Human papillomaviruses were considered by a previous IARC Working Group in 2005 (IARC, 
2007). Since that time, new data have become available, these have been incorporated in 
the Monograph, and taken into consideration in the present evaluation.
1. Exposure Data
1.1 Taxonomy, structure, and biology
A concise overview of the taxonomy, struc-
ture, and biology of the human papillomavirus 
(HPV) is given below. For a more comprehensive 
description, the reader is referred to Volume 90 
of the IARC Monographs (IARC, 2007).
1 .1 .1 Taxonomy
All papillomaviruses belong to the 
Papillomaviridae family, which includes 16 
different genera. Of these, the alpha genus 
contains the viruses associated with the devel-
opment of mucosal tumours in humans, and the 
beta genus contains those that are associated with 
the development of cutaneous tumours (Fig. 1.1).
1 .1 .2 Structure of the virion
Papillomaviruses are small non-enveloped 
icosahedral viruses of approximately 50–60 nm 
in diameter, containing a circular, double-
stranded DNA genome (~7000–8000  bp) that 
exists in a chromatinized state.
1 .1 .3 Structure of the viral genome
The HPV genome is divided into three regions: 
the long control region (LCR), which regulates 
viral gene expression and replication; the early 
(E) region, which encodes proteins required for 
viral gene expression, replication and survival; 
and the late (L) region, which encodes the viral 
structural proteins. The designations E and L 
refer to the phase in the viral life cycle when these 
proteins are first expressed.
1 .1 .4 Host range and target cells
HPVs are restricted in their host range to 
humans, and primarily infect stratified epithelia 
at either cutaneous or mucosal sites. Mucosotropic 
HPVs can be further subdivided into high- and 
low-risk types depending upon their degree of 
association with human malignancy.
1 .1 .5 Function of the gene products
(a) E1
E1 is the only enzyme encoded by the virus 
possessing DNA helicase activity. Once bound 
to the viral origin of replication, this enzyme 
recruits the cellular DNA-replication machinery 
to drive viral DNA replication.
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(b) E2
This protein serves three major functions 
in the viral life cycle. The first is to regulate the 
expression levels of the other viral gene products, 
and – depending upon the binding sites occupied 
in the LCR – to act as a transcriptional repressor 
or activator. Second, it recruits E1 to the viral 
origin, thereby enhancing viral DNA replication. 
Third, it has a critical role in the transfer of the 
viral genome to daughter cells during division of 
the host cell.
(c) E4
E4 is the most abundantly expressed viral 
protein, the function of which is still obscure. It 
has been linked to processes aiding viral DNA 
amplification and viral release.
(d) E5
E5 is one of three oncoproteins encoded by the 
virus (see Section 4.2). Its mode of action is still 
unclear, although it contributes quantitatively to 
the productive stage of the viral life cycle, and 
has been closely linked with the regulation of 
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Figure 1.1 Phylogenetic tree containing the sequences of 118 papillomavirus types
 
Reprinted from Virology 324(1), de Villiers EM, Fauquet C, Broker TR, Bernard HU, zur Hausen H, Classification of papillomaviruses, pp 17–27, 
2004, with permission from Elsevier.
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growth-factor signalling pathways and immune 
avoidance.
(e) E6
E6 is the second HPV-encoded oncoprotein 
(see section 4.2). It cooperates with E7 to provide 
an environment suitable for viral DNA replica-
tion, principally by overcoming cellular apoptotic 
processes. The most well characterized target 
of E6 from high-risk mucosotropic HPV types 
is the tumour-suppressor protein p53, which is 
directed by E6 towards degradation.
(f) E7
E7 is the third HPV-encoded oncoprotein (see 
section 4.2). By targeting cell-cycle regulatory 
pathways controlled by the tumour-suppressor 
protein pRb and the related proteins p107 and 
p130, it provides an environment favourable to 
viral DNA replication by maintaining an S-phase-
like state in the differentiating keratinocytes.
(g) L1 and L2
L1 and L2 are the major and minor constit-
uents, respectively, of the viral capsid. When 
overexpressed in various eukaryotic cells, L1 can 
self-assemble to form virus-like particles (VLPs). 
These VLPs are the basis for prophylactic vaccines 
against HPV, through induction of neutralizing 
antibodies.
1 .1 .6 Life cycle
HPVs are specifically epitheliotropic and 
their life cycle takes place within stratified squa-
mous epithelia.
(a) Entry
It is assumed that HPVs initiate infection 
by penetrating through microtraumas in the 
epithelia to reach the basal cells, which are 
believed to be the target cells for HPV infection. 
The mechanism for virus entry into the basal 
cells is not entirely understood. Subsequent steps 
in the life cycle of the virus can be divided into 
three stages: establishment, maintenance, and 
production.
(b) Establishment of the non-productive 
infectious state
Once an HPV particle enters the host cell, it 
must rely primarily on the cellular machinery 
to replicate its DNA. In infected basal cells, the 
HPV genome becomes established as a low copy-
number nuclear plasmid. Within these cells, only 
early viral gene products are expressed, and this 
is consequently referred to as the ‘non-produc-
tive’ stage of infection.
(c) Maintenance of the non-productive 
infectious state
A hallmark of HPV infection is its long-term 
persistence over many years, which, in the case 
of high-risk types, is a prerequisite for the devel-
opment of cancer. This requires that the viral 
genome be maintained over multiple cell divi-
sions; how this is achieved is still unclear.
(d) Productive stage
This begins when the daughter cells derived 
from the infected basal cells start to differentiate. 
The virus delays the terminal differentiation 
programme of the cell, and redirects the cell’s 
DNA replicative capacity. This then allows ampli-
fication of the viral genome and expression of the 
late viral genes necessary for the production of 
progeny virus, and subsequent viral release.
1.2 Epidemiology of infection
The epidemiology and natural history of 
HPV infection were extensively reviewed in the 
previous IARC Monograph (IARC, 2007).
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1 .2 .1 Prevalence, geographic distribution
Most sexually active individuals will acquire 
at least one genotype of anogenital HPV infec-
tion at some time during their lifetime. The most 
comprehensive data on cervical HPV prevalence in 
women with normal cytology (the great majority 
of infections do not produce concurrently diag-
nosed cytological abnormalities) is provided by 
a meta-analysis including over 150000 women 
(Castellsagué et al., 2007; de Sanjosé et al., 2007). 
After adjusting to the extent possible for study 
design, age, and HPV DNA detection assays, the 
estimated worldwide HPV DNA point preva-
lence was approximately 10%. The highest esti-
mates were found in Africa and Latin America 
(20–30%), and the lowest in southern Europe 
and South East Asia (6–7%). Point prevalence 
estimates are highly dynamic because incidence 
and clearance rates are high; averaging across age 
groups can be particularly misleading.
Fig. 1.2 shows the eight most common HPV 
types (HPV 16, 18, 31, 33, 35, 45, 52, and 58) by 
geographic region. HPV 16 is the most common 
type in all regions with levels of prevalence 
ranging from ~3–4% in North America to 2% 
in Europe. HPV 18 is the second most common 
type worldwide.
 Generally, similar results for the regional 
estimates of point prevalence of HPV DNA were 
observed in an IARC population-based preva-
lence survey conducted in 15613 women aged 
15–74 years from 11 countries around the world 
(Clifford et al., 2005a).
The age-specific prevalence curve showed a 
clear peak in women up to 25 years of age with 
subsequent decline until an age range of 35–44 
years, and an increase again in all regions included 
in the meta-analysis except Asia (de Sanjosé et al., 
2007). In the IARC population-based survey, a 
first peak was observed in women under 25 years 
of age, and a second peak after 45 years of age in 
most Latin American populations, but the HPV 
prevalence was high across all age groups in a few 
places in Asia and in Nigeria (Franceschi et al., 
2006). In this survey, the prevalence of high-risk 
HPV correlates well with cervical cancer inci-
dence, and the strength of the correlation steadily 
increases with age (Maucort-Boulch et al., 2008).
Data on HPV DNA prevalence and natural 
history of genital HPV infection in men is scant, 
and difficult to evaluate. There is great variation 
in the prevalence depending on anatomical sites 
sampled, sampling methods, and HPV DNA 
detection assays. In general, the overall HPV 
prevalence is over 50%, and the proportion of 
low-risk types is higher in men than in women 
(Giuliano et al., 2008). However, the biological 
or clinical meaning of the HPV DNA detected 
in the superficial layers of genital skin is not yet 
clear. Unlike what has been observed in women, 
no clear age pattern is detected in HPV preva-
lence rates in men (Giuliano et al. 2008).
HPV prevalence is lower in the oral cavity 
than in other anogenital sites. Among women 
who practiced prostitution, HPV DNA preva-
lences for specimens from the cervix, vagina, and 
oral cavity have been observed to be 27.8%, 26.1%, 
and 15%, respectively (Cañadas et al., 2004). HPV 
infections of the skin are extremely common, 
but the type distribution is different (beta and 
gamma genera predominating) than the mucosal 
types in the alpha genus that commonly infect 
the anogenital tract and the oral cavity.
1 .2 .2 Transmission and risk factors for 
infection
HPV infections are transmitted mainly 
through direct skin-to-skin or skin-to-mucosa 
contact. The viruses are easily transmitted and 
each genotype has its characteristic tissue tropism 
and characteristic age-specific peak transmission 
curve. In line with the unequivocal demonstra-
tion of sexual transmission of anogenital HPV, 
the number of sexual partners has been shown 
to be the main determinant of anogenital HPV 
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‘Other HR’ includes the 6 most common HPV types in cervical cancer other than 16 and 18: HPV-31, 33, 35, 45, 52, 58
Art work: Laia Bruni  adapted from Bosch et al. (2008) and de Sanjosé et al. (2007)
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incidence of anogenital infection occurs in teens 
and young adults. Increasing age is linked to 
decreasing acquisition of anogenital HPV infec-
tion as a corollary of fewer new partners and, 
possibly, immunity to previously cleared infec-
tions (Burchell et al., 2006; Dunne et al., 2006).
HPV infection probably requires access 
to basal cells through micro-abrasions in the 
epithelium (Burchell et al., 2006). Circumcision 
and condom use have also been associated with 
a reduced risk of infection in men and their part-
ners (Burchell et al., 2006; Dunne et al., 2006). 
Although it has been reported that smoking, 
use of oral contraceptives, parity, other sexually 
transmitted agents, age at first sexual intercourse, 
and host susceptibility may influence the risk of 
acquisition of HPV infection (Burchell et al., 
2006; Moscicki et al., 2006), the epidemiological 
evidence is inconsistent.
Non-sexual routes account for a tiny minority 
of HPV infections, and include perinatal trans-
mission and, possibly, transmission by medical 
procedures and fomites.
1 .2 .3 Persistency, latency, and natural history 
of infection
Most HPV infections clear within 1–2 years. 
However, estimates of duration of infection for 
individual types vary from study to study, and 
depend not only on the statistical methods used 
(definition of clearance, use of mean or median), 
but also on the accuracy of the HPV DNA detec-
tion methods. Although it has been reported that 
infections in older women last longer, suggesting 
greater risk of cancer (Castle et al., 2005a), this 
only pertains to detected infections found at 
the baseline of cross-sectional screening. There 
is no association between HPV incident infec-
tion duration and age, when infections detected 
during follow-up are followed in cohort studies 
(Trottier et al., 2008; Muñoz et al., 2009). 
Persistent HPV infection is a prerequisite for the 
development of high-grade precancerous lesions 
(cervical intraepithelial neoplasia [CIN]3) and 
cervical cancer, but for epidemiological purposes 
there is no consensus on the definition of persis-
tent infection. Most investigators call persistent 
infections those in which the same HPV type 
or group of HPV types is detected during two 
consecutive visits, but these two visits could be 
4 months up to 5–7 years apart, leading to serious 
conceptual problems (Woodman et al., 2007). 
A new definition of persistent HPV infection 
based on the duration of incident infection has 
been proposed (Muñoz et al., 2009). Moreover, 
there are many parameters of the natural history 
that are unknown (e.g., the precise time of HPV 
acquisition, and the probable existence of latent 
infections with possible reactivation as suggested 
by new detection among sexually inactive older 
women); overall, the distinction between tran-
sient and persistent infection is impossible to 
establish accurately.
Despite these limitations, persistence defined 
as HPV positivity at two or more visits has been 
associated with an increased risk of CIN2/3 
lesions in most studies included in a meta-analysis 
(Koshiol et al., 2008). In particular, repeat detec-
tion of HPV 16 is associated with an extremely 
high cumulative risk of subsequent CIN3+ diag-
nosis, exceeding 30% in some cohorts (Wheeler 
et al., 2006; Rodríguez et al., 2008). Persistence 
is not sufficient for carcinogenicity because there 
are non-carcinogenic types, like HPV 61, that 
persist without carcinogenic risk (Schiffman 
et al., 2007).
Host susceptibility factors and immune 
responses are obviously important but poorly 
understood determinants of persistence and 
progression. Other cofactors are discussed under 
Section 2.6.
CIN3 can develop very quickly (within 
2–3  years) following HPV exposure, especially 
in young women (Winer et al., 2005; Ault, 2007). 
Initially, CIN3 lesions are very small, and it takes 
a few years for them to grow and to be detect-
able by cytology and then colposcopy. In young, 
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intensively screened women, the median age of 
CIN3 diagnosis was around 23 years, while it was 
38 years in a cohort of women from New Zealand 
where screening and treatment were inadequate 
(McCredie et al., 2008; Schiffman & Rodríguez, 
2008).
A direct estimate of the rate of progression 
from CIN3 to invasive cervical cancer has been 
reported in the cohort of 1063 women from New 
Zealand for whom treatment for CIN3 was with-
held or delayed in an unethical clinical study 
starting in the 1960s. Cumulative incidence of 
invasive cervical cancer was 31.3% at 30 years 
of follow-up among 143 women who had had 
only diagnostic biopsies, and it was 50.3% in the 
subset of 92 women who had persistent CIN3 
during 24 months. Cancer risk at 30 years was 
0.7% for women whose initial treatment for CIN3 
was considered adequate (McCredie et al., 2008). 
[The Working Group noted that McCredie et al. 
were not responsible for the unethical study but 
gathered data from that study, and did the final 
follow-up.] It is unknown which proportion of 
small early CIN3 lesions will eventually progress 
to invasive cancer.
1 .2 .4 Evaluation of HPV vaccination on 
precancerous lesions occurrence or 
decrease
Two prophylactic HPV vaccines are currently 
marketed. One is bivalent and contains VLP anti-
gens for HPV 16 and 18, and the other is quad-
rivalent and contains VLP antigens for HPV 
16, 18, 6, and 11. Both vaccines are designed to 
prevent HPV infection and HPV-related disease, 
and not to treat women with past or current HPV 
infection or disease. End-points of CIN2/3 or 
adenocarcinoma in situ (AIS) have been widely 
accepted as a proxy for cervical cancer that can 
be studied ethically in efficacy trials.
Both vaccines have efficacies of > 90% against 
CIN2 or higher grade among women aged 15–26 
years who had no evidence of past or current 
infection with HPV types related to type-specific 
VLP antigens. Efficacy estimates vary by vaccine, 
type of study, the population analysed, and dura-
tion of follow-up (Ault et al., 2007; WHO, 2009). 
In addition, the HPV vaccine trials with the 
quadrivalent vaccine have shown an efficacy close 
to 100% against high-grade vulvar (VIN2/3) or 
vaginal intraepithelial lesions (VaIN2/3) related 
to HPV 16 or 18, and against genital warts related 
to HPV 6 or 11 among the per-protocol suscep-
tible population (Garland et al., 2007; Joura et al., 
2007). Although protection with both vaccines 
has been shown to last 5–6 years, their long-term 
protection and their impact on the prevention of 
cervical cancer and of other genital and non-
genital HPV-associated tumours remains to be 
determined.
2. Cancer in Humans
2.1 Cancer of the cervix
Epidemiological evidence for the carcino-
genicity of HPV was originally presented in 
Volume 64 of the IARC Monographs (IARC, 
1995), and was extensively updated in Volume 
90 of the IARC Monographs (IARC, 2007), based 
on data available as of February 2005.
HPV carcinogenicity has been established 
most convincingly for cancer of the cervix. HPV 
behaviour is strongly correlated with phyloge-
netic (i.e. evolutionary or taxonomic) categories 
(Schiffman et al., 2005). All HPV genotypes that 
are known to be cervical carcinogens belong to 
the alpha genus, in an evolutionary branching 
or high-risk clade containing a few genetically 
related species (Table 2.1 and Fig. 2.1). HPV 16 
(alpha-9) and HPV 18 (alpha-7) have been clas-
sified as cervical carcinogens since 1995. HPV 
31 and HPV 33, in alpha-9, were categorized as 
probably carcinogenic. In 2005, the group of 
cervical carcinogens was expanded to include 
the following 13 types: alpha-5 genotype HPV 51, 
261
IARC MONOGRAPHS – 100B
alpha-6 genotypes HPV 56 and HPV 66, alpha-7 
genotypes HPV 18, HPV 39, HPV 45, and HPV 
59, and alpha-9 genotypes HPV 16, HPV 31, HPV 
33, HPV 35, HPV 52, and HPV 58.
 There is virtually no epidemiological 
evidence of cervical carcinogenicity for other 
species in the alpha genus or for other genera. To 
save considerable space presenting null evidence, 
this section will not include data related to HPV 
species alpha-1, -2, -3, -4, -8, -10 (other than HPV 
6 or 11), -13, or -14/15. These species contain HPV 
types that cause skin or genital warts, minor 
cytological atypia, and often no apparent disease.
Since the previous IARC Monograph, new 
evidence has further supported that HPV types 
in the high-risk clade of the alpha genus cause 
virtually all cases of cervical cancer worldwide 
(Smith et al., 2007; Bosch et al., 2008). In case–
control studies, the odds ratios (ORs) associating 
cervical cancer and its immediate precursor, 
CIN3, with HPV DNA positivity for these high-
risk types in pooled probe tests consistently 
exceed 50. It is persistent infections that are 
associated with an extremely high absolute risk 
of CIN3 and cancer. In cohort studies, women 
who test negative for this group of HPV types 
as assayed by hybrid capture 2 (HC2, including 
a mix of the HPV types 16, 18, 31, 33, 35, 39, 45, 
51, 52, 56, 58, 59, 68, and several cross-reacting 
genotypes in the high-risk clade) are at extremely 
low subsequent risk of cancer for at least 10 years 
(Khan et al., 2005).
Because persistent infection with HPV is 
a nearly necessary cause of cervical cancer, a 
reconsideration of HPV and cervical carcino-
genicity based on the new (non-cohort) data must 
be made to decide whether any additional types 
within the high-risk clade are also carcinogenic, 
and whether any types that were previously cate-
gorized as carcinogenic should be downgraded. 
The types in the high-risk clade are listed below.
Given the existence of some HPV types that 
are very carcinogenic, notably HPV 16 and HPV 
18, determining which less common and weaker 
types are also carcinogenic becomes, in epide-
miology, an issue of confounding. The alpha 
genus types share a common route of transmis-
sion, and multiple infections are present in a 
large minority of women, both concurrently and 
sequentially. None of the traditional approaches 
to control confounding is entirely successful. 
Because HPV 16 causes over 50% of cases of 
cervical cancer (Clifford et al., 2003; Smith et al., 
2007), logistic regression and similar approaches 
will parsimoniously attribute to HPV 16, cases 
associated with both HPV 16, and a less impor-
tant type. HPV 18 is the second most important 
cervical carcinogen, responsible for approxi-
mately 15% of cervical cancer of all histological 
types combined (and a higher fraction of adeno-
carcinomas) (Clifford et al., 2003; Smith et al., 
2007). If a type co-occurs with either HPV 16 
or HPV 18, its association with cervical cancer 
might be confounded by either of these powerful 
carcinogens. For types causing only a very small 
fraction of cervical cancer, confounding by any 
of the more important types is possible.
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Table 2 .1 HPV types in the high-risk clade
Alpha HPV species Types classified as Group 1 carcinogens in 
Volume 90
Other Types in Species
5 51 26, 69, 82
6 56, 66 30, 53
7 18, 45, 39, 59 68, 70, 85, 97




Figure 2.1 Phylogenetic tree of 100 human papillomavirus types with an highlight of the high-risk 
alpha species
 
Phylogenetic tree of 100 human papillomavirus types inferred from the nucleotide sequences of 5 ORFs (E7, E1, E2, L2 and L1).
The tree was constructed using the Markov chain Monte Carlo (MCMC) algorithm in BEAST v1.4.8 (Drummond & Rambaut, 2007). HPV species 
were generally classified according to the new classification system for PVs by de Villiers et al. (2004). All subtypes of the alpha PVs were included 
in the tree, followed as HPV 44 is a subtype of HPV 55, AE9 is a subtype of HPV 54, HPV 64 is a subtype of HPV 34, ME180 is a subtype of HPV 
68, and AE2 is a subtype of HPV 82.
In red are highlighted the alpha HPV types previously classified as carcinogenic to humans (Group 1) in Volume 90, and the alpha species (high-risk 
species) to which they belong.
Adapted from an unpublished figure (courtesy of Robert D. Burk and Zigui Chen)
IARC MONOGRAPHS – 100B
Dealing with confounding by exclusion, i.e. 
examining the possibility of carcinogenicity of a 
more minor type among cancer specimens that 
do not contain a more important type, becomes a 
problem of misclassification. The main epidemi-
ological criterion used for the classification of an 
HPV type as a carcinogen, i.e. finding the HPV 
genotype as a single infection in a cervical scrape 
or biopsy specimen in a woman with cancer, 
might sometimes be too lax, and prone to error. 
Colposcopic biopsies and cytology specimens 
can be misdirected and fail to obtain the crit-
ical cells, whereas the contamination of scrapes 
and biopsies from lower-grade lesions that often 
surround cancers can lead to the detection of 
types other than the causal one. Studies relying 
on the testing of microdissected cervical malig-
nancies will address these issues, but large-scale 
highly accurate data are not yet available.
Difficulty with control selection adds another 
level of complexity in assessing carcinogenicity. 
As discussed in the section on the HPV natural 
history of infection (Section 1.2), cervical cancer 
typically follows age of infection by decades. 
HPV DNA and RNA transmitted at young ages 
usually become undetectable and no sensitive 
serological assay exists to measure HPV expo-
sure. Consequently, odds ratios based on a 
comparison of HPV DNA prevalence at the time 
of case diagnosis to age-matched HPV point 
prevalence in controls do not estimate true rela-
tive risks.
See Table 2.2 available at http://monographs.
iarc.fr/ENG/Monographs/vol100B/100B-06-
Table2.2.pdf, Table 2.3 available at http://
monog r aphs . ia rc . f r/ ENG/Monog r aphs/
vol100B/100B-06-Table2.3.pdf, and Table 2.4 
available at http://monographs.iarc.fr/ENG/
Monographs/vol100B/100B-06-Table2.4.pdf.
Only sparse type-specific prospective data is 
available on the carcinogenicity of the full range 
of individual HPV genotypes (Khan et al., 2005; 
Schiffman et al., 2005; Wheeler et al., 2006). 
Studies have categorically shown the unique 
carcinogenicity of HPV 16 (Khan et al., 2005; 
Bulkmans et al., 2007; Kjaer et al., 2009; Muñoz 
et al., 2009). HPV 18 causes a lower and more 
delayed absolute risk of CIN3+ diagnosis. Khan 
et al. (2005) observed that a 10-year cumulative 
risk of ≥ CIN3 for the women who were positive 
by the pooled probe HC2 assay, but negative for 
HPV 16 or HPV 18, was 3.0% (95%CI: 1.9–4.2) 
compared with the risk of 0.8% (95%CI: 0.6–1.1) 
among women who were HC2-negative at base-
line. However, there is not convincing long-term 
prospective evidence for individual HPV types 
other than HPV 16 and HPV 18.
Finally, the accuracy of detection of HPV 
genotypes differs between the major polymerase-
chain-reaction(PCR)-based systems used to 
generate most of the data. The epidemiological 
study of individual HPV genotypes is made more 
difficult with the variety of methods available 
for testing. In the past few years, the major HPV 
genotyping methods have converged towards 
a common, improved standard of analytical 
sensitivity and specificity, but none of the main 
methods is the reference standard (Gravitt 
et al., 2008). Sequencing of PCR products is 
also imperfect because multiple HPV types 
can infect tissues concurrently, and sequencing 
distinguishes multiple infections sub-optimally. 
The methods have evolved over time, producing 
additional testing variability that is difficult 
to appreciate as a reader. The residual error in 
HPV genotyping occurs mainly when multiple 
infections are present, and for the less important 
carcinogenic types. As a result, determining the 
major carcinogenic types can be done rather 
easily, but ruling out confounding in the context 
of multiple infections can be quite difficult.
With these caveats, the cervical carcino-
genicity of the HPV types listed above varies in 
strength in a continuum without clear break-
point, from extremely strong (i.e. HPV 16 and, 
to a lesser degree, HPV 18) to weak, but still may 
cause cervical cancer in rare instances (e.g. HPV 
68, see below). Evaluators taking one extreme 
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position could rightfully claim that there is 
reasonable evidence for the carcinogenicity of 
virtually all the types in the species listed above, 
extending further the list established in the 
previous IARC Monograph. Strict interpreters 
of causal criteria could argue for a return to a 
more limited list. But based on current evidence, 
no clear cut-off between sufficient, limited, and 
inadequate evidence is entirely defensible.
The Working Group chose the following prag-
matic approach to creating an imperfect cut-off 
between sufficient, limited, and inadequate epide-
miological evidence for cervical carcinogenicity:
The Working Group considered only types in 
the high-risk clade because data are inadequate 
for all others. The Working Group evaluated the 
most recent and accumulated data on cervical 
cancers from very large single projects (e.g. 
Bosch et al., 2008), and especially as summarized 
in meta-analyses from IARC (Smith et al., 2007, 
updated as needed by the Working Group). The 
Working Group excluded from consideration 
high-grade precancerous lesions (CIN3 and the 
more equivocal CIN2 which occur in approxi-
mately 1% of screened women) often used as 
ethical surrogate end-points in prospective 
studies and clinical trials, because there are now 
enough data for invasive cancers, and because it 
appears that HPV types have different potential 
to progress from CIN2/3 to invasive cervical 
cancer (Clifford et al., 2003). For comparisons 
with the background frequency of cervical HPV 
infection in the general female population, the 
Working Group noted the prevalence from a 
large meta-analysis of HPV genotypes found in 
women with normal cytology (de Sanjosé et al., 
2007).
About 10–30% of women with detectable HPV 
DNA exhibit definite cytological abnormalities, 
depending on the HPV type, cytological cut-off 
point and DNA test (Kovacic et al., 2006). But 
low-grade or even equivocal lesions represent 
only a few percent of screening cytological tests; 
therefore, the population prevalence of an HPV 
genotype (in controls) can be approximated by 
its prevalence in cytologically normal women.
Comparing the prevalence in women with 
normal cytology (de Sanjosé et al., 2007) to the 
prevalence in women with invasive cervical 
cancers compiled by Smith et al. (2007), one can 
see obvious “case–control” differences. The most 
clearly carcinogenic genotypes, HPV 16 and 
HPV 18 in particular, are more common among 
cervical squamous carcinomas than cytologically 
normal women or even in low-grade squamous 
intraepithelial lesions (Clifford et al., 2005b). 
HPV 18 is especially common in adenocarci-
nomas (Bosch et al., 2008), as are other members 
of the alpha-7 clade of which HPV 18 is a member 
(Clifford & Franceschi, 2008), lending additional 
support to the importance of genetic similarity 
in terms of the carcinogenicity of different HPV 
types. Almost all types of HPV in the high-risk 
clade – except for HPV 16 and HPV 18 – are 
(relatively) more common in low-grade lesions.
Including HPV 16 and HPV 18, eight HPV 
types (alpha-7, HPV types 18 and 45; alpha-9, 
HPV types 16, 31, 33, 35, 52, and 58) are the 
most common types found in cancers in both 
the Catalan Institute of Oncology (ICO) study 
and the IARC meta-analysis (Bosch et al., 2008; 
Clifford & Franceschi, 2008) in all regions of the 
world providing data. These types are all much 
more common in cancer case specimens than 
in controls, providing sufficient epidemiological 
evidence of carcinogenicity.
To move beyond the most clearly carci-
nogenic eight HPV genotypes, the Working 
Group chose the presence of HPV 6 as a surro-
gate for estimating the percentage of cancers 
that might contain HPV DNA by accumulated 
and unknown measurement errors alone. The 
reasons being that HPV 6, the common cause of 
benign condyloma acuminata (external genital 
warts), is an archetype of a low-risk type, is not 
classified as a cervical carcinogen, and is very 
uncommonly detected in cervical cancer speci-
mens. [When detected, even without detection 
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Table 2 .5 Meta-analysis of type-specific HPV DNA prevalence in invasive cervical cancer
Invasive cervical cancer Normal
N tested % pos 95%CI N tested % pos 95%CI
HPV 16 14595 54.4 53.6–55.2 76385 2.6 2.5–2.8
HPV 18 14387 15.9 15.3–16.5 76385 0.9 0.8–1.0
HPV 33 13827 4.3 4.0–4.6 74141 0.5 0.4–0.5
HPV 45 9843 3.7 3.3–4.1 65806 0.4 0.4–0.4
HPV 31 11960 3.5 3.2–3.9 74076 0.6 0.6–0.7
HPV 58 10157 3.3 2.9–3.6 72877 0.9 0.8–1.0
HPV 52 9509 2.5 2.2–2.8 69030 0.9 0.8–1.0
HPV 35 9507 1.7 1.5–2.0 74084 0.4 0.3–0.4
HPV 59 13471 1.28 1.09–1.47 64901 0.3 0.2–0.3
HPV 51 13057 1.16 0.97–1.34 67139 0.6 0.6–0.7
HPV 56 13247 0.78 0.63–0.93 68121 0.5 0.5–0.6
HPV 39 13370 1.29 1.10–1.48 64521 0.4 0.3–0.4
HPV 68 11982 0.61 0.47–0.75 63210 0.3 0.2–0.3
HPV 73 9939 0.48 0.35–0.62 44063 0.1 0.1–0.1
HPV 66 12118 0.39 0.28–0.50 59774 0.4 0.3–0.4
HPV 70 10503 0.33 0.22–0.44 35014 0.3 0.3–0.3
HPV 82 9265 0.27 0.16–0.38 42536 0.1 0.0–0.1
HPV 26 6111 0.13 0.04–0.22 44098 0.0 0.0–0.1
HPV 53 8140 0.42 0.28–0.56 44058 0.4 0.4–0.4
HPV 6 14912 0.45 0.35–0.56 58370 0.3 0.2–0.3
HPV 11 8761 0.2 0.1–0.4 58370 0.2 0.2–0.2
Compiled by the Working Group during the meeting
Data for women with normal cytology is from de Sanjosé et al. (2007)
Data for HPV types 16, 18, 31, 33, 35, 45, 52, and 58 is from Smith et al. (2007), but for other HPV types, the data from Smith et al. (2007) was 
updated by the Working Group using the following 61 published studies: Andersson et al. (2005), Bardin et al. (2008), Beerens et al. (2005), 
Bertelsen et al. (2006), Bhatla et al. (2006), Bryan et al. (2006), Bulk et al. (2006), Bulkmans et al. (2005), Cambruzzi et al. (2005), Castellsagué 
et al. (2008), Chan et al. (2006), Chen et al. (2006), Ciotti et al. (2006), Dabić et al. (2008), Daponte et al. (2006), De Boer et al. (2005), de 
Cremoux et al. (2009), De Vuyst et al. (2008), Del Mistro, et al. (2006), Esmaeili et al. (2008), Fanta (2005), Gargiulo et al. (2007), Ghaffari et 
al. (2006), Gheit et al. (2009), Guo et al. (2007), Hadzisejdć et al. (2007), Hindryckx et al. (2006), Hong et al. (2008), Inoue et al. (2006), Khan 
et al. (2007), Kjaer et al. (2008), Klug et al. (2007), Kulmala et al. (2007), Lai et al. (2007b), Lee et al. (2007), Liu et al. (2005), Maehama (2005), 
Odida et al. (2008), Panotopoulou et al. (2007), Peedicayil et al. (2006), Piña-Sánchez et al. (2006), Prétet et al. (2008), Qiu et al. (2007), 
Ressler et al. (2007), Sigurdsson et al. (2007), Siriaunkgul et al. (2008), Song et al. (2007), Sowjanya et al. (2005), Sriamporn et al. (2006), 
Stevens et al. (2006), Su et al. (2007), Tao et al. (2006), Tawfik El-Mansi et al. (2006), Tong et al. (2007), Tornesello et al. (2006), Wentzensen et 
al. (2009), Wu et al. (2008), Wu et al. (2006), Zhao et al. (2008), Zuna et al. (2007)
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of a more likely causal type, the Working Group 
judged that misclassification of some kind was 
a more likely explanation than causality.] The 
best published estimate of percentage of detec-
tion of HPV 6 in cervical cancers (not neces-
sarily as a single infection) was judged to be 0.5% 
(95%CI: 0.4–0.6), based on 15000 cases of cancer 
(Smith et al., 2007; estimated and confirmed by 
the Working Group update, see Table 2.5). The 
Working Group took the pragmatic approach 
once more and made the following rule—an 
individual HPV type in the high-risk alpha clade 
(i.e. with an elevated prior probability of being 
carcinogenic due to analogy to closely related 
viral types in the same or closely-related species) 
was considered to have sufficient epidemiological 
evidence of carcinogenicity if:
• its prevalence in cancers was significantly 
greater than that of HPV 6.
• its prevalence in cancer was significantly 
enriched in comparison to the back-
ground estimate for the general popula-
tion, i.e. women with normal cytology.
By this logic, four more types were judged, 
as in the previous IARC Monograph, to have 
sufficient epidemiological evidence of cervical 
carcinogenicity: alpha-5 HPV 51, alpha-6 HPV 
56, and alpha-7 HPV types 39 and 59.
The remaining types in the high-risk alpha 
clade (see Table 2.1) were considered, as a group, 
to have limited evidence to support carcino-
genicity. If phylogeny can be taken to predict 
behaviour, it is possible that most of these types 
can very rarely cause cancer. Indeed, many of the 
types have been detected, albeit uncommonly 
(no greater than HPV 6), in cancers. There are 
not enough data, even after testing of many thou-
sands of specimens, to be sure which types are 
definitely carcinogenic or not. But, within this 
group, there are two types, alpha-7 HPV 68 and 
alpha-11 HPV 73, for which the data are slightly 
stronger than for the others despite methodo-
logical challenges. One of the major PCR-based 
testing methods (SPF10) cannot distinguish 
these two types because their amplicons using 
those primers are identical. Neither of these two 
types is optimally detected by MY09-MY11 dot 
blot (Gravitt et al., 2008). Nonetheless, the data 
supporting the carcinogenicity of HPV 68 and 
HPV 73 are suggestive.
This categorization scheme leads to the 
re-classification of HPV 66, for which the 
evidence of carcinogenicity was previously 
judged sufficient. In the assembly of much more 
testing data from cancer cases, HPV 66 has been 
found so rarely that its percentage of detection 
is less than the relative percentage of detection 
among the general population. In the Working 
Group review of each individual article, HPV 66 
was found alone in cancers with extreme rarity, 
well below the possible threshold of confounding 
and misclassification.
2 .1 .1 Summary
The data accumulated supports:
• The unique carcinogenic strength of HPV 
16.
• The importance of HPV 18 and geneti-
cally related types (Clifford & Franceschi, 
2008) in causing adenocarcinoma com-
pared with squamous cell carcinoma.
• The weaker but still clear carcinogenic 
potential of six additional types in alpha-7 
(HPV 45) and alpha-9 (HPV 31, 33, 35, 52, 
and 58), with some regional variation in 
the etiological fractions of cancers due to 
each type. For example, HPV 52 and 58 
are relatively more prevalent in Asia than 
in other regions, HPV 33 is most clearly 
prevalent in Europe, and HPV 45 has par-
ticular regions where it is prominent.
• The small, and less certain, incremen-
tal etiological contributions of another 
group of carcinogenic types from alpha-5 
(HPV 51), alpha-6 (HPV 56), and alpha-7 
(HPV 39 and HPV 59). Each causes a few 
percent at most of cervical cancer cases 
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worldwide, although regional variability 
has been observed.
• Acknowledgement of an unresolved 
dividing line between the HPV types 
with the weakest evidence judged to be 
sufficient, and those with evidence judged 
highly suggestive yet limited (alpha-7 
HPV 68 and alpha-11 HPV 73).
• A re-evaluation of the evidence for HPV 
66. The data were re-evaluated and the 
evidence was judged to be very limited 
now that more cases have been studied 
showing that it is very rarely found in 
cancers despite being relatively common. 
HPV 53, also in alpha-6, shows the same 
pattern of relative common population 
prevalence with extremely rare cases of 
occurrence alone in cancer. The Working 
Group noted that for these types in par-
ticular, there could be harm to public 
health if the types are included as carci-
nogenic in screening assays, which would 
decrease the specificity and positive pre-
dictive value of the assays with virtually 
no gain in sensitivity and negative predic-
tive value.
• The existence of a few types within the 
high-risk clade that have extremely sparse 
or no evidence of carcinogenicity. For 
some types there are anecdotal but very 
interesting cases that merit further study 
of additional carcinogenic types. For 
example, the carcinogenicity of alpha-5 
HPV 26 has been supported by a recent 
report of multiple peri-ungual cancers in 
an immunosuppressed individual, con-
taining high viral loads, and active tran-
scription of HPV 26 alone (Handisurya 
et al., 2007). There have been reports of 
alpha-9 HPV 70 found as single infections 
in cervical cancer (Lai et al., 2007a), but 
the supportive data are sparse. There are 
only a few reports of HPV 67 in cancer 
(Gudleviciene et al., 2006; Wentzensen 
et al., 2009), which is intriguing because 
this is the only known type in the alpha-9 
species that is not categorized as carci-
nogenic. For a few types in the high-risk 
clade, no reports of invasive cancers with 
single-type infections were found, but 
isolated reports might exist.
2.2 Cancer at other anogenital sites
2 .2 .1 Cancer of the vulva
Cancer of the vulva is rare. The tumours 
are generally of epithelial origin and squamous 
cell carcinoma is the most common histological 
type. Tumours can be mainly categorized as 
keratinizing, non-keratinizing, basaloid, warty 
and verrucous vulvar tumours. Basaloid/warty 
types comprise about a third of cases, are more 
common in younger women, tend to harbour 
VIN lesions, and are often associated with HPV 
DNA detection. These tumours appear to share 
the epidemiological factors of cervical cancer. 
On the contrary, keratinizing types, with older 
average age at diagnosis, apparently arise from 
chronic vulvar dermatoses or from squamous 
metaplasia, and are more rarely associated with 
HPV. See Table 2.6 available at http://mono-
graphs.iarc.fr/ENG/Monographs/vol100B/100B-
06-Table2.6.pdf, Table 2.7 available at http://
monog r aphs . ia rc . f r/ ENG/Monog r aphs/




Tables 2.6 and 2.7 (on-line) present case series 
of more than ten cases of VIN3 or invasive cancer 
of the vulva.
A large proportion of VIN3 cases harbour 
HPV DNA with HPV 16 being the most common 
type detected in over 79% of positive samples 
(Table  2.6 on-line). More recent larger series 
confirm the presence also of HPV 33 and more 
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rarely, other cervical carcinogenic HPV types 
such as HPV 31 and HPV 18. HPV 6 is present 
in a small proportion, and HPV 11 is extremely 
rarely identified, pointing to a doubtful role of 
these condyloma types in VIN3.
Table 2.7 (on-line) describes those studies 
that provide HPV detection in cases of invasive, 
basaloid/warty tumours.
A meta-analysis by De Vuyst et al. (2009) 
estimated an HPV prevalence of 40.4% among 
1873 vulvar carcinomas, and confirmed the 
difference in HPV detection by histological type 
(69.4% HPV positivity in warty/basaloid type and 
13.2% in keratinizing type). The place of origin of 
the samples and the age of the women appeared 
both to relate to the prevalence of HPV overall: 
women below 60 years old, and cases from North 
America had significantly higher prevalence 
estimates. HPV 16 was, in all studies, the most 
common type detected (32.2% with a 50–100% 
range among positives), followed by HPV 33 
(4.5%), HPV 18 (4.4%), HPV 6 (2.0%), HPV 45 
(1.0%), HPV 31 (0.6%), and HPV 11 (0.1%).
This observation was also made by Insinga 
et al. (2008) in another meta-analysis restricted 
to studies carried out in the US population. The 
overall HPV detection estimate for squamous 
cell carcinoma of the vulva was higher for the 
US studies (65.3%) than in the De Vuyst et al. 
(2009) meta-analysis for other regions (range, 
24.2–38.2%). The multitype-adjusted prevalence 
estimates reported by Insinga et al. (2008) were 
as follows: HPV 16 (49.5%), HPV 33 (6.0%), HPV 
18 (4.2%), HPV 6 (3.6%), HPV 31 (1.7%), and 
HPV 52 (0.0%).
Low-risk HPV types have been suggested 
to be associated with a small subset of vulvar 
cancers, but their role is not yet clear. Vulvar 
skin is prone to genital condylomas that might 
be concomitant to other neoplasic lesions. In 
some circumstances, these types are present in 
combined lesions such as giant condyloma with 
an invasive lesion or in verrucous carcinoma.
HPV 6 was slightly more frequent in vulvar 
(2.0%) and anal (2.9%) carcinoma than in cervical 
carcinoma (0.5%) (Smith et al. 2007; De Vuyst 
et al., 2009), but it was most often accompanied, 
among cases where this information was avail-
able, by multiple infections with high-risk types. 
De Vuyst et al. (2009) observed that HPV 6 and 
11 were frequently detected in VIN1 and AIN1 
(anal intraepithelial neoplasia, as in anogenital 
warts), but not in VAIN1 (vaginal intraepithelial 
neoplasia).
In Insinga et al. (2008), after multitype adjust-
ment, HPV 6 was estimated to contribute to the 
largest fraction (29.2%) of VIN1 lesions, with the 
top two (HPV 6 and 11), four (HPV 6, 11, 68, and 
16), and eight (HPV 6, 11, 68, 16, 58, 59, 31, and 
66) reported HPV types accounting for 41.7%, 
55.9%, and 67.8% of VIN1 lesions, respectively. 
The attribution of HPV 6 and 11 to VIN1 lesions 
(41.7%) was greater than that estimated for CIN1 
(6.9%; P < 0.0001).
(b) Case–control studies
There are several case–control studies on 
invasive vulvar cancer using serology, but few 
have tested for HPV DNA (Sagerman et al., 
1996; Madsen et al., 2008; see Table 2.9 available 
at http://monographs.iarc.fr/ENG/Monographs/
vol100B/100B-06-Table2.9.pdf). Also, the design 
of these studies was considered inadequate (e.g. 
using endometrial cases as controls). Serological 
studies reported contradictory data on the 
association between type-specific epitopes and 
vulvar cancer. In Bjørge et al. (1997), Madeleine 
et al. (1997), and Carter et al. (2001), statistically 
significant increased risks associated with anti-
bodies against HPV 16 were observed but not 
against HPV 18. Results did not reach statistical 
significance in Hildesheim et al. (1997).
Overall, the data indicate that HPV plays a 
role in vulvar cancer, in particular in tumours 
with basaloid/warty features, with HPV 16 
having a predominant role. Based on case series, 
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HPV 18 and HPV 33 may also be involved in a 
small fraction of these tumours.
2 .2 .2 Cancer of the vagina
Tumours of the vagina are very rare but 
varied. They can be of different cell origin: epithe-
lial, mesenchymal, melanocytic, lymphoid, and 
secondary. Epithelial tumours are the most 
common and include keratinizing, non-kerati-
nizing, basaloid, verrucous, and warty squamous 
cell carcinoma types, and are strongly related to 
HPV. In the previous IARC Monograph, HPV 16 
was reported in more than 50% of the cases, and 
the evidence of an association with HPV 18 was 
reported to be weaker.
The epidemiology of vaginal cancer is not 
clearly understood as few analytical studies are 
available, and it is difficult to disentangle these 
tumours with those that originate in the cervix. 
Approximately 30% of all cases report treatment 
for a prior anogenital tumour compared to 2% in 
controls, most often of the cervix (Daling et al., 
2002).
A recognized independent risk factor for 
vaginal cancer is the exposure to diethylstilbestrol 
during pregnancy. Tumours arising after this 
exposure are clear cell adenocarcinoma of the 
vagina. Recurrent clear cell adenocarcinoma has 
been observed as long as 20 years after primary 
therapy (Herbst & Anderson, 1990).
(a) Case series
In the two recent studies on VAIN3 tissues, 
over 90% harboured HPV DNA. The meta-
analyses by De Vuyst et al. (2009), including 298 
cases of VAIN and 136 cases of invasive cancer, 
reported detection of HPV DNA in 93.6% of 
VAIN3 lesions, and in 69.9% of vaginal carci-
nomas. In both VAIN3 and vaginal carcinomas, 
HPV 16 was by far the most common type 
detected followed by HPV 18, 31, 33, and 6.
The most recent series of invasive cases found 
HPV DNA in 17/21 women [80.9%] (Ferreira 
et al., 2008). HPV 16 was the predominant type 
but HPV 31 and HPV 33 were also relatively 
common. Madsen et al. (2008) detected HPV 
DNA in 24/27 [88.9%] squamous cell carcinomas 
of the vagina. HPV 16 was the most prevalent 
type followed by HPV 33. The meta-analysis by 
De Vuyst et al. (2008) estimated an overall HPV 
prevalence of 69.9% with a geographic range of 
43.8% in Asia to 76.8% in Europe.
See Table 2.10 available at http://mono-
graphs.iarc.fr/ENG/Monographs/vol100B/100B-




Since the previous IARC Monograph, only 
one case–control study of HPV and vaginal 
cancer has been published. Madsen et al. (2008) 
carried out a case–control study on cancer of 
the vagina in Denmark. [The Working Group 
considered this study as inadequate to provide 
analytical evidence of HPV and vaginal cancer 
due to problems with the selection of controls.]
In summary, recent data on HPV and vaginal 
cancer are few, and have not altered the evalu-
ation of the role of genotypes other than HPV 
16. The rarity of these tumours and their conti-
guity with cervical cancer remain difficulties for 
specific epidemiological research of this cancer.
See Table 2.12 available at http://mono-
graphs.iarc.fr/ENG/Monographs/vol100B/100B-
06-Table2.12.pdf and Table 2.13 available at 
http://monographs.iarc.fr/ENG/Monographs/
vol100B/100B-06-Table2.13.pdf.
2 .2 .3 Cancer of the penis
Cancer of the penis is a rare tumour whose 
incidence correlates with that of cervical cancer. 
Analogous to vulvar cancer, some risk factors 
vary by histology. The large majority of penile 
tumours are squamous cell carcinomas although 
making a histological subtype distinction can be 
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controversial. Preneoplasic intraepithelial lesions 
(PIN) are recognized precursor stages in which 
HPV is also generally identified. HPV-negative 
squamous carcinoma cases are suspected to relate 
to chronic inflammation with risk factors such as 
phimosis, lichen sclerosis, and lack of circumci-
sion. Smoking and a history of genital warts have 
also been linked to cancer of the penis.
(a) Case series
The prevalence of HPV DNA in penile cancer 
varies by histological type. Case series tend to 
include a relatively small number of cases per 
histological subtype, ranging from one to over 
170 cases (see Table 2.14 available at http://mono-
graphs.iarc.fr/ENG/Monographs/vol100B/100B-
06-Table2.14.pdf).
Since the previous IARC Monograph, more 
than a dozen new case series on invasive penile 
cancer have been identified in which HPV DNA 
was assessed. No studies on PIN were identified. 
Among these studies, the largest series is that of 
Lont et al. (2006) with 171 paraffin-embedded 
penile tumours, in which the overall detection 
of HPV was 29.2%. The low prevalence of HPV 
among the warty or basaloid types (25% and 
0%, respectively) in this study and in Guerrero 
et al. (2008) contrasts with some smaller series 
showing prevalence estimates over 60–70% 
(Rubin et al., 2001; Salazar et al., 2005; Pascual 
et al., 2007). Intermediate HPV prevalence esti-
mates of < 50% were observed in another small 
serie of warty carcinoma of the penis (Bezerra 
et al., 2001).
Although there is a wide variation of HPV 
prevalence in penile cancer studies, two recent 
meta-analyses provide a summary estimate that 
may be more meaningful (Backes et al., 2009; 
Miralles-Guri et al., 2009). Taking into account 
over 1400 cases of penile cancer, HPV was 
detected in 47% of the cases with the highest HPV 
prevalence (76%) in penile tumours with a basa-
loid squamous cell carcinoma component, and 
the lowest (24.5%) in penile verrucous squamous 
cell carcinoma. Basaloid/warty tumours were 
overall 3.5 times more likely to be HPV-positive.
Contrary to that observed for vulvar cancer, 
Backes et al. (2009) reported a 2.7 times higher 
presence of HPV-positive tumours in Asia as 
compared to cases derived from North America 
(OR, 2.7; 95%CI: 1.8–4.0) without any clear 
explanation of why this should be. Recent studies 
were more likely to report HPV-positive cases. 
Consistent with the previous IARC Monograph, 
HPV 16 was the most common type detected 
(60.2%), irrespective of histology, followed by 
HPV 18 (13.3%) (Miralles-Guri et al., 2009). 
Other cervical carcinogenic HPV types such 
as HPV 35, 45, 51, 52, 56, and 59 were detected 
sporadically as were HPV 68, 70, and 74. Types 
not established to be carcinogenic were observed 
in close to 10% of cases, but it was not clarified 
how many of these were found in combination 
with carcinogenic infections.
HPV 6 was detected in 39 (6.7%) of 580 cases 
that were tested for HPV 6, with a notable pres-
ence of multiple co-infections with high-risk 
types.
(b) Case–control studies
The data from case–control studies in 
which HPV was evaluated using serological 
markers is summarized in Table 2.15 (available 
at http://monographs.iarc.fr/ENG/Monographs/
vol100B/100B-06-Table2.15.pdf). In these small 
studies, which were not included in the previous 
IARC Monograph, no detailed histological evalu-
ation was provided. The risk for penile cancer, 
including in-situ cases, was associated with sero-
positivity to HPV 16 in particular.
In summary, studies of penile cancer suggest 
that HPV infection appears to play an important 
role in almost half of the cases. No additional 
validated information on the specific contribu-
tion of types other than HPV 16 or 18 can be 
derived from recent studies. HPV 6 and HPV 11 
were detected in a small proportion of cases.
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2 .2 .4 Cancer of the anus
Cancer of the anus is a relatively rare disease 
but increasing incidence is being reported in 
some countries with increases of >160% in men 
or 78% in women in the USA over a period of 20 
years (Daling et al., 2004). Established risk factors 
for anal cancer include a high number of sexual 
partners, receptive anal sex, history of venereal 
diseases; smoking has also been proposed (Frisch 
et al., 1997; Daling et al., 2004). Anal cancer is 
more common among HIV-infected subjects (for 
anal cancer in HIV patient see Section 2.8.3b).
The anal canal consists of a segment of 
approximately 4 cm of squamous mucosa limited 
distally by the anal verge or margin (transi-
tional zone between the skin and mucosa) and 
proximally by the dentate line (transitional zone 
between the squamous and glandular mucosa). 
Malignant tumours of the anal canal are largely 
carcinomas of squamous cell origin. Most adeno-
carcinomas arising in the anal mucosa represent 
a downward spread from an adenocarcinoma in 
the rectum or arise in colorectal-type mucosa 
above the dentate line, and generally are excluded 
in the studies specific to the anal canal.
(a) Case series
Case series of precursor lesions, AIN, 
published since the previous IARC Monograph 
have been included in Table  2.16 (available at 
http://monographs.iarc.fr/ENG/Monographs/
vol100B/100B-06-Table2.16.pdf). The more 
recent studies (Hampl et al., 2006; Varnai et al., 
2006) demonstrate that the great majority of 
cases are HPV-positive, mainly with HPV 16. 
Case series of invasive lesions have been included 
in Table  2.17 (available at http://monographs.
iarc.fr/ENG/Monographs/vol100B/100B-06-
Table2.17.pdf) (Kagawa et al., 2006; Varnai et al., 
2006; Laytragoon-Lewin et al., 2007; Tachezy 
et al., 2007). All studies found high proportions 
of HPV in the tumours, predominantly HPV 16. 
Of interest is the lower proportion of HPV-related 
tumours in those cancers localized in the peri-
anal skin as compared to other anal sites (Frisch 
et al., 1999).
De Vuyst et al. (2009), in a meta-analysis of 
1280 cases of AIN (671 AIN1 and 609 AIN2/3) 
of which 805 were HIV positive and 955 cases 
of invasive carcinomas, estimated that the large 
majority of AIN2/3 lesions (93.9%) and of inva-
sive carcinomas (84.3%) were attributable to 
HPV. As seen in Fig. 2.2, the most frequent types 
detected for AIN2/3 were HPV 16 (59.8%), 18 
(17.4%), 33 (13.6%), and 58 (13.1%). In anal carci-
noma, the most frequent types were HPV 16 
(73.4%), followed by HPV 18 (5.2%), and HPV 33 
(4.8%). Although not studied extensively, HPV 
45 was rarely identified, which probably reflects 
the squamous nature of these tumours. HPV 6 
was detected in 2.9% of the anal carcinomas, 
but its presence could not be disentangled from 
concomitant infections with high-risk types.
(b) Case control studies
One case–control study has compared the 
presence of HPV DNA in anal tumours of 417 
individuals (349 squamous cell carcinomas 
and 68 in-situ squamous cell carcinomas) to 
534 individuals with rectal adenocarcinomas 
(Frisch et al., 1997). High-risk types of HPV were 
detected in 84% of the anal cancer specimens, 
but no HPV was identified in the rectal tumours. 
HPV 16 was the most commonly identified 
type, followed by HPV 33, 18, 6, and 31. HPV 
was more commonly identified in tumours of 
women with invasive or in-situ anal cancer (93%) 
as compared to men (69%). Table 2.18 (available 
at http://monographs.iarc.fr/ENG/Monographs/
vol100B/100B-06-Table2.18.pdf) and Table 2.19 
(available at http://monographs.iarc.fr/ENG/
Monographs/vol100B/100B-06-Table2.19.pdf) 
summarize case–control studies of anal cancer 
that relied on HPV serology. The studies (Carter 
et al., 2001; Bjørge et al., 2002; Daling et al., 2004) 
resulted in odds ratios of 3–5 for the association 




Figure 2.2 Prevalence of human papillomavirus types in case series of anal intraepithelial 
neoplasia (AIN) grades 2/3 and anal cancer
 
Adapted from De Vuyst et al. (2009)
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anal cancer, for both men and women. As an 
indication of type specificity, Bjørge et al. (2002) 
found neither association for HPV 33 nor HPV 
73.
Overall, HPV is detected in over 80% of anal 
cancer cases suggesting a causal relationship. The 
large majority of tumours are related to HPV 
16, and although consistently identified in this 
tumour type HPV 18 and HPV 33 are detected 
in smaller proportions.
2.3 Cancer of the upper aerodigestive 
tract
The fraction of cancers of the oral cavity and 
pharynx associated with HPV infection varies 
between studies according to: 1) the accuracy 
in the distinction of cancer of the oropharynx 
and tonsil from other subsites; 2) the competing 
effect of tobacco smoking or chewing; and 3) the 
quality of tissue biopsies and HPV-testing proto-
cols used.
As a consequence of the above, especially 
high proportions of HPV positivity have been 
recently found in the USA, where early cancer 
cases restricted to the oropharynx and detected 
in a substantial proportion among non-smokers 
have been very carefully evaluated (Andrews 
et al., 2009).
2 .3 .1 Cancer of the oral cavity
Cancers of the oral cavity, including the 
tongue, floor of the mouth, gum, palate, and 
other sites of the mouth have a clearly established 
association with smoking or chewing tobacco, 
and with alcohol drinking. However, there is a 
subset of cancers that occurs among subject not 
exposed to smoking or drinking. The previous 
IARC Monograph concluded that, in the oral 
cavity, there was sufficient evidence for the carci-
nogenicity of HPV 16, and limited evidence for 
the carcinogenicity of HPV 18.
Multiple case series have been reported with 
variable prevalence estimates of HPV – between 
4–74% – including the series included in the 
previous IARC Monograph, and those reviewed 
for this current volume (see Table 2.20 available 
at http://monographs.iarc.fr/ENG/Monographs/
vol100B/100B-06-Table2.20.pdf and Table 2.21 
available at http://monographs.iarc.fr/ENG/
Monographs/vol100B/100B-06-Table2.21.pdf).
The recent case series (Koppikar et al., 2005, 
India; Luo et al., 2007, Taiwan, China; da Silva 
et al., 2007, Brazil; Soares et al., 2007, Brazil; 
Liang et al., 2008, USA) confirmed the same 
pattern of variability. In Taiwan, China, and one 
of the Brazilian studies, the reported prevalence 
was about 25%, but the other Brazilian study 
that included only tongue cancers reported a 
prevalence of 74%. In contrast, the study in 
India only detected mucosal HPV types in 6% of 
the tumours, and in the US study, the reported 
prevalence was only 2% in tongue cancers. Three 
of the case series included non-cancer cases as 
comparison groups. In all studies, HPV posi-
tivity was much lower in these control biopsy 
specimen than in tumour specimens. HPV 16 was 
the most common type in all studies, followed or 
equalled by HPV 18, with the exception of one 
of the Brazilian studies, where this pattern was 
reversed (Soares et al., 2007).
In a meta-analysis that included 2642 oral 
cancers tested with PCR methods, the overall 
prevalence of HPV was 23.5%, with predomi-
nance of HPV 16, which was detected in 16% 
of the cases (68% of the positives), followed by 
HPV 18, detected in 8% (34.1% of the positives). 
About 3% had HPV 6 and 1.6% had HPV 11. No 
other type was detected in more than 1% of the 
cases (Kreimer et al., 2005). [The Working Group 
noted a tendency for the largest and more care-
fully conducted studies to yield lower prevalence 
estimates than the smaller studies, suggesting 
the possibility of publication bias.]
Evidence from case–control studies reported 
until the previous IARC Monograph was mainly 
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based on serological studies. Two studies that 
had used exfoliated cells from cases and controls 
failed to demonstrate an association (Schwartz 
et al., 1998; Herrero et al., 2003), and a third 
observed a doubling of the risk (Smith et al., 
2004). A recent case–control study (Hansson 
et al., 2005, Sweden) demonstrated positive asso-
ciations using exfoliated cells of the oral cavity. 
Another study conducted in Canada (Pintos 
et al., 2008) reported a non-significant odds ratio 
of 1.3.
In the study by Hansson et al., (2005), swabs 
of tumours and tonsillar fossa and mouthwash of 
cases and controls were collected. The odds ratios 
adjusted for tobacco and alcohol were 24 (95%CI: 
3.2–180) for the tongue, 51 (95%CI: 3.2–810) for 
the floor of the mouth, and 22 (95%CI: 2.8–170) 
for the other oral sites.
In summary, there is epidemiological evidence 
for the role of HPV 16 and possibly HPV 18 in the 
etiology of cancers of the oral cavity.
2 .3 .2 Cancers of the oropharynx and tonsil
Cancers of the oropharynx and tonsil are also 
associated strongly with smoking and drinking, 
but extensive evidence has accumulated in 
recent years to support a causal role of HPV in 
a sizable fraction of those cancers, which have 
been increasing in incidence in some popula-
tions (Hammarstedt et al., 2006). 
The fraction of cancers of the oropharynx that 
is HPV-related is larger than for the oral cavity, but 
as mentioned above, this fraction varies between 
studies. Many studies confirm this association, 
in particular for the tonsil. HPV 16 is present in 
about 90% of HPV-positive tumours (see Table 
2.22 available at http://monographs.iarc.fr/ENG/
Monographs/vol100B/100B-06-Table2.22.pdf 
and Table 2.23 available at http://monographs.
iarc.fr/ENG/Monographs/vol100B/100B-06-
Table2.23.pdf).
The original case series showed a high vari-
ability in the prevalence of HPV, although in 
general, the prevalence reported was higher than 
for the oral cavity, in particular for the tonsil. In 
recent case series (Tachezy et al., 2005, Czech 
Republic; Hammarstedt et al., 2006, Sweden; 
Ernster et al., 2007, USA; Kim et al., 2007a, 
Republic of Korea; Charfi et al., 2008, France), the 
prevalence of HPV in oropharyngeal tumours 
was close to 60% or more, with a clear predomi-
nance of HPV 16.
An interesting study from Sweden 
(Hammarstedt et al., 2006) retrieved tonsil cancer 
archival specimens from different time periods to 
determine if the observed increase in incidence 
of tonsil cancer in that area could be explained 
by increases in HPV-related tumours. They 
found that cases diagnosed in the 1970s had an 
HPV positivity of only 23.3%, and this increased 
to 68.0% in tumours diagnosed in 2000–02. 
HPV 16 was detected in 42% of cases (all years 
combined, 87.0% of the positives). Patients with 
HPV-positive cancers were younger at diagnosis.
In the meta-analysis by Kreimer et al. (2005), 
HPV positivity in cancer of the oropharynx was 
35.6% with HPV 16 detected in 30.9% (86.8% of 
the positives) of oropharyngeal tumours. HPV 
18 was detected in only 1.0% of the tumours, and 
HPV 6 in 2.5% of the tumours.
An important, well conducted case–control 
study was recently reported by D’Souza et 
al. (2007). They included 100 patients with 
newly diagnosed oropharyngeal cancer, and 
200 gender- and age-matched controls. Sexual 
behaviours (vaginal and oral sex) were strongly 
associated with a risk of oropharyngeal cancer, 
an association that was stronger when the anal-
ysis was restricted to HPV-positive tumours. 
Strong associations with a risk of oropharyngeal 
cancer were detected for serological markers of 
HPV infection or progression (adjusted OR, 32.2; 
95%CI: 14.6–71.3 for antibodies against HPV 16 
L1 VLPs; adjusted OR, 58.4; 95%CI: 24.2–138.3 
for antibodies against HPV 16 E6 or E7), and for 
detection of HPV DNA in oral exfoliated cells 
(OR, 12.3; 95%CI: 5.4–26.4). HPV 16 DNA was 
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detected in 72% (95%CI: 62–81) of tumour biop-
sies by in-situ hybridization.
Two other case–control studies (Pintos et al., 
2008, Canada; Hansson et al., 2005, Sweden) also 
detected strong associations with risk.
In summary, there is strong epidemiological 
evidence for the causal role of HPV 16 in the 
etiology of cancers of the oropharynx and tonsil. 
HPV 18 is detected in 1% of the tumours.
2 .3 .3 Cancer of the oesophagus
Squamous cell carcinoma of the oesophagus 
is also associated with tobacco and alcohol 
consumption, but a potential role of HPV has 
been proposed (Kamangar et al., 2006; Lu et al., 
2008).
There have been many studies of HPV and 
oesophageal cancer, and findings have been 
very inconsistent geographically, with studies 
showing extreme variations in HPV detection 
probably in relation to the lack of standardized 
testing methods. There are areas, particularly in 
Asia, where HPV is more commonly detected in 
oesophageal cancer.
Recent case series have been reported from 
Egypt (Bahnassy et al., 2005), Colombia and 
Chile (Castillo et al., 2006), Brazil (Souto Damin 
et al., 2006), Germany (Pantelis et al., 2007), the 
Republic of Korea (Koh et al., 2008), the Islamic 
Republic of Iran (Far et al., 2007), and China 
(Shuyama et al., 2007; Lu et al., 2008). HPV 
detection in these recent studies ranged from 0% 
(Republic of Korea) to 54% (Egypt). HPV 16 was 
the most common type in all studies, followed 
by HPV 18.
Several case–control studies based on sero-
logical measures of HPV have been reported, 
but the results have not been consistent. A recent 
study was reported from China (Kamangar 
et al., 2006) in which prediagnostic serum was 
tested by enzyme-linked immunosorbent assay 
(ELISA) for antibodies against HPV 16, 18, and 
73 viral capsids; only HPV 16 was (weakly) 
associated. In Australia, another seroepidemio-
logical study (Sitas et al., 2007) showed increasing 
risk of oesophageal cancer with increasing levels 
of antibodies against HPV 16.
See Table 2.24 available at http://mono-
graphs.iarc.fr/ENG/Monographs/vol100B/100B-
06-Table2.24.pdf and Table 2.25 available at 
http://monographs.iarc.fr/ENG/Monographs/
vol100B/100B-06-Table2.25.pdf.
In view of the inconsistency of results, the 
Working Group considered that the epidemio-
logical evidence for a role of HPV in oesophageal 
cancer is inadequate.
2 .3 .4 Cancer of the larynx
HPVs (usually types 6 and 11) cause recur-
rent respiratory papillomatosis, and it has long 
been suggested that some of these viruses could 
be related to cancer of the larynx (IARC, 2007).
Three recent case series (de Oliveira 
et al., 2006, Brazil; Gungor et al., 2007, Turkey; 
Koskinen et al., 2007, Finland, Norway and 
Sweden) reported HPV positivity of 37.3%, 7.4%, 
and 4.4%, respectively. In Brazil, HPV 18 was 
predominant, and in Turkey, HPV 11 was the 
most common type.
The meta-analysis by Kreimer et al. (2005) 
reported on 1435 cases of cancer of the larynx. 
Overall HPV positivity was 24.0%, with HPV 16 
detected in 16.6% of laryngeal tumours (69.2% 
of the positives), followed by HPV 6 in 5.1%, 
and HPV 18 in 3.9% (see Table 2.26 available at 
http://monographs.iarc.fr/ENG/Monographs/
vol100B/100B-06-Table2.26.pdf).
The Working Group considered that the 
epidemiological evidence is not conclusive to 
confirm the role of HPV 16 or 18 in cancer of the 
larynx. Similarly, as discussed in the previous 
IARC Monograph, there is some evidence for 
a role of HPV 6 and 11, which cause laryngeal 




2.4 Cancer of the skin
As summarized in the previous IARC 
Monograph, multiple case series have demon-
strated that HPV DNA is frequently found both 
in skin lesions and in healthy skin. At present, 
it is known that cutaneous HPVs are found in 
five genera: alpha (species 2, 4, 8), beta, gamma, 
mu, and nu (Michael et al., 2008). The cutaneous 
HPV types 1 (genus mu); 2, 27, 3, 10, 57 (genus 
alpha); and, HPV 4 (gamma) belong to different 
genera but are all associated with benign plantar, 
common, and flat skin warts. Certain HPV types 
in the beta-1 species (HPV 5 and 8 in particular) 
are found in the rare hereditary disease epider-
modysplasia verruciformis (EV). It is these beta-1 
HPV types, the other beta species and, more 
recently, the gamma genus HPVs, which have 
elicited the most interest with regard to risk of 
skin cancer. The other motivation for study has 
been the known increased prevalence of skin and 
genital warts and squamous cell cancers among 
individual with immunosuppressive treat-
ments related to organ transplantation. These 
associations have suggested the importance of 
immune surveillance, and a possible direct role 
for HPV that has, nonetheless, proven difficult to 
demonstrate.
Improving test methods continue to detect an 
expanding variety of HPV types that infect the 
non-genital skin; these are largely types not found 
in the anogenital region or in the oral cavity. More 
types in addition to HPV 5 and 8 have now been 
found in the lesions of patients with EV, albeit 
at lower viral loads (Dell’Oste et al., 2009). With 
an expanding number of characterized types, 
the taxonomy of cutaneous HPV types has been 
clarified; in this section, the current terminology 
will be used (de Villiers et al., 2004; Forslund, 
2007) (e.g., “beta papillomaviruses” replaces “EV 
types”). Fully-characterized types are shown in 
Fig. 2.1, but more are already known to exist.
Case–control studies of skin cancer have been 
complicated by methodological issues including: 
the heterogeneity of skin lesions, the multiplicity 
of HPV types including many novel types found 
in skin, evolving methods for sampling lesions 
and healthy control skin, variable and incom-
pletely validated measurement techniques for 
DNA and serology, potential confounding by 
UV light exposure, and the possibility of “reverse 
causality” in which the development of a skin 
lesion could lead to increased HPV positivity 
thereby creating the false impression of a causal 
association.
Skin neoplasia comprises a diverse set of inva-
sive and preinvasive lesions. Most recent studies 
have focused on non-melanoma skin cancers, 
especially squamous cell carcinoma rather than 
nodular or superficial focal basal cell carcinoma. 
The precursors to squamous cell carcinoma, 
called actinic keratoses or solar keratoses have 
also been included in several studies.
One measurement problem that is unique to 
skin cancer studies is the possible confounding 
role of UV light, which might enhance HPV 
replication, HPV detection and/or seropositivity 
through a local immune-modulating effect. The 
scant data are contradictory, and do not permit a 
conclusion. Because UV exposure and sunburn 
are strong risk factors for squamous cell carci-
noma, it is possible that some of the association 
between HPV detection and squamous cell carci-
noma could be due to confounding by the extent 
to which the skin under study is exposed to UV 
light. A fundamental question is whether the 
increased prevalence of HPV DNA in squamous 
cell carcinoma and actinic keratoses compared 
with that in healthy skin proves a causal role for 
HPV in these tumours (Pfister, 2003; Majewski 
& Jablonska, 2006; Bouwes Bavinck et al., 2008; 
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2 .4 .1 Review of case–control studies 
measuring HPV DNA
To date, the studies have reported HPV DNA 
detection in lesions or healthy skin from persons 
with skin cancers compared with various sorts of 
controls. Only one very small study of RNA, not 
large enough to alter conclusions, was found in 
this review (Purdie et al., 2005).
In the previous IARC Monograph, a few case–
control studies were summarized that in aggre-
gate supported a possible association between the 
detection of DNA from beta-species papilloma-
viruses and a risk of squamous cell carcinoma. 
Additional studies reported since then have not 
provided consistent evidence of an etiological 
role for any one viral type or groups of types 
including anogenital HPV types (Gustafsson 
et al., 2004), beta-1 species (Patel et al., 2008), 
beta-2 species (Forslund, 2007), and novel types 
(Alotaibi et al., 2006).
Forslund et al. (2007) observed that heavily 
light-exposed areas of the skin were much more 
likely to test positive for HPV (OR, 4.4), raising 
the important possibility of confounding of the 
more modest positive associations found between 
HPV prevalence and squamous cell carcinoma 
(OR, 2.1), particularly with beta-species such as 
HPV 38.
2 .4 .2 Review of case–control studies 
measuring HPV seroreactivity
Two serological studies were reviewed in the 
previous IARC Monograph, with data on only a 
few beta-species papillomaviruses. Overall, the 
data from Feltkamp et al. (2003) and Masini et 
al. (2003) suggested an association of skin cancer 
with both beta-1 and beta-2 papillomaviruses, 
with the most consistent evidence for HPV 8.
Since, the advent of multiplex serology has 
permitted the assessment of many HPV types at 
once, although it is not known whether the assays 
are equally accurate for all of the types detected. 
In a population-based case–control study of 252 
squamous cell carcinoma case patients, 525 basal 
cell carcinoma case patients, and 461 control 
subjects, Karagas et al. (2006) used multiplex 
serology to detect antibodies in plasma samples 
against HPV types from phylogenetic genera 
alpha, beta, and mu. They observed an association 
between squamous cell carcinoma and seroposi-
tivity to HPV types in genus beta as a group, and 
particularly the beta-1 HPV type 5, but no asso-
ciations with basal cell carcinoma. Individuals 
with tumours on chronically sun-exposed sites 
were more likely to be seropositive for beta HPV 
types than individuals with squamous cell carci-
noma at other anatomical sites. Waterboer et al. 
(2008) also used multiplex serology but observed 
associations with squamous cell carcinoma for 
other types, namely beta-2 species combined, 
and all gamma species combined (43 cases, 77 
controls).
Casabonne et al. (2007) conducted a small 
but potentially revealing study of HPV sero-
positivity in stored plasma, comparing prevalent 
cases of squamous cell carcinoma and incident 
cases of squamous cell carcinoma to controls. 
This is the closest to a cohort study available to 
the Working Group in published form. Using 
a multiplex method, they assayed 38 HPV 
types. There were no differences between the 80 
controls and 39 incident cases that developed 
squamous cell carcinoma subsequently to blood 
draw. However, the 15 cases with prevalent squa-
mous cell carcinoma detected before blood draw 
tended to have non-significantly elevated sero-
positivity to multiple HPV types. Moreover, the 
incident cases diagnosed closest to blood draw 
were more likely than those diagnosed later to be 
seropositive (again non-significantly). Although 
too small to be more than suggestive, these data 
would indicate that antibodies could be produced 
during the process or as a consequence of tumour 
formation.
Casabonne et al. (2009) recently reported a 
null study among organ transplant recipients. 
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They studied 140 transplant recipients and 454 
controls with multiplex serology, and found 
expected strong associations of HPV 16 anti-
bodies in subjects with a history of abnormal Pap 
smears, and HPV 6 antibodies in those with a 
history of genital warts. However, they observed 
no associations between any HPVs in the beta 
genus and squamous cell carcinoma of the skin, 
by history of abnormal Pap smears or genital 
warts, or by examination.
2 .4 .3 Case–control studies combining both 
HPV DNA measurements and serology
Since the previous IARC Monograph, 
Termorshuizen et al. (2004) investigated 156 
patients with squamous cell carcinoma and 320 
controls from outpatient ophthalmology clinics. 
They tested beta HPV types from plucked eyebrow 
hairs, tested sera using ELISA, and administered 
an epidemiological questionnaire focused on 
sunlight exposure and sunburn. The results were 
complex, which probably reflects accurately the 
possible role of HPV in skin cancer etiology. Both 
the DNA and serological measures of HPV were 
associated with case status, but the two measure-
ments were not associated with each other. HPV 
DNA was decreased in controls reporting more 
lifetime sun exposure, but elevated in controls 
reporting painful sunburn at specific ages. The 
type-specific results appeared to show elevations 
for virtually all types tested.
Struijk et al. (2006) compared 64 squa-
mous cell carcinoma cases, 126 actinic kera-
tosis cases, and 57 tumour-free ophthalmology 
clinic patients from the same catchment area in 
Brisbane, Australia. They employed type-specific 
PCR to study EV-type DNA in plucked eyebrow 
hairs, and assessed seropositivity using both L1 
VLP and E6 fusion protein ELISA. The E6 assays 
were not associated with DNA or risk. However, 
HPV DNA prevalence was elevated in the 
actinic keratosis group compared with either the 
squamous cell carcinoma group or the healthy 
controls, and the results for HPV 20 achieved 
statistical significance. In this study, seroposi-
tivity to L1 VLPs was significantly associated 
with HPV DNA positivity among the controls 
and the actinic keratosis group. L1 VLP sero-
positivity was non-significantly associated with 
actinic keratosis and squamous cell carcinoma 
for all types combined, and for squamous cell 
carcinoma, the odds ratios were elevated (often 
significantly) for all the individual HPV types.
Andersson et al. (2008) collected serum and 
biopsy samples from both lesions and healthy 
skin from 434 non-immunosuppressed patients 
(72 squamous cell carcinomas, 160 basal cell 
carcinomas, 81 actinic keratoses, and 121 benign 
lesions). The presence of HPV DNA and of anti-
bodies to the same HPV type was not significantly 
correlated. However, seropositivity to any HPV 
type was significantly more common among 
patients positive for HPV DNA of any HPV 
type. The seroprevalence tended to be somewhat 
higher among squamous cell carcinoma patients 
than among basal cell carcinoma patients.
2 .4 .4 Conclusion
Epidemiological data do not yet support that 
any single HPV type causes skin cancer in the 
general population owing to a lack of consistency 
of the associations described. At present, a posi-
tive association has been observed between HPV 
infection and both squamous cell carcinoma 
and its precursor actinic keratosis. The evidence 
is derived from a tendency, not type-specific, of 
increased odds ratios of DNA detection and sero-
reactivity compared to control study participants 
and/or paired healthy skin. The role of HPV in 
skin cancer may be complex, non-causal, and/or 
linked to other factors like UV damage, immu-
nosuppression, and genetics.
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2.5 Cancer at other sites
The evidence for the carcinogenicity of HPV 
in the following cancers was evaluated in the 
previous IARC Monograph: cancers of the nose 
and nasal sinuses, cancer of the lung, cancer of 
the colon and rectum, cancer of the breast, cancer 
of the ovary, cancer of the prostate, and cancer of 
the urinary bladder and urethra.
2 .5 .1 Cancer of the nose and nasal sinuses
Inverted papillomas of the nasal cavity and 
paranasal sinuses are frequently positive for 
HPV 6, 11 and 57, and a small percentage of rare 
carcinomas arising at those sites sometimes have 
HPV 16, 18, 11, 6 and 57 in decreasing frequency 
(IARC, 2007). The rarity of these tumours makes 
it difficult to evaluate the role of HPV, and no 
case–control studies have been reported
A recent study by El Mofty & Lu (2005) 
conducted in the USA correlated HPV detection 
by PCR with histological subtypes of carcinoma 
of the sinonasal tract. They studied paraffin 
blocks of a small series (n = 39) of keratinizing, 
non-keratinizing, and undifferentiated tumours. 
HPV was detected more often in the small number 
of keratinizing tumours, with a predominance of 
HPV 16. On the other hand, another recent study 
(Kim et al., 2007b) studied 57 paraffin-embedded 
biopsies from inverted papillomas of different 
grades (I – IV, with grade IV being carcinoma 
originating in inverted papilloma). Only 12.3% of 
cases (restricted to grade I and II) had detectable 
HPV DNA, mainly of the mucosal carcinogenic 
type. Alos et al. (2009) recently reported a preva-
lence of HPV in 20% of a series of 60 sinonasal 
tumours, with HPV 16 detected in 11/12 cancers.
2 .5 .2 Cancer of the lung
Multiple groups have tested for HPV in 
lung cancer samples, with variable results. The 
geographic areas where the highest prevalence 
has been reported are predominantly in Asia. 
The rare occurrence of lung cancer in patients 
with recurrent laryngeal papillomatosis has been 
documented, and some studies have reported 
HPV-associated lung cancers among women 
with a history of CIN3.
Since the last IARC Monograph, there have 
been seven new case series reported including at 
least 40 cases of lung cancer, from various loca-
tions including France (Coissard et al., 2005), 
China (Fei et al., 2006), the Islamic Republic of 
Iran (Nadji et al., 2007), the Republic of Korea 
(Park et al., 2007), Chile (Aguayo et al., 2007), 
Taiwan, China (Cheng et al., 2007), and India 
(Jain et al., 2005). HPV detection was variable, 
from 2% in France to 46% in Taiwan, China, 
with a predominance of HPV 16 in all studies. 
In the study from China, a non-cancer group 
was included without detection of HPV 16. In 
the Korean study, HPV 16 was more common in 
biopsies of younger subjects.
See Table 2.28 available at http://mono-
graphs.iarc.fr/ENG/Monographs/vol100B/100B-
06-Table2.28.pdf.
2 .5 .3 Cancer of the colon and rectum
The discussion of the association of HPV 
and cancer of the colon and rectum (usually 
adenocarcinoma) requires a clear distinction of 
the histology and anatomical site, to distinguish 
cases from cancers of the anus (Section 2.2.4), 
which are clearly HPV-related. Several small 
case series have investigated the prevalence of 
HPV in biopsies of colorectal cancer, with vari-
able results. Many of the studies were completely 
negative. However, one study (Bodaghi et al., 
2005) reported 42% HPV positivity in cases, 29% 
in biopsies from adjacent tissues, and no HPV in 
control subjects. HPV 16 was the predominant 
type in tumours.
A recent case series from Brazil (Damin et al., 
2007) investigated 72 cases of primary colorectal 
adenocarcinoma. For each patient, two speci-
mens were collected: one from the tumour and 
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one from the normal colorectal mucosa at least 
15 cm apart from the tumour. In addition, biop-
sies from 30 individuals without cancer were also 
evaluated. HPV DNA was detected in 83.3% of 
cancer patients but in none of the tissues from the 
non-malignant control group (P < 0.001). HPV 
was present only in the tumour of 32% of the 
cases, in the tumour and adjacent tissue of 32% 
of cases, and only in adjacent tissue in 19.5% of 
cases. HPV 16 was the predominant type (68.3% 
of positive cases), followed by HPV 18 (50% of 
positives). More than 30% of cancer patients 
were infected by multiple HPV types. HPV geno-
typing was confirmed by sequencing; there were 
no epidemiological differences between positive 
and negative cases.
2 .5 .4 Cancer of the breast
There is contradictory evidence for the role 
of HPV in breast cancer. Several small nega-
tive studies were reported in the previous IARC 
Monograph, as well as a few studies in which 
HPV was detected in different fractions of breast 
tumours. HPV 16 and 18 were the most common 
types. One of the studies (Hennig et al., 1999) 
reported HPV-type concordance between CIN3 
cases and subsequent breast cancers.
A recent study from Switzerland (Lindel et al., 
2007) analysed paraffin-embedded sections of 
81 patients with breast cancer using the well 
validated SPF10 PCR system; all samples were 
negative. Another study conducted in the Syrian 
Arab Republic (Akil et al., 2008) found extremely 
high HPV positivity in 113 blocks. Cazzaniga et 
al. (2009) investigated the presence of cutaneous 
and cervical carcinogenic HPV types in ductal 
lavages, colostrum, and milk of 90 women at risk 
of breast cancer. A total of 14% (10/70 analysed) 
of the specimens contained cutaneous types, and 
only one had a mucosal type (HPV 16). Removal 
of the superficial epidermal cells significantly 
reduced prevalence, with HPV detection in only 
2/45 specimens (beta HPV types).
2 .5 .5 Cancer of the ovary
There is limited information about the poten-
tial role of HPV in cancer of the ovary, and several 
small negative case series have been reported as 
well as a few studies with positive findings. The 
presence of HPV in the ovary may be related 
to HPV-associated disease ascending from the 
cervix.
A study by Quirk et al. (2006) from the USA 
reported the analysis of fresh frozen biopsies 
from 20 women with ovarian carcinomas. Using 
commercial PCR amplification kits, no HPV 
DNA was detected in any of the tumours. Another 
study in Turkey (Atalay et al., 2007) observed HPV 
in 8.5% of 94 patients. All HPV-positive patients 
had serous papillary tumours and advanced 
stage disease. A third study reported from Italy 
(Giordano et al., 2008) included 71 women with 
borderline (n, 21) and malignant (n, 50) ovarian 
tumours. Three cases (4.2%) of epithelial ovarian 
neoplasm had detectable HPV DNA.
2 .5 .6 Cancer of the prostate
Prostate cancer is associated with sexual 
behaviour in some studies (Damber & Aus, 2008), 
suggesting a possible role for HPV. A variety of 
studies have been conducted, including case 
series and case–control studies mainly based on 
serological measures of exposure. The results are 
inconclusive although most studies are negative.
Two case series of cancer of the prostate 
(Leiros et al., 2005, Argentina; Balis et al., 
2007, Greece) have been reported recently. The 
study from Argentina detected HPV in 41.5% 
of tumours. Most of the tumours where HPV 
was identified harboured HPV 16. All prostatic 
hyperplasias were negative. In contrast, the study 
in Greece only found HPV DNA in 2/42 cases of 
prostatic carcinoma (4.8%).
Several case–control studies, some of them 
nested in prospective cohorts and using sero-
logical measures, have been reported on the 
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association of HPV and prostate cancer (Adami 
et al., 2003, Sweden; Rosenblatt et al., 2003, USA; 
Korodi et al., 2005, Nordic Countries; Bergh 
et al., 2007, Sweden; Sutcliffe et al., 2007, Sweden). 
All of the serology-based studies, some of them 
using pre-diagnostic and some post-diagnostic 
specimens, were basically negative, with no asso-
ciation with antibodies against L1 VLPs of HPV 
16, 18 and 33 as determined by ELISA, except 
for a minor elevation in risk for HPV 33 in one 
of the studies. The study by Bergh et al. (2007) 
also studied paraffin-embedded biopsies without 
detection of HPV in either cases in controls.
See Table 2.29 available at http://mono-
graphs.iarc.fr/ENG/Monographs/vol100B/100B-
06-Table2.29.pdf and Table 2.30 available at 
http://monographs.iarc.fr/ENG/Monographs/
vol100B/100B-06-Table2.30.pdf.
2 .5 .7 Cancer of the urinary bladder and 
urethra
Bladder cancers are predominantly tran-
sitional cell carcinomas, with the exception of 
areas where schistosomiasis is highly prevalent 
where a predominance of squamous cell carci-
nomas is observed. Similarly to other cancer 
sites, case series have reported a variable preva-
lence of HPV across studies.
Since the previous IARC Monograph, a case 
series was reported from the Islamic Republic 
of Iran (Barghi et al., 2005), which included 
paraffin-embedded biopsies of 59 transitional cell 
carcinomas, and detected HPV in 35.6% of the 
tumours. The most common type was HPV 18 but 
HPV 16 was not detected. Moonen et al. (2007) 
reported on 107 cases from the Netherlands, 
testing bladder wash samples. Overall, the preva-
lence of any HPV type was 13.7%. HPV 18 was 
the most common type detected, followed by 
HPV 16.
2.6 Cofactors of HPV in cervical 
cancer
HPV is a necessary cause of cervical cancer. 
However, only a small fraction of women infected 
develops cervical cancer or its high-grade precur-
sors, indicating that there must be additional 
viral, host or environmental factors conditioning 
viral persistence and progression. Cofactors 
were reviewed extensively in the previous IARC 
Monograph.
The study of cofactors has been difficult 
because many of the exposures involved are 
correlated with sexual behaviour and therefore 
with HPV acquisition. Analyses restricted to 
HPV-positive subjects have been considered to be 
the best analytical alternative for control of this 
type of confounding. However, in the context of 
almost universal exposure, women with current 
infection are not necessarily the most appro-
priate control group, because they are a combi-
nation of both persistent and recently acquired 
infections that vary with the population and 
age of the control group, and there is currently 
no adequate measure of past exposure to HPV. 
Other exposures have the analytical difficulty of 
being associated with screening behaviour, and 
most suffer some degree of measurement error.
One of the most studied cofactors is tobacco 
smoking, a well established carcinogen that is 
known to exert its effect in organs not directly 
exposed to smoke. Most studies, using different 
methods to adjust for confounding including the 
restriction to HPV-positive cases and controls, 
have found an approximately 2-fold increase in 
risk of cervical cancer or high-grade precur-
sors (Kjær et al., 1996; Ho et al., 1998a; Krüger-
Kjaer et al.,1998; Olsen et al., 1998a; Ylitalo 
et al., 1999; Kjellberg et al., 2000; Hildesheim 
et al., 2001; Plummer et al., 2003; Giuliano 
et al., 2004), some of them with dose responses 
for the amount of cigarettes smoked and dura-
tion of smoking (Ho et al., 1998a; Kjellberg 
et al., 2000; Hildesheim et al., 2001; Harris et al., 
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2004). In a large meta-analysis including more 
than 13000 cases and 23000 controls from 23 
epidemiological studies, smokers were at an 
increased risk (pooled OR, 1.6; 95%CI: 1.5–1.7) 
of squamous cell but not of adenocarcinoma of 
the cervix. The risk of squamous cell carcinoma 
increased in current smokers with the number 
of cigarettes smoked per day, and with younger 
age at starting smoking (Appleby et al., 2006a). 
Several cohort studies have clearly shown the 
association, particularly for CIN3 (Deacon et al., 
2000; Castle et al., 2002). Cigarette smoking is an 
established cofactor of HPV for cervical cancer, 
although it is still unclear if its effect is mediated 
by genotoxicity or immunomodulation. The role 
of other forms of tobacco exposure, including 
chewing and passive smoking, as well as the role 
of tobacco as a cofactor of HPV in other organs 
requires further research.
Multiple studies have also suggested a poten-
tial role of hormonal contraceptives as HPV 
cofactors. The agents investigated most exten-
sively are oral contraceptives, and several case–
control studies (Ylitalo et al., 1999), but not all 
(Kjær et al., 1996; Lacey et al., 2000; Shapiro 
et al., 2003; Giuliano et al., 2004) detected 
increases in risk, particularly among users of 
oral contraceptives for more than 5 or 10 years 
(Berrington et al., 2002; Moreno et al., 2002). 
One of the studies (Lacey et al., 1999) reported 
an association restricted to glandular lesions. A 
very large pooled re-analysis confirmed the asso-
ciation between oral contraceptives and cervical 
cancer and its precursors, and the observed 
reduction in risk after cessation of use (Appleby 
et al., 2007). These findings were not replicated in 
cohort studies of precursor lesions (Deacon et al., 
2000; Castle et al., 2002), possibly reflecting the 
protective effect of screening among oral contra-
ceptive users. Injectable contraceptives have 
also been shown to increase the risk of cervical 
cancer (Herrero et al., 1990, Appleby et al., 2007), 
and also to increase CIN3 among HPV-positive 
women (Castle et al., 2005b). An important 
consideration when interpreting the role of 
hormonal contraceptives is that most studies and 
systematic reviews evaluated the risk associated 
with the contraceptive products used in previous 
decades. Information is needed about the poten-
tial association of the newer contraceptive agents 
that have different hormonal formulations.
The number of pregnancies is also an estab-
lished cofactor of HPV in cervical cancer, with 
most studies showing increases in risk associated 
with increasing number of pregnancies (Kjær 
et al., 1996; Hildesheim et al., 2001; Muñoz et al., 
2002; Appleby et al., 2006b). A few prospective 
studies of precursor lesions have not confirmed 
this association (Deacon et al., 2000; Castle et al., 
2002), possibly because they had limited numbers 
of highly multiparous women. The possible role 
of a hormonal, nutritional or immune status 
change during pregnancy or potential cervical 
trauma during delivery as a cofactor of HPV 
remains to be determined. It is possible that 
part of the decline in cervical cancer incidence 
and mortality observed in some populations is 
related to declines in fertility rates.
The likely role of nutrients as preventive agents 
in several epithelial cancers is generally accepted. 
However, despite numerous studies using 
different methods for ascertaining the impact of 
dietary exposures, the investigation of the role of 
nutrients as cofactors of HPV in cervical cancer 
and its precursors has yielded inconsistent results, 
with some studies suggesting potential protective 
effects of fruits and vegetables (Rajkumar et al., 
2003), folate (Weinstein et al., 2001), vitamin C 
(Giuliano et al., 2003), carotenoids (Giuliano 
et al., 1997), tocopherols (Giuliano et al., 1997), 
and vitamin B12 (Sedjo et al., 2002), but other 
studies have shown no significant associations 
(Ho et al., 1998b; Wideroff et al., 1998). Notably, 
a recent study (Piyathilake et al., 2007) suggested 
that an increase in risk of CIN2+ was associated 
with a strong interaction between HPV 16 and 
low red-blood cell folate levels. The assessment 
of dietary exposures is difficult, and subject to 
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variation in different populations. In addition, it 
is correlated with sociodemographic and behav-
ioural variables, requiring the consideration of 
multiple confounders. However, further studies 
are needed, particularly for nutrients in the one-
carbon metabolic pathways like folate, given the 
potential for intervention.
There is some evidence of familial aggre-
gation in cervical cancer (Amundadottir 
et al., 2004; Zelmanowicz et al., 2005; Couto & 
Hemminki 2006), suggesting the possibility of 
genetic factors that could act as cofactors of HPV 
infection, although additional studies are needed 
to confirm these associations, to define possible 
mechanisms, and to rule out confounding by 
environmental exposures shared by families.
Immunosuppression, both in transplant 
recipients and in HIV-infected subjects, is an 
established cofactor of HPV infection in the 
development of precursor lesions and inva-
sive cancer at most anatomical sites investi-
gated (see HIV-Monograph in this volume). 
Immunosuppression was reviewed extensively in 
the previous IARC Monograph. In this context, 
the genetics of the immune response is also likely 
to play an important role in the fate of HPV infec-
tions. Some HLA (human leukocyte antigen) 
polymorphisms, related with antigen recogni-
tion, have been proposed as determinants of risk 
of progression, while others have been associ-
ated with protection. Many studies conducted in 
different populations have reported associations 
in both directions, particularly for DR and DQ 
class II genes (Apple et al., 1994, 1995; Duggan-
Keen et al., 1996; Cuzick et al., 2000; Madeleine 
et al., 2002). Some of the difficulties of these 
analyses include variable ethnic compositions of 
the populations and multiple comparisons.
Other infectious agents, including Chlamydia 
trachomatis (Koutsky et al., 1992; Jha et al., 1993; 
de Sanjosé et al., 1994; Bosch et al., 1996; Giuliano 
et al., 2001; Smith et al., 2002a; da Silva et al., 
2004) and herpes simplex virus (Hildesheim 
et al., 1991; Peng et al., 1991; Koutsky et al., 1992; 
Jha et al., 1993; Becker et al., 1994; Olsen et al., 
1998b; Smith et al., 2002b), as well as inflam-
mation associated with various infections have 
been shown in some studies to be associated 
with a risk of cervical cancer or its precursors. 
Most studies of these agents are seroepidemio-
logical, and some have used markers of bacterial 
or viral DNA. The most abundant and consistent 
evidence is for C. trachomatis, but the correlation 
is so high between sexually transmitted agents 
that it is difficult to completely rule out residual 
confounding, and the mechanism for its interac-
tion with HPV, if there is one, remains unknown. 
Cervical inflammation, as ascertained in cyto-
logical specimens has been associated with an 
increase in risk (Schiff et al., 2000; Castle et al., 
2001), and genotoxic damage associated with the 
inflammatory response is a likely mechanism for 
the interaction between HPV and these infec-
tious agents.
Most cofactors appear to act as determinants 
of persistence and progression to advanced 
precursors, but no risk factor has been established 
for progression to invasion, except probably age.
3. Cancer in Experimental Animals
In this volume, the Working Group decided 
not to include a separate section on “Cancer in 
Experimental Animals” in the Monographs on 
viruses but rather to include description of such 
studies under Section 4 (below). The reasoning 




4. Other Relevant Data
4.1 Mechanisms of HPV-associated 
carcinogenesis
There is compelling evidence that certain 
HPVs encode oncoproteins that directly 
contribute to the development and maintenance 
of cervical cancer. This is supported by extensive 
biochemical and biological studies performed 
with animal cells, primary human cells, and 
with cells derived from the cervical cancers.
4 .1 .1 Rodent cells
The earliest assays to confirm that HPV 
encodes proteins with cell-transforming capacity 
were carried out with established cell lines of 
murine origin, such as NIH3T3, Rat-1, and 
Rat3Y1. These tests can be considered to be the 
simplest and least rigorous for establishing the 
oncogenic potential of a given agent, in that the 
cells used in these assays are already immortal. 
The cells are transfected with entire HPV genomes 
or individual gene products, and their trans-
forming capacity is assessed on the basis of either 
growth in an anchorage-independent manner, 
or tumour formation in nude mice. These early 
studies established that HPV 16, in particular, 
had transforming potential in established rodent 
cells (Tsunokawa et al., 1986; Yasumoto et al., 
1986) and that the principal activity resided in 
the E7 oncoprotein (Kanda et al., 1988; Vousden 
et al., 1988), although transforming potential in 
such assays has also been reported for the E5 and 
E6 proteins of both HPV 16 and HPV 18 (Bedell 
et al., 1989; Sedman et al., 1991; Pim et al., 1992).
Oncogene-cooperation assays were next used 
to demonstrate the transforming potential of 
different HPV types. These tests most commonly 
involved primary baby rat kidney cells or primary 
baby mouse kidney cells. The cooperating onco-
gene was typically activated Ras (Matlashewski 
et al., 1987), although co-transforming activity 
has also been reported with activated Fos (Crook 
et al., 1988). In all of these cases, transformation 
was assessed on the basis of the appearance of 
morphologically transformed immortalized 
cells, or the ability of these cells to form tumours 
in syngeneic animals. In baby rat kidney cells, 
the majority of the transforming activity of HPV 
16 appears to be carried by the E7 oncoprotein 
(Storey et al., 1988), but some transforming 
activity is also detectable from the E6 oncopro-
tein in baby mouse kidney cells (Storey & Banks, 
1993).
4 .1 .2 Human cells
Human keratinocytes are the cells of choice 
to study HPV oncoproteins, as these cells are 
the natural target for the virus in vivo. In these 
cells, some mucosal and cutaneous HPVs can 
readily induce immortalization. This property 
has been demonstrated in cervical, foreskin and 
oral keratinocytes as well as tonsil epithelial cells 
(Dürst et al., 1987; Pirisi et al., 1987; Woodworth 
et al., 1989; Klingelhutz et al., 1996; Caldeira 
et al., 2003; Spanos et al., 2008). In the majority 
of cases, these activities required both E6 and E7 
oncoproteins (Barbosa & Schlegel, 1989; Hawley-
Nelson et al., 1989).
Although these assays measure only immor-
talizing capacity, full transformation, i.e. tumour 
growth, can be attained by prolonged passage in 
tissue culture or by transfection of additional 
activated oncogenes, such as RAS (Dürst et al., 
1989; Spanos et al., 2008).
Other primary human cells that are suscep-
tible to the transforming potential of HPVs 
include mammary epithelial cells, which appear 
to be particularly susceptible to the effects of E6 
(Band et al., 1991).
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4 .1 .3 Cells derived from cervical tumours
The clearest demonstration that E6 and E7 
are necessary for the development of cervical 
cancer comes from studies where expression 
of either protein is blocked or inhibited in cells 
derived from cervical tumours. The expression 
of both viral proteins continues many years 
after the establishment of these cell lines in vitro 
(Schwarz et al., 1985; Smotkin & Wettstein, 
1986; Androphy et al., 1987; Banks et al., 1987), 
suggesting a requirement for their continued 
expression for the maintenance of cell prolif-
eration. This has in fact been confirmed in many 
studies using a range of techniques to ablate the 
expression or activity of E6 and E7. This includes 
selective alteration of viral gene expression 
(von Knebel Doeberitz et al., 1988; Goodwin 
& DiMaio, 2000), anti-sense RNA (Steele et al., 
1992; von Knebel Doeberitz et al., 1992), RNAi 
(Butz et al., 2003; Yoshinouchi et al., 2003), and 
blocking peptides (Butz et al., 2000). In all of these 
examples, cervical cancer cells cease to prolif-
erate, and enter into either senescent or apoptotic 
states. This is perhaps the single most important 
evidence of the role of HPV in the maintenance 
of the malignant phenotype of cervical cancer.
4 .1 .4 Transforming capacity of HPVs
HPV 16 and HPV 18 display transforming 
potential in all of the assays listed above. The 
other mucosal types that have been shown to 
posses transforming activity in keratinocyte 
immortalization assays are HPV types 31, 33, 45, 
53, 56, 58, 66, and 82 (Woodworth et al., 1989; 
Hiller et al., 2006; Morandell et al., 2008). It 
should be stressed, however, that except for HPV 
types 31 and 33, this has only been reported once.
Cutaneous beta HPV types also exhibit 
transforming activity under the conditions of 
some of the above assays. HPV 5, 8, and 47 are 
active in established rodent cell transformation 
assays (Kiyono et al., 1992; Schmitt et al., 1994); 
HPV types 12, 14, 15, 24, 36, and 49 are active 
in primary rodent cell co-transformation assays 
(oncogene cooperation assays with activated 
Ras) (Massimi et al., 2008); HPV 38 is active in 
primary human keratinocyte assays (Caldeira 
et al., 2003), and a weak keratinocyte immor-
talizing activity has been reported for HPV 8 
(Schmitt et al., 1994).
4.2 Biochemical properties of HPV 
proteins
4 .2 .1 The E5 protein
The E5 protein is a small hydrophobic poly-
peptide (10  kD) whose localization is believed 
to be in membrane compartments including 
the Golgi apparatus, and the endoplasmatic 
reticulum (Conrad et al., 1993). A possible role 
for the E5 protein of the mucosal high-risk HPV 
types may be at an early stage of carcinogenesis 
given that E5 is not expressed in many invasive 
cancers due to the integration of the viral DNA 
into the host genome, which frequently leads to 
the loss of the E5 ORF or at least loss of its expres-
sion. Surprisingly, there is still very little known 
about the biochemical mode of action of the E5 
protein. There is some evidence to suggest that 
it can alter the processing of epidermal growth 
factor receptors (Straight et al., 1993), most likely 
through interaction with the 16-kD component 
of the vacuolar proton-ATPase, and endosomal 
processing (Conrad et al., 1993; Straight et al., 
1995). However, there is also evidence that E5 
can affect antigen presentation by interac-
tion with, and downregulation of, class 1 HLA 
(Ashrafi et al., 2005, 2006), thereby contributing 
to immune evasion. It should be stressed that all 
the information on biochemical properties of the 
E5 proteins are derived from studies of HPV 16 
and the low-risk HPV type 6. Finally, an anti-
apoptotic function for E5 has also been described 
in keratinocytes, although the molecular basis 
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behind this activity is unknown (Kabsch & 
Alonso, 2002).
It should be noted that many beta HPV 
types do not possess an E5 ORF, so this protein 
would not seem to be relevant in these virus 
types. Whether other viral gene products have 
evolved to carry out some of the functions of 
the E5 protein described above, remains to be 
determined.
4 .2 .2 The E6 protein
The E6 protein is approximately 158 amino 
acids in length, and is one of the most extensively 
studied HPV proteins. A major feature of its 
activity is directed at the degradation of cellular 
binding partners through the combined activity 
of a ubiquitin ligase, E6AP (E6-associated 
protein), and the cellular ubiquitin protea-
some pathway (Scheffner et al., 1993). More 
than a dozen cellular binding partners of the 
E6 protein have been described (Mantovani & 
Banks, 2001; Thomas et al., 2008). Because of the 
complex nature of the E6 structure, it has been 
extremely difficult to determine which partic-
ular binding partner is responsible for any given 
function (Nominé et al., 2006). Clearly, interac-
tion with the tumour-suppressor protein p53 is 
fundamental to the activity of the E6 protein of 
transforming mucosal HPV types. Indeed, E6 
proteins from multiple mucosal types (HPV 16, 
18, 33, 35, 39, 45, 51, 52, 53, 56, 58, 66, 70, and 
82) target p53 for degradation at the 26S protea-
some (Hiller et al. 2006; see also Scheffner et al., 
1990). Similarly, the ability to induce telomerase 
activity is a common theme in HPV-induced 
malignancy, although the precise mechanism 
by which this occurs is subject to considerable 
debate (James et al., 2006; Liu et al., 2008; Sekaric 
et al., 2008). An important feature of these E6 
proteins is the presence of a PDZ-binding motif 
at the C-terminal. At present, multiple binding 
partners have been described, all of which 
are degraded by proteasomes. It remains to be 
determined, however, which of these are func-
tionally important in vivo (Thomas et al., 2008).
The discussion above relates primarily to E6 
proteins of the mucosal HPV types. Much less 
is known about the biochemical activity of the 
beta HPV E6 proteins. They all lack the capacity 
to degrade p53 and none of them, whether they 
are associated with cancer or not, possesses 
PDZ-binding motifs. This suggests major differ-
ences in how the beta HPV types interact with p53, 
and in the pathways that involve PDZ-domain-
containing substrates. Intriguingly, in the case 
of HPV 38, p53-responsive pathways appear 
to be abrogated through the induction of the 
p53 repressor, ΔNp73, although it remains to 
be determined whether this is due to E6 or E7 
(Accardi et al., 2006). The E6 protein of HPV 20 
displays a unique characteristic in that it is actu-
ally targeted for degradation by p53 in a caspase-
dependent manner. However, this does not occur 
if p53 is mutated as is frequently the case in non-
melanoma skin cancer (Fei & de Villiers, 2008). A 
common feature of E6 proteins from cutaneous 
and mucosal HPV types is their ability to interact 
with and inhibit the activity of the pro-apoptotic 
protein Bak. This has now been reported for E6 
proteins of HPV 16, 18, 5, 8, 11, 20, 22, 38, 76, 92, 
and 96 (Thomas & Banks, 1998, 1999; Jackson 
et al., 2000; Dong et al., 2005; Underbrink et al., 
2008). This appears to be an important evolu-
tionarily conserved activity that may also play a 
role in the development of HPV-induced malig-
nancy. Likewise, telomerase activation has also 
been described for the oncoproteins E6 and E7 
of several beta HPV types, in particular HPV 38 
(Bedard et al., 2008; Gabet et al., 2008), with other 
types such as HPV 5, 8, 20 and 22 exhibiting only 
low-to-background levels of telomerase activa-
tion (Bedard et al., 2008).
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4 .2 .3 The E7 protein
The E7 protein is approximately 100 amino 
acids in length and, like E6, targets many of 
its cellular substrates for proteasome-mediated 
degradation. To achieve this, E7 makes use of a 
multiprotein cullin-2 ubiquitin-ligase complex 
(Huh et al., 2007). Again, numerous cellular 
targets have been described for E7 (Münger et al., 
2001). As for E6, a subset of these targets has been 
clearly shown to be important for the biological 
activity of E7. Perhaps the most prominent are 
pRb and the related pocket proteins, p107 and 
p130, all of which are degraded by E7, thereby 
allowing the induction of S-phase progression. 
Paradoxically, E7 can also cause an increase in 
p53 protein levels by a mechanism that is not 
yet understood (Blanton et al. 1992; Seavey et al. 
1999). E6 can overcome E7’s induction of p53, 
which can be at multiple levels, both by directly 
targeting p53 for degradation, and by inhib-
iting p53 acetylation (Thomas & Chiang, 2005; 
Shamanin et al., 2008). Other key regulators of 
the cell cycle that are known interacting partners 
of E7 include the p21/p27 cdk inhibitors, and a 
subset of cyclins (Münger et al., 2001).
E7 also has a profound impact on transcrip-
tional regulation, being found in association 
with AP1 transcription factors (Antinore et al., 
1996), histone deacetylases (Longworth et al., 
2005), and MPP2 (Lüscher-Firzlaff et al., 1999). 
Interestingly, one of the consequences of E7 
activity is the strong upregulation of p16INK4a in 
cervical cancers, a feature that can be used as 
a surrogate marker for the presence of cancer-
associated HPV types (Vinokurova et al., 2005).
As is the case with the E6 protein, the func-
tion of the beta HPV E7 protein is also poorly 
understood at the biochemical level. However, 
the ability to target pRb is a feature of the E7 
protein of some beta HPV types, as has been 
shown for HPV 38 (Caldeira et al., 2003).
Certain biomarkers that reflect the expres-
sion and function of E6 and E7, such as the 
overexpression of p16 induced by E7, and the lack 
of mutation in p53 due to its inactivation by E6, 
have been useful indicators of the involvement 
of HPV in cervical cancer. In several studies, 
the correlation between the presence of HPV, 
an increased level of p16, and the absence of p53 
mutation has been investigated in cancers other 
than cervical cancer. The results are summarized 
in Table 4.1.
4.3 Biological Properties of HPV
4 .3 .1 Immortalization
As discussed above, for many different HPV 
types, effective immortalization of keratinocytes 
requires the combined presence of the viral 
proteins E6 and E7, although there are reports 
of a weak immortalizing activity with E7 alone.
4 .3 .2 DNA-damage responses
HPVs have the capacity to abrogate normal 
DNA-damage responses, which is likely to 
contribute to the accumulation of genetic altera-
tions in HPV-positive cells, including those 
that contribute to HPV-associated cancers (see 
Section 4.3.3).
Because E6 can inactivate p53 by stimulating 
its proteasome-mediated degradation (Scheffner 
et al., 1990), it is not surprising that many studies 
have confirmed that E6 can abrogate cell-cycle 
arrest induced by a variety of DNA-damaging 
agents (Kessis et al., 1993; Foster et al., 1994). In 
vivo, this activity of E6 correlates at least in part 
with its ability to inactivate p53, as was shown in 
mice (Song et al., 1998).
Cell-cycle arrest induced by p53 may arise 
through the induction of p21, and the consequent 
inhibition of cdk-mediated phosphorylation 
of pRb and the related proteins p107 and p130 
(el-Deiry et al., 1993; Harper et al., 1993; Slebos 
et al., 1994). E7 is able to inhibit the activity of 
p21 (Funk et al., 1997; Jones et al., 1997) as well as 
that of the pRb family of proteins (Münger et al., 
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1989; Slebos et al., 1994). The inactivation of pRb 
and p107 by E7 is mediated in part by its ability 
to induce their proteasome-mediated degrada-
tion (Münger et al., 2001). Given the properties 
of E7, and the role of these targets in mediating 
the cellular response to DNA damage, it is not 
surprising that E7 was found to abrogate these 
responses both in tissue culture (Slebos et al., 
1994), and in vivo (Song et al., 1998).
4 .3 .3 Genomic instability
As noted above, HPV E6 and E7 proteins can 
abrogate the cellular response to DNA damage, 
which under normal conditions would help 
prevent the accumulation of genetic changes in 
host chromosomes. It is, therefore, not unex-
pected that a hallmark of E6- and E7-expressing 
keratinocytes is genomic instability (Smith 
et al., 1989; Popescu & DiPaolo, 1990; Hashida 
& Yasumoto, 1991; Steenbergen et al., 1998). 
Abnormalities observed include monosomies 
and trisomies, chromatid gaps and breaks, double 
minutes, and aberrant chromosomes. Structural 
changes are most commonly detected in chro-
mosomes 1, 3 and 5, and less frequently in chro-
mosomes 6, 7, 8, 10, 12, 13, 16 and 22. Some of the 
allelic losses have been associated with particular 
genes that could be involved in malignant conver-
sion and/or progression. Allelic imbalance on 6q 
has been associated with telomerase activation 
(van Duin et al., 2003), which is a crucial step 
for cell immortalization mediated by high-risk 
HPVs (Klingelhutz et al., 1996; Anderson et al., 
1997). Mitotic abnormalities can also be induced 
by E6 and E7 through direct subversion of the 
mitotic spindle checkpoint (Thomas & Laimins 
1998; Duensing et al., 2000).
The ability of E6 to induce genomic insta-
bility most likely reflects its capacity to inhibit 
the function of p53 (see above), leading to the 
disruption of normal DNA-repair processes and 
the consequent accumulation of genetic damage. 
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Table 4 .1 Assessment of the correlations between p16 positivity and HPV status
Site Reference p16/p53 status HPV status p16+:HPV+ correlation
Lung Carlson et al. (2007) All p16+ All negative None
Aguayo et al. (2007) Most p16+ Some positive None
Colorectum Kong et al. (2007) All p16+ All positive Yes but no HPV- samples
Lu et al. (2003) All p16+ All positive Yes but no HPV
Sinus El-Mofty & Lu (2005) 9/39 p16+ 9/39 positive, all 9 were 
p16+ and p53-
Yes
Oesophagus Castillo et al. (2006) Some p16+ Some positive Incomplete: 
some p16- were HPV+, 
some p16+ were HPV-
Tonsil Klussmann et al. (2003) 16/34 p16+ 18/34 HPV+ Near complete (one 
HPV- cancer was p16+)
Larynx Laco et al. (2008) 14/24 p16+ 14/24 HPV16+ 
same 14 that were p16+
Yesa
Oropharynx O’Regan et al. (2008) Some p16+ Some positive (10/24) Incomplete 
Some p16- were HPV+, 
some p16+ were HPV-
Shuyama et al. (2007) Some positive Some positive (19/59) None
Reimers et al. (2007) 25/29 p16+ and 
HPV+
27/96 HPV+ in total Highb: 4 HPV- p16+; 
2 p16- HPV+
a Data for laryngeal carcinoma
b Data for tonsil/base of tongue
Compiled by the Working Group
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In the case of E7, genomic instability may also 
reflect its effect on centrosome biogenesis, and 
the consequent defects in segregation of daughter 
chromosomes during cell division (Duensing & 
Münger, 2002). How E7 induces genomic insta-
bility remains unclear. Although studies in mice 
suggest that the inactivation of pRb in tissues 
that express E7 is sufficient to induce centrosome 
abnormalities (Balsitis et al., 2003), another study 
demonstrates that E7 can induce such abnor-
malities through a pRb-independent mechanism 
(Duensing & Münger, 2003). Furthermore, this 
may occur through cell-cycle perturbations that 
involve cyclin/CDK2 activity (Duensing et al., 
2004).
Chromosomal instability has been associ-
ated with the integration of the viral genome 
upon prolonged culture of the keratinocyte 
cell line W12 harbouring episomal HPV, when 
grown as monolayers (Pett et al., 2004). However, 
the contrary has been shown in raft cultures of 
keratinocytes, in which genomic instability was 
observed in the absence of viral DNA integra-
tion (Duensing et al., 2001). Clearly more work 
is required in this area to fully understand the 
possible effects of viral integration upon genomic 
integrity of the host cell.
4 .3 .4 Cell proliferation and differentiation
The most pronounced effects on cell prolif-
eration and differentiation are exerted by the 
E7 oncoprotein. When expressed in immor-
talized rodent cells, HPV 16 E7 can stimulate 
DNA-synthesis and cell proliferation (Sato et al., 
1989). As E7 enhances proliferation of keratino-
cytes, it reactivates the host DNA-replication 
machinery in suprabasal differentiated, non-
cycling cells (Blanton et al., 1992; Cheng et al., 
1995). Thus, while differentiation still takes place, 
E7 also induces cell proliferation in cells that 
have already migrated away from the basal cell 
layer, suggesting that differentiation occurs, but 
in a modified state (Blanton et al., 1992; Cheng 
et al., 1995; Jones et al., 1997).
4 .3 .5 Inhibition of apoptosis
E6 has long been known to be a potent inhib-
itor of the apoptotic response. This has a major 
impact on the survival of cells that are being 
driven to proliferation by E7. This activity of E6 
can occur in both a p53-dependent and -inde-
pendent manner (Pan & Griep, 1994, 1995), the 
latter probably being related to the ability of E6 
to induce the degradation of the pro-apoptotic 
factor Bak (Thomas & Banks, 1998), which is a 
common feature of both cutaneous and mucosal 
HPV E6 proteins. Recent studies also suggest the 
ability of HPV 16 E6 to inhibit receptor-medi-
ated pathways of apoptosis, such as the TNF- and 
Fas-induced pathways (Filippova et al., 2002, 
2004).
4.4 Role of HPVs in malignant 
conversion
4 .4 .1 Requirement of HPV genome expression 
for cell growth
As previously described for HPV 16 and HPV 
18, E6 and E7 need to be continually expressed 
in cervical-cancer-derived cell lines to maintain 
cell proliferation (von Knebel Doeberitz et al., 
1988, 1992; Butz et al., 2003; Yoshinouchi et al., 
2003). Without either protein, the cells cease to 
proliferate and, depending on the experimental 
conditions, will either enter apoptosis or senesce.
4 .4 .2 Integration of the HPV genome
The integration of the viral genome into the 
genome of the host cell is not a pre-requisite for 
the development of malignancy. Although inte-
grated HPV genomes are still the most prevalent 
form of the viral DNA in tumours, it is apparent 
that cancers can arise, in a significant number 
of cases, before genome integration. It is worth 
noting that there are differences depending upon 
the genotype involved, with HPV 16, 18 and 45 
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being more frequently found in an integrated 
state than HPV 31 and 33 (Vinokurova et al., 
2008). Integration has not been found to be a 
common characteristic of beta HPV types.
4 .4 .3 Alteration of specific cellular proto-
oncogenes
The etiological association of high-risk HPVs 
with anogenital cancers and a subset of head and 
neck cancers is well established. It is also clear, 
however, that other genetic or epigenetic changes 
are required for these HPV-associated cancers to 
develop. This conclusion is based upon the long 
latency period between infection and the onset of 
cancer, and the fact that only a small percentage 
of infected individuals will develop cancer. 
Several studies have looked for alterations in 
cellular proto-oncogenes, particularly the MYC 
and RAS gene families, as possible cofactors 
for the development of cervical cancer, but the 
results are inconsistent. Some investigators have 
reported that MYC is amplified at the gene level 
or increased in its expression in cervical cancers 
and sometimes in CIN lesions, but others have 
not observed this. Likewise, some studies have 
reported upregulation of, and mutation in, genes 
of the RAS family, while others have not. At this 
stage, the overall conclusion is that the activation 
of proto-oncogenes can occur in cervical cancers 
and precursor lesions, but none of those reported 
so far is an absolute pre-requisite for the devel-
opment of the cancer, nor is there evidence that 
any of these alterations have prognostic value 
(for reviews, see Whang & Lee, 1997; Spandidos 
et al., 2000).
4 .4 .4 Effect on the host immune response
Evasion of the host immune system by the 
virus is a likely key event in HPV-mediated 
carcinogenesis. Persistence of the viral infection 
is a necessary condition for the development of 
cancer. Innate immunity is considered as a first 
line of cellular defence against pathogens. HPVs 
activate Toll-Like Receptors (TLRs) in antigen-
presenting cells (Fausch et al., 2003; Yang et al., 
2004; Yan et al., 2005). The high-risk HPV onco-
genes interfere with the innate immune responses 
at multiple levels. Both high-risk HPV E6 and 
E7 can interfere with factors induced by innate 
immune responses including those mediated by 
interferon (Ronco et al., 1998; Li et al., 1999; Park 
et al., 2000; Perea et al., 2000; Nees et al., 2001). 
HPV 16 E6 and E7 together can cause a reduction 
in the expression of TLR9 (Hasan et al., 2007).
Effects of HPV genes on acquired immune 
responses have also been noted. The E6 and E7 
proteins of high-risk HPV can inactivate compo-
nents of the biosynthetic pathway of the major 
histocompatibility class I (MHC I) complex 
such as class I heavy chain, transporter associ-
ated with antigen processing subunit 1 (TAP1), 
and low molecular weight protein 2 (LMP2) 
(Georgopoulos et al., 2000). HPV 16 E5 down-
regulates surface MHC class I (Ashrafi et al., 
2005, 2006) as well as class II (Zhang et al., 2003) 
expression. There is also evidence that beta HPV 
types, specifically HPV 38, can inhibit innate 
immune responses (Cordano et al., 2008). These 
findings may have important implications in 
predicting the overall efficacy of immunothera-
peutic strategies for treating HPV infections.
4.5 Transgenic models for HPV-
associated cancers
The advent of the technology to generate 
germline-transgenic mice has provided investi-
gators with the ability to assess the in vivo prop-
erties of HPV oncogenes implicated in human 
cancers. This section summarizes advances made 
in the assessment of the role of HPV oncogenes in 
anogenital and head and neck cancers in the case 
of high-risk anogenital HPVs, and skin cancers in 
the case of beta HPVs (i.e. EV-associated HPVs).
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4 .5 .1 Cancer of the cervix
Studies on the role of HPV oncogenes in 
anogenital cancers were greatly facilitated by 
the use of the human keratin 14 (K14) transcrip-
tional promoter, which directs the expression 
of HPV genes to the stratified epithelium of the 
lower female reproductive tract and of the oral 
cavity. The first germline-transgenic mouse 
model for HPV-associated cervical cancer was 
developed by the use of a K14HPV 16 transgenic 
mouse line in which the early genes of HPV 
16 were placed under the control of the K14 
promoter (Arbeit et al., 1994). Although these 
mice did not develop cervical cancers spontane-
ously, treatment with exogenous estrogen, suffi-
cient to induce continuous estrus, led to a highly 
penetrant cervical cancer phenotype (Arbeit 
et al., 1996). The cervical cancers occurred in the 
context of a progressive disease much like that 
seen in women, being preceded by the onset of 
CIN grades 1–3. As in women, the cancers prefer-
entially arose in the transformation zone (Arbeit 
et al., 1996). The individual contributions of the 
two HPV 16 oncogenes E6 and E7 have been 
assessed (Riley et al., 2003). From these studies, it 
has become clear that HPV 16 E7 is the dominant 
oncogene in the context of cervical carcinogen-
esis in the mouse. Whereas 100% of K14E7 mice 
treated with exogenous estrogen for 6  months 
developed high-grade dysplasia and/or cervical 
cancers, K14E6 mice only developed cervical 
cancer when estrogen treatment was extended to 
9 months (Shai et al., 2007). Synergy between E6 
and E7 was also observed (Riley et al., 2003; Shai 
et al., 2007, 2008).
The mechanism of action of E6 and E7 in 
cervical cancer has also been studied in the 
context of transgenic mouse models. Although it 
has long been thought that the capacity of E7 to 
inactivate the tumour-suppressor pRB is critical 
in the context of HPV-associated cancers, studies 
in mice indicate that this inactivation is not 
sufficient to account for the oncogenic properties 
of the E7 protein (Balsitis et al., 2003).
Similarly to HPV 16 E7, HPV 16 E6 appears 
to contribute to cervical carcinogenesis through 
multiple activities. A mouse strain expressing a 
mutant form of HPV 16 E6 that is unable to inacti-
vate p53, displayed a reduced tumorigenic pheno-
type in the cervix when treated with estrogen, 
compared with mice expressing the wild-type 
HPV 16 E6; however, this mutant E6-expressing 
strain also displayed an enhanced suscepti-
bility to cervical carcinogenesis compared with 
estrogen-treated non-transgenic mice (Shai 
et al., 2007). These results are consistent with the 
hypothesis that the inactivation of p53 partially 
contributes to the oncogenic potential of the E6 
protein. Consistent with this observation, mice 
conditionally null for p53 displayed an increased 
susceptibility to cervical cancers when treated 
with estrogen compared with treated p53-profi-
cient mice (Shai et al., 2008).
E6 is also known to bind to several cellular 
proteins that contain PDZ domains (see above). 
Transgenic mice expressing a mutant form of 
HPV 16 E6 unable to bind to PDZ-domain 
proteins (Nguyen et al., 2003) had a reduced 
susceptibility to cervical cancers compared 
with mice expressing the wild-type E6 protein 
(Shai et al., 2007). It remains unclear which of 
the interactions with PDZ-domain proteins 
contribute to E6-mediated carcinogenesis in 
vivo, and how E7 contributes to this carcinogenic 
process (Simonson et al., 2005; Shai et al., 2007).
The mechanism by which E5 may contribute 
to cervical carcinogenesis in vivo has yet to be 
determined. In mouse skin, E5 can induce epithe-
lial hyperplasia, and this is dependent upon the 
presence of a functional epidermal growth-
factor receptor (EGFR) (Genther Williams et al., 
2005). E5 has been implicated in two steps in 
skin carcinogenesis, promotion and progres-
sion (Maufort et al., 2007). It remains to be seen 
whether the activation of EGFR contributes to 
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the oncogenic potential of E5 in vivo, in the skin 
or the cervix.
The importance of the continued expression 
of E6 and E7 for maintenance of the tumour 
phenotype in vitro is well documented (see above). 
This has now been evaluated in HPV-transgenic 
mice through the use of a tet-regulated HPV 
16 E7 transgene. In these mice, the continued 
expression of E7 was found to be critical for the 
maintenance not only of cervical cancers but 
also the dysplastic neoplasia that is recognized 
as the precursor lesion to cervical cancer (Jabbar 
et al., 2009). These data support the development 
of therapies aimed at inhibiting the expression 
or function of HPV oncogenes implicated in 
cervical cancers.
Estrogen is an important cofactor in the devel-
opment of cervical cancers in HPV-transgenic 
mouse models (Arbeit et al., 1996). Estrogen was 
found to be necessary not only for the develop-
ment of cervical cancers in HPV-transgenic 
mice, but also for their persistence (Brake & 
Lambert, 2005). Estrogen receptor α (ERα) was 
found to be necessary for cervical carcinogenesis 
in K14E7-transgenic mice (Chung et al., 2008). 
Indirect evidence potentially supporting a role 
of estrogen in human cervical cancers has come 
from studies demonstrating that women who 
have used oral contraceptives for at least 5 years 
or have had multiple pregnancies are at increased 
risk for cervical cancer, although there are also 
conflicting reports (Beral et al., 1999; Hannaford 
et al., 2007; IARC, 2011). Furthermore, a subset 
of human cervical cancers has been found to 
overexpress aromatase, a key enzyme in estrogen 
biosynthesis, suggesting a role of estrogen in 
these cancers (Nair et al., 2005). However, women 
on estrogen replacement therapy have not been 
found to be at increased risk for cervical cancer 
(Archer, 2004). [The Working Group noted that 
this study did not control for HPV status.] The fact 
that tamoxifen treatment did not reduce cervical 
disease in women (Bigler et al. 2004) could be 
explained by the fact that tamoxifen acts as an 
ER-agonist, not antagonist, in the human cervix 
(Senkus-Konefka et al., 2004). It remains to be 
determined whether anti-estrogens (specifically, 
drugs that act as ER-antagonists in the human 
cervix, e.g., fulvestrant) and/or aromatase inhib-
itors will be effective in treating women with 
HPV-associated cervical disease.
4 .5 .2 High-risk HPVs and cancers of the head 
and neck
There is a growing appreciation that the same 
high-risk HPV types etiologically associated 
with anogenital cancers, particularly HPV 16, 
are also associated with a subset of human head 
and neck squamous cell carcinomas (HNSCC), 
most notably of the oropharynx (e.g., tonsils) and 
the base of the tongue. The role of HPV 16 E6 
and E7 oncogenes in HNSCC has been evaluated 
in HPV-transgenic mice that express these viral 
oncogenes in the relevant tissues. These mice do 
not spontaneously develop HNSCC, but when 
treated with the synthetic carcinogen 4-nitro-
quinoline-N-oxide (4-NQO), they become more 
susceptible to head and neck cancers (Strati 
et al., 2006). The progressive disease observed 
in the 4-NQO-treated HPV-transgenic mice was 
similar to that seen in humans. Also, the cancers 
that occurred were primarily high-grade HNSCC 
as observed in HPV-positive HNSCC in humans. 
As in cervical cancer, E7 proved to be the more 
potent oncogene and the inactivation of pRb 
could not fully account for the role of the E7 
protein in HNSCC (Strati & Lambert, 2007).
4 .5 .3 Carcinogenic potential of EV-associated 
beta HPVs in the skin
HPVs of the genus beta are associated with a 
rare, familial benign disease termed epidermod-
ysplasia verruciformis (EV). EV patients are at an 
increased risk for squamous cell carcinomas of 
their skin at sites exposed to the sun. Transgenic 
mouse models have been developed to investigate 
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the role of EV-associated HPVs (specifically HPV 
8 and HPV 38) in skin carcinogenesis. K14HPV-
8-transgenic mice expressing the early genes of 
HPV 8 in the epidermis were found to be suscep-
tible to the spontaneous development of both 
benign and malignant skin cancers (Schaper 
et al., 2005). Likewise, K10-HPV38 E6/E7 trans-
genic mice were highly susceptible to multistage 
skin carcinogenesis, specifically when treated 
with ultraviolet light (UVB) or chemical carcino-
gens (Dong et al., 2005). Interestingly, these mice 
express high levels of ΔNp73, which appears to 
be a primary mechanism for these mice to over-
come the growth-suppressive activities of p53 
(Accardi et al., 2006; Dong et al., 2008).
The synergy between cutaneous HPVs and 
UV in the development of squamous cell carci-
nomas in the skin has also been studied in trans-
genic mice expressing in their epidermis the E6 
and E7 genes of HPV 20, which is commonly 
associated with squamous cell carcinoma 
arising in renal transplant patients, or HPV 
27, which is only associated with benign papil-
lomas. Upon UV irradiation, both HPV-20- and 
HPV-27-transgenic mice are more susceptible to 
tumours than non-transgenic mice, however, the 
HPV-20-transgenic mice displayed an increased 
incidence of malignant tumours. Alterations in 
the expression of both p53 and p63 were noted in 
the UV-exposed transgenic mice (Michel et al., 
2006).
4.6 Synthesis
The characterization of the mechanisms of 
action of the HPV oncoproteins in assays both 
in vitro and in vivo provides compelling evidence 
for a direct role of high-risk mucosotropic HPVs 
in the development of cervical cancer. The 
mechanisms involve immortalization, trans-
formation, inhibition of apoptosis, induction 
of genomic instability, and deregulation of the 
immune response. The mechanistic evidence for 
individual mucosotropic HPV types found in 
cancers is as follows:
• A common feature of mucosotropic HPV-
associated cancers is the expression of the 
viral genes E6 and E7.
• The E6 and E7 genes of HPV 16 and HPV 
18 have been the most extensively studied 
and were found to confer a similar set 
of biological phenotypes (e.g., immor-
talization, inhibition of DNA-damage 
response, genomic instability, inhibition 
of differentiation) on epithelial cells from 
multiple human tissues in which HPV-
associated cancers are found, including 
the cervix, penis, and tonsil.
• The E6 and E7 proteins of the same HPVs 
(16 and 18) share similar sets of biochemi-
cal properties (e.g., for E6: inactivation of 
p53, induction of hTERT, binding to PDZ; 
for E7: inactivation of pRb and related 
pocket proteins, activation of E2Fs) 
that correlate with their transforming, 
immortalizing and tumorigenic proper-
ties both in vitro and in vivo.
• Suppression of HPV 16/18 E6 and E7 
gene expression in cell lines derived from 
human cervical cancers leads to senes-
cence or apoptosis.
Given these observations, there is strong 
mechanistic evidence that HPV 16 and HPV 18 
act directly to cause cancers in those tissues in 
which they are found.
For other mucosotropic HPVs (31, 33) that 
are found in human cancers, there is moderate 
mechanistic evidence from available experi-
mental data (biochemical and/or biological) that 
they are directly acting in causing cancers in 
those tissues in which they are found.
For a third set of mucosotropic HPVs (35, 39, 
45, 51, 52, 53, 56, 58, 66, 68, 82) found in human 
cancers, there is positive mechanistic evidence 
from one or a few studies (biochemical and/or 
biological) that they directly act to cause cancers 
in those tissues in which they are found.
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For HPV 6 and 11, there is little to no 
mechanistic evidence that they can contribute 
to carcinogenesis (weak inactivation of p53, no 
activation of hTERT, no binding to PDZ, weak 
inactivation of pRB, no immortalization, no 
transformation).
With respect to most of the cutaneous HPV 
types of the genus beta, there is a general paucity 
of experimental studies assessing their role in 
cancer development. For a subset, HPV 8, and 
38, which have been analysed in both in vitro and 
in vivo models, there is strong evidence of their 
potential capacity to cause cancer. However, 
unlike what has been found for mucosotropic 
HPVs associated with human cancers, the 
limited data available indicate that the majority 
of, if not all, cells within skin cancers potentially 
associated with beta HPV types do not contain 
the viral genome. Thus, novel mechanisms for 
HPV-induced carcinogenesis would need to 
be invoked, for which there is currently little 
evidence.
5. Evaluation
There is sufficient evidence in humans for the 
carcinogenicity of HPV 16. HPV 16 causes cancer 
of the cervix, vulva, vagina, penis, anus, oral 
cavity, oropharynx, and tonsil. Also, a positive 
association has been observed between infection 
with HPV 16 and cancer of the larynx.
There is sufficient evidence in humans for 
the carcinogenicity of HPV 18. HPV 18 causes 
cancer of the cervix. Also, a positive associa-
tion has been observed between infection with 
HPV 18 and cancer of the vulva, penis, anus, oral 
cavity, and larynx.
There is sufficient evidence in humans for the 
carcinogenicity of HPV types 31, 33, 35, 39, 45, 
51, 52, 56, 58 and 59. HPV types 31, 33, 35, 39, 45, 
51, 52, 56, 58 and 59 cause cancer of the cervix. 
Also, a positive association has been observed 
between infection with HPV 33 and cancer of 
the vulva and of the anus.
There is limited evidence in humans for the 
carcinogenicity of HPV types 26, 53, 66, 67, 68, 
70, 73, and 82. A positive association has been 
observed between infection with HPV types 26, 
53, 66, 67, 68, 70, 73, and 82 and cancer of the 
cervix.
There is inadequate evidence in humans for 
the carcinogenicity of HPV types 30, 34, 69, 85 
and 97. Nonetheless, their phylogenetic analogy 
to HPV types with sufficient or limited evidence 
in humans suggests that these types may be 
potentially carcinogenic.
There is inadequate evidence in humans for 
the carcinogenicity of HPV 6 and HPV 11 in the 
larynx.
There is inadequate evidence in humans for 
the carcinogenicity of HPV genera beta and 
gamma types in the skin. In the rare case of 
patients with epidermodysplasia verruciformis, 
there is limited evidence for the carcinogenicity 
of HPV genus-beta types 5 and 8 in the skin.
HPV types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 
58 and 59 are carcinogenic to humans (Group 1).
HPV 68 is probably carcinogenic to humans 
(Group 2A).
HPV types 26, 53, 66, 67, 70, 73, 82 are possibly 
carcinogenic to humans (Group 2B). 
HPV types 30, 34, 69, 85 and 97 are possibly 
carcinogenic to humans (Group 2B) based on their 
phylogenic analogy to HPV types with sufficient 
or limited evidence in humans.
HPV types 6 and 11 are not classifiable as to 
their carcinogenicity to humans (Group 3).
Some types of HPV genera beta and gamma 
are not classifiable as to their carcinogenicity to 
humans (Group 3), with the notable exception 
that HPV 5 and HPV 8 are possibly carcinogenic 
to patients with epidermodysplasia verruciformis 
(Group 2B).
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HUMAN T-CELL LYMPHOTROPIC 
VIRUS TYPE 1
Human T-cell lymphotropic virus Type 1 was considered by a previous IARC Working Group 
in 1996 (IARC, 1996). Since that time, new data have become available, these have been 
incorporated in the Monograph, and taken into consideration in the present evaluation.
1. Exposure Data
1.1 Taxonomy, structure, and biology
1 .1 .1 Taxonomy
Retroviruses can be classified according to 
the morphology of their virion core or according 
to sequence homologies that become evident after 
phylogenetic analyses. Human T-lymphotropic 
virus type 1 (HTLV-1) is a member of the delta-
type retrovirus group, other members of which 
include HTLV types 2, 3 and 4, bovine leukaemia 
virus (BLV), and simian T-cell leukaemia virus 
(STLV) types 1, 2 and 3 (Matsuoka & Jeang, 2007). 
STLV-1 is found in Old World monkeys and great 
apes. HTLV-1 and STLV-1 are thought to origi-
nate from common ancestors (Vandamme et al., 
1998). Together with the STLVs, HTLVs form 
the primate T–cell lymphotropic viruses (PTLV) 
group. The PTLVs belong to the complex retro-
virus family since, in addition to the structural 
gag, pol and env genes, their genome also contains 
regulatory and accessory genes. Among these 
retroviruses, HTLV-1 and STLV-1 induce T-cell 
neoplasms (Tsujimoto et al., 1987; Gallo, 2002), 
BLV causes a B-cell neoplastic disease in cattle 
and in sheep, and HTLV-3 and HTLV-4 have not 
been clearly associated with any haematological 
disease (Mahieux & Gessain, 2009). A recent 
report demonstrated that HTLV-2 infection 
is linked with higher lymphocyte and platelet 
counts, although it has not been yet associated 
with oncogenesis (Bartman et al., 2008).
1 .1 .2 Structure of the virion
The structure of retroviruses is reviewed in 
the Monograph on HIV-1 in this volume. HTLVs 
are enveloped viruses with a diameter of approx-
imately 80–100 nm. The HTLV virions contain 
two covalently bound genomic RNA strands, 
which are complexed with the viral enzymes 
reverse transcriptase (RT; with associated RNAse 
H activity), integrase and protease, and the capsid 
proteins. The outer part of the virions consists 
of a membrane-associated matrix protein and a 
lipid layer intersected by the envelope proteins 
(IARC, 1996).
1 .1 .3 Structure of the viral genome
As stated above, HTLV-1 is a complex retro-
virus that contains regulatory genes (tax and rex) 
and accessory genes (p12, p13, p30 and HBZ), in 
315
IARC MONOGRAPHS – 100B
addition to structural genes (gag, pol and env) 
(see Fig. 1.1). The Gag precursor protein (53 kD) 
is translated from unspliced genomic RNA. This 
protein is cleaved into p19 (matrix), p24 (capsid), 
and p15 (nucleocapsid) by the viral protease. The 
protease–polymerase products are generated by 
two frameshifts, which produce protease, reverse 
transcriptase, and integrase. The Env precursor 
protein is translated from a single-spliced mRNA, 
and is cleaved by a cellular protease into the 
extracellular protein, gp46, and the transmem-
brane protein, gp21 (Seiki et al., 1983; Sakalian & 
Hunter, 1998; Matsuoka & Jeang, 2007; Verdonck 
et al., 2007).
1 .1 .4 Host range
HTLV-1 naturally infects humans. However, 
several publications have clearly demonstrated 
that HTLV-1 can experimentally be inoculated to 
different animals, including rabbits, rats, mice, 
and New World monkeys (Lairmore et al., 2005).
1 .1 .5 Target cells
HTLV-1 can infect different cell types (T 
cells, B cells, dendritic cells, fibroblasts, etc.) in 
tissue culture. However, it can transform only T 
cells both in vitro and in vivo. HTLV-1 induces 
the clonal proliferation of T lymphocytes, mainly 
CD4-positive T cells, and to a lesser extent, 
CD8-positive T cells (Etoh et al., 1997; Cavrois 
et al., 1998; Yasunaga et al., 2001). Proliferation 
is thought to be mediated by one or several viral 
genes, such as tax, rex, p12, p13, p30, or HBZ.
HTLV-1 infection of dendritic cells has been 
recently shown to play a major role in HTLV-1 
cell-to-cell transmission (Jones et al., 2008). In 
experimentally infected squirrel monkeys (S. 
Sciureus), HTLV-1 was mainly detected in the 
lymphoid organs, which were therefore suggested 
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Fig. 1.1 Scheme of the HTLV-1 genome: alternatively spliced mRNAs and putative proteins encoded 
by each mRNA are shown
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to be a major reservoir of the virus (Kazanji et al., 
2000).
1 .1 .6 Life cycle, replication, and regulation of 
gene expression
The glucose transporter 1 (GLUT1), neuro-
pilin 1, and heparan sulfate proteoglycan form 
the HTLV-1 receptor complex (Manel et al., 2003; 
Ghez et al., 2006). These proteins are ubiquitously 
expressed in cultured cells, therefore allowing 
HTLV-1 to infect a variety of cell types in vitro.
The life cycle of HTLV-1 is similar to that of 
other retroviruses. A characteristic of HTLV-1 
is that it is mainly spread through cell-to-cell 
contact, although the exact mechanism is still 
a matter of debate (Igakura et al., 2003). After 
reverse transcription and integration into the 
genome, HTLV-1 propagates through clonal 
expansion of infected cells (Etoh et al., 1997; 
Cavrois et al., 1998). The limited use of the viral 
reverse transcriptase explains the remarkable 
genetic stability of HTLV-1. This is why the 
administration of reverse transcriptase inhibitors 
in vivo does not influence provirus load (Miyazato 
et al., 2006; Taylor et al., 2006). Consequently, 
the HTLV-1 provirus sequence variability is 
very low (Gessain et al., 1992; Van Dooren et al., 
2004). This striking genetic stability is used as 
a molecular tool to follow the migration of 
infected populations in the recent or distant past 
to gain new insights into the origin, evolution, 
and modes of transmission of such retroviruses 
and their hosts. The few nucleotide substitutions 
observed among virus strains are indeed specific 
to the geographic origin of the patients rather 
than being linked to the pathology.
Three modes of transmission are known for 
HTLV-1, and for each of these routes, cell-to-cell 
contact is required. The transmission is discussed 
in Section 1.2.
(a) Regulation of gene expression
Viral gene expression initiates from the 
5′Long Terminal Repeat (LTR), and is highly 
dependent on the Tax protein. The details on 
the regulation of the viral LTR are described 
in Section 4. However, Tax is a major target of 
cytotoxic T cells in vivo (Koenig et al., 1993), 
and Tax-expressing cells are, therefore, rapidly 
eliminated by cytotoxic T cells (Hanon et al., 
2000; Asquith et al., 2007; Asquith & Bangham, 
2008). Despite a strong cytotoxic T-cell response, 
proliferation of HTLV-1-infected cells in vivo 
is likely to depend on viral gene expression 
(Asquith et al., 2007). Epigenetic changes to the 
5′LTR may control viral gene expression in vivo, 
enabling escape from cytotoxic T cells. A recent 
report demonstrated that the administration 
of valproate, a histone deacetylase inhibitor, to 
tropical spastic paraparesis/HTLV-1-associated 
myelopathy (TSP/HAM) patients decreased 
the provirus load in vivo without, however, 
improving the clinical symptoms (Lezin et al., 
2007). The mechanism by which the infected 
cells are eliminated is unknown, but these results 
indicate that increasing viral expression may 
represent a potential approach to decreasing the 
proviral load.
1.2 Epidemiology of infection
In 1977, Takatsuki et al. described regions in 
Japan with high frequencies of T-cell-associated 
lymphoproliferative disorders and proposed that 
these diseases shared a viral etiology (Takatsuki 
et al., 1977). This led to the discovery of HTLV-1 
just a few years later, and it became the first 
human retrovirus to be implicated as a causative 
agent for human malignancy (Poiesz et al., 1980; 
Hinuma et al., 1981). Its discovery paved the 
way to a greater understanding of retroviruses, 
notably HIV, and their effects on humans. It is 
now apparent that HTLVs have been infecting 
humans for thousands of years. An estimated 
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15–20 million persons worldwide are infected 
with HTLV-1 (Gessain & de Thé, 1996) [The 
Working Group noted that the accuracy of this 
estimate is unknown], and a vaccine is not yet 
available.
All HTLV types have simian counterparts, 
and the viral strains found are predominantly 
related to geography rather than pathology 
(Slattery et al., 1999). These are all believed to 
have originated from Africa, the only continent 
where all PTLVs have been found. From there, 
PTLV migrated to Asia, where it evolved into 
STLV-1. This Asian STLV-1 virus type diffused 
through India, Japan, and Indonesia before 
returning to Africa, where phylogenetic analyses 
and anthropological studies place PTLV-1 spread 
among non-human primates at approximately 
27300 years ago (95% confidence interval [CI]: 
19100–35500) (Van Dooren et al., 2001). 
Interspersed patterns of STLV-1 and HTLV-1 
strains suggest frequent interspecies transmis-
sions between humans and primates in Africa. 
Evidence of these frequent crossings are distin-
guished by the four major geographic subtypes: 
cosmopolitan HTLV-1 subtype A, Central 
African subtype B, Melanesian subtype C, and 
subtype D, also found in Central Africa (Cassar 
et al., 2007). The slave trade and an increase in 
human immigration and mobility facilitated the 
expansion of HTLV-1 into the New World, Japan, 
the Middle East, and North Africa (Verdonck 
et al., 2007). The majority of infected individuals 
from these regions are infected with cosmopol-
itan subtype A (HTLV-1A) (Proietti et al., 2005).
1 .2 .1 Prevalence, geographic distribution
Even though the global geographic distri-
bution of HTLV-1 has been well defined in the 
literature, fine-scale variations in HTLV-1 preva-
lence are less well understood. HTLV-1 is often 
found in micro-epidemic regions surrounded 
by regions with low prevalence (Fig. 1.2). For 
example, regions of Kyushu and Okinawa, Japan, 
have rates as high as 20%; whereas, neighbouring 
the People’s Republic of China and the Republic 
of Korea have rates of less than 0.1% (Proietti 
et al., 2005). In general, regions of high ende-
micity include south-western Japan, parts of 
subSaharan Africa, the Caribbean Islands, and 
South America (IARC, 1996). Infection has also 
been detected in Melanesia, the Solomon Islands, 
and among Australian Aborigines; there is only 
low prevalence in Europe and North America.
 There is a characteristic age- and gender-
dependence of HTLV-1 seroprevalence in many 
populations. HTLV-1 prevalence increases with 
age and is higher in women (Beilke & Murphy, 
2006). Published studies from several countries 
including Jamaica, Japan, Brazil, and the United 
States of America (Beilke & Murphy, 2006) have 
demonstrated similar trends, in addition to a 
significant increase of seropositivity in low soci-
oeconomic strata, and in those with a history of 
blood transfusions. HTLV-1 is most prevalent in 
populations that have a low geographic mobility, 
and correspondingly higher rates of vertical and 
sexual transmission.
1 .2 .2 Transmission, and risk factors for 
infection
There are three main modes of transmission in 
HTLV-1 infection: vertical transmission, sexual 
transmission, and parenteral transmission. 
Each has its respective risk factors: prolonged 
breastfeeding; unprotected sex with an infected 
partner, multiple lifetime sexual partners, infec-
tion with sexually transmitted diseases (STDs); 
blood transfusion before institution of HTLV-
antibody screening of donors, and injection drug 
use.
(a) Vertical transmission
The highest rates of HTLV-1 transmission 
are due to breastfeeding, and in southern Japan, 
the overall infection rate of breastfed children by 
HTLV-1-carrier mothers is estimated at 10–30% 
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(Tajima & Hinuma, 1992). There may be a 
higher rate of transmission of mother-to-female 
compared to mother-to-male infants for HTLV 
in French Guyana (Ureta-Vidal et al., 1999). In 
Japan, there does not appear to be gender differ-
ences in HTLV-1 before the age of 20 years (Hino, 
1990). In a longitudinal study of Japanese chil-
dren born to carrier mothers, those who did 
not seroconvert by the age of 3 years remained 
seronegative until the age of 18 years (Kusuhara 
et al., 1987). In-utero infectivity is much lower, 
probably because of limited trafficking of HTLV-
1-infected lymphocytes across the placenta. The 
risk of infection in children has been shown to 
correspond to the proviral load in the mother’s 
breast milk, and to the duration of breastfeeding 
(Wiktor et al., 1997). In Japan, the avoidance of 
breastfeeding by an HTLV-1-infected mother 
reduced the transmission from 20% to 3%, and 
efforts to eliminate breastfeeding or to at least 
reduce its duration to less than 12 months by 
seropositive mothers, significantly reduced 
HTLV-1 transmission to children. In a subset of 
children with HTLV-1 positive cord blood, none 
had seroconverted (Hino et al., 1996).
(b) Sexual transmission
The second main type of transmission is 
sexual. One prospective study of heterosexual 
discordant couples (one partner seropositive, one 
partner seronegative) suggested higher male- to- 
female transmission (Stuver et al., 1993), but 
another did not (Roucoux et al., 2005). In Latin 
America, gender differences in sexual practices 
and the seroprevalence of STDs between popula-
tions might partially explain these discrepancies 
(Plancoulaine et al., 1998; Sanchez-Palacios et al., 
2003). HTLV-1 carriers infect their spouses at low 
rates (1–2 per 100 person–years); however, within 
long-term sexual relationships, HTLV-1 proviral 
load and lower rates of condom use were shown 
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Fig. 1.2 Global geographic distribution of HTLV-1 infection: It should be noted that HTLV-1 endemic 
areas do not correspond exactly to the country boundarie shown in the map, for example, Brazil, 
Japan and Iran, where HTLV-1 is limited to residents of certain areas of each country
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to increase transmission efficiency (Kaplan et al., 
1996; Iga et al., 2002; Roucoux et al., 2005).
(c) Parenteral transmission
HTLV-1 transmission is also known to occur 
by the transfusion of cellular blood components, 
requiring testing of blood products by blood 
banks in high prevalence regions. The “residual 
risk” of transfusion-transmitted HTLV-1 infec-
tion after serological testing has been estimated 
as 1 in 641000 blood units transfused in the 
USA (95%CI: 256000–2000000) (Schreiber et al., 
1996). Transmission through this route has been 
reduced by improvements in the sensitivity of 
serological assays for HTLV-1 and leukoreduc-
tion of blood products, so the current residual 
risk is probably less than 1 per million blood 
units transfused. Although nucleic-acid testing 
of blood products has been introduced for HIV, 
hepatitis C and hepatitis B viruses (HCV, HBV), 
it has not yet been developed for HTLV-1, because 
HTLV-1 would require a cell-based rather than 
a plasma-based assay (Murphy et al., 1999). 
HTLV-1 is also transmitted via needle-sharing 
associated with injection drug use. However, 
compared to HTLV-2, the prevalence of HTLV-1 
is relatively low among injection drug users and 
their sexual partners in the USA, Italy, Spain, 
Brazil, and Argentina (Gotuzzo, 2000), perhaps 
because injection drug use is less common among 
HTLV-1- as opposed to HTLV-2-risk groups 
(Roucoux & Murphy, 2004). However, increasing 
human mobility and cultural interaction create 
the opportunity for increased HTLV-1 transmis-
sion by this route.
1 .2 .3 Persistence, latency and natural history 
of infection
The lifetime risk of developing adult T-cell 
leukaemia/lymphoma (ATLL) has been esti-
mated at 2–4% among HTLV-1 carriers, and the 
latency period from primary infection until ATLL 
onset is about 60 years in Japan, and 40 years 
in Jamaica (Tajima, 1988; Murphy et al., 1989; 
Takatsuki et al., 1994; Hanchard, 1996; Yasunaga 
& Matsuoka, 2007). The incubation period for 
HTLV-associated myelopathy is thought to be 
shorter: 10–20 years after sexual transmission but 
as little as 6 months after transfusion-transmitted 
HTLV-1 infection (Gout et al., 1990). Several viral 
and immunological markers have been proposed 
as markers for predicting which infected subjects 
will progress from latency to disease (see Section 
2.1), but prospective validation of these markers 
is lacking. HTLV-1 may also be associated with 
increased overall mortality (Arisawa et al., 2003; 
Orland et al., 2004).
Compared to HIV, the HTLV-1’s genome is 
very stable, with proviral integration predomi-
nating over production of viral RNA particles 
(Mortreux et al., 2003). Occasionally, abnormal, 
multilobulated lymphocytes “flower cells” can be 
observed in the peripheral blood (Hisada et al., 
1998; Sacher et al., 1999). Aside from detection 
in the peripheral blood, infected cells have also 
been detected in the cerebrospinal fluid, an indi-
cation of HTLV-1 ability to cross the blood–brain 
barrier (Mortreux et al., 2003). In an assessment 
of the patterns of HTLV-1 proviral DNA and 
antibody titre levels among transfusion recipi-
ents, in early infection, proviral loads are initially 
elevated with corresponding low antibody titres, 
and as proviral load begins to decrease, antibody 
titres increase, and later remain stable within 
each of the cases (Manns et al., 1999). Proviral 
load may also be related to the route of infection, 
with transfusion-transmitted HTLV associated 
with a higher proviral load (Murphy et al., 2004). 
Platelet and lymphocyte counts may be 
chronically elevated in HTLV-1 (Glynn et al., 
2000). Both higher platelet counts and lower 
eosinophils counts were found to be significantly 
associated with HTLV-1 status among blood 
donors from the USA (Bartman et al., 2008). 
HTLV-1 participants also had a small increase 
in absolute lymphocyte count compared with 
controls, which was not statistically significant.
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HTLV-1 preferentially targets CD4-positive T 
cells, and infection is transmitted through direct 
cell-to-cell contact. Recent reports also support 
a role for dendritic cells in HTLV-1 transmis-
sion (Jones et al., 2008). Once inside the cell, 
the HTLV-1 provirus integrates itself into the 
host genome. A study. demonstrated a signifi-
cant rate of viral integration within genes (as 
opposed to non-coding regions of the genome), 
which suggests an HTLV-1 preference to insert 
in growth-related genes over random integration 
(Hanai et al., 2004). Because of clonal expansion, 
T cells with identical integration sites are consid-
ered to have originated from the same infected 
cell. More sensitive assays with the ability to 
amplify regions of the host genome adjacent to 
the integration site, such as inverse polymerase 
chain reaction (PCR), may be used to identify 
clones of infected T lymphocytes in asympto-
matic carriers (Okayama et al., 2004; Tanaka 
et al., 2005).
In contrast to HIV, which produces a large 
amount of cell-free virions in plasma, HTLV-1 
increases its copy number through the prolifera-
tion of infected cells, and infection is maintained 
through this expansion. Early expression of 
viral tax protein and HTLV-1 accessory proteins 
induce and maintain initial replication (Manns 
et al., 1999). An increased proviral load derives 
from this persistent clonal expansion of virus-
infected cells (Wattel et al., 1995). After initial 
infection, individuals are asymptomatic with 
proviral loads ranging from 102–105 per million 
peripheral blood mononuclear cells (Wattel 
et al., 1992; Etoh et al., 1999; Mortreux et al., 
2003). The proviral load remains relatively stable 
within a single infected individual over several 
years (Mortreux et al., 2003; Kwaan et al., 2006).
2. Cancer in Humans
2.1 T-cell malignancies
2 .1 .1 HTLV-1 infection and ATLL
As described in the previous IARC Monograph 
(IARC, 1996), ATLL occurs almost exclusively in 
areas where HTLV-1 infection is endemic, such as 
Japan, the Caribbean, and West Africa. In other 
areas, cases are usually found among immigrants 
from endemic populations. Evidence of HTLV-1 
infection was initially found in at least 90% of 
ATLL cases and subsequently, HTLV-1 infec-
tion became part of the diagnostic criteria for 
ATLL. In ATLL, the virus is monoclonally inte-
grated into the tumour cells. The previous IARC 
Working Group concluded that HTLV-1 infec-
tion was a necessary cause of ATLL (IARC, 1996). 
The current Monograph will focus primarily on 
recent evidence on predictors or risk of ATLL in 
HTLV-1 carriers. To date, no other malignancies 
have been convincingly liked to HTLV-1.
Since 1996, several case series have been 
published on ATLL occurring in diverse HTLV-
1-endemic and –non-endemic populations. 
These include reports from Japan (Tsukasaki 
et al., 1999); Brazil (Farias de Carvalho et al., 
1997; Barbosa et al., 1999; Pombo De Oliveira 
et al., 1999); Argentina (Marin et al., 2002); Chile 
(Cabrera et al., 2003); the Commonwealth of 
Dominica (Adedayo & Shehu, 2004); and Hong 
Kong Special Administrative Region (Chan & 
Liang, 1996; Au & Lo, 2005; see Table 2.1 available 
at http://monographs.iarc.fr/ENG/Monographs/
vol100B/100B-07-Table2.1.pdf). One report 
from the Hong Kong Special Administrative 
Region estimated an HTLV-1 prevalence of only 
4×10−5 but identified six cases of apparent ATLL 
by systematically screening all non-Hodgkin 
lymphoma cases for HTLV-1 antibody (Au & Lo, 
2005).
To date, there are a total of six cohort anal-
yses based in Japan that document the incidence 
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of ATLL among HTLV-1 carriers, and confirm 
that male carriers have about a 3–5 fold higher 
risk of developing ATLL than female carriers 
(Tokudome et al. 1991; Iwata et al., 1994; Arisawa 
et al., 2000, 2003, 2006; Hisada et al., 2001). It is 
worth noting that because HTLV-1-seropositivity 
is part of the diagnosis of ATLL, relative risks 
for ATLL can not be calculated (see Table 2.2 
available at http://monographs.iarc.fr/ENG/
Monographs/vol100B/100B-07-Table2.2.pdf). 
These cohort studies confirm the causal rela-
tionship between HTLV-1 infection and the 
incidence of ATLL, and also underline the higher 
risk among infected men. However, the reason 
for the apparently higher disease penetrance in 
HTLV-1-infected men than HTLV-1-infected 
women seen in Japan, and whether it exists else-
where, is unknown. Modelling data from the 
Carribean have not identified such male excesses 
(Murphy et al., 1989; see Table 2.3 available at 
http://monographs.iarc.fr/ENG/Monographs/
vol100B/100B-07-Table2.3.pdf).
There are four case–control analyses nested 
within prospective HTLV-1 cohorts in Japan 
that have compared incident ATLL cases with 
matched HTLV-1 carriers. These have focused on 
viral or serological predictors of either ATLL or 
the prevalence of circulating abnormal lympho-
cytes that resemble ATLL cells (Hisada et al., 
1998a, b; Arisawa et al., 2002; Okayama et al., 
2004; see Table 2.4 available at http://mono-
graphs.iarc.fr/ENG/Monographs/vol100B/100B-
07-Table2.4.pdf). Pre-diagnosis predictors of 
ATLL included a higher proviral load, higher 
antibody titres, and a higher prevalence of soluble 
interleukin-2 receptor-α (sIL2-R). The predictors 
for higher levels of abnormal lymphocytes were 
a higher proviral load and male gender. However, 
these studies are based on a small number of inci-
dent cases, and have not been repeated in other 
HTLV-1-infected populations.
2 .1 .2 Host susceptibility
As noted above, there is consistent evidence 
from cohorts in Japan that male carriers have a 
higher risk compared to female carriers for this 
malignancy.
It has long been proposed that the risk of 
ATLL is strongly related to very early HTLV-1 
infection. Testing this hypothesis would be diffi-
cult, requiring prospective follow-up of large 
birth cohorts. However, in a recent update of 
an ongoing study in the Caribbean of mothers 
of ATLL- and of HTLV-1-associated TSP/HAM 
patients, 35/36 mothers (97.2%) of ATLL cases 
were seropositive versus 5/15 mothers (33%) 
of TSP/HAM patients (P<0.001; Bartholomew 
et al., 1998). The cells of the sole seronegative 
mother of an ATLL case were also negative on 
PCR. However, the father and one older sister of 
this ATLL case were both HTLV-1 seropositive. 
All patients in the study were breastfed, and none 
of the patients or their mothers had a history of 
a blood transfusion. These findings support the 
proposal that early and/or mother-to-child infec-
tion with HTLV-1 plays an important role in the 
genesis of ATLL.
Finally, much of the notion of the epide-
miology of ATLL is based on epidemiological 
studies conducted in Japan. It is important to 
note that geographically defined social environ-
ments may alter the natural history of this infec-
tion. Specifically, the peak incidence of ATLL 
occurs earlier and at a reduced frequency among 
HTLV-1 carriers in the Caribbean in compar-
ison to Japan. Several studies compared viral 
and immune markers between HTLV-1 carriers 
and uninfected controls, and between Jamaican 
and Japanese HTLV-1 carriers as an approach 
to determine why the penetrance of ATLL may 
differ between populations.
Hisada et al. (2004) analysed viral markers 
between a matched set of Jamaican (n = 51) and 
Japanese carriers (n = 51) (Hisada et al., 2004). 
They found that the anti-HTLV-1 titres were 
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higher among the Jamaicans (P=0.03), as was the 
prevalence of antibodies against the tax protein 
(anti-tax) (P=0.002). There was no significant 
difference in proviral load between the Jamaican 
and Japanese carriers.
Birmann et al. (2009) further added a 
matched HTLV-1 seronegative subject to each 
carrier within each population reported in 
Hisada et al. (2004) to evaluate a set of serum 
immune markers (Birmann et al., 2009). HTLV-1 
infection was associated with activated T-cell 
immunity among the Jamaican subjects as indi-
cated by a higher prevalence of a low EBV nuclear 
antigens (EBNA-1:EBNA-2) ratio, higher serum 
levels of sIL2R, and of soluble CD30. The results 
among the Japanese subjects indicated dimin-
ished T-cell immunity among the carriers, as 
indicated by lower C-reactive protein levels. [The 
Working Group noted that the observed popula-
tion differences in non-carriers between the two 
populations and the impact of HTLV-1 infection 
within the population in immune profiles may 
begin to explain the divergent natural history 
of HTLV-1 infection in the two sentinel popu-
lations, and highlight the importance of social 
environments. Factors that may contribute 
to these findings include differences in age-
specific infection rates, co-existing infections 




2 .2 .1 Cutaneous T-cell lymphoma
One study reported that 60 patients with 
mycosis fungoides had detectable tax-related 
proteins in peripheral blood mononuclear cell 
samples; of these, they reported that 83% also 
had antibodies to HTLV-1 tax proteins (Pancake 
et al., 1996). However, several large studies on 
patients with cutaneous T-cell malignancies, 
including many cases of mycosis fungoides in the 
USA, Republic of Korea, Japan, Spain, Europe, 
Mali, and Taiwan (China) could not replicate 
these results, and did not confirm an asso-
ciation with HTLV-1 (Wood et al., 1996, 1997; 
Bazarbachi et al., 1997; Kikuchi et al., 1997a, b; 
Chang et al., 1998; Fouchard et al., 1998; Kim 
et al., 1998; see Table 2.6 available at http://mono-
graphs.iarc.fr/ENG/Monographs/vol100B/100B-
07-Table2.6.pdf). Overall, there is no consistent 
evidence that HTLV-1 is associated with cuta-
neous T-cell malignancies, with the exception of 
ATLL presenting in the skin.
2 .2 .2 B- and T-cell lymphomas
Since the previous IARC Monograph (IARC, 
1996), several case series have examined HTLV-1 
infection in B- and T-cell lymphomas (Farias 
de Carvalho et al., 1997; Marin et al., 2002; 
Cabrera et al., 2003; Suefuji et al., 2003; Adedayo 
& Shehu, 2004). With the exception of some 
T-cell lymphomas which may, in retrospect, have 
been cases of ATLL (Marin et al., 2002), there 
was no evidence that HTLV-1 infection played a 
role in these lymphomas (see Table 2.7 available 
at http://monographs.iarc.fr/ENG/Monographs/
vol100B/100B-07-Table2.7.pdf).
The majority of primary gastric lymphomas 
are of B-cell origin, and only rarely of T-cell 
phenotype (Isaacson et al., 2008). However, 
a study reported that 18/58 lymphoma-type 
ATLL patients had gastric involvement of ATLL 
cells; and of these, three had primary gastric 
lymphoma (Sakata et al., 2001). Another report 
described 67 cases of surgically resected primary 
gastric lymphoma, of which five were found to 
have T-cell lymphoma: two were HTLV-1 posi-
tive and three were HTLV-1 negative (Shimada-
Hiratsuka et al., 1997). A final report described 
14 T-cell lymphomas in 233 cases of primary 
gastric lymphoma (Nakamura & Tsuneyoshi, 
1998). [The Working Group remarked that 
although further research may be useful, it is not 
clear if gastric lymphoma represents a separate 
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entity, or simply ATLL involving the stomach or 
adjacent lymphoid tissue.] See Table 2.8 available 
at http://monographs.iarc.fr/ENG/Monographs/
vol100B/100B-07-Table2.8.pdf
Except for a few cases of ATLL, two studies 
were unable to find HTLV-1 in post-transplant 
lymphoproliferative disorders. Gentile et al. 
(1998) reported three patients who developed 
T-cell lymphoproliferative disorders after renal 
transplantation, but none had evidence of HTLV-1 
infection. The second study reported on 24 cases 
of post-transplant lymphoid proliferation in 
Japan: 12 B-cell, ten T-cell, and two natural killer 
phenotype. A total of 5/10 T-cell tumours were 
classified as ATLL (Hoshida et al., 2001). See Table 
2.9 available at http://monographs.iarc.fr/ENG/
Monographs/vol100B/100B-07-Table2.9.pdf.
In one study, 12 cases of leukaemia of large 
granular lymphocytes with and tested for IgG 
antibodies to proteins related to HTLV-1 were 
reported (Starkebaum et al., 1987). Sera from 
6/12 cases reacted with the HTLV-1 proteins, 
while none of the ‘control’ serum (from healthy 
persons and patients with other disorders) 
reacted. By analogy, an initial report of HTLV-2 
and large granular lymphocytes (Loughran et al., 
1992) was not confirmed in a controlled study 
(Loughran et al., 1994). A set of 27 specimens 
from cases of splenic lymphoma on Kyushu 
Island, Japan – an HTLV-1-endemic area – were 
tested for anti-HTLV-1 antibody, and all were 
negative (Kumagawa et al., 2001).
2 .2 .3 Non-lymphomatous tumours
DNA from HTLV-1 and human foamy virus 
has been detected in recent studies of thymoma, 
and in 2002, a study reported that 11/12 samples 
from thymoma patients (91.6%) from Italy tested 
positive for the tax gene of HTLV-1/2 and 9/12 
samples (75%) positive for the tax and pol genes 
of HTLV-1 (Manca et al., 2002). However, a later 
study did not find any evidence for HTLV-1 or 
human foamy virus in 21 thymoma patients 
from the USA (Li et al., 2004).
Whether or not HTLV-1 is linked to an 
increased risk of solid malignancies has been 
studied with generally negative results. However, 
there is intriguing evidence for a possible protec-
tive effect of HTLV-1 on gastric carcinoma. In 
a prospective cohort study, 4136 adults living in 
four towns in the Nagasaki Prefecture in south-
western Japan were followed for 6 years (Arisawa 
et al., 2003). A total of 1063 were seropositive for 
anti-HTLV-1 antibodies at baseline, including 
439 (22.9%) men and 624 (26.2%) women. There 
were a total of 290 deaths in the cohort, with 
increased all-cause mortality for HTLV-1 both 
when ATLL was counted among the deaths (RR, 
1.5; 95%CI: 1.2–1.9), and when ATLL deaths were 
excluded (RR, 1.3; 95%CI: 1.0–1.7). HTLV-1 was 
not associated with an increased risk of all-site 
cancer mortality after excluding cases of ATLL 
(RR, 1.1; 95%CI: 0.77–1.7). Other interesting 
findings from the study included a decreased 
incidence of gastric cancer (RR, 0.42; 95%CI: 
0.17–0.99). These negative results for HTLV-1 
and solid tumours are in contrast to previous 
cross-sectional studies, which reported a higher 
HTLV-1 seroprevalence among 394 non-trans-
fused patients with non-ATLL malignancy than 
in age- and sex-matched healthy controls (Asou 
et al., 1986), and a higher prevalence of all malig-
nant neoplasms among siblings of ATLL patients 
compared to siblings of HTLV-1 seronegative 
non-Hodgkin lymphoma cases (Kozuru et al., 
1996).
In a recent retrospective cohort study in 
the Nagasaki Prefecture, Japan, 497 HTLV-1-
positive and 497 HTLV-1-negative persons who 
did not have gastric cancer at baseline were 
followed with serial endoscopy of the stomach 
(Matsumoto et al., 2008). Helicobacter pylori anti-
bodies were found in 61.7% of HTLV-1-positive 
cases compared to 71.6% of the HTLV-1-negative 
cases. There were 14 cases (2.8%) of gastric cancer 
in the HTLV-1-positive subjects compared to 35 
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cases (7%) in the age- and sex-matched HTLV-1-
seronegatives (OR, 0.38; 95%CI: 0.21–0.70). [The 
Working Group noted that these data suggest that 
HTLV-1 infection may reduce the inflammation 
usually associated with H. pylori infection, and 
thereby reduce the risk of gastric carcinoma.]
[The Working Group noted that further 
investigation is warranted on the subject of 
persistent H. pylori infection among HTLV-1 
seropositives to determine whether HTLV-1 
infection may reduce the inflammatory response 
to H. pylori and reduce the risk of gastric carci-
noma, as mentioned above (Arisawa et al., 2003; 
Matsumoto et al., 2008).]
Finally, one study of 85 cases of oesophageal 
squamous cell carcinoma in the Islamic Republic 
of Iran found no increase in HTLV-1 antibody 
prevalence compared to non-cancer controls 
(Mirsadraee et al., 2007).




In addition to the roles of being of masculine 
gender and infected at a younger age (described 
above), undernutrition and repeated exposure to 
filariasis in childhood were proposed as potential 
risk factors for ATLL (Tajima & Hinuma, 1984).
Since then, there is some evidence that 
co-infection with Strongyloides stercoralis is 
detrimental to HTLV-1 carriers. Among 38 ATLL 
cases, those who were positive for S. stercoralis 
were younger at diagnosis then those uninfected 
(Plumelle et al., 1997).
Gabet et al. (2000) reported that among 
HTLV-1 carriers from West Guyana and 
Martinique, those who were co-infected with 
S. stercoralis had a substantially higher HTLV-1 
proviral load, and substantially more oligoclonal 
expansion of HTLV-1-infected lymphocytes 
than carriers who were negative for S. stercor-
alis. These observations were substantiated in a 
Japanese population of HTLV-1 carriers (Satoh 
et al., 2002). [The Working Group noted that, 
together, these papers suggest that co-infection 
with S. stercoralis may increase the risk of ATLL 
in HTLV-1 carriers, and presents a potential 
for risk reduction with parasite treatment and 
control.]
One case series reported three cases of ATLL 
among eight HTLV-1 carriers within 2 years after 
immunosuppression with tacrolimus for liver 
transplantation (Kawano et al., 2006). In another 
study, five cases of ATLL were reported following 
immunosuppression for kidney transplantation 
(Hoshida et al., 2001).
See Table 2.11 available at http://monographs.
iarc.fr/ENG/Monographs/vol100B/100B-07-
Table2.11.pdf.
3. Cancer in Experimental Animals
In this volume, the Working Group decided 
not to include a separate section on “Cancer in 
Experimental Animals” in the Monographs on 
viruses but rather to include description of such 
studies under Section 4 (below). The reasoning 
for this decision is explained in the General 
Remarks.
4. Other Relevant Data
4.1 Mechanism of HTLV-1-linked 
carcinogenesis
4 .1 .1 Transforming capacity of HTLV-1
In vivo, HTLV-1 infection has been reported 
not only in T lymphocytes, but also in B lympho-
cytes, myeloid cells, monocytes, and dendritic 
cells (Koyanagi et al., 1993; Manel et al., 2005; 
Jones et al., 2008). However, HTLV-1 immortal-
izes only T lymphocytes in vitro through the 
action of the Tax viral protein.
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4 .1 .2 Biochemical and biological properties 
of HTLV-1 proteins
HTLV-1 belongs to the complex retroviruses 
family. The pX region, which is localized between 
the env gene and the 3′LTR, encodes regulatory 
genes (tax and rex), and accessory genes (p12, 
p13, p30 and HBZ) (Matsuoka & Jeang, 2007). 
These proteins not only control viral gene tran-
scription, but also modulate the proliferation 
of infected cells. Indeed, the fact that HTLV-1 
induces the proliferation of infected cells facili-
tates its transmission through cell-to-cell contact 
rather than through the release of viral particles 
(see also Section 1 and Fig.1.1).
(a) Rex
The Rex protein binds to Rex-responsive 
elements (RxRE), a highly stable stem-loop 
structure in the R/U3 region of the 3′LTR (Hanly 
et al., 1989). Rex regulates viral gene expression 
at the post-transcriptional level, by increasing 
the level of unspliced RNA in the nucleus, and 
by enhancing the nuclear export and the expres-
sion of the unspliced gag/pol and single-spliced 
env transcripts (Inoue et al., 1991).
(b) p12
The open reading frame I of the pX region 
of HTLV-1 encodes the protein p12, which is 
located in the endoplasmic reticulum and the 
Golgi. In quiescent primary lymphocytes and in 
vivo, p12 is important for establishing HTLV-1 
infection and optimal viral infectivity. The p12 
protein therefore facilitates host-cell activation, 
and the establishment of persistent infection 
(Collins et al., 1998; Albrecht et al., 2000; Nicot 
et al., 2005).
(c) p13
The protein p13 contains a mitochondrial-
targeting signal, and exists in the nucleus and 
mitochondria. Mutation of the p13 gene impairs 
viral proliferation in vivo, indicating that p13 
is critical for viral replication (Hiraragi et al., 
2006). In addition, p13 expression is associated 
with a suppressed cell proliferation in vitro (Silic-
Benussi et al., 2004).
(d) p30
The protein p30 is a nuclear and nucleolar 
protein (Koralnik et al., 1993) that binds to and 
retains the tax/rex mRNA within the nucleus. 
Therefore, p30 is a post-transcriptional nega-
tive regulator of viral replication and viral gene 
expression (Nicot et al., 2004).
(e) Tax
Tax, a 40-kD phosphoprotein, encoded from 
a spliced mRNA, is found mainly in the nucleus 
but also in the cytoplasm (Meertens et al., 2004). 
Tax interacts with several host factors (Boxus 
et al., 2008), which results in trans-activation of 
some genes, trans-repression of others, modula-
tion of the cell cycle, and dysregulation of apop-
tosis (Matsuoka & Jeang, 2007).
The transduction of a pX-containing sequence 
into primary human T Lymphocytes by use of 
a defective simian herpesvirus is sufficient to 
immortalize these cells (Grassmann et al., 1989). 
However, since this vector could express not only 
tax but also the genes p12, p13, p30 and HBZ, it 
was difficult to conclude whether Tax was the only 
responsible viral protein for cell transformation. 
Subsequently, immortalization (IL-2-dependent 
growth) of human CD4-positive T cells was 
demonstrated in vitro by the use of a retroviral 
vector expressing only the tax gene (Akagi et al., 
1995). In addition, the transforming ability of 
Tax was demonstrated in the Rat-1 fibroblast cell 
line in vitro in a soft-agar assay, and in vivo in 
nude mice (Tanaka et al., 1990). These findings 
clearly showed that Tax is oncogenic. In addition, 
several studies with animals transgenic for Tax 
have clearly demonstrated that Tax expression 
leads to the induction of tumours, confirming 
that Tax is oncogenic in vivo (see Section 4.1.6).
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Transcription pathways activated by Tax 
include those of NF-κB, CREB, SRF and AP-1 
(Azran et al., 2004). To turn on the NF-κB 
pathway, Tax binds to IKKγ, and activates the 
IKK complex, leading to phosphorylation of 
IκB (Jin et al., 1999). For survival, the Akt/PI3K 
pathway is also implicated in addition to the 
NF-κB pathway. Tax also activates this pathway 
by binding to the p85α subunit of PI3K, leading 
to activation of AP-1 (Peloponese & Jeang, 2006).
The transcription factor p53 is a crucial 
element in the cellular defence against tumour 
development. Mutations in the TP53 gene are 
frequently found in human cancers (IARC p53 
database available online at http://www.p53.iarc.
fr). Mutations in TP53 occur in less than 30% of 
adult T-cell leukaemia (ATLL) cells, depending 
on the clinical stage, which indicates that other 
mechanisms are involved. The precise mecha-
nism that leads Tax to inhibit the function of p53 
is still a matter of debate: some authors suggested 
that competition with the transcription co-acti-
vators CBP/p300 plays a major role (Mulloy 
et al., 1998; Suzuki et al., 1999), whereas others 
reported that activation of the NF-κB pathway 
was needed (Pise-Masison & Brady, 2005).
Tax activates the transcription of viral genes 
through three imperfect 21 base-pair repeat 
elements, the Tax-responsive element (TRE) 
(Fujisawa et al., 1986). The neighbouring GC-rich 
sequences of TRE are required for the binding of 
Tax (Paca-Uccaralertkun et al., 1994). The TRE 
contains sequences that are similar to that of 
the cyclic adenosine monophosphate (cAMP)-
responsive element (CRE). CRE-binding protein/
activating transcription factor (CREB/ATF) 
family members bind to TRE in a Tax-dependent 
manner (Franklin et al., 1993). Tax can interact 
with transcriptional co-activators, CREB-
binding protein (CBP) and p300, that acetylate 
histones in the promoter region. In addition, 
CREB co-activators – termed transducers of 
regulated CREB activity (TORCs) – activate 
Tax-mediated viral gene transcription through 
the LTR. Tax interacts with TORCs (Siu et al., 
2006). Thus, co-activators, TORCs, and CBP/
p300 are necessary for the Tax-mediated activa-
tion of viral gene transcription.
Tax also inhibits transforming growth factor 
β (TGF-β)-mediated signals. It is likely that the 
inhibition of TGF-β-signalling enables HTLV-1-
infected cells to escape TGF-β-mediated growth 
inhibition (Mori et al., 2001; Lee et al., 2002).
The Tax sequence contains several important 
domains that are involved in CREB and NF-κB 
activation. Recently, the C-terminal sequence of 
Tax was shown to contain a PDZ-binding motif. 
This PDZ-binding motif, which is absent from 
HTLV-2 Tax, seems critical for the ability of 
HTLV-1 Tax to transform cells in vitro (Rousset 
et al., 1998; Endo et al., 2002). It should be noted 
that Tax is not expressed in 60% of ATLL cases, 
due to deletions, epigenetic changes of the 
5′LTR, and genetic changes in the Tax sequence 
(Matsuoka, 2005, 2010; Giam & Jeang, 2007).
(f) HBZ
The HTLV-1 bZIP factor (HBZ) is tran-
scribed from the complementary strand of the 
proviral genome (Larocca et al., 1989; Gaudray 
et al., 2002). Viral transcription from the 5′LTR 
is highly dependent upon Tax expression and 
this is due to the presence of three TREs, as indi-
cated above. Conversely, the transcription from 
the 3′LTR is dependent on Sp1 (Yoshida et al., 
2008). Therefore, HBZ gene transcription is rela-
tively constant, and is correlated with proviral 
load (Usui et al., 2008). Interestingly, and in 
contrast to the finding that the tax gene has not 
been frequently detected in ATLL cells, the HBZ 
mRNA could be detected in all ATLL cases. Even 
if defective proviruses are commonly detected in 
ATLL cells, the HBZ gene always remains intact 
(Miyazaki et al., 2007). Importantly, HBZ expres-
sion is associated with the proliferation of ATLL 
cells since the knock-down of HBZ in ATLL 
cells decreases the growth of the leukaemic cells 
(Satou et al., 2006), which further indicates that 
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HBZ is critical and essential for the growth of 
these cells. Several transcription factors bind 
HBZ, including c-Jun, JunD, JunB, RelA/p65, 
p300, and CREB (Basbous et al., 2003; Hivin 
et al., 2007; Clerc et al., 2008).
4 .1 .3 Biological properties of HTLV-1 proteins 
relevant to carcinogenesis
(a) Immortalization
HTLV-1 can transform CD4-positive T 
lymphocytes in vitro. Among all the viral 
proteins, only Tax has the ability to immortalize 
CD4-positive T cells in vitro (see above).
(b) Genetic instability
Cytogenetic abnormalities that are specific 
to ATLL have not been found, but trisomies, 
deletions, and structural rearrangements are 
frequently reported in two of the four ATLL 
subtypes (acute leukaemia and lymphoma ATLL) 
(Kamada et al., 1992). This is therefore indicative 
of chromosomal instability in ATLL cells where 
the altered functions of several centrosome-
associated proteins seem also to be involved in 
the Tax-driven aneuploidy (Afonso et al., 2007). 
As an example, the functions of HsMAD1 (also 
known as TXBP181) functions are impaired 
in Tax-expressing cells. HsMAD1 acts at the 
G2/M-checkpoint and has been found on the 
centrosome during metaphase. It is tempting 
to speculate that the loss of HsMAD1 function 
could be linked to the loss or modification of the 
centrosomal activity (Jin et al., 1998).
Tax has also been reported to interact with 
the anaphase-promoting complex/cyclosome 
(APC/C). This interaction leads to a premature 
mitotic exit, and may contribute to aneuploidy 
(Liu et al., 2005).
Recently, another partner of Tax, the 
centrosome-associated TAX1BP2 protein (also 
known as TXBP121) was also implicated in the 
Tax-dependent initiation of aneuploidy (Ching 
et al., 2006). By the use of in-situ fluorescence 
microscopy the authors demonstrated that Tax 
binds to and co-localizes with endogenous 
TAX1BP2, forming peri-nuclear dots. In the 
absence of Tax, overexpression of TAX1BP2 leads 
to a reduction in the number of cells that contain 
supernumerary centrosomes. In contrast, deple-
tion of endogenous TAX1BP2 induces centro-
some amplification. Therefore, Tax and TAX1BP2 
have opposite effects. Besides, a Tax mutant that 
does not interact with TAX1BP2 can no longer 
induce centrosome duplication. This suggests 
that Tax targets TAX1BP2 to cause aneuploidy. 
In addition, during mitosis, Tax binds to Ran 
and RanBP1, which fragments spindle poles, 
and induces multipolar segregation (Peloponese 
et al., 2005).
(c) DNA-damage responses
Tax has been reported to suppress the expres-
sion of DNA polymerase β (Jeang et al., 1990), 
which is implicated in DNA repair. This suppres-
sion is associated with impaired DNA repair 
in HTLV-1-infected cells. In addition, it has 
been reported that Tax inhibits ATM-mediated 
DNA-damage response, resulting in premature 
DNA replication in the presence of genomic 
lesions (Chandhasin et al., 2008).
(d) Cell proliferation and differentiation
As mentioned above, the HTLV-1 provirus 
can be detected not only in CD4-positive T 
cells, but also in CD8-positive T cells as well as 
in dentric cells in vivo. Among CD4-positive 
T cells, the HTLV-1 provirus was detected in 
memory/effector T cells. After infection followed 
by a couple of cycles during which HTLV-1 uses 
its reverse transcriptase, the virus is ampli-
fied via clonal proliferation of the infected cells 
(Takemoto et al., 1994; Wattel et al., 1995). The 
same infected clones survive in vivo, indicating 
that clonal proliferation is persistent (Etoh et al., 
1997; Cavrois et al., 1998). A prospective study has 
shown that this clonal proliferation is associated 
with the onset of ATLL in some cases (Okayama 
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et al., 2004), although oligoclonal proliferation 
without ATLL occurs in most asymptomatic 
HTLV-1 carriers. Of note, the proviral load 
ranges from less than 0.1% up to 30% (of total 
peripheral blood mononuclear cells) in asymp-
tomatic carriers. It is likely that a high proviral 
load is associated with a higher risk of developing 
ATLL (Tachibana et al., 1992).
4 .1 .4 Role of HTLV-1 in malignant conversion
(a) Requirement of HTLV-1 expression for cell 
growth
Viral gene expression differs between 
in-vitro-transformed cell lines and primary 
ATLL cells in a manner that is similar to the rela-
tion between EBV-transformed cells and Burkitt 
lymphoma cells. Tax expression is usually high 
in transformed cells in vitro but TAX gene tran-
scription is detected in only about 40% of ATLL 
cells cultured ex vivo (Matsuoka & Jeang, 2007). 
Analyses of the HTLV-1 provirus identified three 
mechanisms that inactivate Tax expression: 1) 
genetic changes in the TAX gene sequence that 
lead to a premature stop codon or to insertions/
deletions; 2) DNA methylation of the provirus; 
and, 3) deletion of the proviral 5′LTR (Matsuoka 
& Jeang, 2007). Deletion or DNA methylation 
of the 5′LTR silenced transcription of the viral 
genes, including TAX, REX, P12, P13, and P30. 
The 3′LTR, on the other hand, was intact and 
unmethylated in all ATLL cases examined, and 
HBZ was shown to be expressed in all ATLL 
cases tested, and to induce lymphocyte prolifera-
tion (Satou et al., 2006). Interestingly, there is a 
correlation between the proviral load and HBZ 
mRNA levels (Li et al., 2009).
(b) Persistence of the HTLV-1 genome
HTLV-1 induces ATLL in a subset of carriers 
after a long latency period. As an example, the 
cumulative lifetime risk of developing ATLL was 
estimated to be 6.6% for men and 2.1% for women 
among Japanese HTLV-1 carriers (Arisawa et al., 
2000). ATLL cells retain the HTLV-1 provirus in 
the genome, but as stated above, defective provi-
ruses are frequently detected, which are classi-
fied into two types. A type-1 defective provirus 
was found in 43% of all defective viruses; it lacks 
internal sequences such as gag, pol and env but 
retains both LTRs. A type-2 defective provirus 
lacks the 5′LTR and internal sequences. It is 
frequently observed in acute and lymphoma-
type ATLLs whereas it is quite rare in chronic 
ATLL, indicating that this defective provirus is 
likely to be associated with disease progression 
(Tamiya et al., 1996). Detailed analyses show 
that the type-2 defective provirus can be gener-
ated before and after integration. A defective 
provirus formed after integration suggests that 
the deletion of the 5′LTR may block Tax expres-
sion, enabling ATLL cells to escape the host 
immune system. The frequency of type-2 defec-
tive proviruses is low in carriers, indicating that 
these defective proviruses were selected during 
leukaemogenesis. Another possibility is that 
infected cells with the type-2 defective provirus 
tend to transform into ATLL cells. ATLL cells 
with the type-2 defective provirus frequently 
cannot produce Tax as a result of the deletion of 
the promoter or the deletion of the second exon. 
However, all cases with the type-2 defective 
provirus maintain an intact HBZ gene sequence 
(Miyazaki et al., 2007).
As a mechanism of retroviral oncogenesis, 
the integrated LTR activates the transcription 
of cellular oncogenes, flanking integration sites. 
However, there are no common integration sites 
of HTLV-1 provirus in ATLL cells (Doi et al., 
2005).
(c) Alterations of oncogenes and tumour-
suppressor genes
Several ways by which tumour-suppressor 
genes can be inactivated have been demon-
strated in cancer cells. Mutations of the TP53 
gene occur in up to 40% of all ATLL patients 
(Sakashita et al., 1992; Yasunaga & Matsuoka, 
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2003). Deletion or mutation of the p16INK4A gene 
has also been reported. Such genetic changes in 
the p53 and p16INK4A gene sequence and/or func-
tion are detected in the more aggressive disease 
states, indicating that somatic DNA changes in 
these two genes are associated with the progres-
sion of ATLL (Yasunaga & Matsuoka, 2003).
Cytogenetic analysis of ATLL cells showed a 
common breakpoint cluster region in chromo-
some 10p11.2. Further analyses have shown that 
the transcription factor 8 (TCF8) is frequently 
disrupted by several mechanisms, including 
epigenetic silencing. Suppressed expression of 
TCF8 is associated with resistance to TGF-β. 
Mice carrying a mutation in TCF8 frequently 
developed thymic T-cell lymphoma, indicating 
that TCF8 is a tumour-suppressor gene (Hidaka 
et al., 2008).
There have been a few reports of cellular 
oncogenes in ATLL cells. By screening cDNA 
expression-libraries derived from leukaemic cells 
of ATLL patients for the potential to transform 
NIH3T3 mouse fibroblasts, a novel transforming 
gene, Tgat, was identified. Expression of Tgat in 
NIH3T3 cells resulted in cell transformation, 
indicated by anchorage-independent growth in 
semisolid medium, and tumorigenicity in nude 
mice (Yoshizuka et al., 2004).
4 .1 .5 Interaction between HTLV-1 and 
environmental agents
The frequency of opportunistic infections is 
fairly high among ATLL patients, indicating that 
T-cell-mediated immunity is severely impaired 
in such patients. The presence of the parasite 
S. stercoralis is commonly seen in immuno-
suppressed patients. In a study in the Japanese 
districts of Kyushu and Okinawa, where stron-
gyloidiasis is endemic, 36 patients were identi-
fied as seropositive for HTLV-1. Fourteen of these 
patients (39%) had HTLV-1 DNA monoclonally 
integrated in their blood lymphocytes. It has 
been suggested that the parasitic infestation with 
S. stercoralis may act as a cofactor for HTLV-1-
induced leukaemogenesis (Nakada et al., 1987).
4 .1 .6 Animal models for HTLV-1-associated 
cancers
Animals, including rabbits, rats, and 
monkeys can be experimentally infected with 
HTLV-1 (Lairmore et al., 2005). In rabbits and 
rats, HTLV-1 infection is persistent, and induces 
host immune response. However, HTLV-1 
does not lead to definite diseases in these two 
species. A large number of Old World monkeys 
are naturally infected with STLV-1. This virus 
is almost identical at the nucleotide level with 
HTLV-1, and several cases of ATLL have been 
described in monkeys (Tsujimoto et al., 1987; 
Akari et al., 1998). Experimental infection with 
HTLV-1 of squirrel monkeys (S. Sciureus) led 
to a substantial decrease in the proliferation 
rate of the CD4-positive T-cell population in 
those infected animals that were affected by a 
pathology similar to ATLL in humans (Debacq 
et al., 2005). Co-infection of rhesus macaques 
(Macaca mulatta) with HTLV-1 and simian 
immunodeficiency virus 1 (SIV-1) increased the 
number of multilobulated lymphocytes in the 
circulation. The study showed that SIV-1 may 
have the potential to upregulate HTLV-1 and 
disease expression (Traina-Dorge et al., 2007). 
So far, non-human primates represent the only 
suitable animal model to study human ATLL.
Several groups have shown that HTLV-1 can 
infect immunocompetent mice, although in 
most of these studies, no viral mRNA produc-
tion or HTLV-1 antibody response were detected. 
In addition, these mice did not show progression 
to ATLL (Lairmore et al., 2005). Several trans-
genic animal models have been established to 
study HTLV-1; the Tax protein has been shown 
to be oncogenic in several of these models. The 
type of tumour depends on the promoter used in 
each study: transgenic mice expressing Tax using 
the granzyme B promoter developed tumours of 
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natural killer cells (Grossman et al., 1995), and 
transgenic mice with Tax expression via the lck 
promoter developed a disease that resembles 
ATLL (Hasegawa et al., 2006). The major differ-
ence between most of these animal tumours 
and ATLL is the fact that, as stated above, a 
subset of human ATLL cells do not express Tax. 
HBZ-transgenic mice have also been shown to 
display increased T-cell proliferation (Satou 
et al., 2006).
4.2 HTLV-1, host immune system, and 
genetic susceptibility
The host immune system influences the 
condition of viral infection, and the diseases 
induced by it. Large interindividual variations in 
proviral load are commonly observed between 
HTLV-1 carriers, but the amount of provirus is 
relatively constant in HTLV-1-infected individ-
uals over time (Kwaan et al., 2006), suggesting 
that host factors, including the immune system, 
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Fig. 4.1 Natural history of HTLV-1 infection leading to onset of ATL
 
After infection, HTLV-1 is transmitted mostly through cell-to-cell contacts. Tax and HBZ viral proteins promote oligoclonal proliferation of 
HTLV-1-infected cells. Tax expression is suppressed by cytotoxic T-lymphocytes in vivo. A fraction of carriers develop ATL after a long period. At 
the leukaemic stage, about 60% of ATL cases do not express Tax. ATLL, adult-T-cell leukaemia
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determine the provirus load. In spite of eliciting 
a strong immune response, HTLV-1 infection 
persists in vivo, mainly in CD4-positive T cells, 
and part of the CD8-positive T cells are infected 
by HTLV-1 (Yasunaga et al., 2001). An in vivo 
study of HTLV-1-infected cells used diuterium-
labelled glucose to investigate lymphocyte 
kinetics, and showed that CD4+CD45RO+ and 
CD8+CD45RO+ T-lymphocyte proliferation was 
elevated in HTLV-1-infected subjects (Asquith 
et al., 2007). This was associated with viral gene 
expression, and indicates that active prolifera-
tion induced by viral infection induces the host 
immune response, and that the proviral load is 
determined by a balance between Cytotoxic T 
Lymphocytes activity and viral gene expression. 
The host immune system probably prevents the 
development of ATLL in vivo as suggested by a 
study where 3/8 HTLV-1-positive carriers, who 
were immunosuppressed during the course of a 
liver transplantation, developed ATLL (Kawano 
et al., 2006).
4.3 Synthesis
There is strong mechanistic evidence 
supporting the role of HTLV-1 in human 
carcinogenesis. The viral protein Tax has the 
ability to immortalize and to transform human 
T cells. At the leukaemic stage, the expression of 
Tax is often not maintained, but the viral protein 
HBZ continues to be expressed, and supports 
the sustained growth of the leukaemic cells (see 
Fig. 4.1).
5. Evaluation
There is sufficient evidence in humans for the 
carcinogenicity of HTLV-1. HTLV-1 causes adult 
T-cell leukaemia/lymphoma.
HTLV-1 is carcinogenic to humans (Group 1).
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OPISTHORCHIS VIVERRINI AND 
CLONORCHIS SINENSIS
Opisthorchis viverrini and Clonorchis sinensis were considered by a previous IARC Working 
Group in 1994 (IARC, 1994). Since that time, new data have become available, these have 
been incorporated in the Monograph, and taken into consideration in the present evaluation.
1. Exposure Data
1.1 Taxonomy, structure and biology 
1 .1 .1 Taxonomy
Opisthorchis viverrini (O. viverrini) and 
Clonorchis sinensis (C. sinensis) are patho-
logically important foodborne members of the 
genus Opisthorchis; family, Opisthorchiidae; 
order, Digenea; class, Trematoda; phylum, 
Platyhelminths; and kingdom, Animalia. They 
belong to the same genus (Opisthorchis) but to 
different species based on morphology; nonethe-
less, the genus Clonorchis is so well established 
in the medical literature that the term is retained 
here.
1 .1 .2 Structure
The adult of O. viverrini and C. sinensis are 
usually about 10–25 mm in length and 3–5 mm 
in width (Liu & Chen, 1998; Sripa et al., 2007).
The yellowish-brown, ovoid eggs have 
a distinct operculum, which opens to release 
the miracidum – a fully formed larva. Eggs are on 
average 29 μm long by 17 μm wide for C. sinensis 
(Liu & Chen, 1998), and 27  μm by 15  μm for 
O. viverrini (Sadun, 1955), and are difficult to 
differentiate between these two species (Kaewkes 
et al., 1991).
1 .1 .3 Structure of the genome
The genomic structures of O. viverrini and C. 
sinensis have not been reported.
O. viverrini is reported to have six pairs of 
chromosomes, i.e. 2n = 12 (Rim, 2005), to have 
neither CpG nor A methylations, but to contain a 
highly repeated DNA element that is very specific 
to the organism (Wongratanacheewin et al., 
2003). Intra- and inter-specific variations in the 
gene sequences of 18S, the second internally tran-
scribed spacer region ITS2, 28S nuclear rDNA, 
and of the mitochondrial cytochrome C oxidase 
subunit I (mtCOI) DNA are low and nearly iden-
tical (Ando et al., 2001). A comparison of the 
ITS2 region sequences of O. viverrini versus C. 
sinensis show a 95% match; the sequences differ 
at 28 nucleotide positions (Park, 2007).
The chromosome number of C. sinensis is 
2n = 56, and the chromosomes can be divided 
into two groups based on their sizes, consisting 
of eight pairs of large and 20 pairs of small chro-
mosomes. The mean total length of the diploid 
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complements of liver flukes collected in the 
People’s Democratic Republic of China is slightly 
longer than that of those collected in the Republic 
of Korea (Park et al., 2000).
1 .1 .4 Host range
Three families of freshwater snails 
(Hydrobiidae, Bithyniidae, and Melaniidae) 
are first intermediate hosts (Harinasuta & 
Harinasuta, 1984; Liu & Chen, 1998). Of these, 
Parafossarulus striatulus, Alocinma longicornis 
(Hydrobiidae), Bithynia fuchsianus (Bithyniidae) 
are currently considered to be of greatest impor-
tance in China in the life cycle of C. sinensis (Lun 
et al., 2005).
Over 130 species of fish (belonging to 16 fami-
lies) are secondary intermediate hosts (Komiya, 
1966; Vichasri et al., 1982; Rim, 1986; Joo, 1988; 
Liu & Chen, 1998). Fish in the family Cypriniidae 
are the major intermediate hosts (Lun et al., 
2005).
In addition to human beings, other fish-eating 
mammals, for example dogs, cats, pigs, minks, 
weasels, civets, and house rats can be definite 
hosts, and some may act as reservoir hosts (Wang, 
1983; Lun et al., 2005; Rim, 2005). There is also 
evidence that rabbits, guinea-pigs, hamsters, 
gerbils, mice, and rats are susceptible to the 
parasite in a laboratory setting (Bhamarapravati 
et al., 1978; Wang, 1983; Boonmars et al., 2009). 
Cats and dogs are considered to be the most 
important animal hosts in the endemic regions 
of China (Lun et al., 2005). In contrast with many 
other countries, most cats and dogs are not kept 
as pets in rural China but roam freely in villages, 
and thus have easy access to the remains of raw 
or undercooked fish in household waste (Wang, 
1983; Jiang, 2001).
1 .1 .5 Target organs
The adult liver flukes usually reside in the 
medium-sized or small intrahepatic bile ducts. 
In heavy infections, adult parasites may be found 
in the gallbladder, the extrahepatic bile duct, and 
the pancreatic duct (Pungpak et al., 1985; Rim, 
1986, 2005; Lim, 1990; Sripa, 2003). Over 100 
flukes were recovered from the gallbladder of one 
patient (Evans et al., 1971), and 5140 and 1348 
flukes of C. sinensis were found, respectively, in 
the bile ducts and in pancreatic ducts of a child 
patient who died of clonorchiasis sinensis (Chen 
et al., 1963).
The pathophysiology and clinical manifesta-
tions for O. viverrini and C. sinensis and infection 
are very similar (Lun et al., 2005; Sripa, 2008).
1 .1 .6 Life cycle
The eggs produced by the mature adult worms 
pass down the bile duct and are excreted in the 
faeces. If the eggs reach a freshwater body (small 
ponds, streams and rivers, flooded rice fields, 
and reservoirs), they are ingested by snails, which 
act as the primary intermediate hosts. Asexual 
reproduction in the snail results in daily release 
of thousands of cercariae, 1–2 months after infec-
tion of the snail. The free-swimming cercariae 
penetrate the tissue of freshwater fish, which act 
as the secondary intermediate host, and encyst to 
become fully infective metacercariae under the 
fish’s skin or in muscle after 21 days.
Humans or other fish-eating animals are 
infected through the ingestion of raw or under-
cooked (salted, pickled, or smoked) freshwater 
fish that contains metacercariae. After ingestion, 
the metacercaria excysts in the duodenum and 
ascends the biliary tract through the ampulla of 
Vater. Maturation to adulthood takes approxi-
mately 1 month.
The life cycle of the liver flukes is shown in 
Fig. 1.1 (for a review, see Rim, 1986; Sripa et al., 
2007).
1 .1 .7 Genes and gene products
Laha et al. (2007) constructed an O. viverrini 
cDNA library that covers ~14% of the entire tran-
scriptome. About 20% of contigs were assigned 
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Figure 1.1 Life cycle of Clonorchis sinensis and Opisthorchis viverrini
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Gene Ontology classifications. Frequently repre-
sented protein families included those involved 
in physiological functions that are essential to 
parasitism, such as anaerobic respiration, repro-
duction, detoxification, surface maintenance, 
and feeding. An assessment of evolutionary rela-
tionships showed that O. viverrini was similar 
to other parasitic flukes such as C. sinensis and 
Schistosoma japonicum. A total of 164 O. viverrini 
contigs contained open reading frames (ORFs) 
with signal sequences, many of which were 
platyhelminth-specific. Moreover, ORFs repre-
senting secreted proteins with known roles in 
tumorigenesis were identified such as granulin, 
kallikrein-like serine proteases, phospholipase 
A2 (PLA-2), saponin-like protein, and thiore-
doxin peroxidase. These proteins might play a 
role in the pathogenesis of O. viverrini-induced 
cholangiocarcinoma (Laha et al., 2007). Gene 
expression profiling of adult O. viverrini was 
also constructed by the first 5′ serial analysis of 
gene expression (5′ SAGE) library, and vitelline B 
precursor protein and myoglobin were found to 
be the most abundant proteins (Chutiwitoonchai 
et al., 2008).
By using the expressed sequence tag (EST) 
approach, Lee et al. (2003) constructed the C. 
sinensis adult cDNA library. A total of 220 genes 
were sorted into seven functional categories 
including: energy metabolism (38), gene expres-
sion/RNA metabolism (21), regulatory/signalling 
components (14), protein metabolism/sorting 
(98), the structure/cytoskeleton (29), membrane 
transporters (10), and antigenic proteins (10). 
The high frequency of cysteine protease expres-
sion (30/415 randomly selected clones) suggests 
an important role of this protein in the metabo-
lism and/or pathogenesis of clonorchiasis. Also 
identified were Cu/Zn-superoxide dismutase and 
glutathione-S-transferase, which are believed to 
play a crucial role in protecting the parasite from 
the host immune effector mechanisms, and are 
being pursued as drug targets in other parasitic 
infections (Lee et al., 2003). Cho et al. (2008) 
reported gene expression profiles in C. sinensis 
metacercariae compared to those of adult 
worms. The genes expressed more abundantly in 
the metacercariae were a group of structural and 
cytoskeletal proteins, followed by transcription 
and translation machinery proteins, and a group 
of energy metabolism proteins. In contrast, adult 
C. sinensis has abundant mRNA clusters encoding 
for regulatory and signal proteins, other meta-
bolic proteins and enzymes, and structural and 
cytoskeletal proteins, in descreasing order (Cho 
et al., 2008). This may be explained by the fact 
that metacercariae in the muscles of freshwater 
fish are in a resting stage wherein they simply 
maintain a basal metabolic status, and adult C. 
sinensis have a high metabolic rate and produce 
a large numbers of eggs in mammalian hosts 
(Rim, 2005).
1.2 Epidemiology of infection
1 .2 .1 Prevalence, geographic distribution
Human liver fluke infection is endemic 
in China, Thailand, the Republic of Korea, 
the Democratic People’s Republic of Korea, 
Viet Nam, Lao People’s Democratic Republic, 
and Cambodia. Endemicity for C. sinensis is 
also suspected in the Russian Federation long 
the Amur River. Persons from Singapore and 
Malaysia with C. sinensis infection have been 
reported infrequently; many of them may be 
infected during travelling in other countries or 
through eating imported fish.
A very crude estimate of the global number 
of infected people is of the order of 45 million, 
comprising 35 million infected with C. sinensis 
(Korea Association of Health Promotion, 2004; 
Lun et al., 2005; Fang et al., 2008), and 10 million 
with O. viverrini (WHO, 1995; Jongsuksuntigul 
& Imsomboon, 2003). The geographic distribu-
tion of O. viverrini and C. sinensis is shown in 
Fig. 1.2.
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(a) Opisthorchis viverrini
Thailand is the most endemic country for 
opisthorchiasis due to O. viverrini. In Thailand 
and neighbouring countries, human opisthor-
chiasis is caused by O. viverrini. In 1980–81, the 
prevalence in the north, north-eastern, centre 
and the south of Thailand was 5.6%, 34.6%, 6.3%, 
and 0.01%, respectively, with an overall preva-
lence of 14% or 7 million people infected. As a 
result of intensive and continuous control activi-
ties, the prevalence of infection in north-eastern 
Thailand declined to 15.7% in 2001, and the rates 
in other areas were as follows: the north (19.3%), 
the centre (3.8%) and the south (0%), with an 
average prevalence of 9.6% or 6  million people 
infected (Jongsuksuntigul & Imsomboon, 2003).
It was estimated that 1.7 million people were 




C. sinensis is distributed in China, Republic of Korea, Democratic People’s Republic of Korea, the Russian Federation, and northern parts of Viet 
Nam, and O. viverrini in Thailand, Laos, Cambodia, Malaysia, and southern part of Viet Nam. The data used for the map were derived from most 
recent national surveys and published literature.
Note that in the legend, “no local transmission” stands for “no reported local transmission”.
A courtesy of Dr Song Liang, College of Public Health, The Ohio state University, USA, who did the art work based on data provided by the 
Working Group.
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1995), mainly along the Mekong River, and as 
far as in the lowlands among people with close 
ethnic ties to the majority of the north-eastern 
Thai population. Based on a national survey of 
primary schoolchildren conducted in 2000–02 
that included 17 provinces and the Vientiane 
Municipality, the prevalence of O. viverrini was 
10.9% (29846 participants). Again, the regions 
along the Mekong River such as Khammuane, 
Saravane or Savannakhet Province showed 
a higher prevalence of O. viverrini (32.2%, 
21.5%, 25.9%, respectively) (Rim et al., 2003). 
More recently, a survey in the Saravane district 
revealed a high prevalence of O. viverrini infec-
tion (58.5%) among 814 persons from 13 villages 
(Sayasone et al., 2007).
A few official reports or published data on 
O. viverrini infection in Cambodia are available. 
A small survey in primary schoolchildren from 
Kampongcham province showed a prevalence of 
Opisthorchis spp. of 4.0% from 251 fecal speci-
mens in 2002 (Lee et al., 2002).
Viet Nam has been reported to be endemic 
for C. sinensis in the northern part, and O. viver-
rini in the southern region (De et al., 2003).
(b) Clonorchis sinensis
C. sinensis was first discovered in the bile 
ducts of a Chinese carpenter in Calcutta, India, 
in 1875. In 1994, archaeologists found a large 
number of C. sinensis eggs in the bowel content 
of a corpse buried at the middle stage of the 
Warring States Period (475–221 BC) in Hubei, 
China (Wu et al., 1996), indicating that this 
parasite has been present in this province for 
more than 2300 years. In a nationwide sampling 
survey on the epidemiological status of para-
sitic diseases in China, a total of 356629 persons 
were investigated, and 2065 were found to be 
infected with C. sinensis, with an overall infec-
tion rate of 0.58% (Office of the National Survey 
on the Important Parasitic Diseases, 2005). In a 
recent survey in Chinese endemic areas, a total of 
217829 persons were investigated, and 5230 were 
found to be infected with C. sinensis, resulting in 
an infection rate of 2.4%. From this, an estimate 
of the number of infected persons in China was 
calculated to be 12.5 million (Fang et al., 2008).
C. sinensis is currently the most prevalent 
human parasitic helminth in the Republic of 
Korea, as detected by faecal examination. There 
has been no decrease in the average national 
infection rate of C. sinensis for almost 30 years; 
the detection rate was 4.6% in 1971, 1.8% in 1976, 
2.6% in 1981, 2.7% in 1986, 2.2% in 1992, 1.4% 
in 1997 and 2.9% in 2004, and about 1.3 million 
people in the Republic of Korea are estimated 
to be infected (Korea Association of Health 
Promotion, 2004; Rim, 2005). In endemic areas 
of the Republic of Korea, along the main rivers, 
prevalence values up to 40% have been reported 
(Rim, 1986, 2005).
Due to a lack of available data from their 
national survey, there is no accurate number for 
infected people in Viet Nam. A study of 1155 
villagers in northern Viet Nam reported a preva-
lence of C. sinensis infection of 26% (Dang et al., 
2008).
A prevalence of C. sinensis infection is 
suspected in the south-eastern part of the 
Russian Federation, in the Amur River basin 
where, based on scarce reports, it was estimated 
at >20% in some villages (e.g. Nanay district) 
(Semenova et al., 1995; Dyk et al., 1997).
1 .2 .2 Transmission and risk factors for 
infection
The definitive host is infected by the liver fluke 
primarily through the ingestion of raw (dried, 
pickled or salted) or undercooked infected fish, 
which contain metacercariae – this is the infective 
stage in the life cycle of liver flukes (Sithithaworn 
& Haswell-Elkins, 2003). Many surveys show that 
people in Thailand (Kaewpitoon et al., 2008), Viet 
Nam (Dang et al., 2008), China (Fang et al., 2008; 
Lun et al., 2005), Laos (Hohmann et al., 2001), 
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and the Republic of Korea (Lim et al., 2006) have 
these eating habits.
In southern China and among the 
Cantonese population in the Hong Kong Special 
Administrative Region, raw fish is tradition-
ally eaten after being dipped in rice porridge. 
Alternatively, large fish are sliced and eaten 
with ginger and garlic known as “yushen.” This 
mode of transmission tends to increase with 
age. In contrast, many children in hilly areas of 
Guangdong and eastern China such as Jiangsu, 
Shandong, and Anhui provinces, often catch fish 
during play, and roast them incompletely before 
consumption. This mode of transmission tends 
to decline with age (Fang et al., 2008).
The population of the Republic of Korea eat 
raw fish soaked in vinegar, red-pepper mash or 
hot bean paste with rice wine at social gatherings. 
The fact that men do so more frequently than 
women has been given as a reason for the higher 
prevalence of infection among men; however, 
in heavily endemic areas, often no significant 
differences are seen between the genders. When 
fish is abundant, raw fish is eaten very regularly 
as opposed to being saved for special occasions 
(Choi, 1984; Rim, 1986). Vietnamese people eat 
raw fish in salads (Kiêu et al., 1990).
In Thailand and the lowland region of Laos, 
three types of uncooked fish preparations are 
noted (Sadun, 1955; Sithithaworn & Haswell-
Elkins, 2003):
• koi pla, eaten soon after preparation;
• pla som, moderately fermented, and 
stored for a few days to weeks; and,
• pla ra and jaewbhong, extensively fer-
mented, highly salted fish, stored for at 
least 2–3 months.
Koi pla is probably the most infective dish, 
followed by fish preserved for <7 days, then pla 
ra and jaewbhong, in which viable metacer-
cariae are rare (Sithithaworn & Haswell-Elkins, 
2003). Several factors can directly or indirectly 
lead to the transmission of the liver flukes 
to humans (for reviews, see Sithithaworn & 
Haswell-Elkins, 2003 for O. viverrini; Lun et al., 
2005 for Clonorchis sinensis): 1) poor educa-
tional level of local residents (Jongsuksuntigul 
& Imsomboon, 2003); 2) lack of sanitation: it 
is common in some endemic regions in China, 
particularly in the province of Guangdong and 
Guangxi, that “lavatories” are built adjacent to 
ponds, so that human excrement containing C. 
sinensis eggs enters the pond water (Lun et al., 
2005). Also, in Laos, 95.5% of houses in some 
rural villages in Bolikhamxay Province do not 
have a latrine, and more than half of the village 
people use animal and/or human faeces as ferti-
lizer (Hohmann et al., 2001); 3) habit to eat raw 
or undercooked freshwater fish; 4) freshwater 
aquaculture is developing rapidly, but adequate 
testing of fish products is lacking (Fang et al., 
2007); 5) dinner-set contamination from infected 
fish (Fang et al., 2007); and 6) the absence of 
systematic control activities to limit transmis-
sion in many endemic areas (Fang et al., 2007).
1 .2 .3 Persistency and latency
It has been reported that C. sinensis may 
survive up to 26 years in a human host, as has 
been shown in a Chinese immigrant living in 
Australia (Attwood & Chou, 1978). The life 
expectancy of O. viverrini is approximately 
10 years (Sithithaworn & Haswell-Elkins, 2003).
2. Cancer in Humans
2.1 Cholangiocarcinoma
2 .1 .1 Opisthorchis viverrini
The Working Group of the previous IARC 
Monograph on liver flukes (IARC, 1994) evalu-
ated infection with O. viverrini based on a 
dozen of descriptive studies (case reports, cases 
series, and correlation studies), and three cross-
sectional or case–control studies (Kurathong 
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et al., 1985; Parkin et al., 1991; Haswell-Elkins 
et al., 1994), which demonstrated a positive asso-
ciation between infection with O. viverrini and 
cholangiocarcinoma.
Currently, primary liver cancer is the leading 
cancer in Thailand in men (annual standard-
ized ratio [ASR], 33.4/100000 population), 
and the third in women (ASR, 12.3/100000) 
(Khuhaprema & Srivatanakul, 2007), with chol-
angiocarcinoma being the predominant type. In 
addition, the highest incidence of liver cancer 
(ASR of up to 113.4/100000 in men) is found in 
the north-eastern regions where O. viverrini is 
endemic, and is 20 times higher than that in the 
south of Thailand where O. viverrini is rare (Sripa 
& Pairojkul, 2008). Furthermore, the proportion 
of histologically verified cases of cholangiocar-
cinoma in men diagnosed with liver cancer in 
the north-eastern regions has been reported 
to be as high as 85.5% compared to 10% in the 
south (Khuhaprema & Srivatanakul, 2007). A 
recent correlation study (Sriamporn et al., 2004) 
found a significant positive association between 
the incidence cases of cholangiocarcinoma from 
the cancer registry and O. viverrini infection in 
Khon Kaen, a province in north-east Thailand, 
with the highest incidence of cholangiocarci-
noma cancer in the world (see Table 2.1).
 Table 2.2 presents the results from all 
the available cross-sectional and case–control 
studies, all conducted in Thailand (descrip-
tive studies are not presented). The odds ratios 
ranged from 1.3–27.1. The highest relative risk, 
reported by Honjo et al. (2005), was adjusted for 
sex, age, residence, alcohol consumption, and 
smoking. Haswell-Elkins et al. (1994) reported 
adjusted prevalence odds ratios (POR) of 1.7 in 
the light infection group, 3.2 in the moderate 
infection group, and 14.1 in the heavy infection 
group (based on 14 exposed cases stratified by 
intensity of infection).
2 .1 .2 Clonorchis sinensis
The Working Group of the previous IARC 
Monograph on liver flukes (IARC, 1994) evalu-
ated infection with C. sinensis as probably 
carcinogenic to humans (Group  2A), based on 
nine case series and three case–control studies 
(Gibson, 1971; Kim, 1974; Chung & Lee, 1976). 
Since then, several studies have been published, 
and are summarized here.
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(r) for the overall 
districts was 0.009. 
Results reported for 
selected districts with 
more than 1000 tested 
for Ov
1122 10.5 93.8 (Nam 
Phong)
1026 13.4 114.9 (Phon)
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1003 25.7 135.7 (Muang)
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Stool specimens Eggs in stool 9/13 [0.94 (0.26–4.22)]
Stool, bile duct 
aspirate or liver 
biopsy
Eggs in any 
tissue or 
fluid
13/13 Χ2 test p<0.05 
[10.95 (1.10–108.48)]
a






patients from 3 
hospitals
103 controls matched 
to cases by sex, age, 
residence, hospital, 
non-malignant 
diseases not related 
to tobacco or alcohol
Antibody titre 
by ELISA
NR 5.0 (2.3–11.0) Consumption 
of ‘sticky rice’ 
and areca nut 
chewing
Haswell-




15 cases of suspected 
CCA among 1807 




Ov eggs+ Age, sex, 
district0 EPG 1 1.0 (ref)
≤1500 EPG 3 1.7 (0.2–16.3)
1500–6000 4 3.2 (0.4–30)
>6000 EPG 7 14.1 (1.7-119)




129 cases of CCA 
diagnosed by 










65 27.09 (6.30–116.57) Smoking, 
alcohol, age, 
sex, residence
a Continuity correction was applied to calculate OR
CCA, cholangiocarcinoma; ELISA, enzyme-linked immunosorbent assay; EPG, egg per gram; NR, not reported; Ov, Opistorchis viverrini
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The incidence of primary liver cancer in the 
Republic of Korea is the highest in the world 
(ASR, 44.9 in men and 12.0 in women), with 
a proportion of microscopically verified cases 
of cholangiocarcinoma of 22.3% and 36.1% in 
men and women, respectively (Curado et al., 
2007). According to the Korean Cancer Registry, 
the incidences of cholangiocarcinoma vary by 
geographic area, with up to 4-fold differences 
(Shin et al., 2008). The region with the highest 
incidence (7.2/100000 in men) was reported to 
be that with the highest prevalence of C. sinensis 
infection in a nationwide survey conducted 20 
years ago (Seo et al., 1981).
A recent correlation study from the Republic 
of Korea showed a high correlation between the 
endemicity of C. sinensis infection with the inci-
dence as well as mortality of cholangiocarcinoma 
(Lim et al., 2006; Table 2.3).
 Since the previous IARC Monograph, two 
case series from China have been published, both 
supporting a relationship between C. sinensis and 
cholangiocarcinoma (Cheng et al., 2000; Wang 
et al., 2003; Table 2.4). Furthermore, three case–
control studies have been published from the 
Republic of Korea (Table 2.5). All three showed 
significant positive associations between C. 
sinensis infection and cholangiocarcinoma. The 
study by Choi et al. (2006) reported an (unad-
justed) odds ratio for any evidence of infection of 
7.3 (95%CI: 3.9–13.3). Shin et al. (1996) reported 
an odds ratio of 2.7 (95%CI: 1.1–6.4), adjusted for 
alcohol consumption, smoking, hepatitis B and 
C, and Lee et al. (2008) found an odds ratio of 
13.6 (95%CI: 6.1–30.3) after adjusting for hepa-
titis B, alcohol consumption, and liver cirrhosis.
In two of the studies (Shin et al., 1996; Choi 
et al., 2006), higher odds ratios were reported for 
evidence of past C. sinensis infection (i.e. based 
on positive history, serology, skin test, radiology) 
compared to current infection (i.e. based on posi-
tive stool microscopy or pathology).
2.2 Hepatocellular carcinoma
2 .2 .1 Opisthorchis viverrini
A correlation analysis of the prevalence of 
O. viverrini infection and liver cancer incidence, 
conducted in five regions with different frequen-
cies of cholangiocarcinoma and hepatocellular 
carcinoma (HCC), showed little geographic vari-
ation in the incidence of HCC, with a correlation 
of −0.37 (P = 0.54) for antibody titre ≥ 1:40, and of 
0.02 (P = 0.96) for faecal egg count (Srivatanakul 
et al., 1991a).
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Three areas by 
endemicity
Faecal egg Incidence of cancera per 
100000 persons
In the survey, alcohol 
drinking and raw 
freshwater fish were 
significant risk factors 




659 14 (2.1%) 0.3
Medium 
(Chungju)




























Table 2 .4 Case series and case reports of cholangiocarcinoma associated with Clonorchis sinensis
Reference and study location Case history Clinical manifestations Treatment Pathological diagnosis
Liang (1995) 
Guangdong Province, People’s 
Hospital, China
27 CCA cases with Cs 
24 CCA cases without Cs
The same CT findings were 
observed in the cases with or 
without Cs
Operation Development of CCA
Kim et al. (1999) 
Korea University Hospital, 
Seoul, Republic of Korea
69-yr-old man 
Eating raw freshwater fish, 
pulmonary tuberculosis
5-kg weight loss, moderate 
dilatation of left IHD and 
CBD, obstruction of proximal 
left HD, Cs eggs + by left HD 
cytology, CBD polyp
Hepaticojejunostomy, partial 
resection of left proximal HD 
Pzq, 75 mg/kg 
Papillary hyperplasia 
Cheng et al. (2000) Lecong 
Hospital, China
35 CCA cases (28 positive for 
Cs)
Cs egg+, abdominal pain, 
weight loss
Operation (14 cases) CT finding pathology proven
Kim et al. (2000) 
Yonsei Medical Center, Seoul, 
Republic of Korea
64-year-old man Abdominal pain, Cs worms 
were removed by percutaneous 
transbiliary drainage, CBD 
polyp
Pancreaticoduodenectomy Composite small cell 
neuroendocrine carcinoma 
and adenocarcinoma
Wang et al. (2003) Guangzhou, 
Zhujiang Hospital, China
29 CCA cases Clonorchiasis 100% Operation Average 20 years of liver fluke 
infection
Shim et al. (2004) 




Abdominal pain, 8-cm-sized 
mass in right liver
Right hepatectomy, recurred 
metastasis
Mucinous adenocarcinoma



































































54 cases among 
1843 records 





















hospital, with liver 
diseases
Stool specimen NR [6.0 (2.8–13)]








41 CCA cases 203 patients of 
other diseases 




























































185 CCA cases 
identified from 
1 hospital in Seoul: 
51 intrahepatic 
CCA, 53 hilar CCA, 
and 81 extrahepatic 
CCA
185 patients with 
non-hepatobiliary 










Stool eggs + 3 0.6 Age, sex, and area
Pathology + 13 1.6
Serology + 25 2.3
Skin test + 19 1.7
Radiology + 156 8.6
History + 94 2.4
Any evidence + 167 7.3 (3.9–13.3)
51 cases of 
intrahepatic CCA 
among the 185 
cases above
51 patients with 
non-hepatobiliary 
diseases
Stool eggs + 0 Not available
Pathology + 0 Not available
Serology + 7 1.75
Skin test + 5 0.8
Radiology + 36 5.0
History + 22 1.5
Any evidence + 42 4.0 (1.5–10.7)



















Stool eggs + 26 13.6 (6.1–30.3) Age, sex, date of 
visit
CCA, cholangiocarcinoma; HCC, hepatocellular carcinoma; NR, not reported; SAR, Special Administrative Region


















































72 patients with 
hepatobiliary tract 
diseases:








5 biopsy proven 4/5 [1.62 (0.16–80.28)]
Srivatanakul 




65 patients living and 
born in the area
65 patients with 
non-malignant 
diseases matched for 
sex, age, residence, 
hospital










83 cases of HCC in a 
consecutive series of 
1484 autopsies
1384 autopsies 














386 and 109 cases 




cases among records 
of autopsies and 
surgical specimens
1061 and 287 
subjects with liver 
diseases from low 
and high prevalence 
areas, respectively
Examination of 
liver tissue or 
stool samples
Cs infection 423 [1.2 (0.80–1.7)]






206 cases in 
consecutive series of 






Stool specimens Eggs in stool 170 1.1 (0.65–1.7) None (crude 
odds ratio)
Overlap with 




CCA, cholangiocarcinoma; Cs, Clonorchis sinensis; HCC, hepatocellular carcinoma; NR, not reported; Ov, Opisthorchis viverrini
Opisthorchis viverrini and Clonorchis sinensis
One cross-sectional study (Kurathong 
et al., 1985) and one case–control (Srivatanakul 
et al., 1991b) study were carried out in north-east 
Thailand to evaluate the association between 
O. viverrini infection and the risk for HCC 
(Table  2.6). Neither study showed a significant 
association.
2 .2 .2 Clonorchis sinensis
A few studies have evaluated the associa-
tion between C. sinensis infection and the risk 
for HCC (Table 2.6). One study was conducted 
in the Hong Kong Special Adminitrative Region 
(Gibson, 1971) and found no association.
Three studies were conducted in the Republic 
of Korea; one (Kim, 1974) in two separate 
regions, of low and high prevalence of C. sinensis 
infection, respectively; the other two studies 
were conducted in Pusan, one of the areas with 
the highest prevalence of C. sinensis infection 
(Chung & Lee, 1976; Shin et al., 1996). In the 
two earlier studies, no increased risks for HCC 
were observed [from crude odd ratios]. In the 
most recent study (Shin et al., 1996), neither C. 
sinensis eggs in stool samples (OR, 2.7; 95%CI: 
0.9–7.7) nor a history of liver fluke infection (OR, 
2.6; 95%CI: 0.6–11.3) were significantly associ-
ated with HCC in a conditional logistic regres-
sion analysis adjusted for socioeconomic status 
(Table 2.6).
2.3 Cofactors
The intake of raw freshwater fish is tradi-
tionally combined with alcohol consumption 
in the Republic of Korea. In this country, one 
study reported a significantly increased risk of 
C. sinensis infection with alcohol consumption 
(Lim et al., 2006).
Shin et al. (1996) reported odds ratios of 4.6 
(95%CI: 1.4–15.2) for heavy alcohol consump-
tion, 5.0 (95%CI:1.2–21.3) for a history of liver 
fluke infection, and 2.7 (95%CI: 1.1–6.3) for C. 
sinensis in stool samples, all adjusted for the other 
factors. Lee et al. (2008) reported odds ratios of 
6.6 (95%CI: 4.8–9.2) for heavy alcohol consump-
tion and 13.6 (95%CI: 6.1–30.3) for C. sinensis 
in stool samples. Honjo et al. (2005) found odds 
ratios of 4.31 (1.12–16.57) for regular alcohol 
drinking and 27.09 (95%CI: 6.3–116.6) for pres-
ence of O. viverrini by antibody detection. No 
specific interactions between alcohol drinking 
and liver fluke infection were estimated in any 
of these studies.
3. Cancer in Experimental Animals
The association between O. viverrini and 
C. sinensis infections and cancers was exten-
sively studied in experimental animal models 
in the 1970s and 1980s. All of these studies 
were reviewed in the previous IARC Monograph 
(IARC, 1994). Only one additional study has 
been published since (Wang et al., 1994).
Thamavit et al. (1978) first reported 
that hamsters given O. viverrini and 
N-nitrosodimethylamine in drinking-water 
could develop cholangiocarcinoma. The gross 
morphology and histology of the experimen-
tally induced cholangiocarcinomas are similar 
to those found in humans, and are considered 
a suitable model for the study of cholangio-
carcinoma. Following this experiment, many 
studies on the administration of N-nitroso 
compounds (N-nitrosodimethylamine or 
N-nitrosodihydroxydi-n-propylamine) in 
combination with O. viverrini infection were 
performed, and all resulted in increased inci-
dences of cholangiocarcinoma. Intraperitoneal 
administration induced cholangiocarcinoma but 
also hepatic neoplastic nodules, and a few HCCs. 
All of these studies clearly established the role of 
O. viverrini in promoting cholangiocarcinoma in 
hamsters (Flavell & Lucas, 1982, 1983; Thamavit 



























Dosing regimen,  
Animals/group at start








Ov 100 MC, NDMA 0.0025% at Week 4 in 
drinking-water for 10 wk
CCA: This is the first experiment of 
NDMA + liver fluke-induced CCA 
in the hamsterGroup 1: Untreated control (n=18) Group 1: 0/18
Group 2: NDMA alone (n=21) Group 2: 0/21
Group 3: Ov (n=18) Group 3: 0/18








Ov 50 MC, NDMA 1.6 mg single oral dose CCA: High mortality in Ov+NDMA 
groups. Tumours found in right lobe. 
No significant difference between 
2 combination groups for tumour 
latency
Group 1: Ov+NDMA (41 days after 
infection) (n=50)
Group 1: 5/50 (10%) [NS]a
Group 2: NDMA+Ov (96 h later) (n=46) Group 2: 9/46 (20%) [p <0.01]
Group 3: NDMA (n=30) Group 3: 0/30 (0%)







Ov 12.5, 25, 50 or 100 MC 
NDMA 6 or 12.5 mg/L in drinking-water 
for 10 wk (2 wk later)
Cholangiofibrosis was also observed 
in Groups 3 and 4. Number 
of animals per group at start 
unspecifiedGroup 1: Untreated Group 1: No CCA
Groups 2: Ov 12, 25, 50 or 100 MC Groups 2 and 3: No CCA in Groups 
2 or 3 at doses of 3 or 6 mg/L
Groups 3: NDMA 3, 6 or 12 mg/L Groups 3: CCA: 2/17 (12%) NDMA 
12.5 mg/L
Groups 4: NDMA 6 or 12.5 mg/L + Ov 12, 
25, 50 or 100 MC  
Total n=280
Groups 4: CCA: 4/10, 7/10, 9/15, 
13/19, 8/15, 10/17, 16/19, 14/15 in 
NDMA+Ov, respectively
p <0.01, all groups 4 



























Dosing regimen,  
Animals/group at start




Thamavit et al. 
(1987b)
OV 60 MC, NDEA 10, 20 or 40 mg/L in 
drinking-water for 12 wk
Hamsters in group 3 showed high 
incidence of cholangiofibrosis. 
One CCA observed in Group 3 
(OV+NDEA20)
Group 1: Untreated control [n=20] Group 1: 0/20
Group 2: Ov only [n=20] Group 2: 0/20
Groups 3: Ov + NDEA (4 wk later) 
[n=20–30]
Groups 3: hepatocellular nodules, 
12/19 with 2.5 nodules/animal 
(OV+NDEA20), 23/25 with 7.1 
nodules/animal (Ov+NDEA40).
[p<0.01]a, [p<0.01]
Groups 4 NDEA only [n=20–25] 
[Total n= 180]
Groups 4: 3/19 with 0.2 nodules/







Ov 100 MC, NDHDPA 1000 mg/kg bw 
(two i.p. injections at 2 wk intervals) 2 wk 
later
Group 1: Ov 100 MC + NDHDPA Group 1: CCA, 6/19; liver 
neoplastic nodules, 9/19
p <0.05; p <0.01 (versus 
Group 2)
Initial number of animals not 
specified
Group 2: DHPN Group 2: CCA, 0/20; liver 
neoplastic nodules, 0/20
Group 3: Ov 100 MC Group 3: CCA, 0/14; liver 
neoplastic nodules, 0/14


























Dosing regimen,  
Animals/group at start




Thamavit et al. 
(1988b)
Ov 100 MC, 0.1% Sodium nitrite and 0.1% 
aminopyrine in the drinking-water for 
8–12 wk
Group 8 and 4: 
8/18, 2/17 hepatocellular nodules 
and 14/18, 3/17 CCA, respectively; 
no tumours observed in group 1, 2, 
3, 5, 6 and 7
P<0.05 (versus Group 
4) and 
P<0.01 (versus Group 4)
Prior infection with Ov induced 
more inflammation and bile duct 
proliferation and is associated with 
a higher incidence of hepatocellular 
nodule, cholangiofibrosis and CCA
Group 1: Untreated control
Group 2 0.1% Sodium nitrite
Group 3: 0.1% Aminopyrine
Group 4: Sodium nitrite and Aminopyrine
Group 5: Ov 100 MC
Group 6: Ov 100 MC + sodium nitrite (4 
wk later)
Group 7: Ov 100 MC + aminopyrine (4 wk 
later)
Group 8: OV 100 MC + sodium nitrite and 





Moore et al. 
(1991)
Ov 80 MC, NDHDPA 500 mg/bw (3 i.p. 
injections at 1 wk interval) 16 wk later
Group 1: OV 80 MC + NDHDPA (n=40) Group 1: CCA, 8/16 [p=0.001]a (versus 
Group 2)
Group 2: NDHDPA (n=30) Group 2: CCA, 0/16
Group 3: Ov 80 MC (n=20) Group 3: CCA, no tumours
Group 4: Untreated control (n=10) Group 4: CCA, no tumours


























Dosing regimen,  
Animals/group at start




Thamavit et al. 
(1993)
NDHDPA 1000 mg/kg bw (i.p.) at 2 wk 
intervals, Ov 60 MC, PZ 250 mg/kg bw 
suspended in corn oil at Weeks 4, 12 or 20
CCA: P<0.05 (between 
Group 1 and Group 
4); [p=0.024 between 
Group 4 and 5]a
It was found that whereas 
praziquantel administration at the 
later two time points was ineffective 
at reducing cholangiocellular 
lesions. Significant reduction only 
being evident in hamsters treated 
4 wk after parasite infestation. 
The findings thus indicate that 
promotion of DHPN-initiated 
bile duct carcinogenesis by 
opisthorchiasis is both rapid and to a 
large degree irreversible
Group 1: 4/22 (18%)
Group 2: 6/22 (28%)
Group 3: 10/16 (63%)
Group 1: NDHDPA +Ov+PZ(4) Group 4: 8/16 (50%)
Group 2: NDHDPA +Ov+PZ(12) Group 5: 0/15
Group 3: NDHDPA +Ov+PZ(20) Group 6: 2/18 (11%)
Group 4: NDHDPA +Ov Group 7: 0/15
Group 5: NDHDPA HCC:
Group 6: Ov Group 1: 1/22 (5%)
Group 7: Untreated Group 2: 1/22 (5%)










Ov 80 MC, NDMA 20 mg/kg bw i.p. 
injection
Group 1:  
19/43, CCA; 
15/43, mucinous cystadenomas; 
2/43, HCC. 
No such tumours in Group 2 
(0/20), 3 (0/15) and 4 (0/15).
[p <0.001]a, [p <0.005], 
[NS]
Group 1: NDMA + Ov (19 d later) (n=50)
Group 2: NDMA (n=25)
Group 3: Ov (n=15)

























Dosing regimen,  
Animals/group at start





Jang et al. 
(1990)
Cs 60 MC, NDMA 25 mg/L in the 
drinking-water for 8 wk
0/101 No malignant tumours seen in 
the rat model. Animals infected 
before NDMA administration had 
significantly (p < 0.05) increased 
numbers of glutathione S-transferase 
P-positive liver foci. No such 
effect was seen when animals were 
infected during or after exposure to 
NDMA
Group 1 Cs + NDMA (4 wk later) (n=20)
Group 2: Cs + NDMA at the same time 
(n=20)
Group 3: NDMA + Cs 1 wk later (n=20)
Group 4: NDMA (n=19)
Group 5: Cs (n=10)







2-AAF 0.03% in the diet for 40 wk, Cs 40 
MC
CCA: In group 1, of 11 animals with liver 
tumours, 5 had metastases. No 
metastases were observed in Group 2Group 1: 2-AAF + Cs (n=60) Group 1: 11/14 animals that lived 
beyond Week 25
p<0.05






Lee et al. 
(1993)
NDMA 15 mg/L in the drinking-water for 
8 wk, Cs 10 MC.
In the hamsters that received either 
DMN or C. sinensis alone, the livers 
showed only hyperplastic changes of 
the bile duct epithelial cells
Group 1: NDMA + Cs 10 MC (7 d later) 
(n=12)
Group 1: 6/8 CCA and 8/8 
cholangiofibromas
[p<0.001]a, CCA and 
cholangiofibromas
Group 2: NDMA (n=12) Group 2: 2/12 cholangiofibromas
Group 3: Cs (n=12) Group 3: 0/12
Group 4: Untreated control (n=12) Group 4: 0/12
Total n=48


























Dosing regimen,  
Animals/group at start





Lee et al. 
(1994)
NDMA 15 mg/L in the drinking-water for 
4 wk, Cs 15 MC, Praziquantel 200 mg/kg 
bw daily for 3 d
CCA: Synergistic effect of Clonorchis 
infection and NDMA promoted the 
development of CCA
Group 1: NDMA+ Cs (1 wk later) + 
praziquantel (5 wk later)
Group 1: 3/15 [p<0.001]a, versus all 
groups
Group 2: Cs (5 wk) + Praziquantel + 
NDMA (3 d later after treatment with 
praziquantel)
Group 2: 0/15
Group 3: Cs + NDMA at the same time Group 3: 11/15
Group 4: NDMA alone Group 4: 0/15
Group 5: Cs alone Group 5: 0/15
Group 6: Untreated control Group 6: 0/15





Wang et al. 
(1994)
Cs 20 MC, NDMA 25 mg/L in the drinking 
water for 17 wk (30 d later)
The authors concluded that 
C. sinensis “may” promote the 
formation of HCC though the 
comparison between Group A and B 
is not significant. Only one CCA in 
Group A.
HCC; CCA
Group A: Cs + NDMA Group A: 4/11; 1/11 [NS]a
Group B; NDMA Group B: 3/15; 0/15
Group C: Cs Group C: 0/12; 0/12
Group D: Untreated Group D: 0/15; 0/15
a Fisher Exact test
2-AAF, 2-Acetylaminofluorene; bw, body weight; CCA, cholangiocarcinoma; Cs, Clonorchis sinensis; d, day or days; DHPN, 2,2’-dihydroxy-di-n-propylnitrosamine;DMN, 
dimethylnitrosamine; HCC, hepatocellular carcinoma; i.p., intraperitoneal; MC, Metacercariae; NDHDPA, N-Nitrosodihydroxidi-n-propylamine; NDMA, N-Nitrosodimethylamine; 
NR, not reported; NS, not significant; Ov, Opisthorchis viverrini; PZ, Praziquantel; SAR, Special Administrative Region;. wk, week or weeks
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Similar experiments were also performed 
following C. sinensis infection in combina-
tion with 2-acetylaminofluorene or N-nitroso 
compounds (N-nitrosodimethylamine or 
N-nitrosodihydroxydi-n-propylamine) in 
hamsters (Iida, 1985; Lee et al., 1993, 1994; Wang 
et al., 1994), and rats (Jang et al., 1990). Three of 
these (Iida, 1985; Lee et al., 1993, 1994) supported 
the role of C. sinensis in promoting cholangio-
carcinoma in hamsters.
See Table 3.1.
4. Other Relevant Data
4.1 Pathological changes in vivo
The main histopathological features of liver 
fluke infection both in man and the rodent 
models are inflammation, epithelial desquama-
tion, epithelial and adenomatous hyperplasia, 
goblet cell metaplasia, periductal fibrosis, and 
granuloma formation. Liver fluke infection in 
humans may also result in cholangiocarcinoma, 
but not in rodents unless they are also given a 
chemical carcinogen (IARC, 1994; Sripa, 2003; 
Rim, 2005; Sripa et al., 2007; see also Section 3).
Liver fluke antigens stimulate both inflam-
matory and hyperplastic changes in the bile 
ducts. The liver fluke excretes or secretes meta-
bolic products from the tegument and excretory 
openings into the bile in vivo or culture medium 
in vitro, some of which are highly immuno-
genic (Wongratanacheewin et al., 1988; Sripa & 
Kaewkes, 2000; Choi et al., 2003). The metabolic 
products themselves, apart from inducing host 
immune responses, may be toxic to or interact 
with the biliary epithelium (Sripa, 2003). Sripa 
& Kaewkes (2000) demonstrated that O. viver-
rini excretory–secretory (ES) antigens can be 
detected in both the parasite and biliary epithe-
lium. The presence of O. viverrini ES antigens in 
the biliary epithelium in association with severe 
inflammation has also been seen in the small 
bile ducts, which the flukes cannot inhabit (Sripa 
& Kaewkes, 2000). Hong et al. (1993) observed 
strong stimulation of the proliferation of bile 
duct epithelial cells located at the base of the 
mucosal layer in Sprague-Dawley rats infected by 
C. sinensis. This finding was directly related to 
hyperplasia of the bile duct epithelium that may 
have been due to direct and local stimulation by 
C. sinensis.
4.2 Carcinogenicity of liver fluke 
infections
4 .2 .1 Cell proliferation in vitro
Adult O. viverrini worms were co-cultured 
with mouse NIH-3T3 fibroblasts. Even though 
worms and fibroblasts were separated by 
Transwell membrane, fibroblast proliferation 
was stimulated more than 4-fold. Moreover, O. 
viverrini ES products increased cell proliferation 
by stimulating the expression of phosphoryl-
ated retinoblastoma (pRB) and cyclin D1, the 
key proteins in driving cells through the G1/S 
transition point of the cell cycle. This led to 
the induction of cells going into the S-phase of 
the cell cycle (Thuwajit et al., 2004). In similar 
experiments with C. sinensis, ES products, and 
the human embryonic kidney epithelial cell line 
HEK293, the ES products induce HEK293 cell 
proliferation, associated with the upregulation of 
cyclin E and the transcription factor E2F1 (Kim 
et al., 2008a). Furthermore, C. sinensis ES prod-
ucts upregulate the phosphorylation of pRB and 
N-nitrosodimethylamine (NDMA) upregulates 
cyclin-dependent kinases, and both synergis-
tically drive the cells to proliferate (Kim et al., 
2008b). An anti-apoptotic effect of C. sinensis 
ES products in human cholangiocarcinoma cells 
has been reported (Kim et al., 2009).
Gene microarrays were used to explore 
transcriptional changes induced in NIH-3T3 
murine fibroblasts co-cultured with O. viver-
rini ES products. mRNAs encoding certain 
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growth-promoting proteins such as transforming 
growth factor (TGF), PKC, EPS 8 and TGF-β 
1I4, that are downstream of epidermal growth 
factor (EGF) or TGF-β-mediated signalling, were 
found to be overexpressed (Thuwajit et al., 2006). 
Moreover, human cholangiocarcinoma cell line 
(KKU-100) underwent excessive proliferation 
upon stimulation with O. viverrini worms (Sripa, 
2003). The promotion of proliferation in vitro is 
consistent with the histopathological findings of 
hyperplasia of biliary epithelial cells in opisthor-
chiasis and clonorchiasis (Bhamarapravati et al., 
1978; Sripa & Kaewkes, 2000; Rim, 2005).
4 .2 .2 Oval cell proliferation and 
differentiation in vivo
Oval cells are typically seen in response to 
certain liver injuries, and more than likely repre-
sent progenitor cells with the potential to differ-
entiate along biliary or hepatocytic lineages, 
including into hepatic neoplasms (Sell & Leffert, 
2008). Lee et al. (1997) reported the appearance 
of increased numbers of periductal oval cells in 
the portal and/or periportal areas of hamster 
liver infected with C. sinensis and administered 
NDMA. 
4 .2 .3 DNA damage and adduct formation in 
vivo
Diffuse nitrosative and oxidative DNA 
damage (8-nitroguanine and 8-oxo-7, 8-dihydro-
2′-deoxyguanosine [8-oxodG]) has been reported 
in the biliary epithelium of hamsters infected 
with O. viverrini (Pinlaor et al., 2003). These 
DNA lesions still persisted for at least 180 days 
post-infection. Moreover, repeated infections 
with liver flukes result in enhanced biliary DNA 
damage (Pinlaor et al., 2004a, b). This may be 
explained by the fact that repeated infection 
increased inducible nitric oxide synthase (iNOS) 
expression in the bile duct epithelium. The DNA 
damage in infected biliary cells is probably a result 
of the inflammatory response caused by O. viver-
rini because 8-nitroguanine and 8-oxodG disap-
pear after praziquantel treatment (Pinlaor et al., 
2006). However, in promoting parasite antigen 
dispersal, treatment with praziquantel may tran-
siently increase inflammation, in association 
with increased NF-κB and iNOS expression in 
the bile duct epithelium and inflammatory cells, 
and elevated levels of plasma nitrate, of end-
products of nitric oxide, and of malondialdehyde 
in the treated hamsters (Pinlaor et al., 2008).
Individuals infected with O. viverrini also 
show evidence of oxidative DNA damage. Urinary 
8-oxodG levels were significantly higher in O. 
viverrini-infected patients (4.45 ± 0.25 µg/g creati-
nine) than in healthy subjects (3.03 ± 0.24 µg/g 
creatinine; P < 0.01). This level decreases signifi-
cantly 2  months after praziquantel treatment, 
and is comparable with levels in healthy subjects 
1  year after treatment. Urinary 8-oxodG levels 
were significantly correlated with leukocyte 
8-oxodG levels (Thanan et al., 2008).
The excretion of lipid peroxida-
tion-derived etheno DNA adducts – 
1,N6-etheno-2’-deoxyadenosine (εdA) and 
3,N4-etheno-2’-deoxycytidine (εdC) – was meas-
ured in urine samples collected from healthy 
volunteers and O. viverrini-infected Thai subjects. 
Mean excreted εdA and εdC levels were 3–4 
times higher in the urine of O. viverrini-infected 
patients and correlated with an increased level 
of urinary malondialdehyde, urinary nitrate/
nitrite, and plasma alkaline phosphatase. After 
fluke elimination by treatment with prazi-
quantel, the level of the two etheno adducts, 
malondialdehyde, nitrate/nitrite, and alkaline 
phosphatase was decreased. The promutagenic 
DNA etheno adducts that are thought to derive 
from bile duct epithelial cells may increase the 
risk of developing cholangiocarcinoma in O. 
viverrini-infected patients. This study highlights 
the biomarker potential of urinary εdA and εdC 
levels as non-invasive risk markers for developing 
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opisthorchiasis-related cholangiocarcinoma 
(Dechakhamphu et al., 2008).
[The Working Group noted that all the 
studies described above relate to O. viverrini; 
studies regarding DNA damage in response to 
C. sinensis infection were not available to the 
Working Group.]
4.3 Gene mutation, methylation, 
and altered expression in 
cholangiocarcinoma
4 .3 .1 O . viverrini-endemic areas
Differences in Ki-RAS mutational status 
have been described when comparing cholan-
giocarcinoma from Japanese patients (where 
fluke infections are very rare) with those from 
cholangiocarcinoma arising in patients living in 
areas of Thailand endemic for O. viverrini (the 
incidence of Ki-RAS mutation was higher in Thai 
patients) (Kiba et al., 1993). Hypermethylation 
of the promoter of the DNA mismatch repair 
enzyme hMLH1 has also been shown in another 
group of Thai patients (Limpaiboon et al., 2005). 
However, these studies did not specifically docu-
ment liver fluke infection status in the two groups 
of patients.
Gene microarray transcriptional profiling 
of cholangiocarcinoma from Japanese versus 
Thai patients (again without certain knowledge 
of liver fluke status) led Jinawath et al. (2006) to 
propose a signature of O. viverrini-associated 
cholangiocarcinoma with an elevated expres-
sion of genes involved in xenobiotic metabolism 
(UGT2B11, UGT1A10, CHST4, SULT1C1) in cases 
from Thailand, but a lower expression of genes 
related to growth-factor signalling (TGFBI, PGF, 
IGFBP1, IGFBP3).
4 .3 .2 Studies in experimental animals
Few mutations of the Ki-RAS gene were 
observed in O. viverrini–NDMA-induced chol-
angiocarcinomas in hamsters (Tangkawattana 
et al., 2008), but TP53 overexpression was reported 
in nearly all O. viverrini-induced hamster chol-
angiocarcinomas (Tesana et al., 2000).
Loilome et al. (2006) investigated the 
molecular mechanism of O. viverrini–NDMA-
induced cholangiocarcinogenesis in hamsters 
by using fluorescence differential display-PCR, 
and found 23 upregulated and one downregu-
lated transcripts among 149 differentially ampli-
fied bands. Among the upregulated genes in the 
liver was the signal transduction protein kinase 
A regulatory subunit Iα (Prkar1α), which was 
significantly higher in cholangiocarcinoma and 
its precursor lesion when compared with normal 
liver and normal gallbladder epithelia (P < 0.05). 
Prkar1 expression tended to increase along 
with the progression of biliary transformation 
from hyperplasia and precancerous lesions to 
carcinoma.
4.4 Host immune system and genetic 
susceptibility
Tesana et al. (2000) explored the role of immu-
nization in hamsters administered a subcarcino-
genic dose of NDMA with O. viverrini infection. 
Pre-immunization with a crude somatic fluke 
antigen accelerated carcinogenesis at 30 weeks 
(71%) compared with the non-immunized group 
(20%), suggesting that an increased immune 
response to liver fluke antigens may increase the 
susceptibility of developing cholangiocarcinoma.
The relationship between immune responses 
to infection with O. viverrini and the synthesis 
of the carcinogen NDMA, nitric oxide (NO) 
and nitrosation of amines in humans has been 
described. The intake of exogenous nitrate and 
nitrite was minimized and assessments were 
carried out before and 4 months after elimination 
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of the infection with praziquantel treatment. No 
variation was observed in the amount of NDMA 
excreted in the urine between the control, 
moderate and heavy liver-fluke-infected groups 
(n = 40–50 subjects per group). However, during 
active infection, a strong negative association 
was observed between in vitro lymphoprolifera-
tive responses to some liver fluke antigens and 
NDMA excretion. This association was reduced 
after praziquantel treatment. Multivariate statis-
tical models revealed a highly significant rela-
tionship between NDMA levels and urinary 
nitrate, stimulation indices for two T-cell 
responses to two parasite antigens (molecular 
weight, 37  kDa and 110  kDa), and gallbladder 
dimensions. NDMA levels after treatment were 
best described by the ratio between parasite-
specific IgG2 and IgE, background levels of 
T-cell proliferation, a urinary marker of nitro-
sation (N-nitrosothioproline), and a normal 
level of alcohol consumption. Thus, individual 
background immunological activity, parasite-
specific responses and/or parasite products and 
NO synthesis may all be determinants of endog-
enous generation of nitrosamines in O. viverrini-
infected humans (Satarug et al., 1998).
In the only study of host genetic polymor-
phisms, a population-based case–control study in 
Thailand failed to show any association between 
glutathione S-transferase polymorphisms and 
cholangiocarcinoma risk (Honjo et al., 2005).
4.5 Synthesis
Although liver fluke ES products may stimu-
late cell proliferation and anti-apoptosis directly, 
liver-fluke-induced cholangiocarcinoma is 
more likely the result of chronic inflammation 
(Holzinger et al., 1999; Sirica, 2005; Kawanishi 
& Hiraku, 2006), involving the activation of 
oxidative stress pathways. Studies on O. viverrini 
provide most of the mechanistic data.
5. Evaluation
There is sufficient evidence in humans 
for the carcinogenicity of chronic infec-
tion with Opisthorchis viverrini. Chronic 
infection with Opisthorchis viverrini causes 
cholangiocarcinoma. 
There is sufficient evidence in humans for 
the carcinogenicity of chronic infection with 
Clonorchis sinensis. Chronic infection with 
Clonorchis sinensis causes cholangiocarcinoma.
There is limited evidence in experimental 
animals for the carcinogenicity of infection with 
Opisthorchis viverrini.
There is limited evidence in experimental 
animals for the carcinogenicity of infection with 
Clonorchis sinensis.
Chronic infection with Opisthorchis viverrini 
is carcinogenic to humans (Group 1).
Chronic infection with Clonorchis sinensis is 
carcinogenic to humans (Group 1).
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Schistosoma haematobium was considered by a previous IARC Working Group in 1994 (IARC, 
1994). Since that time, new data have become available, these have been incorporated into 
the Monograph, and taken into consideration in the present evaluation.
1. Exposure Data
1.1 Taxonomy, structure, and biology
1 .1 .1 Taxonomy
Schistosomes are parasitic blood-dwelling 
fluke worms belonging to the genus Schistosoma; 
family, Schistosomatidae; order, Digenea; class, 
Trematoda; phylum, Plathyhelminths; and 
kingdom, Animalia. The genus Schistosoma 
contains six species that are of major pathological 
importance to man, Schistosoma haematobium 
(S. haematobium), S. mansoni, S. japonicum, 
S. mekongi, S. intercalatum, and S. guineensis 
(Webster et al., 2006). The species differ in their 
final location in the human host, the species of 
the intermediate (snail) host they use in their 
life cycle, the pathology they induce, and the 
number, size and shape of the eggs they produce. 
This Monograph is restricted to S. haematobium.
1 .1 .2 Structure
Unlike all other pathologically important 
trematodes, schistosomes are not hermaphro-
ditic, but have separate sexes. The adult worms 
are 1–2  cm long with a cylindrical body that 
features two terminal suckers, a complex tegu-
ment, a blind digestive tract, and reproductive 
organs. The male’s body forms a groove or 
gynaecophoric channel, in which it holds the 
longer and thinner female. As permanently 
embraced couples, the schistosomes live within 
the perivesical (S. haematobium) or mesenteric 
(other species) venous plexus. Schistosomes feed 
on blood particles through anaerobic glycolysis 
(Rumnajek, 1987).
1 .1 .3 Structure of the genome
The genome of S. mansoni is currently being 
sequenced and is almost completed; an Expressed 
Sequence Tag (EST) sequencing project has also 
started for S. japonicum, and S. haematobium 
(El-Sayed et al., 2004).
1 .1 .4 Life cycle and biology of the worm
The life cycle of S. haematobium is illustrated 
in Fig.  1.1. The female S. haematobium worm 
produces hundreds of eggs per day throughout 
her life. The eggs (144x58  µm, with a charac-
teristic terminal spine) penetrate through the 
bladder wall where they are excreted with urine. 
Each ovum contains a ciliated larva (mira-
cidium), which secretes proteolytic enzymes 
that help the eggs migrate into the lumen of 
the bladder. About half of the eggs produced 
do not reach the vesical lumen, and are carried 
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away with the bloodstream, and/or trapped 
in the tissues. These retained eggs provoke a 
granulomatous inflammatory response, which 
is the main cause of pathology in the human 
host. The excreted eggs hatch if they come into 
contact with water, and release the miracidium. 
These remain viable for up to 48 hours and are 
able to locate a suitable freshwater snail host (i.e. 
Bulinus spp. for S. haematobium) using external 
stimuli such as light and snail-derived chemicals. 
In the snail, asexual multiplication takes place, 
and several generations of multiplying larvae 
(sporocysts) develop. Eventually, these sporo-
cysts produce large numbers of infective larvae 
with a typical bifurcated tail (cercariae). These 
leave the snail at a rate of thousands per day after 
a period of weeks. Shedding of these cercariae 
can continue for months. The cercariae survive 
for up to 72 hours and use water turbulence and 
skin-derived chemicals to locate the human host. 
They attach to and penetrate the human skin 
within 3–5 minutes. They lose their tail, and the 
young parasites (schistosomulae) migrate with 
the bloodstream via the lungs to the liver, where 
they mature into adult worms in the portal vein 
and mate. The paired worms migrate against the 
bloodstream to the perivesicular veins, where 
in a total of 4–7 weeks after infection they start 
producing eggs throughout their adult life. The 
lifespan of an adult worm averages 3–5 years, but 
can be as long as 30 years (Wilkins, 1987). An 
infected person probably harbours an average of 
hundreds (range, 10s–1000s) of worms (Gryseels 
& De Vlas, 1996).
1.2 Epidemiology of infection
1 .2 .1 Prevalence, geographic distribution
Human schistosomiasis is endemic in large 
areas of the (sub)tropics. It has been estimated 
that over 700 million people in 74 countries are 
exposed to the risk of schistosomal infection, and 
almost 200 million were estimated to be infected 
in 2003 (Fenwick, 2006), of which 85% in subSa-
haran Africa. About 95% of the cases are due to 
S. mansoni and S. haematobium infections. S. 
haematobium is endemic in 53 countries, in the 
Middle East and most of the African continent 
(Fig. 1.2; Chitsulo et al., 2000).
 Schistosomiasis is largely an infection 
found in rural areas, but urban schistosomiasis 
is an increasing problem in many countries 
(Mott et al., 1990). Natural streams, ponds and 
lakes are typical sources of infection, but over 
the past few decades, man-made reservoirs and 
irrigation systems, as well as population growth 
and migration, have contributed to the spread of 
schistosomiasis (Gryseels et al., 2006; McManus 
& Loukas, 2008).
Within countries, regions and villages, the 
distribution of schistosomiasis can be very focal, 
depending on variations in snail populations 
and human–water contact behaviour (Gryseels 
& Nkulikyinka, 1988). Also, the distribution 
of schistosomiasis can be highly uneven across 
individuals. The majority of the parasites are 
usually present in a small fraction of the infected 
individuals. Prevalence and intensities of infec-
tion generally show a typical convex-shaped 
curve with a peak at the ages of 5–15 years, and 
a decrease in adults. Sex-related patterns vary in 
relation to behavioural, professional, cultural, 
and religious factors (Jordan & Webbe, 1993).
1 .2 .2 Transmission, and risk factors for 
infection
All Schistosoma infections follow direct 
contact with freshwater-harbouring cercariae 
(see life cycle). Three major factors are respon-
sible for maintaining the transmission of the 
infection: 1) contamination of fresh water with 
excreta containing schistosome eggs, 2) the 
presence of the snail intermediate hosts, and 
3) human contact with water-infested with 
cercariae (Jordan & Webbe, 1993).
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Contact with contaminated freshwater is the 
major risk factor of infection (Jordan & Webbe, 
1993). The main risk groups are school-age chil-
dren, specific occupational groups (fishermen, 
irrigation workers, farmers), and women and 
other groups using infested water for domestic 
purposes (WHO Expert Committee, 2002). 
Many other host-related and environmental risk 
factors have been identified that may affect the 
risk of acquiring schistosome infection, and/or 
influence the distribution, prevalence, intensity 
of infection, morbidity and mortality of schis-
tosomiasis. Among these are genetic factors 
(Quinnell, 2003), behaviour, household clus-
tering (Bethony et al., 2001), climate, immune 
response of the host, and concomitant infections 
(e.g. hepatitis) (IARC, 1994).
373
Figure 1.1 Life cycle of Schistosoma haematobium
 
A: paired adult worms; B: egg; C: miracidium; D: intermediate snail host; E: cercariae
Courtesy of Pr. Bruno Gryseels, Institute for Tropical Medicine, Antwerp, Belgium.
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1 .2 .3 Persistence, latency, and natural history 
of infection
(a) Persistence
Schistosome worms do not multiply in the host. 
The infection status is the result of an accumula-
tion of consecutive infections, where individuals 
with the most intense infections usually have a 
higher risk of developing morbidity (Gryseels 
et al., 2006). In the absence of re-infection, the 
infection subsides when the schistosome worm 
dies, which is usually after 3–5 years. However, 
in endemic areas with continuous exposure, 
re-infection is the rule rather than the exception. 
In highly endemic areas, children start to accu-
mulate worms as soon as they are old enough to 
have contact with water and may, because of the 
chronic nature of the infection and continued 
susceptibility to re-infection, remain infected 
throughout their lives.
The possibility that adults might develop 
immunity to schistosome infections was initially 
suggested based on the shape of the age–intensity 
curve in endemic communities, which character-
istically shows a rise in intensity during the first 
two decades of life, followed by a decline in adults 
to very low levels (Butterworth, 1998). Indeed, 
numerous studies have provided epidemiological 
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Figure 1.2 Global distribution of Schistosoma haematobium
 
Main foci Schistosoma haematobium: found mainly in sub-Saharan Africa, Nile valley in Egypt and Sudan, the Maghreb, and the Arabian 
peninsula.
Courtesy of Pr. Bruno Gryseels, Institute for Tropical Medicine, Antwerp, Belgium.
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and clinical evidence that people living in 
endemic areas acquire some form of protective 
immunity after years of exposure. However, age-
related innate resistance mechanisms may also 
play an important part in the epidemiology of 
schistosomiasis (Butterworth, 1993; Gryseels 
et al., 2006).
(b) Latency and natural history
Not much is known about the latency 
between the onset of infection and the appear-
ance of cancer, nor about the steps that might 
lead to cancer.
Infection with S. haematobium is not synon-
ymous with clinical disease, and many infections 
are asymptomatic. Of those infected, a small 
proportion develops serious chronic disease, 
after varying durations of exposure and infec-
tion (Homeida et al., 1988; Vennervald & Dunne, 
2004). Mostafa et al. (1999) noted that the inci-
dence of bilharzial bladder cancer in various 
African countries peaks between the ages of 
40–49 years, while infection with S. haemato-
bium begins in childhood (as early as 6 months 
of age), and peaks usually in the second decade of 
life (between the ages of 5–15 years). This would 
imply a latency period of 20–30 years.
2. Cancer in Humans
2.1 Cancer of the urinary bladder
Earlier studies reported in the previous IARC 
Monograph (IARC, 1994) have supported an 
association between the occurrence of urinary 
bladder cancer and S. haematobium infection 
(for more recent reviews, see for example Badawi 
et al., 1995; Mostafa et al., 1999; Mayer & Fried, 
2007). A substantial number of descriptive studies 
from Africa have shown that: the estimated inci-
dence of urinary bladder cancer was higher in 
areas with a high prevalence of S. haematobium 
infection than in areas with a low prevalence; the 
estimated incidence of urinary bladder cancer 
was related to the proportion of cancerous 
urinary bladder specimens containing S. haema-
tobium eggs or egg remnants; the sex ratio of 
urinary bladder cancer cases varied widely and 
corresponded to the relative involvement of men 
and women in agricultural work (a risk factor 
for S. haematobium infection); and squamous 
cell cancers of the urinary bladder were propor-
tionately more common in populations with 
a high prevalence of S. haematobium infection 
and a high proportion of urinary bladder cancers 
showing histological evidence of infection than 
in areas without these characteristics.
A large number of case series and case reports 
have repeatedly emphasized the prevalence of 
squamous cell urinary bladder tumours among 
patients with evidence of schistosomal infec-
tion. Clinically, the most notable and consistent 
feature described was the relatively young age of 
the cases that had evidence of a link to S. haema-
tobium infection (IARC, 1994).
A more recent descriptive study by Groeneveld 
et al. (1996) on the incidence of different histo-
logical types of bladder cancer in various racial 
groups living within the same geographic area 
of Kwazulu-Natal, South Africa, reported similar 
results: squamous cell carcinoma occurred in 53% 
of the African patients (who have, according to 
the authors, a much higher risk of exposure and 
infestation to S. haematobium due to socioeco-
nomic, cultural and educational factors), and in 
2% of the Caucasian patients. Moreover, eggs of S. 
haematobium were seen in microscopic sections 
of the bladder tumour in 85% of the patients 
with squamous cell carcinoma, and in 10% of 
the patients with transitional cell carcinoma. 
[The Working Group noted that no mention is 
made of the percentages of S. haematobium ova 
in microscopic sections of African patients with 
bladder cancer of the squamous-cell-carcinoma 
type]. 
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The mean age at presentation of African 
patients was at least 20 years younger than that 
of Caucasian patients.
Table 2.1 (available at http://monographs.
iarc.fr/ENG/Monographs/vol100B/100B-09-
Table2.1.pdf) summarizes the case–control 
studies on the association between S. haemato-
bium infection and urinary bladder cancer. A total 
of 7/8 case–control studies showed significant, 
positive associations between the occurrence 
of urinary bladder cancer and infection with 
S. haematobium, with estimated risks ranging 
from 2–15. The most recent study, from Egypt 
(Bedwani et al., 1998), found that the odds ratio 
(OR) for urinary schistosomiasis was higher in 
subjects who were younger at first diagnosis (OR, 
3.3 for <15 years), and with a long time since first 
diagnosis (OR, 3.0 for ≥35 years), suggesting a 
duration–risk relationship and a long-term effect 
of urinary schistosomiasis on bladder cancer 
(Bedwani et al., 1998).
At the time of writing, no cohort studies on 
urinary bladder cancer and S. haematobium 
infections have been reported.
In contrast to some of the earlier case–control 
studies, all studies after 1994 considered possible 
confounding by age, sex, and smoking.
In one study that considered tobacco smoking 
as a confounding factor (Parkin et al., 1994), no 
significant effect was observed due to tobacco 
smoking (OR, 1.1 for squamous cell bladder 
tumours).
In a study of schistosomiasis and the risk of 
bladder cancer in Egypt, Bedwani et al. (1998) 
assessed the interaction of history of urinary 
schistosomiasis with smoking. The interaction 
was significant (P<0.01), with an odds ratio of 
15.8 (95%CI: 5.1–48.4), and odds ratios for schis-
tosomiasis only and for ever smoking only were 
11.8 (95%CI: 2.8–50.1) and 13.8 (95%CI: 4.7–40.1), 
respectively.
2.2 Others
A number of studies have been conducted on 
the association of S. haematobium infection with 
other cancers, the results of which are summa-
rized per cancer site below.
2 .2 .1 Cancers of the female genital tract
Other than urinary bladder cancer, cervical 
cancer and other malignancies of the female 
genitalia have been the most frequently reported 
cancers in association with S. haematobium 
infection, usually in the form of case reports 
(IARC, 1994). Recently, a number of additional 
cases of female genital malignancy in association 
with evidence of S. haematobium infection have 
been published (e.g. North et al., 2003; Chenault 
& Hoang, 2006).
Two cross-sectional, one case–control and 
one pooled reanalysis studies have been published 
on the association between S. haematobium and 
cervical cancer (Wright et al., 1982; Moubayed 
et al., 1994; Parkin et al., 1994; Riffenburgh et al., 
1997; Table 2.2, available at http://monographs.
iarc.fr/ENG/Monographs/vol100B/100B-09-
Table2.2.pdf). Parkin et al. (1994) consulted the 
same cancer registry from Zimbabwe as previ-
ously described for bladder cancer (Vizcaino 
et al., 1994). Riffenburgh et al. (1997) pooled 
the data from the two earlier published studies. 
None of these studies showed a positive asso-
ciation between the risk for cervical cancer and 
infection with S. haematobium. [The Working 
Group noted that possible confounding by age, 
smoking, or human papillomavirus (HPV) was 
not considered in any of the studies.]
2 .2 .2 Other cancers
Eight cases of prostatic schistosomiasis asso-
ciated with adenocarcinoma of the prostate have 
been reported, three of which were associated 
with S. haematobium, the others with S. mansoni 
or the parasite species was not specified (Cohen 
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et al., 1995; Bacelar et al., 2007). Cohen et al. 
(1995) reported on three patients in South Africa 
(27–29 years of age) with advanced prostate 
cancer associated with the presence of multiple 
eggs of S. haematobium (some viable and others 
calcified).
Other malignancies that have been reported 
in association with S. haematobium infection 
include: squamous cell cancer of the female 
genitals, ovarian cystadenocarcinoma, teratoma 
and Brenner tumours, uterine leiomyosarcoma, 
male breast cancer, hepatocellular carcinoma, 
lymphoma, bladder sarcoma, rectal carcinoid 
tumour, and renal cell carcinoma. The number 
of patients with each malignancy is usually 
small, which precludes any evaluation of the data 
(IARC, 1994; Mayer & Fried, 2007).
2.3 Impact of Schistosoma eradication
Although several authors have suggested 
prevention or control of S. haematobium as a way 
to manage schistosomiasis-associated bladder 
cancer (Badawi et al., 1995; Groeneveld et al., 
1996; Mostafa et al., 1999; Mayer & Fried, 2007), 
no such intervention study has been published 
so far. Some studies have investigated the effect 
of praziquantel, the drug of choice for the treat-
ment of urinary schistosomiasis, on lesions in the 
urinary and genital tract (Richter, 2003; Kjetland 
et al., 2006).
In a recent study of schistosomiasis-associated 
bladder cancer conducted in Egypt (Koraitim 
et al., 1995), both the proportion of transitional 
cell carcinoma (31% in 1960s versus 42% in late 
1980s) and mean age at diagnosis (47 in 1960s 
versus 53 in late 1980s) in Schistosoma-positive 
cases had increased over time. Lower levels of 
schistosome infection (based on the number of 
eggs in the bladder wall) were observed among 
patients with bladder cancer in the late 1980s 
when compared to patients in the 1960s, which 
is likely to result from national efforts to control 
schistosomiasis and the availability of new drugs 
with minimal side-effects (Koraitim et al., 1995). 
Transitional cell carcinomas were slightly more 
common among patients with low infection 
rates (56%), and squamous cell carcinomas were 
slightly more common (58%) among patients with 
moderate-to-high levels of infection (Michaud, 
2007).
3. Cancer in Experimental Animals
Earlier studies reported in the previous IARC 
Monograph on infection with schistosomes 
(IARC, 1994) have examined experimental S. 
haematobium infections in mice, rats, hamsters, 
opossums, and non-human primates.
In mice, hamsters, and opossums, hyper-
plasia of the urinary bladder was observed. 
Urinary bladder tumours were also reported in 
one opossum (IARC, 1994). In several studies 
in non-human primates, hyperplasia and a few 
lesions described as tumours of the urinary 
bladder and ureter were observed. Overall, non-
invasive papillary and nodular transitional cell 
carcinomas of the urinary bladder were observed 
in one talapoin monkey (Cercopithecus talapoin), 
five capuchin monkeys (Cebus apella), and one 
gibbon (Hylobates lar). These types of carci-
nomas were morphologically similar to tumours 
observed in human urinary bladder (IARC, 
1994; Mostafa et al., 1999).
In studies where animals infected with S. 
haematobium were treated with known urinary 
bladder carcinogens, an increase in urinary 
bladder tumour incidence was observed in 
infected mice administered 2-acetylaminoflu-
orene, and in infected baboons (Papio sp.) treated 
with N-butyl-N-(4-hydroxybutyl)nitrosamine. 
The previous IARC Monograph Working Group 
commented on the short duration, the lack of 
verification of infection and inadequate docu-
mentation of experimental details for the study 
in mice, and that some of the diagnostic terms in 
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the report were difficult to interpret in the study 
in baboons (IARC, 1994; Mostafa et al., 1999).
Since then, a new study (Vuong et al., 1996) has 
described histopathological findings following 
experimental S. haematobium infection in ten 
rodents including three marsh rats (Holochilus 
brasiliensis), and seven jirds (four Meriones shawi 
and three M. Unguiculatus). Comparisons were 
made with findings in two infected mice and 
six infected hamsters. All animals were about 
3  months of age, and were exposed to 60–400 
cercariae per animal by transcutaneous exposure 
through water (in an individual bath) containing 
the cercariae, except one marsh rat that received 
750 cercariae transcutaneously on the abdom-
inal skin. Eight rodents died naturally 117–256 
days after infection (three marsh rats, three jirds, 
one mouse and one hamster); the remaining ten 
were sacrificed 100–195 days post infection. One 
marsh rat developed an in-situ squamous cell 
carcinoma of the urinary bladder (175 days post 
infection). Another marsh rat developed precan-
cerous dysplastic changes of the bladder mucosa 
(123 days post infection). Only one jird (Meriones 
shawi) developed squamous metaplasia asso-
ciated with mild-to-moderate dysplasia of the 
urothelial lining (117 days post infection). One 
mouse developed a squamous cell carcinoma of 
the urinary bladder (185 days post infection). No 
neoplastic or preneoplastic lesions were observed 
in the four hamsters.
4. Other Relevant Data
Several reviews have been published on 
the mechanisms of carcinogenesis induced 
by S. haematobium (Rosin et al., 1994a, b; 
Badawi, 1996; Mostafa et al., 1999; Herrera 
& Ostrosky-Wegman, 2001; Mayer & Fried, 
2007). Several studies indicate that the carci-
nogenicity of S. haematobium is a multifac-
torial and multistage process where several 
mechanisms are involved. S. haematobium eggs 
induce a chronic inflammation and irritation 
in the urinary bladder that seems to be associ-
ated with an increased initiation of cancer at the 
site of inflammation (Rosin et al., 1994b). The 
inflammatory response around the eggs gives 
rise to genotoxic factors and products that may 
cause genomic instabilities of host cells, leading 
to modifications in the regulation of tumour-
suppressor genes and oncogenes as well as stimu-
lating a proliferative response of the host cells to 
repair tissue damage caused by the inflammation 
(Rosin et al., 1994a; Badawi, 1996). Furthermore, 
schistosomiasis-induced inflammatory cells have 
been shown to participate in the metabolic acti-
vation of procarcinogens, such as aflatoxins, and 
in the formation of carcinogenic nitrosamines 
from nitric oxide (Rosin et al., 1994a; Mostafa 
et al., 1999).
The following is a review of the studies 
published since the previous IARC Monograph 
(IARC, 1994). The majority of the studies were 
conducted on bladder tissue samples from cancer 
patients with and without schistosomiasis.
4.1 Experimental data
4 .1 .1 Studies in vitro
(a) Mutagenicity
Neither worm nor egg extracts were shown to 
exhibit any in vitro mutagenicity by the umu-test 
or the V79/HGPRT assay with or without S9 mix 
(Osada et al., 2005).
(b) Effect on cell proliferation and on cell-cycle 
regulators
The effect of crude soluble egg antigen of S. 
haematobium on urothelial proliferation was 
tested on bovine endothelial cells (Endo), urothe-
lial human transitional-cell carcinoma (J82), 
and human smooth muscle cell lines. Soluble 
egg antigen induced proliferation in a dose-
dependent manner in both Endo and J82 cells 
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but not in smooth muscle cells. Furthermore, 
soluble egg antigen enhanced the expression of 
mRNA for the cell-cycle regulators, peripheral 
cell nuclear antigen and B-cell translocation 
protein (BTG1) in urothelial cells (El-Awady 
et al., 2001).
4 .1 .2 Studies in experimental animals
(a) Mitogenicity and carcinogenesis
The effect of S. haematobium infection and 
low doses of the bladder carcinogen N-butyl-
N-(4-hydroxybutyl)nitrosamine on the devel-
opment of urothelial neoplasia was studied 
in a small group of baboons (Papio sp.). The 
study showed that proliferative and inflamma-
tory changes occurred in infected animals not 
exposed to the carcinogen, whereas the addition 
of nitrosamine treatment induced neoplastic 
changes (carcinoma in situ). The carcinogen 
alone did not produce any changes (Hicks, 1982).
(b) Inhibition of glutathione-S-transferase (GST) 
activity in animals
Inhibition of GST activity may enhance the 
effect of many environmental carcinogens and 
toxic agents. The activity of GST, glutathione 
reductase (GR), and the levels of glutathione and 
free radicals were measured in different organs 
of male hamsters infected with S. haematobium 
2, 4, 6, 8 and 10 weeks post infection. The total 
activity of GST was significantly increased in 
bladder tissue from infected animals when 
compared to uninfected controls 2, 4 and 6 weeks 
post infection (P < 0.001, P < 0.025 and P < 0.001, 
respectively). The GST activity was signifi-
cantly decreased 8 and 10 weeks post infection 
(P < 0.001). The expression of GST isoenzymes 
was reduced in the kidney and bladder tissues at 
later stages (8 and 10 weeks) of the infection, and 
reduced in spleen and liver tissues at all infection 
stages. Free radicals (measured as thiobarbituric 
acid reactive substances) increased to high levels 
in the bladder, and to a lesser extent in other 
organs (Sheweita et al., 2003). [The Working 
Group noted that the number of animals in the 
S. haematobium and the control groups was 
unspecified.]
4.2 Studies in exposed humans
The majority of the data concerning geno-
toxicity linked to S. haematobium infection are 
derived from studies on bladder tissue samples 
from cancer patients with schistosomiasis or a 
history of exposure to schistosomiasis. A repre-
sentative sample covering various mechanisms 
such as DNA adducts, gene methylation, gene 
mutations, chromosomal alteration, expression 
of oncogenes and presence of oxidative stress 
markers are summarized below.
4 .2 .1 Production of N-nitroso compounds
Bacteria from a superimposed bacterial infec-
tion may reduce dietary nitrate to nitrite, which 
may react with compounds in urine to produce 
N-nitroso compounds. In a study in Egypt, higher 
(P=0.01) levels of N-nitroso compounds and 
N-nitrosodimethylamine (NDMA) were found in 
the urine of individuals infected with S. haema-
tobium compared to uninfected controls (Abdel 
Mohsen et al., 1999). [The Working Group noted 
that many of the study participants were smokers, 
that the history of contracting schistosomiasis 
infection was not available, and that the study 
did not include a control group with bacterial 
infection only.]
4 .2 .2 Oxidative stress markers
Levels of 8-hydroxy-2′-deoxyguanosine 
were markedly increased in bladder squamous 
cell carcinomas (P=0.001) and transitional cell 
carcinomas (P=0.045) associated with schisto-
somiasis when compared to non-schistosomi-
asis-associated cancers. This was accompanied 
by strong overexpression of DNA-repair genes 
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8-oxyguanine-DNA-glycosylase (P = 0.0047) and 
apurinic/apyrimidinic endonuclease (P = 0.0121); 
increased formation of DNA single strand breaks 
(P = 0.0106); and higher inducible nitric oxide 
synthase (P = 0.022), when comparing squamous 
cell carcinomas associated with schistosomiasis 
with non-schistosomiasis-associated cancers 
(Salim et al., 2008).
4 .2 .3 DNA adducts
DNA alkylation damage indicated by 
increased levels of O6-methyldeoxyguanosine 
has been demonstrated in tissue samples from 
schistosomiasis-associated bladder cancer 
patients. O6-alkylguanine-DNA alkyltransferase 
(ATase) activity was significantly higher in 
normal bladders than in bladders with cancers 
(P < 0.005). A negative correlation between the 
levels of O6-methyldeoxyguanosine previously 
measured in the same samples and ATase activity 
was demonstrated (r = −0.67; P < 0.001) (Badawi 
et al., 1992, 1994).
Paired samples from bladder tumour tissue 
and tissue without macroscopic signs of tumour 
invasion were collected in Egyptian patients. 
N7-methyldeoxyguanosine 3’-monophosphate 
(N7-MedGp) was measured by 32P post-labelling. 
Levels of N7-MedGp were highly variable both in 
tumour and normal tissue and the mean differ-
ence in adduct levels between tumour and normal 
DNA was statistically significant. N7-MedGp 
levels were not associated with gender, age or 
presence of schistosomiasis (Saad et al., 2006). 
[The Working Group noted that the study had 
limited power with respect to examining the 
effect of schistosomiasis on the level of adducts 
because most of the patients were infected or had 
a history of infection.]
4 .2 .4 Gene methylation index
Methylation-specific polymerase chain reac-
tion showed that schistosomiasis-associated 
bladder cancer samples had more genes meth-
ylated than non-schistosomal bladder cancer 
samples in a study in Egyptian patients (Gutiérrez 
et al., 2004).
4 .2 .5 Deletions and/or mutations in tumour-
suppressor genes or oncogenes
Deletions and mutations in the p16INK4 gene 
were found to be more frequent in schistosomi-
asis-associated bladder tumours from Egypt than 
in other bladder tumours from the Netherlands 
(Tamimi et al., 1996).
Expression of p53, Rb, EGFR and c-erbB-2 
proteins was detected by immunohistochem-
istry and screened by single-strand conforma-
tion polymorphism and mutations in the ras (H, 
N, K) hotspots (12, 13, 61) and p53 (exons 4–9) 
genes. Among 21 invasive bladder squamous 
cell carcinoma cases from South Africa infected 
with S. haematobium, positive staining for p53, 
EGFR and c-erbB-2 was reported in 38%, 67% 
and 28% of the tumours, respectively. Only one 
poorly differentiated tumour showed an absence 
of nuclear Rb staining. Changes in the H-ras 
gene were detected in three squamous cell carci-
noma cases; two of which had mutations in H-ras 
codon 13 (gly→arg). The H-ras change most 
commonly seen in transitional cell carcinoma 
(gly→val change in codon 12) was not seen in any 
of the squamous cell carcinomas examined. The 
detection of multiple mutations at the p53 locus 
in the schistosomiasis-related cancers suggests 
the involvement of a specific carcinogenic agent, 
possibly nitrosamines (Ramchurren et al., 1995).
Mutations in the p53 gene were assessed 
in tissue specimens from 92 Egyptian bladder 
cancer patients from an area hyperendemic for 
schistosomiasis. About 90% of the patients had 
a history of schistosomiasis and/or evidence of 
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schistosome eggs adjacent to the carcinoma. 
Thirty patients had mutations in exons 5–8 of 
the p53 gene. Of 19 mutations in squamous cell 
carcinoma, 16 were base-pair substitutions, two 
were deletions, and one an insertion. All the 
mutations in transitional cell carcinoma were 
base-pair substitutions. Combining the 33 muta-
tions from this study with six obtained from 
another study (Habuchi et al., 1993) of Egyptian 
schistosomiasis-associated squamous cell carci-
noma, a mutational spectrum was compiled 
and compared with a non-schistosomal bladder 
cancer spectrum assembled from 118 muta-
tions reported in the literature. The proportion 
of base-pair substitutions at CpG dinucleotides 
was significantly higher (18/34 versus 25/103, 
P = 0.003) in schistosomiasis-associated bladder 
cancer than in non-schistosomal bladder cancer 
(Warren et al., 1995).
[The Working Group reported that several 
studies compared tumours from schistosomi-
asis-infected patients to those from countries 
not endemic for schistosomiasis (e.g. Shaw et al., 
1999; Swellam et al., 2004a). These studies were 
not reviewed because of the difficulty of ascribing 
differences to schistosomiasis or to other factors 
that vary between these countries.]
4 .2 .6 Expression of oncogenes
A significant correlation was recognized 
between bcl-2 overexpression and bladder squa-
mous cell carcinoma with schistosomiasis. Bcl-2 
expression was 74.8 U/mg protein in squamous 
cell carcinoma and 45.2 U/mg protein in transi-
tional cell carcinoma. It was 82.41 U/mg protein 
in schistosomiasis cases compared to 35.8 U/mg 
protein in non-schistosomiasis cases (Swellam 
et al., 2004b).
4 .2 .7 Biomarkers of bladder cancer
The detection of the biomarkers associ-
ated with bladder cancer BLCA-4 (a nuclear 
matrix protein involved in gene regulation and 
produced only in neoplastic bladder cells) and 
quantitative nuclear grading was performed in 
a population-based study from an area in Ghana 
endemic for S. haematobium. The results showed 
a close correlation between BLCA-4, quantitative 
nuclear grading and severe bladder damage such 
as bladder wall masses and polyps. The overall 
prevalence of BLCA-4 positivity was 40%. A total 
of 62/73 cytopathology Papanicolaou-stained 
smears were seen to have squamous metaplasia 
(Shiff et al., 2006).
4 .2 .8 Effect of S . haematobium infection on 
detoxifying enzymes
S. haematobium infection has been found 
to markedly decrease the activity of the carcin-
ogen-metabolizing enzymes GST and NDMA-
N-demethylase in human bladder cancer tissue 
(Sheweita et al., 2004). [The Working Group noted 
that this may change the capacity of the bladder 
to detoxify many endogenous compounds, and 
may potentiate the effects of bladder carcinogens 
such as N-nitrosamines.]
4.3 Host susceptibility
Cytological abnormalities in urine sediment 
were investigated in a cross-sectional survey of 
a population (1014 individuals aged 1–91 years) 
living in an area in Kenya endemic for S. haema-
tobium. No cancers were detected in the study 
population. The prevalence of inflammation 
(39%), hyperkeratosis (30%), metaplasia (33%) 
and frank atypia (0.4%) was much higher than 
what had been reported from non-endemic 
areas. S. haematobium infection was strongly 
associated with an increased risk of metaplasia or 
hyperkeratosis (relative risk > 2.8-fold, P < 0.001). 
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Among children, the incidence of metaplasia 
was linked with concurrent schistosome infec-
tion, whereas older individuals tended to have 
metaplasia incidences independent of the level 
of infection or inflammation. The incidence of 
moderate or severe metaplasia displayed two age-
related peaks; one among the age group 10–14 
years, where the intensity of infection is highest, 
and a second among individuals over 60 years of 
age (Hodder et al., 2000).
4.4 Synthesis
It is well established that S. haematobium 
with egg deposition in the tissue leads to severe 
inflammation of the urinary bladder wall with 
accumulation of inflammatory cells resulting in 
increased oxidative stress. Overall, the studies 
summarized above suggest that the observed 
increased levels of oxidative stress in the schisto-
somiasis-associated bladder carcinomas correlate 
with genotoxicity and activation of repair genes, 
and point towards a relationship between oxida-
tive stress induced by continuous and chronic 
inflammation due to schistosome infection and 
possibly nitric-oxide-mediated DNA genotox-
icity. The excess of DNA alterations could result 
from nitric oxide produced by the inflammatory 
response provoked by Schistosoma eggs, and 
alkylation of DNA by N-nitroso compounds.
5. Evaluation
There is sufficient evidence in humans for 
the carcinogenicity of chronic infection with 
Schistosoma haematobium. Chronic infection 
with Schistosoma haematobium causes cancer of 
the urinary bladder.
There is limited evidence in experimental 
animals for the carcinogenicity of infection with 
Schistosoma haematobium.
Chronic infection with Schistosoma haema-
tobium is carcinogenic to humans (Group 1).
References
Abdel Mohsen MA, Hassan AAM, El-Sewedy SM et  al. 
(1999). Biomonitoring of n-nitroso compounds, nitrite 
and nitrate in the urine of Egyptian bladder cancer 
patients with or without Schistosoma haematobium 
infection. Int J Cancer, 82: 789–794. doi:10.1002/
(S IC I )10 9 7- 0 215 (19 9 9 0 9 0 9) 8 2 : 6 < 78 9 : : A I D -
IJC3>3.0.CO;2-C PMID:10446442
Bacelar A, Castro LG, de Queiroz AC, Café E (2007). 
Association between prostate cancer and schistoso-
miasis in young patients: a case report and literature 
review. Braz J Infect Dis, 11: 520–522. doi:10.1590/
S1413-86702007000500014 PMID:17962880
Badawi AF (1996). Molecular and genetic events in 
schistosomiasis-associated human bladder cancer: 
role of oncogenes and tumor suppressor genes. Cancer 
Lett, 105: 123–138. doi:10.1016/0304-3835(96)04284-X 
PMID:8697435
Badawi AF, Cooper DP, Mostafa MH et  al. (1994). 
O6-alkylguanine-DNA alkyltransferase activity in 
schistosomiasis-associated human bladder cancer. 
Eur J Cancer, 30A: 1314–1319. doi:10.1016/0959-
8049(94)90180-5 PMID:7999420
Badawi AF, Mostafa MH, Aboul-Azm T et  al. (1992). 
Promutagenic methylation damage in bladder 
DNA from patients with bladder cancer associ-
ated with schistosomiasis and from normal indi-
viduals. Carcinogenesis, 13: 877–881. doi:10.1093/
carcin/13.5.877 PMID:1587002
Badawi AF, Mostafa MH, Probert A, O’Connor PJ (1995). 
Role of schistosomiasis in human bladder cancer: 
evidence of association, aetiological factors, and basic 
mechanisms of carcinogenesis. Eur J Cancer Prev, 
4: 45–59. doi:10.1097/00008469-199502000-00004 
PMID:7728097
Bedwani R, Renganathan E, El Kwhsky F et  al. (1998). 
Schistosomiasis and the risk of bladder cancer 
in Alexandria, Egypt. Br J Cancer, 77: 1186–1189. 
doi:10.1038/bjc.1998.197 PMID:9569060
Bethony J, Williams JT, Kloos H et al. (2001). Exposure 
to Schistosoma mansoni infection in a rural area in 
Brazil. II: household risk factors. Trop Med Int Health, 
6: 136–145. doi:10.1046/j.1365-3156.2001.00685.x 
PMID:11251910
Butterworth AE (1993) Immunology of schistosomiasis. 
In: Human schistosomiasis. Jordan P, Webbe G Sturrock 
RF, editors. Wallingford, UK: 331-366.
Butterworth AE (1998). Immunological aspects of 
human schistosomiasis. Br Med Bull, 54: 357–368. 
PMID:9830202
Chenault C & Hoang MP (2006). An unusual cervical 
finding. Female genital schistosomiasis with associ-
ated cervical severe squamous dysplasia (cervical 
382
Schistosoma haematobium
intraepithelial neoplasia grade III). Arch Pathol Lab 
Med, 130: e37–e38. PMID:16519583
Chitsulo L, Engels D, Montresor A, Savioli L (2000). The 
global status of schistosomiasis and its control. Acta 
Trop, 77: 41–51. doi:10.1016/S0001-706X(00)00122-4 
PMID:10996119
Cohen RJ, Edgar SG, Cooper K (1995). Schistosomiasis 
and prostate cancer. Pathology, 27: 115–116. 
doi:10.1080/00313029500169682 PMID:7567134
El-Awady MK, Gad YZ, Wen Y et al. (2001). Schistosoma 
hematobium soluble egg antigens induce proliferation 
of urothelial and endothelial cells. World J Urol, 19: 
263–266. doi:10.1007/s003450100217 PMID:11550787
El-Sayed NM, Bartholomeu D, Ivens A et  al. (2004). 
Advances in schistosome genomics. Trends Parasitol, 20: 
154–157. doi:10.1016/j.pt.2004.02.002 PMID:15099549
Fenwick A (2006). Waterborne infectious diseases–could 
they be consigned to history? Science, 313: 1077–1081. 
doi:10.1126/science.1127184 PMID:16931751
Groeneveld AE, Marszalek WW, Heyns CF (1996). 
Bladder cancer in various population groups in the 
greater Durban area of KwaZulu-Natal, South Africa. 
Br J Urol, 78: 205–208. PMID:8813914
Gryseels B & Nkulikyinka L (1988). The distribution of 
Schistosoma mansoni in the Rusizi plain (Burundi). 
Ann Trop Med Parasitol, 82: 581–590. PMID:3151430
Gryseels B & De Vlas SJ (1996). Worm burdens in 
schistosome infections. Parasitol Today, 12: 115–119. 
doi:10.1016/0169-4758(96)80671-5 PMID:15275241
Gryseels B, Polman K, Clerinx J, Kestens L (2006). Human 
schistosomiasis. Lancet, 368: 1106–1118. doi:10.1016/
S0140-6736(06)69440-3 PMID:16997665
Gutiérrez MI, Siraj AK, Khaled H et al. (2004). CpG island 
methylation in Schistosoma- and non-Schistosoma-
associated bladder cancer. Mod Pathol, 17: 1268–1274. 
doi:10.1038/modpathol.3800177 PMID:15154012
Habuchi T, Takahashi R, Yamada H et al. (1993). Influence 
of cigarette smoking and schistosomiasis on p53 gene 
mutation in urothelial cancer. Cancer Res, 53: 3795–
3799. PMID:8339293
Herrera LA & Ostrosky-Wegman P (2001). Do helminths 
play a role in carcinogenesis? Trends Parasitol, 
17: 172–175. doi:10.1016/S1471-4922(00)01942-5 
PMID:11282506
Hicks RM (1982). Nitrosamines as Possible Etiological 
Agents in Bilharzial Bladder Cancer. In: Nitrosamines 
and Human Cancer (Banbury Report No. 12). Magee 
PN, editor. Cold Spring Harbor, New York, CSH Press: 
455-471.
Hodder SL, Mahmoud AA, Sorenson K et  al. (2000). 
Predisposition to urinary tract epithelial metaplasia in 
Schistosoma haematobium infection. Am J Trop Med 
Hyg, 63: 133–138. PMID:11388504
Homeida M, Ahmed S, Dafalla A et al. (1988). Morbidity 
associated with Schistosoma mansoni infection as 
determined by ultrasound: a study in Gezira, Sudan. 
Am J Trop Med Hyg, 39: 196–201. PMID:3136674
IARC (1994). Schistosomes, liver flukes and Helicobacter 
pylori. IARC Working Group on the Evaluation of 
Carcinogenic Risks to Humans. Lyon, 7–14 June 1994. 
IARC Monogr Eval Carcinog Risks Hum, 61: 1–241. 
PMID:7715068
Jordan P, Webbe G (1993) Epidemiology. In: Human schis-
tosomiasis. Jordan P, Webbe G Sturrock RF, editors. 
Wallingford, UK: 87-158.
Kjetland EF, Mduluza T, Ndhlovu PD et  al. (2006). 
Genital schistosomiasis in women: a clinical 12-month 
in vivo study following treatment with praziquantel. 
Trans R Soc Trop Med Hyg, 100: 740–752. doi:10.1016/j.
trstmh.2005.09.010 PMID:16406034
Koraitim MM, Metwalli NE, Atta MA, el-Sadr AA 
(1995). Changing age incidence and pathological types 
of schistosoma-associated bladder carcinoma. J Urol, 
154: 1714–1716. doi:10.1016/S0022-5347(01)66763-6 
PMID:7563329
Mayer DA & Fried B (2007). The role of helminth infec-
tions in carcinogenesis. Adv Parasitol, 65: 239–296. 
doi:10.1016/S0065-308X(07)65004-0 PMID:18063098
McManus DP & Loukas A (2008). Current status of 
vaccines for schistosomiasis. Clin Microbiol Rev, 21: 
225–242. doi:10.1128/CMR.00046-07 PMID:18202444
Michaud DS (2007). Chronic inflammation and bladder 
cancer. Urol Oncol, 25: 260–268. doi:10.1016/j.
urolonc.2006.10.002 PMID:17483025
Mostafa MH, Sheweita SA, O’Connor PJ (1999). 
Relationship between schistosomiasis and bladder 
cancer. Clin Microbiol Rev, 12: 97–111. PMID:9880476
Mott KE, Desjeux P, Moncayo A et  al. (1990). Parasitic 
diseases and urban development. Bull World Health 
Organ, 68: 691–698. PMID:2127380
Moubayed P, Lepère JF, Mwakyoma H, Neuvians D (1994). 
Carcinoma of the uterine cervix and schistosomiasis. 
Int J Gynaecol Obstet, 45: 133–139. doi:10.1016/0020-
7292(94)90120-1 PMID:7915681
North M, Dubinchik I, Hamid A et al. (2003). Association 
between cervical schistosomiasis and cervical cancer. 
A report of 2 cases. J Reprod Med, 48: 995–998. 
PMID:14738030
Osada Y, Kumagai T, Masuda K et al. (2005). Mutagenicity 
evaluation of Schistosoma spp. extracts by the umu-
test and V79/HGPRT gene mutation assay. Parasitol 
Int, 54: 29–34. doi:10.1016/j.parint.2004.08.004 
PMID:15710547
Parkin DM, Vizcaino AP, Skinner ME, Ndhlovu A (1994). 
Cancer patterns and risk factors in the African popu-
lation of southwestern Zimbabwe, 1963–1977. Cancer 
Epidemiol Biomarkers Prev, 3: 537–547. PMID:7827583
Quinnell RJ (2003). Genetics of susceptibility to human 
helminth infection. Int J Parasitol, 33: 1219–1231. 
doi:10.1016/S0020-7519(03)00175-9 PMID:13678637
383
IARC MONOGRAPHS – 100B
Ramchurren N, Cooper K, Summerhayes IC (1995). 
Molecular events underlying schistosomiasis-related 
bladder cancer. Int J Cancer, 62: 237–244. doi:10.1002/
ijc.2910620302 PMID:7628866
Richter J (2003). The impact of chemotherapy on morbidity 
due to schistosomiasis. Acta Trop, 86: 161–183. 
doi:10.1016/S0001-706X(03)00032-9 PMID:12745135
Riffenburgh RH, Olson PE, Johnstone PA (1997). 
Association of schistosomiasis with cervical cancer: 
detecting bias in clinical studies. East Afr Med J, 74: 
14–16. PMID:9145570
Rosin MP, Anwar WA, Ward AJ (1994a). Inflammation, 
chromosomal instability, and cancer: the schisto-
somiasis model. Cancer Res, 54: Suppl1929s–1933s. 
PMID:8137314
Rosin MP, Saad el Din Zaki S, Ward AJ, Anwar WA (1994b). 
Involvement of inflammatory reactions and elevated 
cell proliferation in the development of bladder cancer 
in schistosomiasis patients. Mutat Res, 305: 283–292. 
PMID:7510039
Rumnajek FD (1987) Biochemistry and physiology. In: 
The biology of Schistosomes. Rollinson D, Simpson AJD, 
editors. London, UK: Academic Press, 163-183.
Saad AA, O’Connor PJ, Mostafa MH et  al. (2006). 
Bladder tumor contains higher N7-methylguanine 
levels in DNA than adjacent normal bladder epithe-
lium. Cancer Epidemiol Biomarkers Prev, 15: 740–743. 
doi:10.1158/1055-9965.EPI-05-0813 PMID:16614117
Salim EI, Morimura K, Menesi A et al. (2008). Elevated 
oxidative stress and DNA damage and repair levels in 
urinary bladder carcinomas associated with schistoso-
miasis. Int J Cancer, 123: 601–608. doi:10.1002/ijc.23547 
PMID:18478569
Shaw ME, Elder PA, Abbas A, Knowles MA (1999). Partial 
allelotype of schistosomiasis-associated bladder cancer. 
Int J Cancer, 80: 656–661. doi:10.1002/(SICI)1097-
0215(19990301)80:5<656::AID-IJC4>3.0.CO;2-A 
PMID:10048962
Sheweita SA, El-Shahat FG, Bazeed MA et  al. (2004). 
Effects of Schistosoma haematobium infection on 
drug-metabolizing enzymes in human bladder 
cancer tissues. Cancer Lett, 205: 15–21. doi:10.1016/j.
canlet.2003.09.023 PMID:15036656
Sheweita SA, Mostafa MH, Ebid F, El-Sayed W (2003). 
Changes in expression and activity of glutathione 
S-transferase in different organs of schistosoma haema-
tobium-infected hamster. J Biochem Mol Toxicol, 17: 
138–145. doi:10.1002/jbt.10071 PMID:12815609
Shiff C, Veltri R, Naples J et al. (2006). Ultrasound veri-
fication of bladder damage is associated with known 
biomarkers of bladder cancer in adults chronically 
infected with Schistosoma haematobium in Ghana. 
Trans R Soc Trop Med Hyg, 100: 847–854. doi:10.1016/j.
trstmh.2005.10.010 PMID:16443246
Swellam M, Abd-Elmaksoud N, Halim MH et al. (2004b). 
Incidence of Bcl-2 expression in bladder cancer: 
relation to schistosomiasis. Clin Biochem, 37: 798–802. 
doi:10.1016/j.clinbiochem.2004.05.017 PMID:15329319
Swellam M, El-Aal AA, AbuGabel KM (2004a). Deletions 
of p15 and p16 in schistosomal bladder cancer corre-
late with transforming growth factor-alpha expression. 
Clin Biochem, 37: 1098–1104. doi:10.1016/j.clinbio-
chem.2004.09.006 PMID:15589816
Tamimi Y, Bringuier PP, Smit F et al. (1996). Homozygous 
deletions of p16(INK4) occur frequently in bilharziasis-
associated bladder cancer. Int J Cancer, 68: 183–187. 
doi:10.1002/(SICI)1097-0215(19961009)68:2<183::AID-
IJC7>3.0.CO;2-U PMID:8900425
Vennervald BJ & Dunne DW (2004). Morbidity in 
schistosomiasis: an update. Curr Opin Infect Dis, 17: 
439–447. doi:10.1097/00001432-200410000-00009 
PMID:15353964
Vizcaino AP, Parkin DM, Boffetta P, Skinner ME (1994). 
Bladder cancer: epidemiology and risk factors in 
Bulawayo, Zimbabwe. Cancer Causes Control, 5: 
517–522. doi:10.1007/BF01831379 PMID:7827238
Vuong PN, Bayssade-Dufour C, Albaret JL, Farhati K 
(1996). Histopathological observations in new and 
classic models of experimental Schistosoma haema-
tobium infections. Trop Med Int Health, 1: 348–358. 
doi:10.1046/j.1365-3156.1996.d01-52.x PMID:8673838
Warren W, Biggs PJ, el-Baz M et al. (1995). Mutations in 
the p53 gene in schistosomal bladder cancer: a study of 
92 tumours from Egyptian patients and a comparison 
between mutational spectra from schistosomal and non-
schistosomal urothelial tumours. Carcinogenesis, 16: 
1181–1189. doi:10.1093/carcin/16.5.1181 PMID:7767983
Webster BL, Southgate VR, Littlewood DT (2006). A revi-
sion of the interrelationships of Schistosoma including 
the recently described Schistosoma guineensis. Int J 
Parasitol, 36: 947–955. doi:10.1016/j.ijpara.2006.03.005 
PMID:16730013
WHO Expert Committee (2002). Prevention and control 
of schistosomiasis and soil-transmitted helminthiasis. 
World Health Organ Tech Rep Ser, 912: 1–57. 
Wilkins HA (1987) The epidemiology of schistosome 
infections in man. In: The biology of Schistosomes. 
Rollinson D, Simpson AJD, editors. London, UK: 
Academic Press, 379-397.
Wright ED, Chiphangwi J, Hutt MS (1982). Schistosomiasis 
of the female genital tract. A histopathological study 
of 176 cases from Malawi. Trans R Soc Trop Med 




Helicobacter pylori was considered by a previous IARC Working Group in 1994 (IARC, 1994). 
Since that time, new data have become available, these have been incorporated into the 
Monograph, and taken into consideration in the present evaluation.
1. Exposure Data
Helicobacter pylori is a highly heterogenous 
bacterium with a large genomic diversity. In addi-
tion, humans may sometimes harbour multiple 
strains, and H. pylori can change genotypically 
and phenotypically during colonization in a 
single host (Suerbaum & Josenhans, 2007).
1.1 Taxonomy, structure, and biology
1 .1 .1 Taxonomy
The presence of spiral-shaped bacteria on 
human gastric mucosa was first recognized 
nearly one hundred years ago (Pel, 1913). These 
bacteria were originally named Campylobacter 
pylori (C. pylori) (Warren, 1983).
In 1989, a new genus, Helicobacter, was 
proposed, and C. pylori was renamed Helicobacter 
pylori (Goodwin et al., 1989). Recently (Garrity 
et al., 2005), the genus Helicobacter has been 
included with the genus Wolinella in the 
family Helicobacteraceae which, with the 
family Campylobacteraceae, constitutes the 
Epsilonproteobacteria.
Over the past 20 years, 23 Helicobacter 
species have been validated, and two candidates 
and several strains are awaiting official classifica-
tion (Table 1.1).
 According to the usual site of colonization, 
Helicobacter species can be divided into gastric 
and enteric or enterohepatic Helicobacter types.
Some gastric Helicobacter species from 
animals can infect humans: H. bizzozeroni, 
H. salomonis, H. felis, H. candidates, H. suis. 
Bacausee they are extremely difficult to grow 
in cultures, the exact speciation is usually not 
done, and they are known as “Gastrospirullum 
hominis” or “H. heilmannii” (De Groote et al., 
2005).
1 .1 .2 Structure of the bacterium
H. pylori is a spiral or slightly curved Gram-
negative rod with 2–6 characteristic unipolar 
flagella. The bacterium has bluntly rounded 
ends and measures 2.5–4.0  µm in length and 
0.5–1.0  µm in width. The cell wall is smooth 
and may be coated with a prominent glycocalyx 
with a thickness of up to 40 nm (Goodwin et al., 
1989); it is covered with ring-like subunits with 
a diameter of 12–15 nm. Occasionally, the bacte-
rium may contain bacteriophages. The flagella 
measure 2.5 µm in length and around 30 nm in 
thickness, and have a distinctive terminal bulb 
(Goodwin & Worsley, 1993). The bacterium 
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displays remarkable motility in viscous solutions, 
and the flagella play a central role in this motility 
(Hazell et al., 1986; Suerbaum et al., 1993).
In certain circumstances, H. pylori can evolve 
from this typical helical form to a coccoidal 
form. Some studies suggested that they are live 
organisms (Sisto et al., 2000; Willén et al., 2000), 
but others concluded that they are degenerating 
organisms (Kusters et al., 1997).
1 .1 .3 Structure of the genome
The genome of three H. pylori strains has now 
been fully sequenced: strain 26695 from a patient 
with gastritis, strain J99 from a duodenal ulcer 
patient, and strain HPAG1 from a patient with 
chronic atrophic gastritis (Tomb et al., 1997; Alm 
et al., 1999; Oh et al., 2006).
Strains 26695, J99 and HPAG1 have a 
circular chromosome of 1667867 base pairs (bp), 
1643831 bp and 1596366 bp, respectively. HPAG1 
also has a single 9369 bp plasmid, pHPAG1.
The percentage of genome-coding sequences 
of strains 26695, J99 and HPAG1 is around 
92%, and they contain 1552 (Alm et al., 1999; 
Boneca et al., 2003), 1495 (Tomb et al., 1997; Alm 
et al., 1999), and 1536 (Oh et al., 2006) predicted 
protein-coding genes, respectively. In these three 
small genomes, 1379 open reading frames (ORFs) 
are common to all three strains and about 10% 
of the genes are strain-specific (Alm et al., 1999); 
117 and 89 genes present in strains 26695 and J99, 
respectively, are absent in the other strain (Alm 
et al., 1999); in contrast, 43 of the HPAG1 genes 
are either not detectable at all or incompletely 
represented in the 26695 and J99 genomes (Oh 
et al., 2006).
A comparison of the three genomic sequences 
revealed that the genetic organization was similar 
in all three strains. However, it confirmed the 
panmictic structure of H. pylori, which is the 
result of a high mutation rate (microdiversity, i.e. 
high polymorphism among orthologous genes), 
and free recombinations (Falush et al., 2003). A 
significant macrodiversity (presence or absence 
of the genes) was also observed (Raymond et al., 
2004). A comparative genomic analysis of isolates 
from 15 Caucasians (Salama et al., 2000) allowed 
to extend the pool of strain-specific genes from 
6–7% (as determined from the comparison of the 
first two sequenced genomes) to 18–22%. More 
recently, a large study was conducted on 56 H. 
pylori strains and four H. acinonychis strains, 
with whole genome microarrays. They concluded 
that the core genome present in all H. pylori 
isolates contains 1111 genes, with a weighted 
average of 27% of the genome variably present in 
different isolates (Gressmann et al., 2005).
Besides the cag pathogenicity island, which 
is known to be a variable region, half of the 
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strain-specific genes are clustered in a hypervari-
able region, known as the ‘plasticity zone’ (Salama 
et al., 2000). The group of genes containing the 
most variability are those that comprise genes of 
unknown function (44%), genes associated with 
DNA metabolism (most of them are restriction-
modification systems 54%), outer-membrane 
proteins (22%), cellular processes/cagPAI (40%) 
and others (100%, including transposases) 
(Gressmann et al., 2005).
The genomic analyses suggest that H. pylori 
strains have essentially identical metabolic 
potential (Table 1.2).
1 .1 .4 Host range
H. pylori is the Helicobacter species of 
humans. H. pylori isolation from several other 
animal species (monkey, pig, cat, dog) has been 
reported, but these reports were anecdotal, and 
these bacteria were most likely acquired from 
humans.
1 .1 .5 Target cells and tissues
The target cell of H. pylori is the gastric 
mucus-secreting cells. A low acid output leads 
H. pylori to also infect the corpus (Louw et al., 
1993). H. pylori lives mainly in the surface mucus 
layer and within the pits, and can adhere to 
mucus-secreting cells especially close to inter-
cellular junctions (Hazell et al., 1986). It is not 
found on intestinal-type cells in the case of intes-
tinal metaplasia. In contrast, it has the ability to 
colonize metaplastic gastric cells present in the 
duodenum and elsewhere, for example, in the 
oesophagus, in Meckel’s diverticulum, and in the 
rectum (Hill & Rode, 1998).
The main cell receptor for this adherence is the 
blood group antigen A, and the corresponding 
adhesin is named BabA. In a low proportion of 
the cells, H. pylori may be intracellular, a situa-
tion which contributes to its persistence (Dubois 
& Borén, 2007).
H. pylori can be present transiently in the 
mouth when regurgitated, and may also be 
found in the faeces, but it cannot survive with 
competing organisms (Parsonnet et al., 1999).
1 .1 .6 Function of gene products
(a) Colonizing factors
Colonization by H. pylori involves an inter-
action between a large family of Helicobacter 
outer membrane proteins (Hop) and the gastric 
epithelial cells of the host. Several genes involved 
in determining the composition of the outer 
membrane are differentially regulated by a 
phase variation called slipped-strand repair. This 
phenomenon is possible due to the presence of 
repeated intragenic sequences, allowing replica-
tive shifts and mismatchs, leading to changes 
in the status of a gene (“on/off”) (Salaün et al., 
2004). Such proteins are the blood group antigen 
binding adhesion (BabA), sialic acid binding 
adhesion (SabA), adherence-associated lipopro-
tein (AlpA and AlpB), and HopZ.
Lipopolysaccharides play an important 
role in the interaction between Gram-negative 
bacteria and their host. They are potential stimu-
lators of the immune system (Moran et al., 1996). 
The H. pylori lipopolysaccharides, however, have 
remarkably low activity, and their synthesis may 
involve over 20 genes, scattered throughout the 
genome, unlike other bacteria in which they are 
grouped into a single cluster.
The expression of fucosyltransferase, an 
enzyme essential for the lipopolysaccharide 
biosynthesis pathway, is also subject to phase 
change, and is a key enzyme allowing H. pylori 
to mimic human Lewis antigens, which allows it 
to escape the host immune response (Lozniewski 
et al., 2003).
It has been suggested that this differen-
tial regulation and the strain-specific outer-
membrane-related genes may play a role in the 
severity of H. pylori-related disease, and the 
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ability of H. pylori to persist chronically in its 
host (Mahdavi et al., 2002).
(i) BabA
The blood group antigen Lewis b was iden-
tified as a receptor for H. pylori in 1993 (Borén 
et al., 1993). This is the dominant antigen in the 
gastric mucosa of secretor-positive individuals. 
The adhesion-recognizing Lewis b was charac-
terized as an H. pylori outer-membrane protein, 
namely BabA (Ilver et al., 1998). Another protein 
with almost identical amino terminal and iden-
tical carboxy terminal domains but divergent 
central domains, BabB, does not bind to Lewis b 
antigen (Aspholm-Hurtig et al., 2004).
A babA allele and a babB allele are both present 
in each of the three sequenced strains, but in 
different locations. In the strain from which bab 
genes were initially cloned, there were two babA 
genes but only one of them (babA2) has Lewis b 
binding activity. According to two studies, the 
babA gene is present in approximately 70% of 
H. pylori strains, and the babB gene is present 
in almost them all (Colbeck et al., 2006; Hennig 
et al., 2006).
Several mechanisms have been elucidated 
for the regulation of BabA expression including 
chimera formation (Pride & Blaser, 2002) 
between babA and babB, and phase variation of 
babA through slipped-strain mispairing (Solnick 
et al., 2004).
To date, BabA-Lewis b is the adhesin-receptor 
interaction in H. pylori that is best character-
ized, and probably one of the most important 
(Yamaoka, 2008).
(ii) SabA
Another outer-membrane protein conferring 
adherence to host sialyl Lewis x was identified 
as sialic acid-binding adhesin (SabA) (Mahdavi 
et al., 2002). The sialyl-Lewis x expression is 
induced in the gastric epithelium during persis-
tent H. pylori infection, suggesting that the 
bacterium can trigger the host tissue to modify 
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Table 1 .2 Classification of the genes of two Helicobacter pylori strains sequenced
Annotation category No. of genes in:
H. pylori J99 H. pylori 26695
Functionally classified 877 898
Aminoacid biosynthesis 44 44
Biosynthesis of cofactors etc. 60 59
Cell envelope 160 164
Cellular processes 96 113
DNA replication 23 23
DNA restriction-modification, etc. 66 68
Energy metabolism 104 104
Fatty acid and phospholipid metabolism 28 29
Purine and pyrimidine biosynthesis 34 34
Regulatory functions 32 32
Transcription 13 13
Translation 128 128
Transport and binding proteins 88 87
Conserved with no known function 275 290
Helicobacter pylori specific 343 364
Total 1495 1552
From Doig et al. (1999)
Helicobacter pylori
the mucosal glycosylation patterns for enhanced 
adherence. The event could occur via induction 
of 3GnT5, a GlcNAc transferase essential for the 
biosynthesis of Lewis antigens (Marcos et al., 
2008). SabA could in this way contribute to the 
chronicity of H. pylori infection. SabA can also 
bind specifically to granulocytes and induce an 
oxidative burst (Unemo et al., 2005).
(iii) AlpA and AlpB
A genetic locus involved in H. pylori adherence 
to Kato cells was identified in 1999 (Odenbreit, 
2005). It was named alpAB (adherence-asso-
ciated lipoprotein A and B), and encodes two 
outer-membrane proteins. However, because no 
receptor has been identified for these proteins, 
their role as adhesins is unclear.
(iv) HopZ
HopZ has been described as an adhesin (Peck 
et al., 1999) but no receptor has yet been identi-
fied for this putative adhesin.
(b) Pathogenicity factors
(i) cag Pathogenicity island
In many parts of the world, including Asia and 
most of Africa, almost all H. pylori strains contain 
an intact cag pathogenicity island, whereas about 
30% of strains from Europe and North America 
lack the entire island, and are considered “cag-
negative”. However, both cag-positive and cag-
negative strains can exist together in the same 
stomach, and the cag pathogenicity island can be 
partially deleted with the loss of type 4 secretory 
function (Suerbaum & Josenhans, 2007), there-
fore, the simple designation of cag status as posi-
tive or negative may not be absolute. The CagA 
protein encoded by the cagA gene within the cag 
pathogenicity island is a highly immunogenic 
protein that elicits serum antibody responses 
allowing for the detection of cag-positive strains 
by enzyme-linked immunosorbent assay (ELISA) 
or Western blot analysis in serum samples for 
epidemiological studies.
The cag pathogenicity island of H. pylori is a 
DNA fragment of approximately 40 kbp which 
exhibits the characteristics of pathogenicity 
islands in general: i) a G+C% different from the 
rest of the chromosome (35% vs 39%), ii) two 
direct repeat sequences at its ends, iii) several 
genes linked to virulence, iv) a secretion system, 
and v) an insertion sequence (Censini et al., 
1996).
This pathogenicity island is always located 
between the same two genes: HP519, a gene of 
unknown function, and murI, the glutamate 
racemase gene. It is integrated at the 3′ end of 
the glutamate racemase gene and flanked by 
two repeated 31 bp sequences probably derived 
from the duplication of the 3′ end of this gene 
(Akopyants et al., 1998). Because this island 
appears to be acquired in toto, it may then be 
separated into two regions, namely cagI and 
cagII, by an insertion sequence (IS605) coding for 
two transposases (tnpA and tnpB) (Censini et al., 
1996). There are 27 potential coding sequences in 
the cag pathogenicity island (Censini et al., 1996).
Not all H. pylori strains possess the cag 
pathogenicity island. In addition, it can be lost 
or gained via recombination (Kersulyte et al., 
1999). In addition, partial deletions have been 
described. Among the cag pathogenicity island 
genes, six show sequence similarity with genes 
coding for a secretion system in other bacteria. 
This is a type IV secretion system, a multi-
protein complex that allows the bacterium to 
inject specific molecules into an eukaryotic cell 
(Krause et al., 2000). Among such translocated 
molecules is the product of one of the cag patho-
genicity island genes, CagA. This immunodomi-
nant protein of 120–145  kDa was the first H. 
pylori protein to be linked to more severe disease 
(Crabtree et al., 1991). Phosphorylated CagA was 
also detected inside epithelial cells infected with 
H. pylori (Yamazaki et al., 2003; Higashi et al., 
2005).
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(ii) VacA cytotoxin
A cytotoxic activity was first reported in 
broth culture filtrates of H. pylori incubated with 
mammalian cells in vitro (Leunk et al., 1988). 
The protein responsible for the observed effect of 
large intracellular vacuoles was designated vacu-
olating cytotoxin VacA (Cover & Blaser, 1992). 
It is a high-molecular weight multimeric pore-
forming protein encoded by the chromosomal 
gene vacA (Cover et al., 1994; Schmitt & Haas, 
1994; Telford et al., 1994).
As with cagA, no close homologues of vacA 
exist in other Helicobacter species nor in other 
bacteria or eukaryotic cells. Mature 88  kDa 
VacA toxin molecules are secreted as soluble 
proteins into the extracellular space, but can also 
remain localized on the surface of H. pylori (Ilver 
et al., 2004). The secreted toxin can assemble 
into oligomeric structures (Cover et al., 1997; 
Adrian et al., 2002) for insertion into planar lipid 
bilayers to form anion-selective membrane chan-
nels allowing anions and urea to exit (Iwamoto 
et al., 1999; Tombola et al., 1999). The micro-
scopic analysis of VacA oligomeric complexes 
has shown their dissociation into monomeric 
components with low vacuolating potential that 
can be activated by pH changes.
The secreted mature 88  kDa toxin can be 
cleaved in two fragments: p33 and p55 (Nguyen 
et al., 2001). The p55 domain has a role in the 
binding of VacA to host cells, and the p33 
domain, together with 100 amino acids of the 
p55 domain, is sufficient to induce intracellular 
vacuolation (de Bernard et al., 1998).
Unlike cagA, vacA is conserved among all 
H. pylori strains, but exhibits a high level of 
genetic diversity. Several vacA alleles can be 
distinguished on the basis of diversity in the 5′ 
region, namely in the signal region, (s region) 
s1 and s2, and in the mid-region (m region) 
m1 and m2 (Atherton et al., 1995). Among the 
different combinations, the s1m1 type produces 
the most active vacuolating activity in different 
cell lines, s1m2 produces detectable vacuolation 
in a limited range of cell types, s2m2 is inactive, 
and s2m1 does not appear to exist.
More recently, a third group of alleles has 
been described in the intermediary region (i) – 
i1 and i2 (Rhead et al., 2007).
A strong association between vacA s1 and 
cag pathogenicity island has been described (Van 
Doorn et al., 1999).
1.2 Epidemiology of infection
1 .2 .1 Prevalence, geographic distribution
The most common test used to determine the 
prevalence of infection in healthy populations is 
serology for H. pylori IgG by ELISA (Vaira et al., 
2002; Mueller et al., 2006). Serological testing for 
CagA antibody is more sensitive for individuals 
who are infected with CagA+ H. pylori, but H. 
pylori IgG ELISA is most often used in screening. 
Other diagnostic tests for H. pylori are avail-
able but less often used in large epidemiological 
studies or to estimate population prevalence 
(Mégraud & Lehours, 2007).
H. pylori infection is common, with a global 
prevalence of over 50%, but with substantial 
country-to-country variations (Parsonnet, 1998; 
Suerbaum & Michetti, 2002). Prevalence rates 
differ by age, race/ethnicity, and socioeconomic 
characteristics. As a rule, rates are higher in 
developing countries than in developed ones; 
however, in several eastern European countries 
the prevalence of infection is high.
The prevalence of infection is highest in 
the older age groups (The EUROGAST Study 
Group, 1993). The rate of H. pylori infection has 
been shown to have decreased in successive birth 
cohorts over the past several decades in developed 
countries (Roosendaal et al., 1997). Banatvala et 
al. (1993) screened a total of 631 serum samples 
collected from adults and children in 1969, 1979, 
and 1989, and the cohort effect on H. pylori 
positivity was estimated by Western blot based 
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on year of birth. The seropositivity declined by 
26% (8–41%) per decade (P < 0.008). Eslick (2003) 
reported on 451 pregnant women screened for 
H. pylori infection in Australia, and found that 
infection rates declined from 44% in the birth 
cohort of 1951–60, to 29% in the birth cohort of 
1961–70, to 20% in the birth cohort of 1971–80, 
to 9% in the birth cohort of 1981–90.
Rothenbacher et al. (1998) used 13C–urea 
breath tests for population screening of approxi-
mately 1000 preschool children as part of a 
physician-administered school fitness test. This 
demonstrated its utility for determining current 
infection status in a relatively large population of 
healthy subjects.
Because of the substantial differences in the 
prevalence of infection over time by age group 
and race/ethnicity within a country, interna-
tional comparisons of the overall prevalence of H. 
pylori where the populations were tested during 
different time periods, and different age compo-
sition or race/ethnicity or type of test performed 
are crude comparisons at best, and likely to be 
misleading (for a review, see Everhart, 2000).
The results of the EUROGAST Study Group 
(The EUROGAST Study Group, 1993) illustrate 
the importance of age-specific prevalence esti-
mates. In Japan, the population prevalence was 
61% in the 25–34 years age group, and 89% in 
the 55–64 years age group; in Poland the preva-
lence was 69% in the 25–34 years age group, and 
89% in the 55–64 years age group; in Denmark 
the prevalence was 15% in the 25–34 years age 
group, and 30% in the 55–64 years age group; in 
the United States of America, the prevalence rate 
was 15% in the 25–34 years age group, and 34% 
in the 55–64 years age group.
Similar variations are seen within the USA 
between racial and ethnic groups. Hyams et al. 
(1995) conducted serological testing of 1000 mili-
tary personnel aged 17–50 years. The overall prev-
alence of infection in the group was 25%, ranging 
from 18% in Caucasians to 45% in Hispanics and 
46% in Blacks, with other races at 29%. More 
recently Everhart et al. (2000) conducted a larger 
seroprevalence survey in the USA in which 7465 
adults were tested for H. pylori by IgG ELISA. 
The overall seroprevalence was 32.5%. It was 
substantially higher among non-Hispanic blacks 
(52.7%) and Mexican-Americans (61.6%) than 
among non-Hispanic Caucasians (26.2%).
1 .2 .2 Transmission
(a) Person-to-person route
Humans are the only known significant 
reservoir of H. pylori (Oderda, 1999). Person-
to-person contact is believed to be the primary 
route of transmission in developed countries, 
and is also important in developing countries. 
Close personal contact, particularly within the 
family including mother/parents to child, sibling 
to sibling and spouse to spouse, has been consist-
ently demonstrated as a risk factor for transmis-
sion of infection (Dominici et al., 1999; Escobar 
& Kawakami, 2004).
Brenner et al. (2006) determined current H. 
pylori infection in 670 spousal pairs by 13C-Urea 
breath yest and monoclonal antigen immuno-
assay for H. pylori in stool. The prevalence of 
infection was significantly greater in women 
with infected partners, compared to women 
whose partner was not infected (34.9% vs 14.5%).
Person-to-person transmission can occur in 
several ways. Parsonnet et al. (1999) conducted 
a controlled clinical experimental study to 
determine how humans shed H. pylori into the 
environment. A total of 16 asymptomatic indi-
viduals positive for H. pylori were administered a 
cathartic and an emetic and 1/10 participating H. 
pylori-negative individuals was given an emetic. 
Stool and vomitus samples were collected. All 
vomitus specimens from H. pylori positive indi-
viduals grew H. pylori (confirmed by polymerase 
chain reaction (PCR)). Air was sampled during 
vomiting and H. pylori were grown from 6 of 
16 samples (37.5%). Small quantities of H. pylori 
were grown in three (18.8%) and nine (56.3%) 
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saliva samples obtained from subjects before 
and after emesis, respectively. Cultures from 7/14 
(50%) positive subjects had at least one positive 
culture and 22/101 cathartic stools (21.8%) grew 
H. pylori. Samples from negative subjects did not 
grow the organism on culture.
Transmission of H. pylori was also examined 
by Perry et al. (2006) who tested 2752 household 
members for H. pylori in serum or stool at base-
line and then again 3 months later. A total of 30 
new infections occurred among 1752 persons 
uninfected at baseline. Exposure to a household 
member with gastroenteritis was associated with 
a relative risk of 4.8 (95%CI: 1.4–17.1) for defi-
nite or probable new infection. Risk of infection 
was greater for exposure to vomiting (odds ratio 
(OR), 6.3) than to diarrhoea (OR, 3.0).
Significantly higher than expected prevalence 
rates of H. pylori infection have been observed 
in institutionalized adults and children (Malaty 
et al., 1996; Böhmer et al., 1997).
(b) Oral-oral route
H. pylori DNA has been detected in the saliva 
of H. pylori-positive subjects by PCR (Namavar 
et al., 1995; Madinier et al., 1997). H. pylori 
organisms have also been successfully detected 
from the dental plaque of infected persons 
(Nguyen et al., 1993). In general, isolation has not 
been uniformly successful, however, perhaps as a 
result of the transient presence of H. pylori in the 
oral cavity or poor detection capability resulting 
from the co-occurrence of many other bacteria 
in the oral cavity.
(c) Faecal-oral route
H. pylori has been detected in faeces by culture 
and its DNA by PCR (Kelly et al., 1994; Namavar 
et al., 1995), although other investigators have 
failed to replicate this (van Zwet et al., 1994). One 
study found detectable DNA in the faeces of 73% 
of known infected subjects (Gramley et al., 1999). 
These data, together with those from Parsonnet 
et al. (1999), document the possible role of faecal 
shedding of H. pylori into the environment.
(d) Waterborne transmission
Studies in the People’s Republic of China 
and in Latin America found that the source of 
water used for consumption, bathing or swim-
ming could possibly be associated with H. pylori 
infection (Goodman et al., 1996; Zhang et al., 
1996). Contamination of drinking-water and 
sewage water has been demonstrated. Hegarty et 
al. (1999) found H. pylori in 60% of the samples 
of surface water, and 65% of the shallow ground 
water collected in several states in the USA. A 
Japanese study also reported H. pylori contami-
nation of water from rivers and ponds (Sasaki 
et al., 1999).
(e) Iatrogenic transmission
Endoscopes used routinely in upper gastro-
intestinal procedures may be the source of 
iatrogenic infection as a result of improper disin-
fection between procedures (Langenberg et al., 
1990; Tytgat, 1995).
1 .2 .3 Risk factors for infection
The best established risk factor for H. pylori 
infection is low socioeconomic status, particu-
larly during childhood when initial infection 
generally occurs (Malaty & Graham, 1994). Both 
education and income as components of socio-
economic status are inversely related to risk of 
infection (Replogle et al., 1995). Factors closely 
linked to socioeconomic status that appear 
to contribute to this inverse relation between 
poverty and risk of infection include hygienic 
conditions, household density/crowding, and 
the number of young children in the household 
(Goodman et al., 1996; Ford et al., 2007).
Neither smoking nor alcohol were found to 
be associated with the prevalence of H. pylori 
seropositivity in the large EUROGAST study of 
17 asymptomatic populations (The EUROGAST 
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Study Group, 1993). Because the literature is 
inconsistent, the most recent studies also report 
no significant association between H. pylori infec-
tion and tobacco use (Brown, 2000). Alcohol, 
particularly wine consumption, was found to 
have an inverse association with H. pylori infec-
tion in several studies (Brenner et al., 1997, 1999a, 
b). Other studies have also found modest reduc-
tions in risk that were not statistically significant 
(Fontham et al., 1995; Peach et al., 1997).
1 .2 .4 Persistence, latency, and natural history 
of infection
Acquisition of H. pylori infection typically 
occurs in childhood (Malaty & Graham, 1994; 
Goodman et al., 1996; Brown, 2000). Once infec-
tion is established, it usually lasts for life, unless 
treated. At present there is no vaccine available, 
and the treatment of infection is generally a 
2-week course of triple therapy consisting of an 
antisecretory agent, and two antibiotics.
H. pylori antibody titre has been shown to 
decline over the progression of premalignant 
lesions, and impacts the validity of serology, 
particularly in retrospective studies. Kokkola 
et al. (2003) followed 47 men with advanced 
H. pylori-positive atrophic corpus gastritis by 
endoscopy over a 6-year period, and by serum 
levels of pepsinogen I and antibodies to H. pylori 
over a 10-year period. None was treated for H. 
pylori infection during the study. The mean H. 
pylori antibody titres (IgG and IgA) declined 
during the course of follow-up, and 11 (23%) 
men converted to a seronegative status, and no 
significant changes were observed in the grade of 
atrophy or intestinal metaplasia in the antrum, 
or in the grade of intestinal metaplasia in the 
corpus. Using material from a population-based 
case–control study, Ekström et al. (2001) re-eval-
uated the association between H. pylori and 
gastric cancer by comparing ELISA assay against 
H. pylori IgG with immunoblot against CagA 
antibodies to detect evidence of past H. pylori 
infection. Among cases, the seroprevalence of H. 
pylori was around 70% by ELISA and around 90% 
by immunoblot; among controls, the seropreva-
lence was similar by the two methods (55% posi-
tive). The odds ratios relating H. pylori exposure 
to gastric cancer substantially increased when 
CagA antibody positivity rather than H. pylori 
IgG ELISA was used to classify past exposure.
Yoo et al. (2007) examined the positivity of 
several currently available diagnostic tests for H. 
pylori when atrophic gastritis and/or intestinal 
metaplasia, and presumably more advanced 
lesions as well, are present. The CLO test (based 
on urease activity), has lower sensitivity in 
cases of both atrophy or intestinal metaplasia. 
Histological identification of H. pylori with 
Giemsa stain was markedly reduced as the degree 
of intestinal metaplasia increased (P < 0.01), but 
was not affected in cases of atrophy only. The 
culture test was not affected except at the highest 
grade of atrophy or intestinal metaplasia, with 
0% positivity.
2. Cancer in Humans
2.1 Cancer of the stomach
The previous IARC Monograph (IARC, 1994) 
reviewed results from four cohort and nine case–
control studies that considered gastric carcinoma. 
Since its publication, results from several further 
cohort studies have been published. Some of 
these, together with the cohort studies presented 
in the earlier Monograph, were included in a 
pooled reanalysis (Helicobacter and Cancer 
Collaborative Group, 2001).
In analysing the relationship between gastric 
carcinoma and H. pylori, there is a specific bias 
in retrospective determination of H. pylori status 
in that precancerous subjects may undergo a 
loss of infection, thus producing an underesti-
mate of prevalence in cases but not in controls 
(Kokkola et al., 2003; Yoo et al., 2007). For this 
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reason, relatively little weight is given to case–
control studies in the assessment of the relation-
ship between gastric carcinoma and H. pylori, 
although some are cited below as they provide 
specific evidence.
Since the previous IARC Monograph, it has 
also been reported that H. pylori appears to have 
a different relationship with gastric carcinoma 
arising in the region of the stomach distal to the 
cardia (non-cardia gastric carcinoma) compared 
with the cardia region located adjacent to the 
oesophageal sphincter. As a consequence, the 
following presentation of results, where possible, 
distinguishes non-cardia from cardia gastric 
carcinoma.
2 .1 .1 Non-cardia gastric carcinoma
Results are available from 17 prospective 
cohort studies with nested case–control designs 
and six further full cohort studies. Whereas the 
nested case–control comparisons all specify cases 
defined as non-cardia gastric carcinoma, for the 
full cohort studies, incident cancers are gener-
ally defined as gastric carcinoma without further 
subsite specification. [The Working Group noted 
that in the main, these can be assumed to be of 
the non-cardia.]
(a) Nested case–control analyses within cohort 
studies 
These are summarized in Table  2.1 (avail-
able at http://monographs.iarc.fr/ENG/
Monographs/vol100B/100B-10-Table2.1.pdf). 
The pooled reanalysis (Helicobacter and Cancer 
Collaborative Group, 2001) presented results 
based on 762 cases of non-cardia gastric carci-
noma and 2250 control subjects derived from 
12 independent prospective cohort studies in 
nine countries (China, Finland, Iceland, Japan, 
Norway, Sweden, Taiwan (China), the United 
Kingdom, and USA). The overall matched odds 
ratio for the risk of non-cardia gastric carcinoma 
was 2.97 (95%CI: 2.34–3.77), and odds ratios for 
individual studies varied from 1.52–11.1. There 
were no substantive differences in the odds ratios 
between men and women or between gastric 
carcinoma with intestinal or diffuse histological 
type. Younger cases at diagnosis had a higher 
odds ratio than older cases (OR, 7.10; 95%CI: 
2.93–17.2, for those aged < 50 years at diagnosis).
Six of the individual studies included in 
the pooled reanalysis accrued more cases, and 
updated results have since been published 
(Nomura et al., 2002a; Kamangar et al., 2006a, 
2007; Knekt et al., 2006; Hansen et al., 2007; 
Simán et al., 2007). Using ELISA for H. pylori 
IgG to determine H. pylori infection status, 
odds ratios in these studies varied from 1.6–7.9, 
and all were statistically significant. One study 
(Simán et al., 2007) used immunoblot against H. 
pylori or CagA to determine infection status, and 
reported an increase in the odds ratios from 11.1 
using ELISA (Simán et al., 1997) to 16.8 or 17.8 
respectively, using immunoblot.
New results have been reported from four 
further prospective studies with nested case–
control designs (Shin et al., 2005; Sasazuki et al., 
2006; Palli et al., 2007; Mitchell et al., 2008). Using 
ELISA for IgG to determine H. pylori infection 
status, odds ratios for non-cardia gastric carci-
noma varied from 1.07–5.10, and two were statis-
tically significant (Sasazuki et al., 2006; Palli 
et al., 2007). One study (Mitchell et al., 2008) also 
used immunoblot to determine infection status, 
and reported an increase in the odds ratio from 
2.3 using ELISA to 10.6 using immunoblot.
[The Working Group noted that some of the 
variations between study results may result from 
variation in the sensitivity and specificity of 
the original ELISA assays used (Feldman et al., 
1995). The Working Group noted the substan-
tial increase in estimated odds ratios in recent 
studies using immunoblot assays (Simán et al., 
2007; Mitchell et al., 2008).]
In the pooled reanalysis (Helicobacter and 
Cancer Collaborative Group, 2001), when the 
results were stratified by period of follow-up, the 
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odds ratio for non-cardia gastric carcinoma with 
cases diagnosed less than 10 years after recruit-
ment was 2.39 (95%CI: 1.82–3.12), and for those 
with cases diagnosed 10 or more years after 
recruitment, 5.93 (95%CI: 3.41–10.3). A similar 
relationship in the magnitude of the odds ratio 
with period of follow-up was reported in two of 
the updated studies (Nomura et al., 2002a; Knekt 
et al., 2006), but not in two others (Kamangar 
et al., 2006a, 2007). A study from Iceland, of 
which preliminary results were included in the 
pooled reanalysis, has been reanalysed taking 
into account quantitative changes in antibody 
titre between the time of initial blood sample 
and the diagnosis of gastric carcinoma (Tulinius 
et al., 2001). Repeat blood samples were avail-
able from 23/41 of the original gastric carcinoma 
cases, and 128 controls matched for sex, age, time, 
and number of repeat samples. The odds ratio for 
gastric carcinoma (predominantly non-cardia) 
was 1.16 (95%CI: 1.05–1.28) for those showing 
a decline in antibody titre compared with those 
with constant or rising levels.
(b) Cohort studies
These studies are summarized in Table  2.2 
(available at http://monographs.iarc.fr/ENG/
Monographs/vol100B/100B-10-Table2.2.pdf). 
Three studies, two in Japan (Yamagata et al., 
2000; Yanaoka et al., 2008) and one in China (You 
et al., 2000) followed adult subjects undergoing 
health checks or general screening examinations 
in relation to H. pylori infection status. All three 
showed a statistically significant increased rela-
tive risk of gastric carcinoma associated with 
infection (in Yamagata et al., 2000 only in men), 
with relative risks varying from 1.8–3.48.
Three further studies, two in Japan (Uemura 
et al., 2001; Watabe et al., 2005) and one in 
Taiwan, China (Hsu et al., 2007) followed adult 
patients undergoing endoscopy procedures for 
non-malignant conditions, and found statisti-
cally significant higher rates of gastric carci-
noma in H. pylori-positive subjects, with relative 
risks [estimated by the Working Group] of 3.6 
in one study (Watabe et al., 2005), and infinity 
(no H. pylori-negative subjects) in the other two. 
None of these studies was adjusted for potential 
confounders.
(c) Case–control studies
In a retrospective case–control study of 
234 non-cardia gastric carcinoma cases and 
238 population controls in Sweden (Ekström 
et al., 2001), the reported odds ratio when using 
conventional IgG ELISA to assess H. pylori infec-
tion status was 2.2 (95%CI: 1.4–3.6). The odds 
ratio increased to 21.0 (95%CI: 8.3–53.4) after 
exclusion from the reference group of all subjects 
who were ELISA-negative and CagA-positive by 
immunoblot [The Working Group noted that the 
immunoblot used was reported to be specific for 
CagA-positive strains of H. pylori.]
In a retrospective case–control study of 57 
non-cardia gastric carcinoma cases and 360 
controls (with colorectal cancer) in Germany 
(Brenner et al., 2004), the reported odds ratio 
using an IgG ELISA to assess H. pylori infec-
tion status was 3.7 (95%CI: 1.7–7.9). The odds 
ratio increased to 18.3 (95%CI: 2.4–136.7) after 
exclusion from the analysis of defined groups of 
subjects who might have been susceptible to a 
misclassified serological result.
(d) Meta-analyses
Four meta-analyses of the association between 
gastric carcinoma and H. pylori infection have 
been published. Huang et al. (1998) identified 
19 studies, both retrospective and prospec-
tive, including data from 2491 cases and 3959 
controls. For non-cardia gastric carcinoma, the 
summary odds ratio was 3.08 (95%CI: 1.78–5.31) 
over all study designs, with evidence of signifi-
cant heterogeneity. An inverse monotonic asso-
ciation was observed between age at diagnosis 
and the magnitude of the odds ratio, for non-
cardia and cardia gastric carcinoma combined, 
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from 9.29 (95%CI: 3.43–34.04) at 20–29 years to 
1.05 (95%CI: 0.73–1.52) at 70 years or older.
Danesh (1999) identified 34 retrospective 
and 10 nested prospective case–control studies, 
which included data from 3300 and 800 cases, 
respectively. Because of concerns about the 
validity of the controls, no summary estimate of 
the odds ratio was calculated for the retrospec-
tive studies. For the nested case–control studies, 
the summary odds ratio for gastric carcinoma 
was 2.5 (95%CI: 1.9–3.4), with no evidence of 
significant heterogeneity [The Working Group 
noted that no distinction was made between 
non-cardia and cardia gastric carcinoma.]
Eslick et al. (1999) identified 42 studies: eight 
cohort and 34 case–control designs [The Working 
Group noted that, unlike other meta-analyses, 
this included studies where the assessment of H. 
pylori status included non-serological methods.] 
The summary odds ratio was 2.04 (95%CI: 1.69–
2.45). Cancer subsite (non-cardia vs cardia) was 
not a significant effect modifier. There was statis-
tically significant heterogeneity between studies, 
but no evidence of publication bias.
A more recent meta-analysis focused on 
16 seroprevalence studies of CagA and gastric 
cancer, which included a total of 2284 cases and 
2770 controls from diverse geographic popula-
tions (Huang et al., 2003). Overall, ten studies 
provided results stratified by subsite of the 
tumour. Evidence of H. pylori infection was 
associated with a 2.71-fold risk of developing 
non-cardia gastric cancer. Because antibodies 
against CagA may persist longer than antibodies 
against other H. pylori components normally 
detectable by H. pylori status serology, the risk of 
cancer in patients who were CagA-positive but 
H. pylori-negative was also evaluated. Compared 
with controls who were both H. pylori-negative 
and CagA-negative, the summary odds ratio of 
gastric cancer (non-cardia and cardia combined) 
was 2.89.
(e) Impact of H . pylori CagA status
Many of the nested case–control studies 
identified above reported odds ratios for the risk 
of gastric carcinoma associated with infection 
with CagA-positive strains of H. pylori to see if 
disease was exclusively or predominantly asso-
ciated with this genotype. In the meta-analysis 
by Huang et al. (2003), the analysis confined to 
H. pylori-positive cases and controls showed an 
additional risk of 2.01 (95%CI: 1.21–3.32) associ-
ated with CagA-positive strains.
Eight of the nested case–control studies have 
reported separately on results relating to CagA 
status (Parsonnet et al., 1997; Nomura et al., 
2002a, 2005; Gwack et al., 2006; Kamangar et al., 
2006a, 2007; Sasazuki et al., 2006; Palli et al., 
2007; Simán et al., 2007). Five of these studies 
compared adjusted odds ratios for non-cardia 
gastric carcinoma in subjects with both CagA-
positive and -negative infection status against 
a baseline of H. pylori-negative subjects. The 
reported odds ratios were, respectively, 5.8 vs 2.2 
(Parsonnet et al., 1997), 8.93 vs 6.55 (Kamangar 
et al., 2006a), 6.5 vs 1.6 (Palli et al., 2007), 12.5 
vs 9.5 (Sasazuki et al., 2006), and 1.58 vs 1.62 
(Kamangar et al., 2007). Thus, in 4/5 studies, 
the odds ratio associated with CagA-positive 
infection was substantively greater than that 
for CagA-negative infection. One other study 
(Gwack et al., 2006), in an analysis restricted to 
H. pylori-infected individuals, reported a statisti-
cally significant increased odds ratio in relation 
to CagA-positive status of 3.74 (95%CI: 1.10–
12.73) compared with CagA-negative status, 
even though the risk associated with H. pylori per 
se was not significant (Shin et al., 2005). In the 
other two nested case–control studies reporting 
on CagA-positive status (Nomura et al., 2002a; 
Simán et al., 2007), odds ratios were decreased 




(f) Impact of H . pylori eradication
Results are available from six randomized 
intervention studies in which the subsequent 
risk of gastric carcinoma or gastric precancerous 
lesions has been evaluated in H. pylori-infected 
adult subjects who were randomized to receive 
H. pylori eradication therapy or placebo/no treat-
ment (see Table 2.3 available at http://monographs.
iarc.fr/ENG/Monographs/vol100B/100B-10-
Table2.3.pdf). Only one study (Wong et al., 
2004) was specifically designed to analyse gastric 
carcinoma outcomes. A total of 1630 H. pylori 
positive subjects undergoing endoscopy were 
followed up for a mean of 7.5 years after being 
randomized to eradication therapy (n = 817) or 
placebo (n  =  813). The therapy was successful 
in eradicating the infection in 84% of subjects 
in the intervention arm. There were 7 (0.86%) 
and 11 (1.35%) incident cases of gastric carci-
noma diagnosed in the intervention and placebo 
arms respectively, a non-significant difference 
(P  =  0.33). A post-hoc subgroup analysis of 
subjects with no precancerous lesions at recruit-
ment showed 0 (0.0%) and 6 (1.2%) incident cases 
in the intervention and placebo arms (P = 0.02) 
[The Working Group viewed the design of this 
study to be underpowered to assess adequately 
the relationship between eradication and gastric 
carcinoma outcomes.]
Three studies (Leung et al., 2004; Mera et al., 
2005; You et al., 2006) were designed to analyse 
changes in precancerous histological pathology 
as the primary end-point but also reported 
results for gastric carcinoma outcomes. These 
studies respectively randomized 587, 795 and 
2258 H. pylori-positive subjects to receive eradi-
cation therapy or placebo. In the intervention and 
placebo arms of the three studies, during follow-
up, there were four and six, three and two, and 19 
and 27 incident cases of gastric carcinoma diag-
nosed, respectively. None of these associations 
was statistically significant. In terms of progres-
sion or regression of precancerous pathology 
compared with baseline, all three studies showed 
a statistically significant benefit in the interven-
tion arms as did a further intervention study (Ley 
et al., 2004) of 248 subjects which did not specifi-
cally report on gastric carcinoma as an outcome.
Fukase et al. (2008) reported a study of 544 
H. pylori-positive patients who were all diag-
nosed with early gastric carcinoma, and under-
went endoscopic mucosal resection and were 
followed up for a mean of three years after being 
randomized to eradication therapy (n  =  272) 
or standard care (n = 272). There were 9 (3.3%) 
and 24 (8.8%) incident metachronous cases of 
gastric carcinoma diagnosed in the interven-
tion and placebo arms respectively, a statistically 
significant difference (hazard ratio [HR], 0.35; 
95%CI: 0.16–0.78). In an earlier non-randomized 
study (Uemura et al., 1997), 132 H. pylori posi-
tive patients, 44–85 years of age, diagnosed with 
early gastric carcinoma and treated with endo-
scopic mucosal resection, were followed up for 
two years after 65 patients received eradication 
therapy, and 67 did not. There were no gastric 
carcinomas in the intervention group and six 
(9%) in the control group. [The Working Group 
viewed these two latter studies as not applicable 
to populations outside Japan.]
(g) Synthesis
Since the previous Monograph, a substantial 
number of prospective observational studies, both 
nested case–control and cohort, had provided 
results supportive of an association between H. 
pylori infection and non-cardia gastric carci-
noma. The magnitude of the risk is increased 
when more sensitive assay procedures are used 
and there appears to be a stronger association 
with CagA-positive strains of H. pylori. Results 
from randomized studies have not had sufficient 
power to evaluate the effect of the impact of H. 
pylori eradication on gastric carcinoma risk.
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2 .1 .2 Cardia gastric carcinoma
Results are available from ten prospective 
cohort studies with nested case–control designs. 
These are summarized in Table 2.4 (available at 
http://monographs.iarc.fr/ENG/Monographs/
vol100B/100B-10-Table2.4.pdf).
(a) Nested case–control analyses within cohort 
studies 
The pooled reanalysis (Helicobacter and 
Cancer Collaborative Group, 2001) presented 
results based on 274 cases of cardia gastric carci-
noma and 827 control subjects derived from 
12 independent prospective cohort studies in 
nine countries (the United Kingdom, Finland, 
Sweden, Norway, Iceland, USA, Taiwan (China), 
and Japan) analysed using a nested design. Cases 
were matched to controls on the basis of study, 
sex, age and date of blood sample collection 
but no further adjustment in the analysis was 
possible. In all studies, H. pylori infection status 
was determined by a conventional ELISA for IgG 
antibodies against H. pylori. The overall matched 
odds ratio for the risk of cardia gastric carcinoma 
was 0.99 (95%CI: 0.72–1.35). Odds ratios for indi-
vidual studies varied from 0.40–1.77.
Five of the individual studies included in 
the pooled reanalysis accrued more cases, and 
updated results have since been published 
(Kamangar et al., 2006a, 2007; Knekt et al., 2006; 
Hansen et al., 2007; Simán et al., 2007). Odd 
ratios showed a statistically significant reduced 
risk (0.27 and 0.31) in two studies, no significant 
difference from unity in two further studies (0.82 
and 1.5), and a significantly increased risk in one 
study (1.64).
New results were reported from four further 
prospective studies with nested case–control 
designs (Shin et al., 2005; Sasazuki et al., 2006; 
Palli et al., 2007; Mitchell et al., 2008). Using 
ELISA for IgG status to determine H. pylori 
infection status, odds ratios for cardia gastric 
carcinoma varied from 0.8–3.7 but none was 
statistically significant.
In the pooled reanalysis (Helicobacter and 
Cancer Collaborative Group, 2001) when the 
results were stratified by period of follow-up, the 
odds ratio for gastric carcinoma with cases diag-
nosed less than 10 years after recruitment was 
1.23 (95%CI: 0.86–1.75), and for those with cases 
diagnosed 10 or more years after recruitment, 
0.46 (95%CI: 0.23–0.90). A similar relationship 
in the magnitude of the odds ratio with period 
of follow-up was reported in one of the updated 
studies (Kamangar et al., 2006a), but not in 
another (Kamangar et al., 2007).
In the pooled reanalysis (Helicobacter and 
Cancer Collaborative Group, 2001), no substan-
tive difference in the odds ratios between men 
(0.98; 95%CI: 0.68–1.40) and women (1.03; 95%CI: 
0.55–1.92) was observed. There was, however, 
a difference between gastric carcinoma with 
intestinal (0.42; 95%CI: 0.24–0.75) and diffuse 
(0.93; 95%CI: 0.21–4.10) histological types. [The 
Working Group noted that this difference was 
unexplained.]
(b) Meta-analysis
Only one meta-analysis has reported specifi-
cally on the risk of cardia gastric carcinoma 
(Huang et al., 1998). Based on the results from six 
studies with several study designs, the summary 
odds ratio was 0.93 (95%CI: 0.62–1.38), with no 
significant heterogeneity.
(c) Impact of H . pylori CagA status
A meta-analysis (Huang et al., 2003) including 
results from both retrospective and prospective 
studies identified 16 eligible studies, ten of which 
provided results stratified by cardia subsite loca-
tion of the tumour. The odds ratio associated 
with H. pylori infection (determined by H. pylori 
seroprevalence) was 1.13 (95%CI: 0.75–1.70); a 
further analysis, confined to H. pylori-positive 
cases and controls, showed a risk associated with 
CagA positivity of 0.70 (95%CI: 0.44–1.10).
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Three nested case–control studies have 
reported results in which the risk of cardia gastric 
carcinoma in relation to CagA-positive and 
-negative status can be compared. Respectively, 
these odds ratios were 0.43 and 0.21 (Kamangar 
et al., 2006a), 0.8 and 0.8 (Palli et al., 2007), and 
1.75 and 1.35 (Kamangar et al., 2007). In the other 
nested case–control study reporting on CagA-
positive status (Simán et al., 2007), an increased 
odds ratio of 2.3 in comparison with that for H. 
pylori infection alone (OR, 1.3) was reported.
[The Working Group noted that there are 
substantial difficulties in the reliability of clas-
sification of cardia gastric carcinoma. Some 
studies may be more inclusive of distal non-
cardia gastric carcinoma and other studies may 
be more inclusive of lower oesophageal adeno-
carcinoma cases, which may lead to variability 
of outcome between studies.]
2.2 Gastric mucosa-associated 
lymphoid tissue (MALT) 
lymphoma
Results are available from one prospec-
tive cohort study with a nested case–control 
design and one retrospective case–control study. 
These are summarized in Table 2.5 available at 
http://monographs.iarc.fr/ENG/Monographs/
vol100B/100B-10-Table2.5.pdf and Table  2.6 
available at http://monographs.iarc.fr/ENG/
Monographs/vol100B/100B-10-Table2.6.pdf.
2 .2 .1 Nested case–control analysis within a 
cohort study
Parsonnet et al. (1994) analysed a database 
of 33 cases of gastric non-Hodgkin lymphoma 
and 132 matched controls. H. pylori infection 
status was determined by ELISA for IgG anti-
bodies and the odds ratio for risk of gastric non-
Hodgkin lymphoma was 6.3 (95%CI: 2.0–19.9). 
For low-grade MALT lymphoma, the odds ratio 
was 2.8 (95%CI: 0.2–28.5).
2 .2 .2 Case–control study
A study from Spain (de Sanjosé et al., 2004) 
compared ten cases of gastric lymphoma (four 
gastric MALT) with matched hospital controls. 
H. pylori infection status was determined by 
ELISA for IgG antibodies, the odds ratio for the 
risk of both gastric lymphoma and gastric MALT 
was infinity (all cases infected).
2 .2 .3 Impact of H . pylori eradication
A total of 16 uncontrolled studies 
(Wotherspoon et al., 1993; Stolte et al., 1994; 
Bayerdörffer et al., 1995; Neubauer et al., 1997; 
Pinotti et al., 1997; Savio et al., 2000; Chen et al., 
2001, 2005; Fischbach et al., 2004; Nakamura 
et al., 2005, 2008; Wündisch et al., 2005; Hong 
et al., 2006; El-Zahabi et al., 2007; Terai et al., 
2008; Stathis et al., 2009) reported on the effect 
of H. pylori eradication therapy on B-cell MALT 
gastric lymphoma regression (see Table  2.7 
available at http://monographs.iarc.fr/ENG/
Monographs/vol100B/100B-10-Table2.7.pdf). In 
all studies, the eradication rates were very high 
(in general over 94%), and were accompanied by 
high rates of complete remission of the MALT 
lymphoma (62–100%). Where assessed, remission 
was more strongly associated with the success-
fully treated patients. Subsequent relapse rates, 
where reported, were in the order of 10% over 
the 1–3  year follow-up periods. [The Working 
Group recognized that these results made it 
unlikely that ethics committees would approve 
randomized intervention studies on the effect of 
H. pylori eradication on MALT regression.]
2 .2 .4 Synthesis
Despite the small number of observational 
studies of B-cell lymphoma in relation to H. pylori 
infection, evidence from the eradication studies 
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is critically important. Treatment of patients to 
eradicate H. pylori is strongly associated with 
remission of low-grade lymphomas. Therefore, 
infection with H. pylori causes low-grade B-cell 
MALT gastric lymphoma in humans.
2.3 Cancer of the oesophagus
2 .3 .1 Oesophageal adenocarcinoma
Results are available from two prospective 
cohort studies with nested case–control designs, 
15 retrospective case–control studies, and three 
meta-analyses.
(a) Cohort studies
Two studies (de Martel et al., 2005; Simán 
et al., 2007) analysed a database of 51 and 12 
cases of oesophageal adenocarcinoma, respec-
tively, and reported adjusted odds ratios of 
0.37 (95%CI: 0.16–0.88) and 0.46 (95%CI: 
0.07–2.6) respectively (see Table 2.8 available at 
http://monographs.iarc.fr/ENG/Monographs/
vol100B/100B-10-Table2.8.pdf). Analysis for 
CagA-positive infection status did not substan-
tially modify these results. Both studies adjusted 
for smoking but only the former adjusted for 
body mass index [The Working Group noted 
that this is a potential confounder for this type 
of cancer.]
(b) Case–control studies
Among the available studies, four were popu-
lation-based (El-Omar et al., 2003; Wu et al., 
2003; Ye et al., 2004; Anderson et al., 2008). Two 
studies (Ye et al., 2004; Anderson et al., 2008) 
reported significantly reduced odds ratios of 
0.3 and 0.38, respectively. The other two studies 
(El-Omar et al., 2003; Wu et al., 2003) reported 
odds ratios that were not significantly different 
from unity; however, the odds ratios associated 
with CagA positivity decreased to 0.82 and 0.33, 
respectively, with the latter being statistically 
significant.
Three studies (Wu et al., 2003; Ye et al., 
2004; Anderson et al., 2008) adjusted for body 
mass index, and all of them adjusted for other 
potential confounders. One further hospital-
based study (Früh et al., 2008) that used friends 
and spouses as controls reported an odds ratio 
of 0.71 (0.95%CI: 0.4–1.0) for H. pylori infec-
tion, with borderline statistical significance after 
adjustment for confounders including body mass 
index.
Nine other case–control studies were 
based on comparisons within clinical patient 
groups and all reported odds ratios that were 
either significantly reduced or not significantly 




A meta-analysis (Islami & Kamangar, 2008) 
reviewed the results from 13 studies (2 prospec-
tive and 11 retrospective case–control studies) 
of oesophageal adenocarcinoma. A comparison 
of 840 cases with 2890 controls and an assess-
ment of H. pylori infection status mainly by 
ELISA resulted in a summary odds ratio of 0.56 
(95%CI: 0.46–0.68). There was no statistically 
significant heterogeneity between studies, and no 
evidence of publication bias. Sensitivity analyses 
to include only large studies or only population-
based studies or similar methods for assessment 
of infection did not substantially modify the 
odds ratio. Five studies included comparisons of 
CagA-positive and -negative strain status against 
H. pylori-negative subjects, and for these, the 
summary odds ratios were 0.41 (95%CI: 0.28–
0.62) and 1.08 (95%CI: 0.76–1.53), respectively.
Two further meta-analyses (Rokkas et al., 
2007; Zhuo et al., 2008), which included fewer 
studies, also reported a significant decrease in 
risk with both H. pylori and CagA positivity (see 






The observational epidemiological studies 
are all consistent in showing a lack of associa-
tion between H. pylori infection and an increased 
risk of oesophageal adenocarcinoma. Several of 
these studies as well as the meta-analyses show a 
statistically significant reduced risk of oesopha-
geal cancer.
2 .3 .2 Oesophageal squamous cell carcinoma
Results are available from two prospective 
cohort studies with nested case–control designs, 
five retrospective case–control studies, and three 
meta-analyses.
(a) Cohort studies
Two studies (Kamangar et al., 2007; Simán 
et al., 2007) analysed a database of 300 and 37 
cases of oesophageal squamous cell carcinoma 
respectively. The adjusted odds ratios for H. 
pylori infection were 1.17 (95%CI: 0.88–1.57) and 
0.56 (95%CI: 0.24–1.3), respectively. CagA infec-
tion status did not substantially modify these 




Four studies were population-based (El-
Omar et al., 2003; Wang et al., 2003a; Ye et al., 
2004; Wu et al., 2005). One of these (El Omar 
et al., 2003) included 53 cases and reported a 
statistically significant increased odds ratio of 
2.11; another study (Wu et al., 2005) included 
127 cases and reported a significantly reduced 
odds ratio of 0.51. The other two studies (Wang 
et al., 2003a; Ye et al., 2004) included 63 and 85 
cases, respectively, and reported odds ratios not 
significantly different from unity. The studies all 
adjusted for age and sex but differed in the extent 
of adjustment for other confounding factors. Only 
one study (Wu et al., 2005) adjusted for alcohol 
consumption. One hospital-based study (Iijima 
et al., 2007) reported a non-significantly increased 
odds ratio of 1.40 (95%CI: 0.62–3.15 [calculated 




One meta-analysis (Islami & Kamangar, 
2008) reviewed results from nine studies (two 
prospective and seven retrospective case–control 
studies) of oesophageal squamous cell carcinoma. 
A comparison of 921 cases of oesophageal squa-
mous cell carcinoma with 2743 controls and an 
assessment of H. pylori infection status mainly 
by ELISA resulted in a summary odds ratio of 
1.10 (95%CI: 0.78–1.55). There was statistically 
significant heterogeneity between studies, but no 
evidence of publication bias. Sensitivity analyses 
to include only large studies or only population-
based studies or similar methods for assessment 
of infection did not substantially modify the risk. 
Four studies included comparisons of CagA-
positive and -negative strain status against H. 
pylori-negative subjects: the meta-relative risks 
were 1.01 (95%CI: 0.80–1.27) and 1.41 (95%CI: 
1.00–1.97), respectively. Two further meta-
analyses (Rokkas et al., 2007; Zhuo et al., 2008), 
which included fewer studies, reported similar 




The Working Group concluded that there 
was little evidence of an association between H. 
pylori infection and the risk of oesophageal squa-
mous cell carcinoma.
2.4 Other cancers
2 .4 .1 Cancer of the liver
(a) Hepatocellular carcinoma
Results are available from 17 retrospective 
case–control studies, and a meta-analysis.
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Two studies, based on 46 and 11 cases and 
using ELISA to detect IgG antibodies to H. pylori, 
showed odds ratios [calculated by the Working 
Group] that were significantly increased in one 
study (OR, 3.02; 95%CI: 1.12–8.34) (Leone et al., 
2003), but not in the other (OR, 2.3; 95%CI: 0.15–
15.1) (Dore et al., 2002) (see Table 2.14 available 
at http://monographs.iarc.fr/ENG/Monographs/
vol100B/100B-10-Table2.14.pdf). No adjust-
ment was carried out for potential confounders. 
All the other studies used PCR assays of liver 
biopsy samples from cases and controls to 
detect the presence of Helicobacter species (see 
Table 2.15 available at http://monographs.iarc.fr/
ENG/Monographs/vol100B/100B-10-Table2.15.
pdf). The primers used for the PCR assays (16s 
rDNA primers) were for genes associated with 
the Helicobacter genus but were not specific for 
H. pylori. In some of the studies, DNA from a 
subsample of positive samples was sequenced, 
and found to be specific for H. pylori. A higher 
proportion of positive results in 13/15 studies 
were observed among cases when compared to 
controls. Cases numbers were small in all studies, 
the largest having 48 cases, and studies varied in 
the extent to which they adjusted for potential 
confounding factors.
[The Working Group noted the small size of 
these studies, the potential problems of speci-
ficity associated with PCR assays, the use of 
opportunistic control series selected from patient 
groups, and the lack of adjustment for potential 
confounders.]
A meta-analysis (Xuan et al., 2008) reviewed 
results from ten studies (nine case–control and 
one cross-sectional) (see Table  2.16 available at 
http://monographs.iarc.fr/ENG/Monographs/
vol100B/100B-10-Table2.16.pdf). A comparison 
of 242 cases of hepatocellular carcinoma with 280 
hospital controls and an assessment of H. pylori 
infection status by PCR on liver biopsy samples 
resulted in a summary odds ratio of 13.63 (95%CI: 
7.90–23.49). [The Working Group were concerned 
about the comparability of studies within this 
meta-analysis as a wide variety of control groups 
and methodologies were employed.]
(b) Cholangiocarcinoma
A review (de Martel et al., 2009) summarized 
results from eight studies in which PCR was used 
to detect the presence of Helicobacter species in 
bile or tissue biopsies from patients with biliary 
tract cancers and controls usually with benign 
biliary tract diseases (see Table 2.17 available at 
http://monographs.iarc.fr/ENG/Monographs/
vol100B/100B-10-Table2.17.pdf). The primers 
used for the PCR assays were not specific for 
H. pylori. In 2/8 studies, none of the cases was 
reported as positive but the other six studies all 
showed a higher proportion of positive results in 
cases compared to controls. None of these studies 
included more than 20 cases.
[The Working Group noted the small size of 
these studies, the potential problems of speci-
ficity associated with PCR assays, the use of 
opportunistic control series selected from patient 
groups, and the lack of adjustment for potential 
confounders.]
2 .4 .2 Cancer of the colorectum
Results are available from two prospective 
cohort studies with a nested case–control design, 
12 retrospective case–control studies, and one 
meta-analysis.
(a) Nested case–control analyses with cohort 
studies
Two studies (Thorburn et al., 1998; Limburg 
et al., 2002) were based on 233 and 118 cases of 
colorectal cancer associated with H. pylori infec-
tion, and reported non-significant adjusted odds 
ratios of 0.9 (95%CI: 0.5–1.5) and 1.05 (95%CI: 
0.63–1.74), respectively, associated with H. pylori 
infection (see Table 2.18 available at http://mono-
graphs.iarc.fr/ENG/Monographs/vol100B/100B-
10-Table2.18.pdf). CagA-positive infection status 
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did not influence the latter result, and was not 
tested for in the former study.
(b) Case–control studies
Out of 11 studies, three (Hartwich et al., 2001; 
Machida-Montani et al., 2007; Zumkeller et al., 
2007) were population-based (see Table  2.19 
available at http://monographs.iarc.fr/ENG/
Monographs/vol100B/100B-10-Table2.19.pdf). 
Two of these (Hartwich et al., 2001; Zumkeller 
et al., 2007), based on 80 and 384 cases, respec-
tively, reported statistically significant odds 
ratios of 3.78 and 1.41, respectively, for colo-
rectal cancer associated with H. pylori infection. 
The third study (Machida-Montani et al., 2007) 
included 121 cases, and reported no signifi-
cant risk. CagA-positive status did not affect 
the observed risk. Three studies (Moss et al., 
1995; Fireman et al., 2000; Siddheshwar et al., 
2001) were based within colonoscopy clinics, 
and included 41, 51 and 189 cases, respectively, 
with adjusted odds ratios for colorectal cancer 
associated with H. pylori infection reported to 
be between 0.74–2.43, none of which statisti-
cally significant. One other colonoscopy clinic 
study (Fujimori et al., 2005) included 154 cases 
of adenocarcinomas, and reported a statistically 
significant odds ratio of 1.8.
Four studies were hospital-based (Penman 
et al., 1994; Meucci et al., 1997; Shmuely et al., 
2001; D’Onghia et al., 2007), and did not adjust 
for any potential confounders.
(c) Meta-analysis
A meta-analysis (Zumkeller et al., 2006) 
reviewed results from 11 studies (two prospective 
and nine retrospective case–control studies) (see 
Table 2.20 available at http://monographs.iarc.fr/
ENG/Monographs/vol100B/100B-10-Table2.20.
pdf). A total of 899 cases of colorectal cancer were 
compared with 1476 controls; H. pylori infection 
status was assessed by ELISA in ten studies and 
by urea breath test in one study. The resulting 
meta-relative risk was 1.4 (95%CI: 1.1–1.8). The 
meta-relative risk for the 2 prospective studies 
was 1.0 (95%CI: 0.8–1.4).
2 .4 .3 Cancer of the pancreas
Nilsson et al. (2002) analysed pancreatic 
biopsy specimens from patients undergoing 
surgery for possible pancreatic cancer to detect 
the presence of Helicobacter species and H. pylori 
by bacterial culture, PCR, and DNA sequencing. 
Five of six pancreatic ductal carcinomas and one 
malignant neuroendocrine cancer were positive 
for Helicobacter species by PCR with genus-
specific primers; however, none of the five was 
positive for H. pylori by PCR with genus-specific 
primers. Two of the 16S rDNA PCR fragments 
were sequenced and compared with the GenBank 
database by a BLAST search (www.ncbi.nlm.nih.
gov). One of those was 98% similar to the 16S 
rDNA of Helicobacter species liver 3, clustering 
to a phylogenetic group that includes H. pylori. 
The other was 99% similar to H. pullorum, 
and clustered to a phylogenetic group that also 
contains H. bilis.
Results are available from three informative 
prospective cohort studies with nested case–
control designs, and one retrospective case–
control study.
Two of the three prospective cohort studies 
(de Martel et al., 2008; Lindkvist et al., 2008) 
based on 104 and 87 cases, respectively, of 
pancreatic cancer associated with H. pylori infec-
tion reported non-significant odds ratios of 0.85 
(95%CI: 0.49–1.48) and 1.25 (95%CI: 0.75–2.09), 
respectively. The third study (Stolzenberg-
Solomon et al., 2001) reported an odds ratio of 
1.87 (95%CI: 1.05–3.34) for H. pylori seroposi-
tivity. CagA-positive infection status did not 
influence any of these results. All studies adjusted 
for age, sex, and smoking (see Table 2.21 available 
at http://monographs.iarc.fr/ENG/Monographs/
vol100B/100B-10-Table2.21.pdf).
The retrospective case–control study (Raderer 
et al., 1998) included 92 cases of pancreatic 
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cancer. The odds ratio for the risk of pancreatic 
cancer associated with H. pylori infection was 
2.1 (95%CI: 1.1–4.1) (see Table 2.22 available at 
http://monographs.iarc.fr/ENG/Monographs/
vol100B/100B-10-Table2.22.pdf).
2 .4 .4 Cancer of the lung
Results are available from four retrospective 
case–control studies (see Table 2.23 available at 
http://monographs.iarc.fr/ENG/Monographs/
vol100B/100B-10-Table2.23.pdf).
Two retrospective case–control studies 
(Gocyk et al., 2000; Ece et al., 2005) included 
50 and 43 cases of lung cancer, respectively, 
and showed statistically significant associations 
with H. pylori infection with odds ratios [esti-
mated by the Working Group] of 5.06 and 13.33, 
respectively. The first study was not adjusted for 
smoking, and the second included only smokers. 
Two other studies (Philippou et al., 2004; 
Najafizadeh et al., 2007) included 72 and 40 cases 
of lung cancer, respectively, and neither showed a 
statistically significant association with H. pylori 
infection. [The Working Group noted that none 
of these four studies was adequately adjusted for 
smoking.]
2 .4 .5 Cancer of the head and neck
Results are available from four retrospective 
case–control studies (see Table 2.24 available at 
http://monographs.iarc.fr/ENG/Monographs/
vol100B/100B-10-Table2.24.pdf). The studies 
varied slightly in their case definitions. One 
(Grandis et al., 1997) included 21 cases of squa-
mous cell carcinomas of the head and neck and 
the odds ratio for H. pylori infection was 0.82 
(95%CI: 0.24–2.76). A second study among 
smokers (Aygenc et al., 2001) included 26 cases 
of squamous cell laryngeal cancers and the odds 
ratio for H. pylori infection [estimated by the 
Working Group] was 3.97 (95%CI: 1.32–11.89). A 
third study (Rubin et al., 2003) included 55 cases 
of squamous cell cancer of the upper aerodiges-
tive tract (excluding oesophagus) and six cases 
of laryngeal severe dysplasia, and the odds ratio 
for H. pylori infection [estimated by the Working 
Group] for the risk of cancer/severe dysplasia 
was 1.86 (95%CI: 1.03–3.35). The final study 
(Nurgalieva et al., 2005) included 119 cases of 
squamous cell carcinoma of the laryngopharynx, 
and the adjusted odds ratio for H. pylori infection 
was 1.27 (95%CI: 0.70–2.29).
2 .4 .6 Childhood leukaemia
One prospective cohort study (Lehtinen 
et al., 2005) with a nested case–control design 
compared 341 children with acute lymphocytic 
leukaemia and 61 with other leukaemias with 
1212 matched controls (see Table 2.25 available 
at http://monographs.iarc.fr/ENG/Monographs/
vol100B/100B-10-Table2.25.pdf). H. pylori infec-
tion status was determined on maternal serum 
samples (first trimester) by ELISA for IgG and 
IgM antibodies. The adjusted odds ratio for risk 
of all leukaemias combined was 1.0 (95%CI: 
0.8–1.2) for IgG antibodies. Results for IgM anti-
bodies or specifically for acute lymphoblastic 
leukaemia did not differ substantially.
2.5 Cofactors
Two studies have found an effect modifica-
tion between smoking, H.pylori infection, and 
gastric carcinoma (Zaridze et al., 2000; Brenner 
et al., 2002). Zaridze et al. (2000) reported on 
the relative risk of gastric cancer associated with 
smoking by H. pylori status. Among men, the 
odds ratio for ever smoking compared to never 
smoking among H. pylori negatives was 1.0 
(95%CI: 0.5–2.1), and ever smoking compared to 
never smoking among H. pylori positives was 2.3 
(95%CI: 1.1–4.7), with a P  =  0.07 for the effect 
modification between smoking and H. pylori.
Brenner et al. (2002) evaluated the individual 
and joint association of smoking and H. pylori 
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infection as well as CagA-positive H. pylori infec-
tion. The adjusted relative risk of gastric cancer 
was 2.6 (95%CI: 1.2–5.7) for CagA-positive H. 
pylori infection in non-smokers compared to 
uninfected non-smokers, and CagA-positive H. 
pylori-infected smokers had a relative risk of 7.2 
(95%CI: 2.2–23.6). When analyses were restricted 
to non-cardia gastric cancer, the corresponding 
estimates of relative risk were 6.1 (95%CI: 2.3–16.5) 
for CagA-positive non-smokers and 16.6 (95%CI: 
4.3–67.2) for CagA-positive smokers. Not all 
studies found this effect. Machida-Montani et al. 
(2004) found gastric cancer risk associated with 
smoking and dietary factors to be independent of 
risk associated with H.pylori infection.
Plasma levels of vitamin C are inversely asso-
ciated with gastric cancer risk for both cardia 
and non-cardia, diffuse, and intestinal subsites. 
Vitamin C plasma levels showed no effect modi-
fication with H. pylori infection (Jenab et al., 
2006). Ekström et al. (2000), however, found an 
effect modification on non-cardia gastric carci-
noma risk by dietary intake of ascorbic acid, 
β-carotene, and α-tocopherol by H. pylori infec-
tion status. There was little or no association of 
these antioxidants in H. pylori-negative subjects, 
but 30–70% reductions in the relative risk of non-
cardia gastric carcinoma in H. pylori-positive 
subjects were observed with dietary intake incre-
ments of 50 mg/day of ascorbic acid, 3.0 mg/day 
β-carotene or 8.0 mg/day of α-tocopherol.
A significant effect modification between 
H. pylori infection and salted, smoked foods 
and processed meat has been observed (Phukan 
et al., 2006; Shikata et al., 2006; Epplein et al., 
2008). Two studies from East Asia have corre-
lated dietary salt intake with an increased risk 
of non-cardia gastric cancer over and above that 
attributable to H. pylori alone (Lee et al., 2003; 
Shikata et al., 2006).
In two recent studies, diets rich in fresh 
vegetables [and therefore high in antioxidants] 
intake were shown to be specially beneficial in 
reducing non-cardia gastric cancer risk among 
those who are H. pylori infected (Ekström et al., 
2000; Epplein et al., 2008).
Ekström et al. (1999) found that risk of 
gastric cancer associated with H. pylori infection 
was independent of risk associated with specific 
occupational exposures.
3. Cancer in Experimental Animals
3.1 Mongolian gerbil
The first report of gastric cancer induced 
by H. pylori in an animal model was published 
by Watanabe et al. (1998). The authors infected 
Mongolian gerbils (Meriones unguiculatus) with 
H. pylori strain TN2GF4, and observed the 
gastric lesions after 62 weeks. Gastric adenocar-
cinomas were detected in 10/27 infected animals 
vs 0/30 controls.
The Mongolian gerbil model infected with H. 
pylori has been cited in seven other publications 
(Honda et al., 1998; Hirayama et al., 1999; Zheng 
et al., 2004; Elfvin et al., 2005; Franco et al., 
2005, 2008; Romero-Gallo et al., 2008), and all 
except one (Elfvin et al., 2005) reported gastric 
adenocarcinoma developments. They developed 
late in the animals’ lives (62–90 weeks) except in 
three studies (Franco et al., 2005, 2008; Romero-
Gallo et al., 2008) where the development was 
extremely rapid (8–12 weeks).
It is noteworthy that in other experiments 
using chemical carcinogens in Mongolian gerbils 
and where H. pylori-infected animals were used 
as controls, none of the controls developed 
gastric cancer (Sugiyama et al., 1998; Tokieda 
et al., 1999; Shimizu et al., 1999; Nozaki et al., 
2002; Kato et al., 2006) with a follow-up of 40–53 
weeks, or in the study of Cao et al. (2007) despite 
a follow-up of 70 weeks.
These results indicate that the Mongolian 
gerbil is not the most reliable model for the devel-
opment of gastric adenocarcinomas even after a 
long follow-up. The reason could be linked to 
the animal strain used. Mongolian gerbils were 
first bred in Japan, then exported to the USA, 
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and later to Europe. The genetic background 
of the animals may have evolved differently 
among the different colonies. The H. pylori strain 
used may also be the cause of these discrepant 
results. Two strains were essentially used (ATCC 
43  504 and TN2GF4) but when Franco et al. 
(2005) used a Mongolian gerbil adapted strain 
(7.13) derived from the parent strain B128, they 
observed gastric adenocarcinomas in 59% of the 
animals. The high susceptibility of this strain 
was confirmed in two further studies by Franco 
et al. (2008) and Romero-Gallo et al. (2008). 
Another variable is the criteria used for grading 
the observed pathology. This point was raised 
by Elfvin et al. (2005) who published a negative 
result. Furthermore, in the Mongolian gerbil 
model, no metastasis was reported nor did any 
gerbil die of gastric carcinoma.
The limitation of this model led to test the 
impact of H. pylori infection in Mongolian gerbils 
receiving well known chemical carcinogens, e.g. 
N-methyl-N-Nitrosourea or N-methyl-N’-nitro-
N-nitrosoguanidine at different concentrations. 
Eight studies used such a design and in all of 
them, there was a synergistic effect of H. pylori 
infection on the incidence of gastric carcinomas 
compared to the incidence observed after treat-
ment with the carcinogen alone.
In some studies gerbils were infected with 
H. pylori and then treated also with a chemical 
carcinogen to test the action of pharmacological 
agents such as a cyclooxygenase 2 inhibitor 
(etodolac) (Magari et al., 2005), and an antioxida-
tive and anti-inflammatory compound (canolol) 
(Cao et al., 2008), both of which have a protective 
effect. The impact of a salty diet was also tested 
in two studies (Nozaki et al., 2002; Kato et al., 
2006), and a synergy between H. pylori infection 
and a high-salt diet was observed. Romero-Gallo 
et al. (2008) and Nozaki et al. (2003) showed the 
benefit of an early eradication using clarithro-




3 .2 .1 Inbred mouse
The progression of the gastric lesions after 
H. pylori infection has also been observed in 
inbred mice, C57BL/6 and BALB/c. Despite a 
long follow-up of 80 and 100 weeks by Kim et al. 
(2003) and Wang et al. (2003b), respectively, no 
gastric adenocarcinoma occurred, only gastric 
lymphoma in the latter. When C57BL/6  mice 
crossed with 12996/SvEv mice were infected by 
H. pylori and submitted to a high-salt diet, high-
grade dysplasia occurred but not adenocarci-
noma (Rogers et al., 2005).
In a study where C57BL/6 mice infected with 
H. felis received an eradication treatment after 
different time periods, Cai et al. (2005) observed 
adenocarcinomas in all untreated infected 
animals after 24 months, no adenocarcinomas 
if the treatment was given after 2 or 6  months 
of infection, and a decrease in the incidence of 
adenocarcinomas if the treatment was delayed to 
the 12th month.
3 .2 .2 Transgenic mouse
The first model (of five transgenic models) 
used transgenic mice deficient for TGF-β 
infected with H. pylori. Gastric adenocarcinoma 
or dysplasia developed in 85.7% of the mice after 
36 weeks (Hahm et al., 2002).
The second model involves transgenic mice 
overexpressing gastrin (INS-GAS mice). A first 
study showed that infection of INS-GAS male 
mice with H. pylori strain SS1 could induce 
gastric adenocarcinoma in 4/6 male animals 
within 30 weeks (Fox et al., 2003a). This finding 
was repeated in another study (3/7 gastric adeno-
carcinoma within 28 weeks), and the protective 
effect of estradiol was shown (Ohtani et al., 
2007). In a study designed to determine the 
impact of H. pylori eradication therapy (Lee et al., 
2008), gastric carcinogenesis was inhibited. In 












Table 3 .1 Studies of gastric cancer in Mongolian gerbils infected by H . pylori by gavage with or without modifying agents
Duration 
Reference
Dosing regimen, strain 
Gender 
Animals/group at start
Incidence of tumours Significance Comments
62 wk 
Watanabe et al. (1998)






[P=0.0002] Well differentiated intestinal type 
cancer of the pyloric region
18 mo 
Honda et al. (1998)







23 mo (average) 
Hirayama et al. (1999)
H. pylori, ATCC 43 504 
(M) 
56 (total), 3 (controls)
Adenocarcinoma; Carcinoids 
12–18 mo: 1/16; 4/16 
18–24 mo: 0/14; 3/14 
>24 mo: 0/24; 11/26 
Controls 0/3; 0/3
[NS] Carcinoids were found in the fundus 
region of the stomach
84 wk 
Zheng et al. (2004)
H. pylori, ATCC 43 504 or H. pylori 161 
(M, F)  
1: H. pylori ATCC 43 504: n=18 
2: H. pylori 161: n=18 
3: Controls: n=10
Adenocarcinoma: 
1: 1/6 (16.6%) 
2: 2/11 (18.2%) 
3: 0/10
[NS], Group 1 and 
2 vs 3
18 mo 
Elfvin et al. (2005)
1: H. pylori, TN2GF4: n=23 
2: H. pylori, SS1: n=20 
3: Controls: n=18 
(M) 
Interim sacrifices at 3, 6 and 12 mo 
Group size: 3–10 animals
No adenocarcinoma observed 
in all 12 groups
[Age of the animals at start is 
described as ‘sixty-seven-week-old’, 
which could be a typo.] 
Discussion on the interpretation 
of the pathological findings to 
conclude adenocarcinoma: the 
authors conclude that, so far, 
adenocarcinomas have not yet been 
shown convincingly to develop in 
infected gerbils
4 wk, 8 wk or 16 wk 
Franco et al. (2005)
(M) 
Experiment 1
Adenocarcinoma: [P<0.0001]; Group 
B (8 wk) vs D
H. pylori strains 7.13 is gerbil 
adapted, derived from parent strain 
B128 (human gastric ulcer strain). 
Experiment 2 is very likely to be 
positive at Weeks 8 and 16
A. H. pylori B128: n=16 A: 0/16 (8 wk)
B. H. pylori 7.13: n=16 B: 4 wk: 2/8 (25%), 8 wk: 6/8 
(75%)
Experiment 2 
C. H. pylori 7.13: n=116
C: 4 wk: 17% [incidence NS], 8 
wk: 59% [incidence NS], 16 wk: 
59% [incidence NS]























Dosing regimen, strain 
Gender 
Animals/group at start
Incidence of tumours Significance Comments
14–18 wk 
Romero-Gallo et al. (2008)
5 × 109 CFU H. pylori strain 7.13 Adenocarcinoma:
1. Eradication therapy at 4 wk 
post infection with lansoprazole, 
amoxicillin and clarithromycin, orally, 
for 2 wk (daily). Sacrifice 8 wk after end 
of treatment
0/8 P=0.01 
Group 1 vs 2
Eradication treatment decreased the 
carcinoma incidence
2. Controls infected for 14 wk 6/20 (33%)
3. Eradication therapy at 8 wk 
post infection with lansoprazole, 
amoxicillin and clarithromycin, orally, 
for 2 wk (daily). Sacrifice 8 wk after end 
of treatment
1/14 (7%) P=0.027 
Group 3 vs 4
4. Controls infected for 18 wk 5/10 (50%)
12–52 wk 
Franco et al. (2008)
(M) Adenocarcinoma: cagA, cytotoxin-associated gene 
vacA, vacuolating cytotoxin gene1. H. pylori 7.13 (12–16 wk, n=18; 24–30 
wk, n=19; 40–52 wk, n=9)




2. H. pylori 7.13 cagA- (12–16 wk, n=18; 
24–30 wk, n=20; 40–52 wk, n=17)
0% (0/18), 0% (0/20), 0% (0/17) [NS], [NS], [NS],
3. H. pylori 7.13 vacA- (12–16 wk, n=13; 
24–30 wk, n=9; 40–52 wk, n=17)




4. Controls (12–16 wk, n=19; 24–30 wk, 
n=5; 40–52 wk, n=13)
0% (0/19), 0% (0/5), 0% (0/13)
MNNG (in the drinking-water)
52 wk 
Tokieda et al. (1999)
109 CFU H. pylori, ATCC 43 504 
(M)
Group 3: poorly differentiated GC 
Group 4: well differentiated GC
Adenocarcinoma:
1. Controls: n=30 1: 0/20
2. H. pylori: n=25 2: 0/14
3. MNNG 50 ppm orally (20 wk): n=27 3: 3/17 (17.6%) P<0.05, 
Group 4 vs 34. MNNG 50 ppm orally (20 wk) + H. 
pylori: n=25
4: 4/6 (66.7%)











Table 3 .1 (continued)
Duration 
Reference
Dosing regimen, strain 
Gender 
Animals/group at start
Incidence of tumours Significance Comments
50 wk 
Shimizu et al. (1999)
108 CFU H. pylori, ATCC 43 504 
(M)
Adenocarcinoma:
1: MNNG 300 ppm (10 wk) followed by 
H. pylori
1: 12/27 (44%) P<0.01, Group 1 
vs 2
2: MNNG 300 ppm (10 wk) alone 2: 1/19 (5.3%)
3: MNNG 60 ppm (10 wk) followed by 
H. pylori
3: 6/27 (24%) P<0.05, Group 3 
vs 4
4: MNNG 60 ppm (10 wk) alone 4: 0/20
5: H. pylori followed by MNNG 100 
ppm (30 wk)
5: 4/27 (14.8%)
6: MNNG 100 ppm (30 wk) alone 6: 3/18 (16.7%)
7: H. pylori followed by MNNG 20 ppm 
(30 wk)
7: 15/25 (60%) P<0.001, Group 7 
vs 8
8: MNNG 20 ppm (30 wk) alone 8: 1/19 (5%)
9: H. pylori alone 9: 0/20
10: Controls 10: 0/20
MNU (in the drinking water)
40 wk 
Sugiyama et al. (1998)




A. H. pylori followed by MNU 10 ppm 
(20 wk)
A: 7/19 (36.8%) P<0.01, Group A 
vs B
B. MNU 10 ppm (20 wk) alone B: 0/18
C. H. pylori followed by MNU 3 ppm 
(20 wk)
C: 1/20 (5%)
D. MNU 3 ppm (20 wk) alone D: 0/18
Experiment 2
E. MNU 30 ppm (6 wk) followed by 
H. pylori
E: 6/18 (33.3%) P<0.05, Group E 
vs F
F. MNU 30 ppm (6 wk) alone F: 0/18
G. MNU 10 ppm (10 wk) followed by 
H. pylori
G: 1/19 (5.3%) P<0.005, 
Group 1 vs 3 
NS; Group 2 vs 4H. MNU 10 ppm (10 wk) alone H: 0/20























Dosing regimen, strain 
Gender 
Animals/group at start
Incidence of tumours Significance Comments
50 wk 
Nozaki et al. (2002)
108 CFU H. pylori, ATCC 43 504 
(M) 
- Groups 1,2,3 & 4 
MNU (20 ppm) orally alternate wk for 
a total of 5 wk 
- Groups 5,6,7 & 8 
Controls 
H. pylori infection at Week 11 in 
Groups 1 & 2, 5 & 6 and vehicle in 
groups 3 & 4, 7 & 8. 
High salt diet at Week 12 in Groups 1 
& 3, 5 & 7 and control diet in Groups 2 
& 4, 6 & 8
Carcinoma: 
1: 9/28 (32.1%) 







Synergy between H. pylori infection 
& high salt diet to promote GC
75 wk 
Nozaki et al. (2002)
108 CFU H. pylori, ATCC 43 504 
(M)
Carcinoma:
- Groups A, B, C, D, E 
MNU (30 ppm) orally alternate wks for 




P<0.05 vs C, 
P<0.005 vs D 
P<0.05 vs E
H. pylori eradication can reduce 
cancer incidence when given 
relatively early
- Groups A, B, C, D, F 
H. pylori infection at Week 10
D: 9/16 
E: 1/16
P<0.005 vs E and G
- Groups A, B, C 
Eradication therapy at Week 5, 25 and 
45 post infection with lansoprazole, 
amoxicillin and clarithromycin, orally
F: 0/8 
G: 0/9
- Group G 
not infected
53 wk 
Magari et al. (2005)
3x108 CFU H. pylori, ATCC 43 504; 
MNU: 10 ppm for 24 wk 
(M)
Adenocarcinoma: Etodolac is a selective 
cyclooxygenase 2 inhibitor 
preventing GC induction
A. H. pylori + MNU A: 4/27 (14.8%) p<0.05, group A 
and B vs DB. H. pylori + MNU + etodolac diet 
(5 mg/kg/d)
B: 8/34 (23.5%)
C. H. pylori + MNU + etodolac diet 
(10 mg/kg/d)
C: 3/34 (8.8%)
D. H. pylori + MNU + etodolac diet 
(30 mg/kg/d)
D: 0/39
E. Control (not infected) E: 0/16











Table 3 .1 (continued)
Duration 
Reference
Dosing regimen, strain 
Gender 
Animals/group at start
Incidence of tumours Significance Comments
50 wk 
Kato et al. (2006)
H. pylori, ATCC 43 504 
(M) 
20 groups 
G1–10: MNU (30 ppm) 
G11–20: no MNU 
G1–5 & G11–15: + H. pylori at Week 10  
+ increasing NaCl concentrations 
(0%, 2.5%, 5%, 10% in food or a gavage 
with diet with a saturated salt solution)
Adenocarcinoma: 
G1: 6/40 (15%) 
G2: 8/24 (33%) 
G3: 9/25 (36%) 
G4: 19/30 (63%) 
G5: 5/21 (24%) 
G8: 1/25 (4%) 
G6, G7, G9, G10–20: 0% 
(n=7–27)
 
P for trend <0.01 
(Groups G1→G4) 
p<0.01 
(Group G4 vs G1)
70 wk 
Cao et al. (2007)
108 CFU H. pylori, ATCC 43 504 
(M) 
8 groups A to H 
A & E: inoculated at Week 0 
B & F: inoculated at Week 12 
C & G: inoculated at Week 18  
D & H: Controls 
A, B, C & D received oral MNU (10 
ppm) at Week 20 during 20 wk
Adenocarcinoma: 
A: 13/20 (65%) 
B: 2/10 (20%) 
C: 3/13 (23%) 
D: 0/16 
E, F, G, H: 0/6
 
P<0.01; Group A 
vs D
18 wk 
Cao et al. (2008)
108 CFU H. pylori strain ATCC 43 504; 
(M); 
MNU: 10 ppm; BHT: used at 0.5 ppm 
in the diet; Canolol: 0.1% in the diet
Adenocarcinoma: Canolol, an antioxidative and anti 
inflammatory compound, prevents 
GC induction. 
BHT is an antioxidant additive
- Experiment 1:
A: H. pylori + Canolol + BHT 
B: H. pylori + BHT 
C: H. pylori  
D: Canolol + BHT 
E: BHT 
F: Control
A to F: 0/58
- Experiment 2: No MNU-only treated group
G: H. pylori + MNU + Canolol + BHT 
H: H. pylori + MNU + BHT 
I: H. pylori + MNU + Control diet 
J: Control + Canolol + BHT
G: 6/40 (15%) 
H: 13/33 (39.4%) 
I: 15/36 (41.7%) 
J: 0/5
P=0.031 
(Group G vs H) 
P=0.011 
(Group G vs I)
ATCC, American type culture collection; BHT, butylated hydroxytoluene; CFU, colony forming units; d, day or days; F, female; GC, gastric cancer; H. pylori, Helicobacter pylori; M, 
male; MNNG, N-methyl-N ’-nitro-N-nitrosoguanidine; MNU, N-methyl-N-nitrosourea; mo, month or months; NS, not significant; vs, versus; wk, week or weeks
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(loxtidine) and a CCk-2-receptor antagonist 
were given for 6 months (Takaishi et al., 2005), 
gastric carcinogenesis was also inhibited in H. 
felis-infected animals. [The Working Group 
noted that no tumour incidences were provided.] 
Again, in the Lee et al. (2008) study, an early 
eradication (8 weeks) almost prevented gastric 
cancer development.
The third model used transgenic p27 deficient 
mice infected with H. pylori strain SS1. Infection 
and p27-deficiency were synergistic in gastric 
cancer development (Kuzushita et al., 2005).
The fourth model used Trefoil factor family 
2 (TFF2)-deficient mice, with a B6129Sv strain 
background, infected with H. pylori strain SS1. 
Gastric adenocarcinomas were observed 19 
months after infection (Fox et al., 2007).
The fifth model used transgenic mice over-
expressing IL-1β. The two lines of mice built 
infected with H. felis developed gastric adenocar-
cinomas but at a low incidence (Tu et al., 2008).
3 .2 .3 Mouse models of gastric MALT 
lymphoma
Mouse models have been used as models of 
gastric MALT lymphomas. Gastric lymphomas 
histologically similar to the low-grade lymphoma 
observed in humans have been observed in mice 
infected for about 2 years with Helicobacter 
species, including H. pylori and H. felis. Enno 
et al. (1995) infected BALB/c mice with H. 
felis, and observed lymphoepithelial lesions 
(gastric lymphomas) in 25% of the mice after 
22–26 months. Such lesions were observed in 
both BALB/c and C57BL/6 mice infected with 
H. pylori in the study by Wang et al. (2003b) 
(see above), and in BALB/c mice infected with 
H. felis (Sutton et al., 2004). However, the best 
model corresponds to neonatal thymectomized 
mice because all animals infected by H. pylori 
developed these lesions within 12 months (Fukui 
et al., 2004).
See Table 3.2.
4. Other Relevant Data
It had been well established much before 
the discovery of Helicobacter pylori in 1983 that 
gastric cancers usually arose in a chronically 
inflamed stomach. Since the recognition of the 
role of H. pylori infection as the dominant cause 
of chronic gastritis, affecting approximately half 
of the world’s population, considerable evidence 
has accumulated that the nature of the chronic 
inflammatory process driven by H. pylori is of 
critical importance in gastric carcinogenesis.
H. pylori-related gastric carcinogenesis is 
a slow process, typically developing over 4–6 
decades, and accompanied by specific histolog-
ical changes (Correa et al., 1975). The ‘intestinal’ 
subtype of gastric adenocarcinoma develops 
through a preneoplastic sequence from chronic 
superficial gastritis through atrophic gastritis, 
intestinal metaplasia, and dysplasia. The ‘diffuse’ 
subtype is also usually preceded by many years of 
chronic H. pylori-associated gastritis, although 
the molecular pathways and histological changes 
involved in progression to cancer are less fully 
characterized (Peek & Blaser, 2002).
Investigating the mechanisms responsible for 
gastric carcinogenesis through studies in vivo 
necessitates investigating simultaneously the 
effects of the bacterium together with the asso-
ciated intense neutrophilic and mononuclear 
inflammatory response, which always accom-
panies H. pylori infection. In contrast, exam-
ining direct effects of the bacterium on gastric 
epithelial cells is only possible in co-culture 
experiments in vitro that are subject to numerous 
artefacts including the almost universal use of 
cancer-derived gastric epithelial lines, and the 
lack of the normal stroma, substrate and cell-cell 
















Dosing regimen, strain  
Gender 
Animals/group at start




Kim et al. (2003)
106 CFU H. pylori, SS1 
Gender NR 
H. pylori: n=25 
Controls: n=35
No gastric tumours observed
C57BL/6 & BALB/c 
23 mo 
Wang et al. (2003b)
H. pylori, 119p 
H. pylori, G50 




H. pylori: n=9 (total) 
Controls: n=4
C57BL/6 
 H. pylori 119p: 3/4  
H. pylori G50: 3/3 
 H. pylori SS1: 0/2 
 controls: 0/4
BALB/c 
H. pylori: n=9 (total) 
Controls: n=4
BALB/c 
 H. pylori 119p : 2/4 




Cai et al. (2005)
107 CFU H. felis 
(M) 
H. felis eradication therapy* after 2 , 6 & 
12 mo 
* made of tetracycline, metronidazole & 
bismuth subsalicylate orally for 14 d 
Controls: no eradication 
Number of animals per group NR
Adenocarcinoma when eradication of 
infection after 2 mo: 0%; 6 mo: 0%; 12 mo: 
30% 
Adenocarcinoma when no eradication: 
100%
C57BL/6 × 12 996/SvEv 
15 mo 
Rogers et al. (2005)
108 CFU H. pylori, SS1 
(M, F) (gender distribution NR) 
4 groups: 
1. 0.25% salt diet 
2. 7.5% salt diet 
3. 0.25% salt diet + H. pylori 
4. 7.5% salt diet + H. pylori 
Total n=62
Increased incidence of high-grade 
dysplasia (indefinite dysplasia or atypical 
hyperplasia) in Groups 3 & 4. No 
adenocarcinoma
High-salt diet switch Th1 
to a Th2 immune response. 
Th1: H. pylori-specific 


























Dosing regimen, strain  
Gender 
Animals/group at start
Incidence of tumours Significance Comments
TGF-β deficient mice
pS2-dnRII derived from 
FVB/N strain (wild-type) 
36 wk 
Hahm et al. (2002)
109 CFU H. pylori, 43 504 
(M, F)
Dysplasia or carcinoma:
1. TGF-β-deficient mice (infected): n=48 6/7 (85.7%)
2. wild-type (infected): n=48 0/6





Fox et al. (2003a)




4/6 males; 0/6 females; 0/8 male and female 
controls
Only males developed 
gastric adenocarcinomas
28 wk 
Ohtani et al. (2007)
108 CFU H. pylori strain SS1 
(M, F) 
1. Males: n=29 
2. Ovariectomized females: n=35 
3. Intact females: n=29 
4. Estradiol-treated* ovariectomized 
females: n=16 
Part of each group was infected or not. 
Sacrifice occurred at Weeks 16 & 28 post-
infection 
*Subcutaneous placement of a time-
release estradiol pellet 16 wk post-
infection
Adenocarcinoma: 
A. 3/7 (42%) infected males 
B. 1/10 (10%) infected ovariectomized 
females 
C. 0/7 infected intact females 
D. 0/8 E
2
 treated ovariectomized females 
(infected) 
F. 0% non infected males and females
Protective effect of estradiol
28 wk 
Lee et al. (2008)
109CFU H. pylori, SS1 
(M)
Adenocarcinoma: Protective effect of 
eradication to the greatest 
extent when given early1. Infected and untreated 1. 10/10 (100%) [P<0.0001], 
Group 1 vs 5
2. Eradication therapy* at 8 wk post-
infection
2. 1/11 (9%) [P<0.05], 
Group 1 vs 2
3. Eradication therapy* at 12 wk post-
infection
3. 8/9 (89%)
4. Eradication therapy* at 22 wk post-
infection
4. 6/12 (50%) [P<0.05], 
Group 1 vs 4
5. Non infected 5. 0/7
* with omeprazole, metronidazole and 















Dosing regimen, strain  
Gender 
Animals/group at start
Incidence of tumours Significance Comments
p27-deficient mice
17 mo 
Kuzushita et al. (2005) 
C57BL/6 (p27-deficient) 
C57BL/6 (wild-type)
109 CFU H. pylori, SS1 
(M, F) 
Sacrifice at 15, 30, 45, 60 and 75 wk post-
inoculation
Gastric carcinoma or dysplasia
1. wild-type + H. pylori 0/40, carcinoma Incidence for carcinoma (vs 
dysplasia) in Group 2 can 
not be ascertained from 
data provided






3. Wild-type (controls) 0/9, carcinoma




Fox et al. (2007) 
TFF2-/- C57BL/6 X Sv129 
C57BL/6 X Sv129 (wild-
type)
108 CFU H. pylori, SS1 
(M, F)
Gastric intraepithelial neoplasia
1. TFF2-deficient (infected): 20 2/10 (20%)
2. TFF2-deficient (not infected): 10 0%
3. Wild-type (infected): 20 1/20 (10%)
4. Wild-type (not infected): 10 0%
IL-1β transgenic mice
12 mo 
Tu et al. (2008)
108 CFU H. felis, ATCC 49179 
(M)
Carcinomas:
1. Infected mice overexpressing human 
IL-1β (line 19)
1/12 (8.4%)
2. Infected mice overexpressing human 
IL-1β (line 42)
1/10 (10%)
3. Infected control mice 0%

























Dosing regimen, strain  
Gender 
Animals/group at start
Incidence of tumours Significance Comments
MALT lymphoma mice models
26 mo 
Enno et al. (1995) 
BALB/c
109 CFU H.felis, ATCC 49179 
(F)
Lymphoepithelial lesions (gastric 
lymphoma)
Lesions are B-cell lymphoid 
infiltrates
1. Infected
a. Sacrifice 0–19 mo: 167 1a: 0/167
b. Sacrifice 22–26 mo: 80 1b: 20/80 (25%) [P<0.0001]
2. Controls (uninfected)
a. Sacrifice 0–19 mo: 95 2a: 0/95
b. Sacrifice 22–26 mo: 48 2b: 0/48
22 mo 
Sutton et al. (2004) 
BALB/c
108 CFU H. felis, CS1 
(F)
MALT lymphoma [P<0.0001], 
Group B vs A 
[P<0.0001], 
Group C 




A. Untreated (control): n=17 1/17
B. Infected: n=15 13/15
C. Immunised + infected.
- H. felis positive: n=4 4/4
- H. felis negative: n=15 5/15
12 mo 
Fukui et al. (2004)  
BALB/c
108 CFU H. pylori, TN2GF4 
(M, F) 
Sacrifice at 2, 4, 6 and 12 mo
Lymphoepithelial lesions (gastric 
lymphoma)
1. Non-thymectomized mice uninfected 
(Control): 40
0/40
2. Non-thymectomized mice infected: 40 0/40
3. Neonatal thymectomized (3 d) mice 
(nTx) uninfected: 40
0/40






ATCC, American Type Culture Collection; CFU, colony forming units; d, day or days; F, female; GC, gastric cancer; H. pylori, Helicobacter pylori; IL-1β, interleukin-1β; M, male; 
MALT, mucosa-associated lymphoid tissue; mo, month or months; TFF2, trefoilfactor family 2; vs, versus; wk, week or weeks
Helicobacter pylori
4.1 Data supporting the 
carcinogenicity of H . pylori
4 .1 .1 Genotoxicity linked to H .pylori infection
The intense gastric inflammatory infiltrate 
(gastritis) that accompanies gastric colonization 
by H. pylori in humans (or by related Helicobacter 
species in animal models) can generate potentially 
genotoxic reactive oxygen and nitrogen species 
from the inflammatory cells themselves, and 
from adjacent gastric epithelial cells (Macarthur 
et al., 2004; Ding et al., 2007).
H. pylori is not directly genotoxic in vitro, 
and evidence for genotoxicity related to H. pylori 
and/or the associated inflammatory response in 
vivo is relatively limited. An increased frequency 
of micronuclei in the peripheral blood lympho-
cytes of H. pylori-infected patients (Suárez et al., 
2007), more DNA strand breaks as shown by 
the comet assay (Ladeira et al., 2004), increased 
gastric mucosal DNA adduct (8-hydroxy-2′-
deoxyguanosine) formation (Farinati et al., 
1998), and an increased mutation frequency in 
the gastric mucosa of H. pylori- or felis-infected 
transgenic mutation reporter mice (Touati et al., 
2003; Jenks et al., 2003) have all been reported to 
occur relatively early during Helicobacter infec-
tion, before gastric cancer development.
Increased expression of activation-induced 
cytidine deaminase (AID), a DNA- and 
RNA-editing enzyme, was reported in H. pylori-
infected human gastric biopsies, and was noted 
to decrease following H. pylori eradication. 
When human gastric adenocarcinoma epithe-
lial cells were infected in vitro with H. pylori, 
the resulting AID overexpression occurred in 
parallel with the accumulation of mutations in 
p53, but much less frequently in β-catenin and 
c-myc genes; this supports a relatively specific 
role for AID in the generation of p53 mutation 
by H. pylori (Matsumoto et al., 2007).
4 .1 .2 Changes in gene expression
Several reports have demonstrated that H. 
pylori alters the expression of specific onco-
genes and tumour-suppressor genes implicated 
in gastric carcinogenesis. For example H. pylori 
infection promotes the nuclear translocation 
of β-catenin, thereby activating downstream 
β-catenin-responsive genes including cyclin D 
(Franco et al., 2005), upregulates the p53 homo-
logue p73 in gastric cells to promote apoptosis 
(Wei et al., 2008), and decreases expression of 
the cell-cycle inhibitory protein p27 (Eguchi 
et al., 2003) that is known to be lost in aggressive 
gastric cancers.
Hypermethylation of several genes has been 
found in H. pylori-associated chronic gastritis, 
including E-cadherin and p14, that are of potential 
importance mechanistically in gastric carcino-
genesis. Methylation of the E-cadherin gene has 
been reported to reverse with the eradication 
of H. pylori. In vitro, H. pylori and the reactive 
oxygen species or nitric oxide released during the 
chronic inflammatory process may be respon-
sible for gene methylation (Hmadcha et al., 1999; 
Tamura, 2004; Chan et al., 2006; Maekita et al., 
2006; Nardone et al., 2007; Tahara et al., 2007).
4 .1 .3 Altered cell turnover
It is well established that in human and exper-
imental animal infections, H. pylori is associated 
with increased numbers of both apoptotic and 
proliferating gastric epithelial cells (Shirin et al., 
2001). Increased cell turnover has long been linked 
to a risk of carcinogenesis, based on the increased 
chance of mutations arising under conditions of 
accelerated DNA replication (Preston-Martin 
et al., 1990). In contrast to the stimulation of 
apoptosis in association with H. pylori infec-
tion, some have reported that H. pylori may have 
anti-apoptotic effects (Peek et al., 1997; Mimuro 
et al., 2007), which could directly promote aber-
rant tissue growth and perhaps gastric neoplasia. 
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The development of an acquired resistance to H. 
pylori-induced gastric epithelial apoptosis has 
been associated with decreased expression of 
p27 in vitro (Shirin et al., 2000), and downregula-
tion of Fas-mediated signalling pathways in vivo 
(Houghton et al., 2000). However, there is no 
evidence that the balance between programmed 
cell death and cell proliferation is any different 
in subjects who are at higher risk for cancer 
compared with the H. pylori-infected popula-
tion in general (Moss et al., 1999). [The Working 
Group noted that most studies addressing postu-
lated mechanisms of carcinogenicity in vivo have 
compared only H. pylori-infected patients with 
uninfected patients (or the same patients before 
and after H. pylori eradication), but have not 
compared the minority of subjects who develop 
gastric cancer with the majority who do not.]
4 .1 .4 Changes in gastric acid secretion
While some persons infected by H. pylori 
develop duodenal ulcers related to depletion of 
somatostatin secretion and increased gastrin 
and gastric acid secretion (Calam, 1995), in some 
others, there is a marked decrease of acid secretion 
from the loss of or damage to the acid-secreting 
parietal cells. This state of hypochlorhydria typi-
cally occurs in patients progressing towards the 
‘intestinal’ type of gastric cancer, where the loss 
of acid secretion can promote intragastric colo-
nization of non-Helicobacter bacteria, and the 
formation of luminal N-nitrosamines with some 
genotoxic potential (Sanduleanu et al., 2001).
4 .1 .5 Inflammation and bone-marrow 
derived stem cells
An especially intense inflammatory response 
to H. pylori is thought to induce greater gastric 
epithelial cell damage, faster cell turnover, and 
the eventual emergence of gastric epithelial cells 
carrying cancer-prone mutations (Moss & Blaser, 
2005). An alternative view of the detrimental 
effects of the infiltrating inflammatory cells in the 
gastric mucosa is that of Houghton et al. (2004), 
who provided evidence in H. felis-infected mice 
that the bone-marrow-derived haematopoietic 
stem cells recruited to the gastric mucosa by H. 
felis can repopulate this mucosa, and progress 
through metaplasia and dysplasia to intraepithe-
lial cancer. Whether this occurs during human 
gastric carcinogenesis remains untested thus far.
4.2 Host immune system and genetic 
susceptibility
Some of the genetic factors underpinning 
the pathophysiology of the loss of normal gastric 
secretory function and severe inflammation 
in gastric carcinogenesis have been uncov-
ered in recent years. Based upon evidence that 
interleukin-1β (IL-1β) is both a potent gastric 
acid secretion inhibitor and a pro-inflammatory 
gastric cytokine, El-Omar et al. (2000, 2001) 
documented the association of pro-inflamma-
tory single nucleotide polymorphisms (SNPs) 
in both the IL-1β gene and the IL-1RN gene that 
encode the endogenous IL-1 receptor antagonist 
in association with hypochlorhydria and gastric 
atrophy in first-degree relatives of gastric cancer 
patients in a Scottish population. They also 
showed that pro-inflammatory IL-1β and IL-1RN 
SNPs were associated with a 2–3-fold increase in 
gastric cancer risk in a case–control study from 
Poland. Figueiredo et al. (2002) evaluated simul-
taneously H. pylori vacA and cagA genotypes 
together with IL-1 β and the IL-1RN genotypes 
of a large group of Portuguese shipyard workers 
with chronic gastritis and gastric cancer patients. 
They obtained risk ratios for gastric cancer 
among H. pylori-infected patients that differed 
markedly, based upon a combination of these 
four genes.
Moderate associations between SNPs in other 
genes encoding cytokines or genes involved in 
the initiation and maintenance of inflammation 
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have also been reported that include genes 
that encode tumour necrosis factor α (TNF-α), 
IL-10, IL-8, and toll-like receptor 4 (Amieva & 
El-Omar, 2008). Furthermore, increased non-
cardia gastric cancer risk in H. pylori-infected 
subjects has also been related to polymorphisms 
in IL-1β, IL-1RN, TNF-α and IL-10 in subjects 
from a multicentre case–control study in the US 
population (El-Omar et al., 2003) but not, in that 
same study, to cardia gastric cancer or oesopha-
geal adenocarcinoma risk. Thus, these SNPs 
appear to be relatively specific to increased distal 
gastric cancer risk following H. pylori infection.
There remains considerable debate regarding 
the reproducibility of many of these findings, 
reflecting perhaps differences in the popula-
tions studied, and the relationship of the cases 
to the controls in individual studies (Perri et al., 
2005; Starzyńska et al., 2006). Most studies are 
relatively small and evaluate only a few SNPs 
simultaneously, without adjustment for other 
potential confounding variables such as H. pylori 
genotype or other SNPs. Recent meta-analyses 
suggest that the influence of IL-1β and IL-1RN 
SNPs on gastric cancer risk is relatively weak, 
and/or confined to Caucasians (Camargo et al., 
2006; Kamangar et al., 2006b), whereas the rela-
tionship between non-cardia gastric cancer and 
two specific TNF-α SNPs (especially the −308AA 
SNP) is more consistent, though again mainly in 
Western populations (Gorouhi et al., 2008; Zhang 
et al., 2008). [The Working Group noted that 
larger and more extensive studies are necessary 
to determine the importance of individual SNPs 
in gastric cancer risk in different populations, 
and in understanding how they may modulate 
the risk of cancer following H. pylori infection.]
4.3 Factors associated with gastric 
carcinogenesis
4 .3 .1 H . pylori virulence factors
(a) cag Pathogenicity island
As reviewed in Section 2, although CagA-
positive strains confer an increased risk of 
gastric carcinogenesis, CagA-positive infections 
are also associated with the development of 
duodenal ulcer disease, which is itself inversely 
related to gastric cancer risk (Hansson et al., 
1996; Nomura et al., 2002b). This suggests that 
factors other than just the presence or absence 
of CagA may be important in gastric carcino-
genesis. In regions such as south-eastern Asia, 
where almost all strains are CagA-positive, 
structural variations in tyrosine phosphoryla-
tion sites in the C-terminal domain of the CagA 
protein have been identified. These variations 
within regions encoded by the five amino acids 
sequence Glu-Pro-Ile-Tyr-Ala (EPIYA) serve as 
sites of CagA phosphorylation by gastric epithe-
lial Src kinases. Four types of EPIYA motifs have 
been described (A through D), but the number 
of repeats of the EPIYA-C sequence in particular 
correlates with increased CagA phosphoryla-
tion, and a more marked phenotypic effect on 
infected gastric epithelial cells in vitro. EPIYA 
sequences differ markedly between east Asian 
strains (where gastric cancer is most prevalent), 
and western European/North American strains 
(Yamaoka et al., 1998; Basso et al., 2008). In a 
multivariate analysis of 203 Italian H. pylori-
infected patients, 53 of whom had gastric cancer, 
the number of repeats of the EPIYA-C motif was 
associated with the prevalence of both gastric 
cancer and its histological precursor, intestinal 
metaplasia (Basso et al., 2008). Similar associa-
tions of EPIYA motifs with gastric cancer have 
been described in smaller studies from east Asia 
(Yamaoka et al., 1998).
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(b) Evidence of carcinogenic effect of cag genes 
in animal models
CagA-positive strains of H. pylori are asso-
ciated with more vigorous gastric inflammatory 
responses. Several genes within the cag patho-
genicity island, though not cagA, may facilitate 
colonization (Marchetti & Rappuoli, 2002). Two 
studies have highlighted the importance of an 
intact cag pathogenicity island in the induc-
tion of gastric cancer in rodent species. In the 
gerbil model infected by H. pylori strain 7.13, an 
isogenic mutant lacking the cagA gene failed to 
produce gastric cancer whereas cancers were seen 
in over 50% of the gerbils infected by wild-type 
or vacA-negative strains. There was also much 
less inflammation with the cagA knockout strain 
(Franco et al., 2008). Deletion of cagE, which is 
known to be important in the functionality of 
the type 4 secretory system, delayed, but did not 
prevent, gastric cancer in the INS-GAS mouse 
model (Fox et al., 2003b).
The only direct evidence of oncogenicity of 
the CagA protein in vivo is in transgenic mice 
overexpressing a virulent form of the cagA gene 
(Ohnishi et al., 2008). About 10% of such mice 
developed hyperplastic polyps and about 1% 
gastric or small intestinal cancer after 72 weeks, 
whether the CagA protein was targeted specifi-
cally to parietal cells in the stomach or expressed 
ubiquitously in all cells. Unexpectedly, transgenic 
CagA expression did not induce gastric inflam-
mation, and leukaemias were also observed in 
some of the mice. The latter is consistent with 
the known effect of CagA on activating SHP-2 
tyrosine phosphatase, an event that is also 
involved in leukaemogenesis.
In contrast to the paucity of data regarding 
the carcinogenic effects of cag-encoded proteins 
in animal models, there is a very extensive 
literature describing the cellular and molecular 
consequences of CagA translocation by the type 
4 secretory system that is encoded by multiple 
genes within the cag pathogenicity island 
(reviewed in Buret et al., 2005; Backert & Selbach, 
2008; Wen & Moss, 2009). Following adherence 
of H. pylori to gastric epithelial cells, the CagL 





host cell integrin to initiate CagA translocation. 
Translocated CagA is then phosphorylated by 
host cell Src kinases at EPIYA tyrosine phospho-
rylation sites to promote downstream signalling, 
resulting in reorganization of the actin cytoskel-
eton, and enhanced cellular motility (thus giving 
rise to the so-called “humming bird” phenotype 
in cultured cells). Activation of the transcription 
factor NF-κB by CagA leads to mitogenic signal-
ling through mitogen-activated protein (MAP) 
kinase pathways, and also to pro-inflammatory 
gene activation. Some other cellular events acti-
vated by CagA translocation are not dependent 
on CagA phosphorylation. These events include 
the disruption of tight and adherent junctions 
between adjacent gastric epithelial cells through 
interactions with occludin, zonulin-1, junc-
tional adhesion molecules, claudins, E-cadherin, 
and β-catenin. β-Catenin translocation to 
the nucleus promotes further mitogenic gene 
expression. One of the hallmark epithelial conse-
quences of cag-positive infections is secretion of 
the pro-inflammatory chemokine IL-8, but it is 
currently unclear whether this is dependent on 
CagA translocation or by some other cag-island 
dependent stimulus. The muramyldypeptide 
component of H. pylori’s cell wall, peptidoglycan, 
is also translocated to gastric epithelial cells by 
type 4 secretion, where it can interact with the 
intracellular NOD1 protein, a component of the 
innate immune response to pathogen-associated 
molecular patterns of bacteria. NOD1-binding 
also stimulates NF-κB-dependent signalling.
(c) VacA
In many studies in Western populations, 
peptic ulcer disease has been strongly associ-
ated with the vacA genotype (particularly s1m1), 
while in some of these studies the s1m1 genotype 
has been linked to gastric cancer (Miehlke et al., 
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2000). East Asian strains are almost universally 
s1m1, and are not associated with any particular 
clinical outcome. The recent reports of vacA 
i region polymorphism where the i1 type was 
associated with gastric cancer in Iranian (Rhead 
et al., 2007) and Italian (Basso et al., 2008) popu-
lations are worthy of further corroboration by 
other groups. However, as for cagA, the vacA i 
region polymorphism may not correlate with 
gastric cancer risk in east Asia, where very few 
strains are of the i2 type (Ogiwara et al., 2008).
(d) Evidence of carcinogenic effect of vacA in 
animal models
VacA deletion does not alter the inflammatory 
or carcinogenic effects of H. pylori in the gerbil 
model (Franco et al., 2008). Multiple biological 
effects of VacA have been demonstrated in vitro, 
including the induction of apoptosis in epithe-
lial cells, and the inhibition of T-cell activation 
and proliferation that may allow for H. pylori 
persistence, but the relevance of these observa-
tions to gastric carcinogenesis remains obscure 
(Takeshima et al., 2009; Matsumoto et al., 2011).
(e) BabA and SabA
Some studies have demonstrated an asso-
ciation between the babA2 genotype and gastric 
cancer (Yu et al., 2002) though this association 
may be confounded by the frequent co-associa-
tion of babA2 with vacA s1m1 and cagA positivity. 
Although the induction of SabA expression in 
H. pylori strains has been associated with gastric 
epithelial cell adhesion (Marcos et al., 2008), no 
good evidence points to a more direct role of 
SabA in carcinogenesis.
4 .3 .2 Cofactors and co-infections
Effects of dietary salt on inflammation and 
proliferation have been observed in some animal 
studies, but the data from these is not consistent 
(Rogers et al., 2005).
H. pylori induces a predominantly Th1 
immune response which is more typical of 
intracellular bacteria rather than extracellular 
organisms that produce typically a Th2 response. 
Because gastric cancer is thought to result from 
a Th1 pro-inflammatory immune response, 
it has been postulated that concurrent para-
sitic infection (which is more likely to induce a 
Th2 immune response) may modify the gastric 
inflammation and carcinogenic effects of H. 
pylori. Such a hypothesis is supported by H. felis-
induced gastric atrophy in mice with concurrent 
intestinal nematode infection (Fox et al., 2000). 
Although gastric cancer was not evaluated in this 
model, this hypothesis may perhaps explain the 
low rate of H. pylori-associated cancer despite 
high H. pylori infection rate in areas of the world 
where parasitic infection is common (Whary 
et al., 2005).
4.4 Mechanisms of lymphomagenesis
4 .4 .1 Host immune system and genetic 
susceptibility in humans
Several different host polymorphisms associ-
ated with gastric lymphoma have been reported. 
These include the 49 G/G polymorphism in 
CTLA4, coding for a receptor on CD4-positive 
T cells, which inhibits T-cell functioning on 
ligand binding. This polymorphism was asso-
ciated with a 6-fold higher risk of developing 
MALT lymphoma after H. pylori infection in a 
study from Taiwan, China (Cheng et al., 2006). 
Association of the R702W mutation in the NOD2/
CARD15 gene was demonstrated in a study in 
German/Austrian patients with a 2.4-fold risk 
of gastric lymphoma development (Rosenstiel 
et al., 2006). Susceptible polymorphisms for 
gastric lymphoma have also been reported at 
certain human leukocyte antigen (HLA) loci in 
a small Japanese cohort (Kawahara et al., 2005), 
and within the TNF-α gene (moderate effects at 
distinct loci, which were different for low- and 
421
IARC MONOGRAPHS – 100B
high-grade lymphoma) (Hellmig et al., 2005a), 
and in the toll-like receptor TLR4 in German/
Austrian patients (Hellmig et al., 2005b). Each of 
these findings requires independent corrobora-
tion in other populations, and the understanding 
of additional factors that may predispose certain 
individuals or populations to gastric lymphoma 
following H. pylori exposure remains poor.
4 .4 .2 H . pylori virulence factors
Unlike the large literature regarding the 
importance of certain H. pylori factors in asso-
ciation with gastric cancer, the data for gastric 
lymphoma are inconsistent, and generally not 
supportive of any specific association.
4 .4 .3 Molecular mechanisms 
The normal human gastric stomach contains 
few or no inflammatory cells. On infection by 
H. pylori or other Helicobacter species, such as 
H. heilmanii, an active infiltration of acute and 
chronic inflammatory cells (including B-cell 
lymphoid follicles) results. This so-called MALT 
lymphoma is the precursor of a low-grade 
lymphoma of B cells, gastric MALT lymphoma, 
originating in B cells of the marginal zone of 
the secondary follicles that are generated in 
the inflammatory response to H. pylori (Du & 
Isaccson, 2002). Hussell et al. (1993) demonstrated 
that in the early stages of MALT, lymphoma 
B-cell proliferation was dependent on both H. 
pylori antigens, and tumour-infiltrating T cells.
Most cases of MALT lymphoma are clonal, and 
will respond to H. pylori eradication. However, 
approximately 20% of MALT lymphomas are 
not responsive to eradication therapy, and it is 
thought that this is because they acquire further 
mutations, in particular the API2-MALT1 fusion 
gene that results from a translocation of [t(11;18)
(q21;q21)]. Three other relatively uncommon 
translocations [t(1;14)(p22;q32), t(14;18)(q32;q21), 
and t(3;14)(p13;q32)] are also associated with 
gastric MALT lymphoma. Three of the four above 
translocations lead to the activation of NF-κB, 
a transcription factor important in inhibiting 
programmed cell death (Sagaert et al., 2007). 
Other mutations in gastric MALT lymphoma 
include TP53, c-MYC (approximately 20% of 
cases each), and epigenetic events such as gene 
promoter hypermethylation of p16 (Isaacson, 
1999; Huang et al., 2004).
[The Working Group noted that how H. pylori 
and/or the associated inflammatory response 
promote downstream mutations that result in 
subsequent H. pylori-independent growth and 
high-grade disease that may be refractory to 
removing the offending antigen has not been 
defined. Whether high-grade lymphomas that 
are refractory to H. pylori eradication arise 
through the same pathways that lead H. pylori 
to promote low-grade lymphomagenesis is also 
unclear and worthy of further investigation. 
Little is known of possible environmental cofac-
tors in the predisposition to H. pylori-induced 
gastric lymphomagenesis.]
4.5 Synthesis
Multiple lines of evidence point to a central 
role for the chronic gastric inflammatory 
response and resulting oxidative stress in H. 
pylori-associated gastric carcinogenesis. This 
leads to altered cellular turnover accompanied 
by changes in gene expression, methylation, and 
mutation. The nature and extent of the inflam-
matory response, and the subsequent effects 
of the inflammatory environment on gastric 
epithelial cells are associated with three inter-
related factors: 1) host-determined modulation 
of inflammatory responses, 2) specific H. pylori 





There is sufficient evidence in humans for 
the carcinogenicity of chronic infection with 
Helicobacter pylori. Chronic infection with 
Helicobacter pylori causes non-cardia gastric 
carcinoma and low-grade B-cell MALT gastric 
lymphoma.
For oesophageal adenocarcinoma, there is 
evidence suggesting lack of carcinogenicity of 
chronic infection with Helicobacter pylori in 
humans.
There is sufficient evidence in experimental 
animals for the carcinogenicity of infection with 
Helicobacter pylori.
Chronic infection with Helicobacter pylori is 
carcinogenic to humans (Group 1).
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5′ SAGE 5′ serial analysis of gene expression 
8-oxodG 8-oxo-7,8-dihydro-2′-deoxyguanosine 
AFB1 aflatoxin B1 
AIDS acquired immune deficiency syndrome 
AIN1 anal intraepithelial neoplasia
AlpA, AlpB, and HopZ adherence-associated lipoprotein 
ALT serum alanine aminotransferase 
anti-HBc antibody to hepatitis B core antigen 
anti-HBs antibody to hepatitis B surface antigen 
anti-HCV antibodies to HCV 
ASD  Adult and Adolescent Spectrum of HIV Disease 
ASR annual standardized ratio 
ATase O6-alkylguanine-DNA alkyltransferase 
ATL adult T-cell leukaemia 
ATLL adult T-cell leukaemia/lymphoma 
ATPase adenosine triphosphatase 
BabA blood group antigen binding adhesion 
BLCA-4 a nuclear matrix protein involved in gene regulation and produced only in neoplastic bladder cells
BLV bovine leukaemia virus 
BMI body mass index 
bp base pairs
BRK baby-rat kidney 
BTG1 B-cell translocation protein
C Core protein 
cAMP cyclic adenosine monophosphate 
CCA cholangiocarcinoma 
ccc DNA covalently closed circular 
CDKIs cyclin-dependent kinase-inhibitors 
CDKs cyclin-dependent kinases 
CF/S complement-fixing soluble antigens 
CI confidence interval 
CLL/SLL chronic lymphocytic leukaemia/small lymphocytic lymphoma 
CMV Cytomegalovirus 
CRE cAMP-responsive element 
CREB/ATF CRE-binding protein/activating transcription factor 
Cryo-EM Cryo-Electron Microscopy 
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C. pylori Campylobacter pylori
C. sinensis Clonorchis sinensis
CTAR C-terminal activation region 
CTL cytotoxic T lymphocyte 
CTLs cytotoxic T cells 
DDB1 UV-damaged DNA binding protein 1 
DLBCL diffuse large B-cell lymphoma 
DS dyad symmetry 
E6-associated protein E6AP 
E region early region 
EAs early antigens 
EBER EBV-encoded RNA 
EBNA EBV nuclear antigens 
EBV Epstein-Barr virus 
ECM extracellular matrix 
εdA 1,N6-ethenodeoxyadenosine 
εdC 3,N4-etheno-2'-deoxycytidine 
EGF epidermal growth factor 
EGFR epidermal growth-factor receptor 
EIAs enzyme immunoassays 
ELISAs enzyme-linked immunosorbent assays 
EMT epithelial-to-mesenchymal transdifferentiation 
EPIYA Glu-Pro-Ile-Tyr-Ala 
ES excretory–secretory 
EST Expressed Sequence Tag 
EV epidermodysplasia verruciformis 
FLIP FLICE (Caspase-8)-inhibitory protein 
FR family of repeats 
gamma-HV68 gammaherpesvirus 68 
GLUT1 glucose transporter 1 
GR glutathione reductase 
GRE glucocorticoid responsive element 
GST glutathione-S-transferase 
HAART Highly Active Anti-Retroviral Therapy 
HAV hepatitis A virus 
HBs hepatitis B surface proteins
HBV hepatitis B virus 
HBeAg hepatitis B ‘e’ antigen
HbsAg hepatitis B surface antigen 
HBx X protein 
HBZ HTLV-1 bZIP factor 
HC2 hybrid capture 2 
HCC hepatocellular carcinoma 
HCV hepatitis C virus 
HDL High Density Lipoprotein 
HF1-α hypoxia-induced factor-1α 
HGF hepatocyte growth factor 
HHV-4 human herpesvirus 4 
HHV-8 human herpesvirus 8 
HIV Human immunodeficiency virus 
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Abbreviations
HIV-1 Human immunodeficiency virus type 1 
HIV-NHL HIV-associated non-Hodgkin lymphoma 
HNE trans-4-hydroxy-2-nonenal 
HNSCC human head and neck squamous cell carcinomas 
Hop Helicobacter outer membrane proteins 
HOPS Project and the HIV Outpatient Study 
H. pylori Helicobacter pylori
HPNE 4-hydroperoxy-2-nonenal 
HPV Human papillomavirus
HRC Hodgkin and Reed-Sternberg cells 
HSCs hepatic stellate cells 
HTLV-1 human T-lymphotropic virus type 1 
HVMF-1 herpesvirus Macaca fascicularis 1 
ICC intrahepatic cholangiocarcinoma 
ICO Catalan Institute of Oncology 
IGF insulin-growth factor 
IGF-1 insulin-like growth factor 1 
IGF-2 insulin-like growth factor-2 
IgR immunoglobulin-receptor 
iNOS inducible nitric oxide synthase 
IRAK2 IL1R-associated kinase 2 
IRS insulin receptor substrates, 
ISDR interferon sensitivity determining region
ITAM Immunoglobulin Transactivation Motif 
ITS2 internally transcribed spacer region 
K14 human keratin 14 
KSHV Kaposi-sarcoma-associated herpesvirus 
L region late region 
LANA latent nuclear antigen 
LCR long control region 
LCV lymphocryptovirus 
LDLr low-density lipoprotein receptor 
LHBs large hepatitis B surface proteins 
LMP2 low molecular weight protein 2 
LMPs latent membrane proteins 
LTR long terminal repeat 
M1dG malondialdehyde-deoxyguanine 
MALT Gastric mucosa-associated lymphoid tissue 
MALT mucosa-associated lymphoid tissue 
MALTs muco-associated lymphoid tissue lymphomas 
MAPK Mitogen Activated Protein Kinase
MDA malondialdehyde 
MGUS monoclonal gammopathy of undetermined significance 
MHBs medium hepatitis B surface proteins
MHC major histocompatibility complex 
MHC I complex such as class I heavy chain 
MHV 68 murine herpesvirus 68- 
miRNA micro-RNAs 
mtCOI mitochondrial cytochrome c oxidase subunit I 
MTOC microtubule-organizing centre 
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MTP microsomal triglyceride transfer protein 
N7-MedGp N7-methyldeoxyguanosine 3′monophosphate 
NAFLD non-alcoholic fatty liver disease 
NANBH non-A, non-B hepatitis 
NCRs non-coding regions 
NDMA N-nitrosodimethylamine 
NFĸB nuclear factor-κ-B 
NHANES  III National Health and Nutrition Examination survey 
NRE negative regulatory element 
NTRK2 neurotropic tyrosin receptor kinase 2 
NSI non-syncytia-inducing 
nuclear PML bodies protein-specific nuclear bodies containing the promyelocytic leukaemia protein.
OR odds ratio
ORCs origin recognition complexes 
ORFs open-reading frames 
OriP origin of replication 
O. viverrini Opisthorchis viverrini
P Polymerase 
p42 MAPK1 p42 mitogen-activated protein kinase 1 
PAHs polycyclic aromatic hydrocarbons 
PBM PDZ-binding motif 
PBMC peripheral blood mononuclear cells 
PCNA proliferating cell nuclear antigen 
PCR polymerase chain reaction 
PEG-IFN pegylated interferon 
PIN Preneoplasic intraepithelial lesions 
PKC protein kinase C 
PLA-2 phospholipase A2 
PML nuclear promyelocytic leukaemia bodies
POR prevalence odds ratios 
pRB phosphorylated retinoblastoma 
Prkar1α protein kinase A regulatory subunit Iα 
PTEN Phosphatase and Tensin homology deleted on chromosome 10
PTLV primate T-lymphotropic viruses 
QNG quantitative nuclear grading
RBV ribavirin 
rc DNA relaxed-circular 
RIG-I retinoic-acid-inducible gene I 
RR relative risk 
RT reverse transcriptase 
SabA sialic acid binding adhesion 
SEER Surveillance, Epidemiology and End Results 
SHBs small hepatitis B surface proteins
S. haematobium Schistosoma haematobium
SI syncytia-inducing 
SIGN Safe Injection Global Network 
sIL2R interleukin-2 receptor-α 
SIR standardized incidence ratio 
SIR standardized incidence ratio 
SIV simian immunodeficiency virus 
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SIVsm SIV of sooty mangabeys (Cercocebus atys) 
SMAHRT SEER-Medicare Assessment of Hepatopoietic Malignancy Risk Traits 
SMRs standardized mortality ratios 
SNPs single nucleotide polymorphisms 
SR-BI scavenger receptor B1 
STDs sexually transmitted diseases 
STLV simian T-cell leukaemia virus 
TAP1 transporter associated with antigen processing subunit 1 
TGF-α transforming growth factor-α 
TNFR TNF-receptor 
TNF-α tumour necrosis factor-α 
TORCs transducers of regulated CREB activity 
TPA tetradecanoyl phorbol ester acetate 
TR terminal-repeat 
TRE Tax-responsive element 
TSP/HAM tropical spastic paraparesis/HTLV-1-associated myelopathy 
UVB ultraviolet light 
UNAIDS United Nations programme on HIV/AIDS 
UV ultraviolet 
VaIN Vaginal intraepithelial neoplasia
VCA viral capsid antigens 
VEGF vascular endothelial growth factor 
VIN vulvar intraepithelial neoplasia
vLDL very low density lipoproteins 
VLPs virus-like particles 
WHV woodchuck hepatitis virus 
XAP-1 HBx-associated protein 
XLP X-linked lymphoproliferative syndrome 
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AF-2 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 31, 47 (1983); Suppl. 7, 56 (1987)
Aflatoxins . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1, 145 (1972) (corr. 42, 251); 10, 51 (1976);


















Agaritine . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 31, 63 (1983); Suppl. 7, 56 (1987)
Alcohol consumption  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 44 (1988); 96, 51 (2010); 100E, 373 (2012)
Aldicarb . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 53, 93 (1991)
Aldrin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5, 25 (1974); Suppl. 7, 88 (1987)
Allyl chloride . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 36, 39 (1985); Suppl. 7, 56 (1987); 71, 1231 (1999)
Allyl isothiocyanate  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 36, 55 (1985); Suppl. 7, 56 (1987); 73, 37 (1999)
Allyl isovalerate  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 36, 69 (1985); Suppl. 7, 56 (1987); 71, 1241 (1999)
Aluminium production . . . . . . . . . . . . . . 34, 37 (1984); Suppl. 7, 89 (1987); 92, 35 (2010); 100F, 215 (2012)
Amaranth . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8, 41 (1975); Suppl. 7, 56 (1987)
5-Aminoacenaphthene . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 16, 243 (1978); Suppl. 7, 56 (1987)
2-Aminoanthraquinone  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 27, 191 (1982); Suppl. 7, 56 (1987)
para-Aminoazobenzene . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .8, 53 (1975); Suppl. 7, 56, 390 (1987)
ortho-Aminoazotoluene . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .8, 61 (1975) (corr. 42, 254); Suppl. 7, 56 (1987)
para-Aminobenzoic acid . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 16, 249 (1978); Suppl. 7, 56 (1987)











2-Amino-5-(5-nitro-2-furyl)-1,3,4-thiadiazole . . . . . . . . . . . . . . . . . . . . . . . . 7, 143 (1974); Suppl. 7, 57 (1987)
2-Amino-4-nitrophenol . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 57, 167 (1993)
2-Amino-5-nitrophenol . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 57, 177 (1993)
4-Amino-2-nitrophenol . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 16, 43 (1978); Suppl. 7, 57 (1987)
2-Amino-5-nitrothiazole . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 31, 71 (1983); Suppl. 7, 57 (1987)
2-Amino-9H-pyrido[2,3-b]indole (see A-α-C)
11-Aminoundecanoic acid . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 39, 239 (1986); Suppl. 7, 57 (1987)
Amitrole . . . . . . . . . . . . . . . . . 7, 31 (1974); 41, 293 (1986) (corr. 52, 513; Suppl. 7, 92 (1987); 79, 381 (2001)
Ammonium potassium selenide (see Selenium and selenium compounds)
Amorphous silica (see also Silica)  . . . . . . 42, 39 (1987); Suppl. 7, 341 (1987); 68, 41 (1997) (corr. 81, 383)
Amosite (see Asbestos)
Ampicillin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 50, 153 (1990)
Amsacrine  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 76, 317 (2000)
Anabolic steroids (see Androgenic (anabolic) steroids)
Anaesthetics, volatile . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11, 285 (1976); Suppl. 7, 93 (1987)
Analgesic mixtures containing phenacetin 
(see also Phenacetin) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Suppl. 7, 310 (1987); 100A, 377 (2012)
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Cumulative Index
Androgenic (anabolic) steroids  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Suppl. 7, 96 (1987)
Angelicin and some synthetic derivatives (see also Angelicins) . . . . . . . . . . . . . . . . . . . . . . . . . 40, 291 (1986)
Angelicin plus ultraviolet radiation 
(see also Angelicin and some synthetic derivatives) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Suppl. 7, 57 (1987)
Angelicins. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Suppl. 7, 57 (1987)
Aniline . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4, 27 (1974) (corr. 42, 252); 27, 39 (1982); Suppl. 7, 99 (1987)
ortho-Anisidine. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 27, 63 (1982); Suppl. 7, 57 (1987); 73, 49 (1999)
para-Anisidine  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 27, 65 (1982); Suppl. 7, 57 (1987)
Anthanthrene . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 32, 95 (1983); Suppl. 7, 57 (1987); 92, 35 (2010)
Anthophyllite (see Asbestos)
Anthracene . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 32, 105 (1983); Suppl. 7, 57 (1987); 92, 35 (2010)
Anthranilic acid  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 16, 265 (1978); Suppl. 7, 57 (1987)
Anthraquinones . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 82, 129 (2002)
Antimony trioxide . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 47, 291 (1989)
Antimony trisulfide . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 47, 291 (1989)
ANTU (see 1-Naphthylthiourea)
Apholate . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9, 31 (1975); Suppl. 7, 57 (1987)
para-Aramid fibrils  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 68, 409 (1997)
Aramite®  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5, 39 (1974); Suppl. 7, 57 (1987)
Areca nut (see also Betel quid) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 85, 39 (2004); 100E, 333 (2012)
Aristolochia species (see also Traditional herbal medicines) . . . . . . . . . . . .82, 69 (2002); 100A, 347 (2012)
Aristolochic acids . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .82, 69 (2002); 100A, 347 (2012)
Arsanilic acid (see Arsenic and arsenic compounds)
Arsenic and arsenic compounds .1, 41 (1972); 2, 48 (1973); 23, 39 (1980); Suppl. 7, 100 (1987); 100C, 41 
(2012)
Arsenic in drinking-water . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 84, 39 (2004)
Arsenic pentoxide (see Arsenic and arsenic compounds)
Arsenic trioxide (see Arsenic in drinking-water)
Arsenic trisulfide (see Arsenic in drinking-water)
Arsine (see Arsenic and arsenic compounds)
Asbestos 2, 17 (1973) (corr. 42, 252); 14 (1977) (corr. 42, 256); Suppl. 7, 106 (1987) (corr. 45, 283);  100C, 
219 (2012)
Atrazine . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 53, 441 (1991); 73, 59 (1999)
Attapulgite (see Palygorskite)
Auramine (technical-grade) . . . . . . . . . . 1, 69 (1972) (corr. 42, 251); Suppl. 7, 118 (1987); 100F, 101 (2012)
Auramine, manufacture of 
(see also Auramine, technical-grade) . . . . . . . . . . . . . . . . . . . . . . . . . . . .Suppl. 7, 118 (1987); 100F, 101 (2012)
Aurothioglucose  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13, 39 (1977); Suppl. 7, 57 (1987)
Azacitidine . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 26, 37 (1981); Suppl. 7, 57 (1987); 50, 47 (1990)
5-Azacytidine (see Azacitidine)
Azaserine . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10, 73 (1976) (corr. 42, 255); Suppl. 7, 57 (1987)
Azathioprine . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 26, 47 (1981); Suppl. 7, 119 (1987); 100A, 319 (2012)
Aziridine . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9, 37 (1975); Suppl. 7, 58 (1987); 71, 337 (1999)
2-(1-Aziridinyl)ethanol . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9, 47 (1975); Suppl. 7, 58 (1987)
Aziridyl benzoquinone  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9, 51 (1975); Suppl. 7, 58 (1987)
Azobenzene  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8, 75 (1975); Suppl. 7, 58 (1987)
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IARC MONOGRAPHS – 100B
AZT (see Zidovudine)
B
Barium chromate (see Chromium and chromium compounds)
Basic chromic sulfate (see Chromium and chromium compounds)
BCNU (see Bischloroethyl nitrosourea)
11H-Benz[bc]aceanthrylene  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 92, 35 (2010)
Benz[j]aceanthrylene . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 92, 35 (2010)
Benz[l]aceanthrylene . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 92, 35 (2010)
Benz[a]acridine  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 32, 123 (1983); Suppl. 7, 58 (1987)
Benz[c]acridine . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3, 241 (1973); 32, 129 (1983); Suppl. 7, 58 (1987)
Benzal chloride (see also α-Chlorinated toluenes and
 benzoyl chloride) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 29, 65 (1982); Suppl. 7, 148 (1987); 71, 453 (1999)
Benz[a]anthracene . . . . . . . . . . . . . . . . . . . . . . 3, 45 (1973); 32, 135 (1983); Suppl. 7, 58 (1987); 92, 35 (2010)
Benzene  . . . . . . . . .7, 203 (1974) (corr. 42, 254); 29, 93, 391 (1982); Suppl. 7, 120 (1987); 100F, 249 (2012)
Benzidine . . . . . . . . . . . . . . . . . . . . . . .1, 80 (1972); 29, 149, 391 (1982); Suppl. 7, 123 (1987); 100F, 53 (2012)
Benzidine-based dyes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Suppl. 7, 125 (1987); 100F, 65 (2012)
Benzo[b]chrysene . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 92, 35 (2010)
Benzo[g]chrysene . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 92, 35 (2010)
Benzo[a]fluoranthene . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 92, 35 (2010)
Benzo[b]fluoranthene . . . . . . . . . . . . . . . . . . . 3, 69 (1973); 32, 147 (1983); Suppl. 7, 58 (1987); 92, 35 (2010)
Benzo[j]fluoranthene . . . . . . . . . . . . . . . . . . . . 3, 82 (1973); 32, 155 (1983); Suppl. 7, 58 (1987); 92, 35 (2010)
Benzo[k]fluoranthene  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 32, 163 (1983); Suppl. 7, 58 (1987); 92, 35 (2010)
Benzo[ghi]fluoranthene  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 32, 171 (1983); Suppl. 7, 58 (1987); 92, 35 (2010)
Benzo[a]fluorene . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 32, 177 (1983); Suppl. 7, 58 (1987); 92, 35 (2010)
Benzo[b]fluorene . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 32, 183 (1983); Suppl. 7, 58 (1987); 92, 35 (2010)
Benzo[c]fluorene . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 32, 189 (1983); Suppl. 7, 58 (1987); 92, 35 (2010)
Benzofuran  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 63, 431 (1995)
Benzo[ghi]perylene  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 32, 195 (1983); Suppl. 7, 58 (1987); 92, 35 (2010)
Benzo[c]phenanthrene . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 32, 205 (1983); Suppl. 7, 58 (1987); 92, 35 (2010)
Benzo[a]pyrene 3, 91 (1973); 32, 211 (1983); (corr. 68, 477); Suppl. 7, 58 (1987); 92, 35 (2010); 100F, 111 
(2012)
Benzo[e]pyrene  . . . . . . . . . . . . . . . . . . . . . . . .3, 137 (1973); 32, 225 (1983); Suppl. 7, 58 (1987); 92, 35 (2010)
1,4-Benzoquinone (see para-Quinone)
1,4-Benzoquinone dioxime . . . . . . . . . . . . . . . . . . . . . . . . 29, 185 (1982); Suppl. 7, 58 (1987); 71, 1251 (1999)
Benzotrichloride (see also α-Chlorinated toluenes and
 benzoyl chloride) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 29, 73 (1982); Suppl. 7, 148 (1987); 71, 453 (1999)
Benzoyl chloride (see also α-Chlorinated toluenes and
 benzoyl chloride) . . . . . . . . . . . . . . . . . . . . 29, 83 (1982) (corr. 42, 261); Suppl. 7, 126 (1987); 71, 453 (1999)
Benzoyl peroxide . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 36, 267 (1985); Suppl. 7, 58 (1987); 71, 345 (1999)
Benzyl acetate  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 40, 109 (1986); Suppl. 7, 58 (1987); 71, 1255 (1999)
Benzyl chloride (see also α-Chlorinated toluenes and
 benzoyl chloride) . . . . . 11, 217 (1976) (corr. 42, 256); 29, 49 (1982); Suppl. 7, 148 (1987); 71, 453 (1999)
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Cumulative Index
Benzyl violet 4B . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 16, 153 (1978); Suppl. 7, 58 (1987)
Bertrandite (see Beryllium and beryllium compounds)
Beryllium and beryllium compounds . . . 1, 17 (1972); 23, 143 (1980) (corr. 42, 260); Suppl. 7, 127 (1987); 
58, 41 (1993); 100C, 95 (2012)
Beryllium acetate (see Beryllium and beryllium compounds)
Beryllium acetate, basic (see Beryllium and beryllium compounds)
Beryllium-aluminium alloy (see Beryllium and beryllium compounds)
Beryllium carbonate (see Beryllium and beryllium compounds)
Beryllium chloride (see Beryllium and beryllium compounds)
Beryllium-copper alloy (see Beryllium and beryllium compounds)
Beryllium-copper-cobalt alloy (see Beryllium and beryllium compounds)
Beryllium fluoride (see Beryllium and beryllium compounds)
Beryllium hydroxide (see Beryllium and beryllium compounds)
Beryllium-nickel alloy (see Beryllium and beryllium compounds)
Beryllium oxide (see Beryllium and beryllium compounds)
Beryllium phosphate (see Beryllium and beryllium compounds)
Beryllium silicate (see Beryllium and beryllium compounds)
Beryllium sulfate (see Beryllium and beryllium compounds)
Beryl ore (see Beryllium and beryllium compounds)
Betel quid with added tobacco  . . . .37, 141 (1985); Suppl. 7, 128 (1987); 85, 39 (2004); 100E, 333 (2012)
Betel quid without added tobacco .37, 141 (1985); Suppl. 7, 128 (1987); 85, 39 (2004); 100E, 333 (2012)
BHA (see Butylated hydroxyanisole)
BHT (see Butylated hydroxytoluene)
Biomass fuel (primarily wood),
 indoor emissions from household combustion of . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 95, 41 (2010)
Bis(1-aziridinyl)morpholinophosphine sulfide . . . . . . . . . . . . . . . . . . . . . . . . 9, 55 (1975); Suppl. 7, 58 (1987)
2,2-Bis(bromomethyl)propane-1,3-diol . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 77, 455 (2000)
Bis(2-chloroethyl)ether . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9, 117 (1975); Suppl. 7, 58 (1987); 71, 1265 (1999)
N,N-Bis(2-chloroethyl)-2-naphthylamine  . . 4, 119 (1974) (corr. 42, 253); Suppl. 7, 130 (1987); 100A, 333 
(2012)
Bischloroethyl nitrosourea
 (see also Chloroethyl nitrosoureas) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 26, 79 (1981); Suppl. 7, 150 (1987)
1,2-Bis(chloromethoxy)ethane . . . . . . . . . . . . . . . . . . . . . . 15, 31 (1977); Suppl. 7, 58 (1987); 71, 1271 (1999)
1,4-Bis(chloromethoxymethyl)benzene . . . . . . . . . . . . . 15, 37 (1977); Suppl. 7, 58 (1987); 71, 1273 (1999)
Bis(chloromethyl)ether . . . . . . . . . . . . . 4, 231 (1974) (corr. 42, 253); Suppl. 7, 131 (1987); 100F, 295 (2012)
Bis(2-chloro-1-methylethyl)ether  . . . . . . . . . . . . . . . . . . 41, 149 (1986); Suppl. 7, 59 (1987); 71, 1275 (1999)
Bis(2,3-epoxycyclopentyl)ether . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 47, 231 (1989); 71, 1281 (1999)
Bisphenol A diglycidyl ether (see also Glycidyl ethers)  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 71, 1285 (1999)
Bisulfites (see Sulfur dioxide and some sulfites, bisulfites and metabisulfites)
Bitumens  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 35, 39 (1985); Suppl. 7, 133 (1987)
Bleomycins (see also Etoposide)  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 26, 97 (1981); Suppl. 7, 134 (1987)
Blue VRS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 16, 163 (1978); Suppl. 7, 59 (1987)
Boot and shoe manufacture and repair . . . . . . . . . . . . . . . . . . . . . . . . . . . .25, 249 (1981); Suppl. 7, 232 (1987)
Bracken fern  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 40, 47 (1986); Suppl. 7, 135 (1987)
Brilliant Blue FCF, disodium salt . . . . . . . . . . . . . . . . . . . . . . 16, 171 (1978) (corr. 42, 257); Suppl. 7, 59 (1987)
Bromochloroacetonitrile
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IARC MONOGRAPHS – 100B
 (see also Halogenated acetonitriles) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 71, 1291 (1999)
Bromodichloromethane . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 52, 179 (1991); 71, 1295 (1999)
Bromoethane . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 52, 299 (1991); 71, 1305 (1999)
Bromoform  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 52, 213 (1991); 71, 1309 (1999)
Busulfan . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .(see 1,4-Butanediol dimethanesulfonate)
1,3-Butadiene . .39, 155 (1986) (corr. 42, 264); Suppl. 7, 136 (1987); 54, 237 (1992); 71, 109 (1999); 97,45 
(2008); 100F, 309 (2012)
1,4-Butanediol dimethanesulfonate . . . . . . . . . . . . . . . .4, 247 (1974); Suppl. 7, 137 (1987); 100A, 39 (2012)
2-Butoxyethanol  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 88, 329
1-tert-Butoxypropan-2-ol . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 88, 415
n-Butyl acrylate  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 39, 67 (1986); Suppl. 7, 59 (1987); 71, 359 (1999)
Butylated hydroxyanisole . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 40, 123 (1986); Suppl. 7, 59 (1987)
Butylated hydroxytoluene . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 40, 161 (1986); Suppl. 7, 59 (1987)
Butyl benzyl phthalate  . . . . . . . . . . . . . . . 29, 193 (1982) (corr. 42, 261); Suppl. 7, 59 (1987); 73, 115 (1999)
β-Butyrolactone . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11, 225 (1976); Suppl. 7, 59 (1987); 71, 1317 (1999)
γ-Butyrolactone . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11, 231 (1976); Suppl. 7, 59 (1987); 71, 367 (1999)
C
Cabinet-making (see Furniture and cabinet-making)
Cadmium acetate (see Cadmium and cadmium compounds)
Cadmium and cadmium compounds 2, 74 (1973); 11, 39 (1976) (corr. 42, 255); Suppl. 7, 139 (1987); 58, 
119 (1993); 100C, 121 (2012)
Cadmium chloride (see Cadmium and cadmium compounds)
Cadmium oxide (see Cadmium and cadmium compounds)
Cadmium sulfate (see Cadmium and cadmium compounds)
Cadmium sulfide (see Cadmium and cadmium compounds)
Caffeic acid  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 56, 115 (1993)
Caffeine . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 51, 291 (1991)
Calcium arsenate (see Arsenic in drinking-water)
Calcium carbide production . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 92, 35 (2010)
Calcium chromate (see Chromium and chromium compounds)
Calcium cyclamate (see Cyclamates)
Calcium saccharin (see Saccharin)
Cantharidin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10, 79 (1976); Suppl. 7, 59 (1987)
Caprolactam . . . 19, 115 (1979) (corr. 42, 258); 39, 247 (1986) (corr. 42, 264); Suppl. 7, 59, 390 (1987); 71, 
383 (1999)
Captafol  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 53, 353 (1991)
Captan . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 30, 295 (1983); Suppl. 7, 59 (1987)
Carbaryl  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 12, 37 (1976); Suppl. 7, 59 (1987)
Carbazole . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 32, 239 (1983); Suppl. 7, 59 (1987); 71, 1319 (1999)
3-Carbethoxypsoralen . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 40, 317 (1986); Suppl. 7, 59 (1987)
Carbon black . . . . . . . . . . . . . . . . . .3, 22 (1973); 33, 35 (1984); Suppl.7, 142 (1987); 65, 149 (1996); 93, 2010
Carbon electrode manufacture  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 92, 35 (2010)
Carbon tetrachloride . . . . . . . . . . . . . . . . . 1, 53 (1972); 20, 371 (1979); Suppl. 7, 143 (1987); 71, 401 (1999)
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Cumulative Index
Carmoisine . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8, 83 (1975); Suppl. 7, 59 (1987)
Carpentry and joinery . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .25, 139 (1981); Suppl. 7, 378 (1987)
Carrageenan . . . . . . . . . . . . . . . . . . . . . . . . . . 10, 181 (1976) (corr. 42, 255); 31, 79 (1983); Suppl. 7, 59 (1987)
Cassia occidentalis (see Traditional herbal medicines)
Catechol . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15, 155 (1977); Suppl. 7, 59 (1987); 71, 433 (1999)
CCNU (see 1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea)
Ceramic fibres (see Man-made vitreous fibres)
Chemotherapy, combined, including alkylating agents 
(see MOPP and other combined chemotherapy including alkylating agents)
Chimney sweeps and other exposures to soot . . . . . . . . . . . . . . . . . . . . . . . . . 92, 35 (2010); 100F, 209 (2012)
Chloral (see also Chloral hydrate)  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 63, 245 (1995); 84, 317 (2004)
Chloral hydrate . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 63, 245 (1995); 84, 317 (2004)
Chlorambucil  . . . . . . . . . . . . . . . . . . . . . .9, 125 (1975); 26, 115 (1981); Suppl. 7, 144 (1987); 100A, 47 (2012)
Chloramine . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 84, 295 (2004)
Chloramphenicol . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10, 85 (1976); Suppl. 7, 145 (1987); 50, 169 (1990)
Chlordane (see also Chlordane/Heptachlor) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .20, 45 (1979) (corr. 42, 258)
Chlordane and Heptachlor . . . . . . . . . . . . . . . . . . . . . . . . . Suppl. 7, 146 (1987); 53, 115 (1991); 79, 411 (2001)
Chlordecone . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 20, 67 (1979); Suppl. 7, 59 (1987)
Chlordimeform . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 30, 61 (1983); Suppl. 7, 59 (1987)
Chlorendic acid  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 48, 45 (1990)
Chlorinated dibenzodioxins (other than TCDD)
 (see also Polychlorinated dibenzo-para-dioxins)  . . . . . . . . . . . . . . . . . . . . 15, 41 (1977); Suppl. 7, 59 (1987)
Chlorinated drinking-water . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 52, 45 (1991)
Chlorinated paraffins . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 48, 55 (1990)
α-Chlorinated toluenes and benzoyl chloride . . . . . . . . . . . . . . . . . . . . . .Suppl. 7, 148 (1987); 71, 453 (1999)
Chlormadinone acetate  . . . . . . . . . .6, 149 (1974); 21, 365 (1979); Suppl. 7, 291, 301 (1987); 72, 49 (1999)
Chlornaphazine (see N,N-Bis(2-chloroethyl)-2-naphthylamine)
Chloroacetonitrile (see also Halogenated acetonitriles) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 71, 1325 (1999)
para-Chloroaniline  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 57, 305 (1993)
Chlorobenzilate . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .5, 75 (1974); 30, 73 (1983); Suppl. 7, 60 (1987)
Chlorodibromomethane . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 52, 243 (1991); 71, 1331 (1999)
3-Chloro-4-(dichloromethyl)-5-hydroxy-2(5H)-furanone  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 84, 441 (2004)
Chlorodifluoromethane  . . . . . . . . . . . . 41, 237 (1986) (corr. 51, 483); Suppl. 7, 149 (1987); 71, 1339 (1999)
Chloroethane . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 52, 315 (1991); 71, 1345 (1999)
1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea
 (see also Chloroethyl nitrosoureas) . . . . . . . . . . . . . . . . . 26, 137 (1981) (corr. 42, 260); Suppl. 7, 150 (1987)
1-(2-Chloroethyl)-3-(4-methylcyclohexyl)-1-nitrosourea
 (see also Chloroethyl nitrosoureas) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Suppl. 7, 150 (1987); 100A, 57 (2012)
Chloroethyl nitrosoureas  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Suppl. 7, 150 (1987)
Chlorofluoromethane . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 41, 229 (1986); Suppl. 7, 60 (1987); 71, 1351 (1999)
Chloroform  . . . . . . . . . . . . . . . . . . . . . . . . . . . 1, 61 (1972); 20, 401 (1979); Suppl. 7, 152 (1987); 73, 131(1999)
Chloromethyl methyl ether (technical-grade)
 (see also Bis(chloromethyl)ether) . . . . . . . . . . . . . . . . . 4, 239 (1974); Suppl. 7, 131 (1987); 100F, 295 (2012)
(4-Chloro-2-methylphenoxy)acetic acid (see MCPA)
1-Chloro-2-methylpropene . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 63, 315 (1995)
3-Chloro-2-methylpropene . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 63, 325 (1995)
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IARC MONOGRAPHS – 100B
2-Chloronitrobenzene . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 65, 263 (1996)
3-Chloronitrobenzene . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 65, 263 (1996)
4-Chloronitrobenzene . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 65, 263 (1996)
Chlorophenols (see also Polychlorophenols and their sodium salts) . . . . . . . . . . . . . . .Suppl. 7, 154 (1987)
Chlorophenols (occupational exposures to) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 41, 319 (1986)
Chlorophenoxy herbicides . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Suppl. 7, 156 (1987)
Chlorophenoxy herbicides (occupational exposures to) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 41, 357 (1986)
4-Chloro-ortho-phenylenediamine . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 27, 81 (1982); Suppl. 7, 60 (1987)
4-Chloro-meta-phenylenediamine . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 27, 82 (1982); Suppl. 7, 60 (1987)
Chloroprene  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 19, 131 (1979); Suppl. 7, 160 (1987); 71, 227 (1999)
Chloropropham . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 12, 55 (1976); Suppl. 7, 60 (1987)
Chloroquine  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13, 47 (1977); Suppl. 7, 60 (1987)
Chlorothalonil . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 30, 319 (1983); Suppl. 7, 60 (1987); 73, 183 (1999)
para-Chloro-ortho-toluidine and its strong acid salts
 (see also Chlordimeform)  . . . . 16, 277 (1978); 30, 65 (1983); Suppl. 7, 60 (1987); 48, 123 (1990); 77, 323 
(2000)
4-Chloro-ortho-toluidine (see para-chloro-ortho-toluidine)
5-Chloro-ortho-toluidine . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 77, 341 (2000)
Chlorotrianisene (see also Nonsteroidal estrogens) . . . . . . . . . . . . . . . .21, 139 (1979); Suppl. 7, 280 (1987)
2-Chloro-1,1,1-trifluoroethane . . . . . . . . . . . . . . . . . . . . . 41, 253 (1986); Suppl. 7, 60 (1987); 71, 1355 (1999)
Chlorozotocin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 50, 65 (1990)
Cholesterol. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10, 99 (1976); 31, 95 (1983); Suppl. 7, 161 (1987)
Chromic acetate (see Chromium and chromium compounds)
Chromic chloride (see Chromium and chromium compounds)
Chromic oxide (see Chromium and chromium compounds)
Chromic phosphate (see Chromium and chromium compounds)
Chromite ore (see Chromium and chromium compounds)
Chromium and chromium compounds (see also Implants, surgical) . . . . . . 2, 100 (1973); 23, 205 (1980); 
Suppl. 7, 165 (1987); 49, 49 (1990) (corr. 51, 483); 100C,147 (2012)
Chromium carbonyl (see Chromium and chromium compounds)
Chromium potassium sulfate (see Chromium and chromium compounds)
Chromium sulfate (see Chromium and chromium compounds)
Chromium trioxide (see Chromium and chromium compounds)
Chrysazin (see Dantron)
Chrysene. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .3, 159 (1973); 32, 247 (1983); Suppl. 7, 60 (1987); 92, 35 (2010)
Chrysoidine . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8, 91 (1975); Suppl. 7, 169 (1987)
Chrysotile (see Asbestos)
Ciclosporin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .50, 77 (1990); 100A, 337 (2012)
CI Acid Orange 3  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 57, 121 (1993)
CI Acid Red 114  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 57, 247 (1993)
CI Basic Red 9 (see also Magenta) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 57, 215 (1993)
CI Direct Blue 15 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 57, 235 (1993)
CI Disperse Yellow 3 (see Disperse Yellow 3)
Cimetidine . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 50, 235 (1990)
Cinnamyl anthranilate . . . . . . . . . . . . . . . 16, 287 (1978); 31, 133 (1983); Suppl. 7, 60 (1987); 77, 177 (2000)
CI Pigment Red 3 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 57, 259 (1993)
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Cumulative Index
CI Pigment Red 53:1 (see D&C Red No. 9)
Cisplatin (see also Etoposide) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .26, 151 (1981); Suppl. 7, 170 (1987)
Citrinin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 40, 67 (1986); Suppl. 7, 60 (1987)
Citrus Red No. 2 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8, 101 (1975) (corr. 42, 254); Suppl. 7, 60 (1987)
Clinoptilolite (see Zeolites)
Clofibrate . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 24, 39 (1980); Suppl. 7, 171 (1987); 66, 391 (1996)
Clomiphene citrate . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .21, 551 (1979); Suppl. 7, 172 (1987)
Clonorchis sinensis (infection with)  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .61, 121 (1994); 100B, 341 (2012)
Coal, indoor emissions from household combustion of . . . . . . . . . . . . . . . . 95, 43 (2010); 100E, 515 (2012)
Coal dust . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 68, 337 (1997)
Coal gasification. . . . . . . . . . . . . . . . . . . . 34, 65 (1984); Suppl. 7, 173 (1987); 92, 35 (2010); 100F, 145 (2012)
Coal-tar distillation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 92, 35 (2010); 100F, 153 (2012)
Coal-tar pitches (see also Coal-tars)  . . . . . . . . . . . . . . . 35, 83 (1985); Suppl. 7, 174 (1987); 100F, 161 (2012)
Coal-tars . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 35, 83 (1985); Suppl. 7, 175 (1987); 100F, 161 (2012)
Cobalt[III] acetate (see Cobalt and cobalt compounds)
Cobalt-aluminium-chromium spinel (see Cobalt and cobalt compounds)
Cobalt and cobalt compounds (see also Implants, surgical)  . . . . . . . . . . . . . . . . . . . . . . . . . . . . 52, 363 (1991)
Cobalt[II] chloride (see Cobalt and cobalt compounds)
Cobalt-chromium alloy (see Chromium and chromium compounds)
Cobalt-chromium-molybdenum alloys (see Cobalt and cobalt compounds)
Cobalt metal powder (see Cobalt and cobalt compounds)
Cobalt metal with tungsten carbide . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 86, 37 (2006)
Cobalt metal without tungsten carbide . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 86, 37 (2006)
Cobalt naphthenate (see Cobalt and cobalt compounds)
Cobalt[II] oxide (see Cobalt and cobalt compounds)
Cobalt[II,III] oxide (see Cobalt and cobalt compounds)
Cobalt sulfate and other soluble cobalt(II) salts . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 86, 37 (2006)
Cobalt[II] sulfide (see Cobalt and cobalt compounds)
Coffee  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .51, 41 (1991) (corr. 52, 513)
Coke production . . . . . . . . . . . . . . . . . . 34, 101 (1984); Suppl. 7, 176 (1987); 92, 35 (2010); 100F, 167 (2012)
Combined estrogen–progestogen
 contraceptives . . . . . . . . . . . . . . . . . . . . .Suppl. 7, 297 (1987); 72, 49 (1999); 91, 39 (2007); 100A, 283 (2012)
Combined estrogen–progestogen
 menopausal therapy . . . . . . . . . . . . Suppl. 7, 308 (1987); 72, 531 (1999); 91, 203 (2007); 100A, 249 (2012)
Conjugated equine estrogens  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 72, 399 (1999)
Conjugated estrogens (see also Steroidal estrogens) . . . . . . . . . . . . . . .21, 147 (1979); Suppl. 7, 283 (1987)
Continuous glass filament (see Man-made vitreous fibres)
Copper 8-hydroxyquinoline  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15, 103 (1977); Suppl. 7, 61 (1987)
Coronene . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 32, 263 (1983); Suppl. 7, 61 (1987); 92, 35 (2010)
Coumarin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10, 113 (1976); Suppl. 7, 61 (1987); 77, 193 (2000)
Creosotes (see also Coal-tars) . . . . . . . . . . . . . . . . . . . . . . . . 35, 83 (1985); Suppl. 7, 177 (1987); 92, 35 (2010)
meta-Cresidine . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 27, 91 (1982); Suppl. 7, 61 (1987)
para-Cresidine  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 27, 92 (1982); Suppl. 7, 61 (1987)
Cristobalite (see Crystalline silica)
Crocidolite (see Asbestos)
Crotonaldehyde . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 63, 373 (1995) (corr. 65, 549)
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Crude oil . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 45, 119 (1989)
Crystalline silica (see also Silica) . . 42, 39 (1987); Suppl. 7, 341 (1987); 68, 41 (1997) (corr. 81, 383); 100C, 
355 (2012)
Cycasin 
(see also Methylazoxymethanol) . . . . . . . 1, 157 (1972) (corr. 42, 251); 10, 121 (1976); Suppl. 7, 61 (1987)
Cyclamates . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 22, 55 (1980); Suppl. 7, 178 (1987); 73, 195 (1999)
Cyclamic acid (see Cyclamates)
Cyclochlorotine . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10, 139 (1976); Suppl. 7, 61 (1987)
Cyclohexanone . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 47, 157 (1989); 71, 1359 (1999)
Cyclohexylamine (see Cyclamates)
4-Cyclopenta[def]chrysene  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 92, 35 (2010)
Cyclopenta[cd]pyrene . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 32, 269 (1983); Suppl. 7, 61 (1987); 92, 35 (2010)
5,6-Cyclopenteno-1,2-benzanthracene . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 92, 35 (2010)
Cyclopropane (see Anaesthetics, volatile)
Cyclophosphamide . . . . . . . . . . . . . . . . .9, 135 (1975); 26, 165 (1981); Suppl. 7, 182 (1987); 100A, 63 (2012)
Cyproterone acetate . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 72, 49 (1999)
D
2,4-D (see also Chlorophenoxy herbicides;
 Chlorophenoxy herbicides, occupational exposures to)  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15, 111 (1977)
Dacarbazine  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .26, 203 (1981); Suppl. 7, 184 (1987)
Dantron . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 50, 265 (1990) (corr. 59, 257)
D&C Red No. 9. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8, 107 (1975); Suppl. 7, 61 (1987); 57, 203 (1993)
Dapsone . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 24, 59 (1980); Suppl. 7, 185 (1987)
Daunomycin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10, 145 (1976); Suppl. 7, 61 (1987)
DDD (see DDT)
DDE (see DDT)
DDT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5, 83 (1974) (corr. 42, 253); Suppl. 7, 186 (1987); 53, 179 (1991)
Decabromodiphenyl oxide  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 48, 73 (1990); 71, 1365 (1999)
Deltamethrin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 53, 251 (1991)
Deoxynivalenol (see Toxins derived from Fusarium graminearum, F . culmorum and F . crookwellense)
Diacetylaminoazotoluene  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8, 113 (1975); Suppl. 7, 61 (1987)
N,N’-Diacetylbenzidine . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 16, 293 (1978); Suppl. 7, 61 (1987)
Diallate  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 12, 69 (1976); 30, 235 (1983); Suppl. 7, 61 (1987)
2,4-Diaminoanisole and its salts . . . . . . . 16, 51 (1978); 27, 103 (1982); Suppl. 7, 61 (1987); 79, 619 (2001)
4,4’-Diaminodiphenyl ether . . . . . . . . . . . . . . . . . . . . . . . . . 16, 301 (1978); 29, 203 (1982); Suppl. 7, 61 (1987)
1,2-Diamino-4-nitrobenzene . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 16, 63 (1978); Suppl. 7, 61 (1987)
1,4-Diamino-2-nitrobenzene . . . . . . . . . . . . . . . . . . . . . . . . . 16, 73 (1978); Suppl. 7, 61 (1987); 57, 185 (1993)
2,6-Diamino-3-(phenylazo)pyridine (see Phenazopyridine hydrochloride)
2,4-Diaminotoluene (see also Toluene diisocyanates) . . . . . . . . . . . . . . . . 16, 83 (1978); Suppl. 7, 61 (1987)
2,5-Diaminotoluene (see also Toluene diisocyanates) . . . . . . . . . . . . . . . . 16, 97 (1978); Suppl. 7, 61 (1987)
ortho-Dianisidine (see 3,3’-Dimethoxybenzidine)
Diatomaceous earth, uncalcined (see Amorphous silica)
Diazepam . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13, 57 (1977); Suppl. 7, 189 (1987); 66, 37 (1996)
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Cumulative Index
Diazomethane . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7, 223 (1974); Suppl. 7, 61 (1987)
Dibenz[a,h]acridine  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3, 247 (1973); 32, 277 (1983); Suppl. 7, 61 (1987)
Dibenz[a,j]acridine . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3, 254 (1973); 32, 283 (1983); Suppl. 7, 61 (1987)
Dibenz[a,c]anthracene  . . . . . . . . . . . . . . . . 32, 289 (1983) (corr. 42, 262); Suppl. 7, 61 (1987); 92, 35 (2010)
Dibenz[a,h]anthracene . . . 3, 178 (1973) (corr. 43, 261); 32, 299 (1983); Suppl. 7, 61 (1987); 92, 35 (2010)
Dibenz[a,j]anthracene . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 32, 309 (1983); Suppl. 7, 61 (1987); 92, 35 (2010)
7H-Dibenzo[c,g]carbazole  . . . . . . . . . . . . . . . . . . . . . . . . . . . 3, 260 (1973); 32, 315 (1983); Suppl. 7, 61 (1987)
Dibenzodioxins, chlorinated (other than TCDD) (see Chlorinated dibenzodioxins (other than TCDD))
Dibenzo[a,e]fluoranthene  . . . . . . . . . . . . . . . . . . . . . . . . . . . 32, 321 (1983); Suppl. 7, 61 (1987); 92, 35 (2010)
13H-Dibenzo[a,g]fluorene . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 92, 35 (2010)
Dibenzo[h,rst]pentaphene . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3, 197 (1973); Suppl. 7, 62 (1987); 92, 35 (2010)
Dibenzo[a,e]pyrene  . . . . . . . . . . . . . . . . . . . .3, 201 (1973); 32, 327 (1983); Suppl. 7, 62 (1987); 92, 35 (2010)
Dibenzo[a,h]pyrene . . . . . . . . . . . . . . . . . . . .3, 207 (1973); 32, 331 (1983); Suppl. 7, 62 (1987); 92, 35 (2010)
Dibenzo[a,i]pyrene . . . . . . . . . . . . . . . . . . . . .3, 215 (1973); 32, 337 (1983); Suppl. 7, 62 (1987); 92, 35 (2010)
Dibenzo[a,l]pyrene . . . . . . . . . . . . . . . . . . . . .3, 224 (1973); 32, 343 (1983); Suppl. 7, 62 (1987); 92, 35 (2010)
Dibenzo[e,l]pyrene . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 92, 35 (2010)
Dibenzo-para-dioxin  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 69, 33 (1997)
Dibromoacetonitrile (see also Halogenated acetonitriles) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 71, 1369 (1999)
1,2-Dibromo-3-chloropropane . . . . . . . 15, 139 (1977); 20, 83 (1979); Suppl. 7, 191 (1987); 71, 479 (1999)
1,2-Dibromoethane (see Ethylene dibromide)
2,3-Dibromopropan-1-ol  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 77, 439 (2000)
Dichloroacetic acid . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 63, 271 (1995); 84, 359 (2004)
Dichloroacetonitrile (see also Halogenated acetonitriles)  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 71, 1375 (1999)
Dichloroacetylene . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 39, 369 (1986); Suppl. 7, 62 (1987); 71, 1381 (1999)
ortho-Dichlorobenzene . . . . . . . . . . . . . . 7, 231 (1974); 29, 213 (1982); Suppl. 7, 192 (1987); 73, 223 (1999)
meta-Dichlorobenzene . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 73, 223 (1999)
para-Dichlorobenzene . . . . . . . . . . . . . . . 7, 231 (1974); 29, 215 (1982); Suppl. 7, 192 (1987); 73, 223 (1999)
3,3’-Dichlorobenzidine  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4, 49 (1974); 29, 239 (1982); Suppl. 7, 193 (1987)
trans-1,4-Dichlorobutene . . . . . . . . . . . . . . . . . . . . . . . . . . 15, 149 (1977); Suppl. 7, 62 (1987); 71, 1389 (1999)
3,3’-Dichloro-4,4’-diaminodiphenyl ether  . . . . . . . . . . . . . . . . . . . . . . . . . . 16, 309 (1978); Suppl. 7, 62 (1987)
1,2-Dichloroethane . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 20, 429 (1979); Suppl. 7, 62 (1987); 71, 501 (1999)
Dichloromethane  . . . . . . . . . . . . . . . . . . . 20, 449 (1979); 41, 43 (1986); Suppl. 7, 194 (1987); 71, 251 (1999)
2,4-Dichlorophenol (see Chlorophenols; Chlorophenols, occupational exposures to;
 Polychlorophenols and their sodium salts)
(2,4-Dichlorophenoxy)acetic acid (see 2,4-D)
2,6-Dichloro-para-phenylenediamine . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 39, 325 (1986); Suppl. 7, 62 (1987)
1,2-Dichloropropane . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 41, 131 (1986); Suppl. 7, 62 (1987); 71, 1393 (1999)
1,3-Dichloropropene (technical-grade) . . . . . . . . . . . . . 41, 113 (1986); Suppl. 7, 195 (1987); 71, 933 (1999)
Dichlorvos . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 20, 97 (1979); Suppl. 7, 62 (1987); 53, 267 (1991)
Dicofol . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 30, 87 (1983); Suppl. 7, 62 (1987)
Dicyclohexylamine (see Cyclamates)
Didanosine . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 76, 153 (2000)
Dieldrin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5, 125 (1974); Suppl. 7, 196 (1987)
Dienoestrol (see also Nonsteroidal estrogens) . . . . . . . . . . . . . . . . . . . . .21, 161 (1979); Suppl. 7, 278 (1987)
Diepoxybutane
 (see also 1,3-Butadiene) . . . . . . . . . . . . . . 11, 115 (1976) (corr. 42, 255); Suppl. 7, 62 (1987); 71, 109 (1999)
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Diesel and gasoline engine exhausts . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 46, 41 (1989)
Diesel fuels . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 45, 219 (1989) (corr. 47, 505)
Diethanolamine . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 77, 349 (2000)
Diethyl ether (see Anaesthetics, volatile)
Di(2-ethylhexyl) adipate . . . . . . . . . . . . . . . . . . . . . . . . . . . . 29, 257 (1982); Suppl. 7, 62 (1987); 77, 149 (2000)
Di(2-ethylhexyl) phthalate . . . . . . . . . . . . . 29, 269 (1982) (corr. 42, 261); Suppl. 7, 62 (1987); 77, 41 (2000)
1,2-Diethylhydrazine  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4, 153 (1974); Suppl. 7, 62 (1987); 71, 1401 (1999)
Diethylstilbestrol . . . . . 6, 55 (1974); 21, 173 (1979) (corr. 42, 259); Suppl. 7, 273 (1987); 100A, 175 (2012)
Diethylstilbestrol dipropionate (see Diethylstilbestrol)
Diethyl sulfate . . . . . . . . . . . . . . . . . . . . . . 4, 277 (1974); Suppl. 7, 198 (1987); 54, 213 (1992); 71, 1405 (1999)
N,N’-Diethylthiourea . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 79, 649 (2001)
Diglycidyl resorcinol ether . . . . . . . . . . 11, 125 (1976); 36, 181 (1985); Suppl. 7, 62 (1987); 71, 1417 (1999)
Dihydrosafrole  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .1, 170 (1972); 10, 233 (1976) Suppl. 7, 62 (1987)
1,2-Dihydroaceanthrylene . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 92, 35 (2010)
1,8-Dihydroxyanthraquinone (see Dantron)
Dihydroxybenzenes (see Catechol; Hydroquinone; Resorcinol)
1,3-Dihydroxy-2-hydroxymethylanthraquinone  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 82, 129 (2002)
Dihydroxymethylfuratrizine . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 24, 77 (1980); Suppl. 7, 62 (1987)
Diisopropyl sulfate  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 54, 229 (1992); 71, 1421 (1999)
Dimethisterone (see also Progestins; Sequential oral contraceptives) . . . . .6, 167 (1974); 21, 377 (1979))
Dimethoxane  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15, 177 (1977); Suppl. 7, 62 (1987)
3,3’-Dimethoxybenzidine . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4, 41 (1974); Suppl. 7, 198 (1987)
3,3’-Dimethoxybenzidine-4,4’-diisocyanate . . . . . . . . . . . . . . . . . . . . . . . . 39, 279 (1986); Suppl. 7, 62 (1987)
para-Dimethylaminoazobenzene . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8, 125 (1975); Suppl. 7, 62 (1987)
para-Dimethylaminoazobenzenediazo sodium sulfonate . . . . . . . . . . . . 8, 147 (1975); Suppl. 7, 62 (1987)
trans-2-[(Dimethylamino)methylimino]-5-
[2-(5-nitro-2-furyl)-vinyl]-1,3,4-oxadiazole . . . . . . . . . . . . . 7, 147 (1974) (corr. 42, 253); Suppl. 7, 62 (1987)
4,4’-Dimethylangelicin plus ultraviolet radiation
 (see also Angelicin and some synthetic derivatives) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Suppl. 7, 57 (1987)
4,5’-Dimethylangelicin plus ultraviolet radiation
 (see also Angelicin and some synthetic derivatives) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Suppl. 7, 57 (1987)
2,6-Dimethylaniline  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 57, 323 (1993)
N,N-Dimethylaniline . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 57, 337 (1993)
Dimethylarsinic acid (see Arsenic and arsenic compounds)
3,3’-Dimethylbenzidine . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .1, 87 (1972); Suppl. 7, 62 (1987); 100F, 93 (2012)
Dimethylcarbamoyl chloride . . . . . . . . . . . . . . . . . . . . . . . . 12, 77 (1976); Suppl. 7, 199 (1987); 71, 531 (1999)
Dimethylformamide . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 47, 171 (1989); 71, 545 (1999)
1,1-Dimethylhydrazine  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4, 137 (1974); Suppl. 7, 62 (1987); 71, 1425 (1999)
1,2-Dimethylhydrazine  . . . . . . . . . . . . . . . . 4, 145 (1974) (corr. 42, 253); Suppl. 7, 62 (1987); 71, 947 (1999)
Dimethyl hydrogen phosphite . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 48, 85 (1990); 71, 1437 (1999)
1,4-Dimethylphenanthrene . . . . . . . . . . . . . . . . . . . . . . . . . . 32, 349 (1983); Suppl. 7, 62 (1987); 92, 35 (2010)
Dimethyl sulfate . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4, 271 (1974); Suppl. 7, 200 (1987); 71, 575 (1999)
3,7-Dinitrofluoranthene  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 46, 189 (1989); 65, 297 (1996)
3,9-Dinitrofluoranthene  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 46, 195 (1989); 65, 297 (1996)
1,3-Dinitropyrene  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 46, 201 (1989)
1,6-Dinitropyrene  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 46, 215 (1989)
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1,8-Dinitropyrene  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 33, 171 (1984); Suppl. 7, 63 (1987); 46, 231 (1989)
Dinitrosopentamethylenetetramine  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11, 241 (1976); Suppl. 7, 63 (1987)
2,4-Dinitrotoluene . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 65, 309 (1996) (corr. 66, 485)
2,6-Dinitrotoluene . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 65, 309 (1996) (corr. 66, 485)
3,5-Dinitrotoluene . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 65, 309 (1996)
1,4-Dioxane . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11, 247 (1976); Suppl. 7, 201 (1987); 71, 589 (1999)
2,4’-Diphenyldiamine . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 16, 313 (1978); Suppl. 7, 63 (1987)
Direct Black 38 (see also Benzidine-based dyes)  . . . . . . . . . . . . . . . . . . . . . . . . . 29, 295 (1982) (corr. 42, 261)
Direct Blue 6 (see also Benzidine-based dyes)  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 29, 311 (1982)
Direct Brown 95 (see also Benzidine-based dyes) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 29, 321 (1982)
Disperse Blue 1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 48, 139 (1990)
Disperse Yellow 3 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8, 97 (1975); Suppl. 7, 60 (1987); 48, 149 (1990)
Disulfiram . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 12, 85 (1976); Suppl. 7, 63 (1987)
Dithranol  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13, 75 (1977); Suppl. 7, 63 (1987)
Divinyl ether (see Anaesthetics, volatile)
Doxefazepam . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 66, 97 (1996)
Doxylamine succinate . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 79, 145 (2001)
Droloxifene  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 66, 241 (1996)
Dry cleaning . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 63, 33 (1995)
Dulcin  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 12, 97 (1976); Suppl. 7, 63 (1987)
E
Endrin  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5, 157 (1974); Suppl. 7, 63 (1987)
Enflurane (see Anaesthetics, volatile)
Eosin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15, 183 (1977); Suppl. 7, 63 (1987)
Epichlorohydrin . . . . . . . . . . . . . . . . . . . . . 11, 131 (1976) (corr. 42, 256); Suppl. 7, 202 (1987); 71, 603 (1999)
1,2-Epoxybutane . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 47, 217 (1989); 71, 629 (1999)
1-Epoxyethyl-3,4-epoxycyclohexane (see 4-Vinylcyclohexene diepoxide)
3,4-Epoxy-6-methylcyclohexylmethyl
 3,4-epoxy-6-methyl-cyclohexane carboxylate . . . . . . 11, 147 (1976); Suppl. 7, 63 (1987); 71, 1441 (1999)
cis-9,10-Epoxystearic acid . . . . . . . . . . . . . . . . . . . . . . . . . . 11, 153 (1976); Suppl. 7, 63 (1987); 71, 1443 (1999)
Epstein-Barr virus  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 70, 47 (1997); 100B, 49 (2012)
d-Equilenin  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 72, 399 (1999)
Equilin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 72, 399 (1999)
Erionite . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 42, 225 (1987); Suppl. 7, 203 (1987); 100C, 311 (2012)
Estazolam . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 66, 105 (1996)
Estradiol . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6, 99 (1974); 21, 279 (1979); Suppl. 7, 284 (1987); 72, 399 (1999)
Estradiol-17β (see Estradiol)
Estradiol 3-benzoate (see Estradiol)
Estradiol dipropionate (see Estradiol)
Estradiol mustard  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9, 217 (1975); Suppl. 7, 68 (1987)
Estradiol valerate (see Estradiol)
Estriol . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6, 117 (1974); 21, 327 (1979); Suppl. 7, 285 (1987); 72, 399 (1999)
Estrogen replacement therapy (see Post-menopausal estrogen therapy)
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Estrogens (see Estrogens, progestins and combinations)
Estrogens, conjugated (see Conjugated estrogens)
Estrogens, nonsteroidal (see Nonsteroidal estrogens)
Estrogens, progestins (progestogens)
 and combinations  . . . . . . . . . . . . . . . 6 (1974); 21 (1979); Suppl. 7, 272(1987); 72, 49, 339, 399, 531 (1999)
Estrogens, steroidal (see Steroidal estrogens)
Estrone  . . . . . . . . . . . . . . . 6, 123 (1974); 21, 343 (1979) (corr. 42, 259); Suppl. 7, 286 (1987); 72, 399 (1999)
Estrone benzoate (see Estrone)
Ethanol in alcoholic beverages . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 41, 96 (2010); 100E, 373 (2012)
Ethinyloestradiol . . . . . . . . . . . . . . . . . . . . . . .6, 77 (1974); 21, 233 (1979); Suppl. 7, 286 (1987); 72, 49 (1999)
Ethionamide . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13, 83 (1977); Suppl. 7, 63 (1987)
Ethyl acrylate . . . . . . . . . . . . . . . . . . . . . . . . . 19, 57 (1979); 39, 81 (1986); Suppl. 7, 63 (1987); 71, 1447 (1999)
Ethyl carbamate . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7, 111 (1974); Suppl. 7, 73 (1987); 96, 1295 (2010)
Ethylbenzene  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 77, 227 (2000)
Ethylene . . . . . . . . . . . . . . . . . . . . . . . . . . . . 19, 157 (1979); Suppl. 7, 63 (1987); 60, 45 (1994); 71, 1447 (1999)
Ethylene dibromide . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15, 195 (1977); Suppl. 7, 204 (1987); 71, 641 (1999)
Ethylene oxide 11, 157 (1976); 36, 189 (1985) (corr. 42, 263); Suppl. 7, 205 (1987); 60, 73 (1994); 97, 185 
(2008); 100F, 379 (2012)
Ethylene sulfide . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11, 257 (1976); Suppl. 7, 63 (1987)
Ethylenethiourea . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7, 45 (1974); Suppl. 7, 207 (1987); 79, 659 (2001)
2-Ethylhexyl acrylate . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 60, 475 (1994)
Ethyl methanesulfonate . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7, 245 (1974); Suppl. 7, 63 (1987)
N-Ethyl-N-nitrosourea . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1, 135 (1972); 17, 191 (1978); Suppl. 7, 63 (1987)
Ethyl selenac (see also Selenium and selenium compounds) . . . . . . . . 12, 107 (1976); Suppl. 7, 63 (1987)
Ethyl tellurac . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 12, 115 (1976); Suppl. 7, 63 (1987)
Ethynodiol diacetate  . . . . . . . . . . . . . . . . . 6, 173 (1974); 21, 387 (1979); Suppl. 7, 292 (1987); 72, 49 (1999)
Etoposide . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .76, 177 (2000); 100A, 91 (2012)
Eugenol . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 36, 75 (1985); Suppl. 7, 63 (1987)
Evans blue . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8, 151 (1975); Suppl. 7, 63 (1987)
Extremely low-frequency electric fields  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .80 (2002)
Extremely low-frequency magnetic fields  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .80 (2002)
F
Fast Green FCF . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 16, 187 (1978); Suppl. 7, 63 (1987)
Fenvalerate  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 53, 309 (1991)
Ferbam . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 12, 121 (1976) (corr. 42, 256); Suppl. 7, 63 (1987)
Ferric oxide  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1, 29 (1972); Suppl. 7, 216 (1987)
Ferrochromium (see Chromium and chromium compounds)
Firefighting  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 98, 395 (2010)
Fission products, mixtures of  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 100D, 285 (2012)
Fluometuron . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 30, 245 (1983); Suppl. 7, 63 (1987)
Fluoranthene  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 32, 355 (1983); Suppl. 7, 63 (1987); 92, 35 (2010)
Fluorene . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 32, 365 (1983); Suppl. 7, 63 (1987); 92, 35 (2010)
Fluorescent lighting (exposure to) (see Ultraviolet radiation)
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Fluorides (inorganic, used in drinking-water) . . . . . . . . . . . . . . . . . . . . . .27, 237 (1982); Suppl. 7, 208 (1987)
5-Fluorouracil . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .26, 217 (1981); Suppl. 7, 210 (1987)
Fluorspar (see Fluorides)
Fluosilicic acid (see Fluorides)
Fluroxene (see Anaesthetics, volatile)
Foreign bodies . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .74 (1999)
Formaldehyde  . . 29, 345 (1982); Suppl. 7, 211 (1987); 62, 217 (1995) (corr. 65, 549; corr. 66, 485); 88, 39 
(2006); 100F, 401 (2012)
2-(2-Formylhydrazino)-4-(5-nitro-2-furyl)thiazole . . . . . . 7, 151 (1974) (corr. 42, 253); Suppl. 7, 63 (1987)
Frusemide (see Furosemide)
Frying, emissions from high-temperature  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 95, 309 (2010)
Fuel oils (heating oils)  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 45, 239 (1989) (corr. 47, 505)
Fumonisin B1 (see also Toxins derived from Fusarium moniliforme)  . . . . . . . . . . . . . . . . . . . . 82, 301 (2002)
Fumonisin B2 (see Toxins derived from Fusarium moniliforme)
Furan . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 63, 393 (1995)
Furazolidone . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 31, 141 (1983); Suppl. 7, 63 (1987)
Furfural . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 63, 409 (1995)
Furniture and cabinet-making . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 25, 99 (1981)
Furosemide . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 50, 277 (1990)
2-(2-Furyl)-3-(5-nitro-2-furyl)acrylamide (see AF-2)
Fusarenon-X (see Toxins derived from Fusarium graminearum, F . culmorum and F . crookwellense)
Fusarenone-X (see Toxins derived from Fusarium graminearum, F . culmorum and F . crookwellense)
Fusarin C (see Toxins derived from Fusarium moniliforme)
G
Gallium arsenide . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 86, 163 (2006)
Gamma (γ)-radiation  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 75, 121 (2000); 100D, 103 (2012)
Gasoline . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 45, 159 (1989) (corr. 47, 505)
Gasoline engine exhaust (see Diesel and gasoline engine exhausts)
Gemfibrozil  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 66, 427 (1996)
Glass fibres (see Man-made mineral fibres)
Glass manufacturing industry, occupational exposures in . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 58, 347 (1993)
Glass wool (see Man-made vitreous fibres)
Glass filaments (see Man-made mineral fibres)
Glu-P-1  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 40, 223 (1986); Suppl. 7, 64 (1987)
Glu-P-2  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 40, 235 (1986); Suppl. 7, 64 (1987)
L-Glutamic acid, 5-[2-(4-hydroxymethyl)phenylhydrazide] (see Agaritine)
Glycidaldehyde  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11, 175 (1976); Suppl. 7, 64 (1987); 71, 1459 (1999)
Glycidol . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 77, 469 (2000)
Glycidyl ethers . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 47, 237 (1989); 71, 1285, 1417, 1525, 1539 (1999)
Glycidyl oleate  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11, 183 (1976); Suppl. 7, 64 (1987)
Glycidyl stearate. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11, 187 (1976); Suppl. 7, 64 (1987)
Griseofulvin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10, 153 (1976); Suppl. 7, 64, 391 (1987); 79, 289 (2001)
Guinea Green B  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 16, 199 (1978); Suppl. 7, 64 (1987)
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Gyromitrin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 31, 163 (1983); Suppl. 7, 64, 391 (1987)
H
Haematite  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1, 29 (1972); Suppl. 7, 216 (1987)
Haematite and ferric oxide . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Suppl. 7, 216 (1987)
Haematite mining, underground, with 
exposure to radon . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .1, 29 (1972); Suppl. 7, 216 (1987); 100D, 241 (2012)
Hairdressers and barbers (occupational exposure as) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 57, 43 (1993)
Hair dyes, epidemiology of  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 16, 29 (1978); 27, 307 (1982)
Halogenated acetonitriles . . . . . . . . . . . . . . . . . . . . . . . . . . 52, 269 (1991); 71, 1325, 1369, 1375, 1533 (1999)
Halothane (see Anaesthetics, volatile)
HC Blue No. 1  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 57, 129 (1993)




HC Red No. 3 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 57, 153 (1993)
HC Yellow No. 4  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 57, 159 (1993)
Heating oils (see Fuel oils)
Helicobacter pylori (infection with)  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .61, 177 (1994); 100B, 385 (2012)
Hepatitis B virus . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 59, 45 (1994); 100B, 93 (2012)
Hepatitis C virus . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .59, 165 (1994); 100B, 135 (2012)
Hepatitis D virus . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 59, 223 (1994)
Heptachlor (see also Chlordane/Heptachlor)  . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5, 173 (1974); 20, 129 (1979)
Hexachlorobenzene . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 20, 155 (1979); Suppl. 7, 219 (1987); 79, 493 (2001)
Hexachlorobutadiene . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 20, 179 (1979); Suppl. 7, 64 (1987); 73, 277 (1999)
Hexachlorocyclohexanes . . . . . . . . . . . . . . 5, 47 (1974); 20, 195 (1979) (corr. 42, 258); Suppl. 7, 220 (1987)
Hexachlorocyclohexane, technical-grade (see Hexachlorocyclohexanes)
Hexachloroethane. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 20, 467 (1979); Suppl. 7, 64 (1987); 73, 295 (1999)
Hexachlorophene . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 20, 241 (1979); Suppl. 7, 64 (1987)
Hexamethylphosphoramide . . . . . . . . . . . . . . . . . . . . . . . 15, 211 (1977); Suppl. 7, 64 (1987); 71, 1465 (1999)
Hexestrol (see also Nonsteroidal estrogens) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Suppl. 7, 279 (1987)
Hormonal contraceptives, progestogens only . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 72, 339 (1999)
Human herpesvirus 8 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 70, 375 (1997)
Human immunodeficiency viruses . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 67, 31 (1996); 100B, 215 (2012)
Human papillomaviruses . . . . . . . . . . . . . . . . . . . . . . . . 64 (1995) (corr. 66, 485); 90 (2007); 100B, 255 (2012)
Human T-cell lymphotropic viruses  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .67, 261 (1996); 100B, 315 (2012)
Hycanthone mesylate . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13, 91 (1977); Suppl. 7, 64 (1987)
Hydralazine . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 24, 85 (1980); Suppl. 7, 222 (1987)
Hydrazine . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4, 127 (1974); Suppl. 7, 223 (1987); 71, 991 (1999)
Hydrochloric acid  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 54, 189 (1992)
Hydrochlorothiazide  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 50, 293 (1990)
Hydrogen peroxide . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 36, 285 (1985); Suppl. 7, 64 (1987); 71, 671 (1999)
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Hydroquinone  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15, 155 (1977); Suppl. 7, 64 (1987); 71, 691 (1999)
1-Hydroxyanthraquinone . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 82, 129 (2002)
4-Hydroxyazobenzene  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8, 157 (1975); Suppl. 7, 64 (1987)
17α-Hydroxyprogesterone caproate (see also Progestins) . . . . . . . . . . . . . . . . 21, 399 (1979) (corr. 42, 259)
8-Hydroxyquinoline . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13, 101 (1977); Suppl. 7, 64 (1987)
8-Hydroxysenkirkine  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10, 265 (1976); Suppl. 7, 64 (1987)
Hydroxyurea . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 76, 347 (2000)
Hypochlorite salts . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 52, 159 (1991)
I
Implants, surgical  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .74, 1999
Indeno[1,2,3-cd]pyrene . . . . . . . . . . . . . . . . .3, 229 (1973); 32, 373 (1983); Suppl. 7, 64 (1987); 92, 35 (2010)
Indium phosphide  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 86, 197 (2006)
Inorganic acids (see Sulfuric acid and other strong inorganic acids, occupational exposures to mists 
and vapours from)
Inorganic lead compounds . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Suppl. 7, 230 (1987); 87 (2006)
Insecticides, occupational exposures in spraying and application of . . . . . . . . . . . . . . . . . . . . . 53, 45 (1991)
Insulation glass wool (see Man-made vitreous fibres)
Involuntary smoking (see Tobacco, Second-hand smoke)
Ionizing radiation (all types)  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 100D, 103 (2012)
IQ  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 40, 261 (1986); Suppl. 7, 64 (1987); 56, 165 (1993)
Iron and steel founding . . . . . . . . . . . . . . . . . . . . . . . . . .34, 133 (1984); Suppl. 7, 224 (1987); 100F, 497 (2012)
Iron-dextran complex  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2, 161 (1973); Suppl. 7, 226 (1987)
Iron-dextrin complex . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2, 161 (1973) (corr. 42, 252); Suppl. 7, 64 (1987)
Iron oxide (see Ferric oxide)
Iron oxide, saccharated (see Saccharated iron oxide)
Iron sorbitol-citric acid complex  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2, 161 (1973); Suppl. 7, 64 (1987)
Isatidine  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10, 269 (1976); Suppl. 7, 65 (1987)
Isoflurane (see Anaesthetics, volatile)
Isoniazid (see Isonicotinic acid hydrazide)
Isonicotinic acid hydrazide . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4, 159 (1974); Suppl. 7, 227 (1987)
Isophosphamide . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 26, 237 (1981); Suppl. 7, 65 (1987)
Isoprene . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 60, 215 (1994); 71, 1015 (1999)
Isopropanol . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .15, 223 (1977); Suppl. 7, 229 (1987); 71, 1027 (1999)
Isopropanol manufacture (strong-acid process)
 (see also Isopropanol; Sulfuric acid and other strong inorganic acids, occupational exposures to mists 
and vapours from) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Suppl. 7, 229 (1987); 100F, 479 (2012)
Isopropyl oils . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .15, 223 (1977); Suppl. 7, 229 (1987); 71, 1483 (1999)
Isosafrole  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1, 169 (1972); 10, 232 (1976); Suppl. 7, 65 (1987)
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J
Jacobine . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10, 275 (1976); Suppl. 7, 65 (1987)
Jet fuel . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 45, 203 (1989)
Joinery (see Carpentry and joinery)
K
Kaempferol  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 31, 171 (1983); Suppl. 7, 65 (1987)
Kaposi sarcoma herpesvirus . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .70, 375 (1997); 100B, 169 (2012)
Kepone (see Chlordecone)
Kojic acid  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 79, 605 (2001)
L
Lasiocarpine  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10, 281 (1976); Suppl. 7, 65 (1987)
Lauroyl peroxide . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 36, 315 (1985); Suppl. 7, 65 (1987); 71, 1485 (1999)
Lead acetate (see Lead and lead compounds)
Lead and lead compounds (see also Foreign bodies) . . .1, 40 (1972) (corr. 42, 251); 2, 52, 150 (1973); 12, 
131 (1976); 23, 40, 208, 209, 325 (1980); Suppl. 7, 230 (1987); 87 (2006)
Lead arsenate (see Arsenic and arsenic compounds)
Lead carbonate (see Lead and lead compounds)
Lead chloride (see Lead and lead compounds)
Lead chromate (see Chromium and chromium compounds)
Lead chromate oxide (see Chromium and chromium compounds)
Lead compounds, inorganic and organic . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Suppl. 7, 230 (1987); 87 (2006)
Lead naphthenate (see Lead and lead compounds)
Lead nitrate (see Lead and lead compounds)
Lead oxide (see Lead and lead compounds)
Lead phosphate (see Lead and lead compounds)
Lead subacetate (see Lead and lead compounds)
Lead tetroxide (see Lead and lead compounds)
Leather goods manufacture  . . . . . . . . . . . . . . . . . . . . 25, 279 (1981); Suppl. 7, 235 (1987); 100C, 317 (2012)
Leather industries . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 25, 199 (1981); Suppl. 7, 232 (1987); 100C, 317 (2012)
Leather tanning and processing  . . . . . . . . . . . . . . . . 25, 201 (1981); Suppl. 7, 236 (1987); 100C, 317 (2012)
Ledate (see also Lead and lead compounds) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 12, 131 (1976)
Levonorgestrel . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 72, 49 (1999)
Light Green SF  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 16, 209 (1978); Suppl. 7, 65 (1987)
d-Limonene . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 56, 135 (1993); 73, 307 (1999)
Lindane (see Hexachlorocyclohexanes)
Liver flukes (see Clonorchis sinensis, Opisthorchis felineus and Opisthorchis viverrini)
Lucidin (see 1,3-Dihydro-2-hydroxymethylanthraquinone)
Lumber and sawmill industries (including logging) . . . . . . . . . . . . . . . . . 25, 49 (1981); Suppl. 7, 383 (1987)
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Luteoskyrin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10, 163 (1976); Suppl. 7, 65 (1987)
Lynoestrenol . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 21, 407 (1979); Suppl. 7, 293 (1987); 72, 49 (1999)
M
Madder root (see also Rubia tinctorum) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 82, 129 (2002)
Magenta . . . . . . . . . . . . . 4, 57 (1974) (corr. 42, 252); Suppl. 7, 238 (1987); 57, 215 (1993); 100F, 105 (2012)
Magenta, manufacture of (see also Magenta) . . . . .Suppl. 7, 238 (1987); 57, 215 (1993); 100F, 105 (2012)
Malathion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 30, 103 (1983); Suppl. 7, 65 (1987)
Maleic hydrazide . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4, 173 (1974) (corr. 42, 253); Suppl. 7, 65 (1987)
Malonaldehyde  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 36, 163 (1985); Suppl. 7, 65 (1987); 71, 1037 (1999)
Malondialdehyde (see Malonaldehyde)
Maneb . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 12, 137 (1976); Suppl. 7, 65 (1987)
Man-made mineral fibres (see Man-made vitreous fibres)
Man-made vitreous fibres  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 43, 39 (1988); 81 (2002)
Mannomustine . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9, 157 (1975); Suppl. 7, 65 (1987)
Mate . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 51, 273 (1991)
MCPA (see also Chlorophenoxy herbicides; Chlorophenoxy herbicides, occupational exposures to) 30, 
255 (1983)
MeA-α-C . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 40, 253 (1986); Suppl. 7, 65 (1987)
Medphalan  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9, 168 (1975); Suppl. 7, 65 (1987)
Medroxyprogesterone acetate 6, 157 (1974); 21, 417 (1979) (corr. 42, 259); Suppl. 7, 289 (1987); 72, 339 
(1999)
Megestrol acetate . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Suppl. 7, 293 (1987); 72, 49 (1999)
MeIQ  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 40, 275 (1986); Suppl. 7, 65 (1987); 56, 197 (1993)
MeIQx  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .40, 283 (1986); Suppl. 7, 65 (1987) 56, 211 (1993)
Melamine . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 39, 333 (1986); Suppl. 7, 65 (1987); 73, 329 (1999)
Melphalan . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9, 167 (1975); Suppl. 7, 239 (1987); 100A, 107 (2012)
6-Mercaptopurine . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .26, 249 (1981); Suppl. 7, 240 (1987)
Mercuric chloride (see Mercury and mercury compounds)
Mercury and mercury compounds . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 58, 239 (1993)
Merphalan . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9, 169 (1975); Suppl. 7, 65 (1987)
Mestranol . . . . . . . . . . . . . . . . 6, 87 (1974); 21, 257 (1979) (corr. 42, 259); Suppl. 7, 288 (1987); 72, 49 (1999)
Metabisulfites (see Sulfur dioxide and some sulfites, bisulfites and metabisulfites)
Metallic mercury (see Mercury and mercury compounds)
Methanearsonic acid, disodium salt (see Arsenic and arsenic compounds)
Methanearsonic acid, monosodium salt (see Arsenic and arsenic compounds)
Methimazole . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 79, 53 (2001)
Methotrexate  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .26, 267 (1981); Suppl. 7, 241 (1987)
Methoxsalen (see 8-Methoxypsoralen)
Methoxychlor . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5, 193 (1974); 20, 259 (1979); Suppl. 7, 66 (1987)
Methoxyflurane (see Anaesthetics, volatile)
5-Methoxypsoralen  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .40, 327 (1986); Suppl. 7, 242 (1987)
8-Methoxypsoralen (see also 8-Methoxypsoralen plus ultraviolet radiation) . . . . . . . . . . . . 24, 101 (1980)
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8-Methoxypsoralen plus ultraviolet radiation . . . . . . . . . . . . . . . . . . . Suppl. 7, 243 (1987); 100A, 363 (2012)
Methyl acrylate . . . . . . . . . . . . . . . . . . . . . . . 19, 52 (1979); 39, 99 (1986); Suppl. 7, 66 (1987); 71, 1489 (1999)
5-Methylangelicin plus ultraviolet radiation
 (see also Angelicin and some synthetic derivatives) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Suppl. 7, 57 (1987)
2-Methylaziridine  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9, 61 (1975); Suppl. 7, 66 (1987); 71, 1497 (1999)
Methylazoxymethanol acetate (see also Cycasin) . . . . . 1, 164 (1972); 10, 131 (1976); Suppl. 7, 66 (1987)
Methyl bromide . . . . . . . . . . . . . . . . . . . . . 41, 187 (1986) (corr. 45, 283); Suppl. 7, 245 (1987); 71, 721 (1999)
Methyl tert-butyl ether . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 73, 339 (1999)
Methyl carbamate . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 12, 151 (1976); Suppl. 7, 66 (1987)
Methyl-CCNU (see 1-(2-Chloroethyl)-3-(4-methylcyclohexyl)-1-nitrosourea)
Methyl chloride . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 41, 161 (1986); Suppl. 7, 246 (1987); 71, 737 (1999)
1-, 2-, 3-, 4-, 5- and 6-Methylchrysenes  . . . . . . . . . . . . . . . 32, 379 (1983); Suppl. 7, 66 (1987); 92, 35 (2010)
N-Methyl-N,4-dinitrosoaniline . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1, 141 (1972); Suppl. 7, 66 (1987)
4,4’-Methylene bis(2-chloroaniline)  . . . . 4, 65 (1974) (corr. 42, 252); Suppl. 7, 246 (1987); 57, 271 (1993); 
100F, 73 (2012)
4,4’-Methylene bis(N,N-dimethyl)benzenamine . . . . . . . . . . . . . . . . . . . . . 27, 119 (1982); Suppl. 7, 66 (1987)
4,4’-Methylene bis(2-methylaniline) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4, 73 (1974); Suppl. 7, 248 (1987)
4,4’-Methylenedianiline  . . . . . . . . . . . . . . . . .4, 79 (1974) (corr. 42, 252); 39, 347 (1986); Suppl. 7, 66 (1987)
4,4’-Methylenediphenyl diisocyanate . . . . . . . . . . . . . . 19, 314 (1979); Suppl. 7, 66 (1987); 71, 1049 (1999)
2-Methylfluoranthene . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 32, 399 (1983); Suppl. 7, 66 (1987); 92, 35 (2010)
3-Methylfluoranthene . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 32, 399 (1983); Suppl. 7, 66 (1987); 92, 35 (2010)
Methylglyoxal . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 51, 443 (1991)
Methyl iodide . . . . . . . . . . . . . . . . . . . . . . 15, 245 (1977); 41, 213 (1986); Suppl. 7, 66 (1987); 71, 1503 (1999)
Methylmercury chloride (see Mercury and mercury compounds)
Methylmercury compounds (see Mercury and mercury compounds)
Methyl methacrylate  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 19, 187 (1979); Suppl. 7, 66 (1987); 60, 445 (1994)
Methyl methanesulfonate . . . . . . . . . . . . . . . . . . . . . . . . . . 7, 253 (1974); Suppl. 7, 66 (1987); 71, 1059 (1999)
2-Methyl-1-nitroanthraquinone . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 27, 205 (1982); Suppl. 7, 66 (1987)







N-Methyl-N-nitrosourea  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1, 125 (1972); 17, 227 (1978); Suppl. 7, 66 (1987)
N-Methyl-N-nitrosourethane . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4, 211 (1974); Suppl. 7, 66 (1987)
N-Methylolacrylamide . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 60, 435 (1994)
Methyl parathion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 30, 131 (1983); Suppl. 7, 66, 392 (1987)
1-Methylphenanthrene . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 32, 405 (1983); Suppl. 7, 66 (1987); 92, 35 (2010)
7-Methylpyrido[3,4-c]psoralen . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 40, 349 (1986); Suppl. 7, 71 (1987)
Methyl red . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8, 161 (1975); Suppl. 7, 66 (1987)
Methyl selenac (see also Selenium and selenium compounds) . . . . . . 12, 161 (1976); Suppl. 7, 66 (1987)
Methylthiouracil . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .7, 53 (1974); Suppl. 7, 66 (1987); 79, 75 (2001)
Metronidazole  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .13, 113 (1977); Suppl. 7, 250 (1987)
Microcystin-LR . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 94, 331 (2010)
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Microcystis extracts  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 94, 367 (2010)
Mineral oils  . . . . . . . . . . . .3, 30 (1973); 33, 87 (1984) (corr. 42, 262); Suppl. 7, 252 (1987); 100F, 179 (2012)
Mirex  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5, 203 (1974); 20, 283 (1979) (corr. 42, 258); Suppl. 7, 66 (1987)
Mists and vapours from sulfuric acid and other strong inorganic acids  . 54, 41 (1992); 100F, 487 (2012)
Mitomycin C  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10, 171 (1976); Suppl. 7, 67 (1987)
Mitoxantrone  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 76, 289 (2000)
MNNG (see N-Methyl-N’-nitro-N-nitrosoguanidine)
MOCA (see 4,4’-Methylene bis(2-chloroaniline))
Modacrylic fibres . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 19, 86 (1979); Suppl. 7, 67 (1987)
Monochloramine (see Chloramine)
Monocrotaline . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10, 291 (1976); Suppl. 7, 67 (1987)
Monuron . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 12, 167 (1976); Suppl. 7, 67 (1987); 53, 467 (1991)
MOPP and other combined chemotherapy
 including alkylating agents  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Suppl. 7, 254 (1987); 100A, 119 (2012)
Mordanite (see Zeolites)
Morinda officinalis (see also Traditional herbal medicines) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 82, 129 (2002)
Morpholine . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 47, 199 (1989); 71, 1511 (1999)
5-(Morpholinomethyl)-3-[(5-nitrofurfurylidene)amino]-2-oxazolidinone . . . . . 7, 161 (1974); Suppl. 7, 67 
(1987)
Musk ambrette . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 65, 477 (1996)
Musk xylene  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 65, 477 (1996)
Mustard gas . . . . . . . . . . . . . . . . . . . . . . . . 9, 181 (1975) (corr. 42, 254); Suppl. 7, 259 (1987); 100F, 437 (2012)
Myleran (see 1,4-Butanediol dimethanesulfonate)
N
Nafenopin  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 24, 125 (1980); Suppl. 7, 67 (1987)
Naphthalene . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 82, 367 (2002)
1,5-Naphthalenediamine . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 27, 127 (1982); Suppl. 7, 67 (1987)
1,5-Naphthalene diisocyanate . . . . . . . . . . . . . . . . . . . . . 19, 311 (1979); Suppl. 7, 67 (1987); 71, 1515 (1999)
Naphtho[1,2-b]fluoranthene . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 92, 35 (2010)
Naphtho[2,1-a]fluoranthene . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 92, 35 (2010)
Naphtho[2,3-e]pyrene . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 92, 35 (2010)
1-Naphthylamine  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4, 87 (1974) (corr. 42, 253); Suppl. 7, 260 (1987)
2-Naphthylamine  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4, 97 (1974); Suppl. 7, 261 (1987); 100F, 83 (2012)
1-Naphthylthiourea  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .30, 347 (1983); Suppl. 7, 263 (1987)
Neutron radiation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 75, 361 (2000);  100D, 231 (2012)
Nickel acetate (see Nickel and nickel compounds)
Nickel ammonium sulfate (see Nickel and nickel compounds)
Nickel and nickel compounds (see also Implants, surgical) . . 2, 126 (1973) (corr. 42, 252); 11, 75 (1976); 
Suppl. 7, 264 (1987) (corr. 45, 283); 49, 257 (1990) (corr. 67, 395); 100C, 169 (2012)
Nickel carbonate (see Nickel and nickel compounds)
Nickel carbonyl (see Nickel and nickel compounds)
Nickel chloride (see Nickel and nickel compounds)
Nickel-gallium alloy (see Nickel and nickel compounds)
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Nickel hydroxide (see Nickel and nickel compounds)
Nickelocene (see Nickel and nickel compounds)
Nickel oxide (see Nickel and nickel compounds)
Nickel subsulfide (see Nickel and nickel compounds)
Nickel sulfate (see Nickel and nickel compounds)
Niridazole . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13, 123 (1977); Suppl. 7, 67 (1987)
Nithiazide . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 31, 179 (1983); Suppl. 7, 67 (1987)
Nitrate or nitrite, ingested,
 under conditions that result in endogenous nitrosation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 94, 43 (2010)
Nitrilotriacetic acid and its salts . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 48, 181 (1990); 73, 385 (1999)
Nitrite (see Nitrate or nitrite)
5-Nitroacenaphthene  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 16, 319 (1978); Suppl. 7, 67 (1987)
5-Nitro-ortho-anisidine . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 27, 133 (1982); Suppl. 7, 67 (1987)
2-Nitroanisole . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 65, 369 (1996)
9-Nitroanthracene . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 33, 179 (1984); Suppl. 7, 67 (1987)
7-Nitrobenz[a]anthracene . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 46, 247 (1989)
Nitrobenzene . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 65, 381 (1996)
6-Nitrobenzo[a]pyrene . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 33, 187 (1984); Suppl. 7, 67 (1987); 46, 255 (1989)
4-Nitrobiphenyl . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4, 113 (1974); Suppl. 7, 67 (1987)
6-Nitrochrysene . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 33, 195 (1984); Suppl. 7, 67 (1987); 46, 267 (1989)
Nitrofen (technical-grade) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 30, 271 (1983); Suppl. 7, 67 (1987)
3-Nitrofluoranthene . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 33, 201 (1984); Suppl. 7, 67 (1987)
2-Nitrofluorene. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 46, 277 (1989)
Nitrofural  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7, 171 (1974); Suppl. 7, 67 (1987); 50, 195 (1990)
5-Nitro-2-furaldehyde semicarbazone (see Nitrofural)
Nitrofurantoin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 50, 211 (1990)
Nitrofurazone (see Nitrofural)
1-[(5-Nitrofurfurylidene)amino]-2-imidazolidinone . . . . . . . . . . . . . . . . . . 7, 181 (1974); Suppl. 7, 67 (1987)
N-[4-(5-Nitro-2-furyl)-2-thiazolyl]acetamide . . . . . . . . . . . 1, 181 (1972); 7, 185 (1974); Suppl. 7, 67 (1987)
Nitrogen mustard . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9, 193 (1975); Suppl. 7, 269 (1987)
Nitrogen mustard N-oxide . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9, 209 (1975); Suppl. 7, 67 (1987)
Nitromethane . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 77, 487 (2000)
1-Nitronaphthalene . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 46, 291 (1989)
2-Nitronaphthalene . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 46, 303 (1989)
3-Nitroperylene . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 46, 313 (1989)
2-Nitro-para-phenylenediamine (see 1,4-Diamino-2-nitrobenzene)
2-Nitropropane  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 29, 331 (1982); Suppl. 7, 67 (1987); 71, 1079 (1999)
1-Nitropyrene . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 33, 209 (1984); Suppl. 7, 67 (1987); 46, 321 (1989)
2-Nitropyrene . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 46, 359 (1989)
4-Nitropyrene . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 46, 367 (1989)
N-Nitrosatable drugs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 24, 297 (1980) (corr. 42, 260)
N-Nitrosatable pesticides . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 30, 359 (1983)
N’-Nitrosoanabasine (NAB) . . . . . . . . . . . . . . . . . . . . . . . . . . 37, 225 (1985); Suppl. 7, 67 (1987); 89, 419 (2007)
N’-Nitrosoanatabine (NAT) . . . . . . . . . . . . . . . . . . . . . . . . . . 37, 233 (1985); Suppl. 7, 67 (1987); 89, 419 (2007)
N-Nitrosodi-n-butylamine . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4, 197 (1974); 17, 51 (1978); Suppl. 7, 67 (1987)
N-Nitrosodiethanolamine . . . . . . . . . . . . . . . . . . . . . . . . . . . . 17, 77 (1978); Suppl. 7, 67 (1987); 77, 403 (2000)
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N-Nitrosodiethylamine . . . . 1, 107 (1972) (corr. 42, 251); 17, 83 (1978) (corr. 42, 257); Suppl. 7, 67 (1987)
N-Nitrosodimethylamine . . . . . . . . . . . . . . . .1, 95 (1972); 17, 125 (1978) (corr. 42, 257); Suppl. 7, 67 (1987)
N-Nitrosodiphenylamine  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 27, 213 (1982); Suppl. 7, 67 (1987)
para-Nitrosodiphenylamine  . . . . . . . . . . . . . . . . . . . . . . . . . 27, 227 (1982) (corr. 42, 261); Suppl. 7, 68 (1987)
N-Nitrosodi-n-propylamine . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 17, 177 (1978); Suppl. 7, 68 (1987)
N-Nitroso-N-ethylurea (see N-Ethyl-N-nitrosourea)
N-Nitrosofolic acid . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 17, 217 (1978); Suppl. 7, 68 (1987)
N-Nitrosoguvacine . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 37, 263 (1985); Suppl. 7, 68 (1987); 85, 281 (2004)
N-Nitrosoguvacoline  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 37, 263 (1985); Suppl. 7, 68 (1987); 85, 281 (2004)
N-Nitrosohydroxyproline . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 17, 304 (1978); Suppl. 7, 68 (1987)
3-(N-Nitrosomethylamino)propionaldehyde . . . . . . . . . 37, 263 (1985); Suppl. 7, 68 (1987); 85, 281 (2004)
3-(N-Nitrosomethylamino)propionitrile  . . . . . . . . . . . . . 37, 263 (1985); Suppl. 7, 68 (1987); 85, 281 (2004)
4-(N-Nitrosomethylamino)-4-(3-pyridyl)-1-butanal . . . . . . . . . . . . . . . . . . 37, 205 (1985); Suppl. 7, 68 (1987)
4-(N-Nitrosomethylamino)-1-(3-pyridyl)-1-butanone
   (NNK)  . . . . . . . . . . . . . . . . . . . . . . . . . . .37, 209 (1985); Suppl. 7, 68 (1987); 89, 419 (2007); 100E, 319 (2012)
N-Nitrosomethylethylamine . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 17, 221 (1978); Suppl. 7, 68 (1987)
N-Nitroso-N-methylurea (see N-Methyl-N-nitrosourea)
N-Nitroso-N-methylurethane (see N-Methyl-N-nitrosourethane)
N-Nitrosomethylvinylamine  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 17, 257 (1978); Suppl. 7, 68 (1987)
N-Nitrosomorpholine . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 17, 263 (1978); Suppl. 7, 68 (1987)
N’-Nitrosonornicotine
   (NNN) . . . . . . . . . . . . 17, 281 (1978); 37, 241 (1985); Suppl. 7, 68 (1987); 89, 419 (2007); 100E, 319 (2012)
N-Nitrosopiperidine . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 17, 287 (1978); Suppl. 7, 68 (1987)
N-Nitrosoproline . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 17, 303 (1978); Suppl. 7, 68 (1987)
N-Nitrosopyrrolidine  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 17, 313 (1978); Suppl. 7, 68 (1987)
N-Nitrososarcosine . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 17, 327 (1978); Suppl. 7, 68 (1987)
Nitrosoureas, chloroethyl (see Chloroethyl nitrosoureas)
5-Nitro-ortho-toluidine . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 48, 169 (1990)
2-Nitrotoluene . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 65, 409 (1996)
3-Nitrotoluene . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 65, 409 (1996)
4-Nitrotoluene . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 65, 409 (1996)
Nitrous oxide (see Anaesthetics, volatile)
Nitrovin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 31, 185 (1983); Suppl. 7, 68 (1987)
Nivalenol (see Toxins derived from Fusarium graminearum, F . culmorum and F . crookwellense)
NNK (see 4-(N-Nitrosomethylamino)-1-(3-pyridyl)-1-butanone)
NNN (see N’-Nitrosonornicotine)
Nodularins . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 94, 329 (2010)
Nonsteroidal estrogens . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Suppl. 7, 273 (1987)
Norethisterone . . . . . . . . . . . . . . . . . . . . . . . 6, 179 (1974); 21, 461 (1979); Suppl. 7, 294 (1987); 72, 49 (1999)
Norethisterone acetate . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 72, 49 (1999)
Norethynodrel  . . . . . . . . . .6, 191 (1974); 21, 461 (1979) (corr. 42, 259); Suppl. 7, 295 (1987); 72, 49 (1999)
Norgestrel  . . . . . . . . . . . . . . . . . . . . . . . . . . . 6, 201 (1974); 21, 479 (1979); Suppl. 7, 295 (1987); 72, 49 (1999)
Nylon 6 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 19, 120 (1979); Suppl. 7, 68 (1987)
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IARC MONOGRAPHS – 100B
O
Ochratoxin A . . . . . . . . . 10, 191 (1976); 31, 191 (1983) (corr. 42, 262); Suppl. 7, 271 (1987); 56, 489 (1993)
Oil Orange SS  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8, 165 (1975); Suppl. 7, 69 (1987)
Oestrogen and Oestrogen-type compounds (see Estrogen)
Opisthorchis felineus (infection with)  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 61, 121 (1994)
Opisthorchis viverrini (infection with) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .61, 121 (1994); 100B, 341 (2012)
Oral contraceptives, sequential (see Sequential oral contraceptives)
Orange I  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8, 173 (1975); Suppl. 7, 69 (1987)
Orange G  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8, 181 (1975); Suppl. 7, 69 (1987)
Organic lead compounds . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Suppl. 7, 230 (1987); 87 (2006)
Organolead compounds (see Organic lead compounds)
Oxazepam . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13, 58 (1977); Suppl. 7, 69 (1987); 66, 115 (1996)
Oxymetholone (see also Androgenic (anabolic) steroids)  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13, 131 (1977)
Oxyphenbutazone  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13, 185 (1977); Suppl. 7, 69 (1987)
P
Paint manufacture and painting (occupational exposures in)  . . 47, 329 (1989); 98, 41 (2010); 100F, 509 
(2012)
Palygorskite . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 42, 159 (1987); Suppl. 7, 117 (1987); 68, 245 (1997)
Panfuran S (see also Dihydroxymethylfuratrizine) . . . . . . . . . . . . . . . . . . . . 24, 77 (1980); Suppl. 7, 69 (1987)
Paper manufacture (see Pulp and paper manufacture)
Paracetamol  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 50, 307 (1990); 73, 401 (1999)
Parasorbic acid . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10, 199 (1976) (corr. 42, 255); Suppl. 7, 69 (1987)
Parathion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 30, 153 (1983); Suppl. 7, 69 (1987)
Patulin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10, 205 (1976); 40, 83 (1986); Suppl. 7, 69 (1987)
Paving and roofing with coal-tar pitch  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 92, 35 (2010)
Penicillic acid . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10, 211 (1976); Suppl. 7, 69 (1987)
Pentachloroethane . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 41, 99 (1986); Suppl. 7, 69 (1987); 71, 1519 (1999)
Pentachloronitrobenzene (see Quintozene)
Pentachlorophenol (see also Chlorophenols; Chlorophenols, occupational exposures to;
 Polychlorophenols and their sodium salts) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 20, 303 (1979); 53, 371 (1991)
Permethrin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 53, 329 (1991)
Perylene . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 32, 411 (1983); Suppl. 7, 69 (1987); 92, 35 (2010)
Petasitenine . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 31, 207 (1983); Suppl. 7, 69 (1987)
Petasites japonicus (see also Pyrrolizidine alkaloids) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10, 333 (1976)
Petroleum refining (occupational exposures in)  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 45, 39 (1989)
Petroleum solvents . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 47, 43 (1989)
Phenacetin . . . . . . . . . . . . . . . . . . . . . . 13, 141 (1977); 24, 135 (1980); Suppl. 7, 310 (1987); 100A, 377 (2012)
Phenanthrene . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 32, 419 (1983); Suppl. 7, 69 (1987); 92, 35 (2010)
Phenazopyridine hydrochloride . . . . . . . 8, 117 (1975); 24, 163 (1980) (corr. 42, 260); Suppl. 7, 312 (1987)
Phenelzine sulfate . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .24, 175 (1980); Suppl. 7, 312 (1987)
Phenicarbazide . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 12, 177 (1976); Suppl. 7, 70 (1987)
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Cumulative Index
Phenobarbital and its sodium salt . . . . . . . . . . . . . . . . . . 13, 157 (1977); Suppl. 7, 313 (1987); 79, 161 (2001)
Phenol . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 47, 263 (1989) (corr. 50, 385); 71, 749 (1999)
Phenolphthalein  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 76, 387 (2000)
Phenoxyacetic acid herbicides (see Chlorophenoxy herbicides)
Phenoxybenzamine hydrochloride . . . . . . . . . . . . . . . . . . . 9, 223 (1975); 24, 185 (1980); Suppl. 7, 70 (1987)
Phenylbutazone . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .13, 183 (1977); Suppl. 7, 316 (1987)
meta-Phenylenediamine  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 16, 111 (1978); Suppl. 7, 70 (1987)
para-Phenylenediamine . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 16, 125 (1978); Suppl. 7, 70 (1987)
Phenyl glycidyl ether (see also Glycidyl ethers)  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 71, 1525 (1999)
N-Phenyl-2-naphthylamine . . . . . . . . . . . . . . . . . . . . . . . . . 16, 325 (1978) (corr. 42, 257); Suppl. 7, 318 (1987)
ortho-Phenylphenol . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 30, 329 (1983); Suppl. 7, 70 (1987); 73, 451 (1999)
Phenytoin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13, 201 (1977); Suppl. 7, 319 (1987); 66, 175 (1996)
Phillipsite (see Zeolites)
PhIP  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 56, 229 (1993)
Phosphorus-32 as phosphate . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 100D, 285 (2012)
Picene . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 92, 35 (2010)
Pickled vegetables  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 56, 83 (1993)
Picloram . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 53, 481 (1991)
Piperazine oestrone sulfate (see Conjugated estrogens)
Piperonyl butoxide . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 30, 183 (1983); Suppl. 7, 70 (1987)
Pitches, coal-tar (see Coal-tar pitches)
Plutonium-239 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 100D, 241 (2012)
Polyacrylic acid . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 19, 62 (1979); Suppl. 7, 70 (1987)
Polybrominated biphenyls . . . . . . . . . . . . . . . . . . . . . . . . . 18, 107 (1978); 41, 261 (1986); Suppl. 7, 321 (1987)
Polychlorinated biphenyls . . . . . . . . . . . . . 7, 261 (1974); 18, 43 (1978) (corr. 42, 258); Suppl. 7, 322 (1987)
Polychlorinated camphenes (see Toxaphene)
Polychlorinated dibenzo-para-dioxins
 (other than 2,3,7,8-tetrachlorodibenzodioxin) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 69, 33 (1997)
Polychlorinated dibenzofurans  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 69, 345 (1997)
Polychlorophenols and their sodium salts . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 71, 769 (1999)
Polychloroprene  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 19, 141 (1979); Suppl. 7, 70 (1987)
Polyestradiol phosphate (see Estradiol-17β)
Polyethylene (see also Implants, surgical)  . . . . . . . . . . . . . . . . . . . . . . . . . . 19, 164 (1979); Suppl. 7, 70 (1987)
Poly(glycolic acid) (see Implants, surgical)
Polymethylene polyphenyl isocyanate
 (see also 4,4’-Methylenediphenyl diisocyanate) . . . . . . . . . . . . . . . . . . . . 19, 314 (1979); Suppl. 7, 70 (1987)
Polymethyl methacrylate (see also Implants, surgical)  . . . . . . . . . . . . . . 19, 195 (1979); Suppl. 7, 70 (1987)
Polypropylene (see also Implants, surgical) . . . . . . . . . . . . . . . . . . . . . . . . . 19, 218 (1979); Suppl. 7, 70 (1987)
Polystyrene (see also Implants, surgical) . . . . . . . . . . . . . . . . . . . . . . . . . . . . 19, 245 (1979); Suppl. 7, 70 (1987)
Polytetrafluoroethylene (see also Implants, surgical) . . . . . . . . . . . . . . . . 19, 288 (1979); Suppl. 7, 70 (1987)
Polyurethane foams (see also Implants, surgical)  . . . . . . . . . . . . . . . . . . . 19, 320 (1979); Suppl. 7, 70 (1987)
Polyvinyl acetate (see also Implants, surgical) . . . . . . . . . . . . . . . . . . . . . . . 19, 346 (1979); Suppl. 7, 70 (1987)
Polyvinyl alcohol (see also Implants, surgical) . . . . . . . . . . . . . . . . . . . . . . . 19, 351 (1979); Suppl. 7, 70 (1987)
Polyvinyl chloride (see also Implants, surgical) . . . . . . . . 7, 306 (1974); 19, 402 (1979); Suppl. 7, 70 (1987)
Polyvinyl pyrrolidone . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 19, 463 (1979); Suppl. 7, 70 (1987); 71, 1181 (1999)
Ponceau MX  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8, 189 (1975); Suppl. 7, 70 (1987)
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IARC MONOGRAPHS – 100B
Ponceau 3R . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8, 199 (1975); Suppl. 7, 70 (1987)
Ponceau SX . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8, 207 (1975); Suppl. 7, 70 (1987)
Post-menopausal estrogen therapy . . . . . . . . . . . . . Suppl. 7, 280 (1987); 72, 399 (1999); 100A, 219 (2012)
Potassium arsenate (see Arsenic and arsenic compounds)
Potassium arsenite (see Arsenic and arsenic compounds)
Potassium bis(2-hydroxyethyl)dithiocarbamate  . . . . . . . . . . . . . . . . . . . . 12, 183 (1976); Suppl. 7, 70 (1987)
Potassium bromate . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 40, 207 (1986); Suppl. 7, 70 (1987); 73, 481 (1999)
Potassium chromate (see Chromium and chromium compounds)
Potassium dichromate (see Chromium and chromium compounds)
Prazepam . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 66, 143 (1996)
Prednimustine  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 50, 115 (1990)
Prednisone . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .26, 293 (1981); Suppl. 7, 326 (1987)
Printing processes and printing inks  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 65, 33 (1996)
Procarbazine hydrochloride  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .26, 311 (1981); Suppl. 7, 327 (1987)
Proflavine salts . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 24, 195 (1980); Suppl. 7, 70 (1987)
Progesterone (see also Progestins;
 Combined oral contraceptives) . . . . . . . . . . . . . . . . . . . . . . . . . . . .6, 135 (1974); 21, 491 (1979) (corr. 42, 259)
Progestins (see Progestogens)
Progestogens . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Suppl. 7, 289 (1987); 72, 49, 339, 531 (1999)
Pronetalol hydrochloride . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13, 227 (1977) (corr. 42, 256); Suppl. 7, 70 (1987)
1,3-Propane sultone . . . . . . . . . . . . . . . . . . 4, 253 (1974) (corr. 42, 253); Suppl. 7, 70 (1987); 71, 1095 (1999)
Propham . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 12, 189 (1976); Suppl. 7, 70 (1987)
β-Propiolactone . . . . . . . . . . . . . . . . . . . . . . 4, 259 (1974) (corr. 42, 253); Suppl. 7, 70 (1987); 71, 1103 (1999)
n-Propyl carbamate  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 12, 201 (1976); Suppl. 7, 70 (1987)
Propylene . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 19, 213 (1979); Suppl. 7, 71 (1987); 60, 161 (1994)
Propyleneimine (see 2-Methylaziridine)
Propylene oxide . . . . . . 11, 191 (1976); 36, 227 (1985) (corr. 42, 263); Suppl. 7, 328 (1987); 60, 181 (1994)
Propylthiouracil . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7, 67 (1974); Suppl. 7, 329 (1987); 79, 91 (2001)
Ptaquiloside (see also Bracken fern) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 40, 55 (1986); Suppl. 7, 71 (1987)
Pulp and paper manufacture  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .25, 157 (1981); Suppl. 7, 385 (1987)
Pyrene . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 32, 431 (1983); Suppl. 7, 71 (1987); 92, 35 (2010)
Pyridine . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 77, 503 (2000)
Pyrido[3,4-c]psoralen . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 40, 349 (1986); Suppl. 7, 71 (1987)
Pyrimethamine . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13, 233 (1977); Suppl. 7, 71 (1987)
Pyrrolizidine alkaloids
 (see Hydroxysenkirkine; Isatidine; Jacobine; Lasiocarpine; Monocrotaline; Retrorsine; Riddelliine; 
Seneciphylline; Senkirkine)
Q
Quartz (see Crystalline silica)
Quercetin (see also Bracken fern)  . . . . . . . . . . . . . . . . . . . 31, 213 (1983); Suppl. 7, 71 (1987); 73, 497 (1999)
para-Quinone . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15, 255 (1977); Suppl. 7, 71 (1987); 71, 1245 (1999)




Radiation (see gamma-radiation, neutrons, ultraviolet radiation, 
 X-radiation)
Radionuclides, internalized, that emit α-particles . . . . . . . . . . . . . . . . . . . . . . . . . 78 (2001); 100D, 241 (2012)
Radionuclides, internalized, that emit β-particles . . . . . . . . . . . . . . . . . . . . . . . . . 78 (2001); 100D, 285 (2012)
Radioisotopes of iodine, short-lived, including Iodine-131 . . . . . . . . . . . . . . . . . . . . . . . . . . 100D, 285 (2012)
Radium-224, radium-226, radium-228 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 100D, 241 (2012)
Radon-222 with its decay products  . . . . . . . . . . . . . . . . . . . .43, 173 (1988) (corr. 45, 283); 100D, 241 (2012)
Refractory ceramic fibres (see Man-made vitreous fibres)
Reserpine . . . . . . . . . . . . . . . . . . . . . . . . . . . 10, 217 (1976); 24, 211 (1980) (corr. 42, 260); Suppl. 7, 330 (1987)
Resorcinol. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15, 155 (1977); Suppl. 7, 71 (1987); 71, 1119 (1990)
Retrorsine . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10, 303 (1976); Suppl. 7, 71 (1987)
Rhodamine B . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 16, 221 (1978); Suppl. 7, 71 (1987)
Rhodamine 6G . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 16, 233 (1978); Suppl. 7, 71 (1987)
Riddelliine  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10, 313 (1976); Suppl. 7, 71 (1987); 82, 153 (2002)
Rifampicin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 24, 243 (1980); Suppl. 7, 71 (1987)
Ripazepam . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 66, 157 (1996)
Rock (stone) wool (see Man-made vitreous fibres)
Rubber industry . . . . . . . . . . . . . . . . . . . . . . . 28 (1982) (corr. 42, 261); Suppl. 7, 332 (1987) ; 100F, 541 (2012)
Rubia tinctorum (see also Madder root, Traditional herbal medicines) . . . . . . . . . . . . . . . . . . 82, 129 (2002)
Rugulosin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 40, 99 (1986); Suppl. 7, 71 (1987)
S
Saccharated iron oxide . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2, 161 (1973); Suppl. 7, 71 (1987)
Saccharin and its salts . . . . . . . . . . . . . . . 22, 111 (1980) (corr. 42, 259); Suppl. 7, 334 (1987); 73, 517 (1999)
Safrole . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1, 169 (1972); 10, 231 (1976); Suppl. 7, 71 (1987)
Salted fish, Chinese-style . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 56, 41 (1993); 100E, 501 (2012)
Sawmill industry (including logging)
 (see Lumber and sawmill industry (including logging))
Scarlet Red . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8, 217 (1975); Suppl. 7, 71 (1987)
Schistosoma haematobium (infection with) . . . . . . . . . . . . . . . . . . . . . . . . . . . . 61, 45 (1994); 100B, 371 (2012)
Schistosoma japonicum (infection with)  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 61, 45 (1994)
Schistosoma mansoni (infection with) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 61, 45 (1994)
Selenium and selenium compounds . . . . . . . . . . . . . . . . . . 9, 245 (1975) (corr. 42, 255); Suppl. 7, 71 (1987)
Selenium dioxide (see Selenium and selenium compounds)
Selenium oxide (see Selenium and selenium compounds)
Semicarbazide hydrochloride . . . . . . . . . . . . . . . . . . . . . . . . 12, 209 (1976) (corr. 42, 256); Suppl. 7, 71 (1987)
Senecio jacobaea L. (see also Pyrrolizidine alkaloids)  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10, 333 (1976)
Senecio longilobus
 (see also Pyrrolizidine alkaloids, Traditional) herbal medicines)  . . . . . . . . . 10, 334 (1976); 82, 153 (2002)
Senecio riddellii (see also Traditional herbal medicines) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 82, 153 (1982)
Seneciphylline  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10, 319, 335 (1976); Suppl. 7, 71 (1987)
469
IARC MONOGRAPHS – 100B
Senkirkine  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10, 327 (1976); 31, 231 (1983); Suppl. 7, 71 (1987)
Sepiolite . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 42, 175 (1987); Suppl. 7, 71 (1987); 68, 267 (1997)
Sequential oral contraceptives
 (see also Estrogens, progestins and combinations) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Suppl. 7, 296 (1987)
Shale-oils . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .35, 161 (1985); Suppl. 7, 339 (1987); 100F, 197 (2012)
Shiftwork  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 98, 561 (2010)
Shikimic acid (see also Bracken fern) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 40, 55 (1986); Suppl. 7, 71 (1987)
Shoe manufacture and repair (see Boot and shoe manufacture and repair)
Silica (see also Amorphous silica; Crystalline silica) . . . . . . . . . . . . . . . . . . . . . 42, 39 (1987); 100C, 355 (2012)
Silicone (see Implants, surgical)
Simazine . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 53, 495 (1991); 73, 625 (1999)
Slag wool (see Man-made vitreous fibres)
Sodium arsenate (see Arsenic and arsenic compounds)
Sodium arsenite (see Arsenic and arsenic compounds)
Sodium cacodylate (see Arsenic and arsenic compounds)
Sodium chlorite . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 52, 145 (1991)
Sodium chromate (see Chromium and chromium compounds)
Sodium cyclamate (see Cyclamates)
Sodium dichromate (see Chromium and chromium compounds)
Sodium diethyldithiocarbamate . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 12, 217 (1976); Suppl. 7, 71 (1987)
Sodium equilin sulfate (see Conjugated estrogens)
Sodium estrone sulfate (see Conjugated estrogens)
Sodium fluoride (see Fluorides)
Sodium monofluorophosphate (see Fluorides)
Sodium ortho-phenylphenate
 (see also ortho-Phenylphenol) . . . . . . . . . . . . . . . . . 30, 329 (1983); Suppl. 7, 71, 392 (1987); 73, 451 (1999)
Sodium saccharin (see Saccharin)
Sodium selenate (see Selenium and selenium compounds)
Sodium selenite (see Selenium and selenium compounds)
Sodium silicofluoride (see Fluorides)
Solar radiation  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 55 (1992); 100D, 35 (2012)
Soots  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3, 22 (1973); 35, 219 (1985); Suppl. 7, 343 (1987); 100F, 209 (2012)
Special-purpose glass fibres such as E-glass and ‘475’ glass fibres (see Man-made vitreous fibres)
Spironolactone . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 24, 259 (1980); Suppl. 7, 344 (1987); 79, 317 (2001)
Stannous fluoride (see Fluorides)
Static electric fields . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .80 (2002)
Static magnetic fields . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .80 (2002)
Steel founding (see Iron and steel founding)
Steel, stainless (see Implants, surgical)
Sterigmatocystin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1, 175 (1972); 10, 245 (1976); Suppl. 7, 72 (1987)
Steroidal estrogens  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Suppl. 7, 280 (1987)
Streptozotocin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4, 221 (1974); 17, 337 (1978); Suppl. 7, 72 (1987)
Strobane® (see Terpene polychlorinates)
Strong-inorganic-acid mists containing sulfuric acid (see Mists and vapours from sulfuric acid and 
other strong inorganic acids)
Strontium chromate (see Chromium and chromium compounds)
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Cumulative Index
Styrene 19, 231 (1979) (corr. 42, 258); Suppl. 7, 345 (1987); 60, 233 (1994) (corr. 65, 549); 82, 437 (2002)
Styrene-acrylonitrile copolymers  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 19, 97 (1979); Suppl. 7, 72 (1987)
Styrene-butadiene copolymers . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 19, 252 (1979); Suppl. 7, 72 (1987)
Styrene-7,8-oxide . . . . 11, 201 (1976); 19, 275 (1979); 36, 245 (1985); Suppl. 7, 72 (1987); 60, 321 (1994)
Succinic anhydride . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15, 265 (1977); Suppl. 7, 72 (1987)
Sudan I  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8, 225 (1975); Suppl. 7, 72 (1987)
Sudan II . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8, 233 (1975); Suppl. 7, 72 (1987)
Sudan III  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8, 241 (1975); Suppl. 7, 72 (1987)
Sudan Brown RR. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8, 249 (1975); Suppl. 7, 72 (1987)
Sudan Red 7B . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8, 253 (1975); Suppl. 7, 72 (1987)
Sulfadimidine (see Sulfamethazine)
Sulfafurazole . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .24, 275 (1980); Suppl. 7, 347 (1987)
Sulfallate . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 30, 283 (1983); Suppl. 7, 72 (1987)
Sulfamethazine and its sodium salt  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 79, 341 (2001)
Sulfamethoxazole . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 24, 285 (1980); Suppl. 7, 348 (1987); 79, 361 (2001)
Sulfites (see Sulfur dioxide and some sulfites, bisulfites and metabisulfites)
Sulfur dioxide and some sulfites, bisulfites and metabisulfites . . . . . . . . . . . . . . . . . . . . . . . . . . 54, 131 (1992)
Sulfur mustard (see Mustard gas)
Sulfuric acid and other strong inorganic acids,
 occupational exposures to mists and vapours from  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 54, 41 (1992)
Sulfur trioxide . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 54, 121 (1992)
Sulphisoxazole (see Sulfafurazole)
Sunset Yellow FCF . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8, 257 (1975); Suppl. 7, 72 (1987)
Symphytine . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 31, 239 (1983); Suppl. 7, 72 (1987)
T
2,4,5-T (see also Chlorophenoxy herbicides;
 Chlorophenoxy herbicides, occupational exposures to)  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15, 273 (1977)
Talc . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .42, 185 (1987); Suppl. 7, 349 (1987)
Talc, inhaled, not containing asbestos or asbestiform fibres . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .93 (2010)
Talc-based body powder, perineal use of . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .93 (2010)
Tamoxifen . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .66, 253 (1996); 100A, 131 (2012)
Tannic acid . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10, 253 (1976) (corr. 42, 255); Suppl. 7, 72 (1987)
Tannins (see also Tannic acid) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10, 254 (1976); Suppl. 7, 72 (1987)
TCDD (see 2,3,7,8-Tetrachlorodibenzo-para-dioxin)
TDE (see DDT)
Tea  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 51, 207 (1991)
Temazepam . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 66, 161 (1996)
Teniposide . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 76, 259 (2000)
Terpene polychlorinates . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5, 219 (1974); Suppl. 7, 72 (1987)
Testosterone (see also Androgenic (anabolic) steroids) . . . . . . . . . . . . . . . . . . . 6, 209 (1974); 21, 519 (1979)
Testosterone oenanthate (see Testosterone)
Testosterone propionate (see Testosterone)
2,2’,5,5’-Tetrachlorobenzidine . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 27, 141 (1982); Suppl. 7, 72 (1987)
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2,3,7,8-Tetrachlorodibenzo-para-dioxin  . . . . 15, 41 (1977); Suppl. 7, 350 (1987); 69, 33 (1997); 100F, 339 
(2012)
1,1,1,2-Tetrachloroethane . . . . . . . . . . . . . . . . . . . . . . . . . . . 41, 87 (1986); Suppl. 7, 72 (1987); 71, 1133 (1999)
1,1,2,2-Tetrachloroethane . . . . . . . . . . . . . . . . . . . . . . . . . . 20, 477 (1979); Suppl. 7, 354 (1987); 71, 817 (1999)
Tetrachloroethylene . . . . . . . . . . . . . . . . . 20, 491 (1979); Suppl. 7, 355 (1987); 63, 159 (1995) (corr. 65, 549)
2,3,4,6-Tetrachlorophenol (see Chlorophenols; Chlorophenols, occupational exposures to;
 Polychlorophenols and their sodium salts)
Tetrachlorvinphos . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 30, 197 (1983); Suppl. 7, 72 (1987)
Tetraethyllead (see Lead and lead compounds)
Tetrafluoroethylene  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 19, 285 (1979); Suppl. 7, 72 (1987); 71, 1143 (1999)
Tetrakis(hydroxymethyl)phosphonium salts . . . . . . . . . . . . . . . . . . . . . . . . . . . . 48, 95 (1990); 71, 1529 (1999)
Tetramethyllead (see Lead and lead compounds)
Tetranitromethane . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 65, 437 (1996)
Textile manufacturing industry, exposures in  . . . . . . . . . . . . . . . . . . . . . . . . . . . 48, 215 (1990) (corr. 51, 483)
Theobromine  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 51, 421 (1991)
Theophylline . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 51, 391 (1991)
Thioacetamide . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7, 77 (1974); Suppl. 7, 72 (1987)
4,4’-Thiodianiline . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 16, 343 (1978); 27, 147 (1982); Suppl. 7, 72 (1987)
Thiotepa . . . . . . . . . . . . . . . . . . . . . . . . . . .9, 85 (1975); Suppl. 7, 368 (1987); 50, 123 (1990); 100A, 163 (2012)
Thiouracil . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7, 85 (1974); Suppl. 7, 72 (1987); 79, 127 (2001)
Thiourea . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7, 95 (1974); Suppl. 7, 72 (1987); 79, 703 (2001)
Thiram . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 12, 225 (1976); Suppl. 7, 72 (1987); 53, 403 (1991)
Thorium-232 (as Thorotrast)  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 100D, 241 (2012)
Titanium (see Implants, surgical)
Titanium dioxide . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 47, 307 (1989); 93 (2010)
Tobacco
—Second-hand tobacco smoke . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .83, 1189 (2004); 100E, 213 (2012)
—Smokeless tobacco  . . 37 (1985) (corr. 42, 263; 52, 513); Suppl. 7, 357 (1987); 89, 39 (2007); 100E, 265 
(2012)
—Tobacco smoking . . . . . . . 38 (1986) (corr. 42, 263); Suppl. 7, 359 (1987); 83, 51 (2004); 100E, 43 (2012)
ortho-Tolidine (see 3,3’-Dimethylbenzidine)
2,4-Toluene diisocyanate (see also Toluene diisocyanates)  . . . . . . . . . . . . . . 19, 303 (1979); 39, 287 (1986)
2,6-Toluene diisocyanate (see also Toluene diisocyanates)  . . . . . . . . . . . . . . 19, 303 (1979); 39, 289 (1986)
Toluene . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 47, 79 (1989); 71, 829 (1999)
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Toxins derived from Fusarium sporotrichioides . . . . . . . 31, 265 (1983); Suppl. 7, 73 (1987); 56, 467 (1993)
472
Cumulative Index
Traditional herbal medicines . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .82, 41 (2002); 100A, 347 (2012)
Tremolite (see Asbestos)
Treosulfan  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 26, 341 (1981); Suppl. 7, 363 (1987); 100A, 171 (2012)
Triaziquone (see Tris(aziridinyl)-para-benzoquinone)
Trichlorfon . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 30, 207 (1983); Suppl. 7, 73 (1987)
Trichlormethine . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9, 229 (1975); Suppl. 7, 73 (1987); 50, 143 (1990)
Trichloroacetic acid . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 63, 291 (1995) (corr. 65, 549); 84 (2004)
Trichloroacetonitrile (see also Halogenated acetonitriles) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 71, 1533 (1999)
1,1,1-Trichloroethane . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 20, 515 (1979); Suppl. 7, 73 (1987); 71, 881 (1999)
1,1,2-Trichloroethane . . . . . . . . . . . . . . . 20, 533 (1979); Suppl. 7, 73 (1987); 52, 337 (1991); 71, 1153 (1999)
Trichloroethylene  . . . . . 11, 263 (1976); 20, 545 (1979); Suppl. 7, 364 (1987); 63, 75 (1995) (corr. 65, 549)
2,4,5-Trichlorophenol (see also Chlorophenols; Chlorophenols, occupational exposures to;
 Polychlorophenols and their sodium salts) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 20, 349 (1979)
2,4,6-Trichlorophenol (see also Chlorophenols; Chlorophenols, occupational exposures to;
 Polychlorophenols and their sodium salts) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 20, 349 (1979)
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2,4,6-Trinitrotoluene . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 65, 449 (1996)
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2,4,6-Tris(1-aziridinyl)-s-triazine . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9, 95 (1975); Suppl. 7, 73 (1987)
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Tussilago farfara L . (see also Pyrrolizidine alkaloids) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10, 334 (1976)
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W
Welding . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 49, 447 (1990) (corr. 52, 513)
Wollastonite  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 42, 145 (1987); Suppl. 7, 377 (1987); 68, 283 (1997)




Wood industries . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 25 (1981); Suppl. 7, 378 (1987)
X
X-radiation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 75, 121 (2000); 100D, 103 (2012)
Xylenes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 47, 125 (1989); 71, 1189 (1999)
2,4-Xylidine . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 16, 367 (1978); Suppl. 7, 74 (1987)
2,5-Xylidine . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 16, 377 (1978); Suppl. 7, 74 (1987)
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Y
Yellow AB . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8, 279 (1975); Suppl. 7, 74 (1987)
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Zalcitabine . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 76, 129 (2000)
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Zectran . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 12, 237 (1976); Suppl. 7, 74 (1987)
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Zidovudine  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 76, 73 (2000)
Zinc beryllium silicate (see Beryllium and beryllium compounds)
Zinc chromate (see Chromium and chromium compounds)
Zinc chromate hydroxide (see Chromium and chromium compounds)
Zinc potassium chromate (see Chromium and chromium compounds)
Zinc yellow (see Chromium and chromium compounds)
Zineb . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 12, 245 (1976); Suppl. 7, 74 (1987)
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LIST Of IARC MONOGRAPHS 
Volume 1
Some Inorganic Substances, Chlorinated 
Hydrocarbons, Aromatic Amines, 
N-Nitroso Compounds, and Natural 
Products
1972; 184 pages (out-of-print)
Volume 2
Some Inorganic and Organometallic 
Compounds
1973; 181 pages (out-of-print)
Volume 3
Certain Polycyclic Aromatic Hydrocarbons 
and Heterocyclic Compounds
1973; 271 pages (out-of-print)
Volume 4
Some Aromatic Amines, Hydrazine 
and Related Substances, N-Nitroso 
Compounds and Miscellaneous 
Alkylating Agents
1974; 286 pages (out-of-print)
Volume 5
Some Organochlorine Pesticides
1974; 241 pages (out-of-print)
Volume 6
Sex Hormones
1974; 243 pages (out-of-print)
Volume 7
Some Anti-Thyroid and Related Substances, 
Nitrofurans and Industrial Chemicals
1974; 326 pages (out-of-print)
Volume 8
Some Aromatic Azo Compounds
1975; 357 pages (out-of-print)
Volume 9
Some Aziridines, N-, S- and O-Mustards and 
Selenium
1975; 268 pages (out-of-print)
Volume 10
Some Naturally Occurring Substances
1976; 353 pages (out-of-print)
Volume 11
Cadmium, Nickel, Some Epoxides, 
Miscellaneous Industrial Chemicals 
and General Considerations on Volatile 
Anaesthetics
1976; 306 pages (out-of-print)
Volume 12
Some Carbamates, Thio- carbamates and 
Carbazides
1976; 282 pages (out-of-print)
Volume 13





1977; 106 pages (out-of-print)
Volume 15
Some Fumigants, the Herbicides 2,4-D and 
2,4,5-T, Chlorinated Dibenzodioxins and 
Miscellaneous Industrial Chemicals
1977; 354 pages (out-of-print)
Volume 16
Some Aromatic Amines and Related Nitro 
Compounds—Hair Dyes, Colouring 







Polychlorinated Biphenyls and 
Polybrominated Biphenyls
1978; 140 pages (out-of-print)
Volume 19
Some Monomers, Plastics and Synthetic 
Elastomers, and Acrolein
1979; 513 pages (out-of-print)
Volume 20
Some Halogenated Hydrocarbons





Some Non-Nutritive Sweetening Agents
1980; 208 pages
Volume 23
Some Metals and Metallic Compounds









Some Antineoplastic and 
Immunosuppressive Agents
1981; 411 pages (out-of-print)
Volume 27
Some Aromatic Amines, Anthraquinones 
and Nitroso Compounds, and Inorganic 
Fluorides Used in Drinking-water and 
Dental Preparations
1982; 341 pages (out-of-print)
Volume 28
The Rubber Industry
1982; 486 pages (out-of-print)
Volume 29
Some Industrial Chemicals and Dyestuffs
1982; 416 pages (out-of-print)
Volume 30
Miscellaneous Pesticides
1983; 424 pages (out-of-print)
Volume 31
Some Food Additives, Feed Additives and 
Naturally Occurring Substances
1983; 314 pages (out-of-print)
Volume 32
Polynuclear Aromatic Compounds, Part 
1: Chemical, Environmental and 
Experimental Data
1983; 477 pages (out-of-print)
Volume 33
Polynuclear Aromatic Compounds, Part 2: 
Carbon Blacks, Mineral Oils and Some 
Nitroarenes
1984; 245 pages (out-of-print)
Volume 34
Polynuclear Aromatic Compounds, Part 
3: Industrial Exposures in Aluminium 
Production, Coal Gasification, Coke 
Production, and Iron and Steel Founding
1984; 219 pages (out-of-print)
Volume 35
Polynuclear Aromatic Compounds, Part 
4: Bitumens, Coal-tars and Derived 
Products, Shale-oils and Soots
1985; 271 pages
Volume 36




Tobacco Habits Other than Smoking; Betel-
Quid and Areca-Nut Chewing; and Some 
Related Nitrosamines





Some Chemicals Used in Plastics and 
Elastomers
1986; 403 pages (out-of-print)
Volume 40
Some Naturally Occurring and Synthetic 
Food Components, Furocoumarins and 
Ultraviolet Radiation
1986; 444 pages (out-of-print)
Volume 41
Some Halogenated Hydrocarbons and 
Pesticide Exposures
1986; 434 pages (out-of-print)
Volume 42
Silica and Some Silicates
1987; 289 pages
Volume 43
Man-Made Mineral Fibres and Radon





Occupational Exposures in Petroleum 








Some Organic Solvents, Resin Monomers 
and Related Compounds, Pigments 
and Occupational Exposures in Paint 
Manufacture and Painting
1989; 535 pages (out-of-print)
Volume 48
Some Flame Retardants and Textile 














Chlorinated Drinking-water; Chlorination 
By-products; Some Other Halogenated 




Occupational Exposures in Insecticide 
Application, and Some Pesticides
1991; 612 pages
Volume 54
Occupational Exposures to Mists and 
Vapours from Strong Inorganic Acids; 
and Other Industrial Chemicals
1992; 336 pages
Volume 55
Solar and Ultraviolet Radiation
1992; 316 pages
Volume 56
Some Naturally Occurring Substances: Food 
Items and Constituents, Heterocyclic 
Aromatic Amines and Mycotoxins
1993; 599 pages
Volume 57
Occupational Exposures of Hairdressers 
and Barbers and Personal Use of Hair 
Colourants; Some Hair Dyes, Cosmetic 




Beryllium, Cadmium, Mercury, and 














Wood Dust and Formaldehyde
1995; 405 pages
Volume 63
Dry Cleaning, Some Chlorinated Solvents 






Printing Processes and Printing Inks, Carbon 






Human Immunodeficiency Viruses and 
Human T-Cell Lymphotropic Viruses
1996; 424 pages
Volume 68












Re-evaluation of Some Organic Chemicals, 
Hydrazine and Hydrogen Peroxide
1999; 1586 pages
Volume 72




Some Chemicals that Cause Tumours of the 




Surgical Implants and Other Foreign Bodies
1999; 409 pages
Volume 75




Some Antiviral and Antineoplastic Drugs, 













Non-Ionizing Radiation, Part 1: Static and 







Some Traditional Herbal Medicines, Some 
Mycotoxins, Naphthalene and Styrene
2002; 590 pages
Volume 83
Tobacco Smoke and Involuntary Smoking
2004; 1452 pages
Volume 84








Cobalt in Hard Metals and Cobalt Sulfate, 




Inorganic and Organic Lead Compounds
2006; 506 pages
Volume 88











Combined Estrogen- Progestogen 




Some Non-heterocyclic Polycyclic Aromatic 




Carbon Black, Titanium Dioxide, and Talc
2010; 452 pages
Volume 94











1,3-Butadiene, Ethylene Oxide and Vinyl 




Painting, Firefighting, and Shiftwork
2010; 806 pages
Volume 99
















Personal habits and indoor combustions
2012; 575 pages
Volume 100F
Chemical agents and related occupations
2012; 599 pages
Supplement No. 1
Chemicals and Industrial Processes 
Associated with Cancer in Humans (IARC 
Monographs, Volumes 1 to 20)
1979; 71 pages (out-of-print)
Supplement No. 2
Long-term and Short-term Screening Assays 
for Carcinogens: A Critical Appraisal
1980; 426 pages (out-of-print)
(updated as IARC Scientific Publications No.  
       83, 1986)
Supplement No. 3
Cross Index of Synonyms and Trade 
Names in Volumes 1 to 26 of the IARC 
Monographs
1982; 199 pages (out-of-print)
Supplement No. 4
Chemicals, Industrial Processes and 
Industries Associated with Cancer in 
Humans (IARC Monographs, Volumes 1 
to 29)
1982; 292 pages (out-of-print)
Supplement No. 5
Cross Index of Synonyms and Trade 
Names in Volumes 1 to 36 of the IARC 
Monographs
1985; 259 pages (out-of-print)
Supplement No. 6
Genetic and Related Effects: An Updating of 
Selected IARC Monographs from Volumes 
1 to 42
1987; 729 pages (out-of-print)
Supplement No. 7
Overall Evaluations of Carcinogenicity: An 
Updating of IARC Monographs Volumes 
1–42
1987; 440 pages (out-of-print)
Supplement No. 8
Cross Index of Synonyms and Trade 
Names in Volumes 1 to 46 of the IARC 
Monographs


















© CDC / Dr. Patricia Fiels, 
Dr. Collette Fitzgerald
Volume 100 of the IARC Monographs, A Review of Human Carcinogens, covers all agents 
previously classified by IARC as carcinogenic to humans (Group 1) and was developed by six 
separate Working Groups: Pharmaceuticals; Biological Agents; Arsenic, Metals, Fibres, and 
Dusts; Radiation; Personal Habits and Indoor Combustions; Chemical Agents and Related 
Occupations.
This Volume 100B covers Biological Agents, specifically Epstein-Barr Virus, Hepatitis B Virus, 
Hepatitis C Virus, Kaposi Sarcoma Herpesvirus, Human Immunodeficiency Virus-1, Human 
Papillomaviruses, Human T-cell Lymphotropic Virus Type 1, Opisthorchis Viverrini and Clonorchis 
Sinensis, Schistosoma Haematobium, and Helicobacter Pylori.
Because the scope of Volume 100 is so broad, its Monographs are focused on key information. 
Each Monograph presents a description of a carcinogenic agent and how people are exposed, 
critical overviews of the epidemiological studies and animal cancer bioassays, and a concise 
review of the agent’s toxicokinetics, plausible mechanisms of carcinogenesis, and potentially 
susceptible populations, and life-stages. Details of the design and results of individual 
epidemiological studies and animal cancer bioassays are summarized in tables. Short tables 
that highlight key results are printed in Volume 100, and more extensive tables that include all 
studies appear on the Monographs programme website (http://monographs.iarc.fr).
It is hoped that this volume, by compiling the knowledge accumulated through several decades 
of cancer research, will stimulate cancer prevention activities worldwide, and will be a valued 
resource for future research to identify other agents suspected of causing cancer in humans.
